<?xml version="1.0" encoding="utf-8"?>
<?xml-stylesheet type="text/xsl" href="/html/xsl/rss2html.xsl"?>
<rss version="2.0"
xmlns:dc="http://purl.org/dc/elements/1.1/"
xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
xmlns:admin="http://webns.net/mvcb/"
xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
xmlns:content="http://purl.org/rss/1.0/modules/content/">
<channel><title>Ipsen - DKPHybrids Dashboard</title>
<link>http://ci.beaufour-ipsen.com/traction?type=np&amp;proj=*&amp;sdate=20141231&amp;edate=20140901&amp;rs=</link>
<description>DKPHybrids Dashboard</description><dc:language>en-us</dc:language><copyright>Copyright &amp;copy; 2016  All rights reserved.</copyright><category>News</category><docs>http://backend.userland.com/rss</docs><ttl>20</ttl><rating>A1</rating><image>
<title>Ipsen - DKPHybrids Dashboard</title>
<link>http://ci.beaufour-ipsen.com/traction?type=np&amp;proj=*&amp;sdate=20141231&amp;edate=20140901&amp;rs=</link>
<url>http://ci.beaufour-ipsen.com/share/tsi/logos/ipsenbaseline07.jpg</url>
<width>108</width>
<height>31</height>
</image><admin:generatorAgent rdf:resource="http://tractionsoftware.com" /><item>
<title>Aeterna Zentaris Announces Publication Of Zoptarelin Doxorubicin Data [class:Cytotoxics, class:Antihormonals, dis:Prostate, dis:Gynea]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology10188</link>
<description>Aeterna Zentaris Announces Publication Of Zoptarelin Doxorubicin Data [class:Cytotoxics, class:Antihormonals, dis:Prostate, dis:Gynea]</description><category>class:Cytotoxics</category><category>class:Antihormonals</category><category>dis:Prostate</category><category>dis:Gynea</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology10188</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10188">Aeterna Zentaris Announces Publication Of Zoptarelin Doxorubicin Data</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=class%3aAntihormonals"><font color="#e95e0b">:Oncology:class:Antihormonals</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=class%3aCytotoxics"><font color="#e95e0b">:Oncology:class:Cytotoxics</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=dis%3aGynea"><font color="#e95e0b">:Oncology:dis:Gynea</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10188">Oncology10188</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 30 December 2014 | 16:18</font><br><br><div style="margin-bottom: 10px;">Comment Final data from the Phase 1 portion of the ongoing Phase 1/<wbr>2 trial in 
prostate cancer with zoptarelin doxorubicin (formerly AEZS-108), a targeted LHRH 
cytotoxix agent containing doxorubicin, has been published in the December 
issue of <I>Clinical Cancer Research</I>.<wbr> </div><div style="margin-bottom: 10px;">The article outlines data previously disclosed in June 2013 at the 
ASCO which demonstrated the compound's safety profile and promising 
anti-tumor activity in heavily pre treated men with castration- and 
taxane-resistant prostate cancer.<wbr> The article is available at this link: <A href="http://www.ncbi.nlm.nih.gov/pubmed/25278449" target="_blank">Clin Cancer 
Res</A>.<wbr> </div><div style="margin-bottom: 10px;">Commenting on the data David Dodd, Chairman and CEO of Aeterna 
Zentaris stated, </div><div style="margin-bottom: 10px;">“The Phase 1 portion data are very encouraging and we look forward to further 
results from the current Phase 2 portion of this investigator driven trial.<wbr> 
Because luteinizing hormone-releasing hormone receptors are expressed in a great 
number of prostate cancers, we believe that zoptarelin doxorubicin, which 
specifically targets those receptors, may represent a novel targeted treatment 
for men with this disease.<wbr>" </div><div style="margin-bottom: 10px;">Expansion into prostate cancer with zoptarelin doxorubicin comes after 
previously reported positive Phase 2 results in endometrial and ovarian 
cancer.<wbr> </div><div style="margin-bottom: 10px;"><B>Phase 1 Results </B> </div><div style="margin-bottom: 10px;">In the phI part of the 
study Zoptarelin doxorubicin was administered as an intravenous infusion 
every 21 days until progression or unacceptable toxicity in cohorts of 3 or 6 
patients until the maximum tolerated dose was reached.<wbr> The MTD of zoptarelin 
doxorubicin in this cohort was 210 mg/<wbr>m2, which was lower than that seen in a 
Phase I study conducted in women with endometrial or ovarian cancers.<wbr> The dose 
limiting toxicity was persistent neutropenia.<wbr> </div><div style="margin-bottom: 10px;">Three patients had a prostate-specific antigen (“PSA”) response with an 
additional 10 patients maintaining PSA stable disease.<wbr> Of the 10 patients 
evaluable by RECIST criteria, 9 achieved stable disease.<wbr> </div><div style="margin-bottom: 10px;"><B>Current 
Phase 2 Portion of the Study</B> </div><div style="margin-bottom: 10px;">This is a single-arm Simon Optimum 
design Phase 2 study of zoptarelin doxorubicin involving up to 37 patients with 
pre treated castration-and taxane-resistant prostate cancer, using the dose 
selected (210 mg/<wbr>m2) in the Phase 1 portion.<wbr> The primary endpoint is to evaluate 
the clinical benefit of zoptarelin doxorubicin for these patients.<wbr> Clinical 
benefit will be defined as non-progression at 12 weeks with no dose limiting 
toxicity or other toxicity requiring termination of treatment.<wbr> </div><div style="margin-bottom: 10px;">More 
information on the current Phase 2 portion of the trial is available at this 
link: <A href="https://clinicaltrials.gov/show/NCT01240629" target="_blank">NCT01240629</A>.<wbr> </div><div style="margin-bottom: 10px;">In addition to the ongoing 
investigator-driven Phase 2 trial in prostate cancer, the Company is currently 
conducting a ZoptEC (<B>Zopt</B>arelin doxorubicin in <B>E</B>ndometrial 
<B>C</B>ancer) Phase 3 trial in women with advanced, recurrent or metastatic 
endometrial cancer.<wbr> </div><div style="margin-bottom: 10px;">Aeterna Zentaris owns the worldwide rights (ex.<wbr> China, Hong Kong and Macau) 
to this compound.<wbr><BR> </div><div>Source: <a href="http://www.aezsinc.com" class="defaultlink" title="www.aezsinc.com">aezsinc.com</a> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10188">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-12-30T16:18:54+01:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>Confirmation From Different Sources That Medy-Tox's New Plant Will Not Be Fully  Operational Before Q3 2015 [headline, comp:MediTox, comp:Allergan]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7869</link>
<description>Confirmation From Different Sources That Medy-Tox's New Plant Will Not Be Fully  Operational Before Q3 2015 [headline, comp:MediTox, comp:Allergan]</description><category>headline</category><category>comp:MediTox</category><category>comp:Allergan</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7869</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7869">Confirmation From Different Sources That Medy-Tox's New Plant Will Not Be Fully  Operational Before Q3 2015</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20141231&edate=20140901&cat=comp%3aAllergan"><font color="#e95e0b">:Neurology:comp:Allergan</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20141231&edate=20140901&cat=comp%3aMediTox"><font color="#e95e0b">:Neurology:comp:MediTox</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20141231&edate=20140901&cat=headline"><font color="#e95e0b">:Neurology:headline</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7869">Neurology7869</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 30 December 2014 | 14:41</font><br><br><div style="margin-bottom: 10px;">Comment: Both external primary research and a recent note from Nomura has 
confirmed delays with compliance of MedyTox's new Osong plant with US CGMP.<wbr> 
The consequence of this is a delay in clinical testing by Allergan of MedyTox's 
new liquid toxin formulation, trials with which are now unlikely to 
start until Q3/<wbr>Q4 2015.<wbr> Additionally, surveys of Innotox usage in Korea are 
highlighted by Nomura and raise some interesting points about 
acceptance, price tolerance and increased duration of efficacy 
vs.<wbr> Medytoxin.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>External Intelligence Findings</STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>The FDA terminated its September 2014 inspection of the Osong facility 
  concluding that the Company was not ready to be inspected.<wbr> It recceommended to 
  postpone the inspections until 2015</LI>
<LI>Medytox immediately informed the the EMA that it was not ready to be 
  inspected and cancelled the scheduled October visit</LI>
<LI>The main issues in terms of "inspection readinees" appear to be within the 
  fill finish section of the plant.<wbr></LI>
<LI>The incumbent Director of Quality Assurance who was hired in May 2014 was 
  dismissed in Q3 2014.<wbr> Medytox is now advertising internationally for a new 
  Director of QA</LI>
<LI>The FDA are planning to return to South Korea and visit the Osong facility 
  in either May or June 2015</LI>
<LI>Medytox have requested the EMA to inspect the Osong facility in July or 
  August 2015.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG>Analyst comments in recent Nomura report </STRONG> </div><div style="margin-bottom: 10px;">The new factory has 10x greater capacity relative to the previous production 
site.<wbr> The company started building the factory in June 2012 and plans to 
complete the construction in 2015 (delayed by one year due to the requirements 
to comply with stricter factory standards and construction delays).<wbr> The new 
factory is designed to meet regulatory requirements such as CGMP and EU GMP.<wbr> The 
company anticipates the completion of the factory building in December 2014 and 
government inspection and approval for production to take about six months.<wbr> From 
3Q15, the company expects to start rolling out products from the new 
factory.<wbr> </div><div style="margin-bottom: 10px;">Meanwhile, Medytox has confirmed to analysts its intention to start 
development of Medytoxin for the Chinese market in 2015.<wbr> Analysts estimate the 
current market to be worth around W70bn most of which is controlled by BTXA 
(Lanzhou)  and Botox.<wbr> They envisage a potential partnership in the future 
to strengthen the company's foothold in this market.<wbr>  Market entry of 
the toxin will follow a number of years after Medytox's filler products 
(scheduled for 2015).<wbr> Medytox plans to launch a full filler line-up in 2015 
in Korea, augmenting the Neruamis family with  four new products after 
KFDA approval.<wbr> </div><div style="margin-bottom: 10px;">Finally, Nomura has been conducting several surveys since Innotox was 
launched in Korea to determine acceptance of the product and price 
differentials.<wbr> Its findings have been very positive and led it to increase its 
estimate of potential conversion of Botox to Innotox in overseas markets from 
30% to 50%.<wbr> An estimate that appears optimistic given it takes no account of 
which indications will be pursued or the profitability difference for Allergan 
of an orginal vs, in-licensed product.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7869/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><FONT face="Verdana" size="2">In the clinics utilising Innotox and surveyed, 
which are still small in number because of supply issues, reportely more than 
half of all customers request the new new liquid "Botox" despite its 30% higher 
price as the new "Botox" is perceived as a premium product for being more 
effective and also safer</FONT><FONT face="Times New Roman" size="3">.<wbr></FONT> </div><div style="margin-bottom: 10px;"><FONT face="Times New Roman" size="3">Sources: </FONT> </div><div><OL><LI><FONT face="Times New Roman" size="3">External Intelligence Report 19th 
  December 2014</FONT></LI>
<LI><FONT face="Times New Roman" size="3">Nomura report 17th December, 
  </FONT></LI>
<LI><FONT face="Times New Roman" size="3">Yuanta Securities report December 
  29th</FONT></LI>
</OL> </div><!-- Comment details --><a name="neurology7869attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7869/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(105,2 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7869">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-12-30T14:41:27+01:00</dc:date><dc:creator>jac89886</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7869/1/ScreenCapture1.jpg" length="107715" type="image/jpeg"/></item><item>
<title>Key Dynamics In The Alzheimer Market Of Importance To Both Actavis &amp; Merz [comp:Merz, class:BotulinumToxins]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7868</link>
<description>Key Dynamics In The Alzheimer Market Of Importance To Both Actavis &amp; Merz [comp:Merz, class:BotulinumToxins]</description><category>comp:Merz</category><category>class:BotulinumToxins</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7868</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7868">Key Dynamics In The Alzheimer Market Of Importance To Both Actavis & Merz</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20141231&edate=20140901&cat=class%3aBotulinumToxins"><font color="#e95e0b">:Neurology:class:BotulinumToxins</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20141231&edate=20140901&cat=comp%3aMerz"><font color="#e95e0b">:Neurology:comp:Merz</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7868">Neurology7868</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 29 December 2014 | 17:29</font><br><br><div style="margin-bottom: 10px;">Comment: Actavis pre-Christmas received US FDA approval for its new 
combination therapy to treat Alzheimer's disease.<wbr> Namzaric combines, in one 
capsule, two complementary therapeutic agents which are often 
co-prescribed.<wbr> Approximately 70% of Namenda XR (memantine) patients 
are also on AChEI therapy such as Pfizer's donepezil.<wbr> The financial impact 
of ongoing developments such as this on Merz, the original licensor of 
memantine, whilst not disclosed numerically were acknowledged in a recent 
financial statment by the company.<wbr> Its strategy in terms of aesthetics and 
neurotoxins was also mentiioned in context.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Commercialisation rights</STRONG> </div><div style="margin-bottom: 10px;">Actavis expects to launch the drug in two dosage strengths in the US in 
Q215.<wbr> </div><div style="margin-bottom: 10px;">Co-developer Adamis will retain commercialisation rights outside of the 
US.<wbr> </div><div style="margin-bottom: 10px;">Namzaric is the first FDA-approved FDC product to emerge from Adamas' 
platform for modifying the pharmacokinetic profiles of approved drugs </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7868/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7868/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG>The Financial Impact For Merz</STRONG> </div><div style="margin-bottom: 10px;">The potential financial impact of these developments on Merz, the 
original licensor of memantine is hard to determine but overall can be expected 
to be negative.<wbr> In a relatively recent strategic statement from the group 
Philip Burchard CEO noted the following:- </div><div style="margin-bottom: 10px;">"With patent expiration reducing revenue from the former blockbuster 
Memantine, Merz has been continually and significantly expanding its Aesthetics 
business.<wbr> “In this area, we intend to bring out a steady stream of innovative 
products so that we can offer our customers a complete portfolio,” stressed Mr.<wbr> 
Burchard.<wbr> </div><div style="margin-bottom: 10px;">The statement also noted that in its core Neurotoxins business, the company’s 
primary focus is on the treatment of neurologically induced movement disorders 
and that Merz plans to strengthen its status as a specialist provider and 
tap into the potential of its botulinum toxin by developing new 
indications.<wbr> </div><div>Source: Adamas &amp; Merz Company Websites </div><!-- Comment details --><a name="neurology7868attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7868/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(162,1 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7868/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(177,3 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7868">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-12-29T17:29:04+01:00</dc:date><dc:creator>jac89886</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7868/1/ScreenCapture1.jpg" length="166025" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7868/2/ScreenCapture2.jpg" length="181577" type="image/jpeg"/></item><item>
<title>OncoGenex Releases PhII Bladder Cancer Data With Apatorsen [dis:Bladder]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology10186</link>
<description>OncoGenex Releases PhII Bladder Cancer Data With Apatorsen [dis:Bladder]</description><category>dis:Bladder</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology10186</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10186">OncoGenex Releases PhII Bladder Cancer Data With Apatorsen</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=dis%3aBladder"><font color="#e95e0b">:Oncology:dis:Bladder</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10186">Oncology10186</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 29 December 2014 | 16:07</font><br><br><div style="margin-bottom: 10px;">Comment: Just before Christmas, OncoGenex released phII data from its Borealis-1 trial evaluating its heat-shock protein (Hsp27) drug apatorsen in the treatment of metastatic bladder cancer.<wbr> The study demonstrated that a 600mg dose of the drug added to SOC resulted in a 50% reduction in risk of death in patients with lower performance scores.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Key Findings</STRONG> </div><div style="margin-bottom: 10px;">Overall trial results indicated that the addition of 600mg apatorsen to standard of care chemotherapy showed a 14 percent reduction in risk of death (overall survival hazard ratio (HR) = 0.<wbr>86) and a 17 percent reduction in progressive disease and death (progression-free survival HR = 0.<wbr>83) when compared to chemotherapy alone.<wbr> </div><div style="margin-bottom: 10px;">Over one-third of the patients in the trial had lower performance status, as defined by a Karnofsky score of 80 percent or less.<wbr> These patients derived the greatest benefit from 600mg apatorsen in combination with chemotherapy, resulting in a 50 percent reduction in risk of death (overall survival HR = 0.<wbr>50) compared to chemotherapy alone.<wbr> </div><div style="margin-bottom: 10px;">Less benefit was observed in the 1000mg apatorsen arm due to increased adverse events leading to a higher rate of discontinuation of both apatorsen and chemotherapy.<wbr> </div><div style="margin-bottom: 10px;">Apatorsen 600mg was well tolerated in combination with chemotherapy.<wbr> </div><div style="margin-bottom: 10px;">Data highlighting how the magnitude of Hsp27 knockdown correleated with patient outcomes has yet to be disclosed.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Study Design</STRONG> </div><div style="margin-bottom: 10px;">Borealis-1 enrolled approximately 180 patients with documented metastatic or locally inoperable transitional cell carcinoma (TCC) of the urinary tract who had not previously received chemotherapy for metastatic disease and were not candidates for potentially curative surgery or radiotherapy.<wbr> Patients were randomized to receive standard chemotherapy (gemcitabine/<wbr>cisplatin) in combination with apatorsen at two dose levels (600 mg and 1000 mg) or gemcitabine/<wbr>cisplatin plus placebo.<wbr> </div><div style="margin-bottom: 10px;">Patients received up to six cycles of weekly intravenous therapy.<wbr> Following the discontinuation of a minimum of four cycles of chemotherapy, all patients received weekly apatorsen or placebo maintenance therapy until disease progression or other reason for withdrawal from protocol treatment.<wbr> </div><div style="margin-bottom: 10px;">The primary endpoint of the trial was overall survival.<wbr> Secondary endpoints measured disease response as well as safety of each of the two doses of apatorsen.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Commenting on these results Scott Cormack, President &amp; CEO stated:-</STRONG> </div><div style="margin-bottom: 10px;">"These data provide greater insight into the most appropriate dose and patient type for further evaluation of apatorsen in first-line metastatic bladder cancer.<wbr> Based on these results, as well as those seen in our superficial bladder cancer trial of patients who received single-agent apatorsen intravesically, we are encouraged by the potential of this compound across the paradigm of bladder cancer treatment.<wbr>" </div><div>Source: <a href="http://www" class="defaultlink" title="http://www">www</a>.<wbr> oncogenex.<wbr>com </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10186">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-12-29T16:07:55+01:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>Astellas and Cytokinetics Extend 2013 Agreement to Focus on Spinal Muscular Atrophy (SMA)</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7866</link>
<description>Astellas and Cytokinetics Extend 2013 Agreement to Focus on Spinal Muscular Atrophy (SMA)</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7866</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7866">Astellas and Cytokinetics Extend 2013 Agreement to Focus on Spinal Muscular Atrophy (SMA)</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7866">Neurology7866</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 24 December 2014 | 14:07</font><br><br><div style="margin-bottom: 10px;">Comment: Companies will advance development of CK-2127107 (tirasemtiv), a fast skeletal troponin activator, into Ph2 for SMA, and potentially other neuromuscular indications.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">CK-2127107 (tirasemtiv) Ongoing Development Program</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7866/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">About the 2013 Agreement</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7866/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">See <A href="http://www.genengnews.com/gen-news-highlights/astellas-cytokinetics-partner-on-skeletal-muscle-activator-r-d/81248524/">http:/<wbr>/<wbr>www.<wbr>genengnews.<wbr>com/<wbr>gen-news-highlights/<wbr>astellas-cytokinetics-partner-on-skeletal-muscle-activator-r-d/<wbr>81248524/<wbr></A> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Most Recent Reference in Traction</FONT></STRONG> </div><div><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7116" class="defaultlink">Neurology7116: Cytokinetics Reports Positive Results From Its Neuromuscular Program With Tirasemtiv In ALS</a> </div><!-- Comment details --><a name="neurology7866attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7866/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(89,6 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7866/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(113,6 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7866">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-12-24T14:07:03+01:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7866/1/ScreenCapture1.jpg" length="91786" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7866/2/ScreenCapture2.jpg" length="116280" type="image/jpeg"/></item><item>
<title>re: Astellas to Assess Enzalutamide +/- Leuprolide in Ph3 Registration Trial</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology10184</link>
<description>re: Astellas to Assess Enzalutamide +/- Leuprolide in Ph3 Registration Trial</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology10184</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10184">re: Astellas to Assess Enzalutamide +/<wbr>- Leuprolide in Ph3 Registration Trial</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10184">Oncology10184</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/1056">frv17817</a> | 24 December 2014 | 12:44</font><br><br><div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Astellas to Assess Enzalutamide +/<wbr>- Leuprolide in Ph3 Registration Trial</span>&nbsp;<font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=mkt%3aNorthAmerica"><font color="#e95e0b">:PharmaWorld:mkt:NorthAmerica</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=sub%3aClinicalTrial"><font color="#e95e0b">:PharmaWorld:sub:ClinicalTrial</font></a>]</font></font><br><span style="font-size: 12px;">Comment: The 3-arm study will assess enzalutamide+leuprolide, enzalutamide monotherapy, and placebo+leuprolide in approx.<wbr> 1860 patients with high-risk non metastatic prostate cancer progressing after radical prostatectomy or radiotherapy or both.<wbr> PE will measure metastasis-free survival (MFS).<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10177">...</a><br><font size="-1">Brigitte DESCHAMPS / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10177" class="commentpermalink">Oncology10177</a> / <span class="date">22 December 2014</span> /
<span class="time">18:06:40 o'clock CET</span>
</font></div><div style="margin-bottom: 10px;">Thank you Brigitte! Looks like a potentially paradigm changing trial.<wbr> Some of the below repeats original post as I copy/<wbr>pasted from my email to the team.<wbr> </div><div><UL><LI>A Phase 3, Randomized, Efficacy and Safety Study of Enzalutamide Plus Leuprolide, Enzalutamide Monotherapy, and Placebo Plus Leuprolide in Men With High-Risk Nonmetastatic Prostate Cancer Progressing After Definitive Therapy </LI>
<LI>Patients: Prostate cancer initially treated by radical prostatectomy or radiotherapy (including brachytherapy) or both, with curative intent </LI>
<LI>Duration 2014-2020 </LI>
<LI>N=1860 </LI>
<LI>Important aspects: 
<UL><LI>Pre-chemo </LI>
<LI>Includes an ezalutamide monotherapy arm, compared to a combo arm and a leuprolide mono arm (active control).<wbr> </LI>
<LI>Metastasis – free survival is primary endpoint with overall and PCa specific being secondary.<wbr> Interestingly time to castration resistance is also a specific secondary endpoint.<wbr> </LI>
<LI>Currently only recruiting in US </LI>
</UL></LI>
<LI>Commercial impact: 
<UL><LI>Immediate: In every participating center, market potential will decrease as Astellas will provide leuprolide (3m formulation) in 2 out of 3 treatment arms, for roughly 1200 patients globally.<wbr> </LI>
<LI>Future: May lead to registration and positioning of Xtandi vs LHRH and paradigm shift provided appropriate market access is obtained, requiring a substantial clinical benefit.<wbr> Time to castration is included as a potential additional differentiating endpoint.<wbr> Thinking ahead, companies may need to evaluate doing trials for current or future compounds in enzalutamide combo, not only in LHRH combo.<wbr> The trial looks like a bold move from Astellas as the outcome can either be very favorable or can limit enzalutamide’s pre-chemo potential substantially, but it would be very interesting to have more details on the planned statistical analysis and design (non-inferiority?).<wbr> </LI>
</UL></LI>
</UL> </div><!-- Comment details --><font size="-1">frv17817 / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10184" class="commentpermalink">Oncology10184</a> / <span class="date">24 December 2014</span> /
<span class="time">12:44:36 o'clock CET</span>
</font><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10184">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10177">View thread  Oncology10177: Astellas to Assess Enzalutamide +/<wbr>- Leuprolide in Ph3 Registration Trial</a>]]></content:encoded><dc:date>2014-12-24T12:44:36+01:00</dc:date><dc:creator>frv17817</dc:creator></item><item>
<title>*** Traction Publication Between Dec.25 to 26 *** [Alert]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld11052</link>
<description>*** Traction Publication Between Dec.25 to 26 *** [Alert]</description><category>Alert</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld11052</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20141231&edate=20140901&rec=11052">*** Traction Publication Between Dec.<wbr>25 to 26 ***</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=Alert"><font color="#e95e0b">:PharmaWorld:Alert</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld11052">PharmaWorld11052</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 24 December 2014 | 11:24</font><br><br><div><DIV style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px">Taking the opportunity to announce that Traction publication will not be active during those two days, w<FONT face="Calibri" size="3">e wish you a wonderful X-Mas break.<wbr></FONT></DIV> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20141231&edate=20140901&rec=11052">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-12-24T11:24:57+01:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>New Findings from a RCT of Mesalazine in IBS Published in Gut [dis:IBS]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2174</link>
<description>New Findings from a RCT of Mesalazine in IBS Published in Gut [dis:IBS]</description><comments>http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2174</comments><category>dis:IBS</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2174</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2174">New Findings from a RCT of Mesalazine in IBS Published in Gut</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20141231&edate=20140901&cat=dis%3aIBS"><font color="#e95e0b">:GastroEnterology:dis:IBS</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2174">GastroEnterology2174</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 24 December 2014 | 11:21</font><br><br><div style="margin-bottom: 10px;">Comment: This is the first large randomised controlled trial assessing the efficacy and safety of mesalazine in IBS.<wbr> Conclusion of a Ph3, multicenter, tertiary setting, randomized, double-blind, placebo controlled trial in 185 patients with Rome III confirmed IBS shows that mesalazine did not improve the percentage of patients with satisfactory relief of abdominal pain/<wbr>discomfort for at least half of the weeks of the treatment period.<wbr> However mesalazine significantly improved the percentage of patients with satisfactory relief of overall IBS symptoms if sustained responses were required (&gt;75% of treatment period).<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Publication</FONT></STRONG> </div><div style="margin-bottom: 10px;">Barbara G, et al.<wbr> <EM>Gut</EM> 2014;0:1–9.<wbr> doi:10.<wbr>1136/<wbr>gutjnl-2014-308188 - See @<a href="http://gut.bmj.com/content/early/2014/12/22/gutjnl-2014-308188.full.pdf+html" class="defaultlink" title="http://gut.bmj.com/content/early/2014/12/22/gutjnl-2014-308188.full.pdf+html">gut.bmj.com/<wbr>conte&hellip;</a> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Results</FONT></STRONG> </div><div style="margin-bottom: 10px;">n=185 patients with IBS were enrolled from 21 centres (Italy).<wbr> </div><div style="margin-bottom: 10px;"><U>For the primary endpoint</U>, the responder patients were 68.<wbr>6% in the mesalazine group versus 67.<wbr>4% in the placebo group (p=0.<wbr>870; 95% CI −12.<wbr>8 to 15.<wbr>1).<wbr> In explorative analyses, with the 75% rule or &gt;75% rule, the percentage of responders was greater in the mesalazine group with a difference over placebo of 11.<wbr>6% ( p=0.<wbr>115; 95% CI −2.<wbr>7% to 26.<wbr>0%) and 5.<wbr>9% (p=0.<wbr>404; 95% CI −7.<wbr>8% to 19.<wbr>4%), respectively, although these differences were not significant.<wbr> </div><div style="margin-bottom: 10px;"><U>For the key secondary endpoint</U>, overall symptoms improved in the mesalazine group and reached a significant difference of 15.<wbr>1% versus placebo (p=0.<wbr>032; 95% CI 1.<wbr>5% to 28.<wbr>7%) with the &gt;75% rule </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">About the trial</FONT></STRONG> </div><div style="margin-bottom: 10px;"><U>The primary endpoint</U> was assessed using a binary scale based on the patient answers to the following weekly question: “Did you have satisfactory relief of your abdominal discomfort or pain during the last week?” The patients were classified as responders if they reported an affirmative answer in at least 50% of weeks over a 3-month treatment period (50% rule).<wbr> Explorative analyses were also performed.<wbr> Patients were classified as responders if they reported a percentage of affirmative answers for at least 75% or &gt;75% of the treatment time (75% rule and &gt;75% rule, respectively).<wbr> The 75% rule was preplanned, as documented in the SAP, while the &gt;75% rule was post hoc and performed with the intention of minimising placebo effect and optimising drug–placebo differences.<wbr> </div><div style="margin-bottom: 10px;"><U>The key secondary endpoint</U> was assessed using a binary scale based on the patient answers to the following weekly question: “Did you have satisfactory relief of your overall IBS symptoms during the last week?” The patients were classified as responders if they reported an affirmative answer in at least 50% of weeks over a 3-month treatment period.<wbr> Explorative analyses were also performed.<wbr> Patients were classified as responders if they reported a percentage of affirmative answers for at least 75% or &gt;75% of the treatment time (75% rule and &gt;75% rule, respectively).<wbr> </div><div style="margin-bottom: 10px;">Ref <A href="https://clinicaltrials.gov/ct2/show/NCT00626288?term=NCT00626288&amp;rank=1">NCT00626288</A> </div><div style="margin-bottom: 10px;">Sponsor: SOFAR S.<wbr>p.<wbr>A.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">SOFAR S.<wbr>p.<wbr>A.<wbr> in Brief</FONT></STRONG> </div><div style="margin-bottom: 10px;">Italian company, producing pharmaceutical products, dietary supplements (<STRONG>containing probiotic <STRONG>Lactobacillus casei <img src="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2174/2/dg.png?user-agent=rss"></STRONG></STRONG>) and medical devices.<wbr> </div><div style="margin-bottom: 10px;">The Enterolactis wide range of products are provided in sachets; drinkable bottles, and capsules (see @ <A href="http://www.sofarfarm.it/en/prodotti/area-gastrointestinale/">http:/<wbr>/<wbr>www.<wbr>sofarfarm.<wbr>it/<wbr>en/<wbr>prodotti/<wbr>area-gastrointestinale/<wbr></A>) </div><div style="margin-bottom: 10px;">Recently SOFAR published results on its probiotic strain Lactobacillus casei, which conclusion shows that: </div><div style="margin-bottom: 10px;">- &gt;&gt; the intake of <EM>L.<wbr> paracasei</EM> DG increased the <EM>Blautia</EM>:<EM>Coprococcus</EM> ratio, which, according to the literature, can potentially confer a health benefit on the host.<wbr> The probiotic impact on the microbiota and on short-chain fatty acids, however, seems to strictly depend on the initial characteristics of the intestinal microbial ecosystem.<wbr> In particular, fecal butyrate concentrations could represent an important biomarker for identifying subjects who may benefit from probiotic treatment.<wbr>.<wbr> </div><div><UL><LI>Effect of probiotics on the intestinal microbiota of healthy adults (<A href="http://www.isrctn.com/ISRCTN56945491?q=ISRCTN56945491&amp;filters=&amp;sort=&amp;offset=1&amp;totalResults=1&amp;page=1&amp;pageSize=10&amp;searchType=basic-search">http:/<wbr>/<wbr>www.<wbr>isrctn.<wbr>com/<wbr>ISRCTN56945491?q=ISRCTN56945491&amp;filters=&amp;sort=&amp;offset=1&amp;totalResults=1&amp;page=1&amp;pageSize=10&amp;searchType=basic-search</A>)</LI>
</UL> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="GastroEnterology2179c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">The rationale of the study is the link between inflammation and IBS, the inflammation increasing mucosal permeability.<wbr> Mesalazine is a very potent anti-inflammatory drug acting specifically on the gut and previous POC on its action in IBS have been previously published.<wbr> </div><div style="margin-bottom: 10px;">The primary end point of the study can be discussed : it has been assessed using a binary scale based on the patient answers to the following weekly question: “Did you have satisfactory relief of your abdominal discomfort or pain during the last week?” The patients were classified as responders if they reported an affirmative answer in at least 50% of weeks over a 3-month treatment period (50% rule).<wbr> With this approach, responders were 69% versus 67 in placebo (NS)… </div><div style="margin-bottom: 10px;">If the response was define as an affirmative answer in at least 75% of weeks over a 3-month treatment period (75% rule, as it was exploratory assessed), then the responders were 43% versus 31% in placebo (NS).<wbr> </div><div style="margin-bottom: 10px;">One of the possible explanations for the lack of effect of mesalazine using the 50% cut-off value could be the high placebo response seen in this trial, which likely masked drug efficacy.<wbr> </div><div style="margin-bottom: 10px;">Another limitation of the study is related to the small sample size (136, adjusted to 178) .<wbr> The sample size calculation may have been limited by lack of data from previous placebo-controlled trials.<wbr> </div><div style="margin-bottom: 10px;">Data with 75% rule, indicating that mesalazine tend to a positive effects but did not reach a statistical significance, suggest a type 2 error.<wbr> The &gt;75% rule is a more restrictive outcome measure and selects a smaller percentage of responders.<wbr> These data indicate that a subgroup of patients with IBS tend to respond better to mesalazine than placebo.<wbr> These more restrictive outcome measures have been previously used in the tegaserod and linaclotide trials and help to distinguish the ‘sustained’ responders to the active treatment from those responding to placebo.<wbr> </div><div>In conclusion, we can highlight <STRONG>the authors’ conclusion : « <EM>the results of the present study indicate that a number of patients show a sustained therapy response and benefits from mesalazine therapy.<wbr> Larger studies assessing the clinical predictors and confirming the beneficial effects of mesalazine are now required</EM></STRONG>.<wbr> » </div><font size="-1">Helene Mathiex-Fortunet / <a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2179" class="commentpermalink">GastroEnterology2179</a> / <span class="date">05 January 2015</span> /
<span class="time">17:43:08 o'clock CET</span>
</font></div><a name="gastroenterology2174attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2174/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(30,9 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2174/2/dg.png">dg.png</a>&nbsp;&nbsp;(3 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2174">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-12-24T11:21:17+01:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2174/1/ScreenCapture1.jpg" length="31680" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2174/2/dg.png" length="3109" type="image/x-png"/></item><item>
<title>Menarini's Tachykinin NK2 Receptor Antagonist in Registration Trial for IBS-D in Asia [dis:IBS, dis:Diarrhoea, :PharmaWorld:sub:ClinicalTrial]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2172</link>
<description>Menarini's Tachykinin NK2 Receptor Antagonist in Registration Trial for IBS-D in Asia [dis:IBS, dis:Diarrhoea, :PharmaWorld:sub:ClinicalTrial]</description><category>dis:IBS</category><category>dis:Diarrhoea</category><category>sub:ClinicalTrial</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2172</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2172">Menarini's Tachykinin NK2 Receptor Antagonist in Registration Trial for IBS-D in Asia</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20141231&edate=20140901&cat=dis%3aDiarrhoea"><font color="#e95e0b">:GastroEnterology:dis:Diarrhoea</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20141231&edate=20140901&cat=dis%3aIBS"><font color="#e95e0b">:GastroEnterology:dis:IBS</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=sub%3aClinicalTrial"><font color="#e95e0b">:PharmaWorld:sub:ClinicalTrial</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2172">GastroEnterology2172</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 23 December 2014 | 17:06</font><br><br><div style="margin-bottom: 10px;">Comment: The Ph3 trial aims at the evaluation of the efficacy and safety of oral ibodutant 10 mg once daily as compared to placebo in women with IBS-D over a 12-week treatment period.<wbr> PE will measure weekly response for abdominal pain intensity AND stool consistency over 12 weeks of treatment in at least 50% of the weeks of treatment.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Trial Details</FONT></STRONG> </div><div style="margin-bottom: 10px;">Ref: NCT02320318 </div><div style="margin-bottom: 10px;">Recruitment: approx 500 </div><div style="margin-bottom: 10px;">Timelines: completion Dec 2016 /<wbr> April 2017 </div><div style="margin-bottom: 10px;">Location: Hong-Kong; Korea; Singapore; Taiwan </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">About the Drug</FONT></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>Ibodutant </STRONG>is a small, non-peptide molecule, rationally derived from Menarini peptide antagonists through an extensive process of chemical modifications guided by computer-assisted drug design.<wbr> </div><div style="margin-bottom: 10px;">Ibodutant showed excellent tolerability in toxicological studies, after either intravenous or oral administration.<wbr> Ibodutant has successfully completed <STRONG>Phase I</STRONG> and <STRONG>Phase II</STRONG> clinical studies.<wbr> </div><div style="margin-bottom: 10px;">Pharmacokinetics, safety and tolerability of ibodutant were evaluated in Phase I studies after single IV and single and 7-day repeated oral administration in healthy subjects, respectively.<wbr> </div><div style="margin-bottom: 10px;">A first <STRONG>Phase II</STRONG> study (IRIS: Ibodutant for the Relief of Irritable bowel Syndrome) has evaluated efficacy and safety of the oral treatment with ibodutant versus placebo in over 500 male and female IBS patients in 9 European countries.<wbr> The study showed a consistent trend in terms of satisfactory relief of IBS symptoms, favouring ibodutant vs placebo in the diarrhoea-predominant IBS subtype, especially when patients with abdominal pain of greater than mild intensity are considered.<wbr> </div><div>In July 2012 the second <STRONG>Phase II</STRONG> clinical study IRIS-2 was completed, demonstrating an excellent efficacy of the drug in the treatment of the symptoms of IBS-D together wit a remarkable safety profile.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2172">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-12-23T17:06:53+01:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Conditional Approval Issued for Xtandi by Poland's AOTM [comp:Astellas, :PharmaWorld:sub:Pricing]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology10183</link>
<description>Conditional Approval Issued for Xtandi by Poland's AOTM [comp:Astellas, :PharmaWorld:sub:Pricing]</description><category>comp:Astellas</category><category>sub:Pricing</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology10183</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10183">Conditional Approval Issued for Xtandi by Poland's AOTM</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=comp%3aAstellas"><font color="#e95e0b">:Oncology:comp:Astellas</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=sub%3aPricing"><font color="#e95e0b">:PharmaWorld:sub:Pricing</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10183">Oncology10183</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 23 December 2014 | 12:50</font><br><br><div style="margin-bottom: 10px;">Comment: The transparency board of the Agency for Health Technology Assessment in Poland (Agencja Oceny Technologii Medycznych; AOTM) assessed the application for reimbursement for Xtandi (enzalutamide) in the treatment of metastatic castration-resistant prostate cancer, in men whose disease progresses after or during docetaxel treatment, at its 41st session of 2014, on 24 November.<wbr> The board recommended the reimbursement of the drug in the aforementioned indication on the condition that it be integrated into the existing drug programme for that indication, and that it be placed within a price reference group with the existing medicine in use on that programme – Zytiga (abiraterone acetate; Johnson &amp; Johnson, US).<wbr> Additionally, it made the recommendation conditional on a reduction in the cost of treatment with Xtandi, at least down to the level of the cost of treatment with Zytiga.<wbr> The board also described the proposed risk-sharing agreement put forward by the producer to be "insufficient".<wbr> The director of the AOTM, Wojciech Matusewicz, backed the board’s recommendations.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Significance</FONT></STRONG> </div><div style="margin-bottom: 10px;">Astellas proposed a new drug programme for Xtandi and the prospect of being placed within the existing programme, together with Zytiga, as well as in the same reference group with that drug, would obviously be a less favourable outcome for the company.<wbr> It remains to be seen whether the producer will be willing to reduce the cost of treatment with Xtandi to the extent anticipated by the Polish authorities in order to place the drug within the reimbursement system; this will inevitably entail offering a greater discount than the one that has been offered already.<wbr> </div><div>Source: IHS </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10183">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-12-23T12:50:21+01:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>NCPE Has Rejected Bayer's Xofigo for Reimbursement [comp:BayerSchering, dis:Prostate, :PharmaWorld:sub:Pricing]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology10182</link>
<description>NCPE Has Rejected Bayer's Xofigo for Reimbursement [comp:BayerSchering, dis:Prostate, :PharmaWorld:sub:Pricing]</description><category>comp:BayerSchering</category><category>dis:Prostate</category><category>sub:Pricing</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology10182</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10182">NCPE Has Rejected Bayer's Xofigo for Reimbursement</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=comp%3aBayerSchering"><font color="#e95e0b">:Oncology:comp:BayerSchering</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=sub%3aPricing"><font color="#e95e0b">:PharmaWorld:sub:Pricing</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10182">Oncology10182</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 23 December 2014 | 12:47</font><br><br><div style="margin-bottom: 10px;">Comment: Ireland's National Centre for Pharmacoeconomics (NCPE) has issued a guidance not recommending Bayer's Xofigo (radium-223) for castration-resistant prostate cancer with symptomatic bone metastases and no known visceral metastases.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Significance</FONT></STRONG> </div><div style="margin-bottom: 10px;">The pharmacoeconomic evaluation presented by the company included two comparators: best supportive care for which the evidence was based on data from Phase III clinical trial, ALSYMPCA; and with abiraterone acetate 1,000mg once-daily in combination with prednisolone 10mg/<wbr>day, for which the evidence came from an indirect comparison using information on abiraterone's efficacy from Phase III COU-AA-301 trial.<wbr> </div><div style="margin-bottom: 10px;">The cost-utility analysis included a comparison with best supportive care, and with abiraterone, post docetaxel population only.<wbr> </div><div style="margin-bottom: 10px;">When compared to best supportive care the incremental cost-effectiveness ratio (ICER) was estimated at EUR 79,948 (USD 97,737), with Xofigo not found to be cost effective at the EUR45,000 per quality-adjusted life year (QALY) threshold.<wbr> </div><div style="margin-bottom: 10px;">In comparison to <I>abiraterone</I>, following amendments by the review group, the ICER was estimated at EUR80,361 per QALY.<wbr> The gross budget impact of Xofigo was estimated at around EUR740,000 for 2014 increasing to EUR1,776,000 in 2018.<wbr> </div><div style="margin-bottom: 10px;">The NCPE therefore concluded that Xofigo's cost effectiveness was not demonstrated.<wbr> </div><div>Source: IHS </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10182">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-12-23T12:47:05+01:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>G-BA Announces Astellas' Betmiga Shows No Additional Benefit [dis:Prostate, :PharmaWorld:mkt:Germany, :PharmaWorld:sub:Pricing]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology10181</link>
<description>G-BA Announces Astellas' Betmiga Shows No Additional Benefit [dis:Prostate, :PharmaWorld:mkt:Germany, :PharmaWorld:sub:Pricing]</description><category>dis:Prostate</category><category>mkt:Germany</category><category>sub:Pricing</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology10181</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10181">G-BA Announces Astellas' Betmiga Shows No Additional Benefit</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=mkt%3aGermany"><font color="#e95e0b">:PharmaWorld:mkt:Germany</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=sub%3aPricing"><font color="#e95e0b">:PharmaWorld:sub:Pricing</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10181">Oncology10181</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 23 December 2014 | 12:42</font><br><br><div style="margin-bottom: 10px;">Comment: Germany's Federal Joint Committee (Gemeisamer Bundesausschuss: G-BA) has given its final resolution on the early benefit assessment of Betmiga (mirabegron) in the symptomatic treatment of increased urinary frequency, urge incontinence, and imperative urinary urgency in adults with overactive bladder syndrome.<wbr> The G-BA reached the same conclusion as the German Institute for Quality and Efficiency in Healthcare (Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen: IQWiG), namely that the drug demonstrated no additional benefit against the appropriate comparator therapy.<wbr> The reasons given by the G-BA for its decision follow closely those provided by IQWiG.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Significance</FONT></STRONG> </div><div style="margin-bottom: 10px;">Betmiga was given a positive recommendation by the National Institute for Health and Care Excellence in the United Kingdom last year (see Oncologu8803), and was added to the reimbursement list in Sweden, among other countries.<wbr> </div><div style="margin-bottom: 10px;">The decision by the G-BA will be a blow to the producer, considering the importance of Germany as the largest European pharmaceutical market by some distance.<wbr> However, it has the option to put the product through the benefit assessment system again, and the fact that Betmiga is a first-in-class drug, it is likely to qualify for price negotiations despite not being judged to show an additional benefit.<wbr> </div><div>Source: IHS </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10181">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-12-23T12:42:21+01:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>re: Nuvilex Signed Research Agreement to Study Development of Cannabis-Based Cancer Treatments</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology10180</link>
<description>re: Nuvilex Signed Research Agreement to Study Development of Cannabis-Based Cancer Treatments</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology10180</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10180">re: Nuvilex Signed Research Agreement to Study Development of Cannabis-Based Cancer Treatments</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10180">Oncology10180</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 23 December 2014 | 11:19</font><br><br><div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Nuvilex Signed Research Agreement to Study Development of Cannabis-Based Cancer Treatments</span>&nbsp;<br><span style="font-size: 12px;">Comment: The goal of the research agreement signed with the U.<wbr> of Northern Colorado, is to develop a Cell-in-a-Box<SUP>(R)</SUP> /<wbr>cannabinoid combination that has anticancer effects coupled with low toxicity similar in concept to Nuvilex's pancreatic cancer treatment currently being prepared for Ph2b clinical trials that uses the Cell-in-a-Box<SUP>(R)</SUP> technology with low doses of the chemotherapeutic drug ifosfamide.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=9693">...</a><br><font size="-1">Brigitte DESCHAMPS / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9693" class="commentpermalink">Oncology9693</a> / <span class="date">09 May 2014</span> /
<span class="time">18:23:17 o'clock CEST</span>
</font></div><div style="margin-bottom: 10px;">FDA has granted Nuvilex orphan drug designation for its pancreatic cancer treatment.<wbr> Nuvilex's pancreatic cancer treatment combines Nuvilex's patented and proprietary cellulose-based encapsulation technology, known as Cell-in-a-Box<SUP>&reg;</SUP>, with the cancer prodrug ifosfamide and encapsulated live cells that convert the prodrug into its cancer-killing form.<wbr> These capsules are placed as close to the cancerous tumor as possible to enable the delivery of the highest levels of the cancer-killing drug at the source of the cancer.<wbr> </div><div style="margin-bottom: 10px;">Nuvilex is currently preparing for a Phase 2b clinical trial in advanced pancreatic cancer (the orphan indication) in Australia to gain regulatory approval from agencies like the FDA for Nuvilex's targeted chemotherapy of pancreatic cancer.<wbr> </div><div>Nuvilex's clinical trial is planned to commence in 2015.<wbr> </div><!-- Comment details --><font size="-1">Brigitte DESCHAMPS / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10180" class="commentpermalink">Oncology10180</a> / <span class="date">23 December 2014</span> /
<span class="time">11:19:31 o'clock CET</span>
</font><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10180">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9693">View thread  Oncology9693: Nuvilex Signed Research Agreement to Study Development of Cannabis-Based Cancer Treatments</a>]]></content:encoded><dc:date>2014-12-23T11:19:31+01:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Genomic Diagnosis &amp; Treatment For Cancer &amp; Rare Diseases Gathers Pace As The UK Initiates A Sizeable Genomic Project [sub:Biomarkers, sub:Diagnostic, headline]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology10178</link>
<description>Genomic Diagnosis &amp; Treatment For Cancer &amp; Rare Diseases Gathers Pace As The UK Initiates A Sizeable Genomic Project [sub:Biomarkers, sub:Diagnostic, headline]</description><category>sub:Biomarkers</category><category>sub:Diagnostic</category><category>headline</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology10178</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10178">Genomic Diagnosis & Treatment For Cancer & Rare Diseases Gathers Pace As The UK Initiates A Sizeable Genomic Project</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=headline"><font color="#e95e0b">:Oncology:headline</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=sub%3aBiomarkers"><font color="#e95e0b">:Oncology:sub:Biomarkers</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=sub%3aDiagnostic"><font color="#e95e0b">:Oncology:sub:Diagnostic</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10178">Oncology10178</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 23 December 2014 | 10:43</font><br><br><div style="margin-bottom: 10px;">Comment:  NHS England announced yesterday that eleven centres across 
the country will lead the way in delivering the 100,000 Genomes Project, a 
3-yr project launched by the UK Prime Minister earlier this year that has the 
potential to transform the future of healthcare .<wbr>
It is evisaged that he project could improve the prediction and 
prevention of disease, enable new and more precise diagnostic tests, and 
allow personalisation of drugs and other treatments to specific genetic variants 
in oncological or rare diseases.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Early Project Participation &amp; Plans For Next Wave</STRONG> </div><div style="margin-bottom: 10px;">The 11 designated Genomic Medicine Centres (GMCs) in the wave 1 selection 
process are based across the country, covering areas including Greater 
Manchester, the North West coast, Oxford, Birmingham and the West Midlands, 
Southampton, London, Cambridge and the East of England, Exeter and the South 
West Peninsula, and the North East.<wbr> Over the lifetime of the project NHS 
England’s ambition is to secure over 100 participating NHS trusts.<wbr> A further 
wave of GMCs will be procured to ensure that there is comprehensive coverage 
across the NHS in England.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Project Scale &amp; Timelines</STRONG> </div><div style="margin-bottom: 10px;">It is anticipated that around 75,000 people will be involved, which will 
include some patients with life threatening and debilitating disease.<wbr> 
Recruitment to the project will begin from 2nd February 2015.<wbr> </div><div style="margin-bottom: 10px;">After samples are collected, they will be sent securely to <STRONG>Illumina 
</STRONG>who have been procured by Genomics England to sequence the whole genome 
and to analyse it.<wbr> Results will be sent back to the NHS for validation and 
clinical action.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Some key perspectives highlighted</STRONG> in the press release 
relating to the "Project's" ambition and participation were as 
follows:- </div><div style="margin-bottom: 10px;"><STRONG>Professor Sir Bruce Keogh, NHS England’s National Medical 
Director</STRONG>, said<STRONG>: </STRONG>“This is an achievable ambition which 
positions Britain to unlock longstanding mysteries of disease on behalf of 
humankind.<wbr> <STRONG>Embracing genomics will position us at the forefront of 
science and make the NHS the most scientifically advanced healthcare system in 
the world.<wbr></STRONG> This is the start of a unique, exciting journey that will 
bring benefits for patients, for the NHS and for society at large.<wbr>” </div><div style="margin-bottom: 10px;"><STRONG>Professor Sue Hill, the Chief Scientific Officer for 
England</STRONG>, who chaired the team evaluating the various applicant GMCs 
said: “The NHS has risen to both the challenge and opportunity of delivering its 
contribution to the 100,000 whole genomes project in the most extraordinary and 
unparalleled way.<wbr> Locally in the NHS, there has been clearly demonstrated 
engagement and involvement of senior managers, clinical teams, clinical genetic 
and molecular pathology laboratories and critically patients and the public, all 
committed to using the science of whole genome sequencing to making a real and 
lasting difference for patient benefit.<wbr>” </div><div style="margin-bottom: 10px;"><STRONG>Life Sciences Minister George Freeman</STRONG> added: “Our 
understanding of genomics is transforming the landscape for disease diagnosis 
and medicines research.<wbr> We want to make the UK the best place in the world to 
design and discover 21st century medicines which is why we have invested in the 
100,000 Genomes Project.<wbr> We also want to ensure NHS patients benefit which is 
why we have now selected NHS hospitals to help us sequence genomes on an 
unprecedented scale and bring better treatments to people with cancers and rare 
diseases for generations to come.<wbr>” </div><div style="margin-bottom: 10px;"><STRONG>The first wave of 11 designated Genomic Medicine Centres are: 
</STRONG> </div><div style="margin-bottom: 10px;"><UL><LI><STRONG>East of England NHS GMC – designated for both cancer and rare 
  disease.<wbr> </STRONG>Led by Cambridge University Hospitals NHS Foundation 
  Trust.<wbr></LI>
<LI><STRONG>South London NHS GMC – designated for both cancer and rare 
  disease.<wbr> </STRONG>Led by Guy’s and St Thomas’ NHS Foundation Trust.<wbr></LI>
<LI><STRONG>North West Coast NHS GMC – designated for both cancer and rare 
  disease.<wbr> </STRONG>Led by Liverpool Women’s NHS Foundation Trust.<wbr></LI>
<LI><STRONG>Greater Manchester NHS GMC – designated for both cancer and rare 
  disease.<wbr> </STRONG>Led by Central Manchester University Hospitals NHS 
  Foundation Trust.<wbr></LI>
<LI><STRONG>University College London Partners NHS GMC – designated for both 
  cancer and rare disease.<wbr> </STRONG>Led by Great Ormond Street Hospital NHS 
  Foundation Trust.<wbr></LI>
<LI><STRONG>North East and North Cumbria NHS GMC – designated GMC for rare 
  disease only.<wbr> </STRONG>Led by The Newcastle upon Tyne Hospitals NHS Foundation 
  Trust.<wbr></LI>
<LI><STRONG>Oxford NHS GMC – designated for both cancer and rare disease.<wbr> 
  </STRONG>Led by Oxford University Hospitals Foundation Trust.<wbr></LI>
<LI><STRONG>South West Peninsula NHS GMC – designated for both cancer and rare 
  disease.<wbr> </STRONG>Led by Royal Devon &amp; Exeter NHS Foundation Trust.<wbr></LI>
<LI><STRONG>Wessex NHS GMC – designated for both cancer and rare disease.<wbr> 
  </STRONG>Led by University Hospital Southampton NHS Foundation Trust.<wbr></LI>
<LI><STRONG>Imperial College Health Partners NHS GMC – designated for both 
  cancer and rare disease.<wbr> </STRONG>Led by Imperial College Healthcare NHS 
  Trust.<wbr></LI>
<LI><STRONG>West Midlands NHS GMC – designated for both cancer and rare 
  disease.<wbr> </STRONG>Led by University Hospitals Birmingham NHS Foundation 
  Trust.<wbr></LI>
</UL> </div><div>Source: <A href="http://www.england.nhs.uk/2014/12/22/genomics-project/">http:/<wbr>/<wbr>www.<wbr>england.<wbr>nhs.<wbr>uk/<wbr>2014/<wbr>12/<wbr>22/<wbr>genomics-project/<wbr></A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10178">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-12-23T10:43:54+01:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>Radius Health Reports Compelling Vertebral Fracture Risk Reduction Data In The ACTIVE PhIII Trial [headline]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7895</link>
<description>Radius Health Reports Compelling Vertebral Fracture Risk Reduction Data In The ACTIVE PhIII Trial [headline]</description><category>headline</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7895</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20141231&edate=20140901&rec=7895">Radius Health Reports Compelling Vertebral Fracture Risk Reduction Data In The ACTIVE PhIII Trial</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20141231&edate=20140901&cat=headline"><font color="#e95e0b">:Endocrinology:headline</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7895">Endocrinology7895</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 22 December 2014 | 18:51</font><br><br><div style="margin-bottom: 10px;"><P class="pwrapper">Comment: Last night Radius announced that its rPTH1 drug abaloparatide met the primary endpoint of the phIII ACTIVE study, a randomised double-blind placebo-controlled study conducted in 2,463 patients.<wbr> It demonstrated a satistically significant, 83% reduction in the percentage of patients with incident vertebral fractures as compared to the placebo-treated group.<wbr> The rate observed with teriparatide (Lilly's Forteo) in the ACTIVE trial was 78%.<wbr> The robustness of the data should support registration in the 2H 2015.<wbr> Importantly, from a safety perspective the drug appears to offer advantages over Merck's odantacanib, which recently reported data at the ASBMR meeting showing an increased stroke risk with the product.<wbr></P> </div><div style="margin-bottom: 10px;"><P class="pwrapper"><STRONG>Top-line Secondary Endpoints</STRONG></P> </div><div style="margin-bottom: 10px;"><P class="pwrapper">On the secondary end-points as compared to placebo, abaloparatide subcutaneous achieved:-</P> </div><div style="margin-bottom: 10px;"><UL><LI>a significant fracture reduction rate of 43% in the adjudicated non-vertebral fracture subset of patients,
</LI>
<LI>a statistically significant reduction of 41% in the adjudicated clinical fracture group which includes both vertebral and non-vertebral fracture; and
</LI>
<LI>a statistically significant difference in the time to first incident non-vertebral fracture in both the adjudicated non-vertebral fracture and the clinical fracture subset of patients.<wbr>
</LI>
</UL> </div><div style="margin-bottom: 10px;"><P class="pwrapper"><STRONG>Top-Line Safety Findings</STRONG></P> </div><div style="margin-bottom: 10px;"><P class="pwrapper">Safety results were consistend with results in prior studies.<wbr> Among the most frequently reported AEs the folowing incidence rates were reported:</P> </div><div style="margin-bottom: 10px;"><UL><LI>back pain: placebo (10.<wbr>0%), abaloparatide (8.<wbr>6%), teriparatide (7.<wbr>2%)
</LI>
<LI>arthralgia: placebo (9.<wbr>8%), abaloparatide (8.<wbr>5%), teriparatide (8.<wbr>6%)
</LI>
<LI>upper respiratory infections: placebo (8.<wbr>9%), abaloparatide (9.<wbr>0%), teriparatide (9.<wbr>8%)
</LI>
<LI>hypercalciuria:placebo (8.<wbr>9%), abaloparatide (10.<wbr>9%), teriparatide (12.<wbr>5%)
</LI>
<LI>dizziness: placebo (6.<wbr>1%), aboloparatide (10.<wbr>0%), teriparatide (7.<wbr>3%)
</LI>
</UL> </div><div style="margin-bottom: 10px;"><P class="pwrapper"><STRONG>Commenting on the results Robert Ward President &amp; CEO of Radius stated</STRONG></P> </div><div style="margin-bottom: 10px;"><P class="pwrapper">"We expect to submit an NDA in the second half of 2015 and we're very encouraged by the consistency of our Phase III results with those from our two previously completed Phase II studies.<wbr>"</P> </div><div style="margin-bottom: 10px;"><P class="pwrapper">In its press release, Radius discloses the comparative analysis of abaloparatide subcutaneous versus placebo and teriparatide on a number of BMD secondary endpoints (see below).<wbr> Only arms that achieved statistatical significance are shown, the implication being given comments above that Forteo (teriparatide) may not have achieved statistical significance versus placebo in non-vertebral or clinical fractures.<wbr> However, it could be that Radius is just being cautious about comparative statements being made at this point in time.<wbr></P> </div><div style="margin-bottom: 10px;"><P class="pwrapper"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7895/1/ScreenCapture1.jpg?user-agent=rss"></P> </div><div style="margin-bottom: 10px;"><P class="pwrapper"><STRONG>Sales Analysis</STRONG></P> </div><div style="margin-bottom: 10px;"><P class="pwrapper">Canacord Genuity analysts who have been closely following developments in the osteoporosis market are forecasting total sales of abaloparatide of $882m by 2020 with $583m in the US and $293m ex US.<wbr> They have today raised their price target for Radius Health from $30 to $40 per share.<wbr></P> </div><div style="margin-bottom: 10px;"><P class="pwrapper"><STRONG>Other Development Progress</STRONG></P> </div><div><P class="pwrapper">Robert Ward was also pleased to report that the company has made significant progress towards the development of an optimized, short-wear-time transdermal patch for abaloparatide.<wbr> Together with 3M Drug Delivery Systems.<wbr> It evaluated a number of new transdermal patch configurations with the goal of selecting a configuration that may be capable of demonstrating therapeutic comparability to abaloparatide subcutaneous injection.<wbr></P> </div><!-- Comment details --><a name="endocrinology7895attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7895/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(34,2 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20141231&edate=20140901&rec=7895">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-12-22T18:51:11+01:00</dc:date><dc:creator>jac89886</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7895/1/ScreenCapture1.jpg" length="34988" type="image/jpeg"/></item><item>
<title>Astellas to Assess Enzalutamide +/- Leuprolide in Ph3 Registration Trial [dis:Prostate, :PharmaWorld:sub:ClinicalTrial, :PharmaWorld:mkt:NorthAmerica]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology10177</link>
<description>Astellas to Assess Enzalutamide +/- Leuprolide in Ph3 Registration Trial [dis:Prostate, :PharmaWorld:sub:ClinicalTrial, :PharmaWorld:mkt:NorthAmerica]</description><comments>http://ci.beaufour-ipsen.com/traction/permalink/Oncology10177</comments><category>dis:Prostate</category><category>sub:ClinicalTrial</category><category>mkt:NorthAmerica</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology10177</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10177">Astellas to Assess Enzalutamide +/<wbr>- Leuprolide in Ph3 Registration Trial</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=mkt%3aNorthAmerica"><font color="#e95e0b">:PharmaWorld:mkt:NorthAmerica</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=sub%3aClinicalTrial"><font color="#e95e0b">:PharmaWorld:sub:ClinicalTrial</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10177">Oncology10177</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 22 December 2014 | 18:06</font><br><br><div style="margin-bottom: 10px;">Comment: The 3-arm study will assess enzalutamide+leuprolide, enzalutamide monotherapy, and placebo+leuprolide in approx.<wbr> 1860 patients with high-risk non metastatic prostate cancer progressing after radical prostatectomy or radiotherapy or both.<wbr> PE will measure metastasis-free survival (MFS).<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Tirla Details</FONT></STRONG> </div><div style="margin-bottom: 10px;">Reference: <A href="https://clinicaltrials.gov/ct2/show/NCT02319837?no_unk=Y&amp;phase=012&amp;fund=2&amp;rcv_s=11%2F22%2F2014&amp;rank=21">NCT02319837</A> </div><div style="margin-bottom: 10px;">Timeline: Completion planned in December 2020 </div><div style="margin-bottom: 10px;">Inclusion criteria: </div><div style="margin-bottom: 10px;"><UL><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Histologically or cytologically confirmed adenocarcinoma of the prostate at initial biopsy, without neuroendocrine differentiation, signet cell, or small cell features;</LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Prostate cancer initially treated by radical prostatectomy or radiotherapy (including brachytherapy) or both, with curative intent;</LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">PSA doubling time ≤ 9 months;</LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Screening PSA ≥ 2.<wbr>0 ng/<wbr>mL for patients who had radical prostatectomy as primary treatment for prostate cancer or ≥ 5.<wbr>0 ng/<wbr>mL and greater than or equal to the nadir + 2 ng/<wbr>mL for patients who had radiotherapy as primary treatment for prostate cancer;</LI>
</UL> </div><div><UL><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Serum testosterone ≥ 150 ng/<wbr>dL (5.<wbr>2 nmol/<wbr>L).<wbr></LI>
</UL> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Oncology10184c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">Thank you Brigitte! Looks like a potentially paradigm changing trial.<wbr> Some of the below repeats original post as I copy/<wbr>pasted from my email to the team.<wbr> </div><div><UL><LI>A Phase 3, Randomized, Efficacy and Safety Study of Enzalutamide Plus Leuprolide, Enzalutamide Monotherapy, and Placebo Plus Leuprolide in Men With High-Risk Nonmetastatic Prostate Cancer Progressing After Definitive Therapy </LI>
<LI>Patients: Prostate cancer initially treated by radical prostatectomy or radiotherapy (including brachytherapy) or both, with curative intent </LI>
<LI>Duration 2014-2020 </LI>
<LI>N=1860 </LI>
<LI>Important aspects: 
<UL><LI>Pre-chemo </LI>
<LI>Includes an ezalutamide monotherapy arm, compared to a combo arm and a leuprolide mono arm (active control).<wbr> </LI>
<LI>Metastasis – free survival is primary endpoint with overall and PCa specific being secondary.<wbr> Interestingly time to castration resistance is also a specific secondary endpoint.<wbr> </LI>
<LI>Currently only recruiting in US </LI>
</UL></LI>
<LI>Commercial impact: 
<UL><LI>Immediate: In every participating center, market potential will decrease as Astellas will provide leuprolide (3m formulation) in 2 out of 3 treatment arms, for roughly 1200 patients globally.<wbr> </LI>
<LI>Future: May lead to registration and positioning of Xtandi vs LHRH and paradigm shift provided appropriate market access is obtained, requiring a substantial clinical benefit.<wbr> Time to castration is included as a potential additional differentiating endpoint.<wbr> Thinking ahead, companies may need to evaluate doing trials for current or future compounds in enzalutamide combo, not only in LHRH combo.<wbr> The trial looks like a bold move from Astellas as the outcome can either be very favorable or can limit enzalutamide’s pre-chemo potential substantially, but it would be very interesting to have more details on the planned statistical analysis and design (non-inferiority?).<wbr> </LI>
</UL></LI>
</UL> </div><font size="-1">frv17817 / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10184" class="commentpermalink">Oncology10184</a> / <span class="date">24 December 2014</span> /
<span class="time">12:44:36 o'clock CET</span>
</font></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10177">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-12-22T18:06:40+01:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Bifodan A/S to Develop a New Technology for Microencapsulation of Probiotic [sub:Probiotics]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2169</link>
<description>Bifodan A/S to Develop a New Technology for Microencapsulation of Probiotic [sub:Probiotics]</description><category>sub:Probiotics</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2169</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2169">Bifodan A/<wbr>S to Develop a New Technology for Microencapsulation of Probiotic</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20141231&edate=20140901&cat=sub%3aProbiotics"><font color="#e95e0b">:GastroEnterology:sub:Probiotics</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2169">GastroEnterology2169</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 22 December 2014 | 17:35</font><br><br><div style="margin-bottom: 10px;">Comment: Endorsed and co-funded by Innovation Fund Denmark, Bifodan A/<wbr>S will be joined by U.<wbr> of Copenhagen and Danish Technological Institute to deliver probiotics alive for targeted release in the intestinal tract.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Rationale</FONT></STRONG> </div><div style="margin-bottom: 10px;">Many probiotic strains are sensitive to gastric acid and some may not survive the passage through the stomach in adequate numbers to have positive impact.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Microencapsulation Studies</FONT></STRONG> </div><div style="margin-bottom: 10px;">One study found that encapsulating probiotic bacteria in alginate-coated gelatin microspheres could protect against the stomach and upper intestine (see @ <A href="http://www.ncbi.nlm.nih.gov/pubmed/20659775">http:/<wbr>/<wbr>www.<wbr>ncbi.<wbr>nlm.<wbr>nih.<wbr>gov/<wbr>pubmed/<wbr>20659775</A>) </div><div style="margin-bottom: 10px;">Another demonstrated that coating probiotic bacterial strains with alginate, then applying an extra coating of palm oil and poly-L-lysine could significantly improve the viability of the bacteria (see @ <A href="http://www.ncbi.nlm.nih.gov/pubmed/19323758">http:/<wbr>/<wbr>www.<wbr>ncbi.<wbr>nlm.<wbr>nih.<wbr>gov/<wbr>pubmed/<wbr>19323758</A>) </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">About Bifodan A/<wbr>S</FONT></STRONG> </div><div style="margin-bottom: 10px;">Develops and manufactures probiotic turnkey solutions for private label customers worldwide.<wbr> </div><div style="margin-bottom: 10px;">Based North of Copenhagen, Denmark, </div><div style="margin-bottom: 10px;">Bifodan delivers clinically documented, high quality probiotic products, manufactured at its GMP approved production facility.<wbr> </div><div style="margin-bottom: 10px;">Founded by the first Danish dairy to isolate the lactobacillus acidophilus bacteria in 1938.<wbr> Bifodan has been dedicated to research and development of probiotic nutritional supplements since 1992.<wbr> </div><div>Source: Bifodan </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2169">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-12-22T17:35:44+01:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Janssen Returns Rights of IBD Drug to Galapagos</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2167</link>
<description>Janssen Returns Rights of IBD Drug to Galapagos</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2167</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2167">Janssen Returns Rights of IBD Drug to Galapagos</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2167">GastroEnterology2167</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 22 December 2014 | 14:37</font><br><br><div style="margin-bottom: 10px;">Comment: The experimental inflammatory bowel disease drug GLPG1205 and the backup compound have been returned to Galapagos.<wbr> <SPAN style="FONT-FAMILY: arial,helvetica,sans-serif; COLOR: rgb(51,51,51)"><FONT face="Verdana">The drug has demonstrated target engagement, a good safety profile, and favorable drug properties in a Ph1 study.<wbr> </FONT></SPAN>Further details on the transaction were not disclosed.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">About the Original Agreement</FONT></STRONG> </div><div style="margin-bottom: 10px;">Janssen and Galapagos entered into an agreement in 2007 which granted Janssen the option to global commercial licenses for certain Galapagos inflammatory disease programs, with Galapagos responsible for conducting Ph1 and Ph2a studies with GLPG1205 (<A href="http://www.glpg.com/files/8013/2186/0286/2007_26.pdf">http:/<wbr>/<wbr>www.<wbr>glpg.<wbr>com/<wbr>files/<wbr>8013/<wbr>2186/<wbr>0286/<wbr>2007_26.<wbr>pdf</A>).<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Completed Ph1 Trial</FONT></STRONG> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-FAMILY: arial,helvetica,sans-serif; COLOR: rgb(51,51,51)"><FONT color="#000000" face="Verdana">Trial design: </FONT><A href="https://clinicaltrials.gov/ct2/results?term=GLPG1205&amp;Search=Search"><FONT face="Verdana">https:/<wbr>/<wbr>clinicaltrials.<wbr>gov/<wbr>ct2/<wbr>results?term=GLPG1205&amp;Search=Search</FONT></A><FONT color="#000000" face="Verdana">.<wbr></FONT></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-FAMILY: arial,helvetica,sans-serif; COLOR: rgb(51,51,51)"><FONT face="Verdana">The aim of this study was to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of oral single and multiple ascending doses of GLPG1205.<wbr> The randomized, double-blind, placebo-controlled, single center study was conducted in 40 healthy volunteers in Belgium.<wbr> In the first part of the study, single ascending doses were evaluated.<wbr> In the second part, the new compound was administered daily for 14 days.<wbr> </FONT></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="COLOR: rgb(51,51,51)"><FONT face="Verdana"><SPAN style="FONT-FAMILY: arial,helvetica,sans-serif; COLOR: rgb(51,51,51)"><FONT face="Verdana">Findings:</FONT> <SPAN style="FONT-FAMILY: arial,helvetica,sans-serif; COLOR: rgb(51,51,51)"><FONT face="Verdana">GLPG1205 has demonstrated target engagement, a good safety profile, and favorable drug properties in a Phase 1 study.<wbr> </FONT></SPAN></SPAN>The data shown in Phase 1 encourage Galapagos to progress GLPG1205 into a Phase 2A study in Inflammatory Bowel Disease (IBD).<wbr></FONT></SPAN> </div><div>Source: Galapagos </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2167">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-12-22T14:37:41+01:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Synthetic Biologics's C.difficile Drug Sets to Enter Ph2 Testing in Q1:15</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2166</link>
<description>Synthetic Biologics's C.difficile Drug Sets to Enter Ph2 Testing in Q1:15</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2166</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2166">Synthetic Biologics's C.<wbr>difficile Drug Sets to Enter Ph2 Testing in Q1:15</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2166">GastroEnterology2166</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 22 December 2014 | 14:12</font><br><br><div style="margin-bottom: 10px;">Comment: The company has announced positive topline safety and tolerability results from an ongoing Ph1a of SYN-004, an oral beta-lactamase enzyme for the prevention of <I>Clostridium difficile (C.<wbr> difficile) </I>infection, antibiotic-associated diarrhea and secondary antibiotic-resistant infections in patients receiving intravenous (IV) beta-lactam antibiotic therapy.<wbr> Enrollment of the Ph1b will start before end of 2014.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">About the Findings</FONT></STRONG> </div><div style="margin-bottom: 10px;">Since December 2<SUP>nd</SUP>, the randomized double-blind, placebo-controlled Ph1a clinical trial conducted at Clinical Pharmacology of Miami, has enrolled 24 healthy volunteers in 3 cohorts of 8 patients each.<wbr> </div><div style="margin-bottom: 10px;">A total of 18 volunteers have been administered one dose of SYN-004 at increasing dose levels by cohort, and six volunteers received placebo.<wbr> </div><div style="margin-bottom: 10px;">No clinically significant or relevant adverse events have been reported to date.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Gastro Pipeline</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2166/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2166/2/ScreenCapture2.jpg?user-agent=rss"> </div><div>Source: Synthetic Biologcis </div><!-- Comment details --><a name="gastroenterology2166attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2166/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(15,2 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2166/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(25,9 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2166">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-12-22T14:12:57+01:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2166/1/ScreenCapture1.jpg" length="15612" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2166/2/ScreenCapture2.jpg" length="26474" type="image/jpeg"/></item><item>
<title>AZ's Olaparib Receives Approval Based On FDA's Accelerated Approval Programme For Ovarian Cancer</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology10176</link>
<description>AZ's Olaparib Receives Approval Based On FDA's Accelerated Approval Programme For Ovarian Cancer</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology10176</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10176">AZ's Olaparib Receives Approval Based On FDA's Accelerated Approval Programme For Ovarian Cancer</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10176">Oncology10176</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 22 December 2014 | 13:15</font><br><br><div style="margin-bottom: 10px;">Comment: Astra Zeneca has received approval for its PARP inhibitor LYNPARZA™ 
(olaparib) capsules (400mg twice daily).<wbr> It is the first PARP 
inhibitor to be approved for patients with deleterious or suspected deleterious 
germline BRCA-mutated (gBRCAm) advanced ovarian cancer, who have been treated 
with three or more prior lines of chemotherapy.<wbr> </div><div style="margin-bottom: 10px;">Olaparib has been approved under the FDA’s Accelerated Approval programme, 
based on existing objective response rate and duration of response data.<wbr> 
Continued approval for this indication is contingent upon verification of 
clinical benefit in ongoing confirmatory Phase III trials.<wbr> Its approval has also 
been contingent on the used of the BRACA gene being detected by an FDA 
approved companion diagnostic test, BRACAnalysis CDx™.<wbr> </div><div style="margin-bottom: 10px;">Commenting on this development Dr.<wbr> Briggs Morrison, Executive Vice President, 
Global Medicines Development and Chief Medical Officer at AstraZeneca, is 
quoted as saying “LYNPARZA is an excellent example of how advances in the 
understanding of cancer biology can be used to develop the next generation of 
targeted medicines.<wbr>" </div><div style="margin-bottom: 10px;"><STRONG>Basis For Approval </STRONG> </div><div style="margin-bottom: 10px;">AstraZeneca filed a US regulatory submission for olaparib in February 2014, 
based on data from a Phase II maintenance study<SUP>1</SUP> of olaparib compared 
to placebo in platinum-sensitive relapsed high grade serous ovarian cancer 
patients.<wbr> Following the FDA Oncologic Drugs Advisory Committee recommendation on 
25 June 2014 and in response to an FDA request for additional data, AstraZeneca 
submitted a major amendment to the olaparib New Drug Application on 24 July 
2014.<wbr> The FDA approval is therefore based on efficacy data from a single-arm, 
open-label, Phase II study<SUP>2</SUP> of olaparib in patients with deleterious 
or suspected deleterious germline BRCA-mutated.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Key Efficacy&amp; Safety Findings</STRONG> </div><div style="margin-bottom: 10px;">The efficacy of olaparib is based on analysis of 137 patients with 
measurable, germline BRCA mutated advanced ovarian cancer treated with three or 
more prior lines of chemotherapy.<wbr> </div><div style="margin-bottom: 10px;">The trial results demonstrated an overall response rate of 34% (95% 
Confidence Interval: 26%, 42%).<wbr> The median response duration was 7.<wbr>9 months (95% 
Confidence Interval: 5.<wbr>6, 9.<wbr>6 months).<wbr> </div><div style="margin-bottom: 10px;">The most common adverse events associated with olaparib monotherapy to date 
have been generally mild to moderate and have included nausea, vomiting, fatigue 
and anaemia.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>What Is Required To Gain Full Approval</STRONG> </div><div style="margin-bottom: 10px;">A full review of data from either of two ongoing studies under the SOLO Phase 
III clinical programme will be required for the accelerated approval of olaparib 
in BRCA-mutated advanced ovarian cancer to be converted to a full approval: 
SOLO2 is evaluating olaparib compared to placebo as a maintenance therapy and 
SOLO3 is evaluating olaparib compared to standard chemotherapy for relapsed 
disease.<wbr> Data from the SOLO2 study is expected in 2015 and data from SOLO3 is 
expected in 2019.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Other Indications</STRONG> </div><div style="margin-bottom: 10px;">In addition to ovarian cancer, AstraZeneca is investigating the 
potential of olaparib in multiple tumour types, with Phase III studies in 
adjuvant and metastatic BRCA-mutated breast cancers, BRCA-mutated pancreatic 
cancer and second line gastric cancer underway and a phII study underway in 
mCRPC.<wbr> </div><div>Source: <A href="http://www.astrazeneca.com">www.<wbr>astrazeneca.<wbr>com</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10176">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-12-22T13:15:26+01:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>Korean LG Lifesciences Sets on Taking Over the Markets in China and Japan [mkt:Japan, mkt:China]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld11051</link>
<description>Korean LG Lifesciences Sets on Taking Over the Markets in China and Japan [mkt:Japan, mkt:China]</description><category>mkt:Japan</category><category>mkt:China</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld11051</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20141231&edate=20140901&rec=11051">Korean LG Lifesciences Sets on Taking Over the Markets in China and Japan</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=mkt%3aChina"><font color="#e95e0b">:PharmaWorld:mkt:China</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=mkt%3aJapan"><font color="#e95e0b">:PharmaWorld:mkt:Japan</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld11051">PharmaWorld11051</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 22 December 2014 | 11:09</font><br><br><div style="margin-bottom: 10px;">Comment: LG Lifesicences recently signed an exclusive agreement with Weijian pharma group obtaining exclusive rights to sell its ovulation induction medication-Follitrope in China.<wbr> Two months ago, the company inked a contract with Mochida to co-develop and commercialize its Humira Biosimilar in Japan.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">LG Strategy</FONT></STRONG> </div><div style="margin-bottom: 10px;">The company aims to penetrate developing countries by various type of partnerships.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">About Weijian</FONT></STRONG> </div><div style="margin-bottom: 10px;">HQ: Hong-Kong </div><div style="margin-bottom: 10px;">Focus: oncology, hematology, neurology, gastroenterology, and genitourinary systems </div><div style="margin-bottom: 10px;">Sales Network: network covers all regions of China, which includes over 100 Grade III Class A hospitals and thousands of medical institutions.<wbr> Long-term partnerships with cancer, hematology, radiotherapy, gastroenterology, urology, and IVF fertility centers and departments.<wbr> </div><div style="margin-bottom: 10px;">Products: see @ <A href="http://www.wtpharma.com/en/?page_id=212">http:/<wbr>/<wbr>www.<wbr>wtpharma.<wbr>com/<wbr>en/<wbr>?page_id=212</A> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">About Mochida</FONT></STRONG> </div><div style="margin-bottom: 10px;">HQ: Tokyo </div><div style="margin-bottom: 10px;">Focus: cardiovascular medicine, obstetrics and gynecology, dermatology, emergency medicine and psychiatry </div><div style="margin-bottom: 10px;">Products: see @ <A href="http://www.mochida.co.jp/english/business/mainproducts.html">http:/<wbr>/<wbr>www.<wbr>mochida.<wbr>co.<wbr>jp/<wbr>english/<wbr>business/<wbr>mainproducts.<wbr>html</A> </div><div style="margin-bottom: 10px;"><U>Pipeline</U> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/11051/1/ScreenCapture1.jpg?user-agent=rss"> </div><div>Source: LG Lifesciences; Mochida </div><!-- Comment details --><a name="pharmaworld11051attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/11051/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(85,7 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20141231&edate=20140901&rec=11051">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-12-22T11:09:07+01:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/11051/1/ScreenCapture1.jpg" length="87741" type="image/jpeg"/></item><item>
<title>Development Progress In Post-Herpectic Neuralgia with Pfizer's Lyrica and Allergan's Senrebotase [comp:Allergan]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7865</link>
<description>Development Progress In Post-Herpectic Neuralgia with Pfizer's Lyrica and Allergan's Senrebotase [comp:Allergan]</description><category>comp:Allergan</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7865</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7865">Development Progress In Post-Herpectic Neuralgia with Pfizer's Lyrica and Allergan's Senrebotase</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20141231&edate=20140901&cat=comp%3aAllergan"><font color="#e95e0b">:Neurology:comp:Allergan</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7865">Neurology7865</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 19 December 2014 | 18:30</font><br><br><div style="margin-bottom: 10px;">Comment: It was of interest to note Pfizer's positive top-line results from a 
phIII trial in patients with post herpetic neuralgia pain released yesterday and 
to compare and contrast its development status with that of Allergan's 
ongoing phII trial with senrebotase.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>The Pfizer Study </STRONG> </div><div style="margin-bottom: 10px;">The study demonstrated that pregabalin CR resulted in a statistically 
significant positive effect compared to placebo in the primary endpoint, time to 
loss of therapeutic response in pain reduction.<wbr> </div><div style="margin-bottom: 10px;">The study is final one of three phIII trials undertaken to establish the 
potential use of pregabalin as a once-a-day therapy.<wbr> Two out of the three 
studies has now met its primary endpoint the other positive study having been 
undertaken in patients with fibromyalgia.<wbr> </div><div style="margin-bottom: 10px;"><B>About the Pregabalin Study</B> </div><div style="margin-bottom: 10px;">A total of 796 subjects were enrolled in the single blind phase of the study 
from 116 sites in 17 countries.<wbr> Of the 796 subjectss 418 (51.<wbr>8%) completed the 
single-clind phase had a &gt;50% pain response and were then randomised into a 
double-blind phase.<wbr>The primary endpoint, defined as the time to LTR during the 
double-blind phase (LTR; &lt;30% pain response relative to the baseline mean 
pain or withdrawal due to lack of efficacy or adverse events), occurred in 29 of 
208 (13.<wbr>9%) patients in the pregabalin group as compared with 63 of 205 (30.<wbr>7%) 
subjects in the placebo group.<wbr> The difference between the treatments was 
statistically significant.<wbr> </div><div style="margin-bottom: 10px;">Pregabalin CR was well tolerated and the safety profile was consistent with 
the known profile for pregabalin (immediate release) in PHN patients.<wbr> The most 
common adverse events with pregabalin CR were dizziness, somnolence, peripheral 
edema and weight increase.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Allergan's PhII study NCT01678924</STRONG> </div><div style="margin-bottom: 10px;">Allergan's study has been ongoing since January 2013 and has a primary 
completion of September 2015.<wbr> </div><div style="margin-bottom: 10px;">The orginal patient enrollment target was 150 but this was expanded to 270 in 
March 2014 as the decision was taken to evaluate a further 3rd dose 
cohort.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Key Endpoint (12 week assessment period)</STRONG> </div><div style="margin-bottom: 10px;"><DIV class="body3">Primary Outcome Measures: 
<UL style="MARGIN-BOTTOM: 1ex; MARGIN-TOP: 1ex"><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Change 
  from Baseline in Average Pain Intensity Score 
  </LI>
</UL></DIV> </div><div style="margin-bottom: 10px;"><DIV class="body3">Secondary Outcome Measures: </DIV> </div><div style="margin-bottom: 10px;"><DIV class="body3">
<UL style="MARGIN-BOTTOM: 1ex; MARGIN-TOP: 1ex"><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Percentage of Average Pain 
  Intensity Score Responders 
  </LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Change from Baseline in Maximal 
  Area of Spontaneous Pain 
  </LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Change from Baseline in Area of Allodynia  
  </LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Change 
  from Baseline in Evoked Pain Score in the Area of 
  Allodynia  </LI>
</UL></DIV> </div><div><P class="color-bullet" style="MARGIN-TOP: 0.7ex">This 
large phII study is being undertaken in the US, Austria, Germany and Poland 
in patients who have had postherpetic neuralgia for at least 9 months and have 
not been exposed to any type of botulinum toxin.<wbr></P> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7865">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-12-19T18:30:59+01:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>Carfilzomib  to Enter Ph2 in the US for Advanced Neuroendocrine Cancers [:PharmaWorld:sub:ClinicalTrial, :PharmaWorld:mkt:NorthAmerica]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7893</link>
<description>Carfilzomib  to Enter Ph2 in the US for Advanced Neuroendocrine Cancers [:PharmaWorld:sub:ClinicalTrial, :PharmaWorld:mkt:NorthAmerica]</description><category>sub:ClinicalTrial</category><category>mkt:NorthAmerica</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7893</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20141231&edate=20140901&rec=7893">Carfilzomib  to Enter Ph2 in the US for Advanced Neuroendocrine Cancers</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=mkt%3aNorthAmerica"><font color="#e95e0b">:PharmaWorld:mkt:NorthAmerica</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=sub%3aClinicalTrial"><font color="#e95e0b">:PharmaWorld:sub:ClinicalTrial</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7893">Endocrinology7893</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 19 December 2014 | 17:43</font><br><br><div style="margin-bottom: 10px;">Comment: Clinicaltrials.<wbr>gov is listing a new study which objective is to determine if the drug is safe and effective in patients with advanced neuroendocrine tumors.<wbr> PE will measure ORR.<wbr> The drug was launched in the US (2012) as Kyprolis® for the treatment of multiple myeloma.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">About the Drug</FONT></STRONG> </div><div style="margin-bottom: 10px;">Irreversible proteasome inhibitor with a favorable safety profile that has been studied in a variety of hematologic and solid tumors.<wbr> </div><div style="margin-bottom: 10px;">ONYX (Amgen subsidiary)Carfilzomib received accelerated approval from the U.<wbr>S.<wbr> FDA in 2012, based on a favorable response rate, for the treatment of patients with multiple myeloma who received at least two prior therapies, and demonstrated disease progression within 60 days of completing the last therapy.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Study Details</FONT></STRONG> </div><div style="margin-bottom: 10px;">ID: NCT02318784 </div><div style="margin-bottom: 10px;">Location: USA </div><div style="margin-bottom: 10px;">Recruitment: approx 62 </div><div style="margin-bottom: 10px;"><UL><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Adults with biopsy-proven advanced, unresectable or metastatic, well-to-moderately differentiated (or low grade) neuroendocrine carcinoma, including typical carcinoid, pancreatic islet cell and other well-to-moderately differentiated neuroendocrine carcinomas.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Measurable disease per Response Evaluation Criteria in Solid Tumors RECIST v 1.<wbr>1 criteria.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Patients currently receiving or previously treated with single agent sandostatin LAR® are eligible.<wbr> However, this is not a mandatory criterion to be included in the study.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Adequate hematologic, renal, and hepatic function.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Predicted life expectancy &gt; 12 weeks.<wbr></LI>
</UL> </div><div>Timelines: study planned to start in March 2015, and complete March 2017 /<wbr> Dec 2017 </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20141231&edate=20140901&rec=7893">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-12-19T17:43:31+01:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Halozyme's Pancreatic Drug Received EU ODD</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7892</link>
<description>Halozyme's Pancreatic Drug Received EU ODD</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7892</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20141231&edate=20140901&rec=7892">Halozyme's Pancreatic Drug Received EU ODD</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7892">Endocrinology7892</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 19 December 2014 | 15:58</font><br><br><div style="margin-bottom: 10px;">Comment: Halozyme is currently conducting a Ph2 study on the treatment of metastatic pancreatic cancer with PEGPH20 in combination with gemcitabine and nab-paclitaxel (ABRAXANE<SUP>®</SUP>).<wbr> Last June, FDA removed the clinical hold on patient enrollment permitting the study to resume under a revised protocol.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">US Orphan Drug Status</FONT></STRONG> </div><div style="margin-bottom: 10px;">In <CHRON>October 2014</CHRON>, the Company disclosed that the FDA granted Orphan Drug designation for PEGPH20 for the treatment of pancreatic cancer.<wbr> </div><div style="margin-bottom: 10px;"><B>About PEGPH20</B> </div><div style="margin-bottom: 10px;">PEGPH20 is an investigational PEGylated form of Halozyme's proprietary recombinant human hyaluronidase under development for the systemic treatment of tumors that accumulate hyaluronan </div><div><EM>Source: Halozyme</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20141231&edate=20140901&rec=7892">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-12-19T15:58:32+01:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Synergy Pharm Has Initiated First Ph3 of Plecanatide for IBS-C [dis:Constipation, dis:IBD, :PharmaWorld:sub:ClinicalTrial, :PharmaWorld:mkt:NorthAmerica]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2165</link>
<description>Synergy Pharm Has Initiated First Ph3 of Plecanatide for IBS-C [dis:Constipation, dis:IBD, :PharmaWorld:sub:ClinicalTrial, :PharmaWorld:mkt:NorthAmerica]</description><category>dis:Constipation</category><category>dis:IBD</category><category>sub:ClinicalTrial</category><category>mkt:NorthAmerica</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2165</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2165">Synergy Pharm Has Initiated First Ph3 of Plecanatide for IBS-C</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20141231&edate=20140901&cat=dis%3aConstipation"><font color="#e95e0b">:GastroEnterology:dis:Constipation</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20141231&edate=20140901&cat=dis%3aIBD"><font color="#e95e0b">:GastroEnterology:dis:IBD</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=mkt%3aNorthAmerica"><font color="#e95e0b">:PharmaWorld:mkt:NorthAmerica</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=sub%3aClinicalTrial"><font color="#e95e0b">:PharmaWorld:sub:ClinicalTrial</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2165">GastroEnterology2165</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 19 December 2014 | 15:28</font><br><br><div style="margin-bottom: 10px;">Comment: The primary efficacy endpoint for this trial is the percentage of patients who are Overall Responders during the 12 week treatment period.<wbr> Synergy plans to initiate the second pivotal ph3 in he first half of 2015.<wbr> The company has two ongoing pivotal ph3 trials evaluating 3mg and 6mg doses of plecanatide for chronic idiopathic constipation (CIC), which are scheduled to report topline data in 2Q and 3Q 2015.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Study Details</FONT></STRONG> </div><div style="margin-bottom: 10px;">Design: randomized, 12-week, double-blind, placebo-controlled </div><div style="margin-bottom: 10px;">Location: USA </div><div style="margin-bottom: 10px;">Recruitment: approx 1050 adult patients with IBS-C </div><div style="margin-bottom: 10px;">PE: percentage of patients who are Overall Responders during the 12 week treatment period </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Ph2b Results</FONT></STRONG> </div><div style="margin-bottom: 10px;">In the Ph2b trial, plecanatide showed statistically significant impact on various key efficacy measures, including change from baseline in complete spontaneous bowel movements (CSBMs), improvement in abdominal pain intensity, stool consistency, and overall responder and abdominal pain responder percentages.<wbr> </div><div>The Ph2b data also showed that the safety profile of plecanatide appears to be favorable and competitive with that of linaclotide </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2165">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-12-19T15:28:29+01:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Xofigo Is Likely To Get A Postive NICE Guidance For Post-Docetaxel Setting [dis:Prostate, :PharmaWorld:mkt:UK]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology10175</link>
<description>Xofigo Is Likely To Get A Postive NICE Guidance For Post-Docetaxel Setting [dis:Prostate, :PharmaWorld:mkt:UK]</description><category>dis:Prostate</category><category>mkt:UK</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology10175</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10175">Xofigo Is Likely To Get A Postive NICE Guidance For Post-Docetaxel Setting</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=mkt%3aUK"><font color="#e95e0b">:PharmaWorld:mkt:UK</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10175">Oncology10175</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/994">Jenny Wu</a> | 19 December 2014 | 14:29</font><br><br><div style="margin-bottom: 10px;">Comment: Earlier in March, Xofigo was rejected my NICE as it is too costly and its incremental cost-effectiveness ration was outside value for money boundaries (~&pound;57K per QALY gained).<wbr> However, now its Expert Review Group has concluded that Xofigo is likely to be a cost effective option for patients pre-treated with docetaxel.<wbr> Xofigo is likely to become the third drug that has got green light from NICE in Post-Docetaxel setting.<wbr> </div><div style="margin-bottom: 10px;"><P style="margin: 0px; font-family: Helvetica;">The National Institute for Health and Care Excellence has published draft guideline&rsquo;s endorsing the drug as an option to treat adults with hormone-relapsed prostate cancer, symptomatic bone metastases and no known visceral metastases.<wbr> But this only extends to patients who have already been treated with docetaxel, and the recommendation is contingent upon on Bayer providing the drug with a confidential discount agreed in a patient access scheme.<wbr> Xofigo is a radio-pharmaceutical agent designed to directly deliver alpha radiation to bone metastases without affecting normal bone marrow.<wbr> Bayer estimates the average cost for a six-month course with the drug (administered intravenously every four weeks) to be around &pound;24,240.<wbr></P> </div><div><P style="margin: 0px; font-family: Helvetica;">Source: <a href="http://www.nice.org.uk/guidance/indevelopment/gid-tag345/consultation" class="defaultlink">NICE Prostate cancer (hormone relapsed, bone metastases) - radium-223 dichloride [ID576]</a> 12 December</P> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10175">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-12-19T14:29:48+01:00</dc:date><dc:creator>jew60237</dc:creator></item><item>
<title>Inovio's Active Immunotherapy Has Entered Human Trial</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology10174</link>
<description>Inovio's Active Immunotherapy Has Entered Human Trial</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology10174</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10174">Inovio's Active Immunotherapy Has Entered Human Trial</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10174">Oncology10174</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 19 December 2014 | 13:44</font><br><br><div style="margin-bottom: 10px;">Comment: Inovio has initiated a Ph1 trial of its hTERT DNA immunotherapy (INO-1400) alone or in combination with IL-12 immune activator (INO-9012) in adults with breast, lung, or pancreatic cancer at high risk of relapse after surgery and other cancer treatments.<wbr> Ultimate goal of the study will assess the risk of relapse.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/10174/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">About the Study</FONT></STRONG> </div><div style="margin-bottom: 10px;"><U>Design</U>: open label, dose escalation study in subjects with breast, lung, or pancreatic cancer at high risk of relapse after surgery and other treatments including chemotherapy and radiation.<wbr> </div><div style="margin-bottom: 10px;"><U>Recruitment</U>: Approx 54 subjects </div><div style="margin-bottom: 10px;"><U>PE</U>: to evaluate the safety and tolerability of INO-1400 alone or in combination with INO-9012, delivered intramuscularly in subjects with high-risk breast, lung, or pancreatic cancer with no evidence of disease after surgery and adjuvant therapy.<wbr> </div><div style="margin-bottom: 10px;"><U>Intervention</U>: six treatment groups - to receive INO-1400 alone or in combination with INO-9012.<wbr> T </div><div style="margin-bottom: 10px;"><U>Location</U>: University of Pennsylvania's Abramson Cancer Center, which will fund all site-specific clinical study costs.<wbr> </div><div>Source: Firstwordpharma; Inovio </div><!-- Comment details --><a name="oncology10174attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10174/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(104 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10174">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-12-19T13:44:40+01:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10174/1/ScreenCapture1.jpg" length="106482" type="image/jpeg"/></item><item>
<title>A New Manufacture Site Appointed By Bayer In US To Primarily Supply Xofigo In US and Canada [dis:Prostate]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology10173</link>
<description>A New Manufacture Site Appointed By Bayer In US To Primarily Supply Xofigo In US and Canada [dis:Prostate]</description><category>dis:Prostate</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology10173</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10173">A New Manufacture Site Appointed By Bayer In US To Primarily Supply Xofigo In US and Canada</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10173">Oncology10173</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/994">Jenny Wu</a> | 19 December 2014 | 13:06</font><br><br><div style="margin-bottom: 10px;">Comment: Following the supply issue we heard about few months ago with Xofigo, Bayer announced the signing of a 15-year agreement with Cardinal Health in the US.<wbr> As part of the agreement, Cardinal Health is to build a state-of the art, 64,000 sq foot facility in Indianapolis, which will be dedicated exclusively to the manufacturing of Xofigo.<wbr> </div><div style="margin-bottom: 10px;">The manufacturing facility will be built near and leverage the capabilities and talent of Cardinal Health's existing Indianapolis radiopharmacy, which is one of the two U.<wbr>S.<wbr> locations authorized by Bayer HealthCare to distribute Xofigo.<wbr> Cardinal Health is the sole distributor of Xofigo in the U.<wbr>S.<wbr> Bayer had started the preparations for a second manufacturing site soon after the first marketing authorization for Xofigo was obtained in May 2013.<wbr> The new Cardinal Health manufacturing facility, slated for completion in 2017, will be built and equipped for the unique manufacturing needs of Xofigo.<wbr>  It will be supported by approximately 85 employees, including specialized manufacturing roles, chemists, engineers and other professional positions.<wbr> </div><div>Source: Cardinal Health Press Release 18th December </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10173">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-12-19T13:06:09+01:00</dc:date><dc:creator>jew60237</dc:creator></item><item>
<title>re: AB-Biotics Has Entered Deals with E-Biotics and Sanofi for the Development of its Probiotics</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2163</link>
<description>re: AB-Biotics Has Entered Deals with E-Biotics and Sanofi for the Development of its Probiotics</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2163</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2163">re: AB-Biotics Has Entered Deals with E-Biotics and Sanofi for the Development of its Probiotics</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2163">GastroEnterology2163</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 18 December 2014 | 12:43</font><br><br><div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-size: 12px;">Comment: The November deal involves the introduction of AB-Biotics' probiotics developed by Beijing E-Biotics in international markets, and the collaboration in the development of new probiotics for AB-Biotics' pipeline.<wbr> The October deal with Sanofi concerns the marketing in Spain (date: Q4:14) of Sanogermina&trade;.<wbr> a probiotic in the field of gastropediatric health.<wbr></span>&nbsp;<br><font size="-1">Brigitte DESCHAMPS / <a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2125" class="commentpermalink">GastroEnterology2125</a> / <span class="date">18 November 2014</span> /
<span class="time">13:28:35 o'clock CET</span>
</font></div><div>New deal just signed between AB-Biotics and Abbott.<wbr> The companies have signed exclusive distribution agreement for distribution, promotion and commercialisation of I3.<wbr>1 probiotic in Spain.<wbr> </div><!-- Comment details --><font size="-1">Brigitte DESCHAMPS / <a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2163" class="commentpermalink">GastroEnterology2163</a> / <span class="date">18 December 2014</span> /
<span class="time">12:43:22 o'clock CET</span>
</font><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2163">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2125">View thread  GastroEnterology2125: AB-Biotics Has Entered Deals with E-Biotics and Sanofi for the Development of its Probiotics</a>]]></content:encoded><dc:date>2014-12-18T12:43:22+01:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Andrew Plump to Lead Takeda's Global R&amp;D [comp:Takeda, :PharmaWorld:func:RnD]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology10170</link>
<description>Andrew Plump to Lead Takeda's Global R&amp;D [comp:Takeda, :PharmaWorld:func:RnD]</description><category>comp:Takeda</category><category>func:RnD</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology10170</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10170">Andrew Plump to Lead Takeda's Global R&D</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=comp%3aTakeda"><font color="#e95e0b">:Oncology:comp:Takeda</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=func%3aRnD"><font color="#e95e0b">:PharmaWorld:func:RnD</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10170">Oncology10170</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 18 December 2014 | 11:37</font><br><br><div style="margin-bottom: 10px;">Comment: Takeda has appointed ex senior vice president for research and transitional medicine at Sanofi SA.<wbr> His expertise spans across a number of disease areas with emphasis in cardiovascular, metabolism and neuroscience.<wbr>  He is a true translational physician-scientist, with deep knowledge in biomedical research, experimental medicine, early development, genomics and biomarkers.<wbr> </div><div style="margin-bottom: 10px;">He will report directly to President Christophe Weber.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Plump's Short Bio</FONT></STRONG> </div><div style="margin-bottom: 10px;"><SPAN style="LINE-HEIGHT: 1.3">Dr.<wbr> Plump received his M.<wbr>D.<wbr> from the University of California, San Francisco, his Ph.<wbr>D.<wbr> in cardiovascular genetics with Dr.<wbr> Jan Breslow at the Rockefeller University, and his B.<wbr>S.<wbr> from the Massachusetts Institute of Technology.<wbr> </SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="LINE-HEIGHT: 1.3">He completed a residency in Internal Medicine and a fellowship in Medical Genetics at U.<wbr>C.<wbr>S.<wbr>F.<wbr>  Following his clinical training, Dr.<wbr> Plump trained as a Howard Hughes postdoctoral fellow in neuroscience with Dr.<wbr> Marc Tessier-Lavigne at U.<wbr>C.<wbr>S.<wbr>F.<wbr>, concurrently assuming faculty responsibilities as an Adjunct Clinical Instructor in the Department of Medical Genetics</SPAN>.<wbr> </div><div><EM>Source Takeda</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10170">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-12-18T11:37:04+01:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>One Of the Most Expensive Oncology Drugs In History - Amgen's Blincyto Carries A Price Tag of $178,000 [:PharmaWorld:mkt:NorthAmerica, :PharmaWorld:sub:Pricing]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology10169</link>
<description>One Of the Most Expensive Oncology Drugs In History - Amgen's Blincyto Carries A Price Tag of $178,000 [:PharmaWorld:mkt:NorthAmerica, :PharmaWorld:sub:Pricing]</description><category>mkt:NorthAmerica</category><category>sub:Pricing</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology10169</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10169">One Of the Most Expensive Oncology Drugs In History - Amgen's Blincyto Carries A Price Tag of $178,000</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=mkt%3aNorthAmerica"><font color="#e95e0b">:PharmaWorld:mkt:NorthAmerica</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=sub%3aPricing"><font color="#e95e0b">:PharmaWorld:sub:Pricing</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10169">Oncology10169</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/994">Jenny Wu</a> | 18 December 2014 | 10:48</font><br><br><div style="margin-bottom: 10px;">Comment: Amgen's new drug, Blincyto, was approved on 3rd Dec by FDA for treating acute lyphoblastic leukaemia (ALL).<wbr> An estimated of 6,020 people has been diagnosed with ALL in the US , and almost 1/<wbr>4 of them will die from the disease.<wbr>The initial approval is for relapsed or refractory to prior treatment such as a stem cell transplant or chemotherapy.<wbr> This approval is based on the clinical evidence demonstrating 32% of patients achieved complete remission for ~7 months.<wbr> The launch price would reflect two courses of treatment, at $89,000 per cycle.<wbr> An analyst with RBC Capital commented the high price was not surprising given the <SPAN style="text-decoration: underline;">impressive efficacy</SPAN> and <SPAN style="text-decoration: underline;">small targeted population</SPAN> (~1,000 eligible patients per year).<wbr> </div><div style="margin-bottom: 10px;">Blincyto is estimated to reap annual sales of $100 million for ALL, assuming that half of all eligible patients take the medicine.<wbr> Amgen acquired Blincyto through its $1.<wbr>2 billion purchase in 2012 of Micromet, a biotechnology company founded in Germany.<wbr> At the time, Blincyto was known by its chemical name, blinatumomab.<wbr> Blinatumomab is a bispecific antibody that could prove more potent than conventional antibodies, which have become mainstay treatments for a wide array of cancers.<wbr> </div><div style="margin-bottom: 10px;">Other costly immuno-oncology drugs, which work by harnessing the immune system, include Bristol-Myers Squibb Co's Yervoy treatment for melanoma, which costs about $120,000 for a complete course of four infusions.<wbr> MSD's new Keytruda melanoma drug costs $150,000 for a year of treatment.<wbr> </div><div>Source: Amgen Press Release </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10169">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-12-18T10:48:20+01:00</dc:date><dc:creator>jew60237</dc:creator></item><item>
<title>Olympus' NBI For Improving Non-Muscle Invasive Bladder Cancer (NMIBC) Diagnosis Has Greenlight From FDA [dis:Bladder]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology10166</link>
<description>Olympus' NBI For Improving Non-Muscle Invasive Bladder Cancer (NMIBC) Diagnosis Has Greenlight From FDA [dis:Bladder]</description><category>dis:Bladder</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology10166</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10166">Olympus' NBI For Improving Non-Muscle Invasive Bladder Cancer (NMIBC) Diagnosis Has Greenlight From FDA</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=dis%3aBladder"><font color="#e95e0b">:Oncology:dis:Bladder</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10166">Oncology10166</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/994">Jenny Wu</a> | 17 December 2014 | 16:10</font><br><br><div style="margin-bottom: 10px;">Comment: Olympus' Narrow Band Imaging (NBI) is now cleared by FDA for effective targeting of bladder cancer biopsies and improved visualisation of tumour margins.<wbr>NBI is one of the key competitors for Hexvix as it also claims improved detection rate over white light cystoscopy.<wbr> Olympus now has received FDA clearance for the screening and surveillance of Barrett's oesophagus in addition to bladder cancer.<wbr> Olympus has developed an NBI urology app that is available in App store for physicians under the search term "Olympus NBI".<wbr> The app includes 28 clinical case images, a technology overview, comparison shots of WL and NBI.<wbr> </div><div style="margin-bottom: 10px;">Based on a weighted average, the aggregated FDA-reviewed studies (<a href="%20http://www.ncbi.nlm.nih.gov/pubmed/23113702" class="defaultlink">Li et al. 2013</a>) show NBI has visualized NMIBC lesions in: </div><div style="margin-bottom: 10px;"><UL><LI>17 percent additional patients when compared with white light
</LI>
<LI>24 percent additional tumors
</LI>
<LI>28 percent additional carcinoma in situ (CIS or difficult-to-detect flat lesions)<BR>This finding provides new treatment opportunities for urologists both in-office and in the O.<wbr>R.<wbr> Additionally, it offers the potential for improved cost reduction and better patient outcomes resulting from earlier detection
</LI>
</UL> </div><div>NBI enhances visibility of vascular structures on the mucosal surface.<wbr> Unlike white light, which uses all colors in the spectrum, NBI uses only blue and green.<wbr> Blue and green light are strongly absorbed by blood and appear darker than normal tissue.<wbr> Blue light (415nm) highlights the shallow capillaries and green light (540nm) highlights deeper veins.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10166">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-12-17T16:10:16+01:00</dc:date><dc:creator>jew60237</dc:creator></item><item>
<title>Positive Topline Results from Auspex' SD-809 Registration Trial for Huntington's Disease [dis:Huntington, headline]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7860</link>
<description>Positive Topline Results from Auspex' SD-809 Registration Trial for Huntington's Disease [dis:Huntington, headline]</description><category>dis:Huntington</category><category>headline</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7860</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7860">Positive Topline Results from Auspex' SD-809 Registration Trial for Huntington's Disease</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20141231&edate=20140901&cat=dis%3aHuntington"><font color="#e95e0b">:Neurology:dis:Huntington</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20141231&edate=20140901&cat=headline"><font color="#e95e0b">:Neurology:headline</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7860">Neurology7860</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 17 December 2014 | 10:00</font><br><br><div style="margin-bottom: 10px;">Comment: Primary efficacy endpoint was met in the First-HD registration trial, and significant improvements in both patients and clinical global impressions of change and QoL were observed.<wbr> In addition, results from an analysis of the completed 4-week Switch portion of the ARC-HD study show that patients who switched from the current standard of care, tetrabenazine, to SD-809 maintained chorea control at both week one and week four.<wbr> Auspex anticipates NDA submission by mid-2015.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Topline Results</FONT></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>Efficacy</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7860/4/ScreenCapture4.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG>Secondary Endpoints</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7860/5/ScreenCapture5.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG>Tolerability</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7860/6/ScreenCapture6.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG>Adverse Events</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7860/8/ScreenCapture8.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7860/9/ScreenCapture9.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Anticipated Milestones</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7860/3/ScreenCapture3.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Mid-2015 a Key Period for the Company</FONT></STRONG> </div><div style="margin-bottom: 10px;">- topline data in tardive dyskinesia (PE: change in Abnormla Involuntary Movements Scale 'AIMS) </div><div style="margin-bottom: 10px;">- topline data of Ph1b/<wbr>PK for Tourette's syndrome (PE: change in Yale Global Tic severity Scale (YGTSS) </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Drug Development Programs</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7860/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Business Intelligence Analysis</FONT></STRONG> </div><div style="margin-bottom: 10px;">(version Sept 2014) </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7860/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Competition in the Same Class</FONT></STRONG> </div><div style="margin-bottom: 10px;"><EM><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7860/7/ScreenCapture7.jpg?user-agent=rss"></EM> </div><div><EM>Source: Auspex please cklick </EM><A href="http://investor.auspexpharma.com/releasedetail.cfm?ReleaseID=887958"><EM>here</EM></A> </div><!-- Comment details --><a name="neurology7860attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7860/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(187,8 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7860/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(94,3 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7860/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(44,6 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7860/4/ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(81,6 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7860/5/ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(55 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7860/6/ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(116,3 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7860/7/ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(43,7 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7860/8/ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(88,8 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7860/9/ScreenCapture9.jpg">ScreenCapture9.jpg</a>&nbsp;&nbsp;(78,1 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7860">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-12-17T10:00:31+01:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7860/1/ScreenCapture1.jpg" length="192341" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7860/2/ScreenCapture2.jpg" length="96605" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7860/3/ScreenCapture3.jpg" length="45633" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7860/4/ScreenCapture4.jpg" length="83563" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7860/5/ScreenCapture5.jpg" length="56344" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7860/6/ScreenCapture6.jpg" length="119142" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7860/7/ScreenCapture7.jpg" length="44780" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7860/8/ScreenCapture8.jpg" length="90880" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7860/9/ScreenCapture9.jpg" length="79936" type="image/jpeg"/></item><item>
<title>re: Allergan Receives Reimbursement Approval In Italy For Botox To Treat Chronic Migraine</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7859</link>
<description>re: Allergan Receives Reimbursement Approval In Italy For Botox To Treat Chronic Migraine</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7859</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7859">re: Allergan Receives Reimbursement Approval In Italy For Botox To Treat Chronic Migraine</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7859">Neurology7859</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/68">Patrizia Caglioni</a> | 17 December 2014 | 08:26</font><br><br><div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Allergan Receives Reimbursement Approval In Italy For Botox To Treat Chronic Migraine</span>&nbsp;<br><span style="font-size: 12px;">Comment: Allergan has today announced that Botox has 
obtained authorisation from the AIFA for reimbursement in Italy 
for a new indication: symptomatic relief in adult patients who meet the 
diagnostic criteria for chronic migraine  and have showed a poor response 
or are intolerant to drugs for prophylaxis.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7856">...</a><br><font size="-1">Jacquelyne CANTLE MEYRICK / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7856" class="commentpermalink">Neurology7856</a> / <span class="date">16 December 2014</span> /
<span class="time">17:13:28 o'clock CET</span>
</font></div><div style="margin-bottom: 10px;">Botox receive the AIFA authorization in January 2013 .<wbr> </div><div>Attached the document.<wbr> </div><!-- Comment details --><font size="-1">Patrizia Caglioni / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7859" class="commentpermalink">Neurology7859</a> / <span class="date">17 December 2014</span> /
<span class="time">08:26:20 o'clock CET</span>
</font><br><a name="neurology7859attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7859/1/Autorizzazione%20Botox.doc">Autorizzazione Botox.doc</a>&nbsp;&nbsp;(28 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7859">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7856">View thread  Neurology7856: Allergan Receives Reimbursement Approval In Italy For Botox To Treat Chronic Migraine</a>]]></content:encoded><dc:date>2014-12-17T08:26:20+01:00</dc:date><dc:creator>pac66703</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7859/1/Autorizzazione%20Botox.doc" length="28672" type="application/msword"/></item><item>
<title>New Investor Report Focuses on Highlights Of Actavis Meeting With Brent Saunders [headline, dis:Migraine]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7857</link>
<description>New Investor Report Focuses on Highlights Of Actavis Meeting With Brent Saunders [headline, dis:Migraine]</description><category>headline</category><category>dis:Migraine</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7857</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7857">New Investor Report Focuses on Highlights Of Actavis Meeting With Brent Saunders</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20141231&edate=20140901&cat=dis%3aMigraine"><font color="#e95e0b">:Neurology:dis:Migraine</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20141231&edate=20140901&cat=headline"><font color="#e95e0b">:Neurology:headline</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7857">Neurology7857</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 16 December 2014 | 17:40</font><br><br><div style="margin-bottom: 10px;">Comment: Stern Agee published a report yesterday following a meeting with Actavis's management to discuss the company's new business model following merger with Allergan.<wbr> Some interesting points were made by Actavis's CEO Brent Saunders (ex Forest &amp; ex CEO of opthalmic business Bausch &amp; Lomb) about the revenue synergy potential of the Allergan deal.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Key Opportunties Identified</STRONG> </div><div style="margin-bottom: 10px;"><UL><LI><STRONG>Opthalmology </STRONG>- Near-term opportunity to market Allergan's opthalmic products in primary care and drive greater volume growth, plus longer-term opportunity to leverage Allergan's opthlamology expertise in the generics business.<wbr>
</LI>
<LI><STRONG>Neurology -</STRONG> Given what Saunder's claims is Actavis's <STRONG>"more significant footprint in Neurology" </STRONG> greaterpotential to deliver a stronger launch than Allergan had expected for its migraine product levadex, once approved.<wbr>
</LI>
<LI>S<STRONG>cope to leverage the ANDA business</STRONG> <STRONG>to improve Allergan's Buy &amp; Bill model - </STRONG>By obtaining a specialty pharmacy license for the ANDA business, Saunders forsees and opportunity to offer physicians Rx delivery to patients.<wbr> This he believes could drive greater prescriber loyalty given the additional margin it can provide to practices.<wbr>
</LI>
<LI><STRONG>The</STRONG> <STRONG>largest long-term revenue synergy</STRONG> opportunity -that which can be derived from the <STRONG>company's combined international footprint.<wbr></STRONG>
</LI>
</UL> </div><div>Source: Sterne, Agee &amp; Leach Report 15th December 2014 </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7857">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-12-16T17:40:04+01:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>NICE Has Recommended Three Ulcerative Drugs [dis:IBD]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2160</link>
<description>NICE Has Recommended Three Ulcerative Drugs [dis:IBD]</description><category>dis:IBD</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2160</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2160">NICE Has Recommended Three Ulcerative Drugs</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20141231&edate=20140901&cat=dis%3aIBD"><font color="#e95e0b">:GastroEnterology:dis:IBD</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2160">GastroEnterology2160</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 16 December 2014 | 17:37</font><br><br><div style="margin-bottom: 10px;">Comment: NICE has issued a final appraisal determination (FAD) recommending infliximab (Remicade; Merck &amp; Co, US), adalimumab (Humira; AbbVie, US), and golimumab (Simponi; Merck &amp; Co, US), within their marketing authorisations, as options for the treatment of moderately to severely active ulcerative colitis in adults whose disease has responded inadequately to conventional therapy, including corticosteroids and mercaptopurine, or azathioprine, or who cannot tolerate, or have medical contraindications to, such therapies.<wbr> In particular, golimumab is recommended only if the company provides a 100-milligramme dose of the drug at the same cost as the 50-mg dose, as agreed in the patient access scheme (PAS).<wbr> </div><div style="margin-bottom: 10px;">It is noted in the FAD that choosing between the treatments should be done on an individual basis after the responsible clinician and the patient have discussed the advantages and the disadvantages of these drugs.<wbr> The therapeutic need, as well as whether the patient is likely to adhere to treatment or not, is also to be considered.<wbr> In the event that more than one treatment is suitable, the least costly treatment should be chosen while taking into account administration costs, dosage, and price per dose.<wbr> </div><div style="margin-bottom: 10px;">Infliximab has been recommended as an option for the treatment of severely active ulcerative colitis in children and young people aged between 6 and 17, whose disease has responded inadequately to conventional therapy, including corticosteroids and mercaptopurine, or azathioprine, or who cannot tolerate, or have medical contraindications to, such therapies.<wbr> </div><div style="margin-bottom: 10px;">As per the FAD, infliximab, adalimumab, or golimumab are to be given as a planned course of treatment until it fails, including the need for surgery, or until 12 months after commencing the treatment, depending on which one is shorter.<wbr> Specialists are to consequently discuss with the patient the risks and benefits of continued treatment, and their parent or carer, if appropriate: </div><div style="margin-bottom: 10px;"><UL type="disc"><LI>Treatment is to be continued only in the event of clear evidence of response as determined by clinical symptoms, biological markers, and investigation, including endoscopy if necessary.<wbr> Patients who continue to receive treatment are to be reassessed at least every 12 months to establish whether ongoing treatment is still clinically appropriate.<wbr></LI>
<LI>Trial withdrawal from treatment is to be considered for all patients who are in stable clinical remission.<wbr> Patients whose disease relapses after stopping the treatment should have the option to commence treatment again.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;">It is noteworthy that the FAD specifies that in the case of infliximab, US firm Hospira's Inflectra and South Korean Celltrion's Remsima biosimilars are approved for marketing in the same indications in the UK.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Cost-effectiveness evidence</FONT></STRONG> </div><div style="margin-bottom: 10px;">For adalimumab in comparison with conventional therapy, the company estimated the base case incremental cost-effectiveness ratio (ICER) at GBP34,400 (USD53,368) per quality-adjusted life year (QALY) gained, which was revised to GBP23,000 per QALY gained.<wbr> </div><div style="margin-bottom: 10px;">When comparing medical options only, NICE's assessment group concluded that adalimumab dominated infliximab, and golimumab was also extendedly dominated by adalimumab and conventional therapy.<wbr> In comparison with conventional therapy, the base case ICER for adalimumab was estimated at GBP50,600 per QALY gained.<wbr> It was estimated by the assessment group that the ICER for infliximab versus conventional therapy for children and young people was GBP68,400 per QALY gained.<wbr> </div><div style="margin-bottom: 10px;">Overall, NICE's Appraisal Committee concluded the economic analysis "had tended to underestimate the cost effectiveness of TNF-alpha inhibitors".<wbr> </div><div style="margin-bottom: 10px;">It is noteworthy that a PAS was agreed to between Merck and the Department of Health, according to which the 100-mg dose of golimumab would be made available to the National Health Service at the same cost as the 50-mg dose.<wbr> </div><div style="margin-bottom: 10px;"><P class="bodyHeading2"><STRONG><FONT size="3">Outlook and implications</FONT></STRONG></P> </div><div style="margin-bottom: 10px;">The FAD marks a turnaround from the draft guidance issued in September where the drugs were not recommended in the given indication </div><div style="margin-bottom: 10px;">According to Merck's press release, following the issuing of the draft guidance, "stakeholders have been working with NICE to explore the benefits of this new class of drugs for patients".<wbr> Considering that, according to Chris Probert, Professor of Gastroenterology at the University of Liverpool, chair of the IBD Committee for the British Society of Gastroenterology, and vice-chair of the Clinical Advisers Committee for Crohn's and Colitis UK, the decision represents the "first new class of drugs to be approved by NICE for ulcerative colitis", it would potentially help provide access to alternative treatment options.<wbr> </div><div style="margin-bottom: 10px;">The FAD and the draft guidance came after a review of TA140 guidance in which NICE did not recommend infliximab for the treatment of sub-acute manifestations of moderately to severely active ulcerative colitis and TA262 guidance in which the institute did not recommend adalimumab for the treatment of moderate-to-severe ulcerative colitis, as the manufacturer had not submitted evidence.<wbr> </div><div>The FAD is available for comment until 9 January 2015, with the final guidance also expected in January.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2160">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-12-16T17:37:00+01:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Salix Updates Xifaxan Timelines [dis:IBS, dis:Diarrhoea]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2159</link>
<description>Salix Updates Xifaxan Timelines [dis:IBS, dis:Diarrhoea]</description><category>dis:IBS</category><category>dis:Diarrhoea</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2159</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2159">Salix Updates Xifaxan Timelines</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20141231&edate=20140901&cat=dis%3aDiarrhoea"><font color="#e95e0b">:GastroEnterology:dis:Diarrhoea</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20141231&edate=20140901&cat=dis%3aIBS"><font color="#e95e0b">:GastroEnterology:dis:IBS</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2159">GastroEnterology2159</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 16 December 2014 | 17:28</font><br><br><div style="margin-bottom: 10px;">Comment: Management reported a delay of 3 months to May 27, 2015 in the approval of Xifaxan for IBS-D (a new indication expected to generate around $125-150mn in sales).<wbr> In paralell, Salix stock rose more than 7% when the company announced it expects to reduce the inventory of XIFAXAN<SUP>®</SUP> 550, APRISO<SUP>®</SUP> and UCERIS<SUP>® </SUP>to 3 months by the end of 2015.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Rationale for the PDUFA Delay</FONT></STRONG> </div><div style="margin-bottom: 10px;">Management outlined that the delay is strictly procedural, and was attributed to the “volume of data” that was submitted to the FDA, and a “lot of FDA interaction” around the NDA.<wbr> </div><div style="margin-bottom: 10px;">With 3 pivotal trials + microbiome data management believes the IBS submission does entail a substantial amount of data review.<wbr> </div><div><EM>Source: Leerink Partners; Sterne; Company's PR</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2159">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-12-16T17:28:58+01:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Allergan Receives Reimbursement Approval In Italy For Botox To Treat Chronic Migraine</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7856</link>
<description>Allergan Receives Reimbursement Approval In Italy For Botox To Treat Chronic Migraine</description><comments>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7856</comments><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7856</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7856">Allergan Receives Reimbursement Approval In Italy For Botox To Treat Chronic Migraine</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7856">Neurology7856</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 16 December 2014 | 17:13</font><br><br><div style="margin-bottom: 10px;">Comment: Allergan has today announced that Botox has 
obtained authorisation from the AIFA for reimbursement in Italy 
for a new indication: symptomatic relief in adult patients who meet the 
diagnostic criteria for chronic migraine  and have showed a poor response 
or are intolerant to drugs for prophylaxis.<wbr> </div><div style="margin-bottom: 10px;">Commenting on this approval   Prof.<wbr> Gennaro 
Bussone - Director Department of Clinical 
Neurosciences and the Unit for the diagnosis 
and treatment of Headache Foundation IRCCS - Carlo Besta Neurological Institute 
in Milan stated: "This is an important 
step in the treatment of 
migraine and chronic that it is hoped will 
lead to greater recognition of 
this form of headache that 
seriously compromises the quality 
of life of 
sufferers" - said 
- "treatment 
with BOTOX® has been shown to reduce the frequency of 
days with migraine, 
which results in significant 
benefits for patients.<wbr> Patients with 
chronic migraine has long needed therapeutic approaches based 
on clinical studies with large series and this new therapeutic opportunity offers them 
a real chance of improvement, particularly for that 
category of patients significantly compromised by this disabling condition.<wbr>" </div><div><A href="http://www.dossiermedicina.it/Website/index.php?option=com_content&amp;view=article&amp;id=64:botox%C2%AE-riceve-l%E2%80%99autorizzazione-dall%E2%80%99aifa-per-il-trattamento-profilattico-dell-emicrania-cronica&amp;catid=11:news-sulla-salute-e-medici-on-line&amp;Itemid=254">http:/<wbr>/<wbr>www.<wbr>dossiermedicina.<wbr>it/<wbr>Website/<wbr>index.<wbr>php?option=com_content&amp;view=article&amp;id=64:botox%C2%AE-riceve-l%E2%80%99autorizzazione-dall%E2%80%99aifa-per-il-trattamento-profilattico-dell-emicrania-cronica&amp;catid=11:news-sulla-salute-e-medici-on-line&amp;Itemid=254</A> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Neurology7859c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">Botox receive the AIFA authorization in January 2013 .<wbr> </div><div>Attached the document.<wbr> </div><font size="-1">Patrizia Caglioni / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7859" class="commentpermalink">Neurology7859</a> / <span class="date">17 December 2014</span> /
<span class="time">08:26:20 o'clock CET</span>
</font></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7856">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-12-16T17:13:28+01:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>Interim Data Shows Sophiris' PRX302 May Not Be Effective for Lower Urinary Tract Symptoms of BPH [dis:Prostate]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology10164</link>
<description>Interim Data Shows Sophiris' PRX302 May Not Be Effective for Lower Urinary Tract Symptoms of BPH [dis:Prostate]</description><category>dis:Prostate</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology10164</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10164">Interim Data Shows Sophiris' PRX302 May Not Be Effective for Lower Urinary Tract Symptoms of BPH</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10164">Oncology10164</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 16 December 2014 | 15:53</font><br><br><div style="margin-bottom: 10px;">Comment: The Independent Data Monitoring Committee reported that a predefined efficacy threshold following treatment was not achieved.<wbr> Those findings came from an administrative interim analysis of efficacy in the ongoing Ph3 "PLUS-1" trial.<wbr> Sophiris lost about 80% of its market value.<wbr> </div><div style="margin-bottom: 10px;">PRX302 (topsalysin) is an injectable intraprostatic therapy, and is designed to be administered by a urologist.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Next Milestones</FONT></STRONG> </div><div style="margin-bottom: 10px;">The complete 12 month data analysis are expected in the second half of 2015.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Clinical Trials</FONT></STRONG> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/10164/1/ScreenCapture1.jpg?user-agent=rss"></FONT></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>About the PLUS-1 Trial</STRONG> </div><div style="margin-bottom: 10px;">The Ph3 "PLUS-1" study is an international, multicenter, randomized, double-blind, and vehicle-controlled trial to assess the safety and efficacy of a single intraprostatic administration of PRX302 (0.<wbr>6 µg/<wbr>g prostate) for the treatment of BPH.<wbr> </div><div style="margin-bottom: 10px;">Enrollment and dosing in the study were completed in <CHRON>September 2014</CHRON>.<wbr> </div><div style="margin-bottom: 10px;">The primary endpoint is the IPSS total score change from baseline over 52 weeks.<wbr> </div><div style="margin-bottom: 10px;">Secondary endpoints include Qmax (maximum urine flow) change from baseline over 52 weeks.<wbr> </div><div><EM>Source: Sophiris</EM> </div><!-- Comment details --><a name="oncology10164attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10164/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(57,2 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10164">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-12-16T15:53:23+01:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10164/1/ScreenCapture1.jpg" length="58543" type="image/jpeg"/></item><item>
<title>Signifor LAR Approved In US For Acromegaly [prod:Pasireotide]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7887</link>
<description>Signifor LAR Approved In US For Acromegaly [prod:Pasireotide]</description><category>prod:Pasireotide</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7887</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20141231&edate=20140901&rec=7887">Signifor LAR Approved In US For Acromegaly</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20141231&edate=20140901&cat=prod%3aPasireotide"><font color="#e95e0b">:Endocrinology:prod:Pasireotide</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7887">Endocrinology7887</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/1071">Giorgia VICENTINI</a> | 16 December 2014 | 15:32</font><br><br><div style="margin-bottom: 10px;">Comment: Following the EU approval on November 24th, Novartis has gained FDA approval for Signifor LAR, an injectable suspension for intramuscular use for the treatment of patients with acromegaly who have had an inadequate response to surgery and/<wbr>or for whom surgery is not an option.<wbr> </div><div style="margin-bottom: 10px;">Signifor LAR has orphan drug designation for acromegaly in the US, only granted to products treating a condition that affects less than 200,000 people in the US, and securing seven-year market exclusivity.<wbr> The approval is supported by two Phase III clinical studies, C2305 and C2402 (PAOLA) proving efficacy in medically na&iuml;ve patients and those inadequately controlled on standard of care.<wbr> According to Novartis Press Release, the safety and efficacy profile of Signifor LAR has not yet been established in counties outside the US or the EU in patients with acromegaly.<wbr> It is mentioned that "for various reasons, including the uncertainty of the clinical trials, there is no guarantee Signifor LAR will become commercially available anywhere else in the world".<wbr> </div><div style="margin-bottom: 10px;">The approval is line with Ipsen expectations and further details can be found at the <a href="https://ipsengroup.sharepoint.com/sites/root20/MyEndoCommunity/SitePages/Market%20environment/War%20Games.aspx?RootFolder=%2Fsites%2Froot20%2FMyEndoCommunity%2FWar%20games%20Documents%2Fwargame%20pasireotide&FolderCTID=0x012000E475C893C0FD4640B28FEA2CD9844D0A&View=%7BDA820965%2DC847%2D4410%2D9669%2D359B61D3B6C3%7D" class="defaultlink">link</a> to MyEndoCommunity, including a franchise statement and strategy to respond to Signifor approval in EU and US.<wbr> </div><div>Source: Novartis Press Release </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20141231&edate=20140901&rec=7887">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-12-16T15:32:23+01:00</dc:date><dc:creator>giv91620</dc:creator></item><item>
<title>Novartis Buys 12.8% Stake in BioLineRx [:GastroEnterology:dis:IBD]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld11043</link>
<description>Novartis Buys 12.8% Stake in BioLineRx [:GastroEnterology:dis:IBD]</description><category>dis:IBD</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld11043</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20141231&edate=20140901&rec=11043">Novartis Buys 12.<wbr>8% Stake in BioLineRx</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20141231&edate=20140901&cat=dis%3aIBD"><font color="#e95e0b">:GastroEnterology:dis:IBD</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld11043">PharmaWorld11043</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 16 December 2014 | 15:01</font><br><br><div style="margin-bottom: 10px;">Comment: Under the agreement, Novartis, which invested an initial $10M (and acquired an initial 5M American depositary shares of BioLineRx in a private transaction at $2.<wbr>00 a share), will evaluate projects presented by BioLineRX for development and future licensing.<wbr> The clinical-stage, publicly-traded biopharma development company was founded in 2003 by Teva and other key players in Israeli Life Sciences Industry.<wbr> Amongs a pipeline of 10 assets, it is developing BL-7040 a novel, orally available synthetic oligonucleotide for the treatment of IBD (currently in Ph2a).<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Agreement Focused on Project</FONT></STRONG> </div><div style="margin-bottom: 10px;">Once a project is selected, Novartis will pay BioLineRx an option fee of $5 million and fund half the remaining development costs in the form of an additional equity investment in BioLineRx.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Recent Newsflow from BioLine RX</FONT></STRONG> </div><div style="margin-bottom: 10px;">BioLineRx has provided critical updates on key pipeline projects in recent weeks.<wbr> </div><div style="margin-bottom: 10px;"><UL><LI>It now plans to test a larger cohort at higher doses in its Phase II trial of BL-8040 in acute myeloid leukaemia on the back of encouraging efficacy/<wbr>safety data presented at the ASH conference this week.<wbr> </LI>
<LI>Enrolment for the CE mark trial of Bioabsorbable Cardiac Matrix is expected to be completed by year end and study completion is slated for mid-2015.<wbr> </LI>
<LI>BioLineRx also recently announced positive Phase I/<wbr>II safety data for BL-7010 in coeliac disease, enabling the start of a pivotal efficacy trial in 2015</LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Pipeline</FONT></STRONG> </div><div><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/11043/2/ScreenCapture2.jpg?user-agent=rss"> </div><!-- Comment details --><a name="pharmaworld11043attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/11043/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(75,1 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/11043/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(93,5 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/11043/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(10,1 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20141231&edate=20140901&rec=11043">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-12-16T15:01:19+01:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/11043/1/ScreenCapture1.jpg" length="76866" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/11043/2/ScreenCapture2.jpg" length="95760" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/11043/3/ScreenCapture3.jpg" length="10379" type="image/jpeg"/></item><item>
<title>New Structure Announced Following the Acquisition of Allergan [comp:Allergan]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7853</link>
<description>New Structure Announced Following the Acquisition of Allergan [comp:Allergan]</description><category>comp:Allergan</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7853</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7853">New Structure Announced Following the Acquisition of Allergan</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20141231&edate=20140901&cat=comp%3aAllergan"><font color="#e95e0b">:Neurology:comp:Allergan</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7853">Neurology7853</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 16 December 2014 | 14:08</font><br><br><div style="margin-bottom: 10px;">Comment: The combined company is expected to have &gt;two dozen mid-and near-term products in development, and will have commercial operations in &gt;100 countries, and a more "complex combined portfolio of brand products".<wbr> As President &amp; CEO, Brent Saunders will be leading a team of leaders from both Actavis and Allergan.<wbr> An overview of the new organization is provided below.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Commercial Business</FONT></STRONG> </div><div style="margin-bottom: 10px;">Global brand S&amp;M will be structured into 3 organizations: International Brands, Branded Pharma and Allergan Medical.<wbr> </div><div style="margin-bottom: 10px;"><UL><LI><U>Paul Navarre</U>, Allergan Corporate Vice President and President Europe, Africa and the Middle East, will become Executive Vice President Actavis, and President, International Brands.<wbr> </LI>
<LI><U>William Meury</U>, Actavis Executive Vice President for North American Brands will become Executive Vice President Actavis, and President, Branded Pharma with responsibility for Eye Care, Neurosciences, Gastroenterology, Urology, Women's Health and other Specialty brand portfolios.<wbr> </LI>
<LI><U>Philippe Schaison</U>, Allergan Corporate Vice President, President Allergan Medical, will become Executive Vice President Actavis, President Allergan Medical, which will include Facial Aesthetics, Medical Dermatology, Plastic Surgery and SkinMedica.<wbr> These individuals will report directly to Mr.<wbr> Saunders.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Brand R&amp;D</FONT></STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>Will be led by Actavis' C.<wbr> David Nicholson, PhD, Senior Vice President, Global Brand R&amp;D in the role of Executive Vice President, Branded R&amp;D.<wbr> (Dr.<wbr> Nicholson will report directly to Mr.<wbr> Saunders).<wbr> </LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Generics and Global Operations</FONT></STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>Robert Stewart, currently Actavis' Chief Operating Officer, will become Executive Vice President Actavis, and President, Generics and Global Operations.<wbr> (He will report directly to Mr.<wbr> Saunders).<wbr></LI>
</UL> </div><div>Source: <A href="http://finance.yahoo.com/news/actavis-announces-proposed-senior-leadership-123000490.html">http:/<wbr>/<wbr>finance.<wbr>yahoo.<wbr>com/<wbr>news/<wbr>actavis-announces-proposed-senior-leadership-123000490.<wbr>html</A>; <A href="http://www.actavis.com/news/news/thomson-reuters/actavis-announces-proposed-senior-leadership-t-(1">http:/<wbr>/<wbr>www.<wbr>actavis.<wbr>com/<wbr>news/<wbr>news/<wbr>thomson-reuters/<wbr>actavis-announces-proposed-senior-leadership-t-(1</A>) </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7853">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-12-16T14:08:29+01:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Valneva's C.difficile Vaccine to Enter POC Trial [:GastroEnterology:news, sub:ClinicalTrial, mkt:Germany, mkt:NorthAmerica]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld11041</link>
<description>Valneva's C.difficile Vaccine to Enter POC Trial [:GastroEnterology:news, sub:ClinicalTrial, mkt:Germany, mkt:NorthAmerica]</description><comments>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld11041</comments><category>news</category><category>sub:ClinicalTrial</category><category>mkt:Germany</category><category>mkt:NorthAmerica</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld11041</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20141231&edate=20140901&rec=11041">Valneva's C.<wbr>difficile Vaccine to Enter POC Trial</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20141231&edate=20140901&cat=news"><font color="#e95e0b">:GastroEnterology:news</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=mkt%3aGermany"><font color="#e95e0b">:PharmaWorld:mkt:Germany</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=mkt%3aNorthAmerica"><font color="#e95e0b">:PharmaWorld:mkt:NorthAmerica</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=sub%3aClinicalTrial"><font color="#e95e0b">:PharmaWorld:sub:ClinicalTrial</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld11041">PharmaWorld11041</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 15 December 2014 | 18:52</font><br><br><div style="margin-bottom: 10px;">Comment: Valneva, formed in 2013 through the merger of Intercell AG and Vivalis SA, is a biotech company developing, manufacturing and commercializing vaccines.<wbr> Its vaccine candidate for C.<wbr>difficile is a recombinant protein vaccine consisting of two truncated toxins A and B from C.<wbr>difficile.<wbr>The trial will take place in the US and Germany, and recruit approx 500 subjects.<wbr> PE will measure seroconversion rate (SCR) on D56.<wbr> GSK has got opt-in rights if Ph2 successful.<wbr> </div><div style="margin-bottom: 10px;"><H3><FONT size="2"><FONT size="3">About the Ph2</FONT></FONT></H3> </div><div style="margin-bottom: 10px;">ID: NCT02316470 </div><div style="margin-bottom: 10px;">Timelines: Start date Dec 2014 - Completion date May 2015 /<wbr> October 2015 </div><div style="margin-bottom: 10px;"><H3><FONT size="2"><FONT size="3">Ph1 Results</FONT></FONT></H3> </div><div style="margin-bottom: 10px;">In Sept 2013, Valneva announced positive Ph1 results (favorable safety and tolerabilityprofile in both elderly subjects and adults).<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Vaccine Profile /<wbr> Position</FONT></STRONG> </div><div><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/11041/1/ScreenCapture1.jpg?user-agent=rss"> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="PharmaWorld11329c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">Valneva SE has reported that its VLA84 vaccine met the primary endpoint in a Ph2 study to prevent <EM>Clostridium difficile</EM> infection.<wbr> The study included 500 healthy volunteers who received a 75 &micro;g intramuscular vaccine dose without an alum adjuvant, a 200 &micro;g dose with or without the adjuvant, or placebo, administered at days 0, 7 and 28.<wbr> Valneva said the vaccine induced immune responses to both <EM><EM>C.<wbr> difficile</EM></EM>toxins A and B at all doses, and said the 200 &micro;g dose without alum led to the highest seroconversion rate against both toxins A and B on day 56.<wbr> Next development steps to be announced after final study close-out in Q2 2016 and consultations with regulators and Partner.<wbr> </div><div style="margin-bottom: 10px;"><FONT size="3">The key objectives of this Phase II trial have been met, the vaccine candidate generated strong immune responses against </FONT><EM><FONT face="Arial,Arial" size="3"><FONT face="Arial,Arial" size="3">C.<wbr> difficile </FONT></FONT></EM><FONT size="3">toxins A and B, and the safety and tolerability profile was good.<wbr> </FONT> </div><div style="margin-bottom: 10px;">Valneva&acute;s vaccine candidate is targeting the prevention of primary symptomatic <EM><FONT face="Arial,Arial" size="3"><FONT face="Arial,Arial" size="3">C.<wbr>difficile </FONT></FONT></EM><FONT size="3">infection (CDI).<wbr> </FONT> </div><div><FONT size="3">The vaccine is designed to produce an immune response to neutralize the effects of </FONT><EM><FONT face="Arial,Arial" size="3"><FONT face="Arial,Arial" size="3">C.<wbr> difficile </FONT></FONT></EM><FONT size="3">toxins A and B, considered to be largely responsible for CD </FONT> </div><font size="-1">Brigitte DESCHAMPS / <a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld11329" class="commentpermalink">PharmaWorld11329</a> / <span class="date">01 December 2015</span> /
<span class="time">09:00:09 o'clock CET</span>
</font></div><a name="pharmaworld11041attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/11041/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(178,3 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20141231&edate=20140901&rec=11041">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-12-15T18:52:34+01:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/11041/1/ScreenCapture1.jpg" length="182529" type="image/jpeg"/></item><item>
<title>Interesting New Approach To The Treatment of Huntington's Disease [dis:Huntington]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7851</link>
<description>Interesting New Approach To The Treatment of Huntington's Disease [dis:Huntington]</description><category>dis:Huntington</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7851</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7851">Interesting New Approach To The Treatment of Huntington's Disease</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20141231&edate=20140901&cat=dis%3aHuntington"><font color="#e95e0b">:Neurology:dis:Huntington</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7851">Neurology7851</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 15 December 2014 | 18:47</font><br><br><div style="margin-bottom: 10px;">Comment: Novartis Venture Fund has stepped in to take the lead on a $34 
million venture round for Redwood City, Annexon Bioscience, which believes it 
has the inside track on a new autoimmunity approach to treating Huntington's 
disease.<wbr> </div><div style="margin-bottom: 10px;">Dr.<wbr> Campbell Murray of Novartis Venture Funds has stated "Annexon has what we 
believe to be a uniquely elegant approach to neurodegenerative and autoimmune 
diseases.<wbr> The important role of the classical complement cascade in 
antibody-mediated autoimmune disorders has been known for some time, and the 
discovery that it contributes to loss of nerve connections in neurodegenerative 
disease is highly innovative.<wbr>" </div><div style="margin-bottom: 10px;">A protein called C1q, which initiates an immune response called the 
“complement cascade” that rids the brain of dead cells or bacteria, accumulates 
at junctions where nerve cells meet in the brain.<wbr>  Results recently 
published in the Journal of Neuroscience, indicates that elevated levels of C1q 
at these contact points, or synapses, may prime the junctions for death by the 
very immune cells meant to protect them.<wbr> </div><div>Source: Fiercebiotech </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7851">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-12-15T18:47:37+01:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>OPKO and Pfizer Enter intoWW Agreement for OPKO’s LA Human Growth Hormone [class:GrowthHormone, comp:Pfizer, dis:GrowthHormoneDeficiency, prod:Genotropin]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7885</link>
<description>OPKO and Pfizer Enter intoWW Agreement for OPKO’s LA Human Growth Hormone [class:GrowthHormone, comp:Pfizer, dis:GrowthHormoneDeficiency, prod:Genotropin]</description><category>class:GrowthHormone</category><category>comp:Pfizer</category><category>dis:GrowthHormoneDeficiency</category><category>prod:Genotropin</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7885</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20141231&edate=20140901&rec=7885">OPKO and Pfizer Enter intoWW Agreement for OPKO’s LA Human Growth Hormone</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20141231&edate=20140901&cat=class%3aGrowthHormone"><font color="#e95e0b">:Endocrinology:class:GrowthHormone</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20141231&edate=20140901&cat=comp%3aPfizer"><font color="#e95e0b">:Endocrinology:comp:Pfizer</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20141231&edate=20140901&cat=dis%3aGrowthHormoneDeficiency"><font color="#e95e0b">:Endocrinology:dis:GrowthHormoneDeficiency</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20141231&edate=20140901&cat=prod%3aGenotropin"><font color="#e95e0b">:Endocrinology:prod:Genotropin</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7885">Endocrinology7885</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 15 December 2014 | 17:49</font><br><br><div style="margin-bottom: 10px;">Comment: OPKO to receive upfront payment of $295 million, and eligible to receive up to an additional $275 million upon achievement of regulatory milestones.<wbr> hGH-CTP is currently in a global Ph3 in adults and a global Ph2 in children.<wbr> It has orphan drug designation in the U.<wbr>S.<wbr> and Europe for both adults and children with GHD.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Drug SnapShot</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7885/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Rationale</FONT></STRONG> </div><div style="margin-bottom: 10px;">Novo and Pfizer lead the daily GH business, with approx 1/<wbr>4 of the market each.<wbr> </div><div style="margin-bottom: 10px;">Till this deal with OPKO Pfizer had no LA in development in its pipeline whereas Novo's LA drug is ongoing Ph3 for AGHD.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Additional Terms</FONT></STRONG> </div><div style="margin-bottom: 10px;">OPKO will lead the clinical activities and will be responsible for funding the development programs for the key indications, which includes Adult and Pediatric GHD and Pediatric SGA.<wbr> </div><div style="margin-bottom: 10px;">Pfizer will be responsible for all development costs for additional indications as well as all post-marketing studies.<wbr> </div><div>In addition, Pfizer will fund the commercialization activities for all indications and lead the manufacturing activities covered by the global development plan.<wbr> </div><!-- Comment details --><a name="endocrinology7885attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7885/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(147,4 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20141231&edate=20140901&rec=7885">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-12-15T17:49:51+01:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7885/1/ScreenCapture1.jpg" length="150975" type="image/jpeg"/></item><item>
<title>Positive Results from Ab-Biotics' I3.1 Probiotic Formula for IBS-d [sub:Probiotics]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2158</link>
<description>Positive Results from Ab-Biotics' I3.1 Probiotic Formula for IBS-d [sub:Probiotics]</description><category>sub:Probiotics</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2158</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2158">Positive Results from Ab-Biotics' I3.<wbr>1 Probiotic Formula for IBS-d</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20141231&edate=20140901&cat=sub%3aProbiotics"><font color="#e95e0b">:GastroEnterology:sub:Probiotics</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2158">GastroEnterology2158</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 12 December 2014 | 12:28</font><br><br><div style="margin-bottom: 10px;">Comment: I3.<wbr>1 consists of a cocktail of 3 lactic acid bacteria strains (P.<wbr>acidilactici CECT7483, L.<wbr>plantarum CECT7484 and L.<wbr>plantarum CECT7485).<wbr> The company says the study shows in patients treated with the probiotic formula improvement of the QoL index-twice the number of placebo group.<wbr> It is currently looking for a partner.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Reference</FONT></STRONG> </div><div style="margin-bottom: 10px;">The randomized, double-blind, placebo-controlled trial used as primary efficacy measure QoL for patients with IBS (IBS-QoL).<wbr> </div><div style="margin-bottom: 10px;">I.<wbr>31, a new combination of probiotics, improves irritable bowel syndrome-related quality of life.<wbr> </div><div style="margin-bottom: 10px;"><A href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4093724/">http:/<wbr>/<wbr>www.<wbr>ncbi.<wbr>nlm.<wbr>nih.<wbr>gov/<wbr>pmc/<wbr>articles/<wbr>PMC4093724/<wbr></A> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2158/1/ScreenCapture1.jpg?user-agent=rss"> </div><div><A href="http://www.ab-biotics.com/biblioteca/items/33/I31_v_def.pdf">http:/<wbr>/<wbr>www.<wbr>ab-biotics.<wbr>com/<wbr>biblioteca/<wbr>items/<wbr>33/<wbr>I31_v_def.<wbr>pdf</A> </div><!-- Comment details --><a name="gastroenterology2158attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2158/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(12,6 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2158">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-12-12T12:28:49+01:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2158/1/ScreenCapture1.jpg" length="12862" type="image/jpeg"/></item><item>
<title>Sosei Acquires Leading Japanese Peptide Tech Company [headline, mkt:Japan]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld11039</link>
<description>Sosei Acquires Leading Japanese Peptide Tech Company [headline, mkt:Japan]</description><category>headline</category><category>mkt:Japan</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld11039</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20141231&edate=20140901&rec=11039">Sosei Acquires Leading Japanese Peptide Tech Company</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=headline"><font color="#e95e0b">:PharmaWorld:headline</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=mkt%3aJapan"><font color="#e95e0b">:PharmaWorld:mkt:Japan</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld11039">PharmaWorld11039</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 12 December 2014 | 09:14</font><br><br><div style="margin-bottom: 10px;">Comment: Jitsubo, established in April 2005, is focused on development of peptide generic products and identification of new drug candidates based on the novel peptide synthesis technology, Molecular Hiving<SUP id="yui_3_16_0_1_1418371303361_1529">TM</SUP>, and the molecule modification technology, Peptune.<wbr> This acquisition will enable Sosei to enter the peptide market.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Rationale of the Acquisition for Sosei</FONT></STRONG> </div><div style="margin-bottom: 10px;">- Replenishing the existing pipeline with new peptide products to further enhance corporate value.<wbr> </div><div style="margin-bottom: 10px;">The press release mentions that there are currently over 50 marketed peptide products, and the peptide market is expected to reach $23 billion by 2020.<wbr> Through the acquisition of Jitsubo the Group acquires a state-of-the-art technology that has a potential to become a generator of future revenue and growth.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">About the Technologies</FONT></STRONG> </div><div style="margin-bottom: 10px;"><B id="yui_3_16_0_1_1418371303361_1556">Molecular Hiving™: </B>Molecular Hiving<SUP>TM</SUP> technology is Jitsubo’s patented technology for a novel liquid-phase peptide synthesis.<wbr> Currently, two types of peptide synthesis technologies are widely used: solid-phase peptide synthesis (SPPS) and liquid-phase peptide synthesis (LPPS).<wbr> SPPS is a high cost technology often applied for the small scale manufacturing, whereas LPPS is often applied for larger scale manufacturing, but cannot be used for long-chain peptide synthesis.<wbr> Molecular Hiving<SUP id="yui_3_16_0_1_1418371303361_1555">TM</SUP> technology combines the benefits of both SPPS and LPPS, and provides the solution for efficient peptide synthesis at low costs.<wbr> Moreover, since the monitoring of peptide synthesis process that was not possible with SPPS was enabled with this technology, high-quality peptide can be manufactured more easily than with the currently existing methods.<wbr> </div><div><B>Peptune™: </B>Peptune<SUP>TM</SUP> is a novel technology that enables arbitrary alteration of molecular configuration, without changing the amino acid sequence within the peptide.<wbr> Compared to the existing similar technologies, it has a high structural diversity, which makes possible for pharmacological function and stability to be improved based on the molecular configuration of peptide.<wbr> In addition, introducing a new functional molecule to a cross-linkage is also possible, and this new scientific approach enables the production of novel functional peptide </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20141231&edate=20140901&rec=11039">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-12-12T09:14:44+01:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Allergan Study Reveals The The Trend To Look Younger Is Changing [news, sub:Aesthetics]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7848</link>
<description>Allergan Study Reveals The The Trend To Look Younger Is Changing [news, sub:Aesthetics]</description><category>news</category><category>sub:Aesthetics</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7848</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7848">Allergan Study Reveals The The Trend To Look Younger Is Changing</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20141231&edate=20140901&cat=news"><font color="#e95e0b">:Neurology:news</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20141231&edate=20140901&cat=sub%3aAesthetics"><font color="#e95e0b">:Neurology:sub:Aesthetics</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7848">Neurology7848</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 12 December 2014 | 08:43</font><br><br><div style="margin-bottom: 10px;">Comment: Allergan has recently completed a 2000 subject study evaluating our attitudes to ageing and reportedly to its surprise found that we don't want to look 10 years younger anymore.<wbr> A "gentle softening" appears to be the favoured look.<wbr> </div><div style="margin-bottom: 10px;">The study was undertaken as a social experiment to guage our emerging attitudes to anti-aging </div><div style="margin-bottom: 10px;">To test opinnions, researchers took a photo of five women in their early fifities and went onto to retouch the image to two varying degress- one version undergoing total wrinkle-eradication , while the other image underwnet a "gentle softening" procedurs.<wbr> The images were then evaluated by 2000 individulas comprising the over 18 all-female panel.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Key Findings </STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>Unanimous vote for the "gentle softened" version although two thirds of the women went on to admit they thought each subject looked better with her wrinkles.<wbr>
</LI>
<LI>The five women whose photos were used also agreed that they preferred the image of themselves whey they kept their wrinkles.<wbr> They just did not want to look totally flawless as that was considered not realistic for their age.<wbr>
</LI>
</UL> </div><div style="margin-bottom: 10px;">Honey Lancaster-James, behavioural psychologist who assessed the results of the study.<wbr> "What's really interesting is that women today don't want to look years younger, they want to age well which for them, means looking great for their age," </div><div style="margin-bottom: 10px;">The results flagged up the fact that 69 per cent of the panel pointed out that a "gentle softening" effect had left the fifty-something participants looking more refreshed.<wbr> </div><div style="margin-bottom: 10px;">According to plastic surgeon Dr Jonquilee Chantrey.<wbr> "More people are choosing less invasive treatments with dermal fillers, as it's possible to achieve a very natural and refreshed look.<wbr> </div><div>Source <A href="http://fashion.telegraph.co.uk/article/TMG11287823/Study-by-Botox-makers-reveals-we-dont-want-to-look-younger.html">http:/<wbr>/<wbr>fashion.<wbr>telegraph.<wbr>co.<wbr>uk/<wbr>article/<wbr>TMG11287823/<wbr>Study-by-Botox-makers-reveals-we-dont-want-to-look-younger.<wbr>html</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7848">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-12-12T08:43:13+01:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>First Report Of Clinical Activity With A New CRF-1 antagonist in Congenital Adrenal Hyperplasia [news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7882</link>
<description>First Report Of Clinical Activity With A New CRF-1 antagonist in Congenital Adrenal Hyperplasia [news]</description><comments>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7882</comments><category>news</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7882</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20141231&edate=20140901&rec=7882">First Report Of Clinical Activity With A New CRF-1 antagonist in Congenital Adrenal Hyperplasia</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20141231&edate=20140901&cat=news"><font color="#e95e0b">:Endocrinology:news</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7882">Endocrinology7882</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 11 December 2014 | 17:55</font><br><br><div style="margin-bottom: 10px;">Comment: Neurocrine Biosciences announced today the start of a new clinical programme with a proprietary CRF-1 antagonist NBI-77860 to address congenital adrenal hyperplasia (CAH).<wbr>The Company has successfully completed a pilot clinical trial in adults with classic CAH and is initiating an open-label, single ascending dose trial in approximately fifteen adolescent females with classic CAH.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>What is NBI-77860 &amp; What Advantages May It Offer Versus Today''s Therapy?</STRONG> </div><div style="margin-bottom: 10px;">NBI-77860 is a potent, selective non-peptide CRF receptor antagonist as demonstrated in a range of in vitro/<wbr>in vivo assays and human clinical studies.<wbr> Blockade of CRF receptors at the pituitary has been shown to decrease the release of ACTH, which in turn decreases the production of adrenal steroids including androgens, and potentially the symptoms associated with classic CAH.<wbr> Lower ACTH levels would also reduce the amount of exogenous corticosteroid necessary for classic CAH patients to thrive avoiding the side-effects currently associated with excessive steroid therapy </div><div style="margin-bottom: 10px;">Commenting on this development Christopher F.<wbr> O'Brien, Chief Medical Officer stated "We are very pleased with the results from our pilot study of NBI-77860 in patients that was conducted earlier this year and excited to add another significant program to our clinical development pipeline.<wbr> We have requested orphan drug status from the FDA while we continue to expand our preclinical and clinical efforts around NBI-77860 in classic CAH.<wbr>" </div><div style="margin-bottom: 10px;">Meanwhile, Dr.<wbr> Richard Auchus, Professor of Internal Medicine, Division of Metabolism, Endocrinology &amp; Diabetes at University of Michigan Health System has noted that.<wbr> "This treatment strategy, if validated in future clinical trials, has the potential to revolutionize the treatment for CAH patients and make an important difference in their lives.<wbr>" </div><div style="margin-bottom: 10px;"><STRONG>Results from the Initial Pilot Clinical Study <BR></STRONG><BR>The pilot clinical trial was a blinded, single-site, pharmacokinetic/<wbr>pharmacodynamic study assessing two single, ascending doses of NBI-77860 against placebo in adult females with refractory CAH.<wbr> The eight study participants visited the investigative site for three separate overnight visits consisting of bedtime dosing with placebo or one of two active doses of NBI-77860.<wbr> Each of the visits was separated by a three-week washout period.<wbr> Key biomarker measurements included adrenocorticotropic hormone (ACTH), 17-hydroxyprogesterone (17-OHP), androgen, and cortisol levels collected in the morning after dosing.<wbr> Data from this initial single dose exploratory study demonstrated a robust decrease in ACTH and 17-OHP.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7882/4/ScreenCapture6.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">A full description of the study results and related data will be presented at an upcoming scientific meeting.<wbr> </div><div style="margin-bottom: 10px;">1401 Study Design </div><div style="margin-bottom: 10px;">The 1401 study is a Phase I/<wbr>II open-label, sequential cohort, single ascending dose pharmacokinetic/<wbr>pharmacodynamic study assessing three doses of NBI-77860.<wbr> The fifteen adolescent females with classic CAH will be split into three cohorts and each will receive one dose of NBI-77860 at bedtime.<wbr> Biomarker measurements include ACTH, 17-OHP, androgen, and cortisol levels collected the morning after dosing.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7882/5/ScreenCapture7.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG>What Is CAH?</STRONG> </div><div style="margin-bottom: 10px;"><BR> <img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7882/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7882/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7882/3/ScreenCapture4.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG>Neurocrine Biosciences Development Profile</STRONG> </div><div><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7882/6/ScreenCapture8.jpg?user-agent=rss"> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Endocrinology7929c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">Neurocrine Biosciences has announced that  the steering committee of ENDO 2015 has selected the abstract of their recently completed clinical study of NBI-77860 in classic congenital adrenal hyperplasia for an oral presentation on the initial day of the Endocrine Society's 97th Annual Meeting.<wbr> The presentation will take place on Thursday, March 5, 2015 from 11:30 am to 1:00 pm (PST) during the session entitled "HPA Axis and Adrenal: Receptors to Clinical Impact.<wbr>" </div><div><TABLE style="width: 100%;"><TBODY><TR><TD class="bb">&nbsp;</TD>
</TR>
</TBODY>
</TABLE> </div><font size="-1">Jacquelyne CANTLE MEYRICK / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7929" class="commentpermalink">Endocrinology7929</a> / <span class="date">27 January 2015</span> /
<span class="time">10:11:51 o'clock CET</span>
</font><span style="font-weight: bold; font-style: italic;"></span><a name="Endocrinology7935c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div>This is an interesting approach from the endocrinological perspective.<wbr> The patients will still, however, need to take hydrocortisone replacement therapy.<wbr> The advantage of Chronocort is that it does both - controls ACTH secretion and also provides replacement therapy.<wbr>  Chronocort is also going into Phase III, so it is way ahead </div><font size="-1">Philip HARRIS / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7935" class="commentpermalink">Endocrinology7935</a> / <span class="date">28 January 2015</span> /
<span class="time">14:36:39 o'clock CET</span>
</font></div><a name="Endocrinology7967c"></a><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div>Neurocrine Biosciences has announced on February 17th an underwritten public offering of shares to raise $225M to fund its R&amp;D efforts as well for preparing for commercialization of its lead assets.<wbr> </div><font size="-1">Giorgia VICENTINI / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7967" class="commentpermalink">Endocrinology7967</a> / <span class="date">18 February 2015</span> /
<span class="time">16:21:05 o'clock CET</span>
</font></div></div><a name="endocrinology7882attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7882/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(137,6 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7882/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(136,3 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7882/3/ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(100,9 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7882/4/ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(123,7 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7882/5/ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(116 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7882/6/ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(169,2 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20141231&edate=20140901&rec=7882">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-12-11T17:55:47+01:00</dc:date><dc:creator>jac89886</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7882/1/ScreenCapture1.jpg" length="140885" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7882/2/ScreenCapture2.jpg" length="139571" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7882/3/ScreenCapture4.jpg" length="103304" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7882/4/ScreenCapture6.jpg" length="126649" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7882/5/ScreenCapture7.jpg" length="118778" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7882/6/ScreenCapture8.jpg" length="173289" type="image/jpeg"/></item><item>
<title>Key Messages from Teva's 2015 Business Outlook [:Neurology:dis:Huntington, :Endocrinology:dis:GrowthHormoneDeficiency]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld11037</link>
<description>Key Messages from Teva's 2015 Business Outlook [:Neurology:dis:Huntington, :Endocrinology:dis:GrowthHormoneDeficiency]</description><category>dis:Huntington</category><category>dis:GrowthHormoneDeficiency</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld11037</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20141231&edate=20140901&rec=11037">Key Messages from Teva's 2015 Business Outlook</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20141231&edate=20140901&cat=dis%3aGrowthHormoneDeficiency"><font color="#e95e0b">:Endocrinology:dis:GrowthHormoneDeficiency</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20141231&edate=20140901&cat=dis%3aHuntington"><font color="#e95e0b">:Neurology:dis:Huntington</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld11037">PharmaWorld11037</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 11 December 2014 | 16:51</font><br><br><div style="margin-bottom: 10px;">Comment: During 2014, Teva made progress on a number of fronts including the governance front, putting in place key new executives including a new CEO and head of generics, and converting a large share of the Copaxone market to the new formulation.<wbr> Management reported 2015 being a pivotal year for the company.<wbr> Among the pivotal events, we have noted Ph2/<wbr>3 results of pridopidine for Huntington's disease (FDA subm in 2016) and Ph2 results of Albutropin for PGHD in 2015.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Pridopidine Insights</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/11037/5/ScreenCapture5.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/11037/6/ScreenCapture6.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Business Outlook</FONT></STRONG> </div><div style="margin-bottom: 10px;">Teva is in the top 3 position in &gt; 30 markets </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/11037/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">With an integrated R&amp;D organization </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/11037/3/ScreenCapture3.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">And a focused pipeline expected to deliver 27 submissions between 2015 - 2019 </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/11037/4/ScreenCapture4.jpg?user-agent=rss"> </div><div>Clinical results of Albutropin for PGHD are expected in 2015.<wbr> </div><!-- Comment details --><a name="pharmaworld11037attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/11037/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(56,3 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20141231&edate=20140901&rec=11037">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-12-11T16:51:02+01:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/11037/1/ScreenCapture1.jpg" length="57606" type="image/jpeg"/></item><item>
<title>BioGaia Lactobacillus reuteri Effective in Constipated Adults [dis:Constipation, sub:Probiotics]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2154</link>
<description>BioGaia Lactobacillus reuteri Effective in Constipated Adults [dis:Constipation, sub:Probiotics]</description><category>dis:Constipation</category><category>sub:Probiotics</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2154</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2154">BioGaia Lactobacillus reuteri Effective in Constipated Adults</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20141231&edate=20140901&cat=dis%3aConstipation"><font color="#e95e0b">:GastroEnterology:dis:Constipation</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20141231&edate=20140901&cat=sub%3aProbiotics"><font color="#e95e0b">:GastroEnterology:sub:Probiotics</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2154">GastroEnterology2154</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 11 December 2014 | 15:34</font><br><br><div style="margin-bottom: 10px;">Comment: A recent randomized controlled trial (RCT) showed a positive effect of Lactobacillus reuteri on bowel movement frequency in infants with chronic constipation.<wbr> The aim of the present study was to evaluate the effects of L.<wbr> reuteri in adult patients with functional constipation.<wbr> Findings show that the patients given <EM>Lactobacillus reuteri</EM> Protectis were less constipated after 4 weeks compared to patients given placebo.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">About the Study</FONT></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>Principal investigator</STRONG> Dr Veronica Ojetti, Department of Medical Sciences, Division of Gastroenterology, Catholic University Rome, Italy.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Study design</STRONG> A randomised, placebo-controlled, double-blind trial in 40 adult patients diagnosed with functional constipation according to the Rome III criteria.<wbr> The patients were randomly assigned to supplementation with two chewable tablets of either Lactobacillus reuteri Protectis (2x108 cfu, n=20) or corresponding placebo (n=20) daily for 28 days.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2154/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG>Outcome parameters</STRONG> Primary outcome was increase of bowel movements per week.<wbr> Secondary outcome was improvement of stool consistency </div><div style="margin-bottom: 10px;"><STRONG>Location</STRONG>: Gastro Unit of the Catholic U.<wbr> of Rome (Italy) </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Reference</FONT></STRONG> </div><div><STRONG>The Effect of Lactobacillus reuteri Supplementation in Adults with Chronic Functional Constipation: a Randomized, Double-Blind, Placebo-Controlled Trial </STRONG><EM>Journal of Gastrointestinal and Liver Diseases </EM>Veronica Ojetti, Gianluca Ianiro, Annalisa Tortora, Giovanna D'Angelo, Teresa Antonella Di Rienzo, Stefano Bibbo, Alessio Migneco, Antonio Gasbarrini <A href="http://dx.doi.org/10.15403/jgld.2014.1121.234.elr">http:/<wbr>/<wbr>dx.<wbr>doi.<wbr>org/<wbr>10.<wbr>15403/<wbr>jgld.<wbr>2014.<wbr>1121.<wbr>234.<wbr>elr</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2154">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-12-11T15:34:51+01:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Key Messages from Shire's R&amp;D Day [:GastroEnterology:news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld11034</link>
<description>Key Messages from Shire's R&amp;D Day [:GastroEnterology:news]</description><category>news</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld11034</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20141231&edate=20140901&rec=11034">Key Messages from Shire's R&D Day</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20141231&edate=20140901&cat=news"><font color="#e95e0b">:GastroEnterology:news</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld11034">PharmaWorld11034</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 11 December 2014 | 09:32</font><br><br><div style="margin-bottom: 10px;">Comment: Shire gave a comprehensive update on how it will leverage its pipeline to become a rare diseases biotech.<wbr> CEO reiterated targets to double sales of $10bn sales by 2020 (with $3bn is to come from pipeline products).<wbr> Behind its clinical assets, the company has strong capabilities in leading edge technologies (gene therapy, mRNA replacement technology and protein engineering).<wbr> A selection of key presentations is provided below, with a particular focus on GI/<wbr>metabolic rare diseases.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">$ 7bn Expected from In Line Products</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/11034/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">$3 bn Expected from Existing Pipeline</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/11034/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Highlight of the R&amp;D Strategy</FONT></STRONG> </div><div style="margin-bottom: 10px;">(speaker: Phil Vickers, Ph.<wbr>D.<wbr>, Global Head of R&amp;D) </div><div style="margin-bottom: 10px;">Focused on growth and innovation, efficiency and people.<wbr> </div><div style="margin-bottom: 10px;">Pipeline has grown and increased its focus on rare diseases, and progressed with the intrathecal programs in CNS.<wbr> It is planned to resubmit SHP465 (ADHD), and launch Vyvanse for Binge Eating Disorder (BED) in 1H15.<wbr> </div><div style="margin-bottom: 10px;">Efficiency and effectiveness on decision making in R&amp;D are linked to centralization.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/11034/3/ScreenCapture3.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">GI /<wbr>Metabolic Rare Diseases</FONT></STRONG> </div><div style="margin-bottom: 10px;">(speaker: Ciara Kennedy, PhD and David Piccoli, MD) </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/11034/5/ScreenCapture5.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG>Upcoming Milestones</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/11034/8/ScreenCapture8.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/11034/6/ScreenCapture6.jpg?user-agent=rss"> </div><div><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/11034/7/ScreenCapture7.jpg?user-agent=rss"> </div><!-- Comment details --><a name="pharmaworld11034attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/11034/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(62,6 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/11034/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(101,9 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/11034/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(147,4 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/11034/4/ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(21,2 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/11034/5/ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(112,4 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/11034/6/ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(65,4 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/11034/7/ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(56,4 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/11034/8/ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(49 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20141231&edate=20140901&rec=11034">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-12-11T09:32:15+01:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/11034/1/ScreenCapture1.jpg" length="64080" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/11034/2/ScreenCapture2.jpg" length="104313" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/11034/3/ScreenCapture3.jpg" length="150958" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/11034/4/ScreenCapture4.jpg" length="21748" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/11034/5/ScreenCapture5.jpg" length="115134" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/11034/6/ScreenCapture6.jpg" length="66939" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/11034/7/ScreenCapture7.jpg" length="57733" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/11034/8/ScreenCapture8.jpg" length="50152" type="image/jpeg"/></item><item>
<title>AstraZeneca's Opioid-Induced Constipation Drug Cleared in EU [dis:Constipation, news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2153</link>
<description>AstraZeneca's Opioid-Induced Constipation Drug Cleared in EU [dis:Constipation, news]</description><category>dis:Constipation</category><category>news</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2153</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2153">AstraZeneca's Opioid-Induced Constipation Drug Cleared in EU</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20141231&edate=20140901&cat=dis%3aConstipation"><font color="#e95e0b">:GastroEnterology:dis:Constipation</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20141231&edate=20140901&cat=news"><font color="#e95e0b">:GastroEnterology:news</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2153">GastroEnterology2153</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 10 December 2014 | 19:03</font><br><br><div style="margin-bottom: 10px;">Comment: Moventig (naloxegol) is the first once-daily peripherally-acting mu-opioid receptor antagonist (PAMORA) to be approved in the EU, according to AstraZeneca, and has been approved to constipation in patients who do not respond to laxative therapy.<wbr> The company intends to launch naloxegol in both the US and EU by the end of Q1 201 or early in Q2 2015.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">US Status</FONT></STRONG> </div><div style="margin-bottom: 10px;">FDA approved AZ's Movantik in September 2014 for chronic non-cancer pain suffering from opioid-induced constipation </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2153/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Drug Design</FONT></STRONG> </div><div style="margin-bottom: 10px;">Naloxegol is designed to selectively block mu opioid receptors in the gastrointestinal tract - preventing constipation - while staying out of the central nervous system so pain relief is unaffected.<wbr> </div><div><EM>Source: Pmlive; AstraZeneca; Nektar Therapeutics</EM> </div><!-- Comment details --><a name="gastroenterology2153attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2153/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(42,5 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2153">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-12-10T19:03:29+01:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2153/1/ScreenCapture1.jpg" length="43484" type="image/jpeg"/></item><item>
<title>New Report Highlights An Improving Picture In Terms Of Returns From Pharmaceutical R&amp;D [func:RnD, news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld11033</link>
<description>New Report Highlights An Improving Picture In Terms Of Returns From Pharmaceutical R&amp;D [func:RnD, news]</description><category>func:RnD</category><category>news</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld11033</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20141231&edate=20140901&rec=11033">New Report Highlights An Improving Picture In Terms Of Returns From Pharmaceutical R&D</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=func%3aRnD"><font color="#e95e0b">:PharmaWorld:func:RnD</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=news"><font color="#e95e0b">:PharmaWorld:news</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld11033">PharmaWorld11033</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 10 December 2014 | 13:07</font><br><br><div style="margin-bottom: 10px;">Comment: Today Deloitte's in collaboration with Thomson Reuters have released 
a report highlighting the return from pharmaceutical innovation.<wbr> It is entitiled 
"Weathering The Storm" and suggests that Pharmaceutical R&amp;D returns are 
turning a corner.<wbr> Overall returns have improved to 5.<wbr>5% this year compared to 
5.<wbr>1% in 2013 with the FDA having approved 35 new products this year up from 27 
overall in 2013 and close to the bumper 39 cleared in 2012.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Methodology</STRONG> </div><div style="margin-bottom: 10px;">For the last four years Deloitte and Thomson Reuters have analysed the 
performance of the top 12 life sciences companies by estimating the projected 
financial returns from the investment in their late stage pipelines.<wbr> </div><div style="margin-bottom: 10px;">The cohort of companies comprises the 12 companies reporting the highest 
absolute research and development (R&amp;D) spend for 2008-2009.<wbr> The late stage 
pipeline includes those compounds which are either in Phase III development or 
submitted for approval.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Key Findings</STRONG> </div><div style="margin-bottom: 10px;">This year’s research highlights are as follows:- </div><div style="margin-bottom: 10px;"><UL><LI>the top 12 companies have launched 105 products since 2010, with a 
  projected value of $770 billion</LI>
<LI>since 2010, 167 compounds have been pulled into late stage development 
  with a total risk-adjusted value of $819 billion</LI>
<LI>the cost of bringing an asset from discovery to launch increased by 18%, 
  rising from $1.<wbr>1 billion in 2010 to $1.<wbr>3 billion in 2013</LI>
<LI>late stage terminations continue to take too much value out of company 
  pipelines, amounting to a loss of $243 billion over the four years</LI>
<LI>the average forecast for the peak sales of an asset declined by 43%, 
  dropping from $816 million in 2010 to $466 million in 2013.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;">A copy of the report is freely downloadable from the following site </div><div><A href="http://www2.deloitte.com/view/en_GB/uk/research-and-intelligence/deloitte-research-uk/deloitte-uk-centre-for-health-solutions/pharmaceutical-innovation-2013/index.html">http:/<wbr>/<wbr>www2.<wbr>deloitte.<wbr>com/<wbr>view/<wbr>en_GB/<wbr>uk/<wbr>research-and-intelligence/<wbr>deloitte-research-uk/<wbr>deloitte-uk-centre-for-health-solutions/<wbr>pharmaceutical-innovation-2013/<wbr>index.<wbr>html</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20141231&edate=20140901&rec=11033">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-12-10T13:07:44+01:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>Update on Ph3 Study of PROSTVAC® for  mCRPC [class:Vaccines, dis:Prostate, :PharmaWorld:sub:ClinicalTrial]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology10161</link>
<description>Update on Ph3 Study of PROSTVAC® for  mCRPC [class:Vaccines, dis:Prostate, :PharmaWorld:sub:ClinicalTrial]</description><category>class:Vaccines</category><category>dis:Prostate</category><category>sub:ClinicalTrial</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology10161</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10161">Update on Ph3 Study of PROSTVAC® for  mCRPC</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=class%3aVaccines"><font color="#e95e0b">:Oncology:class:Vaccines</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=sub%3aClinicalTrial"><font color="#e95e0b">:PharmaWorld:sub:ClinicalTrial</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10161">Oncology10161</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 10 December 2014 | 12:13</font><br><br><div style="margin-bottom: 10px;">Comment: Bavarian Nordic has reported it has reached the planned enrollment of 1,200 patients (214 sites in 15 countries).<wbr> The company has 4 other ongoing NCI-sponsored studies assessing PROSTVAC® in different indications of prostate cancer (see details below).<wbr> Last November, alongside the financial results for the first nine months of 2014, management highlighted that contract negotiations on partnering PROSTVAC® were ongoing.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">PROSTVAC® Ongoing Studies</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/10161/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">About the PROSPECT Trial</FONT></STRONG> </div><div style="margin-bottom: 10px;">Ref ID <A href="http://clinicaltrials.gov/ct2/show/NCT01322490?term=prostvac&amp;rank=1">NCT01322490</A> </div><div style="margin-bottom: 10px;">All countries active: Australia, Belgium, Canada, Denmark, Estonia, France, Germany, Iceland, Israel, Netherlands, Poland, Russia, Spain, UK &amp; US.<wbr> </div><div style="margin-bottom: 10px;">Timelines: Dec 2015 /<wbr> Aug 2016 </div><div style="margin-bottom: 10px;"><STRONG>Trial</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/10161/1/ScreenCapture1.jpg?user-agent=rss"> </div><div><EM>Source: Bavarian Nordic</EM> </div><!-- Comment details --><a name="oncology10161attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10161/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(28 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10161/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(89,5 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10161">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-12-10T12:13:16+01:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10161/1/ScreenCapture1.jpg" length="28655" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10161/2/ScreenCapture2.jpg" length="91619" type="image/jpeg"/></item><item>
<title>Pierre Fabre Unveils Strategy to 2018 [func:RnD, mkt:France]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld11029</link>
<description>Pierre Fabre Unveils Strategy to 2018 [func:RnD, mkt:France]</description><category>func:RnD</category><category>mkt:France</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld11029</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20141231&edate=20140901&rec=11029">Pierre Fabre Unveils Strategy to 2018</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=func%3aRnD"><font color="#e95e0b">:PharmaWorld:func:RnD</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=mkt%3aFrance"><font color="#e95e0b">:PharmaWorld:mkt:France</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld11029">PharmaWorld11029</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 10 December 2014 | 11:01</font><br><br><div style="margin-bottom: 10px;">Comment: Pierre Fabre, the third-largest French pharmaceutical laboratory, aims to cut costs in pharmaceuticals to build a consumer healthcare franchise and grow its dermo-cosmetics business (particularly in Asia and the US).<wbr> By 2016, 551 jobs will be cut in R&amp;D, almost in France.<wbr> Sanofi made the same reproach to his company's R&amp;D site in Toulouse in 2012, and finally agreed last week to hand over the site to Evotec.<wbr> Management hopes its plan will give it financial firepower to buy new drugs from other companies </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Dermo-Cosmetics Division</FONT></STRONG> </div><div style="margin-bottom: 10px;">Accounts for 55% of group revenue and the bulk of its profit (whereas the pharmaceuticals division has seen sales fall in France since 2009, hit by deficit-reduction measures that have weighed on drug prices).<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/11029/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">R&amp;D Focus</FONT></STRONG> </div><div style="margin-bottom: 10px;">Management said it would focus its R&amp;D on <A href="http://www.pierre-fabre.com/en/oncology-research-0">oncology</A>, neuropsychiatry and dermatology.<wbr> </div><div style="margin-bottom: 10px;"><U>Traction Reference</U> </div><div>See <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20141231&edate=20140901&rec=11023" class="defaultlink">PharmaWorld11023: Sanofi in Talks toTransfer its Toulouse R&D Site to Evotec</a> </div><!-- Comment details --><a name="pharmaworld11029attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/11029/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(64,2 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20141231&edate=20140901&rec=11029">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-12-10T11:01:45+01:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/11029/1/ScreenCapture1.jpg" length="65788" type="image/jpeg"/></item><item>
<title>Antisense To Evaluate Higher Doses For Inclusion In PhIII Study &amp;  Partnering Opportunities [dis:Acromegaly, news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7880</link>
<description>Antisense To Evaluate Higher Doses For Inclusion In PhIII Study &amp;  Partnering Opportunities [dis:Acromegaly, news]</description><category>dis:Acromegaly</category><category>news</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7880</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20141231&edate=20140901&rec=7880">Antisense To Evaluate Higher Doses For Inclusion In PhIII Study &  Partnering Opportunities</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20141231&edate=20140901&cat=dis%3aAcromegaly"><font color="#e95e0b">:Endocrinology:dis:Acromegaly</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20141231&edate=20140901&cat=news"><font color="#e95e0b">:Endocrinology:news</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7880">Endocrinology7880</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 09 December 2014 | 16:52</font><br><br><div style="margin-bottom: 10px;">Comment: Antisense Therapeutics issued a press release today relating to its ongoing partnering process for ATL1103, scheduled to reach a definitive agreement between March &amp; May next year.<wbr> Additionally, it has announced plans to undertake a small, higher dose (600mg/<wbr>week) study in 4 acromegalic patients to support the use of a higher doses in its phIII trials for patients with more aggressive disease.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Regarding The Additional Dose Cohort</STRONG> </div><div style="margin-bottom: 10px;">The trial application has been submitted, with the Ethics Committee response anticipated by the end of this calendar year.<wbr> Given the relatively low cost of this trial and its eligibility for the 45% R&amp;D tax incentive, and in order to keep the drug&rsquo;s development on track, ANP will conduct this additional trial in parallel with the partnering process outlined.<wbr> </div><div style="margin-bottom: 10px;">It envisages that the trial will add further value to ATL1103 ahead of the Phase III registration trials which would be conducted with a pharmaceutical partner </div><div style="margin-bottom: 10px;"><STRONG>Regarding Partnering</STRONG> </div><div style="margin-bottom: 10px;">Antisense Therapeutics notes that it has escalated its partnering activities following publication of its phII results.<wbr> </div><div style="margin-bottom: 10px;">It is is working closely with US based specialist advisory firm Destum Partners on this process, which it claims is now well advanced and has reached due diligence phase with a number of interested parties.<wbr> </div><div style="margin-bottom: 10px;">Destum and ANP are aiming to complete this process to attract a suitable partner and progress into the definitive agreement within the next three to six months.<wbr> </div><div>Source: <A href="http://www.antisesensetherapeutics.com">www.<wbr>antisesensetherapeutics.<wbr>com</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20141231&edate=20140901&rec=7880">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-12-09T16:52:45+01:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>The First ‘Carcinoid NETs Mobile App’ to Become Available in Early 2015 [:PharmaWorld:sub:Devices]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7877</link>
<description>The First ‘Carcinoid NETs Mobile App’ to Become Available in Early 2015 [:PharmaWorld:sub:Devices]</description><category>sub:Devices</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7877</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20141231&edate=20140901&rec=7877">The First ‘Carcinoid NETs Mobile App’ to Become Available in Early 2015</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=sub%3aDevices"><font color="#e95e0b">:PharmaWorld:sub:Devices</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7877">Endocrinology7877</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/1071">Giorgia VICENTINI</a> | 09 December 2014 | 15:20</font><br><br><div style="margin-bottom: 10px;">Comment: The Carcinoid Cancer Foundation and Self Care Catalyst, a patient intelligence health solution provider, have announced a new partnership on December 8th to launch a new mobile phone app to support patients that have been diagnosed with carcinoids tumours and NETs, including pNETs.<wbr> Creating an app for carcinoid NETs will address the need of patients that, when first diagnosed, turn into technology to understand how the disease will impact into their life and what is the treatment path.<wbr> More, the app will be an invaluable tool for patients to organize their life.<wbr> share experiences, and take information with them on the move such as medications intake, symptoms list and bloodwork results to improve communication with their healthcare providers.<wbr> It will also give access to physicians to understand the day-to-day struggles and behaviors of NET cancer patients.<wbr> </div><div style="margin-bottom: 10px;">"We are very excited to partner with Self Care Catalysts to empower carcinoid and NET patients" says Keith Warner, CEO of the Carcinoid Cancer Foundation.<wbr> "By providing the Carcinoid NETs app to the NET community, we will share an extremely valuable resource.<wbr> It's critical for individuals who are living with a rare disease to have a wide variety of resources.<wbr> These include identifying physicians who specialize in treating with carcinoid /<wbr>NET, creating support circles, learning about treatment options, and accessing clinical trials.<wbr> Additionally, by gathering information from patients and their loves ones, we can further identify and help to meet the needs of the community".<wbr> </div><div style="margin-bottom: 10px;">The app will become available free of charge in early 2015 through computers and mobiles and downloadable from the Google Play and the Apple Store.<wbr> </div><div style="margin-bottom: 10px;">This app comes after the first global survey of patients with NET revealed that 41% of patients believe that a better understanding of how to manage their disease-related symptoms would help them live a better life.<wbr> 60% of patients also revealed their emotional health is affected by having NETs.<wbr> The survey was sponsored by Novartis and INCA and fielded from February to May 2014.<wbr> Results were reported in October 2014 (flyer enclosed).<wbr> You can also find the survey results at the following <a href="http://www.carcinoid.org/sites/default/files/Global%20NET%20Patient%20Survey%20Infographic%202014.pdf" class="defaultlink">link</a>.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7877/1/Global%5fSurvery%5fNETs.JPG?user-agent=rss"> </div><div>Source: Yahoo finance, Carcinoid Cancer Foundation and Self Care Catalysts </div><!-- Comment details --><a name="endocrinology7877attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7877/1/Global%5fSurvery%5fNETs.JPG">Global_Survery_NETs.JPG</a>&nbsp;&nbsp;(87,5 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20141231&edate=20140901&rec=7877">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-12-09T15:20:03+01:00</dc:date><dc:creator>giv91620</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7877/1/Global%5fSurvery%5fNETs.JPG" length="89574" type="image/jpeg"/></item><item>
<title>Merck Acquires Cubist Pharmaceuticals Strengthening its Position in Antibiotics [sub:Acquisition]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld11026</link>
<description>Merck Acquires Cubist Pharmaceuticals Strengthening its Position in Antibiotics [sub:Acquisition]</description><category>sub:Acquisition</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld11026</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20141231&edate=20140901&rec=11026">Merck Acquires Cubist Pharmaceuticals Strengthening its Position in Antibiotics</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=sub%3aAcquisition"><font color="#e95e0b">:PharmaWorld:sub:Acquisition</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld11026">PharmaWorld11026</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/1071">Giorgia VICENTINI</a> | 09 December 2014 | 12:51</font><br><br><div style="margin-bottom: 10px;">Comment: Merck &amp; Company has agreed on Monday 8th December to acquire Cubist Pharmaceuticals for £ 8.<wbr>4 billion, plus the assumption of $ 1.<wbr>1 billion in debt.<wbr> Merck will pay $ 102 a share in cash for Cubist, a 35% premium above Cubist's average share price for the five most recent trading days.<wbr> This deal fits with Merck's strategy of acquiring mid-sized pharmaceutical companies with more focused portfolios to complement its existing products.<wbr> </div><div style="margin-bottom: 10px;">Cubicin, Cubist bigger seller (annual sales around $1 billion) will integrate nicely into Merck's hospital division, one of its four prioritized business areas.<wbr> This deal establishes Merck as the second largest American drug make after Pfizer to control the antibiotics landscape, ensuring deeper ties into the hospital care.<wbr> Also, it reinforces how pharmaceutical companies are becoming committed to the antibiotics area again, especially after the FDA started offering incentives to manufacturers investing in new antibiotics products.<wbr> </div><div style="margin-bottom: 10px;">The acquisition is supposed to close in the first quarter of 2015.<wbr> </div><div><EM>Source: FierceBiotech</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20141231&edate=20140901&rec=11026">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-12-09T12:51:49+01:00</dc:date><dc:creator>giv91620</dc:creator></item><item>
<title>Second Company Sponsored Anti-PD1 Combination Trial In mCRPC [dis:Prostate]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology10155</link>
<description>Second Company Sponsored Anti-PD1 Combination Trial In mCRPC [dis:Prostate]</description><category>dis:Prostate</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology10155</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10155">Second Company Sponsored Anti-PD1 Combination Trial In mCRPC</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10155">Oncology10155</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/994">Jenny Wu</a> | 09 December 2014 | 11:21</font><br><br><div style="margin-bottom: 10px;">Comment: Advaxis announced acceptance of its IND application and therefore commencing Ph1/<wbr>2 clinical trials of their ADXS-PSA in combination with MSD's pembrolizumab (anti-PD1) for mCRPC patients.<wbr> This clinical trial will be the first-in-human study of Advaxis's lead Lm-LLO immunotherapy product candidate in prostate cancer, which is expected to begin patient enrolment in Q1 2015.<wbr> ADXS-PSA is designed to target the PSA and to inhibit the Treg and myeloid-derived suppressor cells (MDSCs).<wbr> </div><div style="margin-bottom: 10px;">The Phase 1 part of the study will be a dose-escalating study designed to establish the maximum tolerated dose of ADXS-PSA when used alone and in combination with KEYTRUDA.<wbr> The Phase 2 portion will assess the safety and efficacy of the combination immunotherapy regimen.<wbr> Advaxis and Merck will collaboratively oversee the conduct of the study and will use the results from the trial to determine the future clinical development program for the combination.<wbr> </div><div style="margin-bottom: 10px;">Currently there are three combination immunotherapy combination in mCRPC: </div><div style="margin-bottom: 10px;"><TABLE border="0" cellpadding="0" cellspacing="0" style="width: 1407px; border-collapse: collapse;"><COLGROUP><COL style="width: 110pt; mso-width-source: userset; mso-width-alt: 5339;" width="146">
</COLGROUP>
<COLGROUP><COL span="2" style="width: 83pt; mso-width-source: userset; mso-width-alt: 4022;" width="110">
</COLGROUP>
<COLGROUP><COL style="width: 161pt; mso-width-source: userset; mso-width-alt: 7862;" width="215">
</COLGROUP>
<COLGROUP><COL style="width: 214pt; mso-width-source: userset; mso-width-alt: 10422;" width="285">
</COLGROUP>
<COLGROUP><COL style="width: 115pt; mso-width-source: userset; mso-width-alt: 5595;" width="153">
</COLGROUP>
<COLGROUP><COL style="width: 68pt; mso-width-source: userset; mso-width-alt: 3328;" width="91">
</COLGROUP>
<COLGROUP><COL style="width: 81pt; mso-width-source: userset; mso-width-alt: 3949;" width="108">
</COLGROUP>
<COLGROUP><COL style="width: 94pt; mso-width-source: userset; mso-width-alt: 4571;" width="125">
</COLGROUP>
<COLGROUP><COL style="width: 48pt;" width="64">
</COLGROUP>
<TBODY><TR height="17" style="height: 12.75pt; mso-height-source: userset;"><TD height="17" style="border: 0px windowtext; width: 110pt; height: 12.75pt; background-color: gray;" width="146"><STRONG><FONT size="2">Intervention (anti-PD-1 + Other Immuno-modulating agents)</FONT></STRONG></TD>
<TD style="border: 0px windowtext; width: 83pt; background-color: gray;" width="110"><STRONG><FONT size="2">Trial Title</FONT></STRONG></TD>
<TD style="border: 0px windowtext; width: 83pt; background-color: gray;" width="110"><STRONG><FONT size="2">Trial Status</FONT></STRONG></TD>
<TD style="border: 0px windowtext; width: 161pt; background-color: gray;" width="215"><STRONG><FONT size="2">Trial Phase</FONT></STRONG></TD>
<TD style="border: 0px windowtext; width: 214pt; background-color: gray;" width="285"><STRONG><FONT size="2">Sponsor Name</FONT></STRONG></TD>
<TD style="border: 0px windowtext; width: 115pt; background-color: gray;" width="153"><STRONG><FONT size="2">Primary IDs</FONT></STRONG></TD>
<TD style="border: 0px windowtext; width: 68pt; background-color: gray;" width="91"><STRONG><FONT size="2">Trial Start Date</FONT></STRONG></TD>
<TD style="border: 0px windowtext; width: 81pt; background-color: gray;" width="108"><STRONG><FONT size="2">Trial End Date</FONT></STRONG></TD>
<TD style="border: 0px windowtext; width: 94pt; background-color: gray;" width="125"><STRONG><FONT size="2">Data Monitoring Committee</FONT></STRONG></TD>
<TD style="border: 0px windowtext; width: 48pt; background-color: gray;" width="64"><STRONG><FONT size="2"># of Subjects Planned</FONT></STRONG></TD>
</TR>
<TR height="17" style="height: 12.75pt; mso-height-source: userset;"><TD height="17" style="border: 0px windowtext; height: 12.75pt; background-color: transparent;"><STRONG><FONT size="2">Pidilizumab (CureTech/<wbr>Medivation) + Sipuleucel-T (Dendreon) + Cyclophosphamide</FONT> </STRONG></TD>
<TD style="border: 0px windowtext; background-color: transparent;"><FONT size="2">Sipuleucel-T, CT-011, and Cyclophosphamide for Advanced Prostate Cancer</FONT></TD>
<TD style="border: 0px windowtext; background-color: transparent;"><FONT size="2">Ongoing, recruiting</FONT></TD>
<TD style="border: 0px windowtext; background-color: transparent;"><FONT size="2">Phase II</FONT></TD>
<TD style="border: 0px windowtext; background-color: transparent;"><FONT size="2">Georgia Regents University</FONT></TD>
<TD style="border: 0px windowtext; background-color: transparent;"><FONT size="2">NCT01420965</FONT></TD>
<TD align="right" style="border: 0px windowtext; background-color: transparent;"><FONT size="2">01-Sep-2012</FONT></TD>
<TD align="right" style="border: 0px windowtext; background-color: transparent;"><FONT size="2">01-Dec-2016</FONT></TD>
<TD style="border: 0px windowtext; background-color: transparent;"><FONT size="2">Yes</FONT></TD>
<TD align="right" style="border: 0px windowtext; background-color: transparent;"><FONT size="2">57</FONT></TD>
</TR>
<TR height="17" style="height: 12.75pt; mso-height-source: userset;"><TD height="17" style="border: 0px windowtext; height: 12.75pt; background-color: transparent;"><STRONG><FONT size="2">Pembrolizumab (MSD) + ADXS-PSA (Advaxis)</FONT></STRONG></TD>
<TD style="border: 0px windowtext; background-color: transparent;"><FONT size="2">Phase I/<wbr>II Clinical Study of ADXS-PSA as Monotherapy and in Combination with Pembrolizumab in Subjects with Previously Treated Metastatic, Castration-Resistant Prostate Cancer</FONT></TD>
<TD style="border: 0px windowtext; background-color: transparent;"><FONT size="2">Planned</FONT></TD>
<TD style="border: 0px windowtext; background-color: transparent;"><FONT size="2">Phase I/<wbr>II</FONT></TD>
<TD style="border: 0px windowtext; background-color: transparent;"><FONT size="2">Advaxis, Inc.<wbr></FONT></TD>
<TD style="border: 0px windowtext; background-color: transparent;">&nbsp;</TD>
<TD align="right" style="border: 0px windowtext; background-color: transparent;"><FONT size="2">01-Jan-2015</FONT></TD>
<TD style="border: 0px windowtext; background-color: transparent;"><FONT size="2">TBD</FONT></TD>
<TD style="border: 0px windowtext; background-color: transparent;"><FONT size="2">No</FONT></TD>
<TD style="border: 0px windowtext; background-color: transparent;">&nbsp;</TD>
</TR>
<TR height="17" style="height: 12.75pt; mso-height-source: userset;"><TD height="17" style="border: 0px windowtext; height: 12.75pt; background-color: transparent;"><STRONG><FONT size="2">Nivolumab (BMS) + Lirilumab (BMS)</FONT> </STRONG></TD>
<TD style="border: 0px windowtext; background-color: transparent;"><FONT size="2">A Phase I Study of an Anti-KIR Antibody in Combination with an Anti-PD1 Antibody in Patients with Advanced Solid Tumours</FONT></TD>
<TD style="border: 0px windowtext; background-color: transparent;"><FONT size="2">Ongoing, recruiting</FONT></TD>
<TD style="border: 0px windowtext; background-color: transparent;"><FONT size="2">Phase I</FONT></TD>
<TD style="border: 0px windowtext; background-color: transparent;"><FONT size="2">Bristol-Myers Squibb Company</FONT></TD>
<TD style="border: 0px windowtext; background-color: transparent;"><FONT size="2">NCT01714739</FONT></TD>
<TD align="right" style="border: 0px windowtext; background-color: transparent;"><FONT size="2">01-Oct-2012</FONT></TD>
<TD align="right" style="border: 0px windowtext; background-color: transparent;"><FONT size="2">01-Sep-2017</FONT></TD>
<TD style="border: 0px windowtext; background-color: transparent;"><FONT size="2">No</FONT></TD>
<TD align="right" style="border: 0px windowtext; background-color: transparent;"><FONT size="2">162</FONT></TD>
</TR>
</TBODY>
</TABLE> </div><div>Source: Advaxis Company Press Release, PharmaeTrack 2014 December </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10155">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-12-09T11:21:55+01:00</dc:date><dc:creator>jew60237</dc:creator></item><item>
<title>Takeda and Monash U. Form Strategic Alliance to Advance Research on New Therapies for GI Diseases [dis:IBD, news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2151</link>
<description>Takeda and Monash U. Form Strategic Alliance to Advance Research on New Therapies for GI Diseases [dis:IBD, news]</description><category>dis:IBD</category><category>news</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2151</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2151">Takeda and Monash U.<wbr> Form Strategic Alliance to Advance Research on New Therapies for GI Diseases</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20141231&edate=20140901&cat=dis%3aIBD"><font color="#e95e0b">:GastroEnterology:dis:IBD</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20141231&edate=20140901&cat=news"><font color="#e95e0b">:GastroEnterology:news</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2151">GastroEnterology2151</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 09 December 2014 | 10:24</font><br><br><div style="margin-bottom: 10px;">Comment: Irritable bowel syndrome, abdominal pain, chronic itch, severe constipation and diarrhea will be the focus of the research alliance.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">About the Alliance</FONT></STRONG> </div><div style="margin-bottom: 10px;">Will be funded by Takeda </div><div style="margin-bottom: 10px;">Pf Nigel Bunnett (Deputy Director , Monash Institute of Pharmaceutical Sciences) together with Dr Daniel Poole, also from MIPS, will lead the three-year research program.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Recent Update of Takeda in Gastro</FONT></STRONG> </div><div style="margin-bottom: 10px;">Takeda’s gastroenterology Drug Discovery Unit is a highly specialized research team that works collaboratively with academic and industry partners.<wbr> The team is actively seeking to leverage the best scientific and pharmaceutical expertise all over the world.<wbr> </div><div style="margin-bottom: 10px;"><UL><LI>
Q2:14 Launch of <STRONG>Entyvio</STRONG> for IBD and marketing of the drug in EU.<wbr> The drug is perceived as a groundbreaking new product that offers new treatment options to paient with the disease who failed to respond to treatment with existingproducts.<wbr> It is anticipated to be a blockbuster global product for the company.<wbr></LI>
<LI>
Q4:14 Acquisition of <STRONG>Amitiza</STRONG> rights beyond the US and Canada to all global markets (except Japan and China).<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><U>Pipeline</U> </div><div style="margin-bottom: 10px;"><UL><LI>
Norovirous Vaccine (prevention of acute gastroenteritis cause by norovirus) in Ph2</LI>
<LI>
TAK-114 (ulcerative colitis) in Ph2 US/<wbr>EU and Ph1/<wbr>Jpn</LI>
</UL> </div><div style="margin-bottom: 10px;"><EM>Source: Takeda</EM> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">About Monash University</FONT></STRONG> </div><div style="margin-bottom: 10px;">Monash University is Australia's largest university and ranked in the Top 100 World Universities according to the Times Higher Education World University Rankings.<wbr> </div><div>The Monash Institute of Pharmaceutical Science (MIPS) is Australia’s largest pharmaceutical sciences research program in translational drug discovery, drug delivery and drug development.<wbr> Pharmacy and Pharmacology at Monash is ranked number one in the Asia-Pacific and top 10 worldwide (2014 QS World University Rankings).<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2151">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-12-09T10:24:27+01:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Millennium Is Now Rebranded As &quot;The Takeda Oncology Company&quot;</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology10153</link>
<description>Millennium Is Now Rebranded As &quot;The Takeda Oncology Company&quot;</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology10153</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10153">Millennium Is Now Rebranded As "The Takeda Oncology Company"</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10153">Oncology10153</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/994">Jenny Wu</a> | 08 December 2014 | 18:15</font><br><br><div style="margin-bottom: 10px;">Comment:In June,Takeda suffered a setback when the company ended development of orteronel.<wbr> Takeda re-focuses itself to re-form an Oncology Business Unit, formerly known as "Millennium", to "Takeda Oncology Company".<wbr> This unit originated from a $8 billion acquisition in 2008.<wbr> Currently Takeda's cancer portfolio is led by Velcade for multiple myeloma (US) which enjoyed a 13.<wbr>3% jump in product sales during the first 6 months of the company's 2014 fiscal year.<wbr> Closed behind in sales is leuprorelin racked up $507.<wbr>6 million in April-Sept 2014, down 6% from a year earlier.<wbr> </div><div style="margin-bottom: 10px;">Takeda's cancer portfolio also includes two investigational compounds.<wbr> One is Alsertib (MLN8237) an oral, selective, inhibitor of Aurora A kinase, which has been shown to be overexpressed in a variety of cancers.<wbr> Alsertib is being explored for a wide range of blood malignancies and solid tumours, including relapsed or refractory peripheral T-cell lymphoma recurrent ovarian cancer, and small cell lung cancer.<wbr> The other compound is Ixazomib (MLN9708), now under study in multiple myeloma (MM), systemic light-chain (AL) amyloidosis, and other malignancies.<wbr> </div><div style="margin-bottom: 10px;">Just last week, Ixazomib won Breakthrough Therapy status from the FDA for the systemic light-chain (AL) amyloidosis indication.<wbr> Data used to support the designation is being presented at the American Society of Hematology (ASH) annual meeting set for December 6-9 in San Francisco.<wbr> </div><div style="margin-bottom: 10px;">The first oral proteasome inhibitor to enter Phase III clinical trials, Ixazomib is being assessed in four ongoing pivotal studies: </div><div style="margin-bottom: 10px;">TOURMALINE-MM1, investigating ixazomib vs.<wbr> placebo in combination with lenalidomide and dexamethasone in relapsed and/<wbr>or refractory MM; </div><div style="margin-bottom: 10px;">TOURMALINE-AL1, investigating ixazomib plus dexamethasone in patients with relapsed or refractory AL amyloidosis; </div><div style="margin-bottom: 10px;">TOURMALINE-MM2, investigating ixazomib vs.<wbr> placebo in combination with lenalidomide and dexamethasone in patients with newly diagnosed MM; </div><div style="margin-bottom: 10px;">TOURMALINE-MM3, investigating ixazomib vs.<wbr> placebo as maintenance therapy in patients with newly diagnosed MM following induction therapy and autologous stem cell transplant </div><div>Source: Takeda News Release </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10153">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-12-08T18:15:33+01:00</dc:date><dc:creator>jew60237</dc:creator></item><item>
<title>re: Ferring Reinforces Committment in the Gastro Field</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2148</link>
<description>re: Ferring Reinforces Committment in the Gastro Field</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2148</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2148">re: Ferring Reinforces Committment in the Gastro Field</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2148">GastroEnterology2148</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 08 December 2014 | 11:05</font><br><br><div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Ferring Reinforces Committment in the Gastro Field</span>&nbsp;<font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20141231&edate=20140901&cat=comp%3aFerring"><font color="#e95e0b">:Endocrinology:comp:Ferring</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20141231&edate=20140901&cat=dis%3aIBD"><font color="#e95e0b">:GastroEnterology:dis:IBD</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20141231&edate=20140901&cat=news"><font color="#e95e0b">:GastroEnterology:news</font></a>]</font></font><br><span style="font-size: 12px;">Comment: TxCell SA, a French biotech developing innovative, personalized cell-based immunotherapies using antigen-specific regulatory T-cells (Ag-Tregs) for chronic inflammatory and autoimmune diseases, has granted Ferring an option to acquire an exclusive WW license for the development, manufacture and marketing of Ovasave<STRONG>®</STRONG> (Ph2 planned H2:14) for IBD, including Crohn's Disease(CD) and Ulcerative Colitis (UC).<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=1943">...</a><br><font size="-1">Brigitte DESCHAMPS / <a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology1943" class="commentpermalink">GastroEnterology1943</a> / <span class="date">18 March 2014</span> /
<span class="time">11:21:51 o'clock CET</span>
</font></div><div style="margin-bottom: 10px;">TxCell SA just announced the enrollment and dosing of the first patient in the Ph2b clinical study.<wbr><STRONG> </STRONG>Ovasave® (<SPAN style="COLOR: #000000">ovalbumin-specific autologous Treg cells)</SPAN><STRONG> </STRONG>is currently approved for study in 6 EU countries, with preliminary results expected by the end of 2016 to early 2017.<wbr> Previously completed studies on Ovasave® demonstrated a favorable tolerance profile and treatment response in 75% of patients, with 38% achieving remission after 5 weeks of treatment.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>About Ph2b study</STRONG> </div><div style="margin-bottom: 10px;"><SPAN style="COLOR: #000000">Lead investigator: Dr.<wbr> Severine Vermeire, Professor of Gastroenterology at the University Hospital Leuven</SPAN> </div><div style="margin-bottom: 10px;">Reference: CATS29 </div><div style="margin-bottom: 10px;">Location: 32 study sites across <SPAN style="COLOR: #000000">Austria, Belgium, France, Germany, Italy and the United Kingdom</SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="COLOR: #000000">Recruitment: approx.<wbr> 160 patients with severe refractory Crohn’s disease.<wbr> </SPAN> </div><div style="margin-bottom: 10px;">Design: multicentre, randomised, double-blinded, placebo-controlled, multi-dose and multi-injection, 4 parallel groups study.<wbr> </div><div style="margin-bottom: 10px;">Objectives: to evaluate the efficacy and the safety of Ovasave (ovalbumin-specific autologous Treg cells (Ova-Treg)) in patients with active refractory Crohn’s disease.<wbr> <SPAN style="COLOR: #000000">CATS29 will be evaluating treatment response rate for one intravenous dose of 1.<wbr>10(6) cells of Ovasave, compared to a placebo 6 weeks following treatment.<wbr> Response rate will be measured according to a decrease of at least 100 points in the Crohn’s Disease Activity Index (CDAI).<wbr></SPAN> </div><div style="margin-bottom: 10px;">Dosing/<wbr>Regimen: Patients will receive, double-blinded, two intravenous (iv) injections 8 weeks apart of either 1.<wbr>10(4), 1.<wbr>10(6), or 1.<wbr>10(7) cells of Ovasave or placebo.<wbr> Patients will then receive either an open-label treatment with 2 additional iv injections of 1.<wbr>10(6) cells of Ovasave or a safety follow-up with no injection.<wbr> </div><div style="margin-bottom: 10px;">Finally, there will be an extended safety follow-up for all patients.<wbr> </div><div><EM>Source: TxCell PR</EM> </div><!-- Comment details --><font size="-1">Brigitte DESCHAMPS / <a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2148" class="commentpermalink">GastroEnterology2148</a> / <span class="date">08 December 2014</span> /
<span class="time">11:05:35 o'clock CET</span>
</font><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2148">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology1943">View thread  GastroEnterology1943: Ferring Reinforces Committment in the Gastro Field</a>]]></content:encoded><dc:date>2014-12-08T11:05:35+01:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>re: Euroscreen's ESN364 to Enter Clinical for Endometriosis and PCOS</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology10152</link>
<description>re: Euroscreen's ESN364 to Enter Clinical for Endometriosis and PCOS</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology10152</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10152">re: Euroscreen's ESN364 to Enter Clinical for Endometriosis and PCOS</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10152">Oncology10152</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 08 December 2014 | 10:57</font><br><br><div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Euroscreen's ESN364 to Enter Clinical for Endometriosis and PCOS</span>&nbsp;<font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20141231&edate=20140901&cat=dis%3aIBS"><font color="#e95e0b">:GastroEnterology:dis:IBS</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20141231&edate=20140901&cat=news"><font color="#e95e0b">:GastroEnterology:news</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=dis%3aGynea"><font color="#e95e0b">:Oncology:dis:Gynea</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=sub%3aPartnership"><font color="#e95e0b">:PharmaWorld:sub:Partnership</font></a>]</font></font><br><span style="font-size: 12px;">Comment: The Belgium based, private company presented at ENDO2013 preclinical PK and efficacy data of its oral small-molecule NK3 receptor antagonist program.<wbr> ESN364, the lead candidate issued from this program, is scheduled for FIM in 4Q:13 (endometriosis and polycystic ovary syndrome).<wbr> Of note, the company is actively seeking partner for ESN282 (inflammatory diseases such as ulcerative colitis).<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=9023">...</a><br><font size="-1">Brigitte DESCHAMPS / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9023" class="commentpermalink">Oncology9023</a> / <span class="date">19 June 2013</span> /
<span class="time">11:09:30 o'clock CEST</span>
</font></div><div style="margin-bottom: 10px;">Following "fully-consistent Ph1 results", the company now plans to start 2 Ph2 trials (3-month dosing, 72 patients) for uterine fibroids and Poly Cystic Ovarian Syndrome in January 2015.<wbr> Company claims the results obtained give  a strong competitive advantage compared to GnRH ligand products to provide a superior product with regard to both safety and efficacy for a large scope of indications such as UF, PCOS and Endometriosis in the treatment of Women&rsquo;s Health.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Study Results</STRONG> </div><div style="margin-bottom: 10px;">The Ph1 trial enrolled 64 healthy subjects (40 male and 24 female).<wbr> </div><div style="margin-bottom: 10px;">Safety was evaluated by means of intensive ECG and vital signs monitoring as well as via the necessary clinical laboratory assessments throughout the entire study (up to 21 days of daily dosing and up to 84 days of follow-up in female volunteers).<wbr> </div><div>No clinically relevant changes were observed in the clinical lab parameters, ECG and/<wbr>or vital signs.<wbr> The reported adverse events were mild-to-moderate in intensity, reversible and of limited duration and non-significant in relation to ESN364 treatment based upon comparison to the placebo group.<wbr> </div><!-- Comment details --><font size="-1">Brigitte DESCHAMPS / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10152" class="commentpermalink">Oncology10152</a> / <span class="date">08 December 2014</span> /
<span class="time">10:57:18 o'clock CET</span>
</font><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10152">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9023">View thread  Oncology9023: Euroscreen's ESN364 to Enter Clinical for Endometriosis and PCOS</a>]]></content:encoded><dc:date>2014-12-08T10:57:18+01:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Daewoong Announces The Completion Of A PhIII Spasticity Study [headline, dis:Spasticity]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7845</link>
<description>Daewoong Announces The Completion Of A PhIII Spasticity Study [headline, dis:Spasticity]</description><category>headline</category><category>dis:Spasticity</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7845</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7845">Daewoong Announces The Completion Of A PhIII Spasticity Study</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20141231&edate=20140901&cat=dis%3aSpasticity"><font color="#e95e0b">:Neurology:dis:Spasticity</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20141231&edate=20140901&cat=headline"><font color="#e95e0b">:Neurology:headline</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7845">Neurology7845</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 05 December 2014 | 16:12</font><br><br><div style="margin-bottom: 10px;">Comment: Daewoong has announced the succesful completion of a phIII clinical study evaluating the safety and efficacy of its botulinum toxin Nabota for "the treatment of stiffness in upper extremity muscles associated with stroke".<wbr> No actual results have been disclosed.<wbr> Comments expressed by the company note its strategic intent to enter the therapeutic as well as the aesthetic market on a global scale.<wbr> However, the nature of the phIII study NCT01945684 conducted in patients is likely to prove insufficient for regulatory purposes in Western markets </div><div style="margin-bottom: 10px;"><STRONG>PhIII Study Title</STRONG> </div><div style="margin-bottom: 10px;">A Randomized, Double Blind, Multi-center, Active Drug Controlled, Phase III Clinical Trial to Compare the Safety and Efficacy of DWP450 Versus Botox&reg; in Treatment of Post Stroke Upper Limb(wrist, finger, elbow, thumb)Spasticity </div><div style="margin-bottom: 10px;">The trial started in 2013 and has as its primary endpoints </div><div style="margin-bottom: 10px;"><UL style="margin-bottom: 1ex; margin-top: 1ex;"><LI class="color-bullet" style="margin-top: 0.7ex;">The change in MAS grade for Wrist flexor [ Time Frame: at 4 week ]
</LI>
<LI class="color-bullet" style="margin-top: 0.7ex;">The change in MAS grade from baseline at week 4 for wrist flexor muscle tone
</LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG>Daewoong's press release states the following:-</STRONG> </div><div>Jeon Seung-ho, Director of Global Marketing at Daewoong Pharmaceuticals expressed high expectations , saying "The license is expected to be issued in late 2015.<wbr> One out of three patients with post-stroke stiffness in muscles can be treated using botulinum toxin.<wbr> Having successfully completed clinical trials, Nabota will gain indications and wide acceptance in the global botulinum toxin treatment market work KRW1.<wbr>4 trillion, as well as the domestic market for stroke treatment.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7845">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-12-05T16:12:22+01:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>Ferring Manufacturing Plant Being Constructed in India for the Global Production of Pentasa [dis:IBD, :PharmaWorld:mkt:India]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2145</link>
<description>Ferring Manufacturing Plant Being Constructed in India for the Global Production of Pentasa [dis:IBD, :PharmaWorld:mkt:India]</description><category>dis:IBD</category><category>mkt:India</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2145</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2145">Ferring Manufacturing Plant Being Constructed in India for the Global Production of Pentasa</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20141231&edate=20140901&cat=dis%3aIBD"><font color="#e95e0b">:GastroEnterology:dis:IBD</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=mkt%3aIndia"><font color="#e95e0b">:PharmaWorld:mkt:India</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2145">GastroEnterology2145</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 05 December 2014 | 15:01</font><br><br><div style="margin-bottom: 10px;">Comment: <A href="http://images.financialexpress.com/2014/12/20141215ep91.jpg"></A>The Danish ambassador to India, HE Freddy Svane recently visited the state-of-the-art manufacturing plant being constructed by Ferring in the MIDC area of Ambernath, district Thane.<wbr> Expected to be inaugurated in 2015, the plant is being built as per the latest EU standards in order to cater to the global supply of Ferring’s Pentasa (for IBD).<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Ferring R&amp;D Facility in the Area</FONT></STRONG> </div><div>2007 Ferring has established its R&amp;D facility in the area for new drug delivery platforms used for the production of Minirin.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2145">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-12-05T15:01:42+01:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Microbiota Suspension Drug Has Entered Ph2b Trial for Recurrent CDI Infection [news, :PharmaWorld:sub:ClinicalTrial]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2142</link>
<description>Microbiota Suspension Drug Has Entered Ph2b Trial for Recurrent CDI Infection [news, :PharmaWorld:sub:ClinicalTrial]</description><comments>http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2142</comments><category>news</category><category>sub:ClinicalTrial</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2142</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2142">Microbiota Suspension Drug Has Entered Ph2b Trial for Recurrent CDI Infection</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20141231&edate=20140901&cat=news"><font color="#e95e0b">:GastroEnterology:news</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=sub%3aClinicalTrial"><font color="#e95e0b">:PharmaWorld:sub:ClinicalTrial</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2142">GastroEnterology2142</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 04 December 2014 | 19:20</font><br><br><div style="margin-bottom: 10px;">Comment: Fecal transplantation is gaining increasing acceptance as an effective method of treating recurrent Clostridium difficile infection (CDI).<wbr> However, there are many unknowns about the therapy including questions about administration.<wbr> Administration via colonoscopy, nasogastric or nasoduodenal tube, and enema have been reported in the literature.<wbr> Definitive superiority has not been established for any one method.<wbr> <SPAN style="FONT-FAMILY: arial, helvetica, sans-serif"><FONT face="Verdana">Rebiotix is developing RBX2660<STRONG>, </STRONG>a new category of biologic drugs that use live human-derived organisms to treat disease.<wbr> </FONT></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-FAMILY: arial, helvetica, sans-serif"><STRONG><FONT face="Verdana" size="3">About RBX2660</FONT></STRONG></SPAN> </div><div style="margin-bottom: 10px;"><STRONG>Clinical Evidence</STRONG>: Poster link <A href="http://www.rebiotix.com/index.php/background-for-microbiota-restoration-therapy/clinical-evidence-rbx2660">http:/<wbr>/<wbr>www.<wbr>rebiotix.<wbr>com/<wbr>index.<wbr>php/<wbr>background-for-microbiota-restoration-therapy/<wbr>clinical-evidence-rbx2660</A> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-FAMILY: arial, helvetica, sans-serif"><FONT size="3"><FONT face="Verdana" size="2">RBX2660 consists of live human-derived microbes, is a next generation version of fecal transplantation.<wbr> </FONT></FONT></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-FAMILY: arial, helvetica, sans-serif"><STRONG><FONT face="Verdana" size="3">Trial Details </FONT></STRONG></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-FAMILY: arial, helvetica, sans-serif">ID <A href="http://clinicaltrials.gov/ct2/show/NCT02299570?recr=Open&amp;no_unk=Y&amp;phase=012&amp;fund=2&amp;rcv_s=11%2F04%2F2014&amp;rank=103">NCT02299570</A> - PUNCH CD 2</SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-FAMILY: arial, helvetica, sans-serif">Location 20 sites in the US and Canada</SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-FAMILY: arial, helvetica, sans-serif">PE: Efficacy of Active Treatment Compared to Placebo at Measured at 8 weeks Post-treatment </SPAN> </div><div style="margin-bottom: 10px;">n=117 </div><div style="margin-bottom: 10px;"><UL><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">≥ 18 years</LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Medical record documentation of recurrent CDI either: a) at least two recurrences after a primary episode and has completed at least two rounds of standard-of-care oral antibiotic therapy or b) has had at least two episodes of severe CDI resulting in hospitalization.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Documented history that the subject's recurrent CDI is controlled while on antibiotics even if the subject is not currently on antibiotics.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">A positive stool test for the presence of C.<wbr> difficile within 30 days prior to enrollment.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;">Completion dates June 2015 /<wbr> June 2017 </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">About Rebiotix</FONT></STRONG> </div><div style="margin-bottom: 10px;">- Founded in 2011 </div><div style="margin-bottom: 10px;">- Aim: <SPAN style="LINE-HEIGHT: 1.3em">to "revolutionize" the treatment of challenging gastrointestinal diseases by harnessing the power of the human microbiome.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="LINE-HEIGHT: 1.3em">The company is developing an entirely new kind of biological drug designed to reverse pathogenic processes responsible for disease through the transplantation of live human-derived microbes into a sick person’s intestinal tract.<wbr></SPAN> </div><div><SPAN style="LINE-HEIGHT: 1.3em"><EM>Source: clinicaltrials.<wbr>gov; Rebiotix</EM></SPAN> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="GastroEnterology2665c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">Rebiotix has announced the completion for enrollment of the Ph2b.<wbr>  A total of 117 patients recruited at more than 20 sites in the U.<wbr>S.<wbr> and Canada were enrolled in the study, which is the largest randomized controlled study of a Microbiota Restoration Therapy (MRT) for recurrent <EM>C.<wbr> diff.<wbr></EM> to date.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>New Timelines</STRONG> </div><div style="margin-bottom: 10px;">As a consequence of the delay in the recruitment, new timelines have been postponed to three months.<wbr> </div><div><TABLE border="0" cellpadding="0" cellspacing="0" class="layout_table" style="margin-bottom: 3ex;" summary="Layout table for enrollment information"><TBODY><TR valign="top"><TD headers="enrollmentInfoTitle" nowrap="nowrap">Estimated Study Completion Date:</TD>
<TD headers="enrollmentInfoData" style="padding-left: 1em;">October 2017</TD>
</TR>
<TR valign="top"><TD headers="enrollmentInfoTitle" nowrap="nowrap">Estimated Primary Completion Date:</TD>
<TD headers="enrollmentInfoData" style="padding-left: 1em;">October 2015 (Final data collection date for primary outcome measure)</TD>
</TR>
</TBODY>
</TABLE> </div><font size="-1">Brigitte DESCHAMPS / <a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2665" class="commentpermalink">GastroEnterology2665</a> / <span class="date">18 November 2015</span> /
<span class="time">16:07:33 o'clock CET</span>
</font></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2142">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-12-04T19:20:57+01:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Controversy Builds Over The Applicability of the 2-point Improvement In The Composite Endpoint For GL Which Revance May Use To Its Advantage</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7844</link>
<description>Controversy Builds Over The Applicability of the 2-point Improvement In The Composite Endpoint For GL Which Revance May Use To Its Advantage</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7844</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7844">Controversy Builds Over The Applicability of the 2-point Improvement In The Composite Endpoint For GL Which Revance May Use To Its Advantage</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7844">Neurology7844</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 04 December 2014 | 17:00</font><br><br><div style="margin-bottom: 10px;">Comment: A very interesting report has been issued by BMO Capital Markets 
post accompanying Revance on an investor tour in Boston &amp; New York.<wbr> 
Subsequently there was also an 
equally informative interactive discussion yesterday at the Piper 
Jaffray H/<wbr>C Conference.<wbr> During both events Dan Brown CEO discussed the recent 
timeline setback and path forward for the company's topical and injectable 
toxins.<wbr> He recognises that there may still be some CMC issues to address, 
similar issues having been incurred by Allergan and J&amp;J.<wbr> However, based 
on the response from the ASDSA and others to recent FDA Draft Guidance on 
Upper Facial Lines, he seems confident that the company can find a way forward 
for RT-001 in lateral canthal lines.<wbr> Moreover, he continues 
to emphasise how development plans for RT-001 in HH and 
RT-002 remain unaffected by any ongoing issues with 
RT-001.<wbr> </div><div style="margin-bottom: 10px;">Below are some of the key feedback points from both events regarding key 
questions:-<B>
</B> </div><div style="margin-bottom: 10px;"><P align="left">Why do you think the product didn’t perform as well as it did in 
Phase II?</P> </div><div style="margin-bottom: 10px;"><P align="left">Revance explained that botulinum is a very complex molecule and 
while results proved to be statistically significant on the 1-point scale, the 
data for the composite endpoint was not in the 35-45% range of signal the 
company had outlined in its S-1.<wbr> Given that the Phase IIb trial serves as a last 
chance to make changes before initiating a Phase III, Revance felt that it 
wanted to work to see data within that 35-45% range of signal and want to have 
the greatest probability of success before starting Phase III.<wbr> Allergan  
Johnson &amp; Johnson and Merz Pharmaceuticals had issues at some point 
during the CMC process.<wbr></P> </div><div style="margin-bottom: 10px;"><P align="left">According to Revance, Allergan, who also used List Biological 
Laboratories, Inc for its initial batches, experienced problems during the CMC 
process, faced stability issues and almost ran out of product.<wbr> JNJ experienced 
setbacks in the CMC process as well, which Revance believes likely happened 
later in the development stage, but notes that it is hard to tell from available 
information.<wbr> Also, further speaking to the complexity of the molecule, Allergan 
at one point had tried to increase dose to get a longer duration, and adverse 
events rose significantly.<wbr></P> </div><div style="margin-bottom: 10px;"><STRONG>What was the nature of the results seen in the recent open-label 
trial with the initial batch from the new plant and  w</STRONG><STRONG>at 
is the latest on the FDA Draft Guidance &amp; Its Implications For 
Revance?</STRONG>
 </div><div style="margin-bottom: 10px;"><P align="left">The initial batch was shown to be statistically significant; the 
variance, however, is in the endpoints.<wbr> The regulatory endpoint is a 2-point 
improvement, whereas the clinical endpoint is a 1-point improvement.<wbr> According 
to the company, it and doctors working with RT001, Botox and other Botox-like 
products feel that the 2-point scale is not the result or look patients are 
seeking.<wbr></P> </div><div style="margin-bottom: 10px;"><P align="left">What Revance is finding is that patients want to avoid the “frozen 
look” and are opting for a result more along the lines of a 1-point improvement.<wbr> 
As a result, many doctors are using smaller dosing to achieve this optimal look 
along the lines of a 1-point improvement.<wbr> At the commercial scale, the 2-point 
improvement was a little less than the results seen in the Phase II 
trial.<wbr></P> </div><div style="margin-bottom: 10px;">Yesterday Dan Brown further endorsed this point about the composite endpoint 
having no influence on the way clinicians are using botulinum toxins.<wbr> He was 
citing the ASDSA letter (see attached) that has been sent to the FDA 
following the issuance of its draft guidance and suggested that in 
essence the regulatory authorities are playing catch up with clinical 
practice.<wbr> </div><div style="margin-bottom: 10px;">The extract from the ASDSA letter he refers to is as shown 
below:-<B>
</B>Other Considerations 
Our members have expressed concern that the "FDA 2 point improvement" 
standard could be perceived as: </div><div style="margin-bottom: 10px;">1) A potential overtreatment, especially as patients now desire a more 
"natural " result.<wbr> Complete lack of facial movement is potentially seen as an 
adverse event - not an aesthetic benefit, particularly in the face.<wbr> (In a 
spastic limb it might be somewhat acceptable.<wbr>) In addition, many of the positive 
results of BTX-A are not related to just muscle weakness and may include 
reduction in erythema, pigmentation, and increases in skin luminosity due to the 
effects on neocollagenesis.<wbr> Reduction in erythema, in pigmentation, increases in 
skin luminosity due to the effects on neocollagenesis.<wbr> </div><div style="margin-bottom: 10px;">2) Not related to the current practice environment and patient expectations.<wbr> </div><div style="margin-bottom: 10px;">3) Unrelated to the previous research standards, requiring the use of a "1 
point improvement" this could hinder future research.<wbr> 
 </div><div style="margin-bottom: 10px;"><P align="left">According to Revance, there have been three responses to the FDA’s 
draft guidance.<wbr> The likely next steps would be for the FDA to incorporate 
feedback and revise the draft in the coming years.<wbr> Revance believes that it does 
not make sense to wait for final draft guidance, as the timing is not clear and 
points out that the guidance does not impact its injectab le product.<wbr> To shed 
further light on the impact of the draft guidance, management provides several 
examples where draft guidance has remained in draft form for an extended period 
of time and to this date has not be resolved into final guidance.<wbr> The company 
feels confident that it will be able to get its topical product approved given 
its previous interactions with the FDA and the fact that the draft guidance does 
not explicitly say that the company’s endpoints are insufficient to receive 
approval.<wbr></P> </div><div style="margin-bottom: 10px;"><P align="left">If anybody would like to see a full copy of the report please 
contact Jacquelyne Cantle</P> </div><div>Source BMO Report November 26th &amp; Pipar Jaffray H/<wbr>C Conference 3rd 
December </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7844">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-12-04T17:00:32+01:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>Ferring Expands Footprint in New Jersey [:Endocrinology:comp:Ferring]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology10151</link>
<description>Ferring Expands Footprint in New Jersey [:Endocrinology:comp:Ferring]</description><category>comp:Ferring</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology10151</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10151">Ferring Expands Footprint in New Jersey</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20141231&edate=20140901&cat=comp%3aFerring"><font color="#e95e0b">:Endocrinology:comp:Ferring</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10151">Oncology10151</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 04 December 2014 | 16:00</font><br><br><div style="margin-bottom: 10px;">Comment: The company has expanded its footprint in New Jersey with the opening of its new U.<wbr>S.<wbr> Operations Center on a 25-acre lot (in Parsippany).<wbr> 
The facility allows the company to reinforce its commitment to New Jersey at a time when many pharmaceutical companies are making out-of-state moves.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">U.<wbr>S.<wbr> Operations Center</FONT></STRONG> </div><div style="margin-bottom: 10px;"><FONT size="3"><FONT size="2">- Will house 275 employees across management, administration, commercial operations, manufacturing and R&amp;D,</FONT></FONT> </div><div style="margin-bottom: 10px;">- Location: 100 Interpace Parkway in Parsippany.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">R&amp;D Site - Ferring International Pharmascience Center U.<wbr>S.<wbr> Inc.<wbr></FONT></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>(FIPCUS) Parsippany, New Jersey, USA</STRONG> </div><div style="margin-bottom: 10px;">- formed in 2008.<wbr> </div><div style="margin-bottom: 10px;">- responsible for U.<wbr>S.<wbr> Clinical Development for local projects (those intended for U.<wbr>S.<wbr> commercialization alone) as well as Global projects.<wbr> </div><div>- charged with rapid identification, development, and regulatory approval of products within the clinical therapeutic areas of Reproductive Health, Orthopedics, Gastroenterology and Urology.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10151">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-12-04T16:00:05+01:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>re: Astellas Terminates ASP015K License Agreement with Janssen and Reports EU Approval of XTANDI</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology10150</link>
<description>re: Astellas Terminates ASP015K License Agreement with Janssen and Reports EU Approval of XTANDI</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology10150</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10150">re: Astellas Terminates ASP015K License Agreement with Janssen and Reports EU Approval of XTANDI</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10150">Oncology10150</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/1056">frv17817</a> | 03 December 2014 | 16:53</font><br><br><div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Astellas Terminates ASP015K License Agreement with Janssen and Reports EU Approval of XTANDI</span>&nbsp;<font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a>]</font></font><br><span style="font-size: 12px;">Comment: Astellas has ended its October 2012 licensing agreement with Janssen regarding the WW development and commercialisation of ASP015K (currently in Ph3 for moderate-to-severe RA).<wbr> In parallel, the company has announced the European approval of XTANDI in the chemo-naïve setting.<wbr> Management expects a launch in the first EU countries, including the UK, from December 2014.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10145">...</a><br><font size="-1">Brigitte DESCHAMPS / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10145" class="commentpermalink">Oncology10145</a> / <span class="date">02 December 2014</span> /
<span class="time">14:44:13 o'clock CET</span>
</font></div><div>and another thing - the indication doesn't specify ADT needs to be continued upon starting enzalutamide (despite the trial's inclusion criteria <a href="http://clinicaltrials.gov/ct2/show/NCT01212991?term=enzalutamide+PREVAIL&amp;rank=1" class="defaultlink" title="http://clinicaltrials.gov/ct2/show/NCT01212991?term=enzalutamide+PREVAIL&amp;amp;rank=1">clinicaltrials.go&hellip;</a>) </div><!-- Comment details --><font size="-1">frv17817 / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10150" class="commentpermalink">Oncology10150</a> / <span class="date">03 December 2014</span> /
<span class="time">16:53:11 o'clock CET</span>
</font><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10150">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10145">View thread  Oncology10145: Astellas Terminates ASP015K License Agreement with Janssen and Reports EU Approval of XTANDI</a>]]></content:encoded><dc:date>2014-12-03T16:53:11+01:00</dc:date><dc:creator>frv17817</dc:creator></item><item>
<title>re: Astellas Terminates ASP015K License Agreement with Janssen and Reports EU Approval of XTANDI</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology10149</link>
<description>re: Astellas Terminates ASP015K License Agreement with Janssen and Reports EU Approval of XTANDI</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology10149</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10149">re: Astellas Terminates ASP015K License Agreement with Janssen and Reports EU Approval of XTANDI</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10149">Oncology10149</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/1056">frv17817</a> | 03 December 2014 | 16:46</font><br><br><div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Astellas Terminates ASP015K License Agreement with Janssen and Reports EU Approval of XTANDI</span>&nbsp;<font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a>]</font></font><br><span style="font-size: 12px;">Comment: Astellas has ended its October 2012 licensing agreement with Janssen regarding the WW development and commercialisation of ASP015K (currently in Ph3 for moderate-to-severe RA).<wbr> In parallel, the company has announced the European approval of XTANDI in the chemo-naïve setting.<wbr> Management expects a launch in the first EU countries, including the UK, from December 2014.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10145">...</a><br><font size="-1">Brigitte DESCHAMPS / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10145" class="commentpermalink">Oncology10145</a> / <span class="date">02 December 2014</span> /
<span class="time">14:44:13 o'clock CET</span>
</font></div><div style="margin-bottom: 10px;">just adding some info on the study (which you may have elsewhere on Traction).<wbr> Based on PREVAIL, it is after failure of ADT.<wbr> I wonder if there is info on how this is to be documented in real-life and what is considered failure: PSA progression or side effects.<wbr> In case of the latter, it opens the door for 'covert' first line treatment.<wbr> Do you know if the updated EPAR is already available that might elucidate this? <A href="http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002639/smops/Positive/human_smop_000742.jsp&amp;mid=WC0b01ac058001d127">http:/<wbr>/<wbr>www.<wbr>ema.<wbr>europa.<wbr>eu/<wbr>ema/<wbr>index.<wbr>jsp?curl=pages/<wbr>medicines/<wbr>human/<wbr>medicines/<wbr>002639/<wbr>smops/<wbr>Positive/<wbr>human_smop_000742.<wbr>jsp&amp;mid=WC0b01ac058001d127</A> </div><div style="margin-bottom: 10px;">The European Commission has amended the marketing authorisation for Xtandi  (enzalutamide) to include first-line treatment for men with metastatic castration-resistant prostate cancer (mCRPC) after failure of androgen deprivation therapy.<wbr> It was originally approved in Europe in June 2013 for mCRPC patients whose disease has progressed on or after docetaxel.<wbr><BR><BR>The latest green light is based on the Phase III PREVAIL study which demonstrated that compared with placebo, Xtandi reduced the risk of death by 29% and the risk of radiographic progression or death by 81%.<wbr> Men treated with the oral, once-daily androgen receptor signalling inhibitor experienced a 17-month delay in the time to initiation of chemo compared to placebo (28.<wbr>0 months versus 10.<wbr>8 months).<wbr> </div><div style="margin-bottom: 10px;">Bertrand Tombal of the Universit&eacute; Catholique de Louvain and European principal investigator for PREVAIL, said Xtandi &ldquo;provides a viable treatment option for a broad population of men with mCRPC, regardless of age, or their readiness for chemotherapy&rdquo;.<wbr> He added that the decision from the European Commission &ldquo;is a very important milestone&rdquo;.<wbr><BR><BR>Astellas expects to launch Xtandi in the chemotherapy-na&iuml;ve setting in the first European countries, including the UK, this month.<wbr> Astellas partner Medivation got US approval for the pre-chemo indication in September.<wbr> </div><div><BR><BR>Read more at: <A href="http://www.pharmatimes.com/Article/14-12-02/EU_okays_Astellas_Xtandi_for_pre-chemo_prostate_cancer.aspx#ixzz3KqjVL5OC" style="color: #003399;"><U>http:/<wbr>/<wbr>www.<wbr>pharmatimes.<wbr>com/<wbr>Article/<wbr>14-12-02/<wbr>EU_okays_Astellas_Xtandi_for_pre-chemo_prostate_cancer.<wbr>aspx#ixzz3KqjVL5OC</U></A> <BR>Follow us: <A href="http://ec.tynt.com/b/rw?id=dolMPOD40r445Bacwqm_6l&amp;u=PharmaTimes" target="_blank"><U><FONT color="#0066cc">@PharmaTimes on Twitter</FONT></U></A> </div><!-- Comment details --><font size="-1">frv17817 / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10149" class="commentpermalink">Oncology10149</a> / <span class="date">03 December 2014</span> /
<span class="time">16:46:31 o'clock CET</span>
</font><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10149">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10145">View thread  Oncology10145: Astellas Terminates ASP015K License Agreement with Janssen and Reports EU Approval of XTANDI</a>]]></content:encoded><dc:date>2014-12-03T16:46:31+01:00</dc:date><dc:creator>frv17817</dc:creator></item><item>
<title>Sanofi in Talks toTransfer its Toulouse R&amp;D Site to Evotec [:Oncology:comp:SanofiAventis]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld11023</link>
<description>Sanofi in Talks toTransfer its Toulouse R&amp;D Site to Evotec [:Oncology:comp:SanofiAventis]</description><category>comp:SanofiAventis</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld11023</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20141231&edate=20140901&rec=11023">Sanofi in Talks toTransfer its Toulouse R&D Site to Evotec</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=comp%3aSanofiAventis"><font color="#e95e0b">:Oncology:comp:SanofiAventis</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld11023">PharmaWorld11023</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 03 December 2014 | 12:15</font><br><br><div style="margin-bottom: 10px;">Comment: Under the agreed deal, to be signed in 1H 2015, Sanofi has reported it would transfer its on-site research and development jobs and activities to Evotec, and invest $310M to develop joint research-programs, notably in oncology.<wbr> France accounts for just 8% of Sanofi's revenue but close to half of its research staff.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">About the Agreement</FONT></STRONG> </div><div style="margin-bottom: 10px;">Sanofi would transfer 209 of the 250 people it employs in Toulouse to Evotec, and would invest €250 million ($309.<wbr>59 million) to develop joint-research programs, notably in oncology.<wbr> </div><div>Evotec will commit to maintaining the site’s work force levels until 2019.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20141231&edate=20140901&rec=11023">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-12-03T12:15:02+01:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Myraid's Prolaris® Could Have An Impact On Healthcare Saving Of $6 Billion Over 10 Years [dis:Prostate]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology10148</link>
<description>Myraid's Prolaris® Could Have An Impact On Healthcare Saving Of $6 Billion Over 10 Years [dis:Prostate]</description><category>dis:Prostate</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology10148</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10148">Myraid's Prolaris® Could Have An Impact On Healthcare Saving Of $6 Billion Over 10 Years</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10148">Oncology10148</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/994">Jenny Wu</a> | 03 December 2014 | 12:12</font><br><br><div style="margin-bottom: 10px;">Comment: Three studies with Prolaris&reg; in prostate cancer pateints will be highlighted at the 2014 Society of Urologic Oncology (SUO) Annual Meeting.<wbr> The additional data presented from three stdueis validates active surveillance threshold using Prolaris Score - implicates a potential saving of $6 billion over 10 years if the physicians are using the Prolaris test appropriately to personalize treatemtn options for their prostate cancer.<wbr> </div><div style="margin-bottom: 10px;"><TABLE cellpadding="0" cellspacing="6" class="gnw_table" style="width: 601px; height: 1439px;"><TBODY><TR><TD class="gnw_label" colspan="2"><U><STRONG>2014 SUO - POSTER PRESENTATIONS</STRONG></U></TD>
</TR>
<TR><TD class="gnw_label">&nbsp;</TD>
<TD class="gnw_label">&nbsp;</TD>
</TR>
<TR><TD class="gnw_label"><STRONG>Title:</STRONG></TD>
<TD class="gnw_label_i20">Evaluation of the Economic Impact of the CCP Assay in Localized Prostate </TD>
</TR>
<TR><TD class="gnw_label">&nbsp;</TD>
<TD class="gnw_label_i20">Cancer.<wbr></TD>
</TR>
<TR><TD class="gnw_label"><STRONG>Presenter:</STRONG></TD>
<TD class="gnw_label_i20">E.<wbr> David Crawford</TD>
</TR>
<TR><TD class="gnw_label"><STRONG>Date:</STRONG></TD>
<TD class="gnw_label_i20">Wednesday, Dec.<wbr> 3, 4:30 p.<wbr>m.<wbr> to 6:00 p.<wbr>m.<wbr> ET</TD>
</TR>
<TR><TD class="gnw_label">Summary </TD>
<TD class="gnw_label_i20">In a study that evaluated the economic impact of the Prolaris test, researchers found the test reduced costs by $2,850 per patient tested, which over a 10-year period could save the healthcare system $6 billion.<wbr> For a health plan of approximately 30 million members, this would translate into more than $48 million in savings.<wbr> It is estimated that two-thirds of these savings would be achieved in the first year after testing.<wbr> The cost savings were driven by more use of active surveillance in low- and intermediate-risk patients and from lower disease progression rates in high-risk patients who received more extensive treatment.<wbr></TD>
</TR>
<TR><TD class="gnw_label"><STRONG>Title:</STRONG></TD>
<TD class="gnw_label_i20">Impact of CCP Test on Personalizing Treatment Decisions: Results from a Large </TD>
</TR>
<TR><TD class="gnw_label">&nbsp;</TD>
<TD class="gnw_label_i20">Prospective Registry of Newly Diagnosed Prostate Cancer Patients.<wbr></TD>
</TR>
<TR><TD class="gnw_label"><STRONG>Presenter:</STRONG></TD>
<TD class="gnw_label_i20">Mark Gonzalgo</TD>
</TR>
<TR><TD class="gnw_label"><STRONG>Date:</STRONG></TD>
<TD class="gnw_label_i20">Wednesday, Dec.<wbr> 3, 4:30 p.<wbr>m.<wbr> to 6:00 p.<wbr>m.<wbr> ET</TD>
</TR>
<TR><TD class="gnw_label"> Summary</TD>
<TD class="gnw_label_i20">These are the interim results from PROCEDE 1000, which is the largest prospective clinical utility study to date that evaluates the impact of the Prolaris test on personalizing prostate cancer treatment.<wbr> The interim data analysis of 816 patients demonstrated that physicians changed their treatment decisions in 44 percent of cases based on results from the Prolaris test.<wbr> In 32 percent of patients, the Prolaris test score led to a reduction in treatment, while 12 percent of patients received more aggressive treatment based on their test score.<wbr></TD>
</TR>
<TR><TD class="gnw_label"><STRONG>Title:</STRONG></TD>
<TD class="gnw_label_i20">Validation of an Active Surveillance Threshold for the CCP Score in </TD>
</TR>
<TR><TD class="gnw_label">&nbsp;</TD>
<TD class="gnw_label_i20">Conservatively Managed Men with Localized Prostate Cancer.<wbr></TD>
</TR>
<TR><TD class="gnw_label"><STRONG>Presenter:</STRONG></TD>
<TD class="gnw_label_i20">Steven Stone</TD>
</TR>
<TR><TD class="gnw_label"><STRONG>Date:</STRONG></TD>
<TD class="gnw_label_i20">Wednesday, Dec.<wbr> 3, 4:30 p.<wbr>m.<wbr> to 6:00 p.<wbr>m.<wbr> ET</TD>
</TR>
</TBODY>
</TABLE> </div><div style="margin-bottom: 10px;"><TABLE cellpadding="0" cellspacing="6" class="gnw_table" style="width: 601px; height: 101px;"><TBODY><TR><TD class="gnw_label" style="text-align: justify;">Summary </TD>
<TD class="gnw_label_i20" style="text-align: justify;">The results showed that there were no observed cancer deaths in patients who fell below the defined threshold.<wbr> In a separate analysis of 1,718 patients from a commercial cohort, approximately 55 percent of the patients qualified for active surveillance based on the threshold.<wbr></TD>
</TR>
</TBODY>
</TABLE> </div><div>Source: News Release Myriad.<wbr>com 2 December 2014 </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10148">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-12-03T12:12:07+01:00</dc:date><dc:creator>jew60237</dc:creator></item><item>
<title>Servier Inks Development &amp; Commercialisation Agreement With GeNeuro In Multiple Sclerosis Valued at $455m [news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7841</link>
<description>Servier Inks Development &amp; Commercialisation Agreement With GeNeuro In Multiple Sclerosis Valued at $455m [news]</description><category>news</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7841</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7841">Servier Inks Development & Commercialisation Agreement With GeNeuro In Multiple Sclerosis Valued at $455m</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20141231&edate=20140901&cat=news"><font color="#e95e0b">:Neurology:news</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7841">Neurology7841</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 02 December 2014 | 18:54</font><br><br><div style="margin-bottom: 10px;">Comment: GeNeuro SA, a biopharmaceutical company focusing on new 
therapies for neurology and autoimmune disorders, announced today that it has 
entered into a strategic partnership with Servier to develop and market 
GNbAC1 in MS.<wbr> The drug is seen as having the potential to 
target a causal factor of the disease and therefore to radically 
change the way MS patients are treated.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>What is GNbAC1 Targeting?</STRONG> </div><div style="margin-bottom: 10px;">GNbAC1, a humanized monoclonal antibody, targets MSRV-Env, the envelope 
protein of MS associated retrovirus, a member of the HERV-W family, the 
expression of which is usually silent but reactivated and expressed in MS 
lesions from an early stage in the disease.<wbr> This protein has been shown to be 
both pro-inflammatory and an inhibitor of remyelination, the two major drivers 
of MS pathophysiology.<wbr> </div><div style="margin-bottom: 10px;">By targeting MSRV-Env, GeNeuro expects to bring to patients a safe, effective 
treatment that can halt progression of both relapsing-remitting and progressive 
forms of the disease without hampering the patient’s immune system.<wbr> GNbAC1 has 
successfully completed Phase IIa, demonstrating an optimal safety profile and 
encouraging signs of efficacy on a first small cohort of patients.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Deal Terms</STRONG> </div><div style="margin-bottom: 10px;">Under the terms of the agreement, GeNeuro will be responsible for the 
development of GNbAC1 until completion of Phase IIb, after which Servier can 
exercise the option to license the product for all markets excluding the USA and 
Japan.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><EM>Financial considerations</EM></STRONG> </div><div style="margin-bottom: 10px;">These include an upfront payment by Servier to GeNeuro of 
US$47 million to finance the completion of Phase IIb.<wbr> </div><div style="margin-bottom: 10px;">Subsequent to exercising the option agreement, Servier will cover the costs 
of the Phase III global development program and pay GeNeuro up to US$408 million 
in future development and sales milestones, as well as royalties on future 
sales.<wbr> </div><div style="margin-bottom: 10px;">Servier will also have the option to take an equity stake in GeNeuro as a 
minority shareholder in the next 12 months.<wbr> </div><div>Source: <A href="http://www.servier.com">www.<wbr>servier.<wbr>com</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7841">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-12-02T18:54:14+01:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>Otsuka Plans To Buy Avanir For $3.5bn [news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7840</link>
<description>Otsuka Plans To Buy Avanir For $3.5bn [news]</description><category>news</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7840</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7840">Otsuka Plans To Buy Avanir For $3.<wbr>5bn</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20141231&edate=20140901&cat=news"><font color="#e95e0b">:Neurology:news</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7840">Neurology7840</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 02 December 2014 | 18:44</font><br><br><div style="margin-bottom: 10px;">Comment: Japanese drug maker Otsuka plans to buy US 
based Avanir to expand its neurologic/<wbr>degenerative disease drug portfolio 
ahead of the expiration of a key drug patent for its schizophrnia drug Abilify 
which represents 40% of group sales.<wbr> The extraordinarily high price it is 
prepared to pay (35x estimated 2014 sales) inidicates the appetite 
that is still out there for perceived growth opportunities, 
particularly one might argue amongst the Japanese who are cash rich 
and looking for international expansion opportunities.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Deal Terms</STRONG> </div><div style="margin-bottom: 10px;">Otsuka will pay $17 per share in cash, a 13.<wbr>3% premium 
to Avanir's closing price on Monday.<wbr> Otsuka will launch a tender offer within 10 
business days to purchase all outstanding shares of Avanir, financied from 
existing cash.<wbr> The transaction is expected to cloase in the first quarter of 
2015.<wbr> </div><div style="margin-bottom: 10px;">It is planned that Avanir will operate as a unit of 
Otsuka America Inc and will partner with the group to enhance its development 
and marketing efforts in central nervous system-related disorders.<wbr> </div><div style="margin-bottom: 10px;">Avanir Profile </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7840/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><FONT face="Times New Roman" size="3"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7840/2/ScreenCapture2.jpg?user-agent=rss"></FONT> </div><div style="margin-bottom: 10px;"><FONT face="Times New Roman" size="3"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7840/3/ScreenCapture3.jpg?user-agent=rss"></FONT> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7840/4/ScreenCapture4.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><FONT face="Times New Roman" size="3"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7840/5/ScreenCapture5.jpg?user-agent=rss"></FONT> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7840/6/ScreenCapture6.jpg?user-agent=rss"> </div><div><FONT face="Times New Roman" size="3">Source: 
<a href="http://www.otsuka.com" class="defaultlink" title="www.otsuka.com">otsuka.com</a></FONT> </div><!-- Comment details --><a name="neurology7840attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7840/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(170,9 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7840/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(208,1 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7840/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(189,4 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7840/4/ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(127,3 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7840/5/ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(200,8 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7840/6/ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(152,2 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7840">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-12-02T18:44:20+01:00</dc:date><dc:creator>jac89886</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7840/1/ScreenCapture1.jpg" length="174991" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7840/2/ScreenCapture2.jpg" length="213074" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7840/3/ScreenCapture3.jpg" length="193976" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7840/4/ScreenCapture4.jpg" length="130388" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7840/5/ScreenCapture5.jpg" length="205640" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7840/6/ScreenCapture6.jpg" length="155843" type="image/jpeg"/></item><item>
<title>Insight on Revance's RT002 Ph2 Comparator Study for Moderate/Severe GL [sub:Aesthetics, :PharmaWorld:sub:ClinicalTrial, :PharmaWorld:mkt:Canada]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7838</link>
<description>Insight on Revance's RT002 Ph2 Comparator Study for Moderate/Severe GL [sub:Aesthetics, :PharmaWorld:sub:ClinicalTrial, :PharmaWorld:mkt:Canada]</description><category>sub:Aesthetics</category><category>sub:ClinicalTrial</category><category>mkt:Canada</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7838</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7838">Insight on Revance's RT002 Ph2 Comparator Study for Moderate/<wbr>Severe GL</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20141231&edate=20140901&cat=sub%3aAesthetics"><font color="#e95e0b">:Neurology:sub:Aesthetics</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=mkt%3aCanada"><font color="#e95e0b">:PharmaWorld:mkt:Canada</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=sub%3aClinicalTrial"><font color="#e95e0b">:PharmaWorld:sub:ClinicalTrial</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7838">Neurology7838</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 02 December 2014 | 16:42</font><br><br><div style="margin-bottom: 10px;">Comment: RT002 is manufactured in house and has not been associated with the same issues as RT001.<wbr> The aim of the 5-arm study is to assess safety/<wbr>efficacy of the drug in approx.<wbr> 250 participants.<wbr> PE will measure proportion of subjects assessed as responders by investigator assessment of severity of glabellar lines at maximum frown, and duration of response assessed by investigator assessment of severity of glabellar lines at maximum frown from the date of injection to when subject reverts to baseline severity.<wbr> Interim results are likely to be reported in 2H:2015.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Upcoming Milestone</FONT></STRONG> </div><div style="margin-bottom: 10px;">1Q2015- Select RT002 therapeutic indication </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Trial ID NCT02303002</FONT></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>Design</STRONG> The five-arm, doser anging study has three active arms, a placebo arm and a Botox arm.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Timelines</STRONG> Start date Dec 2014 Completion dates Dec 2015 /<wbr> March 2016 </div><div style="margin-bottom: 10px;"><STRONG>Inclusion Criteria</STRONG> </div><div style="margin-bottom: 10px;"><UL><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Moderate or severe glabellar frown lines</LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Female or male, 30 to 65 years of age in good general health</LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Women of childbearing potential must agree to use an effective method of birth control during the course of the study</LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Willing to refrain from receipt of facial fillers, laser treatments or use of products that affect skin remodeling and causes an active dermal response</LI>
</UL> </div><div><STRONG>Location</STRONG> Canada </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7838">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-12-02T16:42:28+01:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>FDA Lifts Clinical Hold On Flexion's New Osteoarthritis Drug [news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7837</link>
<description>FDA Lifts Clinical Hold On Flexion's New Osteoarthritis Drug [news]</description><category>news</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7837</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7837">FDA Lifts Clinical Hold On Flexion's New Osteoarthritis Drug</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20141231&edate=20140901&cat=news"><font color="#e95e0b">:Neurology:news</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7837">Neurology7837</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 02 December 2014 | 15:35</font><br><br><div style="margin-bottom: 10px;">Comment: Flexion can now resume its phIIb trial which was halted in 
September after one patient developed a knee infection.<wbr> It has since been 
determined that FX006 did not cause the infection.<wbr> Alongside its announcement 
Felxion has also announced plans to initiate a late-stage study by early next 
year.<wbr> </div><div style="margin-bottom: 10px;">FX006 is a first-in-class injectable, sustained-release, intra-articular 
steroid treatment in development for patients with moderate to severe 
osteoarthritis (OA).<wbr> </div><div style="margin-bottom: 10px;"><STRONG>The Sequence Of Events</STRONG> </div><div style="margin-bottom: 10px;">On September 16, 2014, the FDA placed a clinical hold on FX006 due to a 
single occurrence of what was then described as an infection in the injected 
knee joint of a patient in the pivotal Phase 2b trial.<wbr> The subsequent clinical 
hold letter from the FDA requested that the company: </div><div style="margin-bottom: 10px;"><UL type="disc"><LI>Determine whether the study drug was the source of infection by recovering 
  both the specific study drug vials used in the treatment of the patient who 
  experienced the infection, as well as unused study drug vials from the 
  clinical site where the patient was injected and test them for contamination, 
  and</LI>
<LI>Explore other potential causes for infection, including a compromise of 
  sterile procedures during injection.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;">In accordance with these FDA requests, the company performed industry 
standard contamination tests through a certified third-party sterility-testing 
firm, which demonstrated that no microbial growth could be detected in any of 
the used or unused vials.<wbr> As a result, the company concluded that study drug was 
not contaminated.<wbr> </div><div style="margin-bottom: 10px;">The company also explored other potential causes of possible infection 
including contamination during the preparation or administration of FX006.<wbr> 
Following consultations with the principal investigator, the study coordinator 
that prepared the study drug, and the healthcare professional that administered 
the injection at the clinical site, the company could not find any indication 
that sterile procedures were compromised during the injection.<wbr> There have been 
no other infections noted in the approximately 100 other patients dosed with 
FX006 in this trial.<wbr> </div><div style="margin-bottom: 10px;">On October 28, 2014, the company received notification that based on the 
highly atypical nature of this patient's presentation as it relates to septic 
arthritis and the subsequent clinical course, which was most consistent with 
rheumatoid arthritis, the principal investigator has changed the initial serious 
adverse event diagnosis from septic arthritis, possibly related to study drug 
treatment, to inflammatory arthritis, unrelated to study drug 
treatment.<wbr> </div><div style="margin-bottom: 10px;">Thus there have been no confirmed diagnoses of septic arthritis among the 
more than 300 patients treated with FX006 in all clinical trials to date and no 
serious adverse events that have been attributed to study drug.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Flexion Pipeline Profile</STRONG> </div><div style="margin-bottom: 10px;">The company also has two additional product candidates, FX007, a locally 
administered TrkA receptor antagonist for post-operative pain, and FX005, an 
intra-articular, sustained-release p38 MAP kinase inhibitor for end-stage OA 
patients.<wbr> </div><div>Source: <A href="http://www.flexiontherapeutics.com">www.<wbr>flexiontherapeutics.<wbr>com</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7837">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-12-02T15:35:17+01:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>Astellas Terminates ASP015K License Agreement with Janssen and Reports EU Approval of XTANDI [dis:Prostate]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology10145</link>
<description>Astellas Terminates ASP015K License Agreement with Janssen and Reports EU Approval of XTANDI [dis:Prostate]</description><comments>http://ci.beaufour-ipsen.com/traction/permalink/Oncology10145</comments><category>dis:Prostate</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology10145</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10145">Astellas Terminates ASP015K License Agreement with Janssen and Reports EU Approval of XTANDI</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10145">Oncology10145</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 02 December 2014 | 14:44</font><br><br><div style="margin-bottom: 10px;">Comment: Astellas has ended its October 2012 licensing agreement with Janssen regarding the WW development and commercialisation of ASP015K (currently in Ph3 for moderate-to-severe RA).<wbr> In parallel, the company has announced the European approval of XTANDI in the chemo-naïve setting.<wbr> Management expects a launch in the first EU countries, including the UK, from December 2014.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">More to Come for XTANDI</FONT></STRONG> </div><div style="margin-bottom: 10px;">XTANDI’s results in a Phase 1/<wbr>2 trial for a triple negative breast cancer (TNBC) indication are due to be announced at next week’s San Antonio Breast Cancer Symposium.<wbr> This is a tough indication for which there are no existing treatments.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Licensing Agreement Astellas/<wbr>Janssen Biotech for ASP015K</FONT></STRONG> </div><div style="margin-bottom: 10px;">The deal, valued at $945M ($65M upfront + $880M milestones), was signed in October 2012 for Astellas to maximize the value of its drug (in Ph2b), and Janssen to expand its portfolio in the setting.<wbr> </div><div><EM>Source: Astellas</EM> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Oncology10149c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">just adding some info on the study (which you may have elsewhere on Traction).<wbr> Based on PREVAIL, it is after failure of ADT.<wbr> I wonder if there is info on how this is to be documented in real-life and what is considered failure: PSA progression or side effects.<wbr> In case of the latter, it opens the door for 'covert' first line treatment.<wbr> Do you know if the updated EPAR is already available that might elucidate this? <A href="http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002639/smops/Positive/human_smop_000742.jsp&amp;mid=WC0b01ac058001d127">http:/<wbr>/<wbr>www.<wbr>ema.<wbr>europa.<wbr>eu/<wbr>ema/<wbr>index.<wbr>jsp?curl=pages/<wbr>medicines/<wbr>human/<wbr>medicines/<wbr>002639/<wbr>smops/<wbr>Positive/<wbr>human_smop_000742.<wbr>jsp&amp;mid=WC0b01ac058001d127</A> </div><div style="margin-bottom: 10px;">The European Commission has amended the marketing authorisation for Xtandi  (enzalutamide) to include first-line treatment for men with metastatic castration-resistant prostate cancer (mCRPC) after failure of androgen deprivation therapy.<wbr> It was originally approved in Europe in June 2013 for mCRPC patients whose disease has progressed on or after docetaxel.<wbr><BR><BR>The latest green light is based on the Phase III PREVAIL study which demonstrated that compared with placebo, Xtandi reduced the risk of death by 29% and the risk of radiographic progression or death by 81%.<wbr> Men treated with the oral, once-daily androgen receptor signalling inhibitor experienced a 17-month delay in the time to initiation of chemo compared to placebo (28.<wbr>0 months versus 10.<wbr>8 months).<wbr> </div><div style="margin-bottom: 10px;">Bertrand Tombal of the Universit&eacute; Catholique de Louvain and European principal investigator for PREVAIL, said Xtandi &ldquo;provides a viable treatment option for a broad population of men with mCRPC, regardless of age, or their readiness for chemotherapy&rdquo;.<wbr> He added that the decision from the European Commission &ldquo;is a very important milestone&rdquo;.<wbr><BR><BR>Astellas expects to launch Xtandi in the chemotherapy-na&iuml;ve setting in the first European countries, including the UK, this month.<wbr> Astellas partner Medivation got US approval for the pre-chemo indication in September.<wbr> </div><div><BR><BR>Read more at: <A href="http://www.pharmatimes.com/Article/14-12-02/EU_okays_Astellas_Xtandi_for_pre-chemo_prostate_cancer.aspx#ixzz3KqjVL5OC" style="color: #003399;"><U>http:/<wbr>/<wbr>www.<wbr>pharmatimes.<wbr>com/<wbr>Article/<wbr>14-12-02/<wbr>EU_okays_Astellas_Xtandi_for_pre-chemo_prostate_cancer.<wbr>aspx#ixzz3KqjVL5OC</U></A> <BR>Follow us: <A href="http://ec.tynt.com/b/rw?id=dolMPOD40r445Bacwqm_6l&amp;u=PharmaTimes" target="_blank"><U><FONT color="#0066cc">@PharmaTimes on Twitter</FONT></U></A> </div><font size="-1">frv17817 / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10149" class="commentpermalink">Oncology10149</a> / <span class="date">03 December 2014</span> /
<span class="time">16:46:31 o'clock CET</span>
</font></div><a name="Oncology10150c"></a><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div>and another thing - the indication doesn't specify ADT needs to be continued upon starting enzalutamide (despite the trial's inclusion criteria <a href="http://clinicaltrials.gov/ct2/show/NCT01212991?term=enzalutamide+PREVAIL&amp;rank=1" class="defaultlink" title="http://clinicaltrials.gov/ct2/show/NCT01212991?term=enzalutamide+PREVAIL&amp;amp;rank=1">clinicaltrials.go&hellip;</a>) </div><font size="-1">frv17817 / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10150" class="commentpermalink">Oncology10150</a> / <span class="date">03 December 2014</span> /
<span class="time">16:53:11 o'clock CET</span>
</font></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10145">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-12-02T14:44:13+01:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Ascendis Completes $60M Financing [class:GrowthHormone, dis:GrowthHormoneDeficiency]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7871</link>
<description>Ascendis Completes $60M Financing [class:GrowthHormone, dis:GrowthHormoneDeficiency]</description><category>class:GrowthHormone</category><category>dis:GrowthHormoneDeficiency</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7871</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20141231&edate=20140901&rec=7871">Ascendis Completes $60M Financing</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20141231&edate=20140901&cat=class%3aGrowthHormone"><font color="#e95e0b">:Endocrinology:class:GrowthHormone</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20141231&edate=20140901&cat=dis%3aGrowthHormoneDeficiency"><font color="#e95e0b">:Endocrinology:dis:GrowthHormoneDeficiency</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7871">Endocrinology7871</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 01 December 2014 | 18:11</font><br><br><div style="margin-bottom: 10px;">Comment: The proceeds from the Series D financing are expected to be used to fund late-stage clinical trials of TransCon Growth Hormone for the treatment of growth hormone deficiency, and in 2015, to initiate a Phase 1 proof-of-concept program of TransCon Treprostinil to treat pulmonary arterial hypertension.<wbr> Proceeds are also expected to support drug manufacturing, advance the development of preclinical drug candidates, and to enhance the Ascendis clinical development and research organizations.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">About the GH Platform</FONT></STRONG> </div><div style="margin-bottom: 10px;">Ascendis Pharma is developing once-weekly TransCon Growth Hormone, an investigational new drug, to address the burden of daily injections and suboptimal treatment outcomes that can result from poor patient compliance.<wbr> </div><div style="margin-bottom: 10px;">Ascendis Pharma has successfully completed a Phase 2 study of TransCon Growth Hormone in adults with GHD.<wbr> The Phase 2 pediatric study is currently enroling participants.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7871/1/ScreenCapture1.jpg?user-agent=rss"> <EM>(Source: BI analysis)</EM> </div><div><EM>Source: Ascendis Pharma PR</EM> </div><!-- Comment details --><a name="endocrinology7871attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7871/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(109,5 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20141231&edate=20140901&rec=7871">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-12-01T18:11:22+01:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7871/1/ScreenCapture1.jpg" length="112078" type="image/jpeg"/></item><item>
<title>Takeda's Osaka Plant Will be Dedicated to Leuplin [prod:Lupron, :PharmaWorld:func:MSO, comp:Takeda]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology10143</link>
<description>Takeda's Osaka Plant Will be Dedicated to Leuplin [prod:Lupron, :PharmaWorld:func:MSO, comp:Takeda]</description><category>prod:Lupron</category><category>func:MSO</category><category>comp:Takeda</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology10143</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10143">Takeda's Osaka Plant Will be Dedicated to Leuplin</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=comp%3aTakeda"><font color="#e95e0b">:Oncology:comp:Takeda</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=prod%3aLupron"><font color="#e95e0b">:Oncology:prod:Lupron</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=func%3aMSO"><font color="#e95e0b">:PharmaWorld:func:MSO</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10143">Oncology10143</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 01 December 2014 | 17:40</font><br><br><div style="margin-bottom: 10px;">Comment: Last Thursday, Takeda reported on its website that it will transfer the manufacturing of solid products to Hikari and Orianienburg in order for the Osaka plant to become a specialty manufacturing site for Leuplin.<wbr> The objective of the company is to optimize its global manufacturing network to enhance productivity, reinforce the supply system, to become fit and competitive.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">About the Plants</FONT></STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>
The Hikari Plant will further expand its capacity to produce various ethical drugs, including anticancer drugs and vaccines.<wbr></LI>
<LI>
The Oranienburg Plant which has excellent productivity will further enhance its capacity and continue to deliver products to many countries.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><SPAN style="LINE-HEIGHT: 1.3"><STRONG>Osaka Plant</STRONG></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="LINE-HEIGHT: 1.3">Founded in 1915<BR></SPAN><SPAN style="LINE-HEIGHT: 1.3">Ground area 160,000 m</SPAN><SUP>2<BR></SUP><SPAN style="LINE-HEIGHT: 1.3">Main products<BR></SPAN><SPAN style="LINE-HEIGHT: 1.3">● Drug formulations<BR></SPAN><SPAN style="LINE-HEIGHT: 1.3">Takepron, Adecut, Basen, Leuplin, Blopress, Unisia, Actos, Actos OD, Nesina, Metact, Benet, Azilva, Liovel, Bronica, Solfa, Edarbi, Edarbyclor, Dexilant<BR></SPAN> </div><div style="margin-bottom: 10px;"><STRONG style="LINE-HEIGHT: 1.3">Hikari Plant</STRONG> </div><div style="margin-bottom: 10px;"><SPAN style="LINE-HEIGHT: 1.3">Founded in 1946<BR></SPAN><SPAN style="LINE-HEIGHT: 1.3">Ground area 969,644 m</SPAN><SUP>2<BR></SUP><SPAN style="LINE-HEIGHT: 1.3">Main products<BR></SPAN><SPAN style="LINE-HEIGHT: 1.3">● Active Pharmaceutical Ingredients<BR></SPAN><SPAN style="LINE-HEIGHT: 1.3">Blopress, Takepron, Edarbi, Leuplin, Azilva, etc.<wbr><BR></SPAN><SPAN style="LINE-HEIGHT: 1.3">● Drug formulations<BR></SPAN><SPAN style="LINE-HEIGHT: 1.3">Leuplin, Firstcin, Lansap, Lampion Pack, etc.<wbr><BR></SPAN><SPAN style="LINE-HEIGHT: 1.3">● Biological products<BR></SPAN><SPAN style="LINE-HEIGHT: 1.3">Freeze-dried live attenuated measles-rubella combined vaccines, adsorbed diphtheria-purified pertussis-tetanus combined vaccines, etc.<wbr><BR><BR></SPAN><STRONG style="LINE-HEIGHT: 1.3">Oranienburg Plant</STRONG> </div><div style="margin-bottom: 10px;"><SPAN style="LINE-HEIGHT: 1.3">Founded in 1885<BR></SPAN><SPAN style="LINE-HEIGHT: 1.3">Ground area 150,000 m</SPAN><SUP>2<BR></SUP><SPAN style="LINE-HEIGHT: 1.3">Main products<BR></SPAN><SPAN style="LINE-HEIGHT: 1.3">● Drug formulations<BR></SPAN><SPAN style="LINE-HEIGHT: 1.3">145 solid products, including Pantoprazole, Cardiomagnyl</SPAN> </div><div><SPAN style="LINE-HEIGHT: 1.3"><EM>Source: Takeda PR</EM></SPAN> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10143">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-12-01T17:40:08+01:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>BioGaia Invests in MetaboGen [sub:Probiotics]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2140</link>
<description>BioGaia Invests in MetaboGen [sub:Probiotics]</description><comments>http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2140</comments><category>sub:Probiotics</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2140</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2140">BioGaia Invests in MetaboGen</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20141231&edate=20140901&cat=sub%3aProbiotics"><font color="#e95e0b">:GastroEnterology:sub:Probiotics</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2140">GastroEnterology2140</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 01 December 2014 | 17:24</font><br><br><div style="margin-bottom: 10px;">Comment: The metagenomic field is growing rapidly as the role of the gut microbiota in metabolic disease becomes more and more evident.<wbr> The aim of the collaboration is to develop new treatments and products (for different metabolic and other microbial associated diseases by influencing large parts of the microbiota), as well as next generation of probiotic products.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Structure of the Collaboration</FONT></STRONG> </div><div style="margin-bottom: 10px;">BioGaia to invest SEK 12M in MetaboGen over a 2 year period </div><div style="margin-bottom: 10px;">BioGaia's President to become chairman of the board of MetaboGen </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">MetaboGen Short Profile</FONT></STRONG> </div><div style="margin-bottom: 10px;">Founded in 2011 in Gothenburg </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2140/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">Founders: Professor Fredrik Bäckhed at the University of Gothenburg and Professor Jens B Nielsen at Chalmers University of Technology together with GU Holding, which commercializes research results and develops companies linked to the University of Gothenburg.<wbr> </div><div><EM>Source: BioGaia PR</EM> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="GastroEnterology2691c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">In December 2014 BioGaia reported its decision to invest SEK 12 million in MetaboGen AB, Gothenburg, Sweden.<wbr> The first investment of SEK 4 million took place in December 2014 and as MetaboGen has reached the agreed milestones the second investment of SEK 4 million was made on December 1 2015.<wbr> </div><div>BioGaia thereafter owns 27% of the share capital of MetaboGen, and if further milestones will be reached, the last investment of SEK 4 million will take place at the end of 2016.<wbr> BioGaia's share of the company will then be 35%.<wbr> </div><font size="-1">Brigitte DESCHAMPS / <a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2691" class="commentpermalink">GastroEnterology2691</a> / <span class="date">01 December 2015</span> /
<span class="time">18:12:37 o'clock CET</span>
</font></div><a name="gastroenterology2140attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2140/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(30,9 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2140/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(39,9 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2140">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-12-01T17:24:52+01:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2140/1/ScreenCapture1.jpg" length="31654" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2140/2/ScreenCapture2.jpg" length="40907" type="image/jpeg"/></item><item>
<title>Exelixis Down 7.8% After COMET-2 Ph3 Results of Cabozantinib [dis:Prostate]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology10142</link>
<description>Exelixis Down 7.8% After COMET-2 Ph3 Results of Cabozantinib [dis:Prostate]</description><category>dis:Prostate</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology10142</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10142">Exelixis Down 7.<wbr>8% After COMET-2 Ph3 Results of Cabozantinib</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10142">Oncology10142</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 01 December 2014 | 17:02</font><br><br><div style="margin-bottom: 10px;">Comment: The COMET-2 trial did not meet its primary endpoint of alleviation of bone pain, as determined by comparing the percentage of patients in the two treatment arms who achieved a pain response at Week 6 that was confirmed at Week 12 without increase in narcotic medication.<wbr> Following the COMET-1 disapointing top-line results announced in September, Exelixis management deprioritized the cabozantinib development program in mCRPC.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Additional Findings</FONT></STRONG> </div><div style="margin-bottom: 10px;">15% of patients in the cabozantinib arm reported a pain response, compared to 17% of patients in the control arm receiving mitoxantrone/<wbr> prednisone.<wbr> The difference in pain response between the arms was not statistically significant.<wbr> </div><div style="margin-bottom: 10px;">The safety profile of cabozantinib in the trial was consistent with that observed in previous studies in mCRPC.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Next Steps</FONT></STRONG> </div><div style="margin-bottom: 10px;">Exelixis will submit the results from the COMET program for potential presentation at a future medical meeting.<wbr> </div><div style="margin-bottom: 10px;"><B>About the COMET-2 Trial</B> </div><div style="margin-bottom: 10px;">Design: COMET-2, the second phase 3 study from the COMET program, was a randomized, double-blind, controlled trial designed to enroll patients with CRPC that is metastatic to the bone, who were suffering from moderate to severe pain despite optimized narcotic medication, and whose disease had progressed following treatment with docetaxel as well as abiraterone and/<wbr>or enzalutamide.<wbr> </div><div style="margin-bottom: 10px;">Recruitment: 119 of the planned 246 patients were randomized 1:1 to receive either cabozantinib or mitoxantrone/<wbr>prednisone.<wbr> </div><div style="margin-bottom: 10px;">The primary endpoint was alleviation of bone pain, as determined by comparing the percentage of patients in the two treatment arms who achieve a pain response -- a greater than or equal to 30% decrease from baseline in the average of daily worst pain intensity according to the BPI collected over seven days -- at Week 6 that is confirmed at Week 12 without increase in narcotic medication.<wbr> </div><div style="margin-bottom: 10px;">Secondary endpoints were bone scan response and overall survival, and other endpoints include PFS, safety, and evaluation of bone biomarkers and circulating tumor cells.<wbr> </div><div>Source: Exelixis </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10142">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-12-01T17:02:56+01:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Confirmation For A Ph3 Underway For Roche's Anti-PDL1 In Bladder Cancer [:Oncology:dis:Bladder]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7870</link>
<description>Confirmation For A Ph3 Underway For Roche's Anti-PDL1 In Bladder Cancer [:Oncology:dis:Bladder]</description><category>dis:Bladder</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7870</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20141231&edate=20140901&rec=7870">Confirmation For A Ph3 Underway For Roche's Anti-PDL1 In Bladder Cancer</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=dis%3aBladder"><font color="#e95e0b">:Oncology:dis:Bladder</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7870">Endocrinology7870</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/994">Jenny Wu</a> | 28 November 2014 | 17:47</font><br><br><div style="margin-bottom: 10px;">Comment: Given that Roche has only released a press release of positive outcome from its Ph1 trial on 31st May 2014, the speed of how fast the company has brought their bladder cancer programme forward is astonishing.<wbr> The ambition of the company to file in 2016 (as presented during the company's Q3 update - <A class="title" href="traction/permalink/Endocrinology7827" title="Permanent Link to Endocrinology7827"><U><FONT color="#0066cc">Roche's Sales Presentation Outlines Strong Cancer Franchise</FONT></U></A>) is proved by registration of its Ph3 trial on clinicaltrials.<wbr>gov this week and the study is planned to start recruitment in December.<wbr> The only three Asia/<wbr>Oceanic countries included in the study are Korea, Taiwan and Australia.<wbr> Interestingly the choice of the company to target 2L+ setting in their Ph3 trial (as the current common consensus of immunotherapy is more likely to work better for less bulky disease i.<wbr>e.<wbr> earlier setting) may reflect Roche's ambition with a very aggressive timeline to deliver its anti-PDL1 for bladder cancer in the market by 2017-2018.<wbr> </div><div style="margin-bottom: 10px;">ClinicalTrial ID:<a href="http://clinicaltrial.gov/ct2/show/NCT02302807?term=MPDL3280A&rank=15" class="defaultlink">NCT02302807</a> </div><div style="margin-bottom: 10px;">Target n= 767 patients </div><div style="margin-bottom: 10px;">Control arm : MPDL2380A monotherapy (1200 mg by iv infusion on Day 1 of each 21 day cycle) </div><div style="margin-bottom: 10px;">Comparison arm: Chemotherapy of choice (Vinflunine, Paclitaxel or Docetaxel) </div><div style="margin-bottom: 10px;">Target Patient Population: 2L+ advanced /<wbr> metastatic bladder cancer (patients have to received at least 1 prior platinum containing regimen or have disease progression during platinum containing treatment) </div><div style="margin-bottom: 10px;">Countries: Europe, US, Canada, Australia, Korea, and Taiwan </div><div>Source: clinicaltrial.<wbr>gov </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20141231&edate=20140901&rec=7870">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-11-28T17:47:17+01:00</dc:date><dc:creator>jew60237</dc:creator></item><item>
<title>re: Briefing on Astellas R&amp;D Meeting</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology10141</link>
<description>re: Briefing on Astellas R&amp;D Meeting</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology10141</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10141">re: Briefing on Astellas R&D Meeting</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10141">Oncology10141</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/994">Jenny Wu</a> | 28 November 2014 | 16:43</font><br><br><div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Briefing on Astellas R&D Meeting</span>&nbsp;<font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=comp%3aAstellas"><font color="#e95e0b">:Oncology:comp:Astellas</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=headline"><font color="#e95e0b">:Oncology:headline</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=prod%3aFirmagon"><font color="#e95e0b">:Oncology:prod:Firmagon</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=prod%3aMDV3100"><font color="#e95e0b">:Oncology:prod:MDV3100</font></a>]</font></font><br><span style="font-size: 12px;">Comment: Astellas hosted an R&amp;D meeting on 10 July at which it talked about its stance of accelerating new drug development via the use of external resources.<wbr> The company has been speeding up development in particular in oncology, which it has set up as its 3rd focus domain.<wbr> Management announced its FASTEN project for accelerating R&amp;D.<wbr> The pipeline section outlined that Xtandi's Ph2 results for breast cancer are due around end-2014 to early 2015.<wbr> The development of degarelix 3M is still mentioned being in Ph3/<wbr>Japan.<wbr> Key slides are provided below, and the full presentations are attached.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=9825">...</a><br><font size="-1">Brigitte DESCHAMPS / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9825" class="commentpermalink">Oncology9825</a> / <span class="date">10 July 2014</span> /
<span class="time">11:57:14 o'clock CEST</span>
</font></div><div>Comment: The global PROSPER Ph3 to investigate enzalutamide's safety and efficacy in non-metastatic CRPC (M0 CRPC) patients will also include 18 centres in China.<wbr> This appears to be sponsored by Medivation (CTR20140772).<wbr> Currently the patient recruitment has not yet started.<wbr> Source: <a href="http://www.chinadrugtrials.org.cn/eap/clinicaltrials.searchlistdetail" class="defaultlink">China Drug Trials Registry Platform</a> </div><!-- Comment details --><font size="-1">Jenny Wu / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10141" class="commentpermalink">Oncology10141</a> / <span class="date">28 November 2014</span> /
<span class="time">16:43:23 o'clock CET</span>
</font><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10141">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9825">View thread  Oncology9825: Briefing on Astellas R&D Meeting</a>]]></content:encoded><dc:date>2014-11-28T16:43:23+01:00</dc:date><dc:creator>jew60237</dc:creator></item><item>
<title>Roche's Anti-PDL1 Ph1 Bladder Cancer Cohort Data Is Publisehd In Nature</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology10140</link>
<description>Roche's Anti-PDL1 Ph1 Bladder Cancer Cohort Data Is Publisehd In Nature</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology10140</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10140">Roche's Anti-PDL1 Ph1 Bladder Cancer Cohort Data Is Publisehd In Nature</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10140">Oncology10140</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/994">Jenny Wu</a> | 27 November 2014 | 19:24</font><br><br><div style="margin-bottom: 10px;">Comment: Dr Thomas Powles from Barts Cancer Institute (London) today published in Nature the data from the Ph1 study  for the MPDL3280A (Roche's anti-PDL1) with a focus on bladder cancer cohort.<wbr> The communication effort from Roche/<wbr>Genetech on their PD-L1 development has been non-stop since beginning of the year via various conferences (Immunotherapy conference in April, ASCO in May, ESMO in September).<wbr>  Given the first public presentation of the positive outcome from their Ph1/<wbr>2 trial only took place earlier this year, the data already made available and published in Nature (one of the journals that has the highest impact factor of 42.<wbr>351)  within a short period of time.<wbr> This further illustrates Roche's strategic focus and ambition to accelerate their anti-PDL1 development programme in bladder cancer.<wbr> </div><div style="margin-bottom: 10px;">Dr Tom Powles, Lead Author and Consultant Medical Oncologist, Barts Cancer Institute, Queen Mary University of London, comments:<STRONG> "<EM>This study is a hugely exciting step forward in the search for alternative advanced bladder cancer treatment.<wbr> For decades chemotherapy has been the only option, with a poor outcome and many patients too ill to cope with it.<wbr> Not only has this investigational drug had a striking response rate, we can target this therapy for patients by screening specific protein PD-L1.<wbr>"</EM></STRONG> </div><div style="margin-bottom: 10px;"><STRONG><EM>"</EM></STRONG><STRONG><EM>We now need larger trials to confirm our findings, and as this drug has been given breakthrough designation status by the FDA, we hope to fast track this process so we can begin to give hope to the thousands of people affected by advanced bladder cancer each year.<wbr>"</EM></STRONG> </div><div style="margin-bottom: 10px;">In a phase one, multi-centre international clinical trial, 68 patients with advanced bladder cancer (who had failed all other standard treatments such as chemotherapy) received MPDL3280A, a cancer immunotherapy medicine being developed by Roche.<wbr> In addition, patients were all tested for the protein PD-L1 and around 30 were identified as having PD-L1 positive tumours.<wbr> </div><div style="margin-bottom: 10px;">After six weeks of treatment, 43 per cent of PD-L1-positive patients found their tumour had shrunk.<wbr> This rose to 52 per cent after 12 weeks of follow up.<wbr> In two of these patients (7 per cent) radiological imaging found no evidence of the cancer at all following the treatment.<wbr> Among PD-L1 negative patients, 11 percent responded positively to treatment too.<wbr> </div><div style="margin-bottom: 10px;">Patients who had a positive response to treatment found the benefits were prolonged, and safety results were also encouraging, with fatigue and loss of appetite most commonly reported as side effects.<wbr> </div><div>Source:<a href="http://www.nature.com/nature/journal/v515/n7528/full/nature13904.html#affil-auth" class="defaultlink">Nature 515, 558-562 27 November 2014 (doi:10.1038/nature13904</a>) </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10140">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-11-27T19:24:44+01:00</dc:date><dc:creator>jew60237</dc:creator></item><item>
<title>The First Curative Gene Therapy Drug Is Set For Launch With a €1.1m Price Tag</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld11019</link>
<description>The First Curative Gene Therapy Drug Is Set For Launch With a €1.1m Price Tag</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld11019</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20141231&edate=20140901&rec=11019">The First Curative Gene Therapy Drug Is Set For Launch With a €1.<wbr>1m Price Tag</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld11019">PharmaWorld11019</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 27 November 2014 | 13:04</font><br><br><div style="margin-bottom: 10px;">Comment: According to a Reuters report , Uniquire/<wbr>Cheisi's Glybura is set to go on sales in Germany with a record high price for a medicine to treat a rare disease.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>What Doe Glybura Treat?</STRONG> </div><div style="margin-bottom: 10px;">Glybura fights an ultra-rare genetic disease called lipoprtoein lipase deficienty, a disease that closgs the blood with fat.<wbr> The medicine was approved two years ago but its launch was delayed to allow for the collection of 6-year follow-up data on its benefits.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Glybera's Pricing Scenario</STRONG> </div><div style="margin-bottom: 10px;">Cheisi has filed a pricing dossier with the G-BA which will issue an assessment on the drug's benefit by the end of April 2015.<wbr> The company is seeking a retail price of &euro;53,000 per vial which equates to the &euro;1.<wbr>1m for a typical LPLD patient who will need 42 injections from 21 vials.<wbr> </div><div style="margin-bottom: 10px;">Whilst Cheisi is reponsible for the pricing of the drug, further information on this price positioning will be disclosed at an investor meeting to be held by Uniqure on December 1st in New York.<wbr> As the licensing partner Uniqure will receive a net royalty of 23-30% of sales.<wbr> </div><div style="margin-bottom: 10px;">It is estimated that there are 150-200 patients who might be eligible for Glybera across Europe, the anticipated impact on the H/<wbr>C budget is therefore expected to be small but this case is likely to be closely monitored as a benchmark for other gene therapies.<wbr> In fact Cheisi is lcaiming that the annualised cost is no more that has been charged for some other enzyme replacement therapies for other rare diseases.<wbr> </div><div>Source: Reuters </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20141231&edate=20140901&rec=11019">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-11-27T13:04:38+01:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>BMS China to Reduce Medical Rep Force by &gt;1,000 [mkt:China, :Oncology:comp:BMS]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld11018</link>
<description>BMS China to Reduce Medical Rep Force by &gt;1,000 [mkt:China, :Oncology:comp:BMS]</description><category>mkt:China</category><category>comp:BMS</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld11018</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20141231&edate=20140901&rec=11018">BMS China to Reduce Medical Rep Force by >1,000</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=comp%3aBMS"><font color="#e95e0b">:Oncology:comp:BMS</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=mkt%3aChina"><font color="#e95e0b">:PharmaWorld:mkt:China</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld11018">PharmaWorld11018</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 27 November 2014 | 09:55</font><br><br><div style="margin-bottom: 10px;">Comment: BMS began laying medical reps off 6 months ago.<wbr> Industry insiders note that the medical reps are being replaced by medical liaison officers in response to last year's government crackdown on contacts between hospitals and pharmaceutical companies.<wbr> </div><div style="margin-bottom: 10px;">Bristol-Myers Squibb's JV, Sino-American Shanghai Squibb Pharmaceuticals Ltd.<wbr>, is reportedly cutting its medical representative staff numbers in China by up to 1,000.<wbr> </div><div style="margin-bottom: 10px;">Although not commenting on the scale of the layoffs, BMS  this week confirmed the reports in a statement: "As part of our transformation, we continue to evaluate and determine the appropriate size of the organization and structure in order to best serve our patients […] We will strive to keep the impact on affected employees to a minimum, and undertake to treat those affected in a fair way that complies with applicable Chinese laws”.<wbr> </div><div style="margin-bottom: 10px;">BMS  went on to note that the goal of the reorganization is "to create a more flexible and customer-oriented organization, better able to respond to market demands, and ultimately benefit patients”.<wbr> </div><div style="margin-bottom: 10px;"><EM>Source: gbipharma</EM> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Sino-American Shanghai Squibb Pharmaceuticals Ltd</FONT></STRONG> </div><div style="margin-bottom: 10px;">Was established on October 14, 1982.<wbr> </div><div>Currently, the factory is equipped with a cephalosporin production workshop, a non-cephalosporin production workshop and an oral HBV antiviral drugs production workshop.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20141231&edate=20140901&rec=11018">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-11-27T09:55:27+01:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Lanzhou Institute Is Sponsoring Two New Therapeutic Toxin Trials with HengLi [class:BotulinumToxins, dis:Spasticity]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7833</link>
<description>Lanzhou Institute Is Sponsoring Two New Therapeutic Toxin Trials with HengLi [class:BotulinumToxins, dis:Spasticity]</description><category>class:BotulinumToxins</category><category>dis:Spasticity</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7833</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7833">Lanzhou Institute Is Sponsoring Two New Therapeutic Toxin Trials with HengLi</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20141231&edate=20140901&cat=class%3aBotulinumToxins"><font color="#e95e0b">:Neurology:class:BotulinumToxins</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20141231&edate=20140901&cat=dis%3aSpasticity"><font color="#e95e0b">:Neurology:dis:Spasticity</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7833">Neurology7833</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 26 November 2014 | 17:54</font><br><br><div style="margin-bottom: 10px;">Comment: ClinicalTrials.<wbr>gov is listing another new Chinese therapeutic trial with HengLi&reg;, this time a phIII trials with the toxin in chronic migraine.<wbr> Only days ago we reported on a new upper limb spasticity trial in China.<wbr> </div><div style="margin-bottom: 10px;">This study is being undertaken by the same principal investigator at the same institution (see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7793" class="defaultlink">Neurology7793: Registration Trial of Lanzhou Institute's Botulinum Toxin Type A for Post-Stroke ULS in China</a>) </div><div style="margin-bottom: 10px;"><TABLE border="0" cellpadding="0" cellspacing="0" class="layout_table" style="margin-top: 1ex;" summary="Layout table for additional information"><TBODY><TR valign="top"><TD headers="colTitle">ClinicalTrials.<wbr>gov Identifier:</TD>
<TD headers="colData" style="padding-left: 1em;"><A class="study-link" href="http://clinicaltrials.gov/show/NCT02291380" title="Current version of study NCT02291380 on ClinicalTrials.gov">NCT02291380</A></TD>
</TR>
</TBODY>
</TABLE> </div><div style="margin-bottom: 10px;"><P class="color-bullet" style="margin-top: 0.7ex;">Study Title: A Multi-center, Randomized, Double-blind, Placebo Parallel-Controlled Clinical Study to Evaluate the Safety and Efficacy of Botulinum Toxin Type A for Injection (HengLi &reg;) for Prophylactic Treatment of Chronic Migraine in Adults</P> </div><div style="margin-bottom: 10px;"><P class="color-bullet" style="margin-top: 0.7ex;">In the core phase, two treatments of HengLi&reg; or the placebo will be administrated (randomized at a ratio of 2:1, the target number is 288 subjects).<wbr> In the extension phase, three treatments of HengLi&reg; will be still administrated on 288 subjects recruited.<wbr></P> </div><div style="margin-bottom: 10px;"><P class="color-bullet" style="margin-top: 0.7ex;">Primary Outcome Measures:</P> </div><div style="margin-bottom: 10px;"><UL style="margin-bottom: 1ex; margin-top: 1ex;"><LI class="color-bullet" style="margin-top: 0.7ex;">Change from baseline in average number of days with headache per month.<wbr>Time Frame: Baseline (week -4 to 0) and core phase (week 21 to 24)
</LI>
</UL> </div><div style="margin-bottom: 10px;"><P class="color-bullet" style="margin-top: 0.7ex;">The study has been initiated but not yet started recruitment and is scheduled to complete in terms of primary endpoint in October 2016 and in terms of study completion by April 2017.<wbr></P> </div><div><P class="color-bullet" style="margin-top: 0.7ex;">The PI similarly is Shengyuan Yu from The General Hospital of the People's Liberation Army</P> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7833">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-11-26T17:54:52+01:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>Symprove's Multi-Strain Liquid Probiotic Confers Benefit in IBS [dis:IBS, sub:Probiotics]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2138</link>
<description>Symprove's Multi-Strain Liquid Probiotic Confers Benefit in IBS [dis:IBS, sub:Probiotics]</description><category>dis:IBS</category><category>sub:Probiotics</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2138</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2138">Symprove's Multi-Strain Liquid Probiotic Confers Benefit in IBS</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20141231&edate=20140901&cat=dis%3aIBS"><font color="#e95e0b">:GastroEnterology:dis:IBS</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20141231&edate=20140901&cat=sub%3aProbiotics"><font color="#e95e0b">:GastroEnterology:sub:Probiotics</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2138">GastroEnterology2138</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 25 November 2014 | 16:48</font><br><br><div style="margin-bottom: 10px;">Comment: Symprove Holdings Ltd is a R&amp;D company based in Surrey, with production facility in Farnham.<wbr> It has developed a Unique Delivery System (UDS™) to protect and transport live activated probiotic bacteria through the stomach to the intestines – safely.<wbr> The water-based multi-strain supplement contains 4 unique strains of live activated bacteria (<EM>L.<wbr> rhamnosus, E.<wbr> faecium, L.<wbr> acidophilus, </EM>and<EM> L.<wbr> plantarum).<wbr> </EM>Results from a single-centre, randomised, double-blind, placebo-controlled trial of 152 adult patients with symptomatic IBS show statistically significant improvement in overall symptom severity in patients with IBS.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Competitive Advantage</FONT></STRONG> </div><div style="margin-bottom: 10px;"><UL><LI><FONT size="3" style="FONT-SIZE: 1.4em">Scientists put eight probiotic drinks through three tests to asses health benefits</FONT></LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI><FONT size="3" style="FONT-SIZE: 1.4em">Found that only one of them (<STRONG>Symprove</STRONG>) passed all three tests showing they aid digestion</FONT></LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI><A href="http://www.dailymail.co.uk/health/article-2752798/The-probiotic-drinks-don-t-bring-benefits-Study-finds-good-bacteria-products-does-not-reach-small-intestine.html">http:/<wbr>/<wbr>www.<wbr>dailymail.<wbr>co.<wbr>uk/<wbr>health/<wbr>article-2752798/<wbr>The-probiotic-drinks-don-t-bring-benefits-Study-finds-good-bacteria-products-does-not-reach-small-intestine.<wbr>html</A></LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">What is Symprove ?</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2138/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><A href="http://www.symprove.com/symprove-explained">http:/<wbr>/<wbr>www.<wbr>symprove.<wbr>com/<wbr>symprove-explained</A> </div><div style="margin-bottom: 10px;"><A href="http://www.symprove.com/about-us">http:/<wbr>/<wbr>www.<wbr>symprove.<wbr>com/<wbr>about-us</A> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">About the Study</FONT></STRONG> </div><div style="margin-bottom: 10px;"><A href="http://www.isrctn.com/ISRCTN77512412">http:/<wbr>/<wbr>www.<wbr>isrctn.<wbr>com/<wbr>ISRCTN77512412</A> </div><div style="margin-bottom: 10px;"><FONT size="2"><STRONG>METHODS</STRONG></FONT> </div><div style="margin-bottom: 10px;"><ABSTRACTTEXT label="METHODS">A single-centre, randomised, double-blind, placebo-controlled trial of adult patients with symptomatic IBS.<wbr> Patients received 12 weeks of treatment with the probiotic or placebo (1 mL/<wbr>kg/<wbr>day).<wbr> The primary efficacy measure was the difference in change in the IBS symptom severity score (IBS-SSS) between probiotic vs.<wbr> placebo at week 12.<wbr> Secondary outcome measures included change in the IBS quality of life (IBS-QOL) score and change in the IBS-SSS symptom component scores.<wbr></ABSTRACTTEXT> </div><div style="margin-bottom: 10px;"><H4><FONT size="2">RESULTS</FONT></H4> </div><div style="margin-bottom: 10px;"><ABSTRACTTEXT label="RESULTS">A total of 186 patients were randomised and 152 patients completed the study.<wbr> The mean change in IBS-SSS was -63.<wbr>3 probiotic vs.<wbr> -28.<wbr>3 placebo.<wbr> The mean difference in the IBS-SSS was statistically significant [-35.<wbr>0 (95% CI; -62.<wbr>03, -7.<wbr>87); P = 0.<wbr>01].<wbr> There was no significant improvement in the IBS-QOL.<wbr> No serious adverse events were reported.<wbr></ABSTRACTTEXT> </div><div style="margin-bottom: 10px;">From <A href="http://www.ncbi.nlm.nih.gov/">http:/<wbr>/<wbr>www.<wbr>ncbi.<wbr>nlm.<wbr>nih.<wbr>gov</A>, see <A href="http://www.ncbi.nlm.nih.gov/pubmed/24815298">original source</A>.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Reference </STRONG> </div><div><EM>Aliment Pharmacol Ther.<wbr> 2014 Jul;40(1):51-62. doi: 10.<wbr>1111/<wbr>apt.<wbr>12787.<wbr> Epub 2014 May 11</EM>.<wbr> - <FONT size="2">Randomised clinical trial: A liquid multi-strain probiotic vs.<wbr> placebo in the irritable bowel syndrome--a 12 week double-blind study.<wbr> </FONT>Sisson G, Ayis S, Sherwood RA, Bjarnason I.<wbr> </div><!-- Comment details --><a name="gastroenterology2138attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2138/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(24,4 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2138">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-11-25T16:48:06+01:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2138/1/ScreenCapture1.jpg" length="25032" type="image/jpeg"/></item><item>
<title>Strategic Options For Sinclair Pharma To Be Evaluated [sub:Aesthetics]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7831</link>
<description>Strategic Options For Sinclair Pharma To Be Evaluated [sub:Aesthetics]</description><category>sub:Aesthetics</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7831</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7831">Strategic Options For Sinclair Pharma To Be Evaluated</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20141231&edate=20140901&cat=sub%3aAesthetics"><font color="#e95e0b">:Neurology:sub:Aesthetics</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7831">Neurology7831</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 25 November 2014 | 14:19</font><br><br><div style="margin-bottom: 10px;">Comment: Dermatology, wound and skin care company Sinclair Pharma IS is 
evaluating strategic options including the possible sale of the company 
according to an AGM statement made today.<wbr> Rothschilds has been appointed to 
evaluate various options.<wbr> </div><div style="margin-bottom: 10px;">Sinclair has a market leading aesthetic dermatology portfolio focused on 
hyalluronic fillers and collagen stimulants.<wbr> </div><div style="margin-bottom: 10px;">The company continues to trade well and in-line with expectations but is 
receiving significant attention from a number of international companies 
interested in some form of co-operation including co-promotion, 
distribution and development collaboration and merger and acquisition 
opportunities.<wbr> As such the Board recognises that there may be organisations 
better placed to build on the company's success to date.<wbr> </div><div style="margin-bottom: 10px;">Rothschild's evaluation will look at the optimal way to realise considerable 
value within the company including the sale of part or all of the company or 
partnerships that may assist with the further development of the business.<wbr> </div><div style="margin-bottom: 10px;">The slides below highlight the profile of the company as it currently 
stands.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7831/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7831/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><P align="left"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7831/3/ScreenCapture3.jpg?user-agent=rss"></P> </div><div style="margin-bottom: 10px;"><P align="left"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7831/4/ScreenCapture4.jpg?user-agent=rss"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7831/5/ScreenCapture5.jpg?user-agent=rss"></P> </div><div style="margin-bottom: 10px;"><P align="left"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7831/6/ScreenCapture6.jpg?user-agent=rss"></P> </div><div><P align="left"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7831/7/ScreenCapture7.jpg?user-agent=rss"></P> </div><!-- Comment details --><a name="neurology7831attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7831/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(151,9 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7831/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(121,9 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7831/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(97,7 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7831/4/ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(119,5 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7831/5/ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(110,7 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7831/6/ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(125,5 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7831/7/ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(110,4 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7831">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-11-25T14:19:50+01:00</dc:date><dc:creator>jac89886</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7831/1/ScreenCapture1.jpg" length="155500" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7831/2/ScreenCapture2.jpg" length="124797" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7831/3/ScreenCapture3.jpg" length="100061" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7831/4/ScreenCapture4.jpg" length="122371" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7831/5/ScreenCapture5.jpg" length="113361" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7831/6/ScreenCapture6.jpg" length="128547" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7831/7/ScreenCapture7.jpg" length="113067" type="image/jpeg"/></item><item>
<title>Actavis' Plans After 'Combination' with Allergan [comp:Allergan, :PharmaWorld:mkt:China]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7830</link>
<description>Actavis' Plans After 'Combination' with Allergan [comp:Allergan, :PharmaWorld:mkt:China]</description><category>comp:Allergan</category><category>mkt:China</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7830</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7830">Actavis' Plans After 'Combination' with Allergan</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20141231&edate=20140901&cat=comp%3aAllergan"><font color="#e95e0b">:Neurology:comp:Allergan</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=mkt%3aChina"><font color="#e95e0b">:PharmaWorld:mkt:China</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7830">Neurology7830</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 25 November 2014 | 13:47</font><br><br><div style="margin-bottom: 10px;">Comment: Actavis plans China expansion for Allergan, with a particular focus on Botox.<wbr> Overlaps in corporate functions, human resources and finance will led to job cuts.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Allergan in China</FONT></STRONG> </div><div style="margin-bottom: 10px;">Direct operations since 2009 </div><div style="margin-bottom: 10px;">More than 160 employees (in 2011) </div><div style="margin-bottom: 10px;">BOTOX® Cosmetic (2009, Botox® was approved in China for glabellar lines), and eye care products being the main drivers of growth </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Positions Affected by the Move</FONT></STRONG> </div><div>Number not yet quantified </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7830">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-11-25T13:47:37+01:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>BMS to Initiate A New Trial To Further Evaluate Its Ipilimumab In Chemo Naive Setting [dis:Prostate, comp:BMS]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology10128</link>
<description>BMS to Initiate A New Trial To Further Evaluate Its Ipilimumab In Chemo Naive Setting [dis:Prostate, comp:BMS]</description><category>dis:Prostate</category><category>comp:BMS</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology10128</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10128">BMS to Initiate A New Trial To Further Evaluate Its Ipilimumab In Chemo Naive Setting</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=comp%3aBMS"><font color="#e95e0b">:Oncology:comp:BMS</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10128">Oncology10128</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/994">Jenny Wu</a> | 24 November 2014 | 19:38</font><br><br><div style="margin-bottom: 10px;">Comment: BMS will initiate a global Ph2 trial to evaluate two different dosing - 3 mg/<wbr>Kg and 10 mg/<wbr>Kg - for ipilimumab (anti-CTLA4) in chemo na&iuml;ve setting.<wbr> Following the negative result for ipilimumab in post-docetaxel setting, the lack of solid proof for BMS' intention to develop ipilimumab in prostate cancer leads to long conflicting speculation around the future of ipilimumab in prostate cancer (in particular in chemo na&iuml;ve setting).<wbr> </div><div style="margin-bottom: 10px;">During ESMO in Sept 2014, Dr Sbudhi presented the early combination data of ipilimumab +ADT and suggested a lower dose of 3 mg/<wbr>Kg may have a better tolerability profile and maintaining similar efficacy as the higher dose of 10 mg/<wbr>Kg (Oncology 10041: <a href="http://ci.beaufour-ipsen.com/traction#/single&proj=Oncology&rec=10041" target="_blank" class="defaultlink">ESMO Intelligence Part 4- Progress of Immunotherapy in Prostate And Bladder Cancer)</a>.<wbr> This initiation of the dose finding trial could reflect BMS' confidence level to gain possible positive outcome for ipilimumab in the chemo na&iuml;ve setting (or even earlier setting) and may provide confirmation of BMS' intention to invest in prostate cancer.<wbr> </div><div style="margin-bottom: 10px;">Clinical Trial ID <A href="http://clinicaltrials.gov/ct2/show/NCT02279862?recr=Open&amp;no_unk=Y&amp;phase=012&amp;fund=2&amp;rcv_s=10%2F24%2F2014&amp;rank=169"><U><FONT color="#0066cc">NCT02279862</FONT></U></A> </div><div style="margin-bottom: 10px;"><TABLE border="0" cellpadding="0" cellspacing="0" class="layout_table" style="margin-bottom: 3ex;" summary="Layout table for enrollment information"><TBODY><TR valign="top"><TD headers="enrollmentInfoTitle" nowrap="nowrap">Estimated Enrollment:</TD>
<TD headers="enrollmentInfoData" style="padding-left: 1em;">200</TD>
</TR>
<TR valign="top"><TD headers="enrollmentInfoTitle" nowrap="nowrap">Study Start Date:</TD>
<TD headers="enrollmentInfoData" style="padding-left: 1em;">January 2015</TD>
</TR>
<TR valign="top"><TD headers="enrollmentInfoTitle" nowrap="nowrap">Estimated Study Completion Date:</TD>
<TD headers="enrollmentInfoData" style="padding-left: 1em;">November 2018</TD>
</TR>
<TR valign="top"><TD headers="enrollmentInfoTitle" nowrap="nowrap">Estimated Primary Completion Date:</TD>
<TD headers="enrollmentInfoData" style="padding-left: 1em;">November 2016</TD>
</TR>
</TBODY>
</TABLE> </div><div><EM>Source: clinicaltrial.<wbr>gov</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10128">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-11-24T19:38:57+01:00</dc:date><dc:creator>jew60237</dc:creator></item><item>
<title>The Future of Nuclear Medicine Imaging In NET [dis:MidGutNET, sub:Diagnostic]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7869</link>
<description>The Future of Nuclear Medicine Imaging In NET [dis:MidGutNET, sub:Diagnostic]</description><category>dis:MidGutNET</category><category>sub:Diagnostic</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7869</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20141231&edate=20140901&rec=7869">The Future of Nuclear Medicine Imaging In NET</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20141231&edate=20140901&cat=dis%3aMidGutNET"><font color="#e95e0b">:Endocrinology:dis:MidGutNET</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20141231&edate=20140901&cat=sub%3aDiagnostic"><font color="#e95e0b">:Endocrinology:sub:Diagnostic</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7869">Endocrinology7869</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 24 November 2014 | 18:16</font><br><br><div style="margin-bottom: 10px;">Comment: A recently published review by nuclear imaging 
expert Lisa Bodei (European Institute of Oncology Milan) in the December issue 
of Nucleur Medicine and Molecular Imaging highlights a collective viewpoint on 
the future of nuclear medicine and molecular imaging.<wbr> The review features many 
of the points mentioned by Lisa and other experts at recent meetings (see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20141231&edate=20140901&rec=7625" class="defaultlink">Endocrinology7625: ENETS Intelligence Part 2- New Imaging Techniques For NET Diagnosis & Treatment Prognosis</a>) and (see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20141231&edate=20140901&rec=7504" class="defaultlink">Endocrinology7504: Intelligence From The EANM Congress (Lyon October 2013) - Part 1 Neuroendocrine Tumour Treatment</a>).<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Key take-aways regarding 68Ga-SMS-R-PET 
are:-</STRONG> </div><div style="margin-bottom: 10px;">i) None of the three peptides currently in use 
demonstrate a clear diagnostic superiority over the others </div><div style="margin-bottom: 10px;">ii) Apart from DOTATOC, which has a European 
Pharmacopeia monograph radiopharmacueticals are currently prepared according to 
non-standardized local procedures.<wbr> Furthermore no standardized toxicity and 
sterility data exists.<wbr> </div><div style="margin-bottom: 10px;">iii) The development of an efficient and reproducible 
SSR-based molecular imaging procedures is a strategic necessity to ensure 
clinical acceptance of current and future techniques.<wbr> The granting of IDD to 
68Ga-DOTATOC and 68 Ga-DOTATATE is seen as a step forward to meeting 
uniformity.<wbr> </div><div style="margin-bottom: 10px;">iv) PET with 68Ga-DOTA peptide is supplanting 
Octreoscan.<wbr> Whilst SSAs have been the workhorse of imagery for two decases 
alternative radiopharmaceuticals that provide increased diagnostic accuracy 
should be identified.<wbr> In this respects newly emerging strategies include the use 
of SSR antagonists and GLP-1 R peptides appear highly promising.<wbr> </div><div style="margin-bottom: 10px;">A copy of the full paper can be viewed through the link 
below.<wbr> </div><div><TABLE border="0" cellpadding="0" cellspacing="0" class="mceItemTable" style="WIDTH: 580px; mso-cellspacing: 0cm; mso-yfti-tbllook: 1184; mso-padding-alt: 0cm 0cm 0cm 0cm"><TBODY><TR style="mso-yfti-irow: 0; mso-yfti-firstrow: yes"><TD style="BORDER-TOP: rgb(240,240,240); BORDER-RIGHT: rgb(240,240,240); WIDTH: 435pt; BORDER-BOTTOM: rgb(240,240,240); PADDING-BOTTOM: 0cm; PADDING-TOP: 0cm; PADDING-LEFT: 0cm; BORDER-LEFT: rgb(240,240,240); PADDING-RIGHT: 0cm; BACKGROUND-COLOR: transparent; border-image: none" width="580">
      <P style="MARGIN: 0cm 0cm 0pt"><SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'; mso-fareast-font-family: 'Times New Roman'"><STRONG>Source: 
      </STRONG>The future of nuclear medicine imaging of neuroendocrine tumors: 
      on a clear day one might see forever…</SPAN></P></TD>
</TR>
<TR style="mso-yfti-irow: 1"><TD style="BORDER-TOP: rgb(240,240,240); BORDER-RIGHT: rgb(240,240,240); WIDTH: 435pt; BORDER-BOTTOM: rgb(240,240,240); PADDING-BOTTOM: 0cm; PADDING-TOP: 0cm; PADDING-LEFT: 0cm; BORDER-LEFT: rgb(240,240,240); PADDING-RIGHT: 0cm; BACKGROUND-COLOR: transparent; border-image: none" width="580">
      <P style="MARGIN: 0cm 0cm 0pt"><SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'; COLOR: rgb(0,0,37); mso-fareast-font-family: 'Times New Roman'">Lisa 
      Bodei , Mark Kidd , Vikas Prasad , Richard P.<wbr> Baum , Ignat Drozdov &amp; 
      Irvin M.<wbr> Modlin</SPAN></P></TD>
</TR>
<TR style="HEIGHT: 6pt; mso-yfti-irow: 2"><TD style="BORDER-TOP: rgb(240,240,240); HEIGHT: 6pt; BORDER-RIGHT: rgb(240,240,240); WIDTH: 435pt; BORDER-BOTTOM: rgb(240,240,240); PADDING-BOTTOM: 0cm; PADDING-TOP: 0cm; PADDING-LEFT: 0cm; BORDER-LEFT: rgb(240,240,240); PADDING-RIGHT: 0cm; BACKGROUND-COLOR: transparent; border-image: none" width="580">&nbsp;</TD>
</TR>
<TR style="mso-yfti-irow: 3; mso-yfti-lastrow: yes"><TD style="BORDER-TOP: rgb(240,240,240); BORDER-RIGHT: rgb(240,240,240); WIDTH: 435pt; BORDER-BOTTOM: rgb(240,240,240); PADDING-BOTTOM: 0cm; PADDING-TOP: 0cm; PADDING-LEFT: 0cm; BORDER-LEFT: rgb(240,240,240); PADDING-RIGHT: 0cm; BACKGROUND-COLOR: transparent; border-image: none" valign="bottom" width="580">
      <P>Eur J Nucl Med Mol Imaging (2014) 41:2189<FONT color="#131413" face="WswsrsAdvTT3713a231+20" size="1"><FONT color="#131413" face="WswsrsAdvTT3713a231+20" size="1"><FONT color="#131413" face="WswsrsAdvTT3713a231+20" size="1">–</FONT></FONT></FONT><FONT color="#131413" face="FgckjxAdvTT3713a231" size="1"><FONT color="#131413" face="FgckjxAdvTT3713a231" size="1"><FONT color="#131413" face="FgckjxAdvTT3713a231" size="1">2193</FONT></FONT></FONT></P>
      <P><FONT color="#131413" face="FgckjxAdvTT3713a231" size="1"><FONT color="#131413" face="FgckjxAdvTT3713a231" size="1"><FONT color="#131413" face="FgckjxAdvTT3713a231" size="1"><A href="http://rd.springer.com/article/10.1007/s00259-014-2836-1">http:/<wbr>/<wbr>rd.<wbr>springer.<wbr>com/<wbr>article/<wbr>10.<wbr>1007/<wbr>s00259-014-2836-1</A></FONT></FONT></FONT><BR></P></TD>
</TR>
</TBODY>
</TABLE> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20141231&edate=20140901&rec=7869">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-11-24T18:16:50+01:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>HR Pharma to Start Trial for Metyrapone (Cushing) [dis:Cushing, :PharmaWorld:sub:ClinicalTrial]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7868</link>
<description>HR Pharma to Start Trial for Metyrapone (Cushing) [dis:Cushing, :PharmaWorld:sub:ClinicalTrial]</description><category>dis:Cushing</category><category>sub:ClinicalTrial</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7868</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20141231&edate=20140901&rec=7868">HR Pharma to Start Trial for Metyrapone (Cushing)</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20141231&edate=20140901&cat=dis%3aCushing"><font color="#e95e0b">:Endocrinology:dis:Cushing</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=sub%3aClinicalTrial"><font color="#e95e0b">:PharmaWorld:sub:ClinicalTrial</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7868">Endocrinology7868</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 24 November 2014 | 17:42</font><br><br><div style="margin-bottom: 10px;">Comment: The PROMPT trial has been planned to start Q1:15.<wbr> The purpose of this prospective, international Ph3/<wbr>Ph4 study is to assess the efficacy and safety of metyrapone in patients with endogenous Cushing's syndrome during up to 36 weeks of treatment.<wbr> The ability of metyrapone (250 mg capsules) to normalize urinary free cortisol (UFC) levels will be assessed during up to 36 weeks (9 months) of treatment.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Trial Reference </FONT></STRONG><A href="http://clinicaltrials.gov/ct2/show/NCT02297945?recr=Open&amp;no_unk=Y&amp;phase=012&amp;fund=2&amp;rcv_s=10%2F24%2F2014&amp;rank=53"><STRONG><FONT size="3">NCT02297945</FONT></STRONG></A> </div><div style="margin-bottom: 10px;">- Recruitment Approx 70 </div><div style="margin-bottom: 10px;">This study will include Cushing disease patients with persistent or recurrent disease (after pituitary surgery) or who are newly diagnosed but are unsuitable for early surgery or wish to defer surgery.<wbr> It will also include patients with ectopic ACTH syndrome (either occult, after surgery failure, or inoperable or metastatic) and patients with Cushing's syndrome from adrenal causes.<wbr> </div><div style="margin-bottom: 10px;">- Timelines </div><div>Start date January 2015 /<wbr> completion Jan2018 /<wbr> Sept2018 </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20141231&edate=20140901&rec=7868">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-11-24T17:42:08+01:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>re: EU Clinical Trials Register Listing New PhII Study of CAM2029 In Acromegaly &amp; NET</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7867</link>
<description>re: EU Clinical Trials Register Listing New PhII Study of CAM2029 In Acromegaly &amp; NET</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7867</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20141231&edate=20140901&rec=7867">re: EU Clinical Trials Register Listing New PhII Study of CAM2029 In Acromegaly & NET</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7867">Endocrinology7867</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 24 November 2014 | 17:25</font><br><br><div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">EU Clinical Trials Register Listing New PhII Study of CAM2029 In Acromegaly & NET</span>&nbsp;<font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20141231&edate=20140901&cat=class%3aSomatostatinAnalogue"><font color="#e95e0b">:Endocrinology:class:SomatostatinAnalogue</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20141231&edate=20140901&cat=dis%3aAcromegaly"><font color="#e95e0b">:Endocrinology:dis:Acromegaly</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20141231&edate=20140901&cat=dis%3aMidGutNET"><font color="#e95e0b">:Endocrinology:dis:MidGutNET</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20141231&edate=20140901&cat=headline"><font color="#e95e0b">:Endocrinology:headline</font></a>]</font></font><br><span style="font-size: 12px;">Comment: A new phII open-label randomised PK, PD efficacy &amp; safety study with CAM2029 is now listed by Camurus on the EU Clinical Trial Register.<wbr> The trial will evaluate the drug in both acromegaly and NET patients.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20141231&edate=20140901&rec=7770">...</a><br><font size="-1">Jacquelyne CANTLE MEYRICK / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7770" class="commentpermalink">Endocrinology7770</a> / <span class="date">12 August 2014</span> /
<span class="time">15:43:34 o'clock CEST</span>
</font></div><div><EM>Clinicaltrials.<wbr>gov</EM> is listing the trial under the reference <a href="http://clinicaltrials.gov/ct2/show/NCT02299089?recr=Open&no_unk=Y&phase=012&fund=2&rcv_s=10%2F24%2F2014&rank=25" class="defaultlink">NCT02299089</a>.<wbr> It is indicated that Marianne Pavel will be the principal investigator.<wbr> Of note details have been provided on the countries and the centers.<wbr> </div><!-- Comment details --><font size="-1">Brigitte DESCHAMPS / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7867" class="commentpermalink">Endocrinology7867</a> / <span class="date">24 November 2014</span> /
<span class="time">17:25:13 o'clock CET</span>
</font><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20141231&edate=20140901&rec=7867">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7770">View thread  Endocrinology7770: EU Clinical Trials Register Listing New PhII Study of CAM2029 In Acromegaly & NET</a>]]></content:encoded><dc:date>2014-11-24T17:25:13+01:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Biomarin Acquires Duchenne Muscular Dystrophy Company Prosensa for $890m [dis:MuscularDystrophy]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7825</link>
<description>Biomarin Acquires Duchenne Muscular Dystrophy Company Prosensa for $890m [dis:MuscularDystrophy]</description><category>dis:MuscularDystrophy</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7825</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7825">Biomarin Acquires Duchenne Muscular Dystrophy Company Prosensa for $890m</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20141231&edate=20140901&cat=dis%3aMuscularDystrophy"><font color="#e95e0b">:Neurology:dis:MuscularDystrophy</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7825">Neurology7825</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 24 November 2014 | 16:52</font><br><br><div style="margin-bottom: 10px;">Comment: BioMarin Pharmaceutical Inc.<wbr> and Prosensa Holding N.<wbr>V.<wbr> have 
entered into a definitive agreement today in which BioMarin will purchase 
all of the outstanding ordinary shares of Prosensa for $17.<wbr>75 per share, for a 
total up front consideration of approximately $680 million.<wbr> The acquisition 
effectively strengthens Biomarin's leadership position in rare diseases.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Additional Deal Terms</STRONG> </div><div style="margin-bottom: 10px;">Two approximately $80 million contingent milestones are payable for the 
approval of drisapersen in the U.<wbr>S.<wbr> no later than May 15, 2016 and Europe no 
later than February 15, 2017, respectively.<wbr> </div><div style="margin-bottom: 10px;">In addition, within 5 business days of signing the purchase 
agreement BioMarin will purchase from Prosensa a $50 million convertible 
note.<wbr>  If the transaction fails to close for any reason, the note will 
automatically convert into 4,395,914 shares of Prosensa's stock.<wbr> </div><div style="margin-bottom: 10px;">The transaction is expected to be accounted for as a business 
combination.<wbr> BioMarin will maintain operations at Prosensa's headquarters, 
based in Leiden, The Netherlands and integrate Prosensa personnel from that 
office.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Commenting on the acquisition Jean-Jacques Bienaimé, Chief Executive 
Officer of BioMarin noted</STRONG> </div><div style="margin-bottom: 10px;">"BioMarin is dedicated to the rare disease community, and the acquisition of 
Prosensa fits strategically with our mission of delivering therapies that 
address serious unmet medical needs," We are committed to working closely with 
regulatory authorities worldwide in bringing a potentially breakthrough therapy 
to patients with this devastating condition.<wbr>" </div><div style="margin-bottom: 10px;">"We will leverage our experience at developing rare disease therapies to 
achieve regulatory approvals and bring drisapersen to market as quickly as 
possible.<wbr> Further, if we are successful in advancing drisapersen to early 
regulatory approvals, we believe this transaction would be accretive to 
operating and GAAP profitability in 2017.<wbr>" </div><div style="margin-bottom: 10px;"><STRONG>What Is Included In The Purchase? </STRONG> </div><div style="margin-bottom: 10px;">The acquisition will provide BioMarin with worldwide rights to multiple 
orphan-drug candidates, including drisapersen, which is currently under rolling 
review as part of a NDA with the FDA.<wbr> Prosensa's pipeline is comprised 
of several potential products that leverage its proprietary RNA-modulating 
technology platform for the treatment of various genotypes of Duchenne muscular 
dystrophy and other genetic disorders.<wbr> </div><div>Source: <A href="http://www.biomarin.eu/">http:/<wbr>/<wbr>www.<wbr>biomarin.<wbr>eu/<wbr></A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7825">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-11-24T16:52:34+01:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>Astellas' Myrbetriq and Allergan's Botox Approved in Canada with a Set of Conditions [comp:Allergan, :Oncology:comp:Astellas, :PharmaWorld:mkt:Canada, :PharmaWorld:sub:Pricing, :PharmaWorld:news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7824</link>
<description>Astellas' Myrbetriq and Allergan's Botox Approved in Canada with a Set of Conditions [comp:Allergan, :Oncology:comp:Astellas, :PharmaWorld:mkt:Canada, :PharmaWorld:sub:Pricing, :PharmaWorld:news]</description><category>comp:Allergan</category><category>comp:Astellas</category><category>mkt:Canada</category><category>sub:Pricing</category><category>news</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7824</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7824">Astellas' Myrbetriq and Allergan's Botox Approved in Canada with a Set of Conditions</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20141231&edate=20140901&cat=comp%3aAllergan"><font color="#e95e0b">:Neurology:comp:Allergan</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=comp%3aAstellas"><font color="#e95e0b">:Oncology:comp:Astellas</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=mkt%3aCanada"><font color="#e95e0b">:PharmaWorld:mkt:Canada</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=news"><font color="#e95e0b">:PharmaWorld:news</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=sub%3aPricing"><font color="#e95e0b">:PharmaWorld:sub:Pricing</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7824">Neurology7824</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 24 November 2014 | 14:35</font><br><br><div style="margin-bottom: 10px;">Comment: The Canadian Drug Expert Committee (CDEC), which operated under the Canadian Agency for Drugs and Technologies in Health (CADTH), has issued a "list with conditions" recommendation for Allergan's Botox and Astellas' Myrbetriq (mirabegron) for the treatment of <STRONG>overactive bladder</STRONG> (OAB).<wbr> For Astellas, the recommendation is still significantly favourable, as Myrbetriq demonstrated similar safety and efficacy compared with other anticholinergic medications, while offering a cost-effective treatment option for patients with OAB.<wbr> The CDEC approved the listing of Botox for OB, but limited its use to third-line treatment following at least two other pharmacologic therapies.<wbr> Although Botox demonstrated a significant reduction in OAB symptoms in patients who previously failed other treatments, the drug failed to demonstrate cost effectiveness at the submitted price.<wbr> </div><div style="margin-bottom: 10px;"><P class="bodyHeading2"><B>Allergan's Botox</B></P> </div><div style="margin-bottom: 10px;">The CDEC has issued a positive listing recommendation for Botox to be utilised as a treatment option for overactive bladder with symptoms of urinary incontinence, urgency, and frequency, in adult patients who have an inadequate response to or are intolerant of anticholinergic medication, under certain clinical criteria and conditions.<wbr> The agency approved the drug as a third-line therapy after patients have at least tried two other pharmacologic treatments, and should be limited to three doses per year and no more than once every 12 weeks.<wbr> Furthermore, the prescription of the drug is limited to urologists, and funding should initially be limited to one dose only, and discontinued if efficacy is not established in non-responders who fail to achieve at least a 50% reduction in the frequency of urinary incontinence episodes with one dose.<wbr> The CDEC has also recommended a reduction in price to improve the cost effectiveness of the drug as another condition of listing Botox for OB.<wbr> </div><div style="margin-bottom: 10px;">Based on results from two Phase III randomised controlled trials (RCTs; Study 095 and Study 520), Botox demonstrated a statistically significant reduction in incontinence episodes, urge incontinence episodes, urgency episodes, micturition, and nocturia episodes compared with placebo in patients with symptoms of idiopathic OB who were not adequately controlled with anticholinergic medications.<wbr> However, the agency concluded that based on the estimated incremental cost per quality-adjusted life year (QALY) of CAD59,388 (USD52,848), Botox was not considered a cost-effective treatment option at the submitted price.<wbr> </div><div style="margin-bottom: 10px;">The manufacturer submitted a cost-utility analysis using a Markov model over a five-year time horizon comparing Botox and best supportive care (BSC) to BSC along.<wbr> Allergan's estimated incremental cost per QALY was CAD34,029, but due to certain limitations in the study the Common Drug Review's (CDR's) re-evaluation found the incremental cost utility ration (ICUR) to range between CAD56,932 and CAD60,451.<wbr> At the submitted price of CAD3.<wbr>57 per unit, or CAD357 per dose, annual treatment costs could reach CAD1,428 for those patients who receive four injections each year, and exceed costs of second-line anticholinergic medications.<wbr> </div><div style="margin-bottom: 10px;"><P class="bodyHeading2"><B>Astellas's Myrbetriq</B></P> </div><div style="margin-bottom: 10px;">The CDEC has issued a similar recommendation for Astellas's Myrbetriq for the treatment of OB with symptoms of urgency, urgency incontinence, and urinary frequency, if certain clinical criteria and conditions are met.<wbr> Patients who receive Myrbetriq need to have demonstrated intolerance or inadequate response to an anticholinergic therapy.<wbr> Furthermore, the drug should not be used in combination with other pharmacological treatments, and needs to be listed in a manner similar to other pharmacological treatments for use after oxybutynin.<wbr> The favourable recommendation was based on results from nine RCTs, as well as a meta analysis that demonstrated Myrbetriq's superiority to placebo and non-inferiority to other anticholinergic drugs for improving the symptoms of OB.<wbr> Furthermore, the drug demonstrated fewer incidence of dry mouth side effects compared with other treatments.<wbr> However, at the undisclosed submitted price, Myrbetriq was more expensive than generic oxybutynin immediate release (IR) but cheaper than other second-line anticholinergic medications that are approved for funding by CDR–participating drug plans.<wbr> </div><div style="margin-bottom: 10px;">With regards to cost effectiveness, the manufacturer's cost-minimisation analysis compared mirabegron 25 milligrammes and 50 mg with oxybutynin IR, darifenacin extended release (ER), fesoterodine ER, solifenacin, tolterodine ER, and trospium chloride IR in treatment-naïve and treatment-experienced patients over a one-year time horizon.<wbr> Astellas used data from head-to-head trials comparing Myrbetriq with solifenacin and tolterodine, as well as indirect comparisons with the other anticholinergic drugs, but the CDR noted limited comparative evidence for the safety and efficacy of mirabegron in the sub-group of patients who had failed treatment with anticholinergic drugs.<wbr> Although details of the economic assessment were not disclosed, the CDEC stated that Myrbetriq was shown to be more costly than generic oxybutynin IR at CAD0.<wbr>20–0.<wbr>30 per day, but cheaper than other anticholinergic medications, such as darifenacin ER, fesoterodine ER, solifenacin, tolterodine ER, trospium chloride IR, and oxybutynin ER, with daily costs ranging between CAD1.<wbr>50 and CAD2.<wbr>28 (CAD547.<wbr>5–832.<wbr>2 annually) </div><div style="margin-bottom: 10px;"><P class="bodyHeading2"><B>Outlook and implications</B></P> </div><div style="margin-bottom: 10px;">The positive listing recommendations issued by CADTH for Astellas's Myrbetriq and Allergan's Botox for the same indication come with a notable set of conditions.<wbr> For Astellas, the recommendation is still significantly favourable, as Myrbetriq demonstrated similar safety and efficacy compared with other anticholinergic medications, while offering a cost-effective treatment option for patients with OB.<wbr> However, the CDEC does request that treatment with Myrbetriq be limited to patients who have failed to demonstrate adequate symptom control with another anticholinergic therapy, most likely off-patent oxybutynin commonly used as a first-line treatment.<wbr> Furthermore, the agency stressed on utilisation of the drug as monotherapy, rather than in combination with other second-line treatments, mainly as this would increase costs, and the treatment may no longer be cost effective under those conditions.<wbr> The agency also expressed concerns about the lack of evidence to support Myrbetriq as a treatment option for non-responders to anticholinergic drugs, particularly in light of the results from the BEYOND trial that failed to demonstrate the drug's non-inferiority to solifenacin.<wbr> This particular patient population may be better treated with Botox.<wbr> </div><div style="margin-bottom: 10px;">The CDEC approved the listing of Botox for OB, but limited its use to third-line treatment following at least two other pharmacologic therapies.<wbr> Although Botox demonstrated a significant reduction in OB symptoms in patients who previously failed other treatments, the drug failed to demonstrate cost effectiveness at the submitted price.<wbr> Annual treatment costs could reach CAD1,428 (four injections), according to the CDEC, compared with the cost of second-line therapies for OB that range between CAD547.<wbr>5 and CAD832.<wbr>2 annually; Myrbetriq costs even less, according to the agency.<wbr> Nevertheless, this is good news for Allergan that previously received a "do no list" recommendation for Botox for the treatment of chronic migraines by CADTH.<wbr> </div><div style="margin-bottom: 10px;">All Canadian provinces and territories, except for Québec, use CDEC recommendations for the listing of medicines in drug plan formularies.<wbr> However, individual jurisdictions have the authority to make the final decision regarding reimbursement of these drugs.<wbr> Furthermore, all brand-name drugs processed through the two national health technology assessment agencies – the CDR and the pan-Canadian Oncology Drug Review – will now be considered for negotiation through the recently instated Pan-Canadian Pharmaceutical Alliance.<wbr> </div><div><EM>Source: IHS GlobalInsight</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7824">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-11-24T14:35:21+01:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Synthetic Biologics to Initiate Ph1a/1b of SYN-004 to Protect Microbiome</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2134</link>
<description>Synthetic Biologics to Initiate Ph1a/1b of SYN-004 to Protect Microbiome</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2134</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2134">Synthetic Biologics to Initiate Ph1a/<wbr>1b of SYN-004 to Protect Microbiome</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2134">GastroEnterology2134</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 24 November 2014 | 14:11</font><br><br><div style="margin-bottom: 10px;">Comment: Preclinical data further validating the SYN-004 approach were presented at IDWeek and the 54<SUP>th</SUP> Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC).<wbr> The investigational drug is Synthetic Biologics' oral drug candidate designed to prevent the development of <EM>C.<wbr> difficile</EM> infection, by binding with and neutralizing certain common IV beta-lactam antibiotics in the gut.<wbr> Last year,Sanofi Pasteur's started the <EM>Cdiffense</EM> Ph3 programs to evaluate its toxoid vaccine in this setting.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">SYN-004 Insights</FONT></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>Indications to be Tested</STRONG> </div><div style="margin-bottom: 10px;">prevention of <EM>Clostridium difficile (C.<wbr> difficile) </EM>infection (CDI), antibiotic-associated diarrhea (AAD) and secondary infections with healthcare-acquired, drug-resistant pathogens in patients receiving intravenous (IV) beta-lactam antibiotic therapy.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Intellectual Property</STRONG> </div><div style="margin-bottom: 10px;">the U.<wbr>S.<wbr> Patent and Trademark Office issued a Notice of Allowance for the first composition of matter patent application directly pertaining to SYN-004 in the U.<wbr>S.<wbr>, which carries a patent term to at least 2031.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Literature References</STRONG> </div><div style="margin-bottom: 10px;"><U>Preclinical (SYN-004)</U> </div><div style="margin-bottom: 10px;">Michael Kaleko, J.<wbr> Andrew Bristol, Sheila Connelly, Pertti Koski, PhD.<wbr> SYN-004, a Class A Beta-Lactamase Therapy for the Prevention of Antibiotic-Induced Disruption of Intestinal Microflora.<wbr> IDWeek 2014.<wbr> </div><div style="margin-bottom: 10px;">M.<wbr> Kaleko, J.<wbr> A.<wbr> Bristol, S.<wbr> Connelly, P.<wbr> Koski.<wbr> P4A, a Novel Oral Beta-Lactamase for the Prevention of Cephalosporin-Induced <EM>C.<wbr> difficile </EM>Infection.<wbr> ICAAC 2014.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">About Sanofi Pasteur's Vaccine</FONT></STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>The investigational <EM>C.<wbr>diff</EM> vaccine is a toxoid vaccine which targets the toxins generated by the <EM>C.<wbr>diff</EM> bacteria.<wbr>
</LI>
</UL> </div><div><UL><LI>The vaccine stimulates a person&rsquo;s immune system to fight <EM>C.<wbr>diff</EM> toxins upon exposure and may prevent a future CDI from occurring
</LI>
</UL> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2134">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-11-24T14:11:16+01:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>re: Novartis to Revamp its Portfolio Via Deals with GSK and Lilly</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology10123</link>
<description>re: Novartis to Revamp its Portfolio Via Deals with GSK and Lilly</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology10123</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10123">re: Novartis to Revamp its Portfolio Via Deals with GSK and Lilly</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10123">Oncology10123</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 24 November 2014 | 11:12</font><br><br><div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Novartis to Revamp its Portfolio Via Deals with GSK and Lilly</span>&nbsp;<font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20141231&edate=20140901&cat=comp%3aNovartis"><font color="#e95e0b">:Endocrinology:comp:Novartis</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20141231&edate=20140901&cat=headline"><font color="#e95e0b">:Endocrinology:headline</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=comp%3aNovartis"><font color="#e95e0b">:Oncology:comp:Novartis</font></a>]</font></font><br><span style="font-size: 12px;">Comment: Novartis will acquire GSK's cancer drugs business for $16bn (£9.<wbr>5bn) and sell its vaccines division, excluding the flu unit, to GSK for $7.<wbr>1bn.<wbr> Both companies will combine Novartis OTC with GSK's consumer business in a joint venture, creating a world-leading consumer healthcare business and maintaining Novartis' presence in this sector.<wbr> In a separate deal, Novartis has agreed to sell its animal health division to Lilly for nearly $5.<wbr>4bn.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=9617">...</a><br><font size="-1">Brigitte DESCHAMPS / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9617" class="commentpermalink">Oncology9617</a> / <span class="date">22 April 2014</span> /
<span class="time">09:39:47 o'clock CEST</span>
</font></div><div style="margin-bottom: 10px;">GSK has asked its shareholders to vote at a meeting on Dec.<wbr> 18 on its proposed major deal with Novartis, which will see the two pharmaceutical group trade more than $20 billion of assets.<wbr> </div><div>In a letter to shareholders endorsing the deal, GSK's chairman Christopher Gent said approval would strengthen its franchises in vaccines and consumer healthcare to complement its leading position in respiratory and HIV.<wbr><BR><BR>"This is the most significant transaction for the Company since the creation of GlaxoSmithKline in 2000," he said.<wbr> </div><!-- Comment details --><font size="-1">Brigitte DESCHAMPS / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10123" class="commentpermalink">Oncology10123</a> / <span class="date">24 November 2014</span> /
<span class="time">11:12:09 o'clock CET</span>
</font><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10123">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9617">View thread  Oncology9617: Novartis to Revamp its Portfolio Via Deals with GSK and Lilly</a>]]></content:encoded><dc:date>2014-11-24T11:12:09+01:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>re: Novartis's Acromegaly Drug Closer to EU Approval</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7864</link>
<description>re: Novartis's Acromegaly Drug Closer to EU Approval</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7864</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20141231&edate=20140901&rec=7864">re: Novartis's Acromegaly Drug Closer to EU Approval</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7864">Endocrinology7864</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 24 November 2014 | 10:32</font><br><br><div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Novartis's Acromegaly Drug Closer to EU Approval</span>&nbsp;<font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20141231&edate=20140901&cat=class%3aSomatostatinAnalogue"><font color="#e95e0b">:Endocrinology:class:SomatostatinAnalogue</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20141231&edate=20140901&cat=comp%3aNovartis"><font color="#e95e0b">:Endocrinology:comp:Novartis</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20141231&edate=20140901&cat=dis%3aAcromegaly"><font color="#e95e0b">:Endocrinology:dis:Acromegaly</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=mkt%3aEurope"><font color="#e95e0b">:PharmaWorld:mkt:Europe</font></a>]</font></font><br><span style="font-size: 12px;">Comment: The CHMP of the European Medicines Agency (EMA) adopted a positive opinion for Signifor® LAR (pasireotide) to treat adult patients with acromegaly for whom surgery is not an option or has not been curative and who are inadequately controlled on treatment with a first-generation somatostatin analogue (SSA).<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20141231&edate=20140901&rec=7809">...</a><br><font size="-1">Brigitte DESCHAMPS / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7809" class="commentpermalink">Endocrinology7809</a> / <span class="date">29 September 2014</span> /
<span class="time">14:47:47 o'clock CEST</span>
</font></div><div style="margin-bottom: 10px;">The European Commission has approved Signifor reported Novartis on Monday Nov 24.<wbr> The approval concerns all 27 EU members, plus Iceland and Norway.<wbr> This approval is in line with Ipsen expectations.<wbr> </div><div>An estimated one to two people per 10,000 are affected with the disease in the European Union, according to Novartis.<wbr> </div><!-- Comment details --><font size="-1">Brigitte DESCHAMPS / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7864" class="commentpermalink">Endocrinology7864</a> / <span class="date">24 November 2014</span> /
<span class="time">10:32:38 o'clock CET</span>
</font><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20141231&edate=20140901&rec=7864">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7809">View thread  Endocrinology7809: Novartis's Acromegaly Drug Closer to EU Approval</a>]]></content:encoded><dc:date>2014-11-24T10:32:38+01:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Astellas Opens New Regional Office in Dubai [comp:Astellas, :PharmaWorld:news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology10121</link>
<description>Astellas Opens New Regional Office in Dubai [comp:Astellas, :PharmaWorld:news]</description><category>comp:Astellas</category><category>news</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology10121</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10121">Astellas Opens New Regional Office in Dubai</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=comp%3aAstellas"><font color="#e95e0b">:Oncology:comp:Astellas</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=news"><font color="#e95e0b">:PharmaWorld:news</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10121">Oncology10121</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 21 November 2014 | 16:02</font><br><br><div style="margin-bottom: 10px;">Comment: The new MENA/<wbr>SSA affiliate, lead by Markus Weber (General Manager), will serve as a management hub and platform to expand and develop business activities in countries across the area.<wbr> One of the first priorities for the Astellas MENA/<wbr>SSA team will be to ensure more patients in the region can access the company's portfolio of innovative cancer treatments.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Strategic Rationale</FONT></STRONG> </div><div style="margin-bottom: 10px;">to further expand operations </div><div style="margin-bottom: 10px;">to support more patients in the region </div><div style="margin-bottom: 10px;">to develop clinical trials programme </div><div><EM>Source: Astellas PR</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10121">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-11-21T16:02:27+01:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Post-Chemo Enzalutamide to be Reimbursed in Australia [dis:Prostate, :PharmaWorld:mkt:Australia, :PharmaWorld:sub:Pricing]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology10120</link>
<description>Post-Chemo Enzalutamide to be Reimbursed in Australia [dis:Prostate, :PharmaWorld:mkt:Australia, :PharmaWorld:sub:Pricing]</description><category>dis:Prostate</category><category>mkt:Australia</category><category>sub:Pricing</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology10120</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10120">Post-Chemo Enzalutamide to be Reimbursed in Australia</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=mkt%3aAustralia"><font color="#e95e0b">:PharmaWorld:mkt:Australia</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=sub%3aPricing"><font color="#e95e0b">:PharmaWorld:sub:Pricing</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10120">Oncology10120</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 21 November 2014 | 09:04</font><br><br><div style="margin-bottom: 10px;">Comment: XTANDI™ will be listed on the Pharmaceutical Benefits Scheme (PBS) from 1st of December 2014.<wbr> </div><div style="margin-bottom: 10px;">Reimbursement in Australia has been based on results from the phase III AFFIRM study (Scher H I, et al.<wbr> Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy.<wbr> N Engl J Med 2012; 367:1187-1197).<wbr> </div><div>Prostate cancer is the most common cancer in Australian men with 22,000 men diagnosed each year and close to 120,000 Australian men who are already living with the disease.<wbr> It is estimated that by age 85, 1 in 5 Australian men will be diagnosed with prostate cancer (Australian Institute of Health and Welfare 2013.<wbr> Prostate cancer in Australia.<wbr> Cancer series no.<wbr> 79.<wbr> Cat.<wbr> no.<wbr> CAN 76.<wbr> Canberra: AIHW).<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10120">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-11-21T09:04:07+01:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Updated Timelines on OPKO/Prolor's Long-Acting GH [class:GrowthHormone, dis:GrowthHormoneDeficiency]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7863</link>
<description>Updated Timelines on OPKO/Prolor's Long-Acting GH [class:GrowthHormone, dis:GrowthHormoneDeficiency]</description><category>class:GrowthHormone</category><category>dis:GrowthHormoneDeficiency</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7863</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20141231&edate=20140901&rec=7863">Updated Timelines on OPKO/<wbr>Prolor's Long-Acting GH</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20141231&edate=20140901&cat=class%3aGrowthHormone"><font color="#e95e0b">:Endocrinology:class:GrowthHormone</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20141231&edate=20140901&cat=dis%3aGrowthHormoneDeficiency"><font color="#e95e0b">:Endocrinology:dis:GrowthHormoneDeficiency</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7863">Endocrinology7863</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 20 November 2014 | 15:53</font><br><br><div style="margin-bottom: 10px;">Comment: During its presentation at Jefferies 2014 Global Healthcare Conference, OPKO has indicated a BLA submission in 2016 for adult, and the initiation of a Ph3 pediatric trial in H1:15.<wbr> During the Q3 conference call, Management reported having been approached by "American companies and companies outside the US, but no agreement signed to date".<wbr> </div><div style="margin-bottom: 10px;"><STRONG>OPKO Model</STRONG> </div><div style="margin-bottom: 10px;">- Diversified Pipeline/<wbr>Product company (diagnostics, pharmaceuticals, international markets, oppotunistic investment) </div><div style="margin-bottom: 10px;"><STRONG>OPKO Strategic Investment</STRONG> </div><div style="margin-bottom: 10px;">Has equity interest in proprietary technologies with significant upside potential, among which: </div><div><UL><LI>ARNO Therapeutics (aprrox 4% equity interest): anti-progestins fo breast (Ph2), endometrial and prostate cancers
</LI>
<LI>Zebra Biologics (approx 19% equit interest): Combinatorial antibody librairies based on function in human cell screens
</LI>
<LI>OAO Pharmsynthez (approx 17% equity interest): Russian developer and marketer of new drugs
</LI>
</UL> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20141231&edate=20140901&rec=7863">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-11-20T15:53:01+01:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>AAA Filed with the SEC to Raise $100M in an IPO [headline]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7862</link>
<description>AAA Filed with the SEC to Raise $100M in an IPO [headline]</description><comments>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7862</comments><category>headline</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7862</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20141231&edate=20140901&rec=7862">AAA Filed with the SEC to Raise $100M in an IPO</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20141231&edate=20140901&cat=headline"><font color="#e95e0b">:Endocrinology:headline</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7862">Endocrinology7862</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 20 November 2014 | 12:33</font><br><br><div style="margin-bottom: 10px;">Comment: AAA which plans to list on the NASDAQ under the symbol AAAP, iniitially filed confidentially on August 4, 2014.<wbr> Today, management announced its results for the first nine months of 2014, with sales of &euro;50.<wbr>2M (+28.<wbr>9% vs 9 months 2013).<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Key Financial Figures</STRONG> </div><div style="margin-bottom: 10px;">EBITDA increased by 26.<wbr>5% to &euro;9.<wbr>7M with net income representing &euro;1.<wbr>1 million.<wbr> </div><div style="margin-bottom: 10px;">Cash and cash equivalents are &euro;48.<wbr>7M and net operating cash-flow was &euro;9 million (+33% vs to the &euro;6.<wbr>7M for the first 9 months of 2013).<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Expansion Plans for the US</STRONG> </div><div style="margin-bottom: 10px;">Q2:14 - AAA announced that it has officially opened a new office in the US situated in the heart of Manhattan where its CEO will be based.<wbr> </div><div>Source: <A href="http://www.renaissancecapital.com/news/nuclear-therapy-biotech-advanced-accelerator-applications-files-for-a-$100--22153.html">http:/<wbr>/<wbr>www.<wbr>renaissancecapital.<wbr>com/<wbr>news/<wbr>nuclear-therapy-biotech-advanced-accelerator-applications-files-for-a-$100--22153.<wbr>html</A> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Endocrinology7947c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">AAA announced the terms of its IPO last Tuesday plans to raise $75 million by offering 5.<wbr>4 million shares at a price range of $13 to $15.<wbr> At the midpoint of the proposed range, Advanced Accelerator Applications would command a fully diluted market value of $538 million.<wbr> </div><div style="margin-bottom: 10px;">Source: </div><div><P style="background: white; margin: 0cm 0cm 0pt;"><STRONG><SPAN lang="EN-US" style="color: black; font-family: 'Arial',sans-serif; mso-ansi-language: EN-US;"><A href="http://renaissancecapital.com/news/Nuclear-therapy-biotech-Advanced-Accelerator-Apps-sets-terms-for-$75-millio-22862.html"><U><FONT color="#0563c1" size="3">http:/<wbr>/<wbr>renaissancecapital.<wbr>com/<wbr>news/<wbr>Nuclear-therapy-biotech-Advanced-Accelerator-Apps-sets-terms-for-$75-millio-22862.<wbr>html</FONT></U></A></SPAN></STRONG></P> </div><font size="-1">Jacquelyne CANTLE MEYRICK / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7947" class="commentpermalink">Endocrinology7947</a> / <span class="date">02 February 2015</span> /
<span class="time">17:12:55 o'clock CET</span>
</font></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20141231&edate=20140901&rec=7862">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-11-20T12:33:06+01:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Galeterone Ph3 Pivotal Trial - H2H Comparison With Enzalutamide -Is Underway To Evaluate Efficacy In ARV7+  mCRPC Patients [dis:Prostate]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology10119</link>
<description>Galeterone Ph3 Pivotal Trial - H2H Comparison With Enzalutamide -Is Underway To Evaluate Efficacy In ARV7+  mCRPC Patients [dis:Prostate]</description><category>dis:Prostate</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology10119</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10119">Galeterone Ph3 Pivotal Trial - H2H Comparison With Enzalutamide -Is Underway To Evaluate Efficacy In ARV7+  mCRPC Patients</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10119">Oncology10119</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/994">Jenny Wu</a> | 20 November 2014 | 12:30</font><br><br><div style="margin-bottom: 10px;">Comment: Associate Professor, Mary-Ellen Taplin of the Dana Farber Cancer Institute presented at 26th EORTC-NCI-AACR Symposium on Molecular targets and Cancer Therapeutics in Barcelona, Spain.<wbr> AR-V7 variant has increasingly become one of the hottest topics for the treatment of prostate cancer in the major oncology conferences including ASCO and ESMO.<wbr> It is believed that AR-V7 variant is formed when an androgen receptor loses the C-terminal end (a result of deletion arose during RNA process in tumour cells).<wbr> Galeterone has been demonstrated active in patients with AR-V7 variants, for whom abiraterone or enzalutamide has not shown active response.<wbr> Professor Taplin concludes with an enthusiasm to warrant a Ph3 trial that is going to be the first prostate cancer trial to assess AR-V7 as a biomarker in circulating tumour cells.<wbr> The Ph3 trial is currently planned for 1H 2015 to recruit patients with AR-V7 variant, who will be randomised to either receive galeterone or enzalutamide.<wbr> </div><div style="margin-bottom: 10px;">The data being reported is similar to those we have heard in ESMO a few months ago: </div><div style="margin-bottom: 10px;"><UL><LI>The presence of circulating tumour cells were evaluated in 71 patients and were found to be higher in 90% of patients (n=64) who had more advanced cancer that had failed more previous treatments.<wbr> 
</LI>
<LI>PSA response for patients treated with galeterone:
</LI>
</UL> </div><div style="margin-bottom: 10px;"><TABLE border="0" style="width: 785px; height: 313px;"><TBODY><TR><TD><STRONG>Patients Characteristics</STRONG></TD>
<TD><STRONG>M0 + M1 (non-metastatic and metastatic CRPC) with no prior abi and enzalutamide</STRONG></TD>
</TR>
<TR><TD style="text-align: right;">n=</TD>
<TD>60</TD>
</TR>
<TR><TD style="text-align: right;">PSA30</TD>
<TD>50/<wbr>60 (83%)</TD>
</TR>
<TR><TD style="text-align: right;">PSA50</TD>
<TD>42/<wbr>60 (72%)</TD>
</TR>
<TR><TD>&nbsp;</TD>
<TD>&nbsp;</TD>
</TR>
<TR><TD><STRONG>Patient Characteristics</STRONG></TD>
<TD><STRONG>mCRPC patients who are resistant to abiraterone</STRONG></TD>
</TR>
<TR><TD style="text-align: right;">n=</TD>
<TD>37</TD>
</TR>
<TR><TD style="text-align: right;">Any PSA decline</TD>
<TD>13/<wbr>37 (35%)</TD>
</TR>
<TR><TD>&nbsp;</TD>
<TD>&nbsp;</TD>
</TR>
<TR><TD><STRONG> Patient Characteristics</STRONG></TD>
<TD><STRONG> mCRPC patients who are resistant to enzalutamide</STRONG></TD>
</TR>
<TR><TD style="text-align: right;"> n=</TD>
<TD>9</TD>
</TR>
<TR><TD style="text-align: right;"> Any PSA decline</TD>
<TD>5/<wbr>9 (56%) </TD>
</TR>
</TBODY>
</TABLE> </div><div>Source: <a href="http://www.ecco-org.eu/Global/News/ENA-2014-PR/2014/11/Galeterone-shows-activity-in-a-variant-form-of-castration-resistant-prostate-cancer" class="defaultlink">ECCO</a> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10119">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-11-20T12:30:42+01:00</dc:date><dc:creator>jew60237</dc:creator></item><item>
<title>Sangamo Just Reported Positive PC Data for Huntington's Disease @ Neuroscience 2014 [dis:Huntington]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7823</link>
<description>Sangamo Just Reported Positive PC Data for Huntington's Disease @ Neuroscience 2014 [dis:Huntington]</description><category>dis:Huntington</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7823</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7823">Sangamo Just Reported Positive PC Data for Huntington's Disease @ Neuroscience 2014</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20141231&edate=20140901&cat=dis%3aHuntington"><font color="#e95e0b">:Neurology:dis:Huntington</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7823">Neurology7823</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 20 November 2014 | 11:26</font><br><br><div style="margin-bottom: 10px;">Comment: Sangamo BioSciences just announced that positive preclinical data from its joint program with Shire, to develop a novel ZFP Therapeutic<SUP>&reg;</SUP> approach to Huntington's disease (HD), The data were generated by Sangamo scientists and the CHDI Foundation.<wbr> They provide the first demonstration of a therapeutic approach that can not only prevent, but reverse the accumulation of mutant Huntingtin protein aggregates in the brains of animal models of the disease.<wbr> Furthermore, the treatment does not affect the expression of the normal form of the protein, which is believed to be essential.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>About the Data</STRONG> </div><div style="margin-bottom: 10px;">Data presented at Neuroscience 2014 demonstrate that Sangamo's zinc finger DNA-binding protein (ZFP) gene regulation technology can selectively repress expression of the mutant form of the <EM>huntingtin</EM> gene (<EM>HTT</EM>) which causes the disease, while leaving the normal gene largely unchanged in both patient-derived cells and in several mouse models.<wbr>  Importantly, the data also demonstrate the selective effects over the full range of <EM>HTT</EM> mutations relevant to human disease.<wbr> </div><div style="margin-bottom: 10px;">When delivered to the brain in an animal model of the disease, the ZFP Therapeutic not only prevented formation of aggregates if administered at early time points in disease progression, but reversed aggregate formation when administered at later time points.<wbr> </div><div style="margin-bottom: 10px;">The effects observed in both cases were statistically significant (p &lt; 0.<wbr>001).<wbr>  ZFP treatment of the animals also maintains expression of markers of medium spiny neurons, a particular class of nerve cell in the striatum of the brain primarily lost in patients with HD.<wbr> In addition, ZFP treatment reverses physical indications of disease as manifest in a statistically significant reduction in "clasping behavior" compared to controls (p=0.<wbr>015).<wbr> "Clasping" is an HD-associated symptom exhibited by a mouse model of HD (R6/<wbr>2) that mimics the motor symptoms of the human disease.<wbr> </div><div style="margin-bottom: 10px;"><SPAN style="text-decoration: underline;">Source</SPAN> </div><div style="margin-bottom: 10px;"><EM>Engineering zinc finger transcriptional repressors selectively inhibit mutant huntingtin expression and reverse disease phenotypes in Huntington's disease patient-derived neurons and in rodent models</EM>.<wbr>  H.<wbr> S.<wbr> Zhang, B.<wbr> Zeitler, S.<wbr> Froelich, Q.<wbr> Yu, J.<wbr> Pearl, D.<wbr> E.<wbr> Paschon, J.<wbr> C.<wbr> Miller, A.<wbr> E.<wbr> Kudwa, Y.<wbr> Sedaghat, D.<wbr> Li, K.<wbr> Marlen, D.<wbr> Guschin, L.<wbr> Zhang, M.<wbr> Mendel, E.<wbr> J.<wbr> Rebar, F.<wbr> D.<wbr> Urnov, S.<wbr> Kwak, V.<wbr> Mack, I.<wbr> Munoz-Sanjuan, P.<wbr> D.<wbr> Gregory </div><div style="margin-bottom: 10px;"><STRONG>About the Event</STRONG> </div><div>Neuroscience 2014, which is the world's largest forum for neuroscientists to present their research, is being held in Washington D.<wbr>C.<wbr> from November 15-19, 2014.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7823">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-11-20T11:26:14+01:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Allergan Educates Consumers on Botox Cosmetic with App and Website [sub:Aesthetics]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7822</link>
<description>Allergan Educates Consumers on Botox Cosmetic with App and Website [sub:Aesthetics]</description><category>sub:Aesthetics</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7822</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7822">Allergan Educates Consumers on Botox Cosmetic with App and Website</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20141231&edate=20140901&cat=sub%3aAesthetics"><font color="#e95e0b">:Neurology:sub:Aesthetics</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7822">Neurology7822</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 20 November 2014 | 10:57</font><br><br><div style="margin-bottom: 10px;">Comment: A survey of &gt;2,200 women has shown Allergan that its prospective consumers need further information on safety, price and results.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Digital Education</STRONG> </div><div style="margin-bottom: 10px;">iVisualizer, the company's app lets consumers use their own photo to 'visualize' changes to the lines around the mouth and eyes </div><div style="margin-bottom: 10px;">Botox cosmetic website has been updated and redesigned with the results </div><div style="margin-bottom: 10px;"><STRONG>About the Survey</STRONG> </div><div style="margin-bottom: 10px;">Data will be published on the Botox product site before the end of the year.<wbr> </div><div style="margin-bottom: 10px;"><SPAN style="text-decoration: underline;">Limited results are available:</SPAN> </div><div style="margin-bottom: 10px;">36% of respondents want more information on the safety of the product </div><div style="margin-bottom: 10px;">18% of women questionned are concerned about how naturel treatment results would appear </div><div>54% would like to know cost of Botox treatment </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7822">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-11-20T10:57:07+01:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>re: SOTIO Announced First Patient Enrolled in its Ph3 VIABLE Study for DCVAC/PCa in Combination With Chemotherapy</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology10117</link>
<description>re: SOTIO Announced First Patient Enrolled in its Ph3 VIABLE Study for DCVAC/PCa in Combination With Chemotherapy</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology10117</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10117">re: SOTIO Announced First Patient Enrolled in its Ph3 VIABLE Study for DCVAC/<wbr>PCa in Combination With Chemotherapy</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10117">Oncology10117</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/994">Jenny Wu</a> | 20 November 2014 | 10:46</font><br><br><div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">SOTIO Announced First Patient Enrolled in its Ph3 VIABLE Study for DCVAC/<wbr>PCa in Combination With Chemotherapy</span>&nbsp;<font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=class%3aVaccines"><font color="#e95e0b">:Oncology:class:Vaccines</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a>]</font></font><br><span style="font-size: 12px;">Comment: DCVAC/<wbr>PC is an active cellular immunotherapy treatment for prostate cancer patients.<wbr> VIABLE is a randomized, double blind, multicenter, parallel-group, Phase III study to evaluate the efficacy and safety of DCVAC/<wbr>PCa as an add-on therapy to 1st line standard of care chemotherapy in men with metastatic Castration Resistant Prostate Cancer (mCRPC), which is based on overall survival (OS) in mCRPC patients treated with DCVAC/<wbr>PCa versus placebo with standard of care chemotherapy.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=9737">...</a><br><font size="-1">Jenny Wu / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9737" class="commentpermalink">Oncology9737</a> / <span class="date">22 May 2014</span> /
<span class="time">17:34:21 o'clock CEST</span>
</font></div><div>Comment: Ph3 VIABLE study for DCVAC/<wbr>PCa (a cellular immunotherapy) is enrolling the first US patient and the total target recruitment in US is 250 patients.<wbr> (Source: Satio Company Press Release) </div><!-- Comment details --><font size="-1">Jenny Wu / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10117" class="commentpermalink">Oncology10117</a> / <span class="date">20 November 2014</span> /
<span class="time">10:46:06 o'clock CET</span>
</font><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10117">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9737">View thread  Oncology9737: SOTIO Announced First Patient Enrolled in its Ph3 VIABLE Study for DCVAC/<wbr>PCa in Combination With Chemotherapy</a>]]></content:encoded><dc:date>2014-11-20T10:46:06+01:00</dc:date><dc:creator>jew60237</dc:creator></item><item>
<title>Update on Shire Site Strategy</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld11015</link>
<description>Update on Shire Site Strategy</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld11015</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20141231&edate=20140901&rec=11015">Update on Shire Site Strategy</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld11015">PharmaWorld11015</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 19 November 2014 | 18:01</font><br><br><div style="margin-bottom: 10px;">Comment: Part of the 'One Shire' strategy announced Q2:14, the company plans to relocate &gt;500 positions to Massachussetts from its Chesterbrook, Pennsylvania site and establish Lexington, Massachussetts as its US operational HQs.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/11015/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Rationale</FONT></STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>To streamline business globally through 2 principal locations: Massachussetts and Switzerland</LI>
<LI>To simplify operations and increase efficiencies (will save approx $25M beginning of 2016)</LI>
<LI>To enable greater alignment and execution of priorities between Shire's commercial and R&amp;D teams</LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Plans</FONT></STRONG> </div><div>Shire plans to move employees in several phases beginning in Q1:15, and targets completion by Q1:16 </div><!-- Comment details --><a name="pharmaworld11015attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/11015/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(106,2 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20141231&edate=20140901&rec=11015">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-11-19T18:01:47+01:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/11015/1/ScreenCapture1.jpg" length="108738" type="image/jpeg"/></item><item>
<title>Feedback from AstraZeneca's Investor Day - Updated View of the Strategy and Plans [comp:AstraZeneca]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology10113</link>
<description>Feedback from AstraZeneca's Investor Day - Updated View of the Strategy and Plans [comp:AstraZeneca]</description><category>comp:AstraZeneca</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology10113</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10113">Feedback from AstraZeneca's Investor Day - Updated View of the Strategy and Plans</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=comp%3aAstraZeneca"><font color="#e95e0b">:Oncology:comp:AstraZeneca</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10113">Oncology10113</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 19 November 2014 | 12:36</font><br><br><div style="margin-bottom: 10px;">Comment: Mangement provided a comprehensive update on its strategy implementation and pipeline despite no major news.<wbr> P Soriot introduction was focused on the scientific leadership of the group, and the acceleration and prioritisation of the pipeline.<wbr> Among a list of drugs, oncology submissions in 2016 include Falsodex 1-line for mBC, Lymparza for BCRAm mBC, and Caprelsa for differentiated thyroid cancer.<wbr> M Mallon (EVP, International) outlined a strong presence in emerging markets outside China, where AZ is #2 multi-national company.<wbr> As presented by S Galbraith (Head of Innovative Medicines Oncology iMed) and M Dar (VP, Oncology Clinical Dev) the ambition of AZ is to become a recognised leader in oncology by 2020 with key drivers being combination therapies, personalised treatment, and immuno-oncology (13 ongoing studies and 16 planned combinations to address multiple immune pathways).<wbr> A selection of key slides is provided below.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Pipeline Takeaways</FONT></STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>Q2 2015 US filing of <STRONG>AZD9291</STRONG> in 2L NSCLC - results from larger 1L NSCLC opportunity (FLAURA) not due until 2017</LI>
<LI><STRONG>cediranib</STRONG> is not expected to be a US opportunity</LI>
<LI>lack of efficacy for<STRONG> lesinurad</STRONG> on gout flares and tophi reduction may be a concern for regulators</LI>
<LI>management more optimistic about <STRONG>Lynparza (olaparib)</STRONG> US approval for BRCAm ovarian cancer in January prior to release of SOLO-2 study results in Q3 PEGASUS results expected 1Q15</LI>
<LI>likely only one of three <STRONG>OX40</STRONG> agonists to be developed</LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Oncology - a Core Therapeutic Area</FONT></STRONG> </div><div style="margin-bottom: 10px;">Together with Respiratory, Inflammation &amp; Autoimmunity (RIA) and Cardivoscular &amp; Metabolic Disease (CVMD), Oncology represents a core TA, and is poised to be tansformational for AZ.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Combination therapies</STRONG> may enhance efficacy by 1/<wbr>targeting complementary pathways 2/<wbr>establishing synergitic effects 3/<wbr>overcoming resistance to monotherapy 4/<wbr>improving rik/<wbr>benefit profile </div><div style="margin-bottom: 10px;"><STRONG>Personalised healthcare</STRONG> as key driver </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/10113/7/ScreenCapture7.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG>Four Key Platforms</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/10113/8/ScreenCapture8.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG>Immunotherapy /<wbr> Immuno-Oncology Pipeline</STRONG> </div><div style="margin-bottom: 10px;">Three major components to cancer immune response </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/10113/9/ScreenCapture9.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/10113/4/ScreenCapture4.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG>Late-stage pipeline - Key newslow through 2015</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/10113/10/ScreenCapture10.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/10113/11/ScreenCapture11.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Emerging Markets and Japan</FONT></STRONG> </div><div style="margin-bottom: 10px;"><STRONG><FONT style="BACKGROUND-COLOR: #dfb3f7">China</FONT> - #2 multi-national company</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/10113/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT style="BACKGROUND-COLOR: #dfb3f7">Russia</FONT></STRONG> - <STRONG>returned to double digiy growth rate</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/10113/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT style="BACKGROUND-COLOR: #f0d9a4">Japan</FONT></STRONG> is preparing for first new oncology product AZD9291 </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/10113/3/ScreenCapture3.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Early Pipeline</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/10113/5/ScreenCapture5.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">2015-2016 Submissions</FONT></STRONG> </div><div><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/10113/6/ScreenCapture6.jpg?user-agent=rss"> </div><!-- Comment details --><a name="oncology10113attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10113/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(40,2 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10113/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(39,6 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10113/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(36,8 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10113/4/ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(111 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10113/5/ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(114 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10113/6/ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(99,4 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10113/7/ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(87,1 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10113/8/ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(110,2 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10113/9/ScreenCapture9.jpg">ScreenCapture9.jpg</a>&nbsp;&nbsp;(90,8 KB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10113/10/ScreenCapture10.jpg">ScreenCapture10.jpg</a>&nbsp;&nbsp;(11,9 KB)<br>&nbsp;&nbsp;11.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10113/11/ScreenCapture11.jpg">ScreenCapture11.jpg</a>&nbsp;&nbsp;(43,7 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10113">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-11-19T12:36:19+01:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10113/1/ScreenCapture1.jpg" length="41155" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10113/2/ScreenCapture2.jpg" length="40547" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10113/3/ScreenCapture3.jpg" length="37692" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10113/4/ScreenCapture4.jpg" length="113622" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10113/5/ScreenCapture5.jpg" length="116715" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10113/6/ScreenCapture6.jpg" length="101803" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10113/7/ScreenCapture7.jpg" length="89143" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10113/8/ScreenCapture8.jpg" length="112895" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10113/9/ScreenCapture9.jpg" length="92980" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10113/10/ScreenCapture10.jpg" length="12146" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10113/11/ScreenCapture11.jpg" length="44713" type="image/jpeg"/></item><item>
<title>OBI Pharma Completes Enrolment of its Breast Cancer Vaccine for China Trials [:PharmaWorld:sub:ClinicalTrial, :PharmaWorld:mkt:China, :Neurology:class:BotulinumToxins]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology10112</link>
<description>OBI Pharma Completes Enrolment of its Breast Cancer Vaccine for China Trials [:PharmaWorld:sub:ClinicalTrial, :PharmaWorld:mkt:China, :Neurology:class:BotulinumToxins]</description><category>sub:ClinicalTrial</category><category>mkt:China</category><category>class:BotulinumToxins</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology10112</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10112">OBI Pharma Completes Enrolment of its Breast Cancer Vaccine for China Trials</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20141231&edate=20140901&cat=class%3aBotulinumToxins"><font color="#e95e0b">:Neurology:class:BotulinumToxins</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=mkt%3aChina"><font color="#e95e0b">:PharmaWorld:mkt:China</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=sub%3aClinicalTrial"><font color="#e95e0b">:PharmaWorld:sub:ClinicalTrial</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10112">Oncology10112</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 19 November 2014 | 10:35</font><br><br><div style="margin-bottom: 10px;">Comment: OBI already completed enrollment of OBI-822 in Taiwan, and plans to accelerate its enrollment of ph3 clinical trials in the U.<wbr>S.<wbr> OBI-822 is a first-in-class active immunotherapy licensed from the U.<wbr>S.<wbr>-based Memorial Sloan-Kettering Cancer Center.<wbr> Its program development includes metastatic breast and ovarian cancer, among other potential indications (lung, prostate, stage 4 pancreatic, stomach).<wbr> There is no successful breast cancer drug used for active immunotherapy yet, and the drug could be seen as a breakthrough.<wbr> Of note, the company plans to complete preparation of its boulinum toxin (OBI-858/<wbr>spasticity) for clincial experiments by late 2014.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">About the Trial</FONT></STRONG> </div><div style="margin-bottom: 10px;">Reference <A href="http://clinicaltrial.gov/ct2/show/study/NCT01516307?show_locs=Y#locn">NCT01516307</A> </div><div style="margin-bottom: 10px;">Title: Trial of Active Immunotherapy With Globo H-KLH (OPT-822) in Metastatic Breast Cancer Subjects.<wbr> </div><div style="margin-bottom: 10px;">Taiwan Recruitment: patient enrolment (n=342) completed in July14.<wbr> </div><div style="margin-bottom: 10px;">OBI plans to commence the Ph3 clinical trials in the U.<wbr>S.<wbr> market.<wbr> </div><div style="margin-bottom: 10px;">OBI is in discussion with various breast cancer experts in Europe and America.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Drug Design</FONT></STRONG> </div><div style="margin-bottom: 10px;">OBI-822 is active immunotherapy, triggering human immune system by combining carbohydrate and proteins carrierGlobo H is over-expressed in many cancers.<wbr> </div><div style="margin-bottom: 10px;">The main function of OBI-822/<wbr>821 is to synthesize unique carbohydrate Globo-H on the surfaces of cancer cells (the surfaces of normal cells are without or only have a very few amount of Globo-H) and connect protein carrier KLH to form antigen.<wbr> </div><div style="margin-bottom: 10px;">The injection of antigen into the body helps immunocyte react with antibody, and suppress cancer cells.<wbr> </div><div style="margin-bottom: 10px;">Carbohydrate Globo-H exists on most surfaces of cancer cells.<wbr> <STRONG>Hence, OBI-822/<wbr>821 is suitable for the 3 kinds of breast cancer patients</STRONG> (Hormone receptor-positive breast cancer, HER2-positive breast cancer, and Triple-negative breast cancer), covering over 80% breast cancer patients.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Significant Potential for Growth</STRONG> </div><div style="margin-bottom: 10px;"><EM>Source: MasterLink Securities Corporation (oct2014).<wbr></EM> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/10112/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Company Snapshot</FONT></STRONG> </div><div><UL><LI>Founded: 2002</LI>
<LI>Focus: Cancer &amp; Infection diseases</LI>
<LI>Technology: OPopS synthesis technology developed by Chi-Huey Wong, which greatly shortens the time to synthesize and overcomes the bottleneck of traditional synthesis technology.<wbr> The most important core value and difference is that OBI’s technology allows the mass production of breast cancer vaccine, OBI-822/<wbr>821, which significantly reduces production cost</LI>
<LI>Subsidiaries: US and China</LI>
</UL> </div><!-- Comment details --><a name="oncology10112attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10112/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(72,5 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10112">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-11-19T10:35:51+01:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10112/1/ScreenCapture1.jpg" length="74230" type="image/jpeg"/></item><item>
<title>AB-Biotics Has Entered Deals with E-Biotics and Sanofi for the Development of its Probiotics [sub:Probiotics, :PharmaWorld:mkt:China, headline]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2125</link>
<description>AB-Biotics Has Entered Deals with E-Biotics and Sanofi for the Development of its Probiotics [sub:Probiotics, :PharmaWorld:mkt:China, headline]</description><comments>http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2125</comments><category>sub:Probiotics</category><category>mkt:China</category><category>headline</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2125</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2125">AB-Biotics Has Entered Deals with E-Biotics and Sanofi for the Development of its Probiotics</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20141231&edate=20140901&cat=headline"><font color="#e95e0b">:GastroEnterology:headline</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20141231&edate=20140901&cat=sub%3aProbiotics"><font color="#e95e0b">:GastroEnterology:sub:Probiotics</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=mkt%3aChina"><font color="#e95e0b">:PharmaWorld:mkt:China</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2125">GastroEnterology2125</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 18 November 2014 | 13:28</font><br><br><div style="margin-bottom: 10px;">Comment: The November deal involves the introduction of AB-Biotics' probiotics developed by Beijing E-Biotics in international markets, and the collaboration in the development of new probiotics for AB-Biotics' pipeline.<wbr> The October deal with Sanofi concerns the marketing in Spain (date: Q4:14) of Sanogermina&trade;.<wbr> a probiotic in the field of gastropediatric health.<wbr> <a name="GastroEnterology2163c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div>New deal just signed between AB-Biotics and Abbott.<wbr> The companies have signed exclusive distribution agreement for distribution, promotion and commercialisation of I3.<wbr>1 probiotic in Spain.<wbr> </div><font size="-1">Brigitte DESCHAMPS / <a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2163" class="commentpermalink">GastroEnterology2163</a> / <span class="date">18 December 2014</span> /
<span class="time">12:43:22 o'clock CET</span>
</font></div></div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">E-Biotics Collaboration - (Additional Terms)</FONT></STRONG> </div><div style="margin-bottom: 10px;">Deal also concerns implementation of clinical trials in China, with products of AB-Biotics.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Sanofi Collaboration</FONT></STRONG> </div><div style="margin-bottom: 10px;"><U>Terms</U>: Sanogermina&trade; has been developed and patented by AB-Biotics.<wbr> It is based on probiotics -live microorganisms naturally present in the human gut- and has been specifically designed for the treatment of gastrointestinal problems in children.<wbr> </div><div style="margin-bottom: 10px;">14 days of supplementation with Sanogermina&trade; reduced daily crying time by 67,5%, according to a clinical study developed by AB-Biotics with infants showing a daily average crying time between 60 and 240 minutes.<wbr> </div><div style="margin-bottom: 10px;"><U>Territories</U>: Spain will be the first market in the world where this probiotic formula will be launched.<wbr> AB-Biotics expects the product will be available in other markets by the end of 2014.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">AB-Biotics Snapshot</FONT></STRONG> </div><div style="margin-bottom: 10px;">- management team includes Miquel &Agrave;ngel Bonachera (CEO-CFO) and Sergi Audivert (CEO-COO), both with technicalbackgrounds as well as MBAs (ESADE, Barcelona) and entrepreneurship courses at MIT and Babson Business School in Boston </div><div style="margin-bottom: 10px;">- has developed a pipeline of products with novel, patentable performance characteristics.<wbr> </div><div><img src="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2125/1/ScreenCapture1.jpg?user-agent=rss"> </div><!-- Comment details --><a name="gastroenterology2125attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2125/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(90,5 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2125">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-11-18T13:28:35+01:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2125/1/ScreenCapture1.jpg" length="92706" type="image/jpeg"/></item><item>
<title>Novartis Strategy to Become More Tech Oriented</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology10110</link>
<description>Novartis Strategy to Become More Tech Oriented</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology10110</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10110">Novartis Strategy to Become More Tech Oriented</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10110">Oncology10110</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 18 November 2014 | 12:53</font><br><br><div style="margin-bottom: 10px;">Comment: Interviewed by Reuters, Joe Jimenez spotted that technologies will play a major role in the management of diseases.<wbr> He reported being convinced that remote monitoring technology will play a central role both to help healthcare systems check if patients are improving and also to protect companies that need to ensure they are not penalised for a drug failing if a patient does not take his or her medicine.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Ongoing Strategy at Novartis</FONT></STRONG> </div><div style="margin-bottom: 10px;">Novartis researchers are seeking fresh/<wbr>new ways to monitor exactly how the company's medicines are working and being taken by patients.<wbr> </div><div style="margin-bottom: 10px;">Novartis already has Google contact lens, and smart tablet/<wbr>pill deal with Proteus Digital Health.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Technology Firms Target Health Companies</FONT></STRONG> </div><div>Technology companies, such as Apple Inc <AAPL.O>, Samsung Electronics Co Ltd and Google are increasingly pushing to find new ways for patients to monitor their own health and track chronic conditions using smart/<wbr>wearable devices.<wbr></AAPL.O> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10110">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-11-18T12:53:05+01:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Roche and Inovio Terminate Prostate Cancer Immunotherapy Collaboration [dis:Prostate]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology10109</link>
<description>Roche and Inovio Terminate Prostate Cancer Immunotherapy Collaboration [dis:Prostate]</description><category>dis:Prostate</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology10109</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10109">Roche and Inovio Terminate Prostate Cancer Immunotherapy Collaboration</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10109">Oncology10109</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 18 November 2014 | 12:17</font><br><br><div style="margin-bottom: 10px;">Comment: Now Inovio plans to independently advance INO-5150 (DNA immunotherapy targeting prostate cancer) into a Ph1 trial in H1:2015.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">INO-5150 for Prostate Cancer</FONT></STRONG> </div><div style="margin-bottom: 10px;">Inovio's dual-antigen synthetic DNA immunotherapy (INO-5150) targets prostate-specific membrane antigen (PSMA) and prostate-specific antigen (PSA).<wbr> </div><div style="margin-bottom: 10px;">A study in monkeys showed that vaccination with INO-5150 generated strong and robust T-cell immune responses that were the highest generated by a PSA-targeting immunotherapy in animal studies.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Ongoing Collaboration with Roche for HepB</FONT></STRONG> </div><div style="margin-bottom: 10px;">Inovio and Roche will continue to collaborate and co-develop Inovio's DNA immunotherapy (INO-1800) against hepatitis B virus under their existing license agreement.<wbr> </div><div style="margin-bottom: 10px;">The partnership is on track to move INO-1800 collaboratively into a phase I study in 2015 </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">About the Initial 2013 Collaboration/<wbr>Agreement</FONT></STRONG> </div><div>See <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=9157" class="defaultlink">Oncology9157: Key Messages from Roche and Inovio Strategic Partnership for Immunotherapy Products</a> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10109">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-11-18T12:17:24+01:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>MSD to Start Registration Trial of VivaLAX (Constipation) in Russia [dis:Constipation, :PharmaWorld:mkt:Russia, :PharmaWorld:sub:ClinicalTrial]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2122</link>
<description>MSD to Start Registration Trial of VivaLAX (Constipation) in Russia [dis:Constipation, :PharmaWorld:mkt:Russia, :PharmaWorld:sub:ClinicalTrial]</description><comments>http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2122</comments><category>dis:Constipation</category><category>mkt:Russia</category><category>sub:ClinicalTrial</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2122</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2122">MSD to Start Registration Trial of VivaLAX (Constipation) in Russia</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20141231&edate=20140901&cat=dis%3aConstipation"><font color="#e95e0b">:GastroEnterology:dis:Constipation</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=mkt%3aRussia"><font color="#e95e0b">:PharmaWorld:mkt:Russia</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=sub%3aClinicalTrial"><font color="#e95e0b">:PharmaWorld:sub:ClinicalTrial</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2122">GastroEnterology2122</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 18 November 2014 | 11:59</font><br><br><div style="margin-bottom: 10px;">Comment: Sponsored by Merck Sharp &amp; Dohme (MSD), this pivotal trial will evaluate the complete resolution of constipation in participants taking VivaLAX compared to those taking Forlax.<wbr> PE has been designed to measure number of bowel movements per week.<wbr> <FONT face="Times New Roman,serif" size="3"><SPAN style="FONT-SIZE: 12pt"><FONT color="#000000" face="Calibri,sans-serif" size="2"><SPAN style="FONT-SIZE: 11pt">Ipsen Medical PC BU team has noted that "this open-label study compares one dose of PEG 3350 versus one or two doses of PEG 4000.<wbr> The dose attribution is not explained.<wbr> The patient number seems small for a non-inferiority study (60/<wbr>arm).<wbr> This appears to be a registration study for PEG 3350 in Russia, but has a number of bias".<wbr></SPAN></FONT></SPAN></FONT> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Trial Details</FONT></STRONG> </div><div style="margin-bottom: 10px;">Reference <A href="http://clinicaltrials.gov/ct2/show/NCT02292459?recr=Open&amp;no_unk=Y&amp;phase=012&amp;fund=2&amp;rcv_s=10%2F18%2F2014&amp;rank=128">NCT02292459</A> </div><div style="margin-bottom: 10px;">Recruitment approx 120 </div><div style="margin-bottom: 10px;"><UL><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">meets diagnostic criteria for functional constipation.<wbr> This includes loose stools that are rarely present without the use of laxatives and 2 or more of the following: straining during at least 25% of defecations; lumpy or hard stools in at least 25% of defecations; sensation of incomplete evacuation for at least 25% of defecations; sensation of anorectal obstruction/<wbr>blockage for at least 25% of defecations; manual maneuvers to facilitate at least 25% of defecations [e.<wbr>g.<wbr>, digital evacuation, support of the pelvic floor]; and fewer than 3 defecations per week.<wbr> Criteria for functional constipation must be fulfilled for last 3 months, with symptom onset at least 6 months prior to diagnosis.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">willing to use study drug for up to 7 days as directed, and must agree to record bowel movements (frequency, consistency, etc.<wbr>) accurately and consistently in a daily diary, and make 3 clinic visits.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">except for constipation, must be otherwise in good health, as determined by physical exam and medical history.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">agrees not to use any other products (drug, herbal, dietary supplements including fiber, etc.<wbr>) to treat their constipation during the course of the study.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">agrees not to use any medication known to cause constipation during the course of the study.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">agree to maintain a similar diet from the week prior to randomization through the end of the study.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">females must be either surgically sterile, 2 years post-menopausal, or attest that they are using an acceptable method of contraception (including hormonal birth control, intrauterine device [IUD], double barrier methods, or vasectomized partner).<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">females of childbearing potential must have urine pregnancy test (human chorionic gonadotropin [HCG]) that is negative at Baseline.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">must be able to read the diaries in Russian.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><P class="color-bullet" style="MARGIN-TOP: 0.7ex">Timelines</P> </div><div style="margin-bottom: 10px;">Start date Nov 2014 /<wbr> completion Dec 2014 </div><div style="margin-bottom: 10px;">Location Russia </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">What is VivaLAX</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2122/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">VivaLAX comes in 3 sizes </div><div style="margin-bottom: 10px;">VivaLAX contains a single ingredient Macrogol 3350 (1g/<wbr>g), is taken as a once daily dose and is also sugar, gluten and preservative free.<wbr> </div><div><A href="http://www.vivalax.com.au/why-vivalax/index.aspx">http:/<wbr>/<wbr>www.<wbr>vivalax.<wbr>com.<wbr>au/<wbr>why-vivalax/<wbr>index.<wbr>aspx</A> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="GastroEnterology2281c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">Last update from clinicaltrials.<wbr>gov indicates that the sponsor has changed to Bayer.<wbr> Start and completion timelines initially in November 2014 have been delayed for 13 months.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Rationale</FONT></STRONG> </div><div style="margin-bottom: 10px;">End of 2014, Bayer closed acquisition of consumer care business of Merck&amp;Co </div><div style="margin-bottom: 10px;">Bayer becomes the OTC leader in North and Latin America and achieves top global positions in key OTC categories </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Merck Consumer Health Business</FONT></STRONG> </div><div style="margin-bottom: 10px;"><FONT face="Arial">The consumer care business acquired from Merck &amp; Co.<wbr>, Inc.<wbr> is primarily comprised of products in the cold, allergy, sinus &amp; flu; dermatology (including sun care); foot health; and gastrointestinal categories.<wbr> </FONT> </div><div><FONT face="Arial">The most important brands are Claritin™ (allergy), Coppertone™ (sun care), <STRONG>MiraLAX™ (gastrointestinals),</STRONG> Afrin™ (cold) and – in North and Latin America – Dr.<wbr> Scholl’s™ (foot care).<wbr> These brands complement Bayer's existing OTC portfolio, which includes brands such as Aspirin™ and Aleve™ in the analgesics category, dermatology products including Canesten™ and Bepanthen™/<wbr>Bepanthol™, nutritional brands such as Supradyn™, One A Day™, Berocca™, Elevit™ and Redoxon™, antacids such as Rennie™ and Talcid™, and cough-and-cold products such as Alka-Seltzer Plus™ and White &amp; Black™.<wbr> </FONT> </div><font size="-1">Brigitte DESCHAMPS / <a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2281" class="commentpermalink">GastroEnterology2281</a> / <span class="date">06 March 2015</span> /
<span class="time">16:54:24 o'clock CET</span>
</font></div><a name="gastroenterology2122attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2122/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(25,5 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2122">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-11-18T11:59:15+01:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2122/1/ScreenCapture1.jpg" length="26150" type="image/jpeg"/></item><item>
<title>Dr Falk's Second Registration Trial of Phosphatidylcholine for UC [dis:IBD, :PharmaWorld:sub:ClinicalTrial]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2121</link>
<description>Dr Falk's Second Registration Trial of Phosphatidylcholine for UC [dis:IBD, :PharmaWorld:sub:ClinicalTrial]</description><category>dis:IBD</category><category>sub:ClinicalTrial</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2121</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2121">Dr Falk's Second Registration Trial of Phosphatidylcholine for UC</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20141231&edate=20140901&cat=dis%3aIBD"><font color="#e95e0b">:GastroEnterology:dis:IBD</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=sub%3aClinicalTrial"><font color="#e95e0b">:PharmaWorld:sub:ClinicalTrial</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2121">GastroEnterology2121</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 18 November 2014 | 11:49</font><br><br><div style="margin-bottom: 10px;">Comment: The PROTECT-2 trial is part of a synchronized global pivotal plan in EU and US, and is designed to prove the superiority of a 48-weeks treatment with 3.<wbr>2 g/<wbr>day delayed-release phosphatidylcholine (LT-02) versus placebo.<wbr> PE will measure percentage of patients who are relapse-free and are not a treatment failure.<wbr> The PROTECT-1 trial started in Q2 in in patients with UC refractory to standard treatment with mesalamine.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Trial Details</FONT></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>Title</STRONG> PROTECT-2 Randomized, Double-blind, Double-dummy, Placebo-controlled, Phase III Clinical Trial on the Efficacy and Safety of a <STRONG>48-weeks</STRONG> Treatment With Gastro-resistant Phosphatidylcholine (LT-02) Versus Placebo Versus Mesalamine for Maintenance of Remission in Patients With Ulcerative Colitis </div><div style="margin-bottom: 10px;">Reference <A href="http://clinicaltrials.gov/ct2/show/study/NCT02280629?recr=Open&amp;no_unk=Y&amp;phase=012&amp;fund=2&amp;rcv_s=10%2F18%2F2014&amp;rank=115">NCT02280629</A> </div><div style="margin-bottom: 10px;">Recruitment approx 400 </div><div style="margin-bottom: 10px;">Completion date Oct 2018 /<wbr> Dec 2018 </div><div style="margin-bottom: 10px;">Location Germany </div><div style="margin-bottom: 10px;">PI: Axel Dignass, Prof Dr Agaplesion Markus Krankenhaus </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">About the PROTECT-1</FONT></STRONG> </div><div>(See <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=1974" class="defaultlink">GastroEnterology1974: Dr Falk to Start Registration Trial of Phosphatidylcholine for UC</a>).<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2121">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-11-18T11:49:04+01:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Medy-Tox Has Started Korean Trial to Assess Medytoxin® for Hypertrophy of Masseter Muscle [comp:MediTox, class:BotulinumToxins, :PharmaWorld:mkt:Korea, :PharmaWorld:sub:ClinicalTrial, news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7819</link>
<description>Medy-Tox Has Started Korean Trial to Assess Medytoxin® for Hypertrophy of Masseter Muscle [comp:MediTox, class:BotulinumToxins, :PharmaWorld:mkt:Korea, :PharmaWorld:sub:ClinicalTrial, news]</description><category>comp:MediTox</category><category>class:BotulinumToxins</category><category>mkt:Korea</category><category>sub:ClinicalTrial</category><category>news</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7819</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7819">Medy-Tox Has Started Korean Trial to Assess Medytoxin® for Hypertrophy of Masseter Muscle</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20141231&edate=20140901&cat=class%3aBotulinumToxins"><font color="#e95e0b">:Neurology:class:BotulinumToxins</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20141231&edate=20140901&cat=comp%3aMediTox"><font color="#e95e0b">:Neurology:comp:MediTox</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20141231&edate=20140901&cat=news"><font color="#e95e0b">:Neurology:news</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=mkt%3aKorea"><font color="#e95e0b">:PharmaWorld:mkt:Korea</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=sub%3aClinicalTrial"><font color="#e95e0b">:PharmaWorld:sub:ClinicalTrial</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7819">Neurology7819</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 18 November 2014 | 11:28</font><br><br><div style="margin-bottom: 10px;">Comment: The POC study started a couple of months ago to evaluate Medytoxin® (20U 50U 110U) in subjects with begnin masseteric hypertrophy.<wbr> PE will measure reduction amount of masseter muscle thickness with maximum clenching.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Trial Details</FONT></STRONG> </div><div style="margin-bottom: 10px;">Reference <A href="http://clinicaltrials.gov/ct2/show/NCT02292472?recr=Open&amp;no_unk=Y&amp;phase=012&amp;fund=2&amp;rcv_s=10%2F18%2F2014&amp;rank=73">NCT02292472</A> </div><div style="margin-bottom: 10px;">Recruitment approx 68 </div><div style="margin-bottom: 10px;"><UL><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Subject who shows benign masseteric hypertrophy</LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Male or female subject over 19 years of age and written informed consent is obtained from the patient or LAR.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Subject who has bisymmetry of masster at visual assessment.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Subejects who qualifies the standard meets on ultrasonics wave value</LI>
</UL> </div><div style="margin-bottom: 10px;">Completion dates May 2015 /<wbr> Aug 2015 </div><div style="margin-bottom: 10px;">Location One center in Seoul, Korea (Yonsei U Dental Hospital).<wbr> </div><div style="margin-bottom: 10px;">PI Seong Taek Kim, Ph D </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Of note</FONT></STRONG> </div><div style="margin-bottom: 10px;">Allergan currently is evaluating Botox for the same indication; the Ph2 is recruiting participants (approx 200).<wbr> </div><div>Timelines indicate completion date in December 2016 (delayed by a quarter vs previously indicated).<wbr> (NCT02010775) <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7307" class="defaultlink">Neurology7307: Allergan to Test BOTOX® for Bilateral Masseter Muscle Hypertrophy (MMH)</a>.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7819">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-11-18T11:28:34+01:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Actavis Acquires Allergan for $66 Billion ($219 per Share in Cash and Actavis Shares) [comp:Allergan, headline, news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7814</link>
<description>Actavis Acquires Allergan for $66 Billion ($219 per Share in Cash and Actavis Shares) [comp:Allergan, headline, news]</description><category>comp:Allergan</category><category>headline</category><category>news</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7814</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7814">Actavis Acquires Allergan for $66 Billion ($219 per Share in Cash and Actavis Shares)</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20141231&edate=20140901&cat=comp%3aAllergan"><font color="#e95e0b">:Neurology:comp:Allergan</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20141231&edate=20140901&cat=headline"><font color="#e95e0b">:Neurology:headline</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20141231&edate=20140901&cat=news"><font color="#e95e0b">:Neurology:news</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7814">Neurology7814</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 17 November 2014 | 16:36</font><br><br><div style="margin-bottom: 10px;">Comment: With Actavis, Allergan will continue to have a significant runway for R&amp;D and marketing, as the value driver would not be cost cuts, but, rather, growth of the combined company.<wbr> For Actavis, the deal represents a further pivot into branded products (notably in ophtalmology), add serious R&amp;D capability to Forest’s strong development capability, and add significant organic growth.<wbr> Closing has been anticipated in Q2 2015.<wbr> Commenting on the transaction, Valeant management outlined that '.<wbr>.<wbr>.<wbr> we cannot justify to our own shareholders paying a price of <MONEY>$219</MONEY> or more per share for <ORG value="NYSE:AGN">Allergan'.<wbr> Key messages from the conference call are provided below.<wbr> </ORG> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">About the Acquisition - B<SPAN style="BACKGROUND-COLOR: rgb(255,255,255)">uilding Long-term V</SPAN><SPAN style="BACKGROUND-COLOR: rgb(255,255,255)">alue and not Short-term Cost-cutting</SPAN></FONT></STRONG> </div><div style="margin-bottom: 10px;"><STRONG><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7814/5/ScreenCapture5.jpg?user-agent=rss"></STRONG> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">About the Transaction</FONT></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>Objective and Rationale</STRONG> </div><div style="margin-bottom: 10px;"><P style="PADDING-LEFT: 30px">Allergan's blockbuster franchises in Ophthalmology, Neurosciences, and Medical Aesthetics/<wbr>Dermatology/<wbr>Plastic Surgery will <STRONG>complemen</STRONG>t Actavis' existing blockbuster CNS, Gastroenterology and Women's Health franchises.<wbr></P> </div><div style="margin-bottom: 10px;"><P style="PADDING-LEFT: 30px">The companies' <STRONG>combined U.<wbr>S.<wbr> sales force</STRONG> will have a huge marketing reach and increased relevance with more than a dozen medical specialists, including primary care physicians, ophthalmologists, optometrists, dermatologists, aesthetic physicians, plastic surgeons, neurologists, psychiatrists, infectious disease specialists, cardiologists, pulmonologists, gastroenterologists, OB-GYNs and urologists.<wbr></P> </div><div style="margin-bottom: 10px;"><P style="PADDING-LEFT: 30px"><STRONG>Expanded Commercial Opportunities Across Global Markets</STRONG></P> </div><div style="margin-bottom: 10px;"><P style="PADDING-LEFT: 30px">The combination of Actavis and Allergan will greatly <STRONG>enhance international commercial opportunities</STRONG> by positioning the combined company to extend its blockbuster franchise strategy on a global scale.<wbr></P> </div><div style="margin-bottom: 10px;"><P style="PADDING-LEFT: 30px"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7814/1/ScreenCapture1.jpg?user-agent=rss"></P> </div><div style="margin-bottom: 10px;"><P style="PADDING-LEFT: 30px"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7814/2/ScreenCapture2.jpg?user-agent=rss"></P> </div><div style="margin-bottom: 10px;"><P style="PADDING-LEFT: 30px">The company will have approximately $5 billion in pro forma 2015 international revenue.<wbr></P> </div><div style="margin-bottom: 10px;"><P style="PADDING-LEFT: 30px">Together Actavis and Allergan will have a<STRONG> commercial presence across 100 markets</STRONG>, including an enhanced presence across Canada, Europe, Southeast Asia and Latin America and a strong footprint in China and India.<wbr></P> </div><div style="margin-bottom: 10px;"><P style="PADDING-LEFT: 30px"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7814/3/ScreenCapture3.jpg?user-agent=rss"></P> </div><div style="margin-bottom: 10px;"><P style="PADDING-LEFT: 30px">The combined company will :</P> </div><div style="margin-bottom: 10px;"><P style="PADDING-LEFT: 30px">- benefit from Allergan's global brand equity, industry-leading consumer marketing capabilities and strong consumer awareness of key Allergan products, including BOTOX®.<wbr></P> </div><div style="margin-bottom: 10px;"><P style="PADDING-LEFT: 30px">- have the unique opportunity to drive growth in international markets through its enhanced portfolio of brands, generics, branded-generic and over-the-counter products.<wbr></P> </div><div style="margin-bottom: 10px;"><STRONG>Expanded Pharmaceutical R&amp;D Pipeline</STRONG> </div><div style="margin-bottom: 10px;"><P style="PADDING-LEFT: 30px"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7814/4/ScreenCapture4.jpg?user-agent=rss"></P> </div><div style="margin-bottom: 10px;"><UL><LI>The combined company will provide a strong commitment to R&amp;D, with an exceptional level of annual investment of approximately $1.<wbr>7 billion, focused on the strategic development of innovative and durable value-enhancing products within brands, generics, biologics and OTC portfolios.<wbr> The combination is expected to add approximately 15 projects in near- and mid-term development to Actavis' robust development portfolio.<wbr> </LI>
</UL> </div><div style="margin-bottom: 10px;"><P style="PADDING-LEFT: 30px"><STRONG><FONT size="4">Key Messages from the Confrerence Call with Investors</FONT></STRONG></P> </div><div style="margin-bottom: 10px;"><P style="PADDING-LEFT: 30px">Regarding the <STRONG>ANDA business</STRONG> (generic) Valeant management answered that " .<wbr>.<wbr>.<wbr> we're absolutely committed to generics because we are best-in-class in generics.<wbr> We have the best, fastest-growing generic business in the world with the absolute best pipeline.<wbr> So to be clear, we've already achieved the status of being best in generics and it is our commitment to maintain that status".<wbr> " .<wbr>.<wbr>.<wbr><SPAN style="BACKGROUND-COLOR: rgb(255,255,255)">We have the best business with the best </SPAN><SPAN style="BACKGROUND-COLOR: rgb(255,255,255)">people with the best pipeline".<wbr></SPAN></P> </div><div style="margin-bottom: 10px;"><P style="PADDING-LEFT: 30px">The <STRONG>'combined synergies'</STRONG> topic was discussed by B Saunders " .<wbr>.<wbr>.<wbr> Valeant <SPAN style="BACKGROUND-COLOR: rgb(255,255,255)">wanted to cut $900 million of R&amp;D, where </SPAN><SPAN style="BACKGROUND-COLOR: rgb(255,255,255)">we're cutting $400 million from a much larger combined </SPAN><SPAN style="BACKGROUND-COLOR: rgb(255,255,255)">spend.<wbr> </SPAN><SPAN style="BACKGROUND-COLOR: rgb(255,255,255)">So I think our commitment to growing the </SPAN><SPAN style="BACKGROUND-COLOR: rgb(255,255,255)">business for the long term and commitment to keeping </SPAN><SPAN style="BACKGROUND-COLOR: rgb(255,255,255)">our focus on sales and investments and direct-to-consumer </SPAN><SPAN style="BACKGROUND-COLOR: rgb(255,255,255)">advertising and our salesforce is </SPAN><SPAN style="BACKGROUND-COLOR: rgb(255,255,255)">much stronger than </SPAN><SPAN style="BACKGROUND-COLOR: rgb(255,255,255)">perhaps what was being proposed by the other company.<wbr></SPAN></P> </div><div style="margin-bottom: 10px;"><P style="PADDING-LEFT: 30px"><SPAN style="BACKGROUND-COLOR: rgb(255,255,255)">The '<STRONG>combined footprint'</STRONG> was outlined by D Pyott " .<wbr>.<wbr>.<wbr><SPAN style="BACKGROUND-COLOR: rgb(255,255,255)">combined footprint of the companies </SPAN><SPAN style="BACKGROUND-COLOR: rgb(255,255,255)">around the world, you'll see in many cases that </SPAN><SPAN style="BACKGROUND-COLOR: rgb(255,255,255)">where Allergan historically </SPAN><SPAN style="BACKGROUND-COLOR: rgb(255,255,255)">has been strong Actavis has not </SPAN><SPAN style="BACKGROUND-COLOR: rgb(255,255,255)">been so well represented; and in reverse.<wbr> </SPAN><SPAN style="BACKGROUND-COLOR: rgb(255,255,255)">So I think as the two teams really get to work on Western </SPAN><SPAN style="BACKGROUND-COLOR: rgb(255,255,255)">Europe, China, Japan, Latin America, </SPAN><SPAN style="BACKGROUND-COLOR: rgb(255,255,255)">they will come up with some great ideas"</SPAN>.<wbr></SPAN></P> </div><div style="margin-bottom: 10px;"><P style="PADDING-LEFT: 30px"><SPAN style="BACKGROUND-COLOR: rgb(255,255,255)">When it comes to "<STRONG>revenue synergies'</STRONG> Actavis management reported that : " .<wbr>.<wbr>.<wbr> <SPAN style="BACKGROUND-COLOR: rgb(255,255,255)">we know that some areas are instant-hit revenue synergies, like migraine.<wbr> </SPAN><SPAN style="BACKGROUND-COLOR: rgb(255,255,255)">There are other areas, like perhaps dry eye that Bill alluded to, that we're going to </SPAN><SPAN style="BACKGROUND-COLOR: rgb(255,255,255)">test.<wbr> It's not like we're going to put the whole </SPAN><SPAN style="BACKGROUND-COLOR: rgb(255,255,255)">primary care field force into Restasis; we'll tested in a couple </SPAN><SPAN style="BACKGROUND-COLOR: rgb(255,255,255)">markets and see how it goes.<wbr> </SPAN><SPAN style="BACKGROUND-COLOR: rgb(255,255,255)">That's the beauty of our structure, that's almost 500 markets in primary care in the US.<wbr> </SPAN><SPAN style="BACKGROUND-COLOR: rgb(255,255,255)">So we believe they are real.<wbr> We're very excited </SPAN><SPAN style="BACKGROUND-COLOR: rgb(255,255,255)">about the revenue synergies".<wbr> </SPAN></SPAN></P> </div><div style="margin-bottom: 10px;"><P style="PADDING-LEFT: 30px"><SPAN style="BACKGROUND-COLOR: rgb(255,255,255)"><STRONG>Scale will not be an issue</STRONG>, as reported by B Saunders " .<wbr>.<wbr>.<wbr> <SPAN style="BACKGROUND-COLOR: rgb(255,255,255)">We have a very flat structure.<wbr> </SPAN><SPAN style="BACKGROUND-COLOR: rgb(255,255,255)">We have great discipline about spans and layers </SPAN><SPAN style="BACKGROUND-COLOR: rgb(255,255,255)">inside the organization.<wbr> We don't make decisions by committee.<wbr> We empower our talented employees </SPAN><SPAN style="BACKGROUND-COLOR: rgb(255,255,255)">to drive our business.<wbr> </SPAN><SPAN style="BACKGROUND-COLOR: rgb(255,255,255)">We do make mistakes, but we learn from our mistakes and we tolerate </SPAN><SPAN style="BACKGROUND-COLOR: rgb(255,255,255)">that inside of our organization.<wbr> And we work hard.<wbr> So I think when you look at </SPAN><SPAN style="BACKGROUND-COLOR: rgb(255,255,255)">all the attributes of our Company, very similar to Allergan.<wbr> We have people that compete </SPAN><SPAN style="BACKGROUND-COLOR: rgb(255,255,255)">and like to win.<wbr> And I don't think scale is a question.<wbr> It's all </SPAN><SPAN style="BACKGROUND-COLOR: rgb(255,255,255)">about the talent of the people.<wbr> </SPAN><SPAN style="BACKGROUND-COLOR: rgb(255,255,255)">And our management team combined is best in class".<wbr></SPAN></SPAN></P> </div><div style="margin-bottom: 10px;"><P style="PADDING-LEFT: 30px"><SPAN style="BACKGROUND-COLOR: rgb(255,255,255)"><SPAN style="BACKGROUND-COLOR: rgb(255,255,255)"><STRONG>Overlap in S&amp;M and R&amp;D</STRONG> was discussed " .<wbr>.<wbr>.<wbr> <SPAN style="BACKGROUND-COLOR: rgb(255,255,255)">We overlap in neurology, </SPAN><SPAN style="BACKGROUND-COLOR: rgb(255,255,255)">we overlap in urology, and we overlap in dermatology.<wbr> So there's clearly some key overlap in sales and marketing.<wbr> There's also </SPAN><SPAN style="BACKGROUND-COLOR: rgb(255,255,255)">back-office, sales administration training, fleet, </SPAN><SPAN style="BACKGROUND-COLOR: rgb(255,255,255)">all that kind of stuff, informatics, that are also the target of synergies.<wbr> </SPAN><SPAN style="BACKGROUND-COLOR: rgb(255,255,255)">In R&amp;D it will also be a combination of back-office management of clinical </SPAN><SPAN style="BACKGROUND-COLOR: rgb(255,255,255)">trials, pharmacovigilance, the transactional side of R&amp;D.<wbr> And then of course we'll look at lower value programs </SPAN><SPAN style="BACKGROUND-COLOR: rgb(255,255,255)">and make sure that we're spending </SPAN><SPAN style="BACKGROUND-COLOR: rgb(255,255,255)">our money against the high-value, high probability of success programs .<wbr>.<wbr>.<wbr>"</SPAN>.<wbr></SPAN></SPAN></P> </div><div style="margin-bottom: 10px;"><P style="PADDING-LEFT: 30px"><SPAN style="BACKGROUND-COLOR: rgb(255,255,255)"><SPAN style="BACKGROUND-COLOR: rgb(255,255,255)"><SPAN style="BACKGROUND-COLOR: rgb(255,255,255)"><STRONG>R&amp;D strategy</STRONG> being outlined: " .<wbr>.<wbr>.<wbr> </SPAN><SPAN style="BACKGROUND-COLOR: rgb(255,255,255)">we </SPAN><SPAN style="BACKGROUND-COLOR: rgb(255,255,255)">will be evaluating R&amp;D programs </SPAN><SPAN style="BACKGROUND-COLOR: rgb(255,255,255)">and putting -- and funding our longer-term </SPAN><SPAN style="BACKGROUND-COLOR: rgb(255,255,255)">pipeline in tax-advantageous locations.<wbr> </SPAN><SPAN style="BACKGROUND-COLOR: rgb(255,255,255)">So that's the <STRONG>strategy</STRONG>, is to develop that IP offshore, to successfully launch those products, and to have that tax at a </SPAN><SPAN style="BACKGROUND-COLOR: rgb(255,255,255)">favorable rate"</SPAN>.<wbr></SPAN></SPAN></P> </div><div><P style="PADDING-LEFT: 30px"><SPAN style="BACKGROUND-COLOR: rgb(255,255,255)"><SPAN style="BACKGROUND-COLOR: rgb(255,255,255)"><STRONG>In his closing comments</STRONG>, B Saunders highlighted that " .<wbr>.<wbr>.<wbr> <SPAN style="BACKGROUND-COLOR: rgb(255,255,255)">We do believe this is an historic combination.<wbr> We think we </SPAN><SPAN style="BACKGROUND-COLOR: rgb(255,255,255)">have the potential to create the best pharmaceutical company with the best organic </SPAN><SPAN style="BACKGROUND-COLOR: rgb(255,255,255)">top-line growth profile and bottom-line growth profile.<wbr> </SPAN><SPAN style="BACKGROUND-COLOR: rgb(255,255,255)">We are committed to the long-term value creation </SPAN><SPAN style="BACKGROUND-COLOR: rgb(255,255,255)">for all of our shareholders </SPAN><SPAN style="BACKGROUND-COLOR: rgb(255,255,255)">and making sure our colleagues, and customers, and physicians and patients </SPAN><SPAN style="BACKGROUND-COLOR: rgb(255,255,255)">can continue to count on the combined Actavis and Allergan to make sure that we service their needs".<wbr></SPAN></SPAN></SPAN></P> </div><!-- Comment details --><a name="neurology7814attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7814/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(35,9 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7814/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(98,6 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7814/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(81,9 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7814/4/ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(65,2 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7814/5/ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(73,4 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7814">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-11-17T16:36:36+01:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7814/1/ScreenCapture1.jpg" length="36760" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7814/2/ScreenCapture2.jpg" length="100985" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7814/3/ScreenCapture3.jpg" length="83826" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7814/4/ScreenCapture4.jpg" length="66734" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7814/5/ScreenCapture5.jpg" length="75176" type="image/jpeg"/></item><item>
<title>Pfizer to Co-Develop Merck's Anti-PDL1 Drug [headline]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology10108</link>
<description>Pfizer to Co-Develop Merck's Anti-PDL1 Drug [headline]</description><category>headline</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology10108</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10108">Pfizer to Co-Develop Merck's Anti-PDL1 Drug</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=headline"><font color="#e95e0b">:Oncology:headline</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10108">Oncology10108</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 17 November 2014 | 11:16</font><br><br><div style="margin-bottom: 10px;">Comment: With an upfront fee of $850M, $2bn in potential milestones and co-commercialisation rights, this is a significant transaction for Merck KGaA.<wbr> The companies plan to initiate up to 20 clinical trials in 2015, including pivotal registration studies.<wbr> MSB0010718C, an investigational anti-PD-L1 antibody currently is in development as a potential treatment for multiple tumor types.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Rationale</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/10108/4/ScreenCapture4.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Terms of the Deal</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/10108/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/10108/3/ScreenCapture3.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">The asset will be developed as a single agent as well as in various combinations with Pfizer`s and Merck KGaA's broad portfolio of approved and investigational pipeline candidates.<wbr> </div><div style="margin-bottom: 10px;">The two companies will also combine resources and expertise to advance Pfizer`s anti-PD-1 antibody into Phase 1 trials.<wbr> </div><div style="margin-bottom: 10px;">As part of the agreement, Merck KGaA will co-promote Pfizer`s XALKORI, a medicine to treat non-small cell lung cancer, in the US and several other key markets.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Merck's MSB0010718C Development Programs</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/10108/5/ScreenCapture5.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">- Phase 1 trial, with more than 550 patients have been treated with MSB0010718C across multiple types of cancers.<wbr> As part of the Analyst and Investor Day hosted by Merck KGaA, Darmstadt, Germany, on September 18, 2014, interim data were presented from the ongoing Phase 1 study demonstrating a complete response and partial responses in patients with non-small cell lung cancer and ovarian cancer.<wbr> Additional data are expected to be presented at medical congresses in 2015.<wbr> </div><div style="margin-bottom: 10px;">- ongoing Phase 2 trial evaluating this antibody in patients with m-Merkel cell carcinoma, a rare form of skin cancer.<wbr> </div><div style="margin-bottom: 10px;"><EM><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/10108/6/ScreenCapture6.jpg?user-agent=rss"></EM> </div><div><EM>Source: Merck</EM> </div><!-- Comment details --><a name="oncology10108attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10108/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(82,2 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10108/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(80 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10108/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(70 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10108/4/ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(74,7 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10108/5/ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(114,5 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10108/6/ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(79,7 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10108">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-11-17T11:16:08+01:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10108/1/ScreenCapture1.jpg" length="84180" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10108/2/ScreenCapture2.jpg" length="81900" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10108/3/ScreenCapture3.jpg" length="71670" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10108/4/ScreenCapture4.jpg" length="76528" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10108/5/ScreenCapture5.jpg" length="117253" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10108/6/ScreenCapture6.jpg" length="81577" type="image/jpeg"/></item><item>
<title>New Agreement Signed to Discover Drugs for Huntington's Disease [dis:Huntington]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7813</link>
<description>New Agreement Signed to Discover Drugs for Huntington's Disease [dis:Huntington]</description><category>dis:Huntington</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7813</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7813">New Agreement Signed to Discover Drugs for Huntington's Disease</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20141231&edate=20140901&cat=dis%3aHuntington"><font color="#e95e0b">:Neurology:dis:Huntington</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7813">Neurology7813</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 17 November 2014 | 09:11</font><br><br><div style="margin-bottom: 10px;">Comment: GNS Healthcare, Inc.<wbr> (GNS), a healthcare data analytics company, has entered into a multi-year agreement with CHDI Foundation, Inc.<wbr> GNS Healthcare will apply its patented inference engine and machine-learning technology, REFS, to the enormous CHDI dataset.<wbr> The models developed by GNS allow the Huntington’s disease community to approach the disease in a novel holistic way, providing new insights into the molecular pathology of HD that will advance the understanding of the disease.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Information on the Agreement</FONT></STRONG> </div><div style="margin-bottom: 10px;">The collaboration builds on the success of a previous GNS and CHDI project to develop predictive computer models of the molecular pathology in Huntington’s disease.<wbr> </div><div style="margin-bottom: 10px;">Both projects benefit from an <EM>in silico</EM> approach, using machine learning and cloud-based computing to simulate many of the traditional steps in the drug discovery and development process.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">GNS Snapshot</FONT></STRONG> </div><div style="margin-bottom: 10px;">Big data analytics company </div><div>REFS Technology (Reverse Engineering and Forward Stimulation): scalable, supercomputer-enabled framework for discovering new knowledge from real world data.<wbr> REFS automates the extraction of causal networl models directly from observational data, and uses high-throuput stimulations to generate new knowledge (<A href="http://www.gnshealthcare.com/technology/">http:/<wbr>/<wbr>www.<wbr>gnshealthcare.<wbr>com/<wbr>technology/<wbr></A>).<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7813">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-11-17T09:11:27+01:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>VT-464, A CYP17 Lypase Inhibtor, Is Trialled For Ph2 In mCRPC Patients Who are Resistant To Abiraterone Or Enzalutamide [dis:Prostate]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology10103</link>
<description>VT-464, A CYP17 Lypase Inhibtor, Is Trialled For Ph2 In mCRPC Patients Who are Resistant To Abiraterone Or Enzalutamide [dis:Prostate]</description><category>dis:Prostate</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology10103</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10103">VT-464, A CYP17 Lypase Inhibtor, Is Trialled For Ph2 In mCRPC Patients Who are Resistant To Abiraterone Or Enzalutamide</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10103">Oncology10103</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/994">Jenny Wu</a> | 14 November 2014 | 12:19</font><br><br><div style="margin-bottom: 10px;">Comment: Innocrin Pharmaceuticals (a privately held company) and the Prostate Cancer Foundation (PCF) collaborate to initiate a multi-centre Ph2 study of VT-464 in mCRPC patients who are resistant to abiraterone or enzalutamide.<wbr> PCF is to provide $1 million for this biomarker based study.<wbr> This will be the second trial to explore this patient setting.<wbr> The first trial is being done by Tokai with its Galeterone, of which was highlighted during the ESMO this year in relation to AR-V7.<wbr> AR-V7 has been discussed frequently as early data suggested the link between AR-V7 and treatment outcome with abiraterone and enzalutamide.<wbr> </div><div style="margin-bottom: 10px;">Dr Howard Scher (Chief of GU Oncology Service at Memorial Sloan Kettering Cancer Center) is the PI of the study that is slated to begin in 1H 2015.<wbr> Interestingly, Dr Mary-Ellen Taplin is also one of the co-investigators on this study.<wbr> Dr Taplin is the PI on TOKAI's ARMOR-2 Study (Galeterone) and presenting the interim Ph2 data of the trial at the EORTC-NCI-AACR Symposium on 18-21 November in Barcelona, Spain.<wbr> The presentation entitled " Activity of galeterone in CRPC with C-terminal AR loss: Results from ARMOR2" will be highlighted as an oral presentation during the Plenary Session 2 on Wednesday on 19th Nov at 2.<wbr>05 pm (CET).<wbr> </div><div style="margin-bottom: 10px;">Innocrin's ongoing CRPC clinical trials include </div><div style="margin-bottom: 10px;"><UL><LI>Ph1/<wbr>2 Open label PK, Safety, Tolerability and Efficacy Study: Phase 1/<wbr>2 open-label study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of VT-464 in CRPC patients who are treatment-na&iuml;ve or whose disease has progressed following treatment with either abiraterone, enzalutamide or both (<a href="http://clinicaltrials.gov/ct2/show/NCT02012920" class="defaultlink">NCT0201292</a>0)
</LI>
<LI>Ph2 Open label (NCI funded): A Phase 2 open-label study, that is being funded by the National Cancer Institute, to evaluate the efficacy and safety of VT-464 in patients with metastatic CRPC who have previously been treated with enzalutamide (<a href="http://clinicaltrials.gov/ct2/show/NCT02130700%20" class="defaultlink">NCT02130700</a>)
</LI>
</UL> </div><div style="margin-bottom: 10px;">Innocrin&rsquo;s investors include Novartis Venture Fund, Lilly Ventures, Hatteras Venture Partners, Intersouth Partners, Lurie Holdings, and Astellas Venture Management.<wbr> </div><div>Source: <A href="http://www.innocrinpharma.com">www.<wbr>innocrinpharma.<wbr>com</A>; business wire </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10103">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-11-14T12:19:22+01:00</dc:date><dc:creator>jew60237</dc:creator></item><item>
<title>Real World Observational Study of Pfizer's Sunitinib in Chinese Patients with pNET [comp:Pfizer, dis:pNET, :PharmaWorld:mkt:China]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7861</link>
<description>Real World Observational Study of Pfizer's Sunitinib in Chinese Patients with pNET [comp:Pfizer, dis:pNET, :PharmaWorld:mkt:China]</description><category>comp:Pfizer</category><category>dis:pNET</category><category>mkt:China</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7861</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20141231&edate=20140901&rec=7861">Real World Observational Study of Pfizer's Sunitinib in Chinese Patients with pNET</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20141231&edate=20140901&cat=comp%3aPfizer"><font color="#e95e0b">:Endocrinology:comp:Pfizer</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20141231&edate=20140901&cat=dis%3apNET"><font color="#e95e0b">:Endocrinology:dis:pNET</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=mkt%3aChina"><font color="#e95e0b">:PharmaWorld:mkt:China</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7861">Endocrinology7861</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 13 November 2014 | 17:09</font><br><br><div style="margin-bottom: 10px;">Comment: The purpose of this non-interventional (NI) study is to assess the safety and efficacy of sunitinib in Chinese patients with progressive, unresectable, advanced or metastatic well-differentiated, pancreatic neuroendocrine tumors(pNET).<wbr> Approx.<wbr> 100 adults will be recruited in China hospitals.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Study Details</FONT></STRONG> </div><div style="margin-bottom: 10px;">Reference: <A href="http://clinicaltrials.gov/ct2/show/NCT02282059?recr=Open&amp;no_unk=Y&amp;phase=0123&amp;fund=2&amp;rcv_s=10%2F13%2F2014&amp;rank=69">NCT02282059</A> </div><div style="margin-bottom: 10px;">Timelines: Ph4 expected to start next month and complete Nov 2022 </div><div style="margin-bottom: 10px;">Intervention: subjects will be enrolled to receive at least one dose of sunitinib orally at 37.<wbr>5 mg once a day on a continuous daily dosing regimen (CDD) or dosage modification is based on daily clinic practice.<wbr> </div><div style="margin-bottom: 10px;"><P style="MARGIN-BOTTOM: 1ex; MARGIN-TOP: 0ex">Inclusion Criteria</P> </div><div><UL style="MARGIN-BOTTOM: 1ex; MARGIN-TOP: 1ex"><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Evidence of a personally signed and dated informed consent document indicating that the subject (or a legally acceptable representative) has been informed of all pertinent aspects of the study.<wbr></LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Subjects who are willing to follow up visits within current clinical practice.<wbr></LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Histologically or cytologically proven diagnosis of well-differentiated pancreatic neuroendocrine tumors (according to WHO 2000 classification)</LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Unresectable (as assessed by the investigator) or metastatic disease documented on a scan</LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">A minimum age of 18 years</LI>
</UL> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20141231&edate=20140901&rec=7861">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-11-13T17:09:09+01:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Revance Reports Further Delay for RT001 During its Q3 Earnings Call [class:BotulinumToxins, dis:Hyperhydrosis, sub:Aesthetics]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7812</link>
<description>Revance Reports Further Delay for RT001 During its Q3 Earnings Call [class:BotulinumToxins, dis:Hyperhydrosis, sub:Aesthetics]</description><category>class:BotulinumToxins</category><category>dis:Hyperhydrosis</category><category>sub:Aesthetics</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7812</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7812">Revance Reports Further Delay for RT001 During its Q3 Earnings Call</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20141231&edate=20140901&cat=class%3aBotulinumToxins"><font color="#e95e0b">:Neurology:class:BotulinumToxins</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20141231&edate=20140901&cat=dis%3aHyperhydrosis"><font color="#e95e0b">:Neurology:dis:Hyperhydrosis</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20141231&edate=20140901&cat=sub%3aAesthetics"><font color="#e95e0b">:Neurology:sub:Aesthetics</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7812">Neurology7812</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 13 November 2014 | 16:13</font><br><br><div style="margin-bottom: 10px;">Comment: Alongside its Q3 financial results, Revance reported that the development timeline for RT001 has been further delayed due to inadequate preliminary results from the company’s ongoing open-label study to confirm successful transfer of production of RT001 drug product to its U.<wbr>S.<wbr> commercial manufacturing facility.<wbr> However management emphasized its development programs for RT001 for hyperhidrosis and RT002 for glabellar (frown) lines remain on track, and are unaffected by the delay to RT001 for crow’s feet lines.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">RT001 - Hyperhidrosis</FONT></STRONG> </div><div style="margin-bottom: 10px;"><U>Timelines</U> - planning to initiate Ph2 study in early 2015 </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7812/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">Revance will be using the same RT001 product it is currently using in the ongoing RT001 for CFL trial for its hyperhidrosis Ph2 study, and made sure to point out the difference in anatomy and end points in these indications.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">RT002 - Glabellar (Frown) Lines</FONT></STRONG> </div><div style="margin-bottom: 10px;"><U>Timelines</U> - Revance expects to begin a Ph2 active comparator trial before the end of the year.<wbr> </div><div style="margin-bottom: 10px;"><U>Design</U>: The five-arm, dose-ranging study will have three active arms, a placebo arm and a Botox Cosmetic arm, and will include approx 250 subjects.<wbr> Revance expects interim results in late 2015.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">2015 Milestone Events</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7812/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">2014 FINANCIAL OUTLOOK</FONT></STRONG> </div><div style="margin-bottom: 10px;">Revance completed the company’s initial public offering (IPO) in February 2014, resulting in net proceeds of $98.<wbr>7 million and had a follow-on offering in June 2014 resulting in net proceeds of $131.<wbr>3 million.<wbr> </div><div style="margin-bottom: 10px;">As of November 12, 2014, Revance anticipates 2014 operating expenses excluding amortization, depreciation and stock-based compensation will be in the range of $45 to 50 million.<wbr> </div><div>The Company expects its 2014 cash burn to be in the range of $65 million to $75 million.<wbr> </div><!-- Comment details --><a name="neurology7812attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7812/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(76,5 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7812/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(55,3 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7812">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-11-13T16:13:37+01:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7812/1/ScreenCapture1.jpg" length="78323" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7812/2/ScreenCapture2.jpg" length="56589" type="image/jpeg"/></item><item>
<title>re: EU Registration Trials for Norgine's Novel Low Volume Bowel Preparation</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2119</link>
<description>re: EU Registration Trials for Norgine's Novel Low Volume Bowel Preparation</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2119</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2119">re: EU Registration Trials for Norgine's Novel Low Volume Bowel Preparation</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2119">GastroEnterology2119</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 13 November 2014 | 15:37</font><br><br><div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">EU Registration Trials for Norgine's Novel Low Volume Bowel Preparation</span>&nbsp;<font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20141231&edate=20140901&cat=news"><font color="#e95e0b">:GastroEnterology:news</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20141231&edate=20140901&cat=sub%3aCRCPrevention"><font color="#e95e0b">:GastroEnterology:sub:CRCPrevention</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=mkt%3aEurope"><font color="#e95e0b">:PharmaWorld:mkt:Europe</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=sub%3aClinicalTrial"><font color="#e95e0b">:PharmaWorld:sub:ClinicalTrial</font></a>]</font></font><br><span style="font-size: 12px;">Comment: Newly listed in <EM>clinicaltrials.<wbr>gov</EM>.<wbr> the 2 studies, expected to recruit approx 1,300 participants, have been part of the EU registration trials for Norgine's NER1006.<wbr> T<FONT color="#000000">he DAYB study will compare NER1006 vs CITRAFLEET using a day befre only dosing regimen in adults.<wbr> The MORA study will compare NER1006 vs MOVIPREP using a 2-day split-dosing regimen and a 1-day morning slit-dosing regimen in adults.<wbr> Both studies have similar timelines, and efficacy as primary endpoint.<wbr></FONT></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2105">...</a><br><font size="-1">Brigitte DESCHAMPS / <a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2105" class="commentpermalink">GastroEnterology2105</a> / <span class="date">30 October 2014</span> /
<span class="time">18:00:51 o'clock CET</span>
</font></div><div style="margin-bottom: 10px;">Norgine announced today the enrolment of the first patients into the two EU Ph3 studies (MORA and DAYB), as well as the countries involved in each trial (listed below).<wbr> </div><div style="margin-bottom: 10px;">The following EU countries will be included in the MORA and DAYB clinical trials: </div><div><UL><LI><STRONG>MORA</STRONG>: Belgium, France, Germany, Italy, Poland, Spain and UK
</LI>
<LI><STRONG>DAYB</STRONG>: Germany, Italy, Netherlands, Poland, Spain and UK
</LI>
</UL> </div><!-- Comment details --><font size="-1">Brigitte DESCHAMPS / <a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2119" class="commentpermalink">GastroEnterology2119</a> / <span class="date">13 November 2014</span> /
<span class="time">15:37:55 o'clock CET</span>
</font><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2119">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2105">View thread  GastroEnterology2105: EU Registration Trials for Norgine's Novel Low Volume Bowel Preparation</a>]]></content:encoded><dc:date>2014-11-13T15:37:55+01:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>All Four Divisions of the Merck Group Posted Organic Sales Growth in Q3:14 [class:GrowthHormone, prod:Saizen, :GastroEnterology:sub:Probiotics, :GastroEnterology:dis:Diarrhoea]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7860</link>
<description>All Four Divisions of the Merck Group Posted Organic Sales Growth in Q3:14 [class:GrowthHormone, prod:Saizen, :GastroEnterology:sub:Probiotics, :GastroEnterology:dis:Diarrhoea]</description><category>class:GrowthHormone</category><category>prod:Saizen</category><category>sub:Probiotics</category><category>dis:Diarrhoea</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7860</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20141231&edate=20140901&rec=7860">All Four Divisions of the Merck Group Posted Organic Sales Growth in Q3:14</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20141231&edate=20140901&cat=class%3aGrowthHormone"><font color="#e95e0b">:Endocrinology:class:GrowthHormone</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20141231&edate=20140901&cat=prod%3aSaizen"><font color="#e95e0b">:Endocrinology:prod:Saizen</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20141231&edate=20140901&cat=dis%3aDiarrhoea"><font color="#e95e0b">:GastroEnterology:dis:Diarrhoea</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20141231&edate=20140901&cat=sub%3aProbiotics"><font color="#e95e0b">:GastroEnterology:sub:Probiotics</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7860">Endocrinology7860</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 13 November 2014 | 14:17</font><br><br><div style="margin-bottom: 10px;">Comment: The Merck Serono division generated organic sales growth of 4.<wbr>5%.<wbr> Sales of Saizen®, the top-selling product of the endocrinology franchise, saw an organic increase of 0.<wbr>5% as well as negative exchange rate effects of –1.<wbr>8%.<wbr> Consequently, sales almost reached the previous year’s level of € 60 million.<wbr> More details on growth drivers and strategy are provided below.<wbr> Of note, as of January 1, 2014, two product groups were transferred from the Merck Serono division to the Consumer Health division.<wbr> These are Neurobion®, a vitamin B-based analgesic, and Floratil®, a leading brand in the probiotic antidiarrheal segment in Brazil.<wbr> Sales of the two products totaled € 265 million in 2013.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Organic Growth by Product</FONT></STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>Rebif®, top-selling product, is used to treat relapsing forms of MS, which is one of the most common neurological diseases among young adults.<wbr></LI>
<LI>Erbitux® for the targeted and personalized treatment of metastatic colorectal cancer is the second best-selling drug in Merck Serono’s product portfolio.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7860/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Growth Across All Regions</FONT></STRONG> </div><div style="margin-bottom: 10px;">Emerging markets drive organic growth.<wbr> </div><div><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7860/1/ScreenCapture1.jpg?user-agent=rss"> </div><!-- Comment details --><a name="endocrinology7860attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7860/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(62,5 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7860/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(60 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20141231&edate=20140901&rec=7860">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-11-13T14:17:43+01:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7860/1/ScreenCapture1.jpg" length="63971" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7860/2/ScreenCapture2.jpg" length="61479" type="image/jpeg"/></item><item>
<title>Xofigo Production Is Resumed And Expected To Supply For New Patients On 17th Nov [dis:Prostate]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology10100</link>
<description>Xofigo Production Is Resumed And Expected To Supply For New Patients On 17th Nov [dis:Prostate]</description><category>dis:Prostate</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology10100</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10100">Xofigo Production Is Resumed And Expected To Supply For New Patients On 17th Nov</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10100">Oncology10100</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/994">Jenny Wu</a> | 13 November 2014 | 10:53</font><br><br><div style="margin-bottom: 10px;">Comment: Following the manufacture issue for Xofigo and continuous uncertainty of timeline for Bayer to resume supply, Bayer has announced that the production of Xofigo has now been resumed.<wbr> The issue identified was due to small fibrous particles found in some of the vials during the standard inspection process.<wbr> Bayer has agreed with Health Authorities that now for all the product batch released, filtration is required to be done prior to administration to the patient until further notification.<wbr>The initial batch of Xofigo has been released and Bayer has made this available for the patients.<wbr> </div><div>Source: <A href="http://www.xofigo-us.com/patient">http:/<wbr>/<wbr>www.<wbr>xofigo-us.<wbr>com/<wbr>patient</A>, <A href="http://www.xofigo.com/hcp/resources">http:/<wbr>/<wbr>www.<wbr>xofigo.<wbr>com/<wbr>hcp/<wbr>resources</A>, </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10100">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-11-13T10:53:48+01:00</dc:date><dc:creator>jew60237</dc:creator></item><item>
<title>GP Pharm's Triptorelin Development Program is on Hold [:DKPHybrids:prod:Leuprorelin, :DKPHybrids:prod:Triptorelin, dis:Prostate, headline]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology10099</link>
<description>GP Pharm's Triptorelin Development Program is on Hold [:DKPHybrids:prod:Leuprorelin, :DKPHybrids:prod:Triptorelin, dis:Prostate, headline]</description><category>prod:Leuprorelin</category><category>prod:Triptorelin</category><category>dis:Prostate</category><category>headline</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology10099</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10099">GP Pharm's Triptorelin Development Program is on Hold</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=DKPHybrids&sdate=20141231&edate=20140901&cat=prod%3aLeuprorelin"><font color="#e95e0b">:DKPHybrids:prod:Leuprorelin</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=DKPHybrids&sdate=20141231&edate=20140901&cat=prod%3aTriptorelin"><font color="#e95e0b">:DKPHybrids:prod:Triptorelin</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=headline"><font color="#e95e0b">:Oncology:headline</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10099">Oncology10099</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 13 November 2014 | 09:21</font><br><br><div style="margin-bottom: 10px;">Comment: Feedback from the CPhI congress (October 2014, Paris) has highlighted that triptorelin 1M has been launched in Peru.<wbr> Additionally, recent external intelligence has outlined that GP Pharm's triptorelin development is on hold, and that the company requires a partner to progress with the product.<wbr> EU/<wbr>US timelines for Lutrate 1M &amp; 3M are provided below.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Analysis of Lutrate Timelines</FONT></STRONG> </div><div style="margin-bottom: 10px;">(source: GP Pharm product list; Primary intelligence) </div><div style="margin-bottom: 10px;"><STRONG>Lutrate 1M</STRONG> </div><div style="margin-bottom: 10px;">- Approved in 23 countries (France <STRONG><FONT style="BACKGROUND-COLOR: #fdfd00">still not</FONT></STRONG> included) </div><div style="margin-bottom: 10px;"><UL><LI>currently marketed in Spain, will be commercially available Q1:15 in Germany, Portugal and Eastern Europe (countries not confirmed)</LI>
</UL> </div><div style="margin-bottom: 10px;">- Filled in the US in July 2014, and anticipated to be vailable in Q3:15 </div><div style="margin-bottom: 10px;">- Filled in China/<wbr>HK in June 2014 </div><div style="margin-bottom: 10px;"><STRONG>Lutrate 3M</STRONG> </div><div style="margin-bottom: 10px;">- Filled in EU in April 2014,and anticipated to be available by Q2:15 (if we benchmark with the 1M, first country may be Spain) </div><div style="margin-bottom: 10px;">- Filled in the US in July 2014, and anticipated to have the same timeline as the 1M (Q3:15) </div><div style="margin-bottom: 10px;"><STRONG>Lutrate 6M</STRONG> </div><div>According to the product list, the Ph3 is 'to be started' (timelines unknown) </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10099">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-11-13T09:21:51+01:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Key Messages from Versartis's Long-Acting Growth Hormone Development Plans [class:GrowthHormone, dis:GrowthHormoneDeficiency, news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7856</link>
<description>Key Messages from Versartis's Long-Acting Growth Hormone Development Plans [class:GrowthHormone, dis:GrowthHormoneDeficiency, news]</description><category>class:GrowthHormone</category><category>dis:GrowthHormoneDeficiency</category><category>news</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7856</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20141231&edate=20140901&rec=7856">Key Messages from Versartis's Long-Acting Growth Hormone Development Plans</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20141231&edate=20140901&cat=class%3aGrowthHormone"><font color="#e95e0b">:Endocrinology:class:GrowthHormone</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20141231&edate=20140901&cat=dis%3aGrowthHormoneDeficiency"><font color="#e95e0b">:Endocrinology:dis:GrowthHormoneDeficiency</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20141231&edate=20140901&cat=news"><font color="#e95e0b">:Endocrinology:news</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7856">Endocrinology7856</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 12 November 2014 | 14:59</font><br><br><div style="margin-bottom: 10px;">Comment: Versartis is focused on the execution of VRS-317 pediatric Ph3 study, which is expected to start in the US, Western Europe and Canada in early 2015.<wbr> Six-month height velocity data and 12-month data may be provided by mid-2016 an early 2017 respectively with a potential FDA approval planned by mid-2018.<wbr> The company is currently developing an injection device, which will use a 29-gauge needle.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Establishment of a EU HQ</FONT></STRONG> </div><div style="margin-bottom: 10px;">Versartis has plans to grow its global presence by establishing its European headquarters in Switzerland </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Semi-monthly Ph3 Study in Ped GHD</FONT></STRONG> </div><div style="margin-bottom: 10px;">Design: The Phase 3 trial will be an open label, randomized controlled study to evaluate the noninferiority of VRS-317 dosed <STRONG>semimonthly</STRONG> compared to daily growth hormone therapy.<wbr> Versartis have selected semimonthly dosing because it has a commercial formulation ready for the trial to enable the majority of GHD children to receive a single injection from the small gauge needle twice per month.<wbr> </div><div style="margin-bottom: 10px;">Dosage: 3.<wbr>5 milligrams/<wbr>kg </div><div style="margin-bottom: 10px;">Location: up to 70 clinical sites in the US, Western Europe and Canada </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Japan Ped Ph2/<wbr>3 Clinical Development</FONT></STRONG> </div><div style="margin-bottom: 10px;">Enrolment expected to begin early 2015 </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Adult Ph2/<wbr>3 Program</FONT></STRONG> </div><div style="margin-bottom: 10px;">Management intends to meet with the FDA and obtain scientific advice from EMA in the first half of 2015 on the planned Phase 2/<wbr>3 design to enable registration of monthly VRS-317 dosing GHD adults, and anticipates enrollment to begin in H2:2015.<wbr> </div><div><EM>Source: Versartis transcript</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20141231&edate=20140901&rec=7856">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-11-12T14:59:00+01:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Norgine's MOVIPREP® Can Reduce Long-Term Colorectal Cancer Treatment Costs in Germany [sub:CRCPrevention, headline, :PharmaWorld:sub:Pricing, :PharmaWorld:mkt:Germany]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2116</link>
<description>Norgine's MOVIPREP® Can Reduce Long-Term Colorectal Cancer Treatment Costs in Germany [sub:CRCPrevention, headline, :PharmaWorld:sub:Pricing, :PharmaWorld:mkt:Germany]</description><category>sub:CRCPrevention</category><category>headline</category><category>sub:Pricing</category><category>mkt:Germany</category><category>PCN97</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2116</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2116">Norgine's MOVIPREP® Can Reduce Long-Term Colorectal Cancer Treatment Costs in Germany</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20141231&edate=20140901&cat=headline"><font color="#e95e0b">:GastroEnterology:headline</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20141231&edate=20140901&cat=sub%3aCRCPrevention"><font color="#e95e0b">:GastroEnterology:sub:CRCPrevention</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=mkt%3aGermany"><font color="#e95e0b">:PharmaWorld:mkt:Germany</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=sub%3aPricing"><font color="#e95e0b">:PharmaWorld:sub:Pricing</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2116">GastroEnterology2116</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 12 November 2014 | 13:41</font><br><br><div style="margin-bottom: 10px;">Comment: Results from the MODEC study, presented at IPSOR in Amsterdam, show that the cleansing quality of MOVIPREP<SUP>®</SUP> is greater than NaPic/<wbr>MgCit for all segments of the colon (98.<wbr>0% vs.<wbr> 57.<wbr>5%, p&lt;0.<wbr>0001).<wbr> The long-term cost consequence model also predicts that while the use of MOVIPREP<SUP>®</SUP> vs.<wbr> NaPic/<wbr>MgCit increases the average per-patient cost associated with colonoscopy by €67, MOVIPREP<SUP>®</SUP> enables better bowel cleansing which permits the early detection of polyps and adenomas resulting in less progression to colorectal cancer and an average per-patient saving in colorectal cancer treatment costs of €488.<wbr> The cost consequence model predicts an average overall cost saving of €420 per patient over a 10 year period.<wbr> </div><div style="margin-bottom: 10px;"><FONT size="3"><STRONG>Presentation @ </STRONG><STRONG>ISPOR</STRONG></FONT> </div><div style="margin-bottom: 10px;">Data from the study presented at the International Society for Pharmacoeconomics and Outcome Research (ISPOR) 17th Annual European Congress in Amsterdam (Fischbach W, et al.<wbr> Cost consequence model investigating the impact of bowel cleansing on prevention of colorectal cancer in a German screening population.<wbr> ISPOR 17<SUP>th</SUP> Annual European Congress 2014 abstract ).<wbr> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20141231&edate=20140901&cat=PCN97"><font color="#e95e0b">:GastroEnterology:PCN97</font></a>]</font></font></div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">About the Study</FONT></STRONG> </div><div style="margin-bottom: 10px;"><U>Reference</U>: Pohl J, et al.<wbr> A multicentre, randomised, investigator-blinded study (MODEC) comparing the cleansing quality and the observed lesion detection rate of two bowel preparations: 2L Polyethylene Glycol with Electrolytes + Ascorbate Components (:PEG+ASC) and Sodium Picosulfate/<wbr>Magnesium Citrate (NaPic/<wbr>MgCit).<wbr> ACG Annual Scientific Meeting 2014 abstract.<wbr> </div><div style="margin-bottom: 10px;"><U>Objective</U>: to evaluate the clinical and economic impact of bowel cleansing quality, using efficacy rates of colorectal cancer screening and subsequent cost of treating colorectal cancer in a cohort of patients undergoing screening colonoscopy in Germany </div><div style="margin-bottom: 10px;"><U>Recruitment</U>: 394 </div><div style="margin-bottom: 10px;"><U>Protocol</U>: Patients were randomised to receive either 2L MOVIPREP<SUP>®</SUP> (PEG+ASC, n=201) or sodium picosulfate/<wbr>magnesium citrate (NaPic/<wbr>MgCit, n=193) </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Availability of MOVIPREP<SUP>®</SUP></FONT></STRONG> </div><div style="margin-bottom: 10px;">It is available in EU and Australia through Norgine’s own infrastructure, and in Eastern Europe, the US, India, Japan and Canada via partners.<wbr> </div><div>Additionally, The Ministry of Health of the Russian Federation granted approval for MOVIPREP<SUP>®</SUP> in Russia on 22 September 2014 (see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2095" class="defaultlink">GastroEnterology2095: MOVIPREP® Approved in Russia</a>).<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2116">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-11-12T13:41:46+01:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>AbbVie and Enterome Enter Microbiome-Based Collaboration in Crohn's Disease [headline, dis:IBD, sub:Diagnostic]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2114</link>
<description>AbbVie and Enterome Enter Microbiome-Based Collaboration in Crohn's Disease [headline, dis:IBD, sub:Diagnostic]</description><category>headline</category><category>dis:IBD</category><category>sub:Diagnostic</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2114</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2114">AbbVie and Enterome Enter Microbiome-Based Collaboration in Crohn's Disease</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20141231&edate=20140901&cat=dis%3aIBD"><font color="#e95e0b">:GastroEnterology:dis:IBD</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20141231&edate=20140901&cat=headline"><font color="#e95e0b">:GastroEnterology:headline</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20141231&edate=20140901&cat=sub%3aDiagnostic"><font color="#e95e0b">:GastroEnterology:sub:Diagnostic</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2114">GastroEnterology2114</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 12 November 2014 | 11:54</font><br><br><div style="margin-bottom: 10px;">Comment: The alliance is anchored around Enterome's proprietary metagenomic biomarker portfolio and technologies that may enable the development of novel diagnostic products to support personalized therapies and the development of new drugs in microbiome-related diseases.<wbr> The companies will first collaborate to develop non-invasive monitoring tools of the gut microbiome in Crohn's disease.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Enterome Snapshot</FONT></STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>Paris-based private company</LI>
<LI>spun out from the results of the scientific research of Dr Stanislav Dusko Ehrlich (INRA, Paris) and his team on the measurement and modulation of gut microbiota’s role in health and diseases</LI>
<LI>established in 2012 and has already raised a €7.<wbr>5m series A with three private equity funds (Seventure, Omnes Capital &amp; Lundbeckfond Ventures) and two strategic investors (Danone &amp; Shire).<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><U>Technology</U> </div><div style="margin-bottom: 10px;">The method used by Enterome is based on mapping of total fecal bacterial gene content and functions, leading to the characterization of a personal metagenome (metagenotype®) potentially for each individual.<wbr> </div><div style="margin-bottom: 10px;">Each metagenotype® is analyzed using proprietary algorithms (linking individual metagenotype® to associated phenotypes) allowing proper evaluation of personal risk of each subject to develop a wide variety of pathological conditions.<wbr> </div><div><EM>Source: Enterome PR</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2114">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-11-12T11:54:50+01:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Inhibition of SRPK1 Activity Could Stop Prostate Cancer Progression [dis:Prostate]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology10098</link>
<description>Inhibition of SRPK1 Activity Could Stop Prostate Cancer Progression [dis:Prostate]</description><category>dis:Prostate</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology10098</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10098">Inhibition of SRPK1 Activity Could Stop Prostate Cancer Progression</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10098">Oncology10098</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 12 November 2014 | 11:38</font><br><br><div style="margin-bottom: 10px;">Comment: By analysing samples of human prostate cancer, researchers observed that SRPK1 increases as the cancer gets more aggressive.<wbr> Biotech company Exonate, a spin-out drug development company from the University of Nottingham, aims to develop SRPK1 inhibitors as treatments for age-related macular degeneration (lead program) and cancer (for which a partner is sought).<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Study in Mice</FONT></STRONG> </div><div style="margin-bottom: 10px;">This study has been funded by Prostate Cancer UK, the Biotechnology and Biological Sciences Research Council (BBSRC) and Richard Bright VEGF Research Trust.<wbr> </div><div style="margin-bottom: 10px;">When scientists injected mice three times a week with a drug to stop molcule SRPK1 from working, their tumour growth halted.<wbr> </div><div style="margin-bottom: 10px;">Dr Sebastian Oltean, the study's co-author from the U.<wbr> of Bristol's School of Physiology and Pharmacology shows in his paper that if "we decrease SRPK1 levels in prostate cancer cells we are able to inhibit tumour vasculature and growth".<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Exonate Snapshot</FONT></STRONG> </div><div style="margin-bottom: 10px;">Incorporated in December 2013.<wbr> </div><div style="margin-bottom: 10px;"><U>Technology</U> </div><div style="margin-bottom: 10px;"><A href="http://exonate.com/technology/">http:/<wbr>/<wbr>exonate.<wbr>com/<wbr>technology/<wbr></A> </div><div style="margin-bottom: 10px;"><U>Investors</U> </div><div style="margin-bottom: 10px;">Exonate closed seed round £400,00 in March 2014.<wbr> </div><div style="margin-bottom: 10px;"><U>Team</U> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/10098/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><UL><LI>Dr Catherine Beech (CEO)</LI>
<LI>Prof David Bates (CSO) Prof of Oncology and Head of Cancer Biology, Div of Oncology atht he U of Nottingham.<wbr></LI>
</UL> </div><div><EM>Source: Exonate PR</EM> </div><!-- Comment details --><a name="oncology10098attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10098/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(52,1 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10098">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-11-12T11:38:26+01:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10098/1/ScreenCapture1.jpg" length="53376" type="image/jpeg"/></item><item>
<title>Daewoong Builds Research Institute in China [:PharmaWorld:mkt:China]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7811</link>
<description>Daewoong Builds Research Institute in China [:PharmaWorld:mkt:China]</description><category>mkt:China</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7811</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7811">Daewoong Builds Research Institute in China</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=mkt%3aChina"><font color="#e95e0b">:PharmaWorld:mkt:China</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7811">Neurology7811</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 12 November 2014 | 10:52</font><br><br><div style="margin-bottom: 10px;">Comment: 'Daewoong China Research Institute' is the corporate research institute inside Liaoning Baifeng, the Chinese pharma company acquired in August 2013.<wbr> The company now has offices in Beijing, and factories and labs in Shenyang.<wbr> With these establishments, it plans to reach sales revenue of about $463.<wbr>4M within China by 2020.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Rationale &amp; Strategy</FONT></STRONG> </div><div style="margin-bottom: 10px;">Daewoong China Research Institute plans to recruit about 10 researchers.<wbr> </div><div style="margin-bottom: 10px;">The lab develops oral solution products, and solid formulations for Chinese consumers.<wbr> </div><div style="margin-bottom: 10px;">- collaboration with major institutions in the three Northeast Provinces in China, such as local colleges of pharmacy, research centers and other pharma companies in drug technologies and research.<wbr> </div><div style="margin-bottom: 10px;">According to head researcher of the company, the strategy is expected to help Daewoong expand in not only markets in China and Korea but also elsewhere in the world.<wbr> </div><div><EM>Source: Daewoong PR</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7811">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-11-12T10:52:47+01:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>GTx Provides Corporate Updates for Capesaris® and Ostarine® [dis:Prostate, class:Antihormonals]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology10096</link>
<description>GTx Provides Corporate Updates for Capesaris® and Ostarine® [dis:Prostate, class:Antihormonals]</description><category>dis:Prostate</category><category>class:Antihormonals</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology10096</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10096">GTx Provides Corporate Updates for Capesaris® and Ostarine®</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=class%3aAntihormonals"><font color="#e95e0b">:Oncology:class:Antihormonals</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10096">Oncology10096</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 12 November 2014 | 10:06</font><br><br><div style="margin-bottom: 10px;">Comment: Alongside its financial results for the third quarter and nine months 2014, the company has announced upcoming activities for GTx-024 (Ostarine®; enobosarm), the company's lead product candidate for breast cancer.<wbr> The ongoing Ph2 study of Capesaris® in CRPC is expected to complete enrollment by year-end, with top-line data expected in Q2:15.<wbr> Management said it will evaluate the future development of  Capesaris® after the data readout, including the potential for a partnership.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Highlights</FONT></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>Ph2 trial of enobosarm 9 mg</STRONG> for the treatment of patients with ER positive and AR positive metastatic breast cancer </div><div style="margin-bottom: 10px;"><BLOCKQUOTE dir="ltr" style="MARGIN-RIGHT: 0px">
<P>Updated results from this trial have been accepted as a poster presentation at the San Antonio Breast Cancer Symposium on <CHRON>December 10, 2014</CHRON>, in <LOCATION value="LU/us.tx.sanant">San Antonio, Texas</LOCATION>.<wbr> The results will be presented by the principal clinical investigator Dr.<wbr> <PERSON>Beth A.<wbr> Overmoyer</PERSON>, M.<wbr>D.<wbr>, director of the Inflammatory Breast Cancer Program at the <ORG>Susan F.<wbr> Smith Center</ORG> for Women’s Cancers at <ORG>Dana Farber Cancer Institute</ORG>, and assistant professor of Medicine at <ORG>Harvard Medical School.<wbr> 
<P dir="ltr">The Company plans to commence, in the first half of 2015, 2 additional open-label Ph2 clinical trials of enobosarm; </P>
<BLOCKQUOTE dir="ltr" style="MARGIN-RIGHT: 0px">
<P dir="ltr">- one in patients with ER positive and AR positive metastatic breast cancer - another in patients with advanced AR positive triple negative breast cancer.<wbr> </P></BLOCKQUOTE>
<P dir="ltr">The Company anticipates clinical data from the first stage of each of these Phase 2 clinical trials in the second half of 2016.<wbr></P></ORG>
</P></BLOCKQUOTE> </div><div style="margin-bottom: 10px;"><STRONG>GTx-758 (Capesaris<SUP>®</SUP>)</STRONG> is being studied for secondary hormonal therapy in men with castration resistant prostate cancer and, potentially, as a secondary hormonal treatment for advanced prostate cancer used in combination with ADT </div><div><BLOCKQUOTE dir="ltr" style="MARGIN-RIGHT: 0px">
<P>GTx continues to enroll patients in an open-label, Phase 2 clinical study of GTx-758 to treat men with metastatic and non-metastatic castration resistant prostate cancer (CRPC) and is evaluating the safety and efficacy of two doses (125 mg and 250 mg) of GTx-758.<wbr> </P>
<P class="bwlistitemmargb">The Company has completed enrollment of the 125 mg arm and expects to complete enrollment in the 250 mg arm by the end of 2014.<wbr></P></BLOCKQUOTE> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10096">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-11-12T10:06:28+01:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Tivantinib Met Primary Endpoint Versus Placebo In a Ph2 Trial For mCRPC Patients [dis:Prostate]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology10094</link>
<description>Tivantinib Met Primary Endpoint Versus Placebo In a Ph2 Trial For mCRPC Patients [dis:Prostate]</description><category>dis:Prostate</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology10094</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10094">Tivantinib Met Primary Endpoint Versus Placebo In a Ph2 Trial For mCRPC Patients</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10094">Oncology10094</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/994">Jenny Wu</a> | 11 November 2014 | 15:30</font><br><br><div style="margin-bottom: 10px;">Comment: ArQule announced positive topline Ph2 results for tivantinib (a MET inhibitor) as a single agent in men with asymptomatic or minimally symptomatic metastatic castration resistant prostate cancer.<wbr> Tivantinib is co-developed and co-commercialised by ArQule and Daiichi Sankyo.<wbr> Prostate cancer was not the focus of the development plan for both companies, and therefore this trial was initially conducted under a Cooperative Research and Development Agreement with the NCI's Cancer therapy evaluation programme.<wbr> The trial has now met its primary endpoint of improving median PFS with tivantinib alone and versus placebo.<wbr> Both companies are under discussion with the NCI for the potential to warrant additional trials in prostate cancer.<wbr> The details analyses will be presented in future conferences by the principal investigator (the details of the conference has yet to disclose).<wbr> </div><div style="margin-bottom: 10px;">Clinicaltrials.<wbr>gov Identifier <a href="http://clinicaltrials.gov/show/NCT01519414" class="defaultlink">NCT01519414</a> </div><div style="margin-bottom: 10px;">Number of patients = 78 </div><div style="margin-bottom: 10px;">Principal Investigator Dr.<wbr> J.<wbr>Paul Monk (Ohio State University) &amp; Dr.<wbr> Arthur G.<wbr> James (Cancer Hospital and Solove Research Institute) </div><div style="margin-bottom: 10px;">Trial Design: A randomized (2:1), double-blind, placebo controlled Ph2 Study (NCI Protocol #8986) </div><div style="margin-bottom: 10px;">This study is a randomized Phase 2 trial in which men with asymptomatic or minimally symptomatic metastatic castrate resistant, chemotherapy-na&iuml;ve prostate cancer were randomized 2 to 1 to receive tivantinib 360 milligrams BID or placebo.<wbr> The primary objective of the trial is PFS.<wbr> Secondary objectives include PSA response rate at 12 weeks, radiographic response rate at 12 weeks, proportion of patients who are progression-free at 12 weeks, and safety and tolerability.<wbr> </div><div style="margin-bottom: 10px;">The study is designed to detect an improvement in the median PFS from 3 months to 6 months with tivantinib treatment.<wbr> The proposed sample of 78 patients (26 in the placebo arm, 52 in the Tivantinib arm) provides 90% power to detect an improvement from 3 months median PFS with placebo to a median PFS of at least 6 months with tivantinib.<wbr> This design is based on the assumption of having 58 cumulative events (progressions or deaths).<wbr> </div><div style="margin-bottom: 10px;">During ArQule Q3 2014 Financial Results Presentation, it is clear that the company's focus for Tivantinib at this point  remains in its HCC development programme.<wbr> ArQule aims to complete patient accrual in the Ph3 METIV-HCC trial by the end of 2015.<wbr> </div><div>Source: ArQule Company Press Release </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10094">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-11-11T15:30:12+01:00</dc:date><dc:creator>jew60237</dc:creator></item><item>
<title>Dendreon Is In Chapter 11 - Dendreon's Share Fell 75% After Filing For Bankruptcy [dis:Prostate, headline]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology10091</link>
<description>Dendreon Is In Chapter 11 - Dendreon's Share Fell 75% After Filing For Bankruptcy [dis:Prostate, headline]</description><comments>http://ci.beaufour-ipsen.com/traction/permalink/Oncology10091</comments><category>dis:Prostate</category><category>headline</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology10091</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10091">Dendreon Is In Chapter 11 - Dendreon's Share Fell 75% After Filing For Bankruptcy</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=headline"><font color="#e95e0b">:Oncology:headline</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10091">Oncology10091</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/994">Jenny Wu</a> | 11 November 2014 | 12:22</font><br><br><div style="margin-bottom: 10px;">Comment: Dendreon has filed for voluntary federal bankruptcy protection and has reached an agreement with holders of $620 million in convertible debt.<wbr> The company filed for Chapter 11 with $100 million in cash or cash equivalents, and won't need bankruptcy financing.<wbr> As of the period ended 30th Sept 2014, Dendreon had $340 million in assets and $660.<wbr>7 million in liabilities on a book value basis.<wbr> Cost -containment efforts have reduced from 1,500 employees to the workforce of 698 people.<wbr> Dendreon will pursue sale or reorganization in bankruptcy.<wbr> Unless a buyer can be found that is willing to continue producing Provenge, the ownership of Dedreon and Provenge will default back to the lenders.<wbr> Dendreon combined undue optimism in sales projections with excessive risk in its capital structure.<wbr> It is a case of moderate product success and immoderate management failure.<wbr> However, the fall out over Provenge's promise versus performance still lingers - as speculation of leakage information from Medicare/<wbr>Medicaid Insurance Services to hands of investors is being investigated.<wbr> </div><div style="margin-bottom: 10px;">When Provenge won approval from the Food and Drug Administration in April 2010, it was touted as ushering in a new era of treatments to marshal the immune system to fight cancer, with high hopes for a clear path to profit.<wbr> With its stock at more than $55 a share in May 2010, Dendreon&rsquo;s market capitalization topped $7.<wbr>5 billion.<wbr> Dendreon's stock fell 10% on 7th June 2010 - the same day officials of the agency that oversees billions in health care spending began discussing whether to set new coverage limits on the costly new prostate cancer treatment.<wbr>.<wbr> Dendreon will continue manufacture and supply Provenge while in Chapter 11 - with the support from investors (including one of the big holder Deerfield Management Company LP).<wbr> The investors have agreed to convert their debt to equity in a reorganized company, unless bidders offer to buy the business.<wbr> However, there has been no prospective buyers stepped up during a quiet market test last year.<wbr> </div><div style="margin-bottom: 10px;">At an average of $93,000 for a course of treatment that improved median survival by just over four months, Provenge wasn&rsquo;t adopted readily by doctors.<wbr> Thereafter coming along with strong waves of competition - Zytiga and Xtandi's approval, both were pills that were easy to prescribe and require no upfront investment for doctors in the US.<wbr> One analyst reports a low market share of Provenge under 5% recently and Dendreon's share fell as much as 74.<wbr>5% to 24 cents on 10th Nov 2014.<wbr> The lack of efficiencies in the manufacturing process is the main barrier for Dendreon to make a comeback as a standalone company.<wbr> Also the emergence of Bavarian Nordic's experimental prostate cancer vaccine - that is cheaper to manufacture - could also spell the end of Provenge.<wbr> </div><div>Source: Wall Street Journal, Reuters </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Oncology10199c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div>Comment: Dendreon will hold an auction for bidders on 3rd Feb 2015 with a $275 million minimum bid requirement.<wbr> Unless the company sells for enough to repay its $620 million in notes and other creditors, shareholders are unlikely to receive anything from the bankruptcy.<wbr> Dendreon said in court documents that more than 40 parties had signed nondisclosure agreements, indicating interest in bidding on the company's assets.<wbr> If the company does not hold an auction, Dendreon will emerge from bankruptcy under the control of noteholders.<wbr> Those investors include funds associated with Deerfield Management Co, Aristeria Capital, Empyrean Capital Partners, Wolverine Asset Management and Partner Fund Management.<wbr> (Source: Reuters US) </div><font size="-1">Jenny Wu / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10199" class="commentpermalink">Oncology10199</a> / <span class="date">09 January 2015</span> /
<span class="time">10:00:33 o'clock CET</span>
</font></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10091">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-11-11T12:22:18+01:00</dc:date><dc:creator>jew60237</dc:creator></item><item>
<title>Olaparib, AstraZeneca's PARP Inhibitor, Showed Promise In Prostate Cancer [dis:Prostate, comp:AstraZeneca]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology10090</link>
<description>Olaparib, AstraZeneca's PARP Inhibitor, Showed Promise In Prostate Cancer [dis:Prostate, comp:AstraZeneca]</description><category>dis:Prostate</category><category>comp:AstraZeneca</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology10090</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10090">Olaparib, AstraZeneca's PARP Inhibitor, Showed Promise In Prostate Cancer</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=comp%3aAstraZeneca"><font color="#e95e0b">:Oncology:comp:AstraZeneca</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10090">Oncology10090</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/994">Jenny Wu</a> | 10 November 2014 | 16:32</font><br><br><div style="margin-bottom: 10px;">Comment: Professor Johann de Bono presented data in NCRI Cancer Conference in Liverpool (the biggest oncology annual national conference in UK) and said some patients with advanced aggressive prostate cancer were having impressive responses to PARP inhibitor treatment.<wbr> Olaparib could be effective against prostate tumours that harboured BRCA gene mutations.<wbr> The first part of a phase II trial called TO-PARP, led by researchers at The Institute of Cancer Research, London and The Royal Marsden NHS Foundation Trust, has assessed olaparib in advanced prostate cancer.<wbr> </div><div style="margin-bottom: 10px;">Currently, AstraZeneca has forecasted olaparib's market potential to $2 billion a year, however, only taking into account its promise in ovarian, breast, and gastric cancer.<wbr> This is the first time when the experts highlighting the promise of PARP inhibitor in prostate cancer.<wbr> However, it is still too early to tell if this preliminary result could translate into future success.<wbr> </div><div>Source: <a href="http://conference.ncri.org.uk/abstracts/2014/abstracts/para31.html" class="defaultlink" title="http://conference.ncri.org.uk/abstracts/2014/abstracts/para31.html">conference.ncri.o&hellip;</a> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10090">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-11-10T16:32:26+01:00</dc:date><dc:creator>jew60237</dc:creator></item><item>
<title>Orphan Drug Status For Auspex's PhIII Huntington's Disease Drug [dis:Huntington]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7810</link>
<description>Orphan Drug Status For Auspex's PhIII Huntington's Disease Drug [dis:Huntington]</description><category>dis:Huntington</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7810</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7810">Orphan Drug Status For Auspex's PhIII Huntington's Disease Drug</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20141231&edate=20140901&cat=dis%3aHuntington"><font color="#e95e0b">:Neurology:dis:Huntington</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7810">Neurology7810</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 07 November 2014 | 16:50</font><br><br><div style="margin-bottom: 10px;">Comment: Auspex Pharmaceuticals, today announced that the U.<wbr>S.<wbr> FDA has 
granted orphan drug designation of Auspex's investigational compound SD-809 for 
treatment of Huntington's disease.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Current Status of SD-809</STRONG> </div><div style="margin-bottom: 10px;">Auspex is currently evaluating the efficacy and safety of SD-809 for treating 
chorea associated with this disorder in a Phase 3 registration clinical trial 
and is on track to announce topline data from this study in December 2014.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Commenting on this development Pratik Shah President &amp; CEO of 
Auspex noted</STRONG> </div><div style="margin-bottom: 10px;">"The orphan drug designation of SD-809 marks a major regulatory milestone for 
Auspex and a significant step forward in our goal to bring this novel treatment 
approach to patients as quickly as possible.<wbr> Huntington's disease is a rare and 
devastating genetic disorder with very limited treatment options.<wbr> The orphan 
drug designation recognizes the significant need that exists among individuals 
living with this disease.<wbr>" </div><div style="margin-bottom: 10px;">Addtionally, Auspex is investing in the broad potential of SD-809 for the 
treatment of other movement disorders, including tardive dyskinesia and tics 
associated with Tourette syndrome.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>SD-809's Profile Of Activity</STRONG> </div><div style="margin-bottom: 10px;">Tetrabenazine (marketed as Xenazine® in the United States) is the only 
therapy approved by the U.<wbr>S.<wbr> FDA, for this indication.<wbr> Auspex using its 
deuterium technology, has made chemical modifications at specific positions 
in the tetrabenazine molecule to create the novel drug candidate SD-809 
(dutetrabenazine).<wbr> Deuterium is a non-toxic, naturally occurring form of 
hydrogen.<wbr> The substitution of deuterium (2H) for hydrogen (1H) at specific 
positions, in the case of SD-809, attenuates the breakdown of the drug’s active 
metabolites resulting in a differentiated pharmacokinetic profile compared to 
tetrabenazine.<wbr> </div><div style="margin-bottom: 10px;">This profile should enable less frequent dosing, improved tolerability, 
reduced interpatient variability in drug metabolism, as well as reduced drug 
interactions and reduced need for genotyping for drug-metabolizing enzymes.<wbr> </div><div>Source: <A href="http://www.auspex.com">www.<wbr>auspex.<wbr>com</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7810">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-11-07T16:50:03+01:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>Advance Abstracts From Next Week's AAPMR Meeting [Alert, class:BotulinumToxins, comp:Allergan, comp:Merz, dis:Spasticity, dis:Dystonia]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7809</link>
<description>Advance Abstracts From Next Week's AAPMR Meeting [Alert, class:BotulinumToxins, comp:Allergan, comp:Merz, dis:Spasticity, dis:Dystonia]</description><category>Alert</category><category>class:BotulinumToxins</category><category>comp:Allergan</category><category>comp:Merz</category><category>dis:Spasticity</category><category>dis:Dystonia</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7809</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7809">Advance Abstracts From Next Week's AAPMR Meeting</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20141231&edate=20140901&cat=Alert"><font color="#e95e0b">:Neurology:Alert</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20141231&edate=20140901&cat=class%3aBotulinumToxins"><font color="#e95e0b">:Neurology:class:BotulinumToxins</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20141231&edate=20140901&cat=comp%3aAllergan"><font color="#e95e0b">:Neurology:comp:Allergan</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20141231&edate=20140901&cat=comp%3aMerz"><font color="#e95e0b">:Neurology:comp:Merz</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20141231&edate=20140901&cat=dis%3aDystonia"><font color="#e95e0b">:Neurology:dis:Dystonia</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20141231&edate=20140901&cat=dis%3aSpasticity"><font color="#e95e0b">:Neurology:dis:Spasticity</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7809">Neurology7809</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 07 November 2014 | 16:40</font><br><br><div style="margin-bottom: 10px;">Comment: Evaluating the pre-congress AAPMR abstract book a number of 
interesting posters will be presented by our competitors on the treatment 
of spasticity and cervical dystonia.<wbr> </div><div style="margin-bottom: 10px;">Highlighted below are some of the key abstracts which can 
now be accessed through the following link under the supplement 
section.<wbr> </div><div style="margin-bottom: 10px;"><A href="http://www.pmrjournal.org/">http:/<wbr>/<wbr>www.<wbr>pmrjournal.<wbr>org/<wbr></A> </div><div style="margin-bottom: 10px;"><STRONG>Allergan</STRONG> </div><div style="margin-bottom: 10px;">Poster 398 Onabotulinumtoxin A treatment reduces pain in patients with upper 
limb post stroke spasticity.<wbr> Author Alison Brashear (Wake Forest School of 
Medicine) </div><div style="margin-bottom: 10px;">Poster 339 - Safety profile of repeat onabotulinumtoxinA doses of 400U for 
the treatment of upper limb spasticity.<wbr> Author Lynn James (Allergan) </div><div style="margin-bottom: 10px;">Poster 365 - Evolution of health utility in patients receiving 
onabotulinumtoxin A (Botox) for the treatment of adult focal spasticity results 
from MOBILITY a prospective observation cohort study.<wbr> Author Farooq Ismail 
(Westpark Healthcare Centre Toronto) </div><div style="margin-bottom: 10px;">Poster 507 - Evaluation of pain releif in the cervical dystonia patient 
registry for observation of onabotulinumtoxinA efficacy (CD-PROBE).<wbr> Author Atul 
Patel (Kansas City Bone &amp; Joint clinic Cleveland) </div><div style="margin-bottom: 10px;">Poster 135 - Effectiveness and safety in the cervical dystoni patient 
registry for observation of onabotulinumtoxinA efficacy (CD-PROBE) Author Aubrey 
Manack (Allergan) </div><div style="margin-bottom: 10px;"><STRONG>Merz</STRONG> </div><div style="margin-bottom: 10px;">Poster 397 - Topline results from a randomised placebo controlled, phIII 
study investigating the safety and efficacy of incobotulinumtoxinA in 
treating post-stroke spasticity of the upper limb Author Elle Elovic 
(HealthSouth Rehabilitation Hospital Utah </div><div style="margin-bottom: 10px;"><STRONG>General Posters Of Interest</STRONG> </div><div style="margin-bottom: 10px;">Poster 350- A random effect mixed treatment comparison to compare the 
efficacy of botulinumtoxin type a treatments for cervical dystonia Author Zaltan 
Mari (John Hopkins University School of Medicine Baltimore) </div><div style="margin-bottom: 10px;">Poster 351 - A mixed treatment comparison to compare the efficacy of 
botulinum toxin type A treatments in upper limb spasticity.<wbr> Author Michael Y Lee 
(University of North Carolina) </div><div style="margin-bottom: 10px;">Poster 369 - Development of a picture guide to identify common postures of 
spasticity.<wbr> Author Ib Odderson (University of Washington) Affiliation 
Allergan </div><div>Poster 438 - Development of a clinical practice screening tool to identify 
disabling spasticity.<wbr> Author Richard Zorowitz (John Hopikins Univesity Hospital 
Baltimore) Affiliation Allergan </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7809">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-11-07T16:40:13+01:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>New IND Sumbitted To Investigate Immunomodulatory Doublet Therapy In mCRPC [dis:Prostate]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology10089</link>
<description>New IND Sumbitted To Investigate Immunomodulatory Doublet Therapy In mCRPC [dis:Prostate]</description><category>dis:Prostate</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology10089</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10089">New IND Sumbitted To Investigate Immunomodulatory Doublet Therapy In mCRPC</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10089">Oncology10089</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/994">Jenny Wu</a> | 07 November 2014 | 15:42</font><br><br><div style="margin-bottom: 10px;">Comment: Advaxis - a US based biotechnology - has sumbitted an investigational new drug IND application to FDA for first in human trial of its ADXS31-142 in combination with MSD's anti-PD1 - Pembrolizumab - for mCRPC patients.<wbr> The open label Ph1/<wbr>2 trial is expected to initiate in Q1 2015 and will be jointly overseen by Advaxis and Merck.<wbr> The Ph1 part will explore the recommended dose for ADXS31-142 as monotherapy and in combination with Pembrolizumab.<wbr> The Phase II part will evaluate efficacy and safety of the combination strategy, both of which inhibit immunosuppression in tumour microenvioronment.<wbr> </div><div style="margin-bottom: 10px;">The Advaxis platform technology uses live, attenuated bioengineered <EM>Listeria monocytogenes (Lm)</EM> and then add multiple copies of a plasmid that encodes a fusion protein sequence including a fragment of the LLO (listeriolysin O) molecule joined to the antigen of interest.<wbr> This fusion protein is secreted by the <EM>Listeria</EM> inside the antigen presenting cells, and other cells, which has been shown to result in a stimulation of both the innate and adaptive arms of the immune system and the potential reduction in tumor defense mechanisms.<wbr> AXS31-142 is one of the lead compound from this platform and is designed to target the prostate-specific antigen (PSA) specifically.<wbr> It secretes the PSA antigen, fused to the powerful immunostimulant tLLO, directly inside the antigen presenting cells that are capable of driving a cellular immune response to PSA expressing cells.<wbr> This approach inhibits the Treg and myeloid-derived suppressor cells (MDSCs) that contribute to immunologic tolerance of prostate cancer.<wbr> In preclinical analysis, ADXS-PSA inhibits the immunosuppression caused by Treg and MDSC cells localized inside tumors that may promote immunologic tolerance of prostate cancer.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/10089/1/MOA%20platform.JPG?user-agent=rss"> </div><div style="margin-bottom: 10px;">DXS-HPV, another Advaxis's lead immunotherapy for the treatment of HPV-associated cancers, has demonstrated improved survival and objective tumor responses in a Phase 2 trial in 110 patients with recurrent cervical cancer.<wbr> Advaxis is now planning the registrational program for ADXS-HPV.<wbr> ADXS-HPV is also being evaluated in other HPV-associated cancers including a Phase 2 in advanced cervical cancer, a Phase 1/<wbr>2 in head and neck cancer, and a Phase 1/<wbr>2 in anal cancer.<wbr> ADXS-HPV has orphan drug status for both anal and head and neck cancers.<wbr> As part of its global commercialization strategy to enter into regional licensing deals with other market dominant biopharmaceutical companies in territories where there is a high prevalence of HPV-associated cancers, Advaxis has granted exclusive licenses for the development and commercialization of ADXS-HPV in Asia and India </div><div>Source: <A href="http://www.advaxis.com/technology/platform-technology">http:.<wbr>/<wbr>/<wbr>www.<wbr>advaxis.<wbr>com/<wbr>technology/<wbr>platform-technology</A> </div><!-- Comment details --><a name="oncology10089attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10089/1/MOA%20platform.JPG">MOA platform.JPG</a>&nbsp;&nbsp;(54,4 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10089">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-11-07T15:42:54+01:00</dc:date><dc:creator>jew60237</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10089/1/MOA%20platform.JPG" length="55744" type="image/jpeg"/></item><item>
<title>Macimorelin NDA Is Not Approvable For The Diagnosis Of AGHD [class:GrowthHormone, news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7853</link>
<description>Macimorelin NDA Is Not Approvable For The Diagnosis Of AGHD [class:GrowthHormone, news]</description><category>class:GrowthHormone</category><category>news</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7853</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20141231&edate=20140901&rec=7853">Macimorelin NDA Is Not Approvable For The Diagnosis Of AGHD</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20141231&edate=20140901&cat=class%3aGrowthHormone"><font color="#e95e0b">:Endocrinology:class:GrowthHormone</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20141231&edate=20140901&cat=news"><font color="#e95e0b">:Endocrinology:news</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7853">Endocrinology7853</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 07 November 2014 | 14:24</font><br><br><div style="margin-bottom: 10px;">Comment: Aeterna Zentaris has announced that it has received a Complete Response Letter from the US FDA regarding its NDA for MacrilenTM (macimorelin), a novel orally-active ghrelin agonist, for use in evaluating adult growth hormone deficiency.<wbr> Based on its review, the FDA has determined that the NDA cannot be approved in its present form.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>The FDA's Key Concerns<BR></STRONG><BR>The CRL mentions that the planned analysis of the Company's pivotal trial did not meet its stated primary efficacy objective as agreed to in the Special Protocol Assessment agreement letter between the Company and the FDA.<wbr> </div><div style="margin-bottom: 10px;">The CRL further mentioned issues related to the lack of complete and verifiable source data for determining whether patients were accurately diagnosed with AGHD.<wbr> </div><div style="margin-bottom: 10px;">The FDA concluded that, &ldquo;in light of the failed primary analysis and data deficiencies noted, the clinical trial does not by itself support the indication.<wbr>&rdquo; </div><div style="margin-bottom: 10px;">To address the deficiencies the FDA has stated that a new confirmatory diagnostic trial will be required.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Safety Issue Also Of Concern</STRONG> </div><div style="margin-bottom: 10px;">The CRL also outlined that a serious event of electrocardiogram QT interval prolongation occurred for which attribution to drug could not be excluded.<wbr> Therefore a dedicated thorough QT study to evaluate the effect of macimorelin on the QT interval would be necessary.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Next Steps<BR></STRONG><BR>David Dodd, Chairman and CEO at Aeterna Zentaris said, &ldquo;Following the FDA's decision, we are currently reviewing the outstanding issues stated in the CRL in order to evaluate our options and future plans for MacrilenTM.<wbr>&rdquo; </div><div>Source: <A href="http://www.aezsinc.com/">www.<wbr>aezsinc.<wbr>com</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20141231&edate=20140901&rec=7853">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-11-07T14:24:45+01:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>Caring For Carcinoid Foundation Launches New Immunotherapy Initiative To Try &amp; Improve Treatment Options [dis:MidGutNET, dis:pNET, Alert]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7850</link>
<description>Caring For Carcinoid Foundation Launches New Immunotherapy Initiative To Try &amp; Improve Treatment Options [dis:MidGutNET, dis:pNET, Alert]</description><category>dis:MidGutNET</category><category>dis:pNET</category><category>Alert</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7850</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20141231&edate=20140901&rec=7850">Caring For Carcinoid Foundation Launches New Immunotherapy Initiative To Try & Improve Treatment Options</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20141231&edate=20140901&cat=Alert"><font color="#e95e0b">:Endocrinology:Alert</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20141231&edate=20140901&cat=dis%3aMidGutNET"><font color="#e95e0b">:Endocrinology:dis:MidGutNET</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20141231&edate=20140901&cat=dis%3apNET"><font color="#e95e0b">:Endocrinology:dis:pNET</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7850">Endocrinology7850</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 07 November 2014 | 14:13</font><br><br><div style="margin-bottom: 10px;">Comment.<wbr> The Caring for Carcinoid Foundation (CFCF) has announced the launch of a major immunotherapy initiative.<wbr> Based on the dramatic results seen with immunotherapy for some other forms of cancer it is eager to test the potential of immune-based therapy to provide similar breakthroughs for patients with neuroendocrine cancers.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>What Does The Initiative Involve?</STRONG> </div><div style="margin-bottom: 10px;">The Caring for Carcinoid Foundation&rsquo;s strategy brings leading experts - who have been involved in immunotherapy breakthroughs for other forms of cancer - to the cause of developing better treatments and cures for neuroendocrine cancers.<wbr> Aclinical trial for the two major forms of NET pancreatic and gastrointestinal carcinoid is planned.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Source Of Funding</STRONG> </div><div style="margin-bottom: 10px;">Ron Hollander, Executive Director of the Caring for Carcinoid Foundation, announced that CFCF has received a grant of $1 million to support half of the projected cost of the initial projects in this program.<wbr> &ldquo;We feel a real sense of urgency to test the potential of immunotherapy to provide treatment breakthroughs for NETs,&rdquo; said Ron.<wbr> He continued &ldquo;The grant from the TripAdvisor Charitable Foundation serves as a challenge to CFCF and the entire NET community to rapidly raise the remaining $1 million to pursue these exciting projects.<wbr> We are so grateful for the foundation's commitment and couldn't be more excited about this initiative.<wbr>" </div><div style="margin-bottom: 10px;"><STRONG>The Priority Projects</STRONG> </div><div style="margin-bottom: 10px;">1) The teams that developed a breakthrough immunotherapy technology will specifically target neuroendocrine tumors.<wbr> Leading immunotherapy expert Dr.<wbr> Carl June, and neuroendocrine tumor researcher Dr.<wbr> Xianxin Hua, both from the University of Pennsylvania will modify CAR T-cells to target and kill neuroendocrine tumor cells, a method that has had dramatic results in patients with other cancers.<wbr> </div><div style="margin-bottom: 10px;">2) A clinical trial will evaluate two immunotherapy therapies in pancreatic and carcinoid neuroendocrine patients.<wbr> This project includes a multidisciplinary team led by Dr.<wbr> Pamela Kunz from Stanford University.<wbr> An innovative delivery technique will also be tested to reduce the risk of adverse effects.<wbr> </div><div style="margin-bottom: 10px;">3) The third project will evaluate the immune characteristics of neuroendocrine tumors to guide CFCF's testing of immunotherapy treatments.<wbr> CFCF is inviting immunology experts to systematically characterize neuroendocrine tumors&rsquo; immune features and genomes, and multiple grants will be awarded to study and profile these tumors.<wbr> </div><div style="margin-bottom: 10px;">The attached poster highlights the initiative.<wbr> </div><div>Source: wwwcaringforcarcinoid.<wbr>com </div><!-- Comment details --><a name="endocrinology7850attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7850/1/Immunotherapy%20One%20Pager.pdf">Immunotherapy One Pager.pdf</a>&nbsp;&nbsp;(168,2 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20141231&edate=20140901&rec=7850">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-11-07T14:13:33+01:00</dc:date><dc:creator>jac89886</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7850/1/Immunotherapy%20One%20Pager.pdf" length="172226" type="application/pdf"/></item><item>
<title>Bioniche Disappointed By Lack Of ODD For Its Bladder Cancer Therapy [dis:Bladder]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology10087</link>
<description>Bioniche Disappointed By Lack Of ODD For Its Bladder Cancer Therapy [dis:Bladder]</description><category>dis:Bladder</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology10087</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10087">Bioniche Disappointed By Lack Of ODD For Its Bladder Cancer Therapy</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=dis%3aBladder"><font color="#e95e0b">:Oncology:dis:Bladder</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10087">Oncology10087</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 06 November 2014 | 19:11</font><br><br><div style="margin-bottom: 10px;">Comment: Bioniche Life Sciences hasannounced that it will not continue its dialogue with the FDA concerning its request for Orphan Drug Designation (ODD) for its bladder cancer therapeutic MCNA.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>FDA Questions The Size Of the Patient Population</STRONG> </div><div style="margin-bottom: 10px;">The FDA has indicated that it could not grant Bioniche&rsquo;s request for ODD at this time, because the Company had not established to its satisfaction that the target population estimate for MCNA did not exceed 200,000 potential patients in the US.<wbr> </div><div style="margin-bottom: 10px;">While the Company&rsquo;s internal estimates put the addressable patient population for the treatment of the bladder cancer patient subset for which it will seek label designation (high-grade non-muscle invasive bladder cancer patients who have failed BCG therapy, i.<wbr>e.<wbr> BCG-refractory or BCG-relapsing) at less than 10,000 patients per year, the FDA requested additional data to support that MCNA would not be efficacious in low-grade bladder cancer.<wbr> Given that the Company does not have the clinical or pre-clinical data to address this assertion, it is considered more productive to move forward with other fee waiver requests.<wbr> </div><div style="margin-bottom: 10px;">Source: <A href="http://www.bioniche.com">www.<wbr>bioniche.<wbr>com</A> </div><div style="margin-bottom: 10px;"><STRONG>Commenting on this decision, Dr.<wbr> Michael Berendt, Bioniche CEO and Chief Scientist, noted that:</STRONG> </div><div style="margin-bottom: 10px;">&ldquo;The ODD would have brought a single significant benefit to Bioniche, namely certain Biologics License Application (BLA) filing fee waivers totaling approximately $2.<wbr>6 million.<wbr> The other principal benefit of the designation, consisting of 7-year market exclusivity, is not required, as MCNA is a therapeutic biological product and will benefit from a longer 12-year market exclusivity upon approval, under the Patient Protection and Affordable Care Act's Biologics Price Competition and Innovation Act.<wbr> </div><div>He also noted that in anticipation of this potential decision, fee waiver requests have been made under two additional separate programs to which a positive response is expected from one or both prior to BLA filing in Q115.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10087">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-11-06T19:11:51+01:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>After Re-priortising Its Portfolio GP Pharm Teams Up With A US Development Partner For Octreotide LAR [prod:Octreotide]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7849</link>
<description>After Re-priortising Its Portfolio GP Pharm Teams Up With A US Development Partner For Octreotide LAR [prod:Octreotide]</description><category>prod:Octreotide</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7849</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20141231&edate=20140901&rec=7849">After Re-priortising Its Portfolio GP Pharm Teams Up With A US Development Partner For Octreotide LAR</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20141231&edate=20140901&cat=prod%3aOctreotide"><font color="#e95e0b">:Endocrinology:prod:Octreotide</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7849">Endocrinology7849</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 06 November 2014 | 19:02</font><br><br><div style="margin-bottom: 10px;">Comment: <FONT face="Calibri">Recent external intelligence has 
confirmed that the development of GP Pharm’s octreotide LAR will now move 
forward with an undisclosed top 30 US-based pharmaceutical/<wbr>generic 
company.<wbr></FONT> </div><div style="margin-bottom: 10px;"><FONT face="Calibri">Animal testing 
of the GP Pharm formulation is to be revisited by the partner and is 
expected to start soon.<wbr></FONT> </div><div style="margin-bottom: 10px;"><FONT face="Calibri">The 
drug is scheduled to move into human trials by 2H2015 with the partner 
running those trials.<wbr>  The partner will be responsible for development in 
the US, EU, Russia, and Brazil, whilst GP Pharm will retain rights in South 
America excl Brazil.<wbr> The partner is reportedly working towards 
a US approval in Q217.<wbr></FONT> </div><div style="margin-bottom: 10px;"><FONT face="Calibri">GP Pharm's 
financial resource and development capability was impacted by the sale of its 
parent company to Lubrizol in 2012,  as it was excluded from the 
transaction at that time.<wbr></FONT> </div><div style="margin-bottom: 10px;"><FONT face="Calibri">It continues 
to prioritise the geographic availability of different formulations of 
Luprolide  (1 and 3 months) whilst looking for partners for other 
product development programmes.<wbr></FONT> </div><div style="margin-bottom: 10px;"><FONT face="Calibri">With regard to 
the identity of the potential US partner one approach could 
be to consider the "Orange book" listings of 
US companies already marketing the immediate release form.<wbr> A 
t</FONT><FONT face="Calibri">op 30 US-based pharmaceutical companies amongst 
this list is Mylan.<wbr> Outside of this listing other top 30 companies that 
could logically be considered are Pfizer, Hospira and Amgen.<wbr></FONT> </div><div><FONT face="Calibri">If anybody 
learns more about this potential partnership through local sources, please do 
share the information with the ENDO Franchise or the Business Intelligence 
Unit.<wbr></FONT> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20141231&edate=20140901&rec=7849">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-11-06T19:02:45+01:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>AstraZeneca Q3 Financial Results Key Takeaway - Progress In Immuno-Oncology [:Oncology:comp:AstraZeneca]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld11010</link>
<description>AstraZeneca Q3 Financial Results Key Takeaway - Progress In Immuno-Oncology [:Oncology:comp:AstraZeneca]</description><category>comp:AstraZeneca</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld11010</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20141231&edate=20140901&rec=11010">AstraZeneca Q3 Financial Results Key Takeaway - Progress In Immuno-Oncology</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=comp%3aAstraZeneca"><font color="#e95e0b">:Oncology:comp:AstraZeneca</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld11010">PharmaWorld11010</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/994">Jenny Wu</a> | 06 November 2014 | 18:50</font><br><br><div style="margin-bottom: 10px;">Comment: AstraZeneca today released their Q3 2014 financial result - AZ now expects sales to grow in low single digits at constant exchange rate this year (as previous prediction is that AZ's sales should remain flat this year).<wbr> Chief Executive Pascal Soriot, said he would use the better financial outlook to speed up investment in the company's promising pipeline of new drugs.<wbr> In the eyes of analysts, however, AZ still has a lot to demonstrate despite of the proven pipeline momentum - in particular, immuno-oncology is one of AZ's focus area.<wbr> During the presentation, it appears that current AZ's PD-1 development programmes are focusing on NSCLC, and Head &amp; Neck Cancer.<wbr> AZ's business development focus is aimed to supplement its strategic priorities.<wbr> One of which being highlighted in oncology is the recent deal to partner with J&amp;J and Pharmacyclics that will supplement and expand its current P-1 portfolio to haematological cancers.<wbr> The big question still yet to be demonstrated is if AZ is able to deliver the  promise given the strong competitions with rivals such as BMS, MSD, and Roche in the horizon.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/11010/1/1.png?user-agent=rss"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/11010/2/2.png?user-agent=rss"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/11010/3/3.png?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/11010/4/4.png?user-agent=rss"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/11010/5/5.png?user-agent=rss"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/11010/6/6.png?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/11010/7/7.png?user-agent=rss"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/11010/8/8.png?user-agent=rss"> </div><div>Source: AstraZeneca.<wbr>com </div><!-- Comment details --><a name="pharmaworld11010attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/11010/1/1.png">1.png</a>&nbsp;&nbsp;(140,7 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/11010/2/2.png">2.png</a>&nbsp;&nbsp;(74,7 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/11010/3/3.png">3.png</a>&nbsp;&nbsp;(174,2 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/11010/4/4.png">4.png</a>&nbsp;&nbsp;(103,1 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/11010/5/5.png">5.png</a>&nbsp;&nbsp;(190,8 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/11010/6/6.png">6.png</a>&nbsp;&nbsp;(165,8 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/11010/7/7.png">7.png</a>&nbsp;&nbsp;(115,9 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/11010/8/8.png">8.png</a>&nbsp;&nbsp;(62,7 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20141231&edate=20140901&rec=11010">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-11-06T18:50:18+01:00</dc:date><dc:creator>jew60237</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/11010/1/1.png" length="144120" type="image/x-png"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/11010/2/2.png" length="76455" type="image/x-png"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/11010/3/3.png" length="178352" type="image/x-png"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/11010/4/4.png" length="105544" type="image/x-png"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/11010/5/5.png" length="195360" type="image/x-png"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/11010/6/6.png" length="169775" type="image/x-png"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/11010/7/7.png" length="118711" type="image/x-png"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/11010/8/8.png" length="64186" type="image/x-png"/></item><item>
<title>Court Ruling Supportive of Valeant's Fight For Allergan</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7807</link>
<description>Court Ruling Supportive of Valeant's Fight For Allergan</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7807</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7807">Court Ruling Supportive of Valeant's Fight For Allergan</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7807">Neurology7807</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 05 November 2014 | 11:19</font><br><br><div style="margin-bottom: 10px;">Comment: Yesterday Bill Ackmann one a significant victory in his battle to 
force Allergan to sell itself to Valeant, when a court denied Allergan's request 
to prevent Pershing from voting its 10% stake at a shareholder meeting on 
December 18th.<wbr>This ruling makes it easier for Mr Ackman and Valeant to win 
enough investor support to replace the majority of the Allergan board.<wbr> </div><div style="margin-bottom: 10px;">Allergan not pleased by this ruling is reportedly to file an emergency 
appeal.<wbr> </div><div style="margin-bottom: 10px;">Judge Carter calimed that the court needed to be "neutral and to leave 
decisions regarding a company's future and management in the hands of 
shareholders".<wbr> </div><div style="margin-bottom: 10px;">Meanwhile, the potential rival bidder for Allergan, noted in the company's 
security filing.<wbr> remains undisclosed but is believed to be Actavis.<wbr> </div><div><BR>Source: Financial Times </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7807">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-11-05T11:19:33+01:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>Expanded Clinical Development Of Laquinimod [dis:Huntington]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7806</link>
<description>Expanded Clinical Development Of Laquinimod [dis:Huntington]</description><category>dis:Huntington</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7806</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7806">Expanded Clinical Development Of Laquinimod</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20141231&edate=20140901&cat=dis%3aHuntington"><font color="#e95e0b">:Neurology:dis:Huntington</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7806">Neurology7806</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 05 November 2014 | 11:03</font><br><br><div style="margin-bottom: 10px;">Comment: Teva Pharmaceuticals and its partner Active Biotech 
have announced the expansion of the laquinimod clinical development program 
with the initiation of the ARPEGGIO trial,  to treat primary progressive 
multiple sclerosis (PPMS).<wbr> Additionally, Teva has also screened the first 
patient in the LEGATO-HD trial, which will evaluate laquinimod in Huntington’s 
disease.<wbr> 
Commenting on this development Michael Hayden, M.<wbr>D.<wbr>, Ph.<wbr>D.<wbr>, President of 
Global R&amp;D and Chief Scientific Officer at Teva 
Pharmaceuticals noted “Laquinimod has been shown to modulate several 
significant pathways common to key neurodegenerative disease.<wbr> More specifically, 
it modulates the immune cell lineages in the periphery and in the CNS.<wbr> We look 
forward to the results from both of these studies.<wbr>” </div><div style="margin-bottom: 10px;"><STRONG>Study Designs</STRONG> </div><div style="margin-bottom: 10px;">The ARPEGGIO study will evaluate the efficacy, safety and tolerability of 
laquinimod in patients with PPMS with a primary endpoint of percent brain volume 
change (PBVC) through MRI analysis.<wbr> Approximately 15 percent of MS patients fall 
into the PPMS category.<wbr> </div><div style="margin-bottom: 10px;">The LEGATO-HD study will evaluate the efficacy, safety and tolerability of 
once-daily oral laquinimod as a potential treatment for adult patients with 
Huntington’s disease.<wbr> The primary endpoint for LEGATO-HD is change from baseline 
in the Unified Huntington’s Disease Rating Scale-Total Motor Scale (UHDRS-TMS) 
as defined by the sum of the scores of all UHDRS-TMS sub-items after 12 months 
of treatment.<wbr> </div><div>Source: <A href="http://www.tevapharm.com">www.<wbr>tevapharm.<wbr>com</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7806">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-11-05T11:03:50+01:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>Exelixis Business Update - Good Progress With COMETRIQ But Awaiting CRPC Results From COMET-2 [dis:Prostate]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology10086</link>
<description>Exelixis Business Update - Good Progress With COMETRIQ But Awaiting CRPC Results From COMET-2 [dis:Prostate]</description><category>dis:Prostate</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology10086</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10086">Exelixis Business Update - Good Progress With COMETRIQ But Awaiting CRPC Results From COMET-2</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10086">Oncology10086</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 05 November 2014 | 09:38</font><br><br><div style="margin-bottom: 10px;">Comment: <SPAN lang="EN-US" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'; mso-bidi-font-size: 12.0pt; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA">Net 
revenue for the quarter was $6.<wbr>3 million, consisting entirely of product revenue 
from the sale of COMETRIQ for medullary thyroid cancer.<wbr> From an R&amp;D 
perspective, the group reported final overall survival results from the EXAM 
study, timelines for readouts of the CRPC COMET-2 study and the ongoing 
enrollment status of its renal cell &amp; HCC studies.<wbr> With $200m in cash the 
group has sufficient financial resources to support its business throughout 
2015.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'; mso-bidi-font-size: 12.0pt; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA">Excluding 
the $1.<wbr>8m project management fee Exelixis had to pay its European partner SOBI 
net sales of COMETRIQ in the quarter  increased by 32% vs last year.<wbr> Sales 
growth in the US was driven by ioncreases in treated patients as well as 
extended treatment duration.<wbr></SPAN>
Total operating 
expenses for the quarter were $57.<wbr>9 million.<wbr> The decrease of $3.<wbr>5 million as 
compared to Q3 last year reflects the changes in R&amp;D ($43.<wbr>6m 
vs.<wbr>$47.<wbr>4m) and SG&amp;A ($9.<wbr>9m vs $13.<wbr>6m)  offset by the 
increases to the restructuring expenses ($3.<wbr>8m).<wbr> </div><div style="margin-bottom: 10px;">Trial 
Update </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'; mso-bidi-font-size: 12.0pt; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA">COMET-2, Exelixis</SPAN><SPAN lang="EN-US" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'; mso-bidi-font-size: 12.0pt; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"> second 
Phase 3 study in CRPC stopped patient enrollment in September with top 
line data now expected before the end of this year.<wbr> This study is 
assessing pain response comparing cabozantinib versus mitoxantrone prednisone 
and metastatic CRPC patients who have previously received docetaxel and 
abiraterone and/<wbr>or enzalutamide, and are suffering from moderate-to-severe pain 
due to metastatic bone lesions despite narcotic medication.<wbr> Once all data from 
COMET-1 and COMET-2 are available, the company will formulate its 
regulatory strategy for CRPC, if any</SPAN> </div><div style="margin-bottom: 10px;"><P style="MARGIN: 0cm 0cm 0pt">EXAM Exelixis's Phase 3 study in patients with progressive 
unresectable locally advanced or metastatic medullary thyroid cancer that 
compared cabozantinib versus placebo led to the full regulatory approval of 
COMETRIQ for patients with progressive metastatic MTC in the United States in 
late 2012 and to conditional approval in the EU in early 2014.<wbr> The approvals 
were based on the results of the primary endpoint of progression-free survival, 
showing a 2.<wbr>8 fold longer median progression-free survival for the cabozantinib 
arm compared to placebo.<wbr></P> </div><div style="margin-bottom: 10px;">At the time of 
the PFS analysis in October 2011, the study was unblinded and placebo patients 
were allowed to receive other available therapies.<wbr> Overall survival a secondary 
endpoint that was to be analyzed once a total of 217 death events have been 
reached.<wbr> With an additional three years of follow up, the 217 death events 
required for the analysis have recently being reached and top line final results 
for OS are now available.<wbr> </div><div style="margin-bottom: 10px;">These data are 
in line with what has been previously seen in an interim analysis for overall 
survival in 2012.<wbr> The estimated median overall survival for the cabozantinib arm 
was 26.<wbr>6 month and 21.<wbr>1 months for the placebo arm, for an HR of 0.<wbr>85 and a p 
value of 0.<wbr>2409, which is not statistically significant.<wbr> </div><div style="margin-bottom: 10px;">Management 
noted that given the rare patient population, the study overall was 
relatively small for the assessment of overall survival.<wbr> The study had 80% power 
to detect a 50% improvement in overall survival risk statistical significance.<wbr> 
Additionally, more placebo patients than cabozantinib patients received 
subsequent anticancer treatments.<wbr> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'; mso-bidi-font-size: 12.0pt; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA">However, 
the subset analysis among subjects positive for RET M918T mutation showed a 
large and statistically significant overall survival benefit of 25.<wbr>4 months with 
median overall survival for the cabozantinib arm of 44.<wbr>3 months and a median 
overall survival for the placebo arm of 18.<wbr>9 months, for an HR of 0.<wbr>6 and a p 
value of 0.<wbr>026.<wbr></SPAN> Exelixis intends to submit this data to both the U.<wbr>S.<wbr> FDA and EMA in the first half of 2015 as part 
of its post-marketing commitment.<wbr> This may potentially lead to label 
updates in the future.<wbr> </div><div style="margin-bottom: 10px;"><P style="MARGIN: 0cm 0cm 0pt">The CELESTIAL 
trial in second-line HCC patients, who received prior sorafenib comparing 
cabozantinib versus placebo, is also proceeding well.<wbr> It is actively enrolling 
globally and is designed to enroll 760 patients randomized in a 2 to 1 ratio to 
cabozantinib versus placebo and the primary endpoint is overall 
survival.<wbr></P> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'; mso-bidi-font-size: 12.0pt; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA">Enrollment 
in METEOR, Exelixis's Phase 3 pivotal trial in metastatic second-line RCC, 
is nearly complete.<wbr> The group is now confident that the enrollment 
goal of 650 patients will be met in the coming days.<wbr> Top line results 
for the trial’s primary endpoint, progression fee survival is now 
expected in the second quarter of 2015.<wbr></SPAN> </div><div><SPAN lang="EN-US" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'; mso-bidi-font-size: 12.0pt; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA">Source: 
<a href="http://www.exelixis.com" class="defaultlink" title="www.exelixis.com">exelixis.com</a></SPAN> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10086">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-11-05T09:38:44+01:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>New Endocrine Society Guideline For The Diagnosis &amp; Treatment Of Acromegaly [dis:Acromegaly]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7848</link>
<description>New Endocrine Society Guideline For The Diagnosis &amp; Treatment Of Acromegaly [dis:Acromegaly]</description><category>dis:Acromegaly</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7848</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20141231&edate=20140901&rec=7848">New Endocrine Society Guideline For The Diagnosis & Treatment Of Acromegaly</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20141231&edate=20140901&cat=dis%3aAcromegaly"><font color="#e95e0b">:Endocrinology:dis:Acromegaly</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7848">Endocrinology7848</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 04 November 2014 | 19:32</font><br><br><div style="margin-bottom: 10px;">Comment: Last Friday the Endocrine Society issued a Clinical Practice 
Guideline for the diagnosis and treatment of acromegaly.<wbr> This appears in 
the November 2014 issue of the Journal of Clinical Endocrinology &amp; 
Metabolism.<wbr> Tumout removal is reccommended as first-line treatment.<wbr> </div><div style="margin-bottom: 10px;">In the CPG, the Endocrine Society recommends that surgery to remove tumours 
from the pituitary gland be considered as the primary therapy for most patients.<wbr> 
Successful surgery has the advantage of immediately lowering growth hormone 
levels.<wbr> Five-year disease recurrence rates are small, ranging from 2% to 8%.<wbr> 
This approach also provides an opportunity to examine the tumour sample to learn 
more about the individual’s condition.<wbr> </div><div style="margin-bottom: 10px;">When acromegaly symptoms persist after surgery, the Endocrine Society 
recommends pursuing medical therapy.<wbr> Some patients may require radiation therapy 
if there is tumour tissue remaining after surgery or in cases where medication 
is ineffective or causes side effects.<wbr> </div><div style="margin-bottom: 10px;">Other recommendations from the CPG include: </div><div style="margin-bottom: 10px;">• IGF-1 levels should be measured in people who have facial features or large 
extremities associated with acromegaly.<wbr> </div><div style="margin-bottom: 10px;">• When a person has a mass on the pituitary gland, IGF-1 levels should be 
measured to rule out acromegaly.<wbr> </div><div style="margin-bottom: 10px;">• Physicians should not rely on random growth hormone measurements to 
diagnose the condition.<wbr> </div><div style="margin-bottom: 10px;">• An acromegaly diagnosis should be confirmed by testing whether the body 
continues to produce growth hormone after the patient drinks sugar water for an 
oral glucose tolerance test.<wbr> </div><div style="margin-bottom: 10px;">• People with acromegaly should be assessed to see whether the pituitary 
tumour has caused damage and created a deficiency of other pituitary hormones, a 
condition called hypopituitarism.<wbr> </div><div style="margin-bottom: 10px;">• After surgery to remove the pituitary tumour, an imaging study (usually an 
MRI) to visualise any residual tumour tissue should be conducted at least 12 
weeks later.<wbr> </div><div style="margin-bottom: 10px;">• Patients receiving radiation therapy should undergo annual growth hormone 
and IGF-1 reassessments after medication withdrawal.<wbr> </div><div style="margin-bottom: 10px;">• People who develop gigantism as children also should be treated using 
surgery as the primary therapy, and then using medication or radiation treatment 
based on the individual'’ condition and response to treatment.<wbr> </div><div>SOURCE: The Endocrine Society </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20141231&edate=20140901&rec=7848">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-11-04T19:32:17+01:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>Cortendo Changes Course &amp; Targets US IPO [dis:Cushing]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7847</link>
<description>Cortendo Changes Course &amp; Targets US IPO [dis:Cushing]</description><category>dis:Cushing</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7847</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20141231&edate=20140901&rec=7847">Cortendo Changes Course & Targets US IPO</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20141231&edate=20140901&cat=dis%3aCushing"><font color="#e95e0b">:Endocrinology:dis:Cushing</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7847">Endocrinology7847</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 04 November 2014 | 18:43</font><br><br><div style="margin-bottom: 10px;">Comment In an attempt to inject capital into its business, Cortendo AB,  
has elected to sell approximately 19.<wbr>3 million of its shares at $0.<wbr>58 per 
share to its investors in a private placement.<wbr> Assuming certain shareholder 
hurdles are overcome, Arctic Fund Management, Storebrand, the Third Swedish 
National Pension Fund, and HealthCap will finance Cortendo with approximately 
$11m.<wbr> This bridge financing has triggered Cortendo to delist its 
publically traded shares from the Norwegian Over the Counter market and abandon 
its ambition of listing on the Oslo Stock Exchange.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Why The Change of Heart?</STRONG> </div><div style="margin-bottom: 10px;">Instead, the drug developer plans to utilize some of this money to 
launch an initial public offering (IPO) in the US.<wbr> Floating Cortendo on a 
US stock exchange will augment NormoCort’s recognition in that market, 
positioning the company well to successfully commercialize the drug in 
the US.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>GlobalData's Perspective On The Market Opportunity For 
NormoCort</STRONG> </div><div style="margin-bottom: 10px;">From a commercial standpoint, NormoCort has a large, target patient pool 
owing to the fact that the drug targets all CS subtypes.<wbr> Its closest rival 
is generic ketoconazole, which represents the current gold standard of 
care, but, unlike its competitor, NormoCort is being prospectively evaluated in 
clinical trials exclusively in CS patients.<wbr> Consequently, if approved, 
NormoCort will be much more readily available to US CS sufferers than 
ketoconazole is.<wbr> </div><div style="margin-bottom: 10px;">However, NormoCort’s expensive price tag, which GlobalData predicts will give 
it a US annual cost of therapy (ACOT) of $192,499, will likely impede 
the drug’s uptake.<wbr> In comparison, generic ketoconazole has an ACOT of 
approximately $3,942.<wbr> </div><div style="margin-bottom: 10px;">One Key Opinion Leader interviewed by GlobalData reiterated this concern, 
stating that, due to current economic restraints, NormoCort’s adoption 
into clinical practice will depend on its price.<wbr> Furthermore, Cortendo’s 
small size, relatively unknown reputation, limited resources, and weak marketing 
and sales force strength will all detrimentally influence NormoCort’s 
performance.<wbr> </div><div style="margin-bottom: 10px;">GlobalData anticipates near-simultaneous launches of both NormoCort and 
Novartis’ LCI699, the new and improved version of HRA Pharma’s 
Metopirone (metyrapone), in the US market in 2018.<wbr> </div><div style="margin-bottom: 10px;">The Swiss drug developer’s pharmacological agent possesses clinical and 
commercial attributes that are superior to NormoCort, including being 
backed by a global pharmaceutical giant.<wbr> Accordingly, GlobalData is led to 
believe that, despite Cortendo’s claim that NormoCort is safer and more 
efficacious than ketoconazole, LCI699 will muscle NormoCort out for patient 
share and will eventually surpass ketoconazole as the first-line medical 
therapy for CS patients.<wbr> </div><div>Source: GlobalData </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20141231&edate=20140901&rec=7847">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-11-04T18:43:53+01:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>Astellas and Proteostasis to Investigate Diseases Caused by Protein Defects [dis:Huntington, :Oncology:comp:Astellas]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7804</link>
<description>Astellas and Proteostasis to Investigate Diseases Caused by Protein Defects [dis:Huntington, :Oncology:comp:Astellas]</description><category>dis:Huntington</category><category>comp:Astellas</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7804</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7804">Astellas and Proteostasis to Investigate Diseases Caused by Protein Defects</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20141231&edate=20140901&cat=dis%3aHuntington"><font color="#e95e0b">:Neurology:dis:Huntington</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=comp%3aAstellas"><font color="#e95e0b">:Oncology:comp:Astellas</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7804">Neurology7804</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 04 November 2014 | 13:12</font><br><br><div style="margin-bottom: 10px;">Comment: Astellas is licensing one project from Cambridge, Massachusetts-based Proteostasis for &gt;$400m, and has taken an option on two more that could triple that investment.<wbr> Specifically, the two companies will use Proteostasis' platform technology to modulate a cellular pathway known as the unfolded protein response (UPR), a stress response that tries to repair protein-folding defects and prevent accumulation of mis-folded proteins within cells.<wbr> Along with Alzheimer's and CJD, disorders that involve a UPR component include Parkinson's and Huntington's disease.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Astellas Strategy</FONT></STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>revamp approach to R&amp;D, scaling back some traditional research areas</LI>
<LI>accelerate shift into biopharmaceuticals and vaccines</LI>
<LI>increase emphasis on emerging technoogies (such as regenerative medicine)</LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Proteostasis</FONT></STRONG> </div><div style="margin-bottom: 10px;"><FONT size="3"><FONT size="2"><STRONG>Mini Profile</STRONG></FONT></FONT> </div><div style="margin-bottom: 10px;"><FONT size="3"><FONT size="2">Proteostasis Therapeutics is developing disease-modifying therapeutics for orphan and neurodegenerative diseases.<wbr> </FONT></FONT> </div><div style="margin-bottom: 10px;"><FONT size="3"><FONT size="2">The Company’s lead programs in Cystic Fibrosis (CF) and protein aggregation disorders such as Parkinson’s disease modulate protein chaperone and proteasomal degradation pathways within the cell.<wbr> </FONT></FONT> </div><div style="margin-bottom: 10px;"><FONT size="3"><FONT size="2">These pathways are part of the cellular ‘quality control’ machinery, called the protein homeostasis network or Proteostasis Network (PN) that regulates protein folding, trafficking, and clearance.<wbr> By enhancing the function and capacity of the PN, the Company’s product candidates correct for imbalances in the PN resulting from the cumulative effects of disease, genetic mutations, environmental factors, and aging.<wbr></FONT> </FONT><STRONG>Platform</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7804/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Partnerships</FONT></STRONG> </div><div style="margin-bottom: 10px;">Dec.<wbr> 2013 - Biogen Idec <A href="http://www.proteostasis.com/media/news/220-proteostasis-therapeutics-announces-collaboration-with-biogen-idec.html">http:/<wbr>/<wbr>www.<wbr>proteostasis.<wbr>com/<wbr>media/<wbr>news/<wbr>220-proteostasis-therapeutics-announces-collaboration-with-biogen-idec.<wbr>html</A> </div><div style="margin-bottom: 10px;">May 2011 - <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=5737" class="defaultlink">Neurology5737: Elan And Proteostasis Form Drug Discovery Initiative in the Neurodegenerative Area</a> </div><div><EM>Source: Proteostasis</EM> </div><!-- Comment details --><a name="neurology7804attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7804/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(51,5 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7804">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-11-04T13:12:12+01:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7804/1/ScreenCapture1.jpg" length="52717" type="image/jpeg"/></item><item>
<title>AstraZeneca Strengthens Its Immuno-Oncology Business By Focusing On Surrogate Biomarker Test And Combination Strategy For Its PD-1</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology10084</link>
<description>AstraZeneca Strengthens Its Immuno-Oncology Business By Focusing On Surrogate Biomarker Test And Combination Strategy For Its PD-1</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology10084</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10084">AstraZeneca Strengthens Its Immuno-Oncology Business By Focusing On Surrogate Biomarker Test And Combination Strategy For Its PD-1</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10084">Oncology10084</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/994">Jenny Wu</a> | 04 November 2014 | 11:31</font><br><br><div style="margin-bottom: 10px;">Comment: AstraZeneca has signed three deals with the intention to strengthen its current oncology portfolio.<wbr> The collaboration includes an agreement to acquire Definiens (a private tissue diagnostic company) and two collaborations with J&amp;J and Pharmacyclics to explore combination strategy with Imbruvica in haematological cancers.<wbr> These colloaborations will extend its current reach in solid tumours (including lung cancer) into haematological cancers.<wbr> </div><div style="margin-bottom: 10px;">Definien's proprietary Cognition Network Technology&reg; was developed by Professor Gerd Binning, the 1986 Nobel Laureate in Physics.<wbr> The technology is aimed to unlock information from cancer tissue samples by measuring the identity, locations and most importantly the relationships between the many and varied components of the complex tumour microenvironment.<wbr>  Under the terms of the agreement, Medimmune will acquire 100% of Definiens' shares for an initial consideration of $ 150 million and make additional predetermined milestone payments.<wbr> Definiens will continue to operate its business with third party customers.<wbr> </div><div><P style="font: 12px/1.6em Arial, Helvetica, sans-serif; margin: 0px 0px 18px; padding: 0px; outline: 0px; border: 0px currentColor; border-image: none; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; vertical-align: baseline; white-space: normal; font-size-adjust: none; font-stretch: normal; background-color: #ffffff; -webkit-text-stroke-width: 0px;">Source: <a href="http://www.astrazeneca.com/Media/Press-releases/Article/20141104--medimmune-strengthens-immunooncology-capabilities-acquisition-Definiens" class="defaultlink">AstraZeneca Press Release</a></P> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10084">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-11-04T11:31:58+01:00</dc:date><dc:creator>jew60237</dc:creator></item><item>
<title>Undisclosed  Company Interested in Buying Allergan [comp:Allergan, news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7800</link>
<description>Undisclosed  Company Interested in Buying Allergan [comp:Allergan, news]</description><category>comp:Allergan</category><category>news</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7800</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7800">Undisclosed  Company Interested in Buying Allergan</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20141231&edate=20140901&cat=comp%3aAllergan"><font color="#e95e0b">:Neurology:comp:Allergan</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20141231&edate=20140901&cat=news"><font color="#e95e0b">:Neurology:news</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7800">Neurology7800</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 04 November 2014 | 09:27</font><br><br><div style="margin-bottom: 10px;">Comment: In a regulatory filing with the Securities and Exchange Commission (SEC), Allergan has reported having being approached by 'another party' regarding a potential transaction.<wbr> Reuters reported in early October that Actavis, which had already reached out to Allergan once in the prior months, was planning a second approach to the company with an offer worth more than $200 per share.<wbr> </div><div style="margin-bottom: 10px;">Management said in the filing that " .<wbr>.<wbr>.<wbr> Our board has determined that premature disclosure with respect to the possible terms of any transaction might jeopardize continuation of any discussions or negotiations".<wbr> </div><div><EM>Source: Allergan;LA Times; Reuters</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7800">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-11-04T09:27:11+01:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>re: Allergan Launches a 3D Juvederm iPAD App in Canada</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7799</link>
<description>re: Allergan Launches a 3D Juvederm iPAD App in Canada</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7799</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7799">re: Allergan Launches a 3D Juvederm iPAD App in Canada</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7799">Neurology7799</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/463">amr28973</a> | 03 November 2014 | 23:00</font><br><br><div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Allergan Launches a 3D Juvederm iPAD App in Canada</span>&nbsp;<font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20141231&edate=20140901&cat=comp%3aAllergan"><font color="#e95e0b">:Neurology:comp:Allergan</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20141231&edate=20140901&cat=sub%3aAesthetics"><font color="#e95e0b">:Neurology:sub:Aesthetics</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=mkt%3aCanada"><font color="#e95e0b">:PharmaWorld:mkt:Canada</font></a>]</font></font><br><span style="font-size: 12px;">Comment: Users can create a 3D image of the potential results of Juvederm(R) facial filler, showing all angle sof their face.<wbr> The technology will allow consumers to visualize what they could look like if treated with the facial filler in full 3D.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7796">...</a><br><font size="-1">Brigitte DESCHAMPS / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7796" class="commentpermalink">Neurology7796</a> / <span class="date">03 November 2014</span> /
<span class="time">11:14:24 o'clock CET</span>
</font></div><div>How can the authorities allow this there is no way of checking in advance that the treatment will have that effect.<wbr>  Doesn't promotional material generally have to be approved in advance by most authorities? </div><!-- Comment details --><font size="-1">amr28973 / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7799" class="commentpermalink">Neurology7799</a> / <span class="date">03 November 2014</span> /
<span class="time">23:00:40 o'clock CET</span>
</font><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7799">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7796">View thread  Neurology7796: Allergan Launches a 3D Juvederm iPAD App in Canada</a>]]></content:encoded><dc:date>2014-11-03T23:00:40+01:00</dc:date><dc:creator>amr28973</dc:creator></item><item>
<title>Ph3 MAESTRO Pancreatic Trial Fully Enrolled [news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology10080</link>
<description>Ph3 MAESTRO Pancreatic Trial Fully Enrolled [news]</description><category>news</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology10080</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10080">Ph3 MAESTRO Pancreatic Trial Fully Enrolled</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=news"><font color="#e95e0b">:Oncology:news</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10080">Oncology10080</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 03 November 2014 | 16:00</font><br><br><div style="margin-bottom: 10px;">Comment: Merck has announced completion of target enrollment of 660 patients.<wbr> The study is being conducted under a SPA and compares TH-302/<wbr>gemcitabine with gemcitabine alone.<wbr> The primary overall survival endpoint of this study is event driven and management is currently guiding to completion in 1Q:16, with top-line results being reported shortly thereafter.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">About the MAESTRO Trial</FONT></STRONG> </div><div style="margin-bottom: 10px;">MAESTRO is a randomized, placebo-controlled, international, multi-center, double-blind Phase 3 trial of TH-302 plus gemcitabine compared with placebo plus gemcitabine.<wbr> </div><div style="margin-bottom: 10px;">The primary efficacy endpoint is overall survival; the secondary endpoints include efficacy measured by progression-free survival (PFS), overall response rate and disease control rate, as well as assessments of safety and tolerability, pharmacokinetics and biomarkers.<wbr> </div><div style="margin-bottom: 10px;">The study is being conducted under a Special Protocol Assessment (SPA) agreement with the <ORG>U.<wbr>S.<wbr> Food and Drug Administration</ORG> (FDA).<wbr> The study design was also discussed with the <ORG value="ACORN:3106670068">European Medicines Agency</ORG> (EMA) during a scientific advice procedure </div><div style="margin-bottom: 10px;">See <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=8746" class="defaultlink">Oncology8746: Threshold and Merck KGaA Progress with Their Pancreatic Cancer Program</a> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Hypoxia-Targeted Drug TH-302</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/10080/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/10080/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Drug Development Programs</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/10080/3/ScreenCapture3.jpg?user-agent=rss"> </div><div><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/10080/4/ScreenCapture4.jpg?user-agent=rss"> </div><!-- Comment details --><a name="oncology10080attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10080/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(50 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10080/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(72 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10080/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(95,6 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10080/4/ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(7,3 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10080">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-11-03T16:00:03+01:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10080/1/ScreenCapture1.jpg" length="51242" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10080/2/ScreenCapture2.jpg" length="73731" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10080/3/ScreenCapture3.jpg" length="97889" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10080/4/ScreenCapture4.jpg" length="7522" type="image/jpeg"/></item><item>
<title>Nymox Drug Did Not Produce Intended Results [dis:Prostate]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology10078</link>
<description>Nymox Drug Did Not Produce Intended Results [dis:Prostate]</description><category>dis:Prostate</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology10078</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10078">Nymox Drug Did Not Produce Intended Results</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10078">Oncology10078</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 03 November 2014 | 12:35</font><br><br><div style="margin-bottom: 10px;">Comment: Nymox has reported that two ph3 studies of NX-1207, “failed to meet their primary efficacy endpoints".<wbr> According to the company website, the drug, a treatment for an enlarged prostate that can restrict the flow of urine from the bladder, has been the pharmaceutical company’s most promising drug.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">BPH Trials</FONT></STRONG> </div><div style="margin-bottom: 10px;"><DIV class="copy-paste-block">NX02-0017 and NX02-0018, failed to meet their primary efficacy endpoints.<wbr></DIV> </div><div style="margin-bottom: 10px;"><DIV class="copy-paste-block"><STRONG><FONT size="3">Prostate Cancer</FONT></STRONG></DIV> </div><div style="margin-bottom: 10px;"><DIV class="copy-paste-block">The drug remains promising for low-grade localised prostate cancer” where Ph2 results showed evidence that NX-1207 had “a positive effect on biopsy results and clinical and biochemical progression”.<wbr> </DIV> </div><div style="margin-bottom: 10px;"><DIV class="copy-paste-block"><STRONG><FONT size="3">Partnership</FONT></STRONG></DIV> </div><div style="margin-bottom: 10px;"><DIV class="copy-paste-block">The drug is partnered with Recordati, which holds European and other non-US rights to the drug in BPH.<wbr></DIV> </div><div style="margin-bottom: 10px;"><DIV class="copy-paste-block"><STRONG><FONT size="3">Consequence</FONT>s</STRONG></DIV> </div><div><DIV class="copy-paste-block">Nymox’s shares fell 1.<wbr>5 percent to $5.<wbr>14 on Oct.<wbr> 31.<wbr></DIV> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10078">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-11-03T12:35:28+01:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Allergan Launches a 3D Juvederm iPAD App in Canada [comp:Allergan, :PharmaWorld:mkt:Canada, sub:Aesthetics]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7796</link>
<description>Allergan Launches a 3D Juvederm iPAD App in Canada [comp:Allergan, :PharmaWorld:mkt:Canada, sub:Aesthetics]</description><comments>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7796</comments><category>comp:Allergan</category><category>mkt:Canada</category><category>sub:Aesthetics</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7796</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7796">Allergan Launches a 3D Juvederm iPAD App in Canada</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20141231&edate=20140901&cat=comp%3aAllergan"><font color="#e95e0b">:Neurology:comp:Allergan</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20141231&edate=20140901&cat=sub%3aAesthetics"><font color="#e95e0b">:Neurology:sub:Aesthetics</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=mkt%3aCanada"><font color="#e95e0b">:PharmaWorld:mkt:Canada</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7796">Neurology7796</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 03 November 2014 | 11:14</font><br><br><div style="margin-bottom: 10px;">Comment: Users can create a 3D image of the potential results of Juvederm(R) facial filler, showing all angle sof their face.<wbr> The technology will allow consumers to visualize what they could look like if treated with the facial filler in full 3D.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">About the Application</FONT></STRONG> </div><div style="margin-bottom: 10px;">Powered by <A href="http://modiface.com/about.php">ModiFace</A> </div><div style="margin-bottom: 10px;">Objectives: to stimlulate the effects of Juverderm(R) facial filler by creating a 3D image of the user's face.<wbr> </div><div style="margin-bottom: 10px;">Features </div><div style="margin-bottom: 10px;"><UL><LI>Upload a photo to produce a 3D image of your face that can be rotated and viewed from all angles</LI>
<LI>Apply and adjust more than 10 Juvederm(R) treatment effects</LI>
<LI>View and share virtual "Before" and "After" pictures with friends and/<wbr>or a doctor.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7796/1/ScreenCapture1.jpg?user-agent=rss"> </div><div><EM>Source: Allergan Canada; ModiFace</EM> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Neurology7799c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div>How can the authorities allow this there is no way of checking in advance that the treatment will have that effect.<wbr>  Doesn't promotional material generally have to be approved in advance by most authorities? </div><font size="-1">amr28973 / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7799" class="commentpermalink">Neurology7799</a> / <span class="date">03 November 2014</span> /
<span class="time">23:00:40 o'clock CET</span>
</font></div><a name="neurology7796attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7796/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(88,8 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7796">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-11-03T11:14:24+01:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7796/1/ScreenCapture1.jpg" length="90974" type="image/jpeg"/></item><item>
<title>New Report Highlights Daewoong 3Q Results [class:BotulinumToxins]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7795</link>
<description>New Report Highlights Daewoong 3Q Results [class:BotulinumToxins]</description><category>class:BotulinumToxins</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7795</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7795">New Report Highlights Daewoong 3Q Results</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20141231&edate=20140901&cat=class%3aBotulinumToxins"><font color="#e95e0b">:Neurology:class:BotulinumToxins</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7795">Neurology7795</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 03 November 2014 | 10:57</font><br><br><div style="margin-bottom: 10px;">Comment: The report from KDB Daewoo, issued on November 3rd, outlines +10.<wbr>8% increased in revenue vs the same period last year, and a good performance of Nabota both in Korea and abroad.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Selected Figures</FONT></STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>
3Q domestic sales of W1.<wbr>9bn (+W600mn QoQ)</LI>
<LI>
exports of W250mn (to Thailand) - see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7612" class="defaultlink">Neurology7612: Update of Daewoong's Nabota in Thailand</a></LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG>Situation in the US</STRONG> </div><div style="margin-bottom: 10px;">Alphaeon, Daewoong Pharmaceutical’s US partner, announced that Evosyal (Nabota’s US brand) received investigational new drug (IND) approval from the FDA in September (with patient recruitment for clinical trials taking place by the end of this year).<wbr> </div><div><UL><LI>Analyst with Mirae Asset expect Nabota to be released in the US in 2017, following the likely completion of Phase IIIa clinical trials in 2015 (source: report issues on Oct 14 2014).<wbr></LI>
</UL> </div><!-- Comment details --><a name="neurology7795attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7795/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(691 B)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7795">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-11-03T10:57:28+01:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7795/1/ScreenCapture1.jpg" length="691" type="image/jpeg"/></item><item>
<title>Astellas/Medivation Is To Initiate Ph3 Study To Envaluate Enzalutamide In M0 CRPC Patients [dis:Prostate, comp:Astellas]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology10075</link>
<description>Astellas/Medivation Is To Initiate Ph3 Study To Envaluate Enzalutamide In M0 CRPC Patients [dis:Prostate, comp:Astellas]</description><category>dis:Prostate</category><category>comp:Astellas</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology10075</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10075">Astellas/<wbr>Medivation Is To Initiate Ph3 Study To Envaluate Enzalutamide In M0 CRPC Patients</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=comp%3aAstellas"><font color="#e95e0b">:Oncology:comp:Astellas</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10075">Oncology10075</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/994">Jenny Wu</a> | 31 October 2014 | 19:48</font><br><br><div style="margin-bottom: 10px;">Comment: Astellas and Medivation announced initiation of Global <STRONG>Ph3 Enzalutamide </STRONG>trial in <STRONG>M0 CRPC </STRONG>patients with the objective to evaluate the efficacy and safety of enzalutamide.<wbr> Currrently there is no approved treatment in this setting.<wbr> The trial is aimed to enroll 1,860 patients from 160 sites and randomized into three arms : enzalutamide monotherapy vs placebo + leuprolide vs enzalutamide + leuprolide.<wbr> </div><div style="margin-bottom: 10px;">During the press release, Lynn Seely (CMO, Medivation) said "<EM> one third of men in the United States experience a rising PSA, also known as biochemical recurrence, after localized therapy for the treatment of prostate cancer.<wbr> This trial will determine if enzalutamide can delay the development of metastatic prostate cancer in high-risk men with a rapidly rising PSA</EM>" </div><div>Source: <a href="http://newsroom.astellas.us/index.php?s=31393&item=137075" class="defaultlink">Astellas/Medivation Press Release</a> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10075">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-10-31T19:48:31+01:00</dc:date><dc:creator>jew60237</dc:creator></item><item>
<title>Registration Trial of Lanzhou Institute's Botulinum Toxin Type A for Post-Stroke ULS in China [class:BotulinumToxins, dis:Spasticity, :PharmaWorld:mkt:China, :PharmaWorld:sub:ClinicalTrial]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7793</link>
<description>Registration Trial of Lanzhou Institute's Botulinum Toxin Type A for Post-Stroke ULS in China [class:BotulinumToxins, dis:Spasticity, :PharmaWorld:mkt:China, :PharmaWorld:sub:ClinicalTrial]</description><category>class:BotulinumToxins</category><category>dis:Spasticity</category><category>mkt:China</category><category>sub:ClinicalTrial</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7793</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7793">Registration Trial of Lanzhou Institute's Botulinum Toxin Type A for Post-Stroke ULS in China</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20141231&edate=20140901&cat=class%3aBotulinumToxins"><font color="#e95e0b">:Neurology:class:BotulinumToxins</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20141231&edate=20140901&cat=dis%3aSpasticity"><font color="#e95e0b">:Neurology:dis:Spasticity</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=mkt%3aChina"><font color="#e95e0b">:PharmaWorld:mkt:China</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=sub%3aClinicalTrial"><font color="#e95e0b">:PharmaWorld:sub:ClinicalTrial</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7793">Neurology7793</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 31 October 2014 | 17:12</font><br><br><div style="margin-bottom: 10px;">Comment: According to clinicaltrials.<wbr>gov, the Ph3 RCT started in Q3:14, and is designed to compare HengLi® with placebo on the efficacy and safety of treatment in post-stroke subjects with focal wrist, finger and in some cases, thumb spasticity.<wbr> Approximately 180 subjects will be enrolled.<wbr> PE will measure change from baseline at wk6 of wrist flexor muscle tone.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Trial Details</FONT></STRONG> </div><div style="margin-bottom: 10px;">Reference<A href="http://clinicaltrials.gov/ct2/show/NCT02280083?phase=012&amp;fund=2&amp;rcv_s=09%2F31%2F2014&amp;rank=62"> NCT02280083</A> </div><div style="margin-bottom: 10px;">Timelines completion expected Nov 2015 /<wbr> Jan 2016 </div><div style="margin-bottom: 10px;">Intervention </div><div style="margin-bottom: 10px;">Subjects will receive a single treatment session of intramuscular HengLi® 200U or 240U (if thumb spasticity is present) or placebo after they first enroll the core phase randomly.<wbr> Totally 180 subjects will be recruited in this part.<wbr> </div><div style="margin-bottom: 10px;">Each completed subject should finish 8 (visit 0 to 7) clinic visits.<wbr> Subjects will receive a single intramuscular treatment with either HengLi® or placebo at day 0 (visit 0).<wbr> The else 7 visits are at week 1, 4, 6, 8, 12, 16 and 18 (visits 1 to 7) and week 6 (visit 3) is appointed as the primary visit to determine efficacy.<wbr> </div><div style="margin-bottom: 10px;"><U>Principal Investigator</U> </div><div>Shengyuan Yu (The General Hospital of People's Liberation Army(301 hospital) </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7793">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-10-31T17:12:20+01:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Teva Provided Q3 Results and Outcomes of its Strategic Review of Core Specialty TA [:Endocrinology:class:GrowthHormone, :Endocrinology:dis:GrowthHormoneDeficiency, :Neurology:dis:Huntington, sub:Finance]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld11007</link>
<description>Teva Provided Q3 Results and Outcomes of its Strategic Review of Core Specialty TA [:Endocrinology:class:GrowthHormone, :Endocrinology:dis:GrowthHormoneDeficiency, :Neurology:dis:Huntington, sub:Finance]</description><category>class:GrowthHormone</category><category>dis:GrowthHormoneDeficiency</category><category>dis:Huntington</category><category>sub:Finance</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld11007</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20141231&edate=20140901&rec=11007">Teva Provided Q3 Results and Outcomes of its Strategic Review of Core Specialty TA</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20141231&edate=20140901&cat=class%3aGrowthHormone"><font color="#e95e0b">:Endocrinology:class:GrowthHormone</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20141231&edate=20140901&cat=dis%3aGrowthHormoneDeficiency"><font color="#e95e0b">:Endocrinology:dis:GrowthHormoneDeficiency</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20141231&edate=20140901&cat=dis%3aHuntington"><font color="#e95e0b">:Neurology:dis:Huntington</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=sub%3aFinance"><font color="#e95e0b">:PharmaWorld:sub:Finance</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld11007">PharmaWorld11007</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 31 October 2014 | 16:53</font><br><br><div style="margin-bottom: 10px;">Comment: Alongside the presentation of its financial results for Q3:14, Teva reported the strenghtening of its global leadership in generics, and results of its comprehensive review of core specialty therapeutic areas.<wbr> The company is seeking partners for two assets, including a first in class early stage gastroenterology/<wbr>immunology.<wbr> On the other hand, it is worth noting for next year, the clinical Ph2 results of pridopidine (HD), and Albutropin (PGHD).<wbr> </div><div style="margin-bottom: 10px;">Take Home Messages </div><div style="margin-bottom: 10px;">Criteria assessed: </div><div style="margin-bottom: 10px;"><UL><LI>presence &amp; capabilities</LI>
<LI>unmet patient needs</LI>
<LI>competitive landscape</LI>
<LI>barriers t entry</LI>
<LI>profitability</LI>
</UL> </div><div style="margin-bottom: 10px;">Purpose of the review: </div><div style="margin-bottom: 10px;"><UL><LI>drive organic groqth</LI>
<LI>pursue highest potential external opportunities</LI>
<LI>develop a winning strategy for global leadership in core TAs</LI>
</UL> </div><div style="margin-bottom: 10px;">Results </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/11007/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Non-Core Assets Divested/<wbr>Deprioritized</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/11007/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Focused Pipeline</FONT></STRONG> </div><div style="margin-bottom: 10px;">30 launches are expected by 2019, with total of $4B in new revenue.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/11007/3/ScreenCapture3.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">Revenues by Segment </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/11007/4/ScreenCapture4.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">Revenues by Market </div><div><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/11007/5/ScreenCapture5.jpg?user-agent=rss"> </div><!-- Comment details --><a name="pharmaworld11007attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/11007/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(75,9 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/11007/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(57,6 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/11007/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(139,3 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/11007/4/ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(44,7 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/11007/5/ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(27 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20141231&edate=20140901&rec=11007">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-10-31T16:53:07+01:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/11007/1/ScreenCapture1.jpg" length="77724" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/11007/2/ScreenCapture2.jpg" length="58958" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/11007/3/ScreenCapture3.jpg" length="142596" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/11007/4/ScreenCapture4.jpg" length="45734" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/11007/5/ScreenCapture5.jpg" length="27686" type="image/jpeg"/></item><item>
<title>UEGW (Vienna) - Biocodex Sympo Focused on Cost-Effectiveness and New Insights  of Saccharomyces Boulardii CNCM I-745 [news, :PharmaWorld:congress:UEGW]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2112</link>
<description>UEGW (Vienna) - Biocodex Sympo Focused on Cost-Effectiveness and New Insights  of Saccharomyces Boulardii CNCM I-745 [news, :PharmaWorld:congress:UEGW]</description><category>news</category><category>congress:UEGW</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2112</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2112">UEGW (Vienna) - Biocodex Sympo Focused on Cost-Effectiveness and New Insights  of Saccharomyces Boulardii CNCM I-745</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20141231&edate=20140901&cat=news"><font color="#e95e0b">:GastroEnterology:news</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=congress%3aUEGW"><font color="#e95e0b">:PharmaWorld:congress:UEGW</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2112">GastroEnterology2112</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 31 October 2014 | 15:55</font><br><br><div style="margin-bottom: 10px;">Comment: Introduced and chaired by Ph.<wbr> Marteau (MD, PhD, head of the Unit of Digestive Disease, Lariboisière Hosp, and professor of gastroenterology Paris 7 University), the symposium started with the results from the first multinational survey on probiotics awareness, which was conducted by the International Study Group on Probiotics (ISGoP) in 10 countries.<wbr> C.<wbr> Kelly then provided recent data on the impact of CNCM I-745 on gut microbiota in AAD and CDI.<wbr> The cost-effectiveness of using CNCM I-745 to reduce hospitalization was demonstrated by Ir.<wbr> S.<wbr> Vermeersch.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Take Home Messages from the ISGoP Survey</FONT></STRONG> </div><div style="margin-bottom: 10px;"><U>Material &amp; Methods</U> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2112/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">Highlligts of the study: </div><div style="margin-bottom: 10px;"><UL><LI>Most physicians feel well informed about probiotics</LI>
<LI>There is an unclear definition of probiotic</LI>
</UL> </div><div style="margin-bottom: 10px;"><BLOCKQUOTE dir="ltr" style="MARGIN-RIGHT: 0px">
<BLOCKQUOTE dir="ltr" style="MARGIN-RIGHT: 0px">
<P>- more recognized as bacteria than yeast</P>
<P>- no consensus on clinically proven strains</P></BLOCKQUOTE></BLOCKQUOTE> </div><div style="margin-bottom: 10px;"><UL><LI>&gt;50% recommend probiotics for AID and AAD</LI>
<LI>2/<wbr>3 use probiotics for their relatives or themselves</LI>
<LI>Positive perception on probiotics safety</LI>
<LI>Lack of information is a key obstacle for not prescribing probiotics</LI>
<LI>&gt;89% read at least 1 article/<wbr>year on probiotics</LI>
<LI>Continuous medical education on probiotics is key to promote awareness</LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG>Dr Ch Boggio Marzet</STRONG> (MD, Head of the Paediatric Gastroenterology and Nutrition Section at Hospital General de Agudos) outlined that physicians knowledge in the field of probiotics is crucial for a full understanding of human microbiota in health and disease.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Key Findings on the Impact of CNCM I-745 on Gut Microbiota</FONT></STRONG> </div><div style="margin-bottom: 10px;"><STRONG><img src="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2112/4/ScreenCapture4.jpg?user-agent=rss"></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>Dr.<wbr> Ciarán Kelly</STRONG>, Professor of Medicine at Harvard Medical School and Director of Gastroenterology Training at Beth Israel Deaconess Medical Center and Dr.<wbr> Toufic Kabbani, Gastroenterology fellow at Beth Israel Deaconess Medical Center, utilized DNA technology to investigate the effects of <EM>Saccharomyces boulardii </EM>CNCM I-745 (<EM>Sb</EM>), and Amoxicillin/<wbr>Clavulanate, and the combination on the microbiome of the <STRONG>healthy human GI tract</STRONG>, where 70% of our immune system resides.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Study Design</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2112/5/ScreenCapture5.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG>Results</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2112/8/ScreenCapture8.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2112/10/ScreenCapture10.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">Antibiotic treatment reduces Ralstonia and increases parabacteroides, escherischia/<wbr>shighella in different genera </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2112/11/ScreenCapture11.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2112/12/ScreenCapture12.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2112/13/ScreenCapture13.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG>Key findings</STRONG> show the probiotic <EM>Sb</EM> can help to maintain and restore a healthy and balanced intestinal ecosystem.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2112/9/ScreenCapture9.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Economic Evaluation of CNCM I-745</FONT></STRONG> </div><div style="margin-bottom: 10px;">In a cost study based on a decision tree analysis (comparing the cost with/<wbr>without preventive treatment with sb) for patients on antibiotic therapy, the economic impact of the preventive use of sb in adult hospitalized patients taking antibiotics was established.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>S Vermeersch</STRONG> (computer science engineer) concluded that: </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2112/3/ScreenCapture3.jpg?user-agent=rss"> </div><div><STRONG><FONT size="4">Full presentation of the Biocodex sympo is available on demand to Brigitte Deschamps</FONT></STRONG> </div><!-- Comment details --><a name="gastroenterology2112attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2112/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(84,9 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2112/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(81,1 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2112/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(98,3 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2112/4/ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(104,5 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2112/5/ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(118,2 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2112/6/ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(86,9 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2112/7/ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(94,4 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2112/8/ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(88,9 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2112/9/ScreenCapture9.jpg">ScreenCapture9.jpg</a>&nbsp;&nbsp;(43,9 KB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2112/10/ScreenCapture10.jpg">ScreenCapture10.jpg</a>&nbsp;&nbsp;(98 KB)<br>&nbsp;&nbsp;11.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2112/11/ScreenCapture11.jpg">ScreenCapture11.jpg</a>&nbsp;&nbsp;(74 KB)<br>&nbsp;&nbsp;12.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2112/12/ScreenCapture12.jpg">ScreenCapture12.jpg</a>&nbsp;&nbsp;(67 KB)<br>&nbsp;&nbsp;13.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2112/13/ScreenCapture13.jpg">ScreenCapture13.jpg</a>&nbsp;&nbsp;(70,3 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2112">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-10-31T15:55:38+01:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2112/1/ScreenCapture1.jpg" length="86974" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2112/2/ScreenCapture2.jpg" length="83075" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2112/3/ScreenCapture3.jpg" length="100657" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2112/4/ScreenCapture4.jpg" length="107057" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2112/5/ScreenCapture5.jpg" length="121078" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2112/6/ScreenCapture6.jpg" length="89015" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2112/7/ScreenCapture7.jpg" length="96652" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2112/8/ScreenCapture8.jpg" length="91024" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2112/9/ScreenCapture9.jpg" length="44951" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2112/10/ScreenCapture10.jpg" length="100364" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2112/11/ScreenCapture11.jpg" length="75805" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2112/12/ScreenCapture12.jpg" length="68580" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2112/13/ScreenCapture13.jpg" length="72037" type="image/jpeg"/></item><item>
<title>CEO Claims Q3 'Best Quarter Ever' For Probi [sub:Probiotics, :PharmaWorld:sub:Finance]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2110</link>
<description>CEO Claims Q3 'Best Quarter Ever' For Probi [sub:Probiotics, :PharmaWorld:sub:Finance]</description><category>sub:Probiotics</category><category>sub:Finance</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2110</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2110">CEO Claims Q3 'Best Quarter Ever' For Probi</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20141231&edate=20140901&cat=sub%3aProbiotics"><font color="#e95e0b">:GastroEnterology:sub:Probiotics</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=sub%3aFinance"><font color="#e95e0b">:PharmaWorld:sub:Finance</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2110">GastroEnterology2110</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 31 October 2014 | 14:14</font><br><br><div style="margin-bottom: 10px;">Comment: Growth was attributed to the Cosnsumer H/<wbr>C business (+54% vs corresponding period in 2013), primarily driven by successful launches in the US and South Korea.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Business Development</FONT></STRONG> </div><div style="margin-bottom: 10px;"><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2038" class="defaultlink">GastroEnterology2038: Probi and Pharmavite Expand Probiotic Product Partnership in the US and International Markets</a>; </div><div style="margin-bottom: 10px;"><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=1966" class="defaultlink">GastroEnterology1966: Sanofi Korea to Launch Probi Digestis® for IBS</a>; </div><div style="margin-bottom: 10px;"><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=1956" class="defaultlink">GastroEnterology1956: DongKook to Distribute Probi's Gut Health Product in Korea</a>; </div><div style="margin-bottom: 10px;"><FONT size="3"><STRONG>Key Figures for Q3:14 (Q3:13)</STRONG></FONT> </div><div style="margin-bottom: 10px;"><UL><LI>
<FONT size="2">NET SALES amounted to MSEK 37.<wbr>1 (24.<wbr>1)</FONT></LI>
<LI>
<FONT size="2">OPERATING PROFIT totalled MSEK 9.<wbr>0 (4.<wbr>5)</FONT></LI>
<LI>
<FONT size="2">PROFIT AFTER TAX amounted to MSEK 7.<wbr>1 (3.<wbr>7)</FONT></LI>
<LI>
<FONT size="2">PROFIT AFTER TAX PER SHARE was SEK 0.<wbr>77 (0.<wbr>41)</FONT></LI>
<LI>
<FONT size="2">CASH FLOW amounted to MSEK 3.<wbr>3 (4.<wbr>2).<wbr></FONT></LI>
</UL> </div><div><EM>Source: Probi PR</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2110">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-10-31T14:14:09+01:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>New Platform of Immunotherapies for IBD [dis:IBD, :PharmaWorld:sub:xLicensing, :PharmaWorld:sub:Partnership, :PharmaWorld:sub:ClinicalTrial]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2109</link>
<description>New Platform of Immunotherapies for IBD [dis:IBD, :PharmaWorld:sub:xLicensing, :PharmaWorld:sub:Partnership, :PharmaWorld:sub:ClinicalTrial]</description><category>dis:IBD</category><category>sub:xLicensing</category><category>sub:Partnership</category><category>sub:ClinicalTrial</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2109</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2109">New Platform of Immunotherapies for IBD</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20141231&edate=20140901&cat=dis%3aIBD"><font color="#e95e0b">:GastroEnterology:dis:IBD</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=sub%3aClinicalTrial"><font color="#e95e0b">:PharmaWorld:sub:ClinicalTrial</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=sub%3aPartnership"><font color="#e95e0b">:PharmaWorld:sub:Partnership</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=sub%3axLicensing"><font color="#e95e0b">:PharmaWorld:sub:xLicensing</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2109">GastroEnterology2109</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 31 October 2014 | 13:00</font><br><br><div style="margin-bottom: 10px;">Comment: Qu Biologics hypothesizes that a Site Specific Immunomodulator (SSI) derived from a type of bacteria that commonly infects the colon would be a potential treatment for patients with inflammatory bowel disease (IBD).<wbr> The ongoing clinical trial with QBECO SSI (fo CD) just completed independent safety review generated from 30 patients (50% enrollment).<wbr> The company is currently seeking to raise additional funds to expand their clinical trial program to include additional indications in cancer (e.<wbr>g.<wbr>, late-stage lung cancer, late-stage colon cancer, inoperable pancreatic cancer) and immune-related disease (e.<wbr>g.<wbr>, rheumatoid arthritis and ulcerative colitis).<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Qu Biologics IBD Programs</FONT></STRONG> </div><div style="margin-bottom: 10px;">for CD &gt; The company is looking for investment to finance the large-scale good manufacturing practices (GMP)-accredited manufacture of their lead candidate Site Specific Immunomodulator (SSI) in preparation for a phase 3 multi-national clinical trial in Crohn’s disease.<wbr> </div><div style="margin-bottom: 10px;">for UC &gt; The company is also preparing to initiate a Ph2a clinical trial of QBECO SSI in ulcerative colitis (UC) in H1:15.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">SSI Mechanism of Action</FONT></STRONG> </div><div style="margin-bottom: 10px;">Qu Biologics is developing a new platform of immunotherapies called Site Specific Immunomodulators (SSIs), designed to ‘reboot’ the immune response in the targeted organ, reversing the immune dysfunction and chronic inflammation underlying cancer and immune mediated diseases, including Crohn’s disease (CD).<wbr> </div><div style="margin-bottom: 10px;">SSIs are novel complex biologics, each derived from components of a single species of inactivated pathogenic bacteria.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3"><img src="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2109/1/ScreenCapture1.jpg?user-agent=rss"></FONT></STRONG> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">About the Trial</FONT></STRONG> </div><div style="margin-bottom: 10px;"><A href="http://www.qucrohnstrial.com/trial-info/about-this-crohns-disease-trial/">Design</A>: Ph1/<wbr>2 RCT </div><div style="margin-bottom: 10px;">PE: to evaluate the safety profile </div><div style="margin-bottom: 10px;">Administration: sc injection (just under skin) using fine needle (like an insulin injection) </div><div style="margin-bottom: 10px;">Recruitment: approx 60 participants with moderate-to-severe CD </div><div style="margin-bottom: 10px;">Location: US; Canada </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Qu Biologics Snapshot</FONT></STRONG> </div><div style="margin-bottom: 10px;">private clinical-stage biopharmaceutical company incorporated in the province of British Columbia, Canada, in Sept.<wbr> 2007.<wbr> </div><div style="margin-bottom: 10px;">has raised $14.<wbr>3M to date from angel investors and an additional $2.<wbr>7M in government funding, through the National Research Council Industrial Research Assistance Program (NRC-IRAP), the Scientific Research and Experimental Development (SR&amp;ED) Tax Incentive Program and the US National Cancer Institute (NCI).<wbr> </div><div><EM>Source: Qu Biologics</EM> </div><!-- Comment details --><a name="gastroenterology2109attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2109/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(104,2 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2109">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-10-31T13:00:58+01:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2109/1/ScreenCapture1.jpg" length="106714" type="image/jpeg"/></item><item>
<title>EU Registration Trials for Norgine's Novel Low Volume Bowel Preparation [news, sub:CRCPrevention, :PharmaWorld:sub:ClinicalTrial, :PharmaWorld:mkt:Europe]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2105</link>
<description>EU Registration Trials for Norgine's Novel Low Volume Bowel Preparation [news, sub:CRCPrevention, :PharmaWorld:sub:ClinicalTrial, :PharmaWorld:mkt:Europe]</description><comments>http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2105</comments><category>news</category><category>sub:CRCPrevention</category><category>sub:ClinicalTrial</category><category>mkt:Europe</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2105</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2105">EU Registration Trials for Norgine's Novel Low Volume Bowel Preparation</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20141231&edate=20140901&cat=news"><font color="#e95e0b">:GastroEnterology:news</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20141231&edate=20140901&cat=sub%3aCRCPrevention"><font color="#e95e0b">:GastroEnterology:sub:CRCPrevention</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=mkt%3aEurope"><font color="#e95e0b">:PharmaWorld:mkt:Europe</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=sub%3aClinicalTrial"><font color="#e95e0b">:PharmaWorld:sub:ClinicalTrial</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2105">GastroEnterology2105</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 30 October 2014 | 18:00</font><br><br><div style="margin-bottom: 10px;">Comment: Newly listed in <EM>clinicaltrials.<wbr>gov</EM>.<wbr> the 2 studies, expected to recruit approx 1,300 participants, have been part of the EU registration trials for Norgine's NER1006.<wbr> T<FONT color="#000000">he DAYB study will compare NER1006 vs CITRAFLEET using a day befre only dosing regimen in adults.<wbr> The MORA study will compare NER1006 vs MOVIPREP using a 2-day split-dosing regimen and a 1-day morning slit-dosing regimen in adults.<wbr> Both studies have similar timelines, and efficacy as primary endpoint.<wbr></FONT> </div><div style="margin-bottom: 10px;"><STRONG><FONT color="#000000">Trial Details</FONT></STRONG> </div><div style="margin-bottom: 10px;"><UL><LI><FONT color="#000000">Reference: </FONT><a href="http://clinicaltrials.gov/ct2/show/NCT02273141?recr=Open&no_unk=Y&phase=012&fund=2&rcv_s=09%2F30%2F2014&rank=91" class="defaultlink">NCT0227314</a>1 /<wbr> NER1006-03/<wbr>2014 (<STRONG>DAYB</STRONG>)
</LI>
</UL> </div><div style="margin-bottom: 10px;">Recruitment: approx 484 </div><div style="margin-bottom: 10px;">Timelines: Start date indicated: Oct 2014 - Completion date: Aug 2015 /<wbr> Jan 2016 </div><div style="margin-bottom: 10px;">Intervention NER1006, Day Before-Only Dosing A 1-day day before-only split-dosage regimen of NER1006.<wbr> </div><div style="margin-bottom: 10px;">Principal Investigator Stefan Schreiber U of Schleswig-Holstein </div><div style="margin-bottom: 10px;"><UL><LI>Reference <a href="http://clinicaltrials.gov/ct2/show/NCT02273167?recr=Open&no_unk=Y&phase=012&fund=2&rcv_s=09%2F30%2F2014&rank=106" class="defaultlink">NCT02273167</a> /<wbr> NER1006-02/<wbr>2014 (<STRONG>MORA</STRONG>)
</LI>
</UL> </div><div style="margin-bottom: 10px;">Recruitment approx 810 </div><div style="margin-bottom: 10px;">Timelines start date indicated Oct 2014 - Completion date: Aug 2015 /<wbr> Jan 2016 </div><div style="margin-bottom: 10px;">Intervention </div><div style="margin-bottom: 10px;">NER1006, 2-Day Split-Dosing: The subject will self-administer the first dose of the assigned investigational product in the evening prior to the scheduled colonoscopy and take any mandatory additional clear fluid.<wbr> Subject will take the second dose together with any required additional clear fluids on the morning of the colonoscopy.<wbr> </div><div style="margin-bottom: 10px;">NER1006,1-Day Morning Split-Dosing: The subject will self-administer the first dose of the investigational product on the morning of the colonoscopy and take any mandatory additional clear fluid.<wbr> </div><div style="margin-bottom: 10px;"><DIV class="indent2" style="margin-top: 0.5ex;">
<P style="margin-top: 0ex; margin-bottom: 1ex;">After a 1-2 hour break the subject will self-administer the second dose plus any additional clear mandatory fluid.<wbr></P>
</DIV> </div><div>Principal Investigator Raf Bisschops, MD UZ Leuven </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="GastroEnterology2119c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">Norgine announced today the enrolment of the first patients into the two EU Ph3 studies (MORA and DAYB), as well as the countries involved in each trial (listed below).<wbr> </div><div style="margin-bottom: 10px;">The following EU countries will be included in the MORA and DAYB clinical trials: </div><div><UL><LI><STRONG>MORA</STRONG>: Belgium, France, Germany, Italy, Poland, Spain and UK
</LI>
<LI><STRONG>DAYB</STRONG>: Germany, Italy, Netherlands, Poland, Spain and UK
</LI>
</UL> </div><font size="-1">Brigitte DESCHAMPS / <a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2119" class="commentpermalink">GastroEnterology2119</a> / <span class="date">13 November 2014</span> /
<span class="time">15:37:55 o'clock CET</span>
</font></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2105">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-10-30T18:00:51+01:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Novo Reports Revenues Broadly In-Line with Company Consensus</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld11006</link>
<description>Novo Reports Revenues Broadly In-Line with Company Consensus</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld11006</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20141231&edate=20140901&rec=11006">Novo Reports Revenues Broadly In-Line with Company Consensus</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld11006">PharmaWorld11006</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 30 October 2014 | 16:17</font><br><br><div style="margin-bottom: 10px;">Comment: During the first nine months, the company's sales gained 8% in local currencies (4% in Danish kroner to DKK 64.<wbr>2 billion) As per usual growth drivers include North America (the main contributor to growth), International Operations and Region China.<wbr> When it comes to products, sales of modern insulin and Victoza increased by 13%, 15% respectively, and sales of Norditropin registered a 10% increase (in lc, compared to the same period in 2013).<wbr> Promising pipeline includes haemophilia and growth hormone disorder drugs.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Sales Development</STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>Sales increased by 8% in local currencies and 4% in Danish kroner North America, International Operations and Region China grew by 11%, 13% and 14% in local currencies, respectively
</LI>
<LI>Modern insulin increased by 13% in local currencies driven by solid Levemir growth
</LI>
<LI>Victoza increased by 15% in local currencies, and continues to drive growthon the GLP-1 market
</LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG>Outlook for 2015</STRONG> </div><div style="margin-bottom: 10px;">The preliminary outlook for 2015 indicates high single-digit sales growth and around 10% operating profit growth, both measured in local currencies.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>GHD Pipeline</STRONG> </div><div style="margin-bottom: 10px;"><a href="http://clinicaltrials.gov/ct2/show/NCT02229851?recr=Open&no_unk=Y&cond=growth+hormone+deficiency&fund=2&rank=3" class="defaultlink">Ph3</a> to be started next month with once weekly dosing of NNC0195-0092 compared to placebo and once-daily dosing of somatropin after 35 weeks of treatment in AGHD.<wbr> </div><div><EM>Source: Novo Nordisk; clinicaltrials.<wbr>gov</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20141231&edate=20140901&rec=11006">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-10-30T16:17:17+01:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Leadership In GI &amp; Oncology Is A Key Strategic Goal For Takeda [dis:Constipation, dis:IBD]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2103</link>
<description>Leadership In GI &amp; Oncology Is A Key Strategic Goal For Takeda [dis:Constipation, dis:IBD]</description><category>dis:Constipation</category><category>dis:IBD</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2103</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2103">Leadership In GI & Oncology Is A Key Strategic Goal For Takeda</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20141231&edate=20140901&cat=dis%3aConstipation"><font color="#e95e0b">:GastroEnterology:dis:Constipation</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20141231&edate=20140901&cat=dis%3aIBD"><font color="#e95e0b">:GastroEnterology:dis:IBD</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2103">GastroEnterology2103</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 30 October 2014 | 12:08</font><br><br><div style="margin-bottom: 10px;">Comment: Alongside its Q3 earnings, Takeda's new President &amp; COO presented a strategic update focusing on Takeda's assets and strengths and what it needs to improve e.<wbr>g.<wbr> patient &amp; customer centricity plus clear accountability and ownership.<wbr> Fuelling its leadership position in the fast growing GI market is Takeda's new IBD therapy Entyvio approved for both Crohns disease and ulcerative colitis, with the group predicting that this will become a $2bn product.<wbr> </div><div style="margin-bottom: 10px;">A copy of the full presentation is attached.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2103/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><FONT face="Times New Roman" size="3"><img src="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2103/2/ScreenCapture2.jpg?user-agent=rss"></FONT> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2103/3/ScreenCapture3.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2103/4/ScreenCapture4.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2103/5/ScreenCapture5.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2103/6/ScreenCapture6.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2103/7/ScreenCapture7.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2103/8/ScreenCapture8.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2103/9/ScreenCapture9.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">In terms of the performance of individual products in the last quarter and first half the slides below highlight the declining sales of leuprorelin which to some extent were stemmed in the second quarter </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2103/10/ScreenCapture10.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2103/11/ScreenCapture11.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">In terms of its R&amp;D pipeline the latest update shows that TAK-385 an oral LHRH-antagonist is in phII development for prostate cancer in the US &amp; EU and in phII for endometriosis and uterine fibroids in Jpn.<wbr> </div><div style="margin-bottom: 10px;">TAP-144-SR a 6 month formulation of leuprorelin being developed for prostate cancer and premenopausal breast cancer was filed in Japan as of September this year.<wbr> This formulation has already been approved in the US and European markets.<wbr> </div><div>The phIII development of a liquid formulation of lubipostone (Amitiza) for pediatric functional constipation is ongoing in the US.<wbr> </div><!-- Comment details --><a name="gastroenterology2103attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2103/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(108,2 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2103/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(132,4 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2103/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(125,9 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2103/4/ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(104,2 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2103/5/ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(111,6 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2103/6/ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(118,8 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2103/7/ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(233,4 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2103/8/ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(87,7 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2103/9/ScreenCapture9.jpg">ScreenCapture9.jpg</a>&nbsp;&nbsp;(134,6 KB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2103/10/ScreenCapture10.jpg">ScreenCapture10.jpg</a>&nbsp;&nbsp;(208,8 KB)<br>&nbsp;&nbsp;11.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2103/11/ScreenCapture11.jpg">ScreenCapture11.jpg</a>&nbsp;&nbsp;(209,3 KB)<br>&nbsp;&nbsp;12.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2103/12/Takeda%20Strategy%20Presentation%20Q214.pdf">Takeda Strategy Presentation Q214.pdf</a>&nbsp;&nbsp;(7,3 MB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2103">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-10-30T12:08:31+01:00</dc:date><dc:creator>jac89886</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2103/1/ScreenCapture1.jpg" length="110826" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2103/2/ScreenCapture2.jpg" length="135577" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2103/3/ScreenCapture3.jpg" length="128930" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2103/4/ScreenCapture4.jpg" length="106724" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2103/5/ScreenCapture5.jpg" length="114289" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2103/6/ScreenCapture6.jpg" length="121641" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2103/7/ScreenCapture7.jpg" length="239031" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2103/8/ScreenCapture8.jpg" length="89825" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2103/9/ScreenCapture9.jpg" length="137832" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2103/10/ScreenCapture10.jpg" length="213855" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2103/11/ScreenCapture11.jpg" length="214350" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2103/12/Takeda%20Strategy%20Presentation%20Q214.pdf" length="7604958" type="application/pdf"/></item><item>
<title>First-In-Class p53 Suppressor Moves Into PhI Development</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology10074</link>
<description>First-In-Class p53 Suppressor Moves Into PhI Development</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology10074</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10074">First-In-Class p53 Suppressor Moves Into PhI Development</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10074">Oncology10074</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 30 October 2014 | 08:44</font><br><br><div style="margin-bottom: 10px;">Comment: Stapled peptide developer Aileron Therapeutics has secured $33m in 
series E venture financing to advance its first in class oncology drug into 
phase I clinical development for liquid and solid tumours.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Nature of The Financial Support</STRONG> </div><div style="margin-bottom: 10px;">The financing was co-led by three new investors including AJU IB and two 
undisclosed private investors, the round also included full participation by all 
existing investors including Apple Tree PArtners, Excel Venture Management, 
Lillym Novartis and Roche Venture Funds and SR One.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Profile of ALRN-6924</STRONG> </div><div style="margin-bottom: 10px;">The finance will be used to advance ALRN-6924 a potent specifc re-activator 
of p53 into clinical trials.<wbr>ALRN-6924 will be the first clinical drug candidate 
that targets both the MDM2 and the MDMX suppressor proteins of p53, in contrast 
to all other drugs in clinical development that involve small molecules 
targeting only MDM2.<wbr> </div><div style="margin-bottom: 10px;">P53, known as "the guardian of the genome" because it enables repair of 
damaged DNA or triggers cell death, is one of the most important tumor 
suppressor proteins, as it is known to be inactivated in virtually all human 
cancers.<wbr> As half of all cancers circumvent p53's protective mechanisms by the 
inhibitory proteins MDM2 and MDMX, Aileron's stapled peptide, ALRN-6924, is 
novel in that it can selectively bind to and inhibit both proteins equally, 
thereby restoring p53 function.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Aileron's Current Drug Portfolio</STRONG> </div><div style="margin-bottom: 10px;">ALRN-6294 is the company's second drug to move into early clinical 
development with the first being ALRN-5281 a proprietary, long-acting 
growth-hormone-releasing hormone agonist for treating orphan endocrine 
disorders, including adult growth hormone deficiency and HIV lipodystrophy.<wbr> </div><div>Source: <A href="http://www.aileronrx.com">www.<wbr>aileronrx.<wbr>com</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10074">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-10-30T08:44:55+01:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>New Epidemiology Report On Cushing's Syndrome [dis:Cushing]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7846</link>
<description>New Epidemiology Report On Cushing's Syndrome [dis:Cushing]</description><category>dis:Cushing</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7846</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20141231&edate=20140901&rec=7846">New Epidemiology Report On Cushing's Syndrome</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20141231&edate=20140901&cat=dis%3aCushing"><font color="#e95e0b">:Endocrinology:dis:Cushing</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7846">Endocrinology7846</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 29 October 2014 | 17:56</font><br><br><div style="margin-bottom: 10px;">Comment: GlobalData has released a new epidemiology report on Cushing's 
syndrome  provides an overview of the risk factors, comorbidities, and the 
global and historical epidemiological trends for CS in the six major markets 
(US, France, Germany, Italy, Spain, and UK).<wbr> The report also includes a 10-year 
epidemiological forecast for the diagnosed prevalent cases of CS, Cushing’s 
disease, ectopic ACTH CS, adrenal adenoma CS, and adrenal carcinoma CS segmented 
by age (18 to ≥85 years) and sex in these markets.<wbr> </div><div style="margin-bottom: 10px;">Additionally, GlobalData epidemiologists provide the immediate outcome of 
transsphenoidal adenomectomy surgery (TSS) in patients with Cushing’s 
disease.<wbr> </div><div style="margin-bottom: 10px;"><TABLE border="0" cellpadding="5" cellspacing="0" id="LanguageTarget" width="100%"><TBODY><TR><TD valign="top">
      <P class="paratext">For this analysis, GlobalData epidemiologists used data 
      available from Orphanet to construct the 10-year epidemiological forecast 
      for the diagnosed prevalent cases of Cushing’s disease, ectopic ACTH CS, 
      adrenal adenoma CS, and adrenal carcinoma CS in the 6MM.<wbr> </P></TD>
</TR>
<TR><TD valign="top">
      <P class="paratext">As shown in below Figure, GlobalData epidemiologists 
      forecast an increase in the diagnosed prevalent cases of CS in the 6MM, 
      from 32,634 diagnosed prevalent cases in 2013 to 34,573 diagnosed 
      prevalent cases in 2023, with an annual growth rate (AGR) of 0.<wbr>59%.<wbr> In 
      2023, the US will have the highest number of diagnosed prevalent cases of 
      CS, with 17,162 diagnosed prevalent cases.<wbr> </P>
      <P class="paratext">Additionally, each of the 6MM will see an increase in 
      diagnosed prevalent cases over the 10-year forecast period, except for 
      Germany, which will have a negative AGR of 0.<wbr>14%.<wbr> Because GlobalData 
      epidemiologists applied a constant diagnosed prevalence in each of the 
      6MM, the trends in the diagnosed prevalent cases of CS are attributed to 
      changing population demographics in the 
6MM.<wbr> </P></TD>
</TR>
</TBODY>
</TABLE> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7846/1/ScreenCapture1.jpg?user-agent=rss"> </div><div>For those interested in a full copy of the report please contact the Business 
Intelligence Dept.<wbr> </div><!-- Comment details --><a name="endocrinology7846attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7846/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(90,8 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20141231&edate=20140901&rec=7846">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-10-29T17:56:14+01:00</dc:date><dc:creator>jac89886</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7846/1/ScreenCapture1.jpg" length="93010" type="image/jpeg"/></item><item>
<title>New Trial To Be Started To Compare WL vs NBI vs PDD In Denmark For Non Muscle Invasive Bladder Cancer [dis:Bladder]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology10073</link>
<description>New Trial To Be Started To Compare WL vs NBI vs PDD In Denmark For Non Muscle Invasive Bladder Cancer [dis:Bladder]</description><category>dis:Bladder</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology10073</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10073">New Trial To Be Started To Compare WL vs NBI vs PDD In Denmark For Non Muscle Invasive Bladder Cancer</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=dis%3aBladder"><font color="#e95e0b">:Oncology:dis:Bladder</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10073">Oncology10073</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/994">Jenny Wu</a> | 29 October 2014 | 17:47</font><br><br><div style="margin-bottom: 10px;">Comment: Dr.<wbr> Bryan Qvick (Hexvix Medical Director, Uro-Onco Franchise) has kindly provided soft intelligence regarding to a new trial that is to compare the sensitivity and specificity of white light vs NBI vs PDD in carcinoma in situ (CIS) and flat lesions.<wbr> The trial is initiated in Denmark (DaBlaCa-8) and planned to include 150 patients within 18 months.<wbr> The trial is expected to start end of 2014.<wbr> </div><div style="margin-bottom: 10px;"><FONT face="Calibri" size="3">&ldquo;Two weeks ago the final results of the 1st phase III trial comparing the three imaging modalities White light, PDD and NBI has failed and did not show any significant difference in the detection rate between those three imaging techniques (Doehn et al, DGU 2014).<wbr> Now a new trial will be initiated in Denmark (DaBlaCa-8)  comparing the sensitivity and specificity  of White light vs.<wbr> NBI vs.<wbr> PDD in CIS and flat lesions.<wbr> The assumption is that there won&acute;t be any difference between the sensitivity of NBI vs.<wbr> PDD  but a lower specificity for PDD.<wbr> It is planned to include 150 patients within 18 months, start end of the year.<wbr>&rdquo;</FONT> </div><div><FONT face="Times New Roman" size="3">Please find </FONT><a href="http://ducg.dk/fileadmin/www.ducg.dk/Blaerecancer/DaBlaCa-8.pdf" class="defaultlink">Protocol Reference Here.</a> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10073">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-10-29T17:47:24+01:00</dc:date><dc:creator>jew60237</dc:creator></item><item>
<title>Heat Biologics Commences First Patient Dosing For The Phase 2 of HS-410 in Bladder Cancer [dis:Bladder]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology10072</link>
<description>Heat Biologics Commences First Patient Dosing For The Phase 2 of HS-410 in Bladder Cancer [dis:Bladder]</description><category>dis:Bladder</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology10072</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10072">Heat Biologics Commences First Patient Dosing For The Phase 2 of HS-410 in Bladder Cancer</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=dis%3aBladder"><font color="#e95e0b">:Oncology:dis:Bladder</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10072">Oncology10072</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/994">Jenny Wu</a> | 29 October 2014 | 16:24</font><br><br><div style="margin-bottom: 10px;">Comment: Heat Biologics initiated patient dosing in its Ph2 clinical trial of HS-410 (Vesigenurtacel-L) in subjects wit high risk, non muscle invasive bladder cancer (NMIBC).<wbr> Vesigenurtacel-L is Heat's investigational drug in a series of proprietary Immune Pan Antigen Cytotoxic Therapy based allogeneic cell lines designed to direct killer T cells to attack cancer.<wbr> This is a major milestone for Heat Biologics as the dosing initiation is one quarter ahead of schedule.<wbr> The company is expecting patient enrolment to complete in Q3 2015 and topline results will be reported in Q3 2016.<wbr> </div><div>The multi-center Phase 2 (<STRONG>NCT02010203</STRONG>) portion of Heat's bladder cancer study is designed to determine whether vaccination with one of two doses of vesigenurtacel-L in combination with Bacillus Calmette-Gu&eacute;rin (BCG) after transurethral resection of bladder tumor (TURBT) increases disease-free survival at one year compared to BCG in combination with placebo.<wbr> The blinded, randomized placebo-controlled study will enroll approximately 75 patients.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10072">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-10-29T16:24:28+01:00</dc:date><dc:creator>jew60237</dc:creator></item><item>
<title>re: Take Home Messages from the Aesthetic &amp; Anti-Aging Medicine European Congress (Oct.24-25)</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7792</link>
<description>re: Take Home Messages from the Aesthetic &amp; Anti-Aging Medicine European Congress (Oct.24-25)</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7792</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7792">re: Take Home Messages from the Aesthetic & Anti-Aging Medicine European Congress (Oct.<wbr>24-25)</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7792">Neurology7792</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/283">brv82696</a> | 29 October 2014 | 14:19</font><br><br><div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Take Home Messages from the Aesthetic & Anti-Aging Medicine European Congress (Oct.<wbr>24-25)</span>&nbsp;<font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20141231&edate=20140901&cat=class%3aBotulinumToxins"><font color="#e95e0b">:Neurology:class:BotulinumToxins</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20141231&edate=20140901&cat=comp%3aMerz"><font color="#e95e0b">:Neurology:comp:Merz</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20141231&edate=20140901&cat=dis%3aHyperhydrosis"><font color="#e95e0b">:Neurology:dis:Hyperhydrosis</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20141231&edate=20140901&cat=news"><font color="#e95e0b">:Neurology:news</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20141231&edate=20140901&cat=prod%3aXeomin"><font color="#e95e0b">:Neurology:prod:Xeomin</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20141231&edate=20140901&cat=sub%3aAesthetics"><font color="#e95e0b">:Neurology:sub:Aesthetics</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=congress%3aOTHERS"><font color="#e95e0b">:PharmaWorld:congress:OTHERS</font></a>]</font></font><br><span style="font-size: 12px;">Comment: Following to the success of the 1st AMEC launched last year in Paris, the second edition listed over 130 leading companies, and gathered 170 experienced international experts and speakers.<wbr> We have attended Merz symposium focused on the Russian consensus on Incobotulinum toxin, as well as a session on neuromodulators during which Michael Kane (plastic surgeon) provided new findings on Revance's drugs.<wbr> For the injectable RT-002 (GL) he outlined 6-month improvement data, and for RT-001 (migraine) change in HIT-6 score at week 4.<wbr> Updated with recent publications, W Philipp-Dormston (director of Cologne Dermatology) highlighted the safety/<wbr>effectiveness of Botox for axillary hyperhidrosis.<wbr> Answering a question from the audience, Doris Day (MD, dermatologist) outlined that for tear troughs she uses in a same vial a mix of 10U of botulinum toxin and hyaluronic acid filler to obain nicer results and soft diffusion.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7787">...</a><br><font size="-1">Brigitte DESCHAMPS / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7787" class="commentpermalink">Neurology7787</a> / <span class="date">28 October 2014</span> /
<span class="time">11:52:56 o'clock CET</span>
</font></div><div>RT002 is a liquid formulation of Botulinum Neurotoxin type A.<wbr> The studied indication is glabellar lines.<wbr> </div><!-- Comment details --><font size="-1">brv82696 / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7792" class="commentpermalink">Neurology7792</a> / <span class="date">29 October 2014</span> /
<span class="time">14:19:11 o'clock CET</span>
</font><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7792">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7787">View thread  Neurology7787: Take Home Messages from the Aesthetic & Anti-Aging Medicine European Congress (Oct.<wbr>24-25)</a>]]></content:encoded><dc:date>2014-10-29T14:19:11+01:00</dc:date><dc:creator>brv82696</dc:creator></item><item>
<title>Novartis Q3 Webcast Focuses On New Product Growth &amp; Transformational Change</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7843</link>
<description>Novartis Q3 Webcast Focuses On New Product Growth &amp; Transformational Change</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7843</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20141231&edate=20140901&rec=7843">Novartis Q3 Webcast Focuses On New Product Growth & Transformational Change</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7843">Endocrinology7843</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 28 October 2014 | 21:53</font><br><br><div style="margin-bottom: 10px;">Comment: Strong Sandostatin Q3 sales ($433 +9% c.<wbr>c versus 6% for the nine months) and the first time disclosure of Afinitor's pNET performance were notable points of relevance, with management also emphasising the new overall survival data from the RADIANT-3 study (released last month at ESMO).<wbr> FDA action on Signifor for acromegaly is still expected before the year-end whilst planned filings still refer to an Afinitor submission for non-functioning Lung &amp; GI NET in 2015 based on yet to be disclosed RADIANT-4 data.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Transformation Continues</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7843/6/ScreenCapture6.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">Group Performance </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7843/7/ScreenCapture7.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7843/3/ScreenCapture3.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7843/4/ScreenCapture4.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7843/8/ScreenCapture8.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7843/5/ScreenCapture5.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7843/9/ScreenCapture9.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">Commenting on this slide management noted that "Aftinitor is growing nicely, and in fact there are multiple sources of growth even beyond breast cancer.<wbr> For example, you can now see that even a small indication or orphan indication like pancreatic neuroendocrine tumor now represents 10% of the sales ($40m).<wbr> We recently showed overall survival benefit in this indication of more than 3.<wbr>5 years, which means over time this indication will become more important for the brand".<wbr> (see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20141231&edate=20140901&rec=7821" class="defaultlink">Endocrinology7821: ESMO Intelligence - Novartis's Activities At ESMO</a>) </div><div style="margin-bottom: 10px;"><P style="margin: 0cm 0cm 0pt;"><SPAN lang="EN-US" style="color: #0a0a0a; font-family: 'Trebuchet MS','sans-serif'; font-size: 9.5pt; mso-ansi-language: EN-US;">In fact the word benefit is misleading as the OS is 3.<wbr>5 years (44) with Afinitor but 37.<wbr>7 with placebo so everolimus showed a clinically ( but not statistically) longer median OS than placebo of 6.<wbr>3 months ( and not 3.<wbr>5 years benefit)</SPAN></P> </div><div style="margin-bottom: 10px;"><STRONG>Key R&amp;D Achievements</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7843/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7843/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7843/10/ScreenCapture10.jpg?user-agent=rss"> </div><div><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7843/11/ScreenCapture11.jpg?user-agent=rss"> </div><!-- Comment details --><a name="endocrinology7843attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7843/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(67,9 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7843/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(92,1 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7843/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(86,6 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7843/4/ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(98,3 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7843/5/ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(86,4 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7843/6/ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(83,2 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7843/7/ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(82,9 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7843/8/ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(74,7 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7843/9/ScreenCapture9.jpg">ScreenCapture9.jpg</a>&nbsp;&nbsp;(84,2 KB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7843/10/ScreenCapture10.jpg">ScreenCapture10.jpg</a>&nbsp;&nbsp;(100,4 KB)<br>&nbsp;&nbsp;11.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7843/11/ScreenCapture11.jpg">ScreenCapture11.jpg</a>&nbsp;&nbsp;(158,2 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20141231&edate=20140901&rec=7843">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-10-28T21:53:53+01:00</dc:date><dc:creator>jac89886</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7843/1/ScreenCapture1.jpg" length="69546" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7843/2/ScreenCapture2.jpg" length="94327" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7843/3/ScreenCapture3.jpg" length="88709" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7843/4/ScreenCapture4.jpg" length="100623" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7843/5/ScreenCapture5.jpg" length="88495" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7843/6/ScreenCapture6.jpg" length="85154" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7843/7/ScreenCapture7.jpg" length="84903" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7843/8/ScreenCapture8.jpg" length="76511" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7843/9/ScreenCapture9.jpg" length="86195" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7843/10/ScreenCapture10.jpg" length="102777" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7843/11/ScreenCapture11.jpg" length="162009" type="image/jpeg"/></item><item>
<title>Real Life Assessment of Pentasa (mesalazine) as UC Treatment [dis:IBD, :Endocrinology:comp:Ferring, :PharmaWorld:sub:ClinicalTrial, news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2101</link>
<description>Real Life Assessment of Pentasa (mesalazine) as UC Treatment [dis:IBD, :Endocrinology:comp:Ferring, :PharmaWorld:sub:ClinicalTrial, news]</description><category>dis:IBD</category><category>comp:Ferring</category><category>sub:ClinicalTrial</category><category>news</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2101</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2101">Real Life Assessment of Pentasa (mesalazine) as UC Treatment</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20141231&edate=20140901&cat=comp%3aFerring"><font color="#e95e0b">:Endocrinology:comp:Ferring</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20141231&edate=20140901&cat=dis%3aIBD"><font color="#e95e0b">:GastroEnterology:dis:IBD</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20141231&edate=20140901&cat=news"><font color="#e95e0b">:GastroEnterology:news</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=sub%3aClinicalTrial"><font color="#e95e0b">:PharmaWorld:sub:ClinicalTrial</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2101">GastroEnterology2101</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 28 October 2014 | 18:27</font><br><br><div style="margin-bottom: 10px;">Comment: The aims of the IMACT study, sponsored by Ferring, will be to assess how mesalazine is used in clinical practice, at which doses and for how long and how these differences impact the patient disease state and work productivity.<wbr> PE will measure time to dose reduction.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Trial Details</STRONG> </div><div style="margin-bottom: 10px;">Reference: <a href="http://clinicaltrials.gov/ct2/show/NCT02261636?recr=Open&no_unk=Y&fund=2&rcv_s=09%2F28%2F2014&rank=157" class="defaultlink">NCT02261636</a> </div><div style="margin-bottom: 10px;">Recruitment approx 250 out-patient clinics in the Netherlands </div><div style="margin-bottom: 10px;"><UL><LI>Patients with mild to moderate active ulcerative colitis with disease extension beyond the rectum (&ge; 10 cm) who will receive oral Pentasa treatment (Compact sachets and/<wbr>or tablets) for the treatment of the current active episode or in whom on oral Pentasa maintenance treatment induction of remission treatment will be initiated by dose escalation.<wbr> 
</LI>
<LI>Treatment combined with Pentasa enema (1g/<wbr>100ml) is allowed
</LI>
</UL> </div><div>Timelines: Planned to start this month; final data collection date for PE in January 2017 </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2101">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-10-28T18:27:58+01:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>A Registry for NETs in the USA [dis:BronchioNET, dis:pNET, :PharmaWorld:sub:ClinicalTrial, :PharmaWorld:mkt:NorthAmerica]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7842</link>
<description>A Registry for NETs in the USA [dis:BronchioNET, dis:pNET, :PharmaWorld:sub:ClinicalTrial, :PharmaWorld:mkt:NorthAmerica]</description><category>dis:BronchioNET</category><category>dis:pNET</category><category>sub:ClinicalTrial</category><category>mkt:NorthAmerica</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7842</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20141231&edate=20140901&rec=7842">A Registry for NETs in the USA</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20141231&edate=20140901&cat=dis%3aBronchioNET"><font color="#e95e0b">:Endocrinology:dis:BronchioNET</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20141231&edate=20140901&cat=dis%3apNET"><font color="#e95e0b">:Endocrinology:dis:pNET</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=mkt%3aNorthAmerica"><font color="#e95e0b">:PharmaWorld:mkt:NorthAmerica</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=sub%3aClinicalTrial"><font color="#e95e0b">:PharmaWorld:sub:ClinicalTrial</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7842">Endocrinology7842</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 28 October 2014 | 18:12</font><br><br><div style="margin-bottom: 10px;">Comment: The RegisterNET registry aims at collecting data and blood samples from approx 500 patients presenting with a histologically confirmed diagnosis of a neuroendocrine tumour, gastroenteropancreatic and pulmonary, in the USA.<wbr> The primary objectives of the project are to monitor patients with NETs, provide descriptive statistical analyses and assessment of diagnostic accuracy of molecular-based blood tests.<wbr> Wren Laboratories, a Connecticut-based company, will be sponsoring the project.<wbr> </div><div style="margin-bottom: 10px;"><SPAN style="text-decoration: underline;">Pupose</SPAN> </div><div style="margin-bottom: 10px;">Data will be entered prospectively and anonymized after informed consent.<wbr> All physicians who treat neuroendocrine tumor patients are invited to participate to the registry.<wbr> </div><div style="margin-bottom: 10px;">Data will be evaluated within regular time frames, focusing on diagnostic accuracy for biomarkers in the different types and grades of tumors, treatment modalities and patient outcomes (e.<wbr>g.<wbr> disease recurrence and survival), thereby contributing to an understanding of the role of biomarkers in tumor management.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Trial Details</STRONG> </div><div style="margin-bottom: 10px;">Reference: <a href="http://clinicaltrials.gov/ct2/show/NCT02270567?recr=Open&no_unk=Y&fund=2&rcv_s=09%2F28%2F2014&rank=59" class="defaultlink">NCT02270567</a> </div><div style="margin-bottom: 10px;">Timelines: Start date: Oct 2014 /<wbr> completion Sept 2019 /<wbr> March 2020 </div><div><STRONG>Wren</STRONG> has developed a molecular biomarker test called the NETest that trends the proliferation of NETs prior to tumor(s) showing up on imaging.<wbr> The NETest can accurately illustrate NETs cell activity in a proactive fashion, empowering the physician and patient to determine the efficacy/<wbr>inadequacy of the patient&rsquo;s current therapies.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20141231&edate=20140901&rec=7842">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-10-28T18:12:48+01:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Receptos' UC Drug (RPC1063) Meets Primary Efficacy and All Secondary Endpoints [dis:IBD, :PharmaWorld:sub:ClinicalTrial]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2097</link>
<description>Receptos' UC Drug (RPC1063) Meets Primary Efficacy and All Secondary Endpoints [dis:IBD, :PharmaWorld:sub:ClinicalTrial]</description><category>dis:IBD</category><category>sub:ClinicalTrial</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2097</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2097">Receptos' UC Drug (RPC1063) Meets Primary Efficacy and All Secondary Endpoints</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20141231&edate=20140901&cat=dis%3aIBD"><font color="#e95e0b">:GastroEnterology:dis:IBD</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=sub%3aClinicalTrial"><font color="#e95e0b">:PharmaWorld:sub:ClinicalTrial</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2097">GastroEnterology2097</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 28 October 2014 | 15:52</font><br><br><div style="margin-bottom: 10px;">Comment: During the Ph2 study, 16.<wbr>4% patients treated in the 1 mg dose group met the main goal of clinical remission at the eighth week, compared with 6.<wbr>2% in the placebo group.<wbr> Of note, this is numerically superior to what was observed in Humira's Ph3 (16.<wbr>5%/<wbr>9.<wbr>3%), and only slightly less than Simponi (17.<wbr>8%/<wbr>6.<wbr>4%) and vedolizumab (16.<wbr>9%/<wbr>5.<wbr>4%).<wbr> Clinical response rates were also very impressive, at 58.<wbr>2% vs.<wbr> 36.<wbr>39% for placebo, and compare favorably to drugs currently approved for UC.<wbr> Next year, Receptos plans to initiate Ph3 program in ulcerative colitis and Ph2 program in Crohn's disease.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Partnership Discussion During Conference Call</FONT></STRONG> </div><div style="margin-bottom: 10px;">Management held a conf call to discuss the positive Ph2 results in UC.<wbr> The strong results obtained in UC should attract large pharma interest, and when it comes to potential partnership Faheem Hasnain (President &amp; CEO) highlighted: </div><div style="margin-bottom: 10px;">' .<wbr>.<wbr>.<wbr>So clearly, I mean this data does give us more options to consider and we're going to take some time, to really think about those options, this is really a great opportunity for us to just step back and actually think about strategy going forward, thinking about the choices that we've got available to us.<wbr> There's no question that one can assume that given this data now broadens potentially interested parties, but as I said, we really need to kind of think through our strategy as we go forward in terms of what has the opportunity to create the best value proposition for the Company.<wbr> So we're in a better place than we were yesterday.<wbr> I think that's pretty fair to assume and it does broaden the cadre of potential partners.<wbr> But over the next month, weeks and month, we will think about choices and how we evaluate those choices".<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Trial Design</FONT></STRONG> </div><div style="margin-bottom: 10px;">Reference: NCT01647516 </div><div style="margin-bottom: 10px;">TOUCHSTONE is a randomized, double-blind, placebo-controlled Phase 2 trial investigating the effect of two orally administered doses of RPC1063 versus placebo in patients with moderately to severely active ulcerative colitis.<wbr> The study consists of an 8-week induction period and a 24-week maintenance period </div><div style="margin-bottom: 10px;">Primary Endpoint: remission </div><div style="margin-bottom: 10px;">Recruitment: 199 patients </div><div style="margin-bottom: 10px;"><UL><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Ulcerative colitis (UC) confirmed on endoscopy</LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Moderately to severely active UC (Mayo score 6-12)</LI>
</UL> </div><div style="margin-bottom: 10px;">Location: 88 study locations (57 sites in <LOCATION value="LB/nam">North America</LOCATION>, <LOCATION value="LR/eur">Europe</LOCATION> and <LOCATION value="LR/asp">Asia Pacific)</LOCATION>.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Drug Profile</FONT></STRONG> </div><div style="margin-bottom: 10px;">RPC1063, is a sphingosine 1-phosphate 1 receptor (S1P1R) small molecule modulator candidate.<wbr> </div><div><EM>Sources: Receptos PR; ThomsonOne; clinicaltrials.<wbr>gov</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2097">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-10-28T15:52:17+01:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>MOVIPREP® Approved in Russia [sub:CRCPrevention, headline, :PharmaWorld:mkt:Russia]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2095</link>
<description>MOVIPREP® Approved in Russia [sub:CRCPrevention, headline, :PharmaWorld:mkt:Russia]</description><category>sub:CRCPrevention</category><category>headline</category><category>mkt:Russia</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2095</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2095">MOVIPREP® Approved in Russia</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20141231&edate=20140901&cat=headline"><font color="#e95e0b">:GastroEnterology:headline</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20141231&edate=20140901&cat=sub%3aCRCPrevention"><font color="#e95e0b">:GastroEnterology:sub:CRCPrevention</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=mkt%3aRussia"><font color="#e95e0b">:PharmaWorld:mkt:Russia</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2095">GastroEnterology2095</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 28 October 2014 | 14:08</font><br><br><div style="margin-bottom: 10px;">Comment: Takeda (Norgine partner) has received approval for bowel cleansing prior to any clinical procedures requiring a clean bowel.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Business Development</FONT></STRONG> </div><div style="margin-bottom: 10px;">MOVIPREP® is available in EU through Norgine’s own infrastructure.<wbr> </div><div style="margin-bottom: 10px;">In Eastern Europe (Valeant), the US (Salix), India (Modi-Mundipharma), Japan (Ajinimoto) and Canada (Medical Futures) via partners.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>In 2011</STRONG>, Takeda acquired the commercialisation rights for MOVIPREP<SUP>® </SUP>for the Russian Federation and the Commonwealth of Independent States (CIS).<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">MOVIPREP® Opportunities</FONT></STRONG> </div><div style="margin-bottom: 10px;">According to the company website, partners are sought <EM>for </EM>MOVIPREP® in Latin America and China </div><div><EM>Source: Norgine PR</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2095">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-10-28T14:08:43+01:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>re: Update on Arno's Trial with Onapristone for Advanced CRPC</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology10069</link>
<description>re: Update on Arno's Trial with Onapristone for Advanced CRPC</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology10069</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10069">re: Update on Arno's Trial with Onapristone for Advanced CRPC</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10069">Oncology10069</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/994">Jenny Wu</a> | 28 October 2014 | 12:12</font><br><br><div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Update on Arno's Trial with Onapristone for Advanced CRPC</span>&nbsp;<font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a>]</font></font><br><span style="font-size: 12px;">Comment: After approval of an Invstigational Medicinal Product Dossier from the UK Health Authority, Medicines and Healthcare products Regulatory Agency, the company yesterday announced the enrollment of the first patient in a Ph1/<wbr>2 trial.<wbr> A CRO has been engaged, and additional UK sites planned.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=9589">...</a><br><font size="-1">Brigitte DESCHAMPS / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9589" class="commentpermalink">Oncology9589</a> / <span class="date">08 April 2014</span> /
<span class="time">12:13:10 o'clock CEST</span>
</font></div><div style="margin-bottom: 10px;">Comment: Arno Therapeutics, Inc.<wbr>, presented data from its ongoing Phase I/<wbr>II clinical trial (NCT02049190) evaluating investigational lead compound onapristone in men with advanced castration-resistant prostate cancer (CRPC) after failure of abiraterone or enzalutamide at the 21st Annual Prostate Cancer Foundation (PCF) Scientific Retreat, being held October 23-25, 2014 at the La Costa Hotel in Carlsbad, California.<wbr> The randomized, open-label Phase I/<wbr>II trial is evaluating onapristone in extended-release tablet formulations in up to five dose levels (10-50 mg BID) in patients with advanced CRPC.<wbr> </div><div style="margin-bottom: 10px;">The study is being conducted in two stages, with an expansion component; the first stage evaluates dose selection and the second will expand the number of patients at the determined recommended Phase II dose (RP2D) to confirm the safety profile and provide a preliminary assessment of anti-tumour activity.<wbr> The DRC has approved the study to proceed to the escalation portion of stage 1 and has opened the next three dosing levels, evaluating onapristone at 30, 40 or 50 mg BID with six randomized patients per cohort.<wbr> In addition, the APR diagnostic method is being refined and will be used for selective biomarker-driven patient enrichment by way of a design that guarantees greater than 75% of patients at the RP2D are biomarker-positive.<wbr> </div><div style="margin-bottom: 10px;">In stage 1, researchers randomized patients at two dose levels at either 10 or 20 mg onapristone twice a day (BID) with three to six patients per cohort.<wbr> At baseline, researchers evaluated tumour biopsies of hormone-naive and castration-resistant study subjects for PR expression, which will support the companion diagnostic being developed to identify patients who are more likely to respond to onapristone.<wbr> As progesterone expression in prostate cancer has been reported to increase in CRPC specimens, the transcriptionally activated PR (APR) offers a potential biomarker target in advanced CRPC.<wbr> </div><div style="margin-bottom: 10px;"><SPAN style="text-decoration: underline;"><STRONG>Updated Data:</STRONG></SPAN> </div><div style="margin-bottom: 10px;">Of the CRPC specimens tested at baseline, 13 of 45 (28.<wbr>9%) demonstrated PR expression (measured as greater than 1% of cells tested expressing PR) and two of 45 (4.<wbr>4%) had strong PR expression (measured as greater than 50% of cells tested).<wbr> To date, 14 patients have been screened, of whom 11 have been enrolled and are being treated.<wbr> All patients are white males with a median age of 72 years (54--89), an ECOG score of 1, and a baseline prostate-specific antigen (PSA) showing high values (median of 141 ng/<wbr>dl).<wbr> No dose-limiting toxicities (DLTs) were identified at the first two dose-levels and no significant liver function test abnormalities were observed.<wbr> </div><div>Treatment-emergent adverse events (AEs) of greater than or equal to Grade 2 included fatigue (2 patients), constipation (2 patients), hyponatremia (low sodium level) and aggressive behaviour (1 patient), and Grade 4 central retinal artery occlusion, which occurred 14 days after treatment discontinuation (1 patient), but were all considered unrelated to onapristone.<wbr> Two serious adverse events were reported, but were both also considered unrelated to onapristone.<wbr> Six of 11 (55%) patients reported drug-related AEs, all Grade 1, with no discontinuations secondary to onapristone-related adverse events.<wbr> Pharmacokinetics (PK) of the drug also appeared dose proportional.<wbr> </div><!-- Comment details --><font size="-1">Jenny Wu / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10069" class="commentpermalink">Oncology10069</a> / <span class="date">28 October 2014</span> /
<span class="time">12:12:50 o'clock CET</span>
</font><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10069">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9589">View thread  Oncology9589: Update on Arno's Trial with Onapristone for Advanced CRPC</a>]]></content:encoded><dc:date>2014-10-28T12:12:50+01:00</dc:date><dc:creator>jew60237</dc:creator></item><item>
<title>Take Home Messages from the Aesthetic &amp; Anti-Aging Medicine European Congress (Oct.24-25) [class:BotulinumToxins, comp:Merz, prod:Xeomin, :PharmaWorld:congress:OTHERS, sub:Aesthetics, news, dis:Hyperhydrosis]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7787</link>
<description>Take Home Messages from the Aesthetic &amp; Anti-Aging Medicine European Congress (Oct.24-25) [class:BotulinumToxins, comp:Merz, prod:Xeomin, :PharmaWorld:congress:OTHERS, sub:Aesthetics, news, dis:Hyperhydrosis]</description><comments>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7787</comments><category>class:BotulinumToxins</category><category>comp:Merz</category><category>prod:Xeomin</category><category>congress:OTHERS</category><category>sub:Aesthetics</category><category>news</category><category>dis:Hyperhydrosis</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7787</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7787">Take Home Messages from the Aesthetic & Anti-Aging Medicine European Congress (Oct.<wbr>24-25)</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20141231&edate=20140901&cat=class%3aBotulinumToxins"><font color="#e95e0b">:Neurology:class:BotulinumToxins</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20141231&edate=20140901&cat=comp%3aMerz"><font color="#e95e0b">:Neurology:comp:Merz</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20141231&edate=20140901&cat=dis%3aHyperhydrosis"><font color="#e95e0b">:Neurology:dis:Hyperhydrosis</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20141231&edate=20140901&cat=news"><font color="#e95e0b">:Neurology:news</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20141231&edate=20140901&cat=prod%3aXeomin"><font color="#e95e0b">:Neurology:prod:Xeomin</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20141231&edate=20140901&cat=sub%3aAesthetics"><font color="#e95e0b">:Neurology:sub:Aesthetics</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=congress%3aOTHERS"><font color="#e95e0b">:PharmaWorld:congress:OTHERS</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7787">Neurology7787</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 28 October 2014 | 11:52</font><br><br><div style="margin-bottom: 10px;">Comment: Following to the success of the 1st AMEC launched last year in Paris, the second edition listed over 130 leading companies, and gathered 170 experienced international experts and speakers.<wbr> We have attended Merz symposium focused on the Russian consensus on Incobotulinum toxin, as well as a session on neuromodulators during which Michael Kane (plastic surgeon) provided new findings on Revance's drugs.<wbr> For the injectable RT-002 (GL) he outlined 6-month improvement data, and for RT-001 (migraine) change in HIT-6 score at week 4.<wbr> Updated with recent publications, W Philipp-Dormston (director of Cologne Dermatology) highlighted the safety/<wbr>effectiveness of Botox for axillary hyperhidrosis.<wbr> Answering a question from the audience, Doris Day (MD, dermatologist) outlined that for tear troughs she uses in a same vial a mix of 10U of botulinum toxin and hyaluronic acid filler to obain nicer results and soft diffusion.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">AMEC Figures</FONT></STRONG> </div><div style="margin-bottom: 10px;">Over 2000 participants representing 80 countries, 170 international speakers and over 130 exhibiting companies.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Revance's New Data</FONT></STRONG> </div><div style="margin-bottom: 10px;"><U>RT-002 For Glabellar Line</U> </div><div style="margin-bottom: 10px;">On top of the duration and safety data recently presented (indicating less spread and double duration vs Botox), M.<wbr> Kane provided new findings from the Ph1/<wbr>2 open-label, dose escalating, 4 cohort trial, showing GL severity scale at maximum frown <STRONG>at 6-month being 86% (1-point) and 29% (2-points).<wbr> </STRONG>Previous 1-month data showed 98% (1-point) and 67% (2-point).<wbr> </div><div style="margin-bottom: 10px;"><U>RT-001 For Migraine</U> </div><div style="margin-bottom: 10px;">He presented a new slide summarising the preliminary outcomes of the Ph1/<wbr>2 study, showing change in the HIT-6 score for RT-001 vs placebo, and compared to Botox's PREEMPT-1 and PREEMPT-2 studies.<wbr> </div><div style="margin-bottom: 10px;">In the Revance study, RT-001 has a -5.<wbr>4 change vs -2.<wbr>1 for placebo.<wbr> Comparing with the PREEMPT studies -4.<wbr>7 and -4.<wbr>9 vs -2.<wbr>4 for Botox.<wbr> </div><div style="margin-bottom: 10px;"><BLOCKQUOTE dir="ltr" style="margin-right: 0px;">
<P>At week 4, RT-001 shows greater change over placebo and Botox.<wbr></P>
</BLOCKQUOTE> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7787/7/ScreenCapture7.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Merz Symposium</FONT></STRONG> </div><div style="margin-bottom: 10px;">The first part, dedicated to the 'Russian consensus on incobotulinum toxin use in aesthetic medicine', was followed by live injection of diluted Radiesse as a new skin tightening technique.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Yana Yutskovskaya</STRONG> (MD, professor, head of department of dermatology and venereology and cosmetology of Pacific State U.<wbr> of Health Ministry of Russia) presented the perception of BT in Russia, new toxin on the Russian market and the expectations of patients.<wbr> </div><div style="margin-bottom: 10px;">The purpose of a consensus paper is 1/<wbr>to recommend safe and effective regimen of IncoBT treatment in aesthetics; 2/<wbr> to identify key techniques and injection points for Xeomin, and 3/<wbr> to develop a consensus expert opinion on the major factors effecting patient's satisfaction with botulinum toxin treatment.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7787/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><EM><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7787/3/ScreenCapture3.jpg?user-agent=rss"></EM> </div><div style="margin-bottom: 10px;"><UL><LI>Treatment effect and patient satisfaction are optimized when the dose is selected according to the types of muscle activity.<wbr>
</LI>
<LI>Standard doses recommended by experts should be used for the kinetic muscle type.<wbr>
</LI>
<LI>For the hyperkinetic muscle type, common for males, experts advise to inject a higher dose (at least by 1.<wbr>5 times).<wbr> Combination with fillers is recommended for the hypertonic muscle types.<wbr>
</LI>
<LI>Experts agreed that it is not necessary to reduce the dose of BoNT-A for the older patients, assuming that the type of muscle activity is more important than the patient age.<wbr>
</LI>
</UL> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7787/4/ScreenCapture4.jpg?user-agent=rss"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7787/5/ScreenCapture5.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7787/6/ScreenCapture6.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Botox for Axillary Hyperhidrosis</FONT></STRONG> </div><div style="margin-bottom: 10px;">Before the procedure, correct identification of the affected area is mandatory to avoid wastage of drug and neglect of target areas, and to enhance efficacy, as the hyperhidrotic location may not match the hairy axillary region.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7787/12/ScreenCapture12.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">Utilization of botulinum toxin, such as dilution and injection techniques, depends on medical experience and may have some variations, including methods to make the procedure as painless as possible.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7787/13/ScreenCapture13.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">W Philipp-Dormston outlined the <STRONG>Cologne approach</STRONG> for the treatment of axillary HH.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7787/11/ScreenCapture11.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">He then presented results from 2 studies; one showing <STRONG>Botox preference vs suction curettage</STRONG> (the cheapest procedure), and another one comparing <STRONG>Botox with/<wbr>without lidocaine.<wbr></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>Trial</STRONG>: to compare effectiveness of suction currettage vs neurotoxin in 20 patients (randomized; received OnaBTX injections to one axilla and suction-curettage to the contralateral axilla).<wbr> PE: reduction of sweat rate measured by gravimetry </div><div style="margin-bottom: 10px;"><BLOCKQUOTE dir="ltr" style="margin-right: 0px;">
<P>- &gt;&gt; Findings: By objective measures 3 months after treatment, neurotoxin injections are nominally more effective than suction-curettage in all cases, and markedly more effective in heavy sweaters.<wbr> Patients have a very significant preference for neurotoxin injections at 3 months, and this is maintained at 6 months ( (<EM>J Am Acad Dermatol.<wbr> 2013 Jul;69(1):88-95. doi: 10.<wbr>1016/<wbr>j.<wbr>jaad.<wbr>2013.<wbr>02.<wbr>013.<wbr> Epub 2013 Apr 13</EM>).<wbr></P>
</BLOCKQUOTE> </div><div style="margin-bottom: 10px;"><STRONG>Trial</STRONG>: to compare the efficacy, safety and pain tolerance of lidocaine diluted BTX-A vs saline diluted BTX-A for the treatment of axillary HH in <STRONG>8</STRONG> patients injected with 50U of BTX-A diluted in 0.<wbr>5ml of saline and 1ml of 2% lidocaine onto one axilla and 50U of BTX-A diluted in 1.<wbr>5ml of saline into the other axilla in a randomized fashion </div><div><BLOCKQUOTE dir="ltr" style="margin-right: 0px;">
<P>- &gt;&gt; Findings: Botulinum toxin A diluted in lidocaine causes significantly less pain than BTX-A diluted in saline, whereas it is is equally effective and safe as the latter one in treating axillary hyperhidrosis.<wbr> Therefore, we suggest that lidocaine-diluted BTX-A may be a better treatment option for the patients with primary axillary hyperhidrosis (<EM>J Eur Acad Dermatol Venereol.<wbr> 2012 Mar;26(3):314-8. doi: 10.<wbr>1111/<wbr>j.<wbr>1468-3083.<wbr>2011.<wbr>04066.<wbr>x.<wbr> Epub 2011 Apr 15</EM>).<wbr></P>
</BLOCKQUOTE> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Neurology7792c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div>RT002 is a liquid formulation of Botulinum Neurotoxin type A.<wbr> The studied indication is glabellar lines.<wbr> </div><font size="-1">brv82696 / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7792" class="commentpermalink">Neurology7792</a> / <span class="date">29 October 2014</span> /
<span class="time">14:19:11 o'clock CET</span>
</font></div><a name="neurology7787attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7787/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(57,2 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7787/8/ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(88,6 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7787/9/ScreenCapture9.jpg">ScreenCapture9.jpg</a>&nbsp;&nbsp;(88,3 KB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7787/10/ScreenCapture10.jpg">ScreenCapture10.jpg</a>&nbsp;&nbsp;(57,1 KB)<br>&nbsp;&nbsp;14.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7787/14/ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(71,2 KB)<br>&nbsp;&nbsp;15.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7787/15/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(103,8 KB)<br>&nbsp;&nbsp;16.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7787/16/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(122,3 KB)<br>&nbsp;&nbsp;17.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7787/17/ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(102,5 KB)<br>&nbsp;&nbsp;18.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7787/18/ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(92,9 KB)<br>&nbsp;&nbsp;19.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7787/19/ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(105,7 KB)<br>&nbsp;&nbsp;20.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7787/20/ScreenCapture11.jpg">ScreenCapture11.jpg</a>&nbsp;&nbsp;(56,7 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7787">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-10-28T11:52:56+01:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7787/1/ScreenCapture1.jpg" length="58611" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7787/8/ScreenCapture8.jpg" length="90746" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7787/9/ScreenCapture9.jpg" length="90376" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7787/10/ScreenCapture10.jpg" length="58496" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7787/14/ScreenCapture7.jpg" length="72914" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7787/15/ScreenCapture2.jpg" length="106304" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7787/16/ScreenCapture3.jpg" length="125278" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7787/17/ScreenCapture4.jpg" length="104937" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7787/18/ScreenCapture5.jpg" length="95133" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7787/19/ScreenCapture6.jpg" length="108248" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7787/20/ScreenCapture11.jpg" length="58073" type="image/jpeg"/></item><item>
<title>NCCN Guideline Includes Prolaris® Diagnostic Test For Localized Prostate Cancer Patients [dis:Prostate, :PharmaWorld:mkt:NorthAmerica]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology10068</link>
<description>NCCN Guideline Includes Prolaris® Diagnostic Test For Localized Prostate Cancer Patients [dis:Prostate, :PharmaWorld:mkt:NorthAmerica]</description><category>dis:Prostate</category><category>mkt:NorthAmerica</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology10068</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10068">NCCN Guideline Includes Prolaris® Diagnostic Test For Localized Prostate Cancer Patients</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=mkt%3aNorthAmerica"><font color="#e95e0b">:PharmaWorld:mkt:NorthAmerica</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10068">Oncology10068</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/994">Jenny Wu</a> | 28 October 2014 | 10:57</font><br><br><div style="margin-bottom: 10px;">Comment: Myriad Genetics' Prolaris&reg; test is included in the updated NCCN guideline to help patients better assess their risk of disease specific mortality and biochemical recurrence.<wbr> This is based on the proven evidences in 7 peer-reviewed publications to identify men who can safely forgo initial surgery or radiation and be managed with active surveillance.<wbr> </div><div style="margin-bottom: 10px;">Prolaris&reg; is a novel 46-gene RNA-expression test.<wbr> The test measures tumour cell growth characteristics that could stratify the risk of disease progression in prostate cancer patients.<wbr> Prolaris&reg; provides a quantitative measure of the RNA expression levels of genes.<wbr> These gene are involved in the progression of tumor growth.<wbr> Low gene expression is associated with a low risk of disease progression in men who may be candidates for active surveillance and high gene expression is associated with a higher risk of disease progression in patients who may benefit from additional therapy.<wbr> </div><div style="margin-bottom: 10px;"><UL><LI>Proven and validated based on gold standard clinical endpoints of disease recurrence and prostate cancer-specific death in untreated men, thus identifying men who can safely forgo initial surgery or radiation and be managed with active surveillance;
</LI>
<LI>Proven in clinical utility studies to change treatment recommendations for up to 65% of prostate cancer patients in all risk categories, which may enhance adherence to recommended treatments; and
</LI>
<LI>To receive a draft local coverage determination (LCD) for Medicare reimbursement for low-risk patients on 17th Oct 2014.<wbr>
</LI>
</UL> </div><div>The LCD is posted to the Medicare Coverage Database on the Centers for Medicare &amp; Medicaid Services (CMS) website and establishes the coverage policy for Medicare beneficiaries.<wbr> The current language in the draft LCD provides reimbursement coverage for the approximately 50% of prostate cancer patients defined as low and very low risk.<wbr> Under Medicare rules, the draft LCD is subject to a minimum 45-day public comment period.<wbr>  After comments are considered, a final LCD is issued, which goes into effect after a minimum 45-day notification period - </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10068">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-10-28T10:57:18+01:00</dc:date><dc:creator>jew60237</dc:creator></item><item>
<title>Tactical Manoeuvres Continue As Allergan Reports A Strong Set Of Q3 Figures [comp:Allergan, dis:Migraine, dis:iOAB, dis:Spasticity]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7785</link>
<description>Tactical Manoeuvres Continue As Allergan Reports A Strong Set Of Q3 Figures [comp:Allergan, dis:Migraine, dis:iOAB, dis:Spasticity]</description><category>comp:Allergan</category><category>dis:Migraine</category><category>dis:iOAB</category><category>dis:Spasticity</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7785</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7785">Tactical Manoeuvres Continue As Allergan Reports A Strong Set Of Q3 Figures</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20141231&edate=20140901&cat=comp%3aAllergan"><font color="#e95e0b">:Neurology:comp:Allergan</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20141231&edate=20140901&cat=dis%3aiOAB"><font color="#e95e0b">:Neurology:dis:iOAB</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20141231&edate=20140901&cat=dis%3aMigraine"><font color="#e95e0b">:Neurology:dis:Migraine</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20141231&edate=20140901&cat=dis%3aSpasticity"><font color="#e95e0b">:Neurology:dis:Spasticity</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7785">Neurology7785</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 27 October 2014 | 18:54</font><br><br><div style="margin-bottom: 10px;">Comment:Trying to provide a distraction alongside Allergan's strong Q3 figures, Valeant issued a letter to the Board today stating it is prepared to potentially raise its offer to at least $200 per share compared to its current offer of $179.<wbr> However, interestingly it stopped short of doing so.<wbr> Meanwhile, David Pyott refused to comment either on this development or directly on the prospect of a counter move by Allergan, although he did outline the timeline should such an event be feasible.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Botox Performance</STRONG> </div><div style="margin-bottom: 10px;">Q3 sales increased year-over-year by 16.<wbr>0% in local currencies with double-digit growth in both the therapeutic and aesthetic categories, and by 15.<wbr>3% in dollars marking acceleration in trend as year to date growth stands at 13.<wbr>8% growth in local currencies and at 12.<wbr>7% and dollars.<wbr> In the U.<wbr>S.<wbr>, all key indications including chronic migraine, the two bladder conditions, and upper limb spasticity continued on their strong upswing, reportedly driven by high levels of injector training, practice support, and reimbursement programs.<wbr> </div><div style="margin-bottom: 10px;"><P class="pwrapper">Moreover patient awareness increased as a result of DTC advertising with commercials for chronic migraine running since the end of July for overactive bladder.<wbr></P> </div><div style="margin-bottom: 10px;"><P class="pwrapper">At the end of September, Merz increased the list price for XEOMIN therapeutic as well as cosmetic.<wbr> In Europe, despite tenders and mandated price decreases, Allergan claims to have grown the therapeutic category by double-digits, driven by the new indications for chronic migraine, bladder and the most recently improved indication of lower limb spasticity.<wbr></P> </div><div style="margin-bottom: 10px;"><P class="pwrapper"><STRONG>Recent Approvals</STRONG></P> </div><div style="margin-bottom: 10px;"><P class="pwrapper">The lower limb spasticity indication was recently launched in Germany and Scandinavia and since the last earnings call, overactive bladder was approved in Brazil, Venezuela, Singapore, Jordan, and Kuwait.<wbr></P> </div><div style="margin-bottom: 10px;"><P class="pwrapper"><STRONG>Aesthetic Performance</STRONG></P> </div><div style="margin-bottom: 10px;"><P class="pwrapper">Moving to the aesthetic side, Allergan estimates based on survey data suggest the U.<wbr>S.<wbr> market in Q3 grew around 10%, with BOTOX sales growth being further boosted by the 3% price increase posted in January.<wbr> BOTOX share in August, 2015 remained high, at over 77% with a point of share loss to competitors versus August, 2013 with more share gained by DYSPORT than XEOMIN.<wbr></P> </div><div style="margin-bottom: 10px;"><P class="pwrapper"><STRONG>Research &amp; Development</STRONG></P> </div><div style="margin-bottom: 10px;"><P class="pwrapper">The only key point of note regarding development candidates was that phase II studies with Botox for osteoarthritis and depression are recruiting well.<wbr></P> </div><div style="margin-bottom: 10px;"><P class="pwrapper"><STRONG>Acquisitions &amp; Valeant</STRONG></P> </div><div style="margin-bottom: 10px;"><P class="pwrapper">David Pyott declined to answer questions directly about whether Alelrgan is pursuing a "White Knight" as a defensive move to out-smart Valeant but did respond in an interesting manner to a question from Seamus Fernandez from Leerink.<wbr></P> </div><div style="margin-bottom: 10px;"><P class="pwrapper">Q: David, can you just give us your general thoughts a little bit more on the timeframe within which you believe an all-cash acquisition could be executed should you choose to find an asset that actually fits in that timeframe?</P> </div><div style="margin-bottom: 10px;"><P class="pwrapper">A: Yes, I think the way I would answer that is clearly if there were to be a transaction, it would have to be announced somewhere in the early part of December so that stockholders would have adequate time to assess how they gauge the value of that particular option.<wbr> I think also, as we've stated in the past, I should add another point which is should we not have announced the transaction, many stockholders have told us that they would then believe that we should go to, in their view, the second choice of the second preference, which would be to consider a stock repurchase program.<wbr> So I just want to make sure in the full balance that all of those options are on the table and are in the public view of all stockholders.<wbr></P> </div><div><P class="pwrapper">Source: <A href="http://www.allergan.com/">www.<wbr>allergan.<wbr>com</A></P> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7785">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-10-27T18:54:21+01:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>Ph2 Randomized Study To Evaluate Enzalutamide + Leuprolide +/- Abiraterone (With Prednisone) As Neoadjuvant Therapy [dis:Prostate]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology10066</link>
<description>Ph2 Randomized Study To Evaluate Enzalutamide + Leuprolide +/- Abiraterone (With Prednisone) As Neoadjuvant Therapy [dis:Prostate]</description><category>dis:Prostate</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology10066</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10066">Ph2 Randomized Study To Evaluate Enzalutamide + Leuprolide +/<wbr>- Abiraterone (With Prednisone) As Neoadjuvant Therapy</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10066">Oncology10066</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/994">Jenny Wu</a> | 27 October 2014 | 12:38</font><br><br><div style="margin-bottom: 10px;">Comment: A Phase 2 Randomized, Open label, uncontrolled, multicentre study of enzalutamide + leuprolide vs enzalutamide +leuprolide + abiraterone (with prednisone) is being evaluated as neoadjuvant therapy for high risk prostate cancer patients undergoing prostatectomy.<wbr> The study is estimated to run for 3 years and 8 months starting from Oct 2014.<wbr> </div><div style="margin-bottom: 10px;">This is a research study aimed to comparing the effectiveness of enzalutamide with or without abiraterone acetate for men with high-risk, localized prostate cancer.<wbr> The Principal Investigator is Dr.<wbr> Mary-Ellen Taplin (MD, Dana Farber Cancer Institute).<wbr> Currently there are only two centres involved in this study - Dana Farber Cancer Institute and Beth Israel Deaconess Medical Center (Principal Investigator: Glenn Bubley, MD).<wbr> </div><div style="margin-bottom: 10px;">Recruitment Status: Planned/<wbr>Not yet opened for recruitment </div><div style="margin-bottom: 10px;">ClinicalTrial.<wbr>Gov ID: NCT02268175 </div><div style="margin-bottom: 10px;">Study Design: </div><div style="margin-bottom: 10px;">Subjects will be randomized into two arms of 2:1 ratio.<wbr> </div><div style="margin-bottom: 10px;"><DIV>
<TABLE border="1" cellpadding="0" cellspacing="0" valign="top"><TBODY><TR><TD>&nbsp;</TD>
<TD>
<P>Type</P>
</TD>
<TD>
<P>Assigned Intervention</P>
</TD>
<TD>
<P>Description</P>
</TD>
</TR>
<TR><TD>
<P>Arm I</P>
</TD>
<TD>
<P>Experimental</P>
</TD>
<TD>
<P>Enzalutamide with Abiraterone, Prednisone and Leuprolide</P>
</TD>
<TD>
<P>Subjects will receive enzalutamide at a dose of 160mg (four 40mg capsules) orally once daily with abiraterone at a dose of 1000mg (four 250mg tablets) orally once daily, without food for at least two hours before the dose and for at least one hour after the dose, prednisone at a dose of 5mg orally once daily with food, preferred to be taken in the morning for 28 days (4 weeks) for maximum of 6 cycles and leuprolide at a dose of 7.<wbr>5mg monthly or 22.<wbr>5mg for every three months intramuscularly monthly or for every three months.<wbr></P>
</TD>
</TR>
<TR><TD>
<P>Arm II</P>
</TD>
<TD>
<P>Experimental</P>
</TD>
<TD>
<P>Enzalutamide and Leuprolide</P>
</TD>
<TD>
<P>Subjects will receive enzalutamide at a dose of 160mg (four 40mg capsules) orally once daily for 28 days (4 weeks) for maximum of 6 cycles and leuprolide at a dose of 7.<wbr>5mg monthly or 22.<wbr>5mg and leuprolide at a dose of 7.<wbr>5mg monthly or 22.<wbr>5mg for every three months intramuscularly monthly or for every three months.<wbr></P>
</TD>
</TR>
</TBODY>
</TABLE>
</DIV> </div><div style="margin-bottom: 10px;">Expected enrolment = 75 </div><div><DIV>
<TABLE border="0" cellpadding="0" cellspacing="0" valign="top"><TBODY><TR><TD>
<P>Estimated Start Date</P>
</TD>
<TD>
<P>01 Oct 2014</P>
</TD>
</TR>
<TR><TD>
<P>Estimated Completion Date</P>
</TD>
<TD>
<P>01 Jun 2018</P>
</TD>
</TR>
<TR><TD>&nbsp;</TD>
<TD>&nbsp;</TD>
</TR>
<TR><TD>
<P>Primary Objectives</P>
</TD>
<TD>
<UL><LI>
<UL><LI>Percentage of Participants with pCR and MRD - 2 Years
</LI>
<LI>Fisher's exact test
</LI>
</UL>

</LI>
</UL>
</TD>
</TR>
<TR><TD>
<P>Secondary Objectives</P>
</TD>
<TD>
<UL><LI>
<UL><LI>Percentage of participants with pCR at RP - 2 Years
</LI>
<LI>Percentage of Participants with favorable RCB at RB - 2 Years
</LI>
<LI>Percentage of Participants with cribriform or intraductal spread at RP - 2 Years
</LI>
<LI>Percentage of participants with positive surgical margins extracapsular extension, positive seminal vesicles, and positive lymph - 2 Years
</LI>
<LI>To evaluate the frequency of positive surgical margins, extracapsular extension, positive seminal vesicles, and positive lymph nodes at time of RP following treatment with ARM 1 compared to ARM 2
</LI>
<LI>Percentage of participants with PSA - Baseline, Day 169
</LI>
<LI>Time to biochemical recurrence - 2 Years
</LI>
</UL>
<UL><LI>Kaplan Meier method and comparison between arms will be conducted by the log-rank test
</LI>
</UL>
<UL><LI>Number of Participants with Serious and Non-Serious Adverse Events - 24 Weeks
</LI>
</UL>

</LI>
</UL>
</TD>
</TR>
</TBODY>
</TABLE>
</DIV> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10066">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-10-27T12:38:08+01:00</dc:date><dc:creator>jew60237</dc:creator></item><item>
<title>Ph2 Data Showed Progenics' PSMA Imaging Agent Could Provide A Better Prognostic Value Than MRI In Prostate Cancer [dis:Prostate]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology10064</link>
<description>Ph2 Data Showed Progenics' PSMA Imaging Agent Could Provide A Better Prognostic Value Than MRI In Prostate Cancer [dis:Prostate]</description><category>dis:Prostate</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology10064</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10064">Ph2 Data Showed Progenics' PSMA Imaging Agent Could Provide A Better Prognostic Value Than MRI In Prostate Cancer</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10064">Oncology10064</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/994">Jenny Wu</a> | 27 October 2014 | 12:10</font><br><br><div style="margin-bottom: 10px;"><P style="margin: 0in; font-family: arial; font-size: 9.75pt;">Comment: Phase 2 Data for Progenics' 1404 Imaging Agent was Presented at EANM Congress and trial data showed Trial Data Show 1404 More Sensitive Than MRI in Detecting Primary and Metastatic Prostate Cancer.<wbr> The Phase 1 and 2 Data Featured in Two Oral Presentations, Selected for Highlights Lecture.<wbr> The Phase 2 data are quite impressive and demonstrate how SPECT/<wbr>CT with 1404 may provide a more accurate assessment of the presence, location and extent of prostate cancer.<wbr> 1404 may provide prognostic information for both primary and metastatic disease in a single procedure, which could greatly enhance the clinical decision-making process.<wbr> The evidences presented support strong rationale for continued development of this promising molecular imaging agent in prostate cancer.<wbr></P> </div><div style="margin-bottom: 10px;"><P style="margin: 0in; font-family: arial; font-size: 9.75pt;">1404 is a developmental stage radiopharmaceutical imaging agent designed to highlight the expression of distinct proteins by diseased cells.<wbr> It is a targeted small molecule designed to "visualize" prostate cancer by targeting prostate specific membrane antigen (PSMA).<wbr> The image created provides the opportunity to "visualize cancer," potentially allowing for improved detection and staging, more precise biopsies, and a targeted treatment plan including active surveillance as a disease management tool.<wbr></P> </div><div style="margin-bottom: 10px;"><P style="margin: 0in; font-family: arial; font-size: 9.75pt;">Complete results from the Phase 2 trial in high-risk patients undergoing radical prostatectomy were presented by Gabriella Dabasi, Ph.<wbr>D.<wbr> of the Department of Nuclear Medicine at Semmelweis University in Budapest, Hungary.<wbr> Data related to the uptake of 1404 in the lobes of the prostate gland, and new data on the detection of metastatic prostate cancer in the lymph nodes using SPECT/<wbr>CT with 1404.<wbr></P> </div><div style="margin-bottom: 10px;"><P style="margin: 0in; font-family: arial; font-size: 9.75pt;">In the Phase 2 study, SPECT/<wbr>CT with 1404 showed superior diagnostic utility over traditional methods, with improved sensitivity compared to histopathology and increased accuracy compared to MRI.<wbr> In addition, imaging with 1404 detected lymph node involvement better than MRI.<wbr> SPECT/<wbr>CT imaging with 1404 showed 94% sensitivity in detecting and imaging cancer in the prostate gland of high-risk patients prior to prostatectomy.<wbr> In addition, 1404 was more sensitive than MRI in detecting primary prostate cancer (94% vs.<wbr> 86%) and was a good predictor of lymph node involvement at prostatectomy.<wbr> SPECT/<wbr>CT imaging with 1404 identified 14 (19%) more patients with suspicious lymph node sites than MRI.<wbr> Uptake of 1404 in the lobes of the prostate gland showed a highly significant correlation with Gleason score (p&lt;0.<wbr>0001).<wbr> The data also showed uptake of 1404 in the primary tumour was significantly lower in treated patients (p&lt;0.<wbr>0001), corresponding to a decrease in PSA over time observed in these treated patients.<wbr></P> </div><div><P style="margin: 0in; font-family: arial; font-size: 9.75pt;">Previously reported Ph1 results were also presented as part of another oral presentation by Professor Shankar Vallabhajosula, Ph.<wbr>D.<wbr>, of Weill Cornell Medical College in New York City.<wbr> A poster presented by Dr.<wbr> Julia Reinfelder from FAU Erlangen-N&uuml;rnberg, Germany, was featured during the Highlights Lecture at the EANM Closing Ceremonies on 22nd October.<wbr></P> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10064">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-10-27T12:10:32+01:00</dc:date><dc:creator>jew60237</dc:creator></item><item>
<title>KOL Impressed by Celgene's Mongersen Data for IBD</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2094</link>
<description>KOL Impressed by Celgene's Mongersen Data for IBD</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2094</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2094">KOL Impressed by Celgene's Mongersen Data for IBD</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2094">GastroEnterology2094</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 27 October 2014 | 10:28</font><br><br><div style="margin-bottom: 10px;">Comment: Leerink hosted a conference call with two MEDACorp IBD key opinion leaders to obtain their first reactions to the data.<wbr> Both KOLs were impressed by the results, which one of the KOLs called spectacular.<wbr> The drug has the potential to be a paradigm-changing drug for Crohn's disease and potentially other IBDs.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Efficacy @ 2 weeks</STRONG> </div><div style="margin-bottom: 10px;"><P align="left">For placebo and 10mg, 40mg, 160mg cohorts, remission (CDAI score &lt;150) was 21.<wbr>4/<wbr>14.<wbr>3/<wbr>21.<wbr>4%, 14.<wbr>6/<wbr>29.<wbr>3/<wbr>29.<wbr>3%, 57.<wbr>5/<wbr>70.<wbr>0/<wbr>62.<wbr>5%, 67.<wbr>4/<wbr>72.<wbr>1/<wbr>67.<wbr>4% at day 15, 28, and 84, respectively.<wbr></P> </div><div style="margin-bottom: 10px;"><P align="left">With only 2-week treatment, the KOLs were impressed by the remission rate &gt;60% at week 12.<wbr></P> </div><div style="margin-bottom: 10px;"><P align="left"><STRONG>KOL's Considerations for a Ph3 trial design</STRONG></P> </div><div style="margin-bottom: 10px;"><P align="left"><FONT face="Arial" size="2"><FONT face="Arial" size="2"><FONT face="Arial" size="2">The KOLs would target Phase III trials in a similar </FONT></FONT></FONT>population as the Phase II</P> </div><div style="margin-bottom: 10px;"><P align="left">Recruitment: TNF inhibitor na&iuml;ve is the right setting for positioning GED- 0301.<wbr> They would stratify patient population based on high/<wbr>low CRP and steroid co-treatment/<wbr>no treatment and would design a 3-arm study to compare efficacy of placebo, induction (e.<wbr>g.<wbr>, 2-week) treatment and continuous treatment.<wbr></P> </div><div style="margin-bottom: 10px;"><P align="left">Biomarkers : KOLs would like to include additional objective biomarkers for inflammation, such as fecal calprotectin, and would aim for data at 6-months and 12-months.<wbr></P> </div><div style="margin-bottom: 10px;"><P align="left">PE endpoint: KOLs are not certain CDAI will remain a feasible regulatory endpoint, and alternative primary endpoints include endoscopy, fecal calprotectin (as a true hard endpoint), and the Harvey Bradshaw Index (although it is not considered to be very good).<wbr> KOLs suggested that the FDA may be interested in some measures of clinical improvement.<wbr></P> </div><div style="margin-bottom: 10px;"><P align="left">They also consider patient reported outcomes to be important.<wbr> It was noted that patients with IBD have lack of control of bowel movement.<wbr> This has a severe impact on the QoL and cannot be reported by the indices.<wbr></P> </div><div><P align="left"><STRONG>Last Reference in Traction: Please see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2076" class="defaultlink">GastroEnterology2076: Results of Antisense Therapy for Active CD</a></STRONG></P> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2094">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-10-27T10:28:54+01:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Takeda Further Invests in Amitiza [dis:Constipation]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2091</link>
<description>Takeda Further Invests in Amitiza [dis:Constipation]</description><category>dis:Constipation</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2091</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2091">Takeda Further Invests in Amitiza</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20141231&edate=20140901&cat=dis%3aConstipation"><font color="#e95e0b">:GastroEnterology:dis:Constipation</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2091">GastroEnterology2091</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 27 October 2014 | 09:52</font><br><br><div style="margin-bottom: 10px;">Comment: Sucampo has entered into a global license with Takeda, which expands Takeda's rights beyond the U.<wbr>S.<wbr> and Canada to develop and commercialize Amitiza, in global markets (excluding Japan and China).<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Takeda Committment with Amitiza</STRONG> </div><div style="margin-bottom: 10px;">Ph3 ongoing in the US for a liquid formulation of lubiprostone, and for pediatric functional constipation.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Terms of the Agreement</STRONG> </div><div style="margin-bottom: 10px;"><OL><LI>The agreement includes a $14M upfront payment from Takeda and up to $35M in additional milestones based on achieving revenue targets.<wbr>
</LI>
<LI>Takeda will also be taking on development costs after the first $6M incurred by Sucampo.<wbr>
</LI>
</OL> </div><div style="margin-bottom: 10px;"><P align="left"><STRONG>Takeda Presentation @ the American College of Gastroenterology (ACG) Annual Meeting</STRONG></P> </div><div style="margin-bottom: 10px;"><P align="left">Takeda had a number of posters at ACG, such as an <SPAN style="text-decoration: underline;">analysis of Amitiza's impact on serum electrolytes</SPAN> (which can become unbalanced with laxative use) and markers of renal function in OIC and CIC, which indicated Amitiza did not affect either.<wbr></P> </div><div style="margin-bottom: 10px;"><P align="left"><STRONG>Drug Info</STRONG></P> </div><div style="margin-bottom: 10px;">AMITIZA (lubiprostone) is a prostone and is a locally acting chloride channel activator, indicated in the U.<wbr>S for the treatment of chronic idiopathic constipation (CIC) in adults and opioid-induced constipation (OIC) in adults with chronic, non-cancer pain (24 mcg twice daily).<wbr> </div><div>AMITIZA is also indicated in the U.<wbr>S.<wbr> for IBS-C (8 mcg twice daily) in women 18 years of age and older.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2091">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-10-27T09:52:03+01:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Astellas' XTANDI (enzalutamide) Capsules Receives Positive CHMP Opinion for Chemo Naive mCRPC [prod:MDV3100, dis:Prostate, comp:Astellas]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology10063</link>
<description>Astellas' XTANDI (enzalutamide) Capsules Receives Positive CHMP Opinion for Chemo Naive mCRPC [prod:MDV3100, dis:Prostate, comp:Astellas]</description><category>prod:MDV3100</category><category>dis:Prostate</category><category>comp:Astellas</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology10063</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10063">Astellas' XTANDI (enzalutamide) Capsules Receives Positive CHMP Opinion for Chemo Naive mCRPC</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=comp%3aAstellas"><font color="#e95e0b">:Oncology:comp:Astellas</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=prod%3aMDV3100"><font color="#e95e0b">:Oncology:prod:MDV3100</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10063">Oncology10063</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/994">Jenny Wu</a> | 24 October 2014 | 22:12</font><br><br><div style="margin-bottom: 10px;">Comment: Astellas Pharma Europe Ltd.<wbr> today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion recommending a variation to amend the Marketing Authorisation for enzalutamide.<wbr> The positive opinion relates to the use of enzalutamide for the treatment of adult men with metastatic castrate-resistant prostate cancer (mCRPC) who are asymptomatic or mildly symptomatic after failure of androgen-deprivation therapy in whom chemotherapy is not yet clinically indicated.<wbr> The final positive decision from CHMP is expected in one month time.<wbr> </div><div style="margin-bottom: 10px;">The positive CHMP opinion is based on results from the phase III PREVAIL study which showed that men treated with enzalutamide demonstrated a statistically significant reduction both in the risk of death and a delay in cancer progression and the time to initiation of chemotherapy as compared to those treated with placebo.<wbr> </div><div style="margin-bottom: 10px;">Enzalutamide reduced the risk of death by 29% (HR=0.<wbr>71; p&lt;0.<wbr>001), compared with placebo.<wbr> In addition, treatment with enzalutamide significantly reduced the risk of radiographic progression or death by 81% compared with placebo treatment (HR=0.<wbr>19; p&lt;0.<wbr>001).<wbr> Men taking enzalutamide experienced a 17-month delay in the time to initiation of chemotherapy compared with men taking placebo (28.<wbr>0 months versus 10.<wbr>8 months; HR=0.<wbr>35; p&lt;0.<wbr>0001) </div><div><UL><LI>For chemotherapy naive patients, enzalutamide demonstrated a significant impact on overall survival compared to placebo
</LI>
<LI>Enzalutamide reduced the risk of death by 29% versus placebo
</LI>
<LI>Enzalutamide significantly reduced the risk of radiographic progression or death by 81% compared with placebo
</LI>
<LI>Patients experienced delayed time to initiation of chemotherapy with enzalutamide compared with those taking placebo
</LI>
</UL> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10063">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-10-24T22:12:34+02:00</dc:date><dc:creator>jew60237</dc:creator></item><item>
<title>re: Xofigo Plant Contamination Stops Drug Manufacture &amp; Supply</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology10062</link>
<description>re: Xofigo Plant Contamination Stops Drug Manufacture &amp; Supply</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology10062</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10062">re: Xofigo Plant Contamination Stops Drug Manufacture & Supply</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10062">Oncology10062</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/994">Jenny Wu</a> | 24 October 2014 | 21:59</font><br><br><div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Xofigo Plant Contamination Stops Drug Manufacture & Supply</span>&nbsp;<font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=comp%3aBayerSchering"><font color="#e95e0b">:Oncology:comp:BayerSchering</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a>]</font></font><br><span style="font-size: 12px;">Comment: A problem has arisen with the manufacturing process for radium-223 
(Xofigo) necessitating that the plant where the drug is made in Norway be 
temporarily shut down.<wbr> The supply of Xofigo to the market seemingly ran out last 
Friday.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10040">...</a><br><font size="-1">Jacquelyne CANTLE MEYRICK / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10040" class="commentpermalink">Oncology10040</a> / <span class="date">14 October 2014</span> /
<span class="time">16:44:14 o'clock CEST</span>
</font></div><div>Comment: Bayer has issued an update on the shortage of Xofigo - although they are yet to provide a timeline when Xofigo's supply can be resumed, Bayer has examined available data from ALSYMPCA to understand the impact of treatment delays for patients.<wbr> In the ad hoc analysis of this trial, ~30% (n=178/<wbr>600) of patients had a delay in receiving radium 223.<wbr> Of these 178 patients, 56 patients had elays caused by an adverse event an the remaining 122 patients had delays caused by other reasons.<wbr> The exposure to a full course of 6 injections was similar regarless of whether patients experienced a delay.<wbr> In the statement, Bayer did caution around this is an unplanned sub group analysis.<wbr> </div><!-- Comment details --><font size="-1">Jenny Wu / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10062" class="commentpermalink">Oncology10062</a> / <span class="date">24 October 2014</span> /
<span class="time">21:59:59 o'clock CEST</span>
</font><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10062">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10040">View thread  Oncology10040: Xofigo Plant Contamination Stops Drug Manufacture & Supply</a>]]></content:encoded><dc:date>2014-10-24T21:59:59+02:00</dc:date><dc:creator>jew60237</dc:creator></item><item>
<title>re: Colon Capsule Maker to Raise $40-60M in IPO</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2090</link>
<description>re: Colon Capsule Maker to Raise $40-60M in IPO</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2090</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2090">re: Colon Capsule Maker to Raise $40-60M in IPO</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2090">GastroEnterology2090</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 24 October 2014 | 17:48</font><br><br><div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Colon Capsule Maker to Raise $40-60M in IPO</span>&nbsp;<font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20141231&edate=20140901&cat=sub%3aCRCPrevention"><font color="#e95e0b">:GastroEnterology:sub:CRCPrevention</font></a>]</font></font><br><span style="font-size: 12px;">Comment: Check-Cap's disposable capsules which relies on X-ray technology is expected to be approved in 2015 (EU/<wbr>US).<wbr> The X-ray Radar technology is designed to image only the colon interior through which it travels.<wbr> It is self-administered, non-invasive and<STRONG> does not require</STRONG> <STRONG>preparation</STRONG>.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2022">...</a><br><font size="-1">Brigitte DESCHAMPS / <a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2022" class="commentpermalink">GastroEnterology2022</a> / <span class="date">12 September 2014</span> /
<span class="time">14:36:08 o'clock CEST</span>
</font></div><div style="margin-bottom: 10px;">Check-Cap has announced the closing of a financing to support clinical development of the Check-Cap imaging system.<wbr>  The financing was led by Fosun Pharma, a leading Chinese healthcare company, joined by existing investors; General Electric Ventures, Pontifax, Docor, Counterpoint, together with MNS and several additional investors.<wbr> The Check-Cap imaging system requires <STRONG>no fasting or prior bowel cleansing</STRONG> as the imaging capsule employs X-rays for colon section measurements.<wbr> </div><div style="margin-bottom: 10px;">The X-rays are ultra-low dose (with radiation exposure approximating that of a single chest X-ray) and allow for 3-dimensional imaging of the lining of the colon even when the capsule is surrounded by intestinal content.<wbr> The ability to transmit a full 360-degree radius around the capsule is expected to allow for the detection of polyps including those located behind colon folds.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>About the Clinical Programs</STRONG> </div><div style="margin-bottom: 10px;">Check-Cap plans to expand its clinical program by launching a pivotal study in Europe and expects to submit a request for CE mark toward the end of 2015.<wbr> </div><div style="margin-bottom: 10px;">A pivotal study in the U.<wbr>S.<wbr> is planned subsequently.<wbr> </div><div>The company also intends to pursue regulatory approvals in China and Japan </div><!-- Comment details --><font size="-1">Brigitte DESCHAMPS / <a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2090" class="commentpermalink">GastroEnterology2090</a> / <span class="date">24 October 2014</span> /
<span class="time">17:48:29 o'clock CEST</span>
</font><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2090">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2022">View thread  GastroEnterology2022: Colon Capsule Maker to Raise $40-60M in IPO</a>]]></content:encoded><dc:date>2014-10-24T17:48:29+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Medivation Secures WW Rights for Cure Tech's Pidilizumab</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology10061</link>
<description>Medivation Secures WW Rights for Cure Tech's Pidilizumab</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology10061</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10061">Medivation Secures WW Rights for Cure Tech's Pidilizumab</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10061">Oncology10061</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 24 October 2014 | 17:33</font><br><br><div style="margin-bottom: 10px;">Comment: CT-011, or pidilizumab, targets the checkpoint molecule known as PD-1.<wbr> The PD-1 target is one of the hottest in the oncology sector today, as it has been implicated in the mechanism via which cancer cells mask their presence vis-&agrave;-vis the immune system.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Terms of the Agreement</STRONG> </div><div style="margin-bottom: 10px;">Medivation will be responsible for all development, regulatory and commercialization activities for pidilizumab for all indications, including oncology.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><SPAN style="font-family: Arial; font-size: 10pt;">Drug Development Programs</SPAN></STRONG> </div><div style="margin-bottom: 10px;"><SPAN style="font-family: Arial; font-size: 10pt;">A Phase II program has been initiated including 3 sponsored studies: the first, a Phase II clinical trial in patients with diffuse large B cell lymphoma has been completed.<wbr> Enrolment to 2 additional Phase II studies in patients with metastatic colorectal cancer and metastatic melanoma has been completed.<wbr> </SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-family: Arial; font-size: 10pt;">In addition to these 3 studies, several investigator-initiated studies in different indications including follicular lymphoma, multiple myeloma, AML, renal cell carcinoma, pancreatic cancer and prostate cancer are ongoing.<wbr></SPAN> </div><div><SPAN style="font-family: Arial; font-size: 10pt;">Source: Medivation; Cure Tech</SPAN> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10061">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-10-24T17:33:55+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Roche and NewLink Genetics' Entered an $1 Billion Deal To Develop A New Class Of Immunomodulation Agent - IDO Inhibitor [dis:Prostate]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology10057</link>
<description>Roche and NewLink Genetics' Entered an $1 Billion Deal To Develop A New Class Of Immunomodulation Agent - IDO Inhibitor [dis:Prostate]</description><category>dis:Prostate</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology10057</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10057">Roche and NewLink Genetics' Entered an $1 Billion Deal To Develop A New Class Of Immunomodulation Agent - IDO Inhibitor</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10057">Oncology10057</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/994">Jenny Wu</a> | 24 October 2014 | 13:15</font><br><br><div style="margin-bottom: 10px;">Comment: Under the agreement, Roche will develop a NewLink's candidate, NLG919, that is designed to disrupt the mechanism by which tumours evade the patients immune system.<wbr> Roche/<wbr> Genetech will fund future research, development, manufacturing and marketing costs related to NLG919.<wbr> NLG919 is an IDO inhibitor IDO pathway inhibitors are another class of immune check point inhibitors akin to the recently developed antibodies targeting CTLA-4, PD-1, and PD-L1 that represent potential breakthrough approaches to cancer therapy.<wbr> NLG919 is currently in Ph1 This agreement will allow NewLink to explore IDO pathway inhibitors further for wider oncology indications.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Terms of the Agreement</STRONG> </div><div style="margin-bottom: 10px;">NewLink will receive an upfront payment of $150 million.<wbr> NewLink will be eligible to receive in excess of $1 billion in milestone payments based on achievement of certain predetermined milestones as well as escalating double-digit royalties on potential commercial sales of multiple products by Genentech.<wbr>NewLink will retain the option for co-promotion rights for NLG919 and potential next generation IDO/<wbr>TDO compounds in the U.<wbr>S.<wbr> The completion of the agreement is subject to customary closing conditions, including clearance under the Hart-Scott-Rodino Antitrust Improvements Act.<wbr> </div><div style="margin-bottom: 10px;">NewLink's another lead IDO inhibitor - Indoximod - is currently being explored in combination with docetaxel in metastatic breast cancer and as follow-on therapy after sipuleucel-T treatment in metastatic CRPC.<wbr> The mCRPC trial is a Ph2 study currently still opens for patient recruitment (<a href="http://clinicaltrials.gov/ct2/show/NCT01560923?term=indoximod&rank=2" class="defaultlink">NCT01560923</a>).<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/10057/1/Indoximod%20mCRPC%20Trial%20design.JPG?user-agent=rss"> </div><div>source: NLG919 Abstract presented in AACR 2013- <a href="http://newlinkgenetics.com/assets/pdfs/AACR_2013_-_NLG919_and_Indoximod.pdf" class="defaultlink" title="http://newlinkgenetics.com/assets/pdfs/AACR_2013_-_NLG919_and_Indoximod.pdf">newlinkgenetics.c&hellip;</a> </div><!-- Comment details --><a name="oncology10057attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10057/1/Indoximod%20mCRPC%20Trial%20design.JPG">Indoximod mCRPC Trial design.JPG</a>&nbsp;&nbsp;(78,4 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10057">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-10-24T13:15:45+02:00</dc:date><dc:creator>jew60237</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10057/1/Indoximod%20mCRPC%20Trial%20design.JPG" length="80317" type="image/jpeg"/></item><item>
<title>Xtandi's Package Insert Is Changed In Japan To Reflect PH3 PREVAIL Data [comp:Astellas, prod:MDV3100, dis:Prostate, :PharmaWorld:mkt:Japan]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology10056</link>
<description>Xtandi's Package Insert Is Changed In Japan To Reflect PH3 PREVAIL Data [comp:Astellas, prod:MDV3100, dis:Prostate, :PharmaWorld:mkt:Japan]</description><category>comp:Astellas</category><category>prod:MDV3100</category><category>dis:Prostate</category><category>mkt:Japan</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology10056</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10056">Xtandi's Package Insert Is Changed In Japan To Reflect PH3 PREVAIL Data</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=comp%3aAstellas"><font color="#e95e0b">:Oncology:comp:Astellas</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=prod%3aMDV3100"><font color="#e95e0b">:Oncology:prod:MDV3100</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=mkt%3aJapan"><font color="#e95e0b">:PharmaWorld:mkt:Japan</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10056">Oncology10056</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/994">Jenny Wu</a> | 24 October 2014 | 12:23</font><br><br><div style="margin-bottom: 10px;">Comment: Astellas announced the revision of the package insert for Xtandi&reg; Capsules 40mg to reflect the results of the Ph3 PREVAIL trial in chemo na&iuml;ve setting.<wbr> &ldquo;The efficacy and safety of the drug have not been established in patients with prostate cancer who have not received chemotherapy&rdquo;, has been deleted from the &ldquo;Precautions regarding indication&rdquo; item.<wbr> Also, the items &ldquo;Side effects&rdquo; and &ldquo;Clinical results&rdquo; of the package insert have been revised.<wbr> In addition to the revisions, thrombocytopenia&rdquo; has been added to the &ldquo;Significant side effects&rdquo; in the &ldquo;Side effects&rdquo; item in accordance with Authorities' instruction.<wbr> </div><div style="margin-bottom: 10px;">The revision of the &ldquo;Precautions regarding indication&rdquo; item of the package insert triggers a $45 million milestone payment to Medivation under its collaboration agreement with Astellas.<wbr> </div><div>Source: <A href="http://www.astellas.com">www.<wbr>astellas.<wbr>com</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10056">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-10-24T12:23:14+02:00</dc:date><dc:creator>jew60237</dc:creator></item><item>
<title>re: Allergan Looks To Strengthen Its Botox Cosmetic Label</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7784</link>
<description>re: Allergan Looks To Strengthen Its Botox Cosmetic Label</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7784</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7784">re: Allergan Looks To Strengthen Its Botox Cosmetic Label</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7784">Neurology7784</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/283">brv82696</a> | 24 October 2014 | 10:15</font><br><br><div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Allergan Looks To Strengthen Its Botox Cosmetic Label</span>&nbsp;<font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20141231&edate=20140901&cat=prod%3aBotox"><font color="#e95e0b">:Neurology:prod:Botox</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20141231&edate=20140901&cat=sub%3aAesthetics"><font color="#e95e0b">:Neurology:sub:Aesthetics</font></a>]</font></font><br><span style="font-size: 12px;">Comment: Allergan has initiated two significant phIII trials aimed at 
extending its label for Botox Cosmetic to include the frontalis.<wbr> Together 
the trials will include1150 patients.<wbr> The studies are scheduled to start 
this month and complete in terms of PE in August 15 
and SE October 2016.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7774">...</a><br><font size="-1">Jacquelyne CANTLE MEYRICK / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7774" class="commentpermalink">Neurology7774</a> / <span class="date">16 October 2014</span> /
<span class="time">14:54:55 o'clock CEST</span>
</font></div><div>We will expect Botox/<wbr>Vistabel to get the "upper face" indication approved in 2017-2018 (Glabellar Lines, Lateral Canthal Lines and Frontalis Lines).<wbr> </div><!-- Comment details --><font size="-1">brv82696 / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7784" class="commentpermalink">Neurology7784</a> / <span class="date">24 October 2014</span> /
<span class="time">10:15:16 o'clock CEST</span>
</font><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7784">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7774">View thread  Neurology7774: Allergan Looks To Strengthen Its Botox Cosmetic Label</a>]]></content:encoded><dc:date>2014-10-24T10:15:16+02:00</dc:date><dc:creator>brv82696</dc:creator></item><item>
<title>Hutchison's Sulfatinib to Enter Ph1b in Advanced NETs [headline, :PharmaWorld:sub:ClinicalTrial]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7840</link>
<description>Hutchison's Sulfatinib to Enter Ph1b in Advanced NETs [headline, :PharmaWorld:sub:ClinicalTrial]</description><category>headline</category><category>sub:ClinicalTrial</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7840</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20141231&edate=20140901&rec=7840">Hutchison's Sulfatinib to Enter Ph1b in Advanced NETs</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20141231&edate=20140901&cat=headline"><font color="#e95e0b">:Endocrinology:headline</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=sub%3aClinicalTrial"><font color="#e95e0b">:PharmaWorld:sub:ClinicalTrial</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7840">Endocrinology7840</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 23 October 2014 | 16:53</font><br><br><div style="margin-bottom: 10px;">Comment: Hutchison MediPharma LTd has planned a Ph1b trial in China to evaluate safety, tolerability PK and preliminary efficacy of sulfatinib (300mg once a day on a 28-day cycle).<wbr> PE will measure safety (incidence and severity of AE/<wbr>SAEs).<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Trial Details</FONT></STRONG> </div><div style="margin-bottom: 10px;">Ref NCT02267967 </div><div style="margin-bottom: 10px;">Timelines: start date Oct 2014 /<wbr> commpletion Oct 2016 /<wbr> Dec 2017 </div><div style="margin-bottom: 10px;">Recruitment: approx.<wbr> 30 </div><div style="margin-bottom: 10px;"><UL><LI>patients with low- or intermediate-grade (G1 or G2) advanced NET who have failed in standard treatment or are unable to receive standard treatment.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;">Investigators will evaluate the clinical tumor response to Sulfatinib, and if investigators determine that the patient can benefit from the continuation of treatment, the patient will continue the Sulfatinib treatment.<wbr> </div><div style="margin-bottom: 10px;">The duration of study will be 2 years.<wbr> At the time of study completion, if investigators believe patients can continue to benefit from the investigational product, patients may be provided with Sulfatinib with the agreement of the sponsor </div><div style="margin-bottom: 10px;">Location Academy of Military Medical Affiliated Hopital </div><div style="margin-bottom: 10px;"><TR><TD colspan="2" nowrap="" style="PADDING-LEFT: 4em">Beijing, China, 100071</TD>
</TR> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Last reference in Traction</FONT></STRONG> please see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20141231&edate=20140901&rec=7753" class="defaultlink">Endocrinology7753: Phase Ib Study of HMPL-012 (Sulfatinib) in NETS</a> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Company Pipeline</FONT></STRONG> </div><div style="margin-bottom: 10px;">Novel oral compounds for cancer and inflammation in development in North America, Europe, Australia and China.<wbr> </div><div style="margin-bottom: 10px;">These products include: </div><div><UL><LI>a novel oral therapy for inflammatory bowel disease, which is Phase III for UC (ulcerative colitis) in the US &amp; Europe;</LI>
<LI>a novel oral selective c-Met inhibitor in phase II in Australia, China &amp; the United States; </LI>
<LI>four differentiated oral NCEs in oncology in Phase I &amp; Phase II in China; </LI>
<LI>one oral NCE for inflammation in Phase I in Australia.<wbr> </LI>
<LI>Multiple NCEs are also in preclinical development.<wbr></LI>
</UL> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20141231&edate=20140901&rec=7840">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-10-23T16:53:50+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>UEGW (Vienna) - Takeda Symposium [dis:IBD, :PharmaWorld:congress:UEGW]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2087</link>
<description>UEGW (Vienna) - Takeda Symposium [dis:IBD, :PharmaWorld:congress:UEGW]</description><category>dis:IBD</category><category>congress:UEGW</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2087</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2087">UEGW (Vienna) - Takeda Symposium</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20141231&edate=20140901&cat=dis%3aIBD"><font color="#e95e0b">:GastroEnterology:dis:IBD</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=congress%3aUEGW"><font color="#e95e0b">:PharmaWorld:congress:UEGW</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2087">GastroEnterology2087</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 23 October 2014 | 16:15</font><br><br><div style="margin-bottom: 10px;">Comment: In a fully attended symposium, a panel of experts presented new horizons in IBD therapy.<wbr> We have selected below slides from Silvio Danese (director of the Research and Therapy Center of Intestinal Diseases, Milan), which highlighted present and future treatment options.<wbr> In his presentation, he outlined that tofacinitib (Pfizer) and ustekinumab (Janssen) are among the drugs that have shown promise in late-stage trials.<wbr> He also stressed leucocyte adhesion and gut selectivity being key to therapeutic success.<wbr> Takeda's Entyvio (vedolizumab, a gut-selective humanized monoclonal antibody) clinical trial programs was largely detailed during his talk, and dissiminated during the congress through posters and free paper sessions.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">General Overview of Success and Failure in IBD</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2087/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Late-Stage Drug Pipeline</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2087/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG>Clinical Response of Tofacinitb for UC and Ustekinumab for CD</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2087/3/ScreenCapture3.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2087/4/ScreenCapture4.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Gut Selectivity</FONT></STRONG> </div><div style="margin-bottom: 10px;">Danese S, Panès J Gastroenterlogy 2014; epub 14 September (DOI:10.<wbr>1053/<wbr>j.<wbr>gastro.<wbr>2014.<wbr>08.<wbr>044) </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2087/5/ScreenCapture5.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2087/6/ScreenCapture6.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Vedolizumab (VDZ) References During the Congress</FONT></STRONG> </div><div style="margin-bottom: 10px;">LONG-TERM EFFICACY OF VEDOLIZUMAB THERAPY FOR CROHN'S DISEASE </div><div style="margin-bottom: 10px;"><UL><LI>The efficacy of VDZ observed in GEMINI 2 was maintained over the course of an additional 52 weeks in GEMINI LTS, regardless of TNF antagonist exposure prior to GEMINI 2</LI>
</UL> </div><div style="margin-bottom: 10px;">LONG-TERM EFFICACY OF VEDOLIZUMAB THERAPY FOR ULCERATIVE COLITIS </div><div style="margin-bottom: 10px;"><UL><LI>The efficacy of VDZ observed in GEMINI 1 was maintained for an additional 52 weeks in GEMINI LTS, regardless of previous TNF antagonist exposure</LI>
</UL> </div><div style="margin-bottom: 10px;">EFFECTS OF INCREASED VEDOLIZUMAB DOSING FREQUENCY ON DISEASE ACTIVITY IN ULCERATIVE COLITIS AND CROHN'S DISEASE </div><div style="margin-bottom: 10px;"><UL><LI>Patients who lost response to VDZ Q8W had improvements in mean disease activity scores with an increase in VDZ dosing frequency to Q4W without an apparent accompanying increased risk for AEs.<wbr> Although uncontrolled, these data provide insight regarding possible utility of VDZ Q4W dosing</LI>
</UL> </div><div style="margin-bottom: 10px;">SAFETY OF VEDOLIZUMAB <STRONG>ALONE OR WITH CONCOMITANT CORTICOSTEROIDS AND/<wbr>OR IMMUNOSUPPRESSANTS</STRONG> IN PATIENTS WITH ULCERATIVE COLITIS OR CROHN'S DISEASE </div><div style="margin-bottom: 10px;"><UL><LI>These data suggest that the infection AE and SAE profiles in patients with UC or CD are similar whether VDZ is used as monotherapy or with concomitant IM and/<wbr>or CS therapy.<wbr> Infection rates were generally similar among the VDZ and PBO groups, although length of exposure tended to be longer for VDZ than for PBO.<wbr> The rarity of individual infection SAEs limits the interpretation of these data.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;">DURABILITY OF CLINICAL REMISSION WITH VEDOLIZUMAB IN CROHN'S DISEASE </div><div style="margin-bottom: 10px;"><UL><LI>The definition of <EM>durable clinical remission</EM> has not been standardized.<wbr> These post hoc analyses of patients with CD, including those with previous TNF antagonist failure, showed that VDZ (vs PBO) led to durable clinical remission through wk 52 as defined by multiple clinically relevant alternative end points.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;">INDIRECT COMPARISON OF ADALIMUMAB AND VEDOLIZUMAB IN INFLAMMATORY BOWEL DISEASE IN THE UNITED KINGDOM: COST PER RESPONDER/<wbr>REMITTER ANALYSIS </div><div><UL><LI>Costs per responder and remitter in IBD in the UK were numerically lower for ADA-treated patients compared to VDZ-treated patients, indicating that ADA may have better economic value than VDZ in patients with IBD</LI>
</UL> </div><!-- Comment details --><a name="gastroenterology2087attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2087/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(107,2 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2087/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(83,6 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2087/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(90 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2087/4/ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(80,5 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2087/5/ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(116,2 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2087/6/ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(68,9 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2087">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-10-23T16:15:32+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2087/1/ScreenCapture1.jpg" length="109732" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2087/2/ScreenCapture2.jpg" length="85560" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2087/3/ScreenCapture3.jpg" length="92151" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2087/4/ScreenCapture4.jpg" length="82460" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2087/5/ScreenCapture5.jpg" length="118961" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2087/6/ScreenCapture6.jpg" length="70595" type="image/jpeg"/></item><item>
<title>UEGW (Vienna) - Probiotics in IBS [dis:IBS, sub:Probiotics, :PharmaWorld:congress:UEGW]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2086</link>
<description>UEGW (Vienna) - Probiotics in IBS [dis:IBS, sub:Probiotics, :PharmaWorld:congress:UEGW]</description><category>dis:IBS</category><category>sub:Probiotics</category><category>congress:UEGW</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2086</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2086">UEGW (Vienna) - Probiotics in IBS</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20141231&edate=20140901&cat=dis%3aIBS"><font color="#e95e0b">:GastroEnterology:dis:IBS</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20141231&edate=20140901&cat=sub%3aProbiotics"><font color="#e95e0b">:GastroEnterology:sub:Probiotics</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=congress%3aUEGW"><font color="#e95e0b">:PharmaWorld:congress:UEGW</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2086">GastroEnterology2086</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 23 October 2014 | 14:58</font><br><br><div style="margin-bottom: 10px;">Comment: Viola Andresen (Israelitisches Krankenhaus, Hamburg) started the second part of her talk highligthing significant benefit for VSl#3 on bloating, and that bifidobacterium infantis 35624 seems to be the best probiotic in IBS.<wbr> In the second part, she presented meta-analyses which suggest significant, moderate superiority of probiotics in IBS.<wbr> Although data are conflicting and effects not consistent across studies, she oultined that the overall probiotic concept is promising in this setting.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Significant Benefit for VSL#3 on Bloating in IBS</FONT></STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>Kim HJ et al, Neurogastroenterol Motil 2005;17:687-96</LI>
</UL> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2086/5/ScreenCapture5.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Bifidobacterium infantis 35624 in IBS</FONT></STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>Whorwell PJ, et al, Am J gastroenterol 2006;101:1581-1590</LI>
</UL> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2086/6/ScreenCapture6.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">The FU study with the <STRONG>same</STRONG> bifidobacterium infantis 35624, but in a <STRONG>much larger</STRONG> sample, only showed efficacy in a lower dose.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Use of Probiotics in IBS Most recent Meta Analyses</FONT></STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>Ford A.<wbr> et al, Am J Gastroenterol <STRONG>2014</STRONG>;109:1547-1561</LI>
</UL> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2086/3/ScreenCapture3.jpg?user-agent=rss"> <img src="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2086/4/ScreenCapture4.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Meta-analyses Probiotics for global IBS improvement</FONT></STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>Mc Farland LV et al, World J Gastroenterol 2008;14:2650-61</LI>
</UL> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2086/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><UL><LI>Moayyedi P et al, Gut 2010;59:325-32</LI>
</UL> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2086/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">In her conclusion</FONT></STRONG>, Dr Andresen highlighted that many open questions still remain: </div><div style="margin-bottom: 10px;"><UL><LI>Mechanism of action; duration, formulation, quantity</LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI>Short-term influence or long-term modulation</LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI>Which strains in which patients/<wbr>for which symptoms</LI>
</UL> </div><div><UL><LI>Individualized selection? based on personal microbiota ?</LI>
</UL> </div><!-- Comment details --><a name="gastroenterology2086attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2086/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(117,6 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2086/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(98,5 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2086/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(119,5 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2086/4/ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(118,7 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2086/5/ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(80,3 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2086/6/ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(93,2 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2086">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-10-23T14:58:05+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2086/1/ScreenCapture1.jpg" length="120400" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2086/2/ScreenCapture2.jpg" length="100869" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2086/3/ScreenCapture3.jpg" length="122388" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2086/4/ScreenCapture4.jpg" length="121562" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2086/5/ScreenCapture5.jpg" length="82190" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2086/6/ScreenCapture6.jpg" length="95483" type="image/jpeg"/></item><item>
<title>UEGW (Vienna) - Iron-Deficiency Anemia in IBS Patients [:PharmaWorld:congress:UEGW]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2083</link>
<description>UEGW (Vienna) - Iron-Deficiency Anemia in IBS Patients [:PharmaWorld:congress:UEGW]</description><category>congress:UEGW</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2083</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2083">UEGW (Vienna) - Iron-Deficiency Anemia in IBS Patients</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=congress%3aUEGW"><font color="#e95e0b">:PharmaWorld:congress:UEGW</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2083">GastroEnterology2083</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 23 October 2014 | 13:52</font><br><br><div style="margin-bottom: 10px;">Comment: Michael A Kamm (Professor of Gastroenterology at St Vincent's Hospital &amp; University of Melbourne Imperial College, London) presented Shield Therapeutics' ST10 (ferric maltol), a novel oral ferric iron for iron deficiency anemia(IDA) in IBD, the 'forgotten therapeutic need'.<wbr> Ph3 positive results provided confirmatory pivotal clinical data which will form the basis of a MAA submission to the European regulatory authorities during 2014.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Figures</FONT></STRONG> </div><div style="margin-bottom: 10px;">Anemia occurs in &gt;70% of patients with CD and UC </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Treatments</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2083/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">ST10 Profile</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2083/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Findings Related to the AEGIS Ph3</FONT></STRONG> </div><div style="margin-bottom: 10px;">The two AEGIS protocols recruited 128 patients with anaemia secondary to either Crohn’s disease or ulcerative colitis who had previously failed therapy with oral ferrous products due to intolerance and/<wbr>or inadequate therapeutic benefit.<wbr> </div><div style="margin-bottom: 10px;">Patients were recruited from expert centres in Austria, Germany, Hungary and the UK and were randomised (1:1) to receive ST10 or a matched placebo capsule.<wbr> </div><div style="margin-bottom: 10px;">Other iron therapies were not permitted during the study.<wbr> </div><div style="margin-bottom: 10px;">Adverse events recorded during the study were mainly gastrointestinal in nature and occurred in the ST10-treated arm with placebo-like frequency (38% of ST10-treated subjects and 40% of placebo-treated subjects).<wbr> </div><div style="margin-bottom: 10px;">Withdrawal from the study before 12 weeks (due to adverse events or subject decision) occurred in seven ST10-treated and nine placebo-treated subjects.<wbr> </div><div style="margin-bottom: 10px;">Patients who completed the 12-week double-blind phase of the study continued treatment in a 12-month open-label extension phase and results of this will be available later this year.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2083/3/ScreenCapture3.jpg?user-agent=rss"> </div><div>Conclusion highlights that Ferric Maltol should be considered as an alternative to IV iron for the treatment of IDA.<wbr> </div><!-- Comment details --><a name="gastroenterology2083attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2083/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(79 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2083/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(110,6 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2083/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(96,9 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2083">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-10-23T13:52:45+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2083/1/ScreenCapture1.jpg" length="80892" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2083/2/ScreenCapture2.jpg" length="113234" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2083/3/ScreenCapture3.jpg" length="99220" type="image/jpeg"/></item><item>
<title>BioGaia Reports Interim Results [sub:Probiotics]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2082</link>
<description>BioGaia Reports Interim Results [sub:Probiotics]</description><category>sub:Probiotics</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2082</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2082">BioGaia Reports Interim Results</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20141231&edate=20140901&cat=sub%3aProbiotics"><font color="#e95e0b">:GastroEnterology:sub:Probiotics</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2082">GastroEnterology2082</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 23 October 2014 | 13:13</font><br><br><div style="margin-bottom: 10px;">Comment: From Jan 1 to Sept 30 2014, net sales amounted to SEK 360.<wbr>4 million (vs 225.<wbr>7 in 2013), an increase of SEK 134.<wbr>7 million (60%).<wbr> The company reported focus on US, Brazil and Japan, and a number of projects, studies and product developments with Nestlé.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Sales Q3 and January-September</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2082/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG>Breakdown by Market</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2082/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">BioGaia Research</FONT></STRONG> </div><div style="margin-bottom: 10px;">To date, 124 clinical studies using BioGaia’s human strains of <EM>Lactobacillus reuteri</EM> have been performed on more than 10,000 individuals of all ages.<wbr> </div><div style="margin-bottom: 10px;">The results have been published in 90 articles in scientific journals (February 2014).<wbr> </div><div style="margin-bottom: 10px;"><EM><img src="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2082/3/ScreenCapture3.jpg?user-agent=rss"></EM> </div><div><EM>Source: BioGaia</EM> </div><!-- Comment details --><a name="gastroenterology2082attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2082/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(32,8 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2082/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(40,2 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2082/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(49,2 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2082">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-10-23T13:13:29+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2082/1/ScreenCapture1.jpg" length="33596" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2082/2/ScreenCapture2.jpg" length="41135" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2082/3/ScreenCapture3.jpg" length="50356" type="image/jpeg"/></item><item>
<title>IMMUNE Looks  to Partner Ph3 Development/Commercialization of Bertilimumab for Ulcerative Colitis [dis:IBD, :PharmaWorld:sub:xLicensing, :PharmaWorld:func:BusDev, :PharmaWorld:congress:UEGW]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2079</link>
<description>IMMUNE Looks  to Partner Ph3 Development/Commercialization of Bertilimumab for Ulcerative Colitis [dis:IBD, :PharmaWorld:sub:xLicensing, :PharmaWorld:func:BusDev, :PharmaWorld:congress:UEGW]</description><category>dis:IBD</category><category>sub:xLicensing</category><category>func:BusDev</category><category>congress:UEGW</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2079</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2079">IMMUNE Looks  to Partner Ph3 Development/<wbr>Commercialization of Bertilimumab for Ulcerative Colitis</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20141231&edate=20140901&cat=dis%3aIBD"><font color="#e95e0b">:GastroEnterology:dis:IBD</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=congress%3aUEGW"><font color="#e95e0b">:PharmaWorld:congress:UEGW</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=func%3aBusDev"><font color="#e95e0b">:PharmaWorld:func:BusDev</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=sub%3axLicensing"><font color="#e95e0b">:PharmaWorld:sub:xLicensing</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2079">GastroEnterology2079</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 23 October 2014 | 11:42</font><br><br><div style="margin-bottom: 10px;">Comment: Bertilimumab, which bloks the activity of eotaxin-1, is among the first biologic drugs for auto-immune diseases with a biomarker strategy.<wbr> A poster was presented at UEGW (Vienna) demonstrating elevated tissue eotaxin-1 levels as a hallmark of both UC and CD, especially in active disease.<wbr> UC phase 2 data are expected in 2015.<wbr> The company has planned additional studies for Crohn’s disease.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Presentation @UEGW (Vienna 2014)</FONT></STRONG> </div><div style="margin-bottom: 10px;">Dr.<wbr> Tomer Adar, a gastro-enterologist at the Institute for Digestive Diseases at Shaare Zedek Medical Center, Israel, presented an abstract entitled: </div><div style="margin-bottom: 10px;"><UL><LI>"The importance of intestinal eotaxin-1 - Eosinophil axis in inflammatory bowel disease, Results of a prospective observational study.<wbr>" </LI>
</UL> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2079/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Bertilimumab Profile</FONT></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>Market Data</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2079/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG>MOA</STRONG>: blocks the activity of eotaxin-1, a protein that attracts eosinophils and makes them move toward inflammatory sites.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Dev Program</STRONG>: ongoing trial Ph2 in patients with active moderate to severe UC <FONT color="#0485bc" face="Arial"><FONT color="#0485bc" face="Arial"><FONT color="#0485bc" face="Arial"><A href="http://clinicaltrials.gov/ct2/show/NCT01671956?term=NCT01671956&amp;rank=1">NCT01671956</A></FONT></FONT></FONT> </div><div style="margin-bottom: 10px;"><UL><LI>randomised, double blind, placebo-controlled, parallel group multi-centre study in adult patients with active moderate to severe UC.<wbr> Eligible patients will be randomly assigned in a 2:1 ratio to one of two treatment groups, bertilimumab 10 mg/<wbr>kg or matching placebo, respectively.<wbr> The study will consist of three periods: a screening period of up to two weeks, a four-week double-blind treatment period (three IV infusions over 30 minutes, at two-week intervals), and a safety and efficacy follow-up period of approximately nine weeks.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Company Description</FONT></STRONG> </div><div style="margin-bottom: 10px;">Immune Pharmaceuticals Inc.<wbr>, formerly EpiCept Corporation, is a clinical stage biopharmaceutical company specializing in the development and commercialization of targeted therapeutics, including monoclonal antibodies (mAbs), nano-therapeutics and antibody drug conjugates, for the treatment of inflammatory diseases and cancer.<wbr> </div><div style="margin-bottom: 10px;">The Company is focused on the development of the NanomAbs technology platform for the treatment of cancer.<wbr> </div><div>The Company is also seeking to partner its pain compound AmiKet, a topical cream consisting of a combination of amitriptyline and ketamine that is in late stage development for the treatment of peripheral neuropathies.<wbr> </div><!-- Comment details --><a name="gastroenterology2079attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2079/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(71,5 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2079/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(85,4 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2079">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-10-23T11:42:02+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2079/1/ScreenCapture1.jpg" length="73203" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2079/2/ScreenCapture2.jpg" length="87491" type="image/jpeg"/></item><item>
<title>Merz Opens New PhIII Sialorrhea Trial [headline, dis:Palsy]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7783</link>
<description>Merz Opens New PhIII Sialorrhea Trial [headline, dis:Palsy]</description><category>headline</category><category>dis:Palsy</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7783</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7783">Merz Opens New PhIII Sialorrhea Trial</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20141231&edate=20140901&cat=dis%3aPalsy"><font color="#e95e0b">:Neurology:dis:Palsy</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20141231&edate=20140901&cat=headline"><font color="#e95e0b">:Neurology:headline</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7783">Neurology7783</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 22 October 2014 | 13:02</font><br><br><div style="margin-bottom: 10px;">Comment: ClinicalTrials.<wbr>gov is listing a new phIII randomised placebo 
controlled trial in children and adolescents who have chronic 
troublesome sialorrhea associated with neurological disorders (e.<wbr>g.<wbr> cerebral 
palsy, traumatic brain injury) and or intellectual disabity who are naive to 
BoNT-A treatment.<wbr> The trial has yet to start recruitment.<wbr> </div><div style="margin-bottom: 10px;">Patients will be dosed with on average 2 units incobotulinumtoxinA per kg 
body weight per treatment cycle (subjects with a body weight ≥ 30 kg will 
receive a fixed total dose of 75 U per cycle).<wbr> Four 
injections will be administered at the beginning of each treatment cycle 
(parotid and submandibular glands, bilateral) </div><div style="margin-bottom: 10px;">Key Endpoints </div><div style="margin-bottom: 10px;"><DIV class="body3">Primary Outcome Measures: 
<UL style="MARGIN-BOTTOM: 1ex; MARGIN-TOP: 1ex"><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Change 
  in unstimulated salivary flow rate [uSFR] from baseline to Week 4 
  [ Time Frame: Baseline to week 4 ] 
  For subjects aged 6-17 years only.<wbr> 
  uSFR: weighing of dental rolls soaked with saliva over 5 minutes; procedure 
  repeated after 30 minutes.<wbr> The reduction of measured weight over the study 
  relates to improvement of sialorrhea.<wbr>
  </LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">
  Global Impression of Change Scale [GICS] at Week 4 
  representing the functional improvement in drooling 
  since baseline as assessed by the carer/<wbr>parent(s).<wbr> 
  [ Time Frame: Week 4 ] 
  </LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Occurrence of treatment emergent AEs [TEAEs] overall and by 
  injection cycle [ Time Frame: Baseline up to week 64 ] 
  <BR></LI>
</UL></DIV> </div><div style="margin-bottom: 10px;"><DIV class="body3">Secondary Outcome Measures: 
<UL style="MARGIN-BOTTOM: 1ex; MARGIN-TOP: 1ex"><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Change 
  in uSFR from baseline to Week 8 and 12.<wbr> [ Time Frame: Baseline 
  up to week 12 ] For subjects aged 6-17 years only.<wbr>
  </LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">GICS 
  at Week 8 and 12.<wbr> [ Time Frame: Up to week 12 ] For 
  subjects aged 6-17 years only.<wbr>
  </LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Occurrence of treatment 
  emergent AESIs [TEAESIs] overall and by injection cycle 
  [ Time Frame: Baseline up to week 64 ]
  </LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Occurrence of treatment 
  emergent SAEs [TESAEs] overall and by injection cycle 
  [ Time Frame: Baseline up to week 64 ]
  </LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Occurrence of TEAEs related to treatment as assessed by the 
  investigator overall and by injection cycle 
  [ Time Frame: Baseline up to week 64 ] 
  </LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Occurrence of TEAEs leading to 
  discontinuation overall and by injection cycle 
  [ Time Frame: Baseline up to week 
64 ] </LI>
</UL></DIV> </div><div style="margin-bottom: 10px;"><STRONG>Timelines</STRONG> </div><div style="margin-bottom: 10px;">249 patients will be recruited supposedly starting this month.<wbr> The estimated 
primary completion date is February 2017 but overall study completion is 
scheduled for June 2018.<wbr> Trial locations have yet to be disclosed.<wbr> </div><div><TABLE border="0" cellpadding="0" cellspacing="0" class="layout_table" style="MARGIN-TOP: 1ex" summary="Layout table for additional information"><TBODY><TR valign="top"><TD headers="colTitle">ClinicalTrials.<wbr>gov Identifier:</TD>
<TD headers="colData" style="PADDING-LEFT: 1em"><A class="study-link" href="http://clinicaltrials.gov/show/NCT02270736" title="Current version of study NCT02270736 on ClinicalTrials.gov">NCT02270736</A>   
     </TD>
</TR>
</TBODY>
</TABLE> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7783">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-10-22T13:02:09+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>re: Late Breaking Presentation By Peter Trainer On ATL1103 At the Recent Growth Hormone Society Meeting</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7839</link>
<description>re: Late Breaking Presentation By Peter Trainer On ATL1103 At the Recent Growth Hormone Society Meeting</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7839</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20141231&edate=20140901&rec=7839">re: Late Breaking Presentation By Peter Trainer On ATL1103 At the Recent Growth Hormone Society Meeting</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7839">Endocrinology7839</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/359">Philip HARRIS</a> | 22 October 2014 | 11:36</font><br><br><div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Late Breaking Presentation By Peter Trainer On ATL1103 At the Recent Growth Hormone Society Meeting</span>&nbsp;<br><span style="font-size: 12px;">Comment: On Saturday, Peter Trainer from the Christie Hospital Manachester gave a presentation highlighting the modern management of acromegaly providing background on the disease and its current treatment but importantly presenting for the first time new results from the phII study with Antisense Therapeutics's ALT1103.<wbr> The results provide proof of concept and suggest that by administering the drug at a higher dose over a longer period of time a significant number of acromegaly patients should benefit from treatment.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20141231&edate=20140901&rec=7836">...</a><br><font size="-1">Jacquelyne CANTLE MEYRICK / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7836" class="commentpermalink">Endocrinology7836</a> / <span class="date">21 October 2014</span> /
<span class="time">13:19:41 o'clock CEST</span>
</font></div><div>It's an interesting approach, demonstrating POC in acromegaly.<wbr>  It is most unlikely, however, that ATL1103 will succeed in providing a clinically meaningful advantage vs SS analogues.<wbr>  The approach is, however of interest in ACTH-dependent Cushing's syndrome, with antisense drug targeting of MC2R.<wbr> ISIS have declared an interest developing their antisense technology in Cushings.<wbr> </div><!-- Comment details --><font size="-1">Philip HARRIS / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7839" class="commentpermalink">Endocrinology7839</a> / <span class="date">22 October 2014</span> /
<span class="time">11:36:53 o'clock CEST</span>
</font><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20141231&edate=20140901&rec=7839">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7836">View thread  Endocrinology7836: Late Breaking Presentation By Peter Trainer On ATL1103 At the Recent Growth Hormone Society Meeting</a>]]></content:encoded><dc:date>2014-10-22T11:36:53+02:00</dc:date><dc:creator>phh74924</dc:creator></item><item>
<title>Roche Upgrades Basel Site [:Endocrinology:comp:Roche]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld11003</link>
<description>Roche Upgrades Basel Site [:Endocrinology:comp:Roche]</description><category>comp:Roche</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld11003</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20141231&edate=20140901&rec=11003">Roche Upgrades Basel Site</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20141231&edate=20140901&cat=comp%3aRoche"><font color="#e95e0b">:Endocrinology:comp:Roche</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld11003">PharmaWorld11003</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 22 October 2014 | 10:34</font><br><br><div style="margin-bottom: 10px;">Comment: Roche said in a statement it would spend 3 billion Swiss francs ($3.<wbr>2 billion) to upgrade its Basel headquarters.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Investment Details</STRONG> </div><div style="margin-bottom: 10px;">The company will spend 1.<wbr>7 billion francs on a new research building for 1,900 employees and will also build a new high-rise office block, which will house 1,700 workers at a cost of 550 million francs.<wbr> </div><div>A further 700 million francs will be spent on upgrading investing building and infrastructure.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20141231&edate=20140901&rec=11003">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-10-22T10:34:28+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Repeated Treatments of Drooling with Neurobloc [class:BotulinumToxins]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7782</link>
<description>Repeated Treatments of Drooling with Neurobloc [class:BotulinumToxins]</description><category>class:BotulinumToxins</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7782</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7782">Repeated Treatments of Drooling with Neurobloc</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20141231&edate=20140901&cat=class%3aBotulinumToxins"><font color="#e95e0b">:Neurology:class:BotulinumToxins</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7782">Neurology7782</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 22 October 2014 | 10:08</font><br><br><div style="margin-bottom: 10px;">Comment: New publication indicate that in the first series, BoNT-B treatment resulted in marked reduction of drooling and saliva flow rate with some relapse after 12 weeks.<wbr> The viscous saliva was ascribed to increased total protein content and compensatory mechanisms related to &szlig;-adrenergic receptor-specific actions.<wbr> With patients needing long-term treatment, it should be noted that the efficacy of repeated BoNT-B may fade with time.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Abstract </STRONG>(Acta Neurol Scand.<wbr> 2014 Oct 1.<wbr> doi: 10.<wbr>1111/<wbr>ane.<wbr>12309.<wbr> [Epub ahead of print]) </div><div style="margin-bottom: 10px;"><SPAN style="text-decoration: underline;">OBJECTIVES</SPAN>: to investigate efficacy, saliva flow, and composition in repeated BoNT-B treatments of drooling.<wbr> </div><div style="margin-bottom: 10px;"><BR><SPAN style="text-decoration: underline;">MATERIALS AND METHODS:</SPAN><BR>Seventeen neurological patients (median 66 years), referred for treatment of drooling participated in this observational study.<wbr> </div><div style="margin-bottom: 10px;">Median total doses of 4000 units botulinum toxin type B (BoNT-B, Neurobloc&reg; ) were injected with at least 3 months intervals into parotid and submandibular glands using ultrasound guidance.<wbr> </div><div style="margin-bottom: 10px;">Measures of drooling and saliva collection for analysis were obtained before treatment, and 6, 12, and eventually 18 weeks after.<wbr> </div><div><SPAN style="text-decoration: underline;">RESULTS</SPAN>:<BR>Number of treatment series in each patient was 1-7.<wbr> Compared to baseline, saliva flow rate and drooling were reduced 30-70% 6 weeks after treatment in the first series, while sodium, chloride, and total protein increased 20-80% (t-tests; P &lt; 0.<wbr>05).<wbr> After 12 weeks, drooling was still significantly reduced, saliva flow tended to be, and saliva composition was back to baseline.<wbr> Frequent side effects were viscous saliva and dry mouth.<wbr> Due to fading effect in eight patients, individual decisions were taken to change from BoNT-B to BoNT-A.<wbr> Similarly, the outcome was significantly reduced over time in six patients completing five subsequent BoNT-B treatment series (ANOVA; P &lt; 0.<wbr>05).<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7782">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-10-22T10:08:05+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>re: Synergy Pharm Reports Q2 Results and Progress with its Constipation Clinical Programs</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2078</link>
<description>re: Synergy Pharm Reports Q2 Results and Progress with its Constipation Clinical Programs</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2078</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2078">re: Synergy Pharm Reports Q2 Results and Progress with its Constipation Clinical Programs</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2078">GastroEnterology2078</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 22 October 2014 | 09:59</font><br><br><div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Synergy Pharm Reports Q2 Results and Progress with its Constipation Clinical Programs</span>&nbsp;<font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20141231&edate=20140901&cat=dis%3aConstipation"><font color="#e95e0b">:GastroEnterology:dis:Constipation</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20141231&edate=20140901&cat=dis%3aIBS"><font color="#e95e0b">:GastroEnterology:dis:IBS</font></a>]</font></font><br><span style="font-size: 12px;">Comment: Synergy expects top-line data from its Ph2 trial of SP-333 in opioid-induced constipation (OIC) in 4Q:14.<wbr> Management plans to start Ph3 trial of Plecanatide for IBS-C in 4Q:14.<wbr> The chronic idiopathic constipation (CIC) program is underway, with a wrap up expected in 2H:15, and a launch at a very end of 2016.<wbr> Both drugs are unique analogs of the naturally occurring human GI hormone, uroguanylin.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2004">...</a><br><font size="-1">Brigitte DESCHAMPS / <a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2004" class="commentpermalink">GastroEnterology2004</a> / <span class="date">13 August 2014</span> /
<span class="time">13:19:40 o'clock CEST</span>
</font></div><div style="margin-bottom: 10px;">Ph2b data presented at ACG demonstrate that plecanatide, once-daily oral tablet, significantly improved complete spontaneous bowel movement (CSBM) frequency, bowel habits, treatment satisfaction and significantly reduced abdominal pain in patients with IBS-C throughout the 12 week treatment period.<wbr> Synergy plans to initiate the pivotal phase 3 IBS-C clinical development program in Q4:14.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Additional Findings</STRONG> </div><div style="margin-bottom: 10px;">Patients taking 3.<wbr>0 and 9.<wbr>0 mg plecanatide showed statistically significant improvement in the Overall Responder rate, a secondary analysis in this study and the endpoint required for FDA approval in IBS-C (41.<wbr>9% and 40%, respectively, compared to 24.<wbr>7% for placebo).<wbr> </div><div>The data were presented by lead author, Philip B.<wbr> Miner Jr.<wbr>, M.<wbr>D.<wbr>, President and Medical Director of the Oklahoma Foundation for Digestive Research.<wbr> </div><!-- Comment details --><font size="-1">Brigitte DESCHAMPS / <a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2078" class="commentpermalink">GastroEnterology2078</a> / <span class="date">22 October 2014</span> /
<span class="time">09:59:46 o'clock CEST</span>
</font><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2078">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2004">View thread  GastroEnterology2004: Synergy Pharm Reports Q2 Results and Progress with its Constipation Clinical Programs</a>]]></content:encoded><dc:date>2014-10-22T09:59:46+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Omeros Suspends PDE10 Drug Huntington's Disease PhII Trial [dis:Huntington]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7777</link>
<description>Omeros Suspends PDE10 Drug Huntington's Disease PhII Trial [dis:Huntington]</description><category>dis:Huntington</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7777</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7777">Omeros Suspends PDE10 Drug Huntington's Disease PhII Trial</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20141231&edate=20140901&cat=dis%3aHuntington"><font color="#e95e0b">:Neurology:dis:Huntington</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7777">Neurology7777</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 21 October 2014 | 17:17</font><br><br><div style="margin-bottom: 10px;">Comment: Omeros has suspended its trial after discussions with the FDA as it further evaluates observations from a nonclinical study in rats.<wbr> The rat study demonstrated OMS824 free-plasma concentrations substantially higher than those measured in patients.<wbr> Non-human primates exposed to plasma concentrations equal to those in the rat have also demonstrated no findings similar to the observation reported from the rat study and OMS824 has been well tolerated in all human clinical trials to date.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Background To This Development</STRONG> </div><div style="margin-bottom: 10px;">Earlier this year, Omeros initiated a Phase 2 trial of OMS824 in patients with Huntington's disease.<wbr> That trial is a sequential-cohort dose-escalation study that evaluates the safety and tolerability of OMS824 dosed for four weeks in patients with Huntington's disease.<wbr> </div><div style="margin-bottom: 10px;">Concurrent with the clinical OMS824 program, Omeros has been conducting nonclinical studies to allow clinical trials of longer duration.<wbr> Following preliminary data collection from a 13‑week nonclinical study in rats, Omeros submitted a report on an observation in several of the rats receiving the maximum dose administered in the study to FDA'sDivision of Neurology Products and its Division of Psychiatry Products where Omeros has its IND applications for Huntington's disease and schizophrenia.<wbr> </div><div style="margin-bottom: 10px;">The drug exposure at that maximum dose in the rat study is multiples above the drug exposure in humans at the doses used in the Huntington's disease trial, and the potential relevance of the nonclinical findings to humans, if any, is unknown.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Outcome Of FDA Discussions</STRONG> </div><div style="margin-bottom: 10px;">Based on follow-up communications with FDA, Omeros has taken the decision to suspended the ongoing Huntington's disease trial, FDA has requested that Omeros further evaluate the nonclinical data from the 13-week rat study as well as nonclinical studies that did not yield the observation in order to characterize it more fully prior to reinitiating the clinical trial.<wbr> </div><div>Source: <A href="http://www.omeros.com">www.<wbr>omeros.<wbr>com</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7777">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-10-21T17:17:00+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>Late Breaking Presentation By Peter Trainer On ATL1103 At the Recent Growth Hormone Society Meeting</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7836</link>
<description>Late Breaking Presentation By Peter Trainer On ATL1103 At the Recent Growth Hormone Society Meeting</description><comments>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7836</comments><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7836</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20141231&edate=20140901&rec=7836">Late Breaking Presentation By Peter Trainer On ATL1103 At the Recent Growth Hormone Society Meeting</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7836">Endocrinology7836</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 21 October 2014 | 13:19</font><br><br><div style="margin-bottom: 10px;">Comment: On Saturday, Peter Trainer from the Christie Hospital Manachester gave a presentation highlighting the modern management of acromegaly providing background on the disease and its current treatment but importantly presenting for the first time new results from the phII study with Antisense Therapeutics's ALT1103.<wbr> The results provide proof of concept and suggest that by administering the drug at a higher dose over a longer period of time a significant number of acromegaly patients should benefit from treatment.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7836/1/ScreenCapture3.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">In addition to the POC results with ATL1103 some interesting slides were included in the presentation poistioning pegvisoment as the forerunner of ATL1103.<wbr> </div><div style="margin-bottom: 10px;">PhII results with pegvisoment were highlighted from a perspective of design equivalence to the study with ATL1103, with a 30% fall in IGF-1 observed and regarded as postiive POC.<wbr> However, only 2 patients were considered responders so the phIII proceeded with a higher daily dose as opposed to weekly dose.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7836/2/ScreenCapture5.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7836/3/ScreenCapture6.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">Normalisation of IGF-1 achieved with 20mg once daily in 90% of patients.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7836/4/ScreenCapture7.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7836/5/ScreenCapture8.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">Pfizer had an obligation on approval of pegvisomant to set up a registry, data from which is highlighted below.<wbr> In this real-life situation only 60% of patients achieve adequate control of their IGF-1, due it is believed to hesitation by some doctors to optimise the dose principally because of the high cost of therapy.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7836/6/ScreenCapture9.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">Following the pegvisomant data, Peter Trainer re-orientated his talk to the main topic of his presentation, the outcome of the phII study with ATL1103, highlighting the MOA of the drug plus the phI findings before focusing on the detailed phi results.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7836/7/ScreenCapture10.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7836/8/ScreenCapture11.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">GHBP3 levels fall nicely indicating that you are knocking out the activity of the growth hormone receptor.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7836/9/ScreenCapture12.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7836/10/ScreenCapture13.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7836/11/ScreenCapture14.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7836/12/ScreenCapture15.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">Serious AEs were not drug related and involved 1 middle ear infection after a patient swam for a week on holiday in an unmaintained swimming pool and one case of a patient experiencing acute cholestasis ( a recognised complication of discontinuing SSAs.<wbr> The only other notable safety issue observed were injection site reactions.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7836/13/ScreenCapture16.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7836/14/ScreenCapture17.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">In terms of efficacy no significant fall in IGF-1 levels was observed with once weekly admininistation but with twice weekly a profound fall was observed that didn't reach its nadir.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7836/15/ScreenCapture19.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7836/16/ScreenCapture20.jpg?user-agent=rss"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7836/17/ScreenCapture21.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">Change in signs and symptoms didn't reach statistical significance neither did QOL parameters.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7836/18/ScreenCapture22.jpg?user-agent=rss"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7836/19/ScreenCapture23.jpg?user-agent=rss"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7836/20/ScreenCapture24.jpg?user-agent=rss"> </div><div>Source: <A href="http://webcasting.brrmedia.com/broadcast/127892">http:/<wbr>/<wbr>webcasting.<wbr>brrmedia.<wbr>com/<wbr>broadcast/<wbr>127892</A> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Endocrinology7839c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div>It's an interesting approach, demonstrating POC in acromegaly.<wbr>  It is most unlikely, however, that ATL1103 will succeed in providing a clinically meaningful advantage vs SS analogues.<wbr>  The approach is, however of interest in ACTH-dependent Cushing's syndrome, with antisense drug targeting of MC2R.<wbr> ISIS have declared an interest developing their antisense technology in Cushings.<wbr> </div><font size="-1">Philip HARRIS / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7839" class="commentpermalink">Endocrinology7839</a> / <span class="date">22 October 2014</span> /
<span class="time">11:36:53 o'clock CEST</span>
</font></div><a name="endocrinology7836attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7836/1/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(99,8 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7836/2/ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(79,4 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7836/3/ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(61,4 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7836/4/ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(65,5 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7836/5/ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(74,7 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7836/6/ScreenCapture9.jpg">ScreenCapture9.jpg</a>&nbsp;&nbsp;(58,6 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7836/7/ScreenCapture10.jpg">ScreenCapture10.jpg</a>&nbsp;&nbsp;(89,4 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7836/8/ScreenCapture11.jpg">ScreenCapture11.jpg</a>&nbsp;&nbsp;(76,1 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7836/9/ScreenCapture12.jpg">ScreenCapture12.jpg</a>&nbsp;&nbsp;(88,9 KB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7836/10/ScreenCapture13.jpg">ScreenCapture13.jpg</a>&nbsp;&nbsp;(82,4 KB)<br>&nbsp;&nbsp;11.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7836/11/ScreenCapture14.jpg">ScreenCapture14.jpg</a>&nbsp;&nbsp;(59,8 KB)<br>&nbsp;&nbsp;12.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7836/12/ScreenCapture15.jpg">ScreenCapture15.jpg</a>&nbsp;&nbsp;(83,7 KB)<br>&nbsp;&nbsp;13.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7836/13/ScreenCapture16.jpg">ScreenCapture16.jpg</a>&nbsp;&nbsp;(90,8 KB)<br>&nbsp;&nbsp;14.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7836/14/ScreenCapture17.jpg">ScreenCapture17.jpg</a>&nbsp;&nbsp;(55,9 KB)<br>&nbsp;&nbsp;15.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7836/15/ScreenCapture19.jpg">ScreenCapture19.jpg</a>&nbsp;&nbsp;(57,4 KB)<br>&nbsp;&nbsp;16.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7836/16/ScreenCapture20.jpg">ScreenCapture20.jpg</a>&nbsp;&nbsp;(57,8 KB)<br>&nbsp;&nbsp;17.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7836/17/ScreenCapture21.jpg">ScreenCapture21.jpg</a>&nbsp;&nbsp;(72,3 KB)<br>&nbsp;&nbsp;18.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7836/18/ScreenCapture22.jpg">ScreenCapture22.jpg</a>&nbsp;&nbsp;(90,8 KB)<br>&nbsp;&nbsp;19.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7836/19/ScreenCapture23.jpg">ScreenCapture23.jpg</a>&nbsp;&nbsp;(90,2 KB)<br>&nbsp;&nbsp;20.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7836/20/ScreenCapture24.jpg">ScreenCapture24.jpg</a>&nbsp;&nbsp;(56 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20141231&edate=20140901&rec=7836">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-10-21T13:19:41+02:00</dc:date><dc:creator>jac89886</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7836/1/ScreenCapture3.jpg" length="102239" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7836/2/ScreenCapture5.jpg" length="81327" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7836/3/ScreenCapture6.jpg" length="62839" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7836/4/ScreenCapture7.jpg" length="67117" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7836/5/ScreenCapture8.jpg" length="76449" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7836/6/ScreenCapture9.jpg" length="60022" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7836/7/ScreenCapture10.jpg" length="91506" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7836/8/ScreenCapture11.jpg" length="77935" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7836/9/ScreenCapture12.jpg" length="91064" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7836/10/ScreenCapture13.jpg" length="84403" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7836/11/ScreenCapture14.jpg" length="61237" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7836/12/ScreenCapture15.jpg" length="85685" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7836/13/ScreenCapture16.jpg" length="92951" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7836/14/ScreenCapture17.jpg" length="57237" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7836/15/ScreenCapture19.jpg" length="58793" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7836/16/ScreenCapture20.jpg" length="59151" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7836/17/ScreenCapture21.jpg" length="74034" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7836/18/ScreenCapture22.jpg" length="92948" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7836/19/ScreenCapture23.jpg" length="92394" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7836/20/ScreenCapture24.jpg" length="57314" type="image/jpeg"/></item><item>
<title>re: First Patient Enroled in Norgine US Ph3 to Assess Novel Low Volume Bowel Preparation</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2077</link>
<description>re: First Patient Enroled in Norgine US Ph3 to Assess Novel Low Volume Bowel Preparation</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2077</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2077">re: First Patient Enroled in Norgine US Ph3 to Assess Novel Low Volume Bowel Preparation</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2077">GastroEnterology2077</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 21 October 2014 | 12:47</font><br><br><div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">First Patient Enroled in Norgine US Ph3 to Assess Novel Low Volume Bowel Preparation</span>&nbsp;<font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20141231&edate=20140901&cat=headline"><font color="#e95e0b">:GastroEnterology:headline</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20141231&edate=20140901&cat=sub%3aCRCPrevention"><font color="#e95e0b">:GastroEnterology:sub:CRCPrevention</font></a>]</font></font><br><span style="font-size: 12px;">Comment: Norgine's NER1006 is a novel, low volume polyethylene glycol based bowel preparation that has been developed to provide whole bowel cleansing, with an additional focus on the <STRONG>ascending</STRONG> colon.<wbr> The Ph3 programme also includes 2 studies in Europe, planned to start late 2014.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2050">...</a><br><font size="-1">Brigitte DESCHAMPS / <a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2050" class="commentpermalink">GastroEnterology2050</a> / <span class="date">03 October 2014</span> /
<span class="time">15:19:31 o'clock CEST</span>
</font></div><div style="margin-bottom: 10px;">Norgine presented positive Ph2 data at the 79<SUP>th</SUP> Annual Scientific Meeting of the American College of Gastroenterology (ACG), Philadelphia, PA, and today at the UEGW, Vienna.<wbr> </div><div style="margin-bottom: 10px;">Study Design </div><div style="margin-bottom: 10px;">The Phase II open-label, randomised study (OPT, n=240) investigated the pharmacodynamics (stool weight), clinical efficacy and tolerability of dose and taste-optimised low-volume PEG-based formulations (NER1006), after split dosing, compared with MOVIPREP<SUP>&reg;</SUP>.<wbr> </div><div style="margin-bottom: 10px;">Ph2 Findings </div><div>Results demonstrate that NER1006 achieved high quality bowel cleansing in screening colonoscopy patients, comparable with MOVIPREP<SUP>&reg;</SUP>.<wbr> Cleansing success rates were 90-100%.<wbr> Stool output was consistently higher with NER1006, and safety and tolerability profiles between treatments were comparable.<wbr><SUP>[</SUP><SUP>1</SUP><SUP>]</SUP> In addition, most subjects in the NER1006 arms reached clear effluent </div><!-- Comment details --><font size="-1">Brigitte DESCHAMPS / <a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2077" class="commentpermalink">GastroEnterology2077</a> / <span class="date">21 October 2014</span> /
<span class="time">12:47:02 o'clock CEST</span>
</font><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2077">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2050">View thread  GastroEnterology2050: First Patient Enroled in Norgine US Ph3 to Assess Novel Low Volume Bowel Preparation</a>]]></content:encoded><dc:date>2014-10-21T12:47:02+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Results of Antisense Therapy for Active CD [dis:IBD, :PharmaWorld:congress:UEGW]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2076</link>
<description>Results of Antisense Therapy for Active CD [dis:IBD, :PharmaWorld:congress:UEGW]</description><category>dis:IBD</category><category>congress:UEGW</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2076</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2076">Results of Antisense Therapy for Active CD</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20141231&edate=20140901&cat=dis%3aIBD"><font color="#e95e0b">:GastroEnterology:dis:IBD</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=congress%3aUEGW"><font color="#e95e0b">:PharmaWorld:congress:UEGW</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2076">GastroEnterology2076</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 20 October 2014 | 22:27</font><br><br><div style="margin-bottom: 10px;">Comment: Induction therapy with orally administered, topically active Celgene's Mongersen for CD was well tolerated; toxicities previously reported with systemically active antisense agents were not observed.<wbr> Mongersen treatment resulted in significant improvements in clinical remission and response rates within 4 weeks of initiation of treatment.<wbr> The drug is being presented in the section "new drugs in IBD" at UEGW in Vienna.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Trial Reference</STRONG> (EUDRACT NUMBER 2011-002640-27).<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Poster</STRONG> MONGERSEN, AN ORAL SMAD7 ANTISENSE OLIGONUCLEOTIDE, IN ACTIVE CROHN'S DISEASE </div><div style="margin-bottom: 10px;"><STRONG>About GED-0301</STRONG> </div><div><DIV class="copy-paste-block" style="top: 588px; left: 20px;">
<DIV class="copy-paste-block">
<P>The investigational oral drug GED-0301 is an antisense oligonucleotide that targets the messenger RNA (mRNA) for Smad7, thereby reducing Smad7 protein levels.<wbr> In patients with Crohn&rsquo;s disease, abnormally high levels of Smad7 interfere with TGF-&beta;1 anti-inflammatory pathways in the gut, leading to increased inflammation.<wbr> The distinct formulation of the tablet is designed to release GED-0301 into the far end of the small intestine (the terminal ileum) and near the end of the colon (right colon), where it is thought to act locally to reduce Smad7 levels</P>
</DIV>
</DIV> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2076">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-10-20T22:27:44+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Valeant Demonstrates Strong Robust Third Quarter Growth [news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7775</link>
<description>Valeant Demonstrates Strong Robust Third Quarter Growth [news]</description><category>news</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7775</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7775">Valeant Demonstrates Strong Robust Third Quarter Growth</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20141231&edate=20140901&cat=news"><font color="#e95e0b">:Neurology:news</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7775">Neurology7775</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 20 October 2014 | 17:24</font><br><br><div style="margin-bottom: 10px;">Comment: Valeant reported stronger than anticipated Q3 earnings posting a 
profit of $275.<wbr>4million of 81 cents per share vs a loss last year of 
£973.<wbr>2m when the company took a restructuring charge related to the 
acquisition of Bausch &amp; Lomb &amp; an impairment charge of $645m.<wbr> 
Although there has been some speculation about a raised offer for Allergan 
nothing was forthcoming today.<wbr> </div><div style="margin-bottom: 10px;">In fact, omly a brief update on the bid situation was highlighted as shown 
below.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7775/7/ScreenCapture8.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">Countering some of Allergan's assertions about the true underlying growth of 
the business organic growth of 19% including the impact from generics is 
impressive especially given the group's diversified product revenues.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7775/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7775/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7775/3/ScreenCapture3.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7775/4/ScreenCapture4.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7775/5/ScreenCapture5.jpg?user-agent=rss"> </div><div><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7775/6/ScreenCapture7.jpg?user-agent=rss"> </div><!-- Comment details --><a name="neurology7775attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7775/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(45,4 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7775/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(68,2 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7775/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(56,9 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7775/4/ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(68,3 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7775/5/ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(62,1 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7775/6/ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(72,7 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7775/7/ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(64,3 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7775">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-10-20T17:24:45+02:00</dc:date><dc:creator>jac89886</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7775/1/ScreenCapture1.jpg" length="46482" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7775/2/ScreenCapture2.jpg" length="69810" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7775/3/ScreenCapture3.jpg" length="58261" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7775/4/ScreenCapture4.jpg" length="69973" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7775/5/ScreenCapture5.jpg" length="63566" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7775/6/ScreenCapture7.jpg" length="74396" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7775/7/ScreenCapture8.jpg" length="65869" type="image/jpeg"/></item><item>
<title>First Trial With Lutathera In Pancreatic Neuroendocrine Carcinoma [news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7834</link>
<description>First Trial With Lutathera In Pancreatic Neuroendocrine Carcinoma [news]</description><category>news</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7834</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20141231&edate=20140901&rec=7834">First Trial With Lutathera In Pancreatic Neuroendocrine Carcinoma</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20141231&edate=20140901&cat=news"><font color="#e95e0b">:Endocrinology:news</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7834">Endocrinology7834</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 17 October 2014 | 19:26</font><br><br><div style="margin-bottom: 10px;">Comment: Starting this month at Gustav Rousy will be a randomised phII study (OCLURANDOM) evaluating Lutathera vs.<wbr> Sunitinib in patients with unresectable progressive well-differentiated neuroendocrine pancreatic carcinoma.<wbr> This will be the first randomised phII with a radionuclide in this indication.<wbr> AAA is a collaborator but no the main sponsor.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Entry Criteria</STRONG> </div><div style="margin-bottom: 10px;">The 80 Subjects entering this trial must have experienced documented progression of disease within 1 year prior to the start of the study.<wbr> The control group of patients receiving Sutent will be used as internal control to assess the hypothesis of 12 months PFS equal to 35% in patients receiving Sutent.<wbr> </div><div style="margin-bottom: 10px;"><DIV class="body3"><STRONG>Primary Outcome Measures</STRONG>:
<UL style="margin-bottom: 1ex; margin-top: 1ex;"><LI class="color-bullet" style="margin-top: 0.7ex;">To determine the 12 months PFS [ Time Frame: Assessed 12 months after randomization ]
</LI>
</UL>
</DIV> </div><div style="margin-bottom: 10px;"><DIV class="body3"><STRONG>Secondary Outcome Measures:</STRONG></DIV> </div><div style="margin-bottom: 10px;"><DIV class="body3">
<UL style="margin-bottom: 1ex; margin-top: 1ex;"><LI class="color-bullet" style="margin-top: 0.7ex;">Overall Survival [ Time Frame: Assessed every 3 months until death ]
</LI>
<LI class="color-bullet" style="margin-top: 0.7ex;">Best response [ Time Frame: Assessed every 12 weeks until progression up to 48 months ] according to RECIST V1.<wbr>1
</LI>
</UL>
</DIV> </div><div style="margin-bottom: 10px;"><P class="color-bullet" style="margin-top: 0.7ex;">Whilst starting this month the trial is not estimated to complete until October 2023.<wbr></P> </div><div style="margin-bottom: 10px;"><P class="color-bullet" style="margin-top: 0.7ex;">The PI for this study is Eric Baudin</P> </div><div><TABLE border="0" cellpadding="0" cellspacing="0" class="layout_table" style="margin-top: 1ex;" summary="Layout table for additional information"><TBODY><TR valign="top"><TD headers="colTitle">ClinicalTrials.<wbr>gov Identifier:</TD>
<TD headers="colData" style="padding-left: 1em;"><A class="study-link" href="http://clinicaltrials.gov/show/NCT02230176" title="Current version of study NCT02230176 on ClinicalTrials.gov">NCT02230176</A></TD>
</TR>
</TBODY>
</TABLE> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20141231&edate=20140901&rec=7834">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-10-17T19:26:21+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>Lead Indication For Nanobiotix's NBTXR3 Is Soft Tissue Sarcoma [news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology10055</link>
<description>Lead Indication For Nanobiotix's NBTXR3 Is Soft Tissue Sarcoma [news]</description><category>news</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology10055</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10055">Lead Indication For Nanobiotix's NBTXR3 Is Soft Tissue Sarcoma</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=news"><font color="#e95e0b">:Oncology:news</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10055">Oncology10055</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 17 October 2014 | 18:05</font><br><br><div style="margin-bottom: 10px;">Comment: Nanobiotix, a clinical-stage nanomedicine company announced that it 
has received approval from the French ANSM to start a Phase II/<wbr>III 
registration trial of its lead product, NBTXR3, in patients with locally 
advanced Soft Tissue Sarcoma.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Current Treatment Options For STS <BR></STRONG>Patients with locally 
advanced STS have very limited therapeutic options.<wbr> Today, a standard treatment 
of care before surgery is radiotherapy aiming to reduce the tumor volume.<wbr> 
Thereafter surgery is still required to remove the tumor.<wbr> But despite of 
radiotherapy, a considerable proportion of patients with advanced tumors cannot 
be resected in their entirety.<wbr> The remaining tumor mass promotes the further 
development of the disease resulting in a poor prognosis for the patient.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>What Does NBTXR3 Offer<BR></STRONG>NBTXR3 has the potential to 
provide a significant clinical benefit by improving radiotherapy efficacy, 
destroying locally advanced tumors more efficiently and to improve the quality 
of surgery enabling a more complete removal of the tumor.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Study Design</STRONG><BR>This international multi-center pivotal 
study will start in France and then be conducted in around 25-30 sites 
throughout Europe once further authorizations are received.<wbr> </div><div style="margin-bottom: 10px;">This pivotal trial is expected to be the final step before registration in 
Europe (CE mark) and should be –completed towards the end of 2016.<wbr> </div><div style="margin-bottom: 10px;">In the Asia-Pacific region, as announced recently, PharmaEngine intends to 
participate in this pivotal study by opening clinical sites in several 
countries.<wbr> </div><div style="margin-bottom: 10px;">In parallel, Nanobiotix is establishing industrialization, 
market access and reimbursement strategies for NBTXR3 to prepare for a potential 
product launch at the end of 2016.<wbr> </div><div>Source: <A href="http://www.nanobiotix.com">www.<wbr>nanobiotix.<wbr>com</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10055">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-10-17T18:05:34+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>Germany's IQWiG Decides Takeda's Entyvio Lacks Additional Benefits for UC and CD [dis:IBD, :PharmaWorld:mkt:Germany]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2075</link>
<description>Germany's IQWiG Decides Takeda's Entyvio Lacks Additional Benefits for UC and CD [dis:IBD, :PharmaWorld:mkt:Germany]</description><category>dis:IBD</category><category>mkt:Germany</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2075</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2075">Germany's IQWiG Decides Takeda's Entyvio Lacks Additional Benefits for UC and CD</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20141231&edate=20140901&cat=dis%3aIBD"><font color="#e95e0b">:GastroEnterology:dis:IBD</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=mkt%3aGermany"><font color="#e95e0b">:PharmaWorld:mkt:Germany</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2075">GastroEnterology2075</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 17 October 2014 | 14:12</font><br><br><div style="margin-bottom: 10px;">Comment: The German Institute for Quality and Efficiency in Healthcare (IQWiG) has completed its dossier evaluation for Takeda's Entyvio (vedolizumab) that is indicated in the treatment of moderate-to-severe Crohn's disease or ulcerative colitis (UC).<wbr> The IQWiG has decided that no additional benefit can be elicited from the data supplied in the dossier, stating that no appropriate data is provided in the case of either indication.<wbr> The Federal Joint Committee (G-BA) determined Humira (adalimumab; AbbVie, US) or infliximab as appropriate comparator therapies in both indications.<wbr> The IQWiG states that because no direct comparison between Entyvio and Humira is provided in the case of Crohn's disease, but only an indirect comparison, which is not based on randomised controlled trials (RCTs), no proper assessment of any additional benefit can be made.<wbr> </div><div style="margin-bottom: 10px;">As a result, a verdict of no additional benefit is given.<wbr> In the case of moderate-to-severe UC, no direct comparison is provided either; in this case, data from an RCT comparing Entyvio with placebo are provided, with the placebo acting as a bridging comparator, as well as data from three RCTs comparing Humira with placebo.<wbr> The IQWiG has found problems with this data, including the fact that the compared population groups are insufficiently similar and that side effects in the Entyvio study were not adequately analysed.<wbr> For this reason, no additional benefit is accorded in this indication either.<wbr> </div><div style="margin-bottom: 10px;"><B>Significance</B> </div><div>As <I>Deutsche Apotheker Zeitung </I>reports, Takeda's analysis claims that Entyvio substantially reduces risks of severe adverse side effects and treatment cessation.<wbr> Takeda hopes that the G-BA will take these factors into consideration when it makes its final decision on the extent of the drug's additional benefit in approximately three months.<wbr> Entyvio received marketing authorisation in the European Union in May.<wbr> The G-BA's negative decision could also affect the drug's chances in other EU markets.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2075">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-10-17T14:12:42+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>re: Diagnostic for Patients with GEP-NETS Granted ODD by EMA</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7831</link>
<description>re: Diagnostic for Patients with GEP-NETS Granted ODD by EMA</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7831</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20141231&edate=20140901&rec=7831">re: Diagnostic for Patients with GEP-NETS Granted ODD by EMA</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7831">Endocrinology7831</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/1038">Elena RITSOU</a> | 17 October 2014 | 12:03</font><br><br><div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Diagnostic for Patients with GEP-NETS Granted ODD by EMA</span>&nbsp;<font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20141231&edate=20140901&cat=headline"><font color="#e95e0b">:Endocrinology:headline</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20141231&edate=20140901&cat=sub%3aDiagnostic"><font color="#e95e0b">:Endocrinology:sub:Diagnostic</font></a>]</font></font><br><span style="font-size: 12px;">Comment: OctreoPharm's OPS202 (future trade name SOMscan) is a new <SUP>68</SUP>Gallium-labeled radiopharmaceutical in clinical development for positron emission tomography (PET, PET/<wbr>CT) with the potential to detect even smallest lesions of NETs.<wbr> Depending on the labeled radionuclide OPS202 can be used for diagnosis (<SUP>68</SUP>Ga) as well as for therapy (<SUP>90</SUP>Y).<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20141231&edate=20140901&rec=7583">...</a><br><font size="-1">Brigitte DESCHAMPS / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7583" class="commentpermalink">Endocrinology7583</a> / <span class="date">29 January 2014</span> /
<span class="time">16:12:51 o'clock CET</span>
</font></div><div><STRONG>Please note that Novartis does not have an option or any other rights for OctreoPharm&rsquo;s OPS202 diagnostic (SomScan).<wbr> </STRONG>Novartis had an option for another product (a Pasireotide based diagnostic) that OctreoPharm is not developing anymore.<wbr> The confusion comes from the fact that at the time they had used the name Som Scan for that product as well.<wbr> </div><!-- Comment details --><font size="-1">Elena RITSOU / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7831" class="commentpermalink">Endocrinology7831</a> / <span class="date">17 October 2014</span> /
<span class="time">12:03:36 o'clock CEST</span>
</font><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20141231&edate=20140901&rec=7831">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7583">View thread  Endocrinology7583: Diagnostic for Patients with GEP-NETS Granted ODD by EMA</a>]]></content:encoded><dc:date>2014-10-17T12:03:36+02:00</dc:date><dc:creator>elr18175</dc:creator></item><item>
<title>NICE Says &quot;Provenge' Cost to NHS too high to be recommended in draft guidance&quot; [dis:Prostate, news, :PharmaWorld:mkt:UK, class:Vaccines]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology10052</link>
<description>NICE Says &quot;Provenge' Cost to NHS too high to be recommended in draft guidance&quot; [dis:Prostate, news, :PharmaWorld:mkt:UK, class:Vaccines]</description><comments>http://ci.beaufour-ipsen.com/traction/permalink/Oncology10052</comments><category>dis:Prostate</category><category>news</category><category>mkt:UK</category><category>class:Vaccines</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology10052</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10052">NICE Says "Provenge' Cost to NHS too high to be recommended in draft guidance"</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=class%3aVaccines"><font color="#e95e0b">:Oncology:class:Vaccines</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=news"><font color="#e95e0b">:Oncology:news</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=mkt%3aUK"><font color="#e95e0b">:PharmaWorld:mkt:UK</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10052">Oncology10052</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/994">Jenny Wu</a> | 17 October 2014 | 10:36</font><br><br><div style="margin-bottom: 10px;">Comment: NICE has issued preliminary draft guidance not recommending sipuleucel-T for prostate cancer in people whose disease has spread, who have few symptoms and when chemotherapy would not yet have been given.<wbr>The available evidence showed that the price the NHS is being asked to pay for the drug is too high for the benefit it may provide - Sir Andrew Dillon commented that although Sipeuleucel-T dose show significant overall survival benefit, it was also not proven to delay the progression of the disease unlike current treatments.<wbr> </div><div style="margin-bottom: 10px;">In preliminary draft guidelines, the National Institute for Health and Care Excellence has rejected the drug's use to treat patients with metastatic prostate cancer before they have received chemotherapy.<wbr> Offering a novel approach to treating the disease, Provenge is the first drug for metastatic hormone-resistant prostate cancer that is not cytotoxic or based on hormone-related therapy.<wbr> Around 4, 600 patients in England would be eligible for treatment as per its licence.<wbr> </div><div style="margin-bottom: 10px;">But NICE says available evidence shows the price the NHS is being asked to pay for the drug is too high for the benefit it may provide to patients.<wbr>The Committee noted that, for the subgroup of patients who had not had prior chemotherapy, the cost per QALY (quality-adjusted life year) was at least &pound;512,000 (company's analyses) or at least &pound;244,000 (Evidence Review Group's analyses) for Provenge compared with Johnson &amp; Johnson's (discounted) Zytiga (abiraterone).<wbr> When Zytiga was not included in the ERG's analysis, the cost per QALY for the drug compared with best supportive care was - at &pound;112,000 or &pound;61,400 for a subgroup of patients with certain levels of prostate-specific antigen levels - still well above normal cost-effectiveness thresholds.<wbr> </div><div>Aside from clinical uncertainties, there were also fears that the NHS may incur additional costs because of the treatment's complex administration, of which the UK has no experience, NICE noted.<wbr> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Oncology10212c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div>Comment: The final draft guidance issued by NICE on 13 Jan remains consistent with NICE's preliminary decision - Dendreon has so far been unable to show that it works better than other treatments currently available.<wbr> The final draft guidance is now with consultees, who have the opportunity to appeal against it.<wbr> Until NICE issues final guidance, NHS bodies should make decisions locally on the funding of specific treatments.<wbr> Given the current position of Dendreon as they are awaiting for bidders, the future of Provenge in European markets is questionable.<wbr> (Source: <a href="https://www.nice.org.uk/news/press-and-media/cost-to-nhs-of-providing-sipuleucel-t-too-high-to-be-recommended-in-draft-guidance" class="defaultlink">NICE PRESS RELEASE Jan 2015</a>) </div><font size="-1">Jenny Wu / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10212" class="commentpermalink">Oncology10212</a> / <span class="date">14 January 2015</span> /
<span class="time">15:55:11 o'clock CET</span>
</font><span style="font-weight: bold; font-style: italic;"></span><a name="Oncology10292c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div>The final NICE guidance is being published with the final decision that Provenge is not recommended within its marketing authorisation for treating adults who have asymptomatic or minimally symptomatic metastatic non visceral hormone relapsed prostate cancer for which chemotherapy is not yet clinically indicated.<wbr> (Source:<A href="http://www.nice.org.uk/guidance/ta332/chapter/1-guidance">http:/<wbr>/<wbr>www.<wbr>nice.<wbr>org.<wbr>uk/<wbr>guidance/<wbr>ta332/<wbr>chapter/<wbr>1-guidance</A>) </div><font size="-1">Jenny Wu / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10292" class="commentpermalink">Oncology10292</a> / <span class="date">25 February 2015</span> /
<span class="time">14:40:01 o'clock CET</span>
</font></div></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10052">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-10-17T10:36:44+02:00</dc:date><dc:creator>jew60237</dc:creator></item><item>
<title>Roche's Sales Presentation Outlines Strong Cancer Franchise [comp:Roche, dis:Acromegaly, prod:Octreotide, :Oncology:news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7827</link>
<description>Roche's Sales Presentation Outlines Strong Cancer Franchise [comp:Roche, dis:Acromegaly, prod:Octreotide, :Oncology:news]</description><category>comp:Roche</category><category>dis:Acromegaly</category><category>prod:Octreotide</category><category>news</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7827</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20141231&edate=20140901&rec=7827">Roche's Sales Presentation Outlines Strong Cancer Franchise</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20141231&edate=20140901&cat=comp%3aRoche"><font color="#e95e0b">:Endocrinology:comp:Roche</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20141231&edate=20140901&cat=dis%3aAcromegaly"><font color="#e95e0b">:Endocrinology:dis:Acromegaly</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20141231&edate=20140901&cat=prod%3aOctreotide"><font color="#e95e0b">:Endocrinology:prod:Octreotide</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=news"><font color="#e95e0b">:Oncology:news</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7827">Endocrinology7827</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 17 October 2014 | 09:37</font><br><br><div style="margin-bottom: 10px;">Comment: Roche has reported a solid performance with sales being driven by growth of the group's new breast cancer drugs (Perjeta and Kaldyca).<wbr> Japan is driving sales (+7%), followed by US (+5%) EU (+3%) and International.<wbr> Management outlined that discussion are ongoing with the FDA regarding the PDL1 program for bladder cancer, and that " .<wbr>.<wbr>.<wbr> bladder represents a very interesting opportunity for an early market entrant".<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">More on the Anti-PDL1 (cancer immunotherapy)</FONT></STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>
Ph2 - FPI Q2:14 n=330 indication: locally advanced or metastatic urothelial bladder cancer /<wbr> submission planned in 2016</LI>
<LI>
Ph1 - n=344 - data from the bladder cohort presented at ASCO 2014</LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG>2014 Outlook</STRONG> </div><div style="margin-bottom: 10px;">For the full year 2014, Roche expects low- to mid-single digit growth in Group sales at constant exchange rates.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">First nine month of 2014</FONT></STRONG> </div><div style="margin-bottom: 10px;"><SPAN style="TEXT-DECORATION: underline">Sales: 4% higher sales in Pharmaceuticals Division, with strong growth of oncology portfolio, as well as Actemra for rheumatoid arthritis and Xolair for asthma and chronic hives.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="TEXT-DECORATION: underline"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7827/1/ScreenCapture1.jpg?user-agent=rss"></SPAN> </div><div style="margin-bottom: 10px;">Japan is driving sales (+7%), followed by US (+5%) EU (+3%) and International (<FONT size="1">Asia–Pacific, EEMEA (Eastern Europe, Middle East, Africa), Latin America, Canada, Others )</FONT> </div><div style="margin-bottom: 10px;"><SPAN style="TEXT-DECORATION: underline"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7827/2/ScreenCapture2.jpg?user-agent=rss"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="TEXT-DECORATION: underline">Growth Drivers:</SPAN>driven by the oncology portfolio, in particular the medicines for HER2-positive breast cancer, Herceptin, Perjeta and Kadcyla (+21%) </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7827/3/ScreenCapture3.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">Oncology sales up 5% </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7827/4/ScreenCapture4.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG>Roche in Cancer Immunotherapy</STRONG> </div><div><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7827/5/ScreenCapture5.jpg?user-agent=rss"> </div><!-- Comment details --><a name="endocrinology7827attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7827/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(19,6 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7827/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(22,3 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7827/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(34,9 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7827/4/ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(49,8 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7827/5/ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(49,7 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20141231&edate=20140901&rec=7827">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-10-17T09:37:41+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7827/1/ScreenCapture1.jpg" length="20036" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7827/2/ScreenCapture2.jpg" length="22834" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7827/3/ScreenCapture3.jpg" length="35735" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7827/4/ScreenCapture4.jpg" length="50953" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7827/5/ScreenCapture5.jpg" length="50872" type="image/jpeg"/></item><item>
<title>re: Diagnostic for patients with GEP-NETS Granted ODD by EMA</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7825</link>
<description>re: Diagnostic for patients with GEP-NETS Granted ODD by EMA</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7825</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20141231&edate=20140901&rec=7825">re: Diagnostic for patients with GEP-NETS Granted ODD by EMA</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7825">Endocrinology7825</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 16 October 2014 | 18:38</font><br><br><div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Diagnostic for Patients with GEP-NETS Granted ODD by EMA</span>&nbsp;<font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20141231&edate=20140901&cat=headline"><font color="#e95e0b">:Endocrinology:headline</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20141231&edate=20140901&cat=sub%3aDiagnostic"><font color="#e95e0b">:Endocrinology:sub:Diagnostic</font></a>]</font></font><br><span style="font-size: 12px;">Comment: OctreoPharm's OPS202 (future trade name SOMscan) is a new <SUP>68</SUP>Gallium-labeled radiopharmaceutical in clinical development for positron emission tomography (PET, PET/<wbr>CT) with the potential to detect even smallest lesions of NETs.<wbr> Depending on the labeled radionuclide OPS202 can be used for diagnosis (<SUP>68</SUP>Ga) as well as for therapy (<SUP>90</SUP>Y).<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20141231&edate=20140901&rec=7583">...</a><br><font size="-1">Brigitte DESCHAMPS / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7583" class="commentpermalink">Endocrinology7583</a> / <span class="date">29 January 2014</span> /
<span class="time">16:12:51 o'clock CET</span>
</font></div><div style="margin-bottom: 10px;">OctreoPharm's OPS202 has received US FDA ODD for the management of neuroendocrine tumors.<wbr> </div><div style="margin-bottom: 10px;">Status: Ph1/<wbr>2 </div><div>MOA: has the potential to improve the Imaging of NET patients </div><!-- Comment details --><font size="-1">Brigitte DESCHAMPS / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7825" class="commentpermalink">Endocrinology7825</a> / <span class="date">16 October 2014</span> /
<span class="time">18:38:02 o'clock CEST</span>
</font><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20141231&edate=20140901&rec=7825">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7583">View thread  Endocrinology7583: Diagnostic for Patients with GEP-NETS Granted ODD by EMA</a>]]></content:encoded><dc:date>2014-10-16T18:38:02+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Study Assessed Different Bowel Preparations for Colonoscopy in Children [sub:CRCPrevention]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2074</link>
<description>Study Assessed Different Bowel Preparations for Colonoscopy in Children [sub:CRCPrevention]</description><category>sub:CRCPrevention</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2074</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2074">Study Assessed Different Bowel Preparations for Colonoscopy in Children</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20141231&edate=20140901&cat=sub%3aCRCPrevention"><font color="#e95e0b">:GastroEnterology:sub:CRCPrevention</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2074">GastroEnterology2074</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 16 October 2014 | 18:31</font><br><br><div style="margin-bottom: 10px;">Comment: Recently published findings indicate that sodium picosulfate plus magnesium oxide and citric acid would appear as the most suitable regimen because of its higher tolerability and acceptability profile, and thus represent a promising regimen for bowel preparation in children.<wbr> Although the composition of the preparation relates to PrepoPik, the study was not sponsored by Ferring.<wbr> </div><div style="margin-bottom: 10px;"><H4>BACKGROUND</H4> </div><div style="margin-bottom: 10px;">The ideal preparation regimen for pediatric colonoscopy remains elusive, and available preparations continue to represent a challenge for children.<wbr> The aim of this study was to compare the efficacy, safety, tolerability, and acceptance of 4 methods of bowel cleansing before colonoscopy in children.<wbr> </div><div style="margin-bottom: 10px;"><H4>METHODS</H4> </div><div style="margin-bottom: 10px;">This randomized, investigator-blinded, noninferiority trial enrolled all children aged 2 to 18 years undergoing elective colonoscopy in a referral center for pediatric gastroenterology.<wbr> Patients were randomly assigned to receive polyethylene glycol (PEG) 4000 with simethicon (PEG-ELS group) or PEG-4000 with citrates and simethicone plus bisacodyl (PEG-CS+Bisacodyl group), or PEG 3350 with ascorbic acid (PEG-Asc group), or sodium picosulfate plus magnesium oxide and citric acid (NaPico+MgCit group).<wbr> Bowel cleansing was evaluated according to the Boston Bowel Preparation Scale.<wbr> The primary end point was overall colon cleansing.<wbr> Tolerability, acceptability, and compliance were also evaluated.<wbr> </div><div style="margin-bottom: 10px;"><H4>RESULTS</H4> </div><div style="margin-bottom: 10px;">Two hundred ninety-nine patients were randomly allocated to the 4 groups.<wbr> In the per-protocol analysis, PEG-CS+Bisacodyl, PEG-Asc, and NaPico+MgCit were noninferior to PEG-ELS in bowel-cleansing efficacy of both the whole colon (P = .<wbr>910) and colonic segments.<wbr> No serious adverse events occurred in any group.<wbr> Rates of tolerability, acceptability, and compliance were significantly higher in the NaPico+MgCit group.<wbr> </div><div style="margin-bottom: 10px;"><H4>CONCLUSIONS</H4> </div><div style="margin-bottom: 10px;">Low-volume PEG preparations (PEG-CS+Bisacodyl, PEG-Asc) and NaPico+MgCit are noninferior to PEG-ELS in children, representing an attractive alternative to high-volume regimens in clinical practice.<wbr> Because of the higher tolerability and acceptability profile, NaPico+MgCit would appear as the most suitable regimen for bowel preparation in children.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Trial Details </FONT></STRONG><A href="http://clinicaltrials.gov/ct2/show/NCT01711437?term=colonoscopy+children&amp;rank=4&amp;submit_fld_opt=">NCT01711437</A> </div><div>Reference Bowel Preparations for Colonoscopy: An RCT - Pediatrics.<wbr> 2014 Aug;134(2):249-56. doi: 10.<wbr>1542/<wbr>peds.<wbr>2014-0131.<wbr> Epub 2014 Jul 7.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2074">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-10-16T18:31:36+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Allergan Looks To Strengthen Its Botox Cosmetic Label [sub:Aesthetics, prod:Botox]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7774</link>
<description>Allergan Looks To Strengthen Its Botox Cosmetic Label [sub:Aesthetics, prod:Botox]</description><comments>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7774</comments><category>sub:Aesthetics</category><category>prod:Botox</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7774</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7774">Allergan Looks To Strengthen Its Botox Cosmetic Label</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20141231&edate=20140901&cat=prod%3aBotox"><font color="#e95e0b">:Neurology:prod:Botox</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20141231&edate=20140901&cat=sub%3aAesthetics"><font color="#e95e0b">:Neurology:sub:Aesthetics</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7774">Neurology7774</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 16 October 2014 | 14:54</font><br><br><div style="margin-bottom: 10px;">Comment: Allergan has initiated two significant phIII trials aimed at 
extending its label for Botox Cosmetic to include the frontalis.<wbr> Together 
the trials will include1150 patients.<wbr> The studies are scheduled to start 
this month and complete in terms of PE in August 15 
and SE October 2016.<wbr> </div><div style="margin-bottom: 10px;">Details of the studies are as follows:- </div><div style="margin-bottom: 10px;">1.<wbr> A safety and efficacy study of onabotulinumtoxinA in subjects with 
moderate to severe forehead lines, glabellar lines, and 
crow's feet lines (N=750) </div><div style="margin-bottom: 10px;">Primary Endpoint:-Percentage of Subjects with at Least 
a 2-Grade Improvement from Baseline in Forehead Line Severity at Maximum Eyebrow 
Elevation as Assessed by Both the Investigator and Subject on the 4-Point Facial 
Wrinkle Scale (FWS) [ Time Frame: Baseline, Day 30 ] </div><div style="margin-bottom: 10px;">Secondary Outcome Measure: Duration of Drug Effect for Subjects Who 
Receive Clinical Benefit at Day 30 Using the 4-Point Facial Wrinkle Scale (FWS) 
[ Time Frame: 12 Months ] </div><div style="margin-bottom: 10px;"><TABLE border="0" cellpadding="0" cellspacing="0" class="layout_table" style="MARGIN-TOP: 1ex" summary="Layout table for additional information"><TBODY><TR valign="top"><TD headers="colTitle">ClinicalTrials.<wbr>gov Identifier:</TD>
<TD headers="colData" style="PADDING-LEFT: 1em"><A class="study-link" href="http://clinicaltrials.gov/show/NCT02261493" title="Current version of study NCT02261493 on ClinicalTrials.gov">NCT02261493</A></TD>
</TR>
</TBODY>
</TABLE> </div><div style="margin-bottom: 10px;">Location Miami </div><div style="margin-bottom: 10px;">2.<wbr> A safety and efficacy study of onabotulinumtoxinA in subjects with 
moderate to severe forehead and glabellar 
linesforehead and glabellar facial rhytides 
(frown lines).<wbr> </div><div style="margin-bottom: 10px;">Primary Endpoint : Percentage of Subjects with at 
Least a 2-Grade Improvement from Baseline in Forehead Line Severity at Maximum 
Eyebrow Elevation as Assessed by Both the Investigator and Subject on the 
4-Point Facial Wrinkle Scale (FWS) [ Time Frame: Baseline, Day 
30 ] </div><div style="margin-bottom: 10px;">Secondary Endpoint Duration of Drug Effect for 
Subjects Who Receive Clinical Benefit at Day 30 Using the 4-Point Facial Wrinkle 
Scale (FWS) [ Time Frame: 12 Months ] </div><div style="margin-bottom: 10px;"><TABLE border="0" cellpadding="0" cellspacing="0" class="layout_table" style="MARGIN-TOP: 1ex" summary="Layout table for additional information"><TBODY><TR valign="top"><TD headers="colTitle">ClinicalTrials.<wbr>gov Identifier:</TD>
<TD headers="colData" style="PADDING-LEFT: 1em"><A class="study-link" href="http://clinicaltrials.gov/show/NCT02261467" title="Current version of study NCT02261467 on ClinicalTrials.gov">NCT02261467</A></TD>
</TR>
</TBODY>
</TABLE> </div><div>Location -Metairie, Louisiana, United States </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Neurology7784c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div>We will expect Botox/<wbr>Vistabel to get the "upper face" indication approved in 2017-2018 (Glabellar Lines, Lateral Canthal Lines and Frontalis Lines).<wbr> </div><font size="-1">brv82696 / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7784" class="commentpermalink">Neurology7784</a> / <span class="date">24 October 2014</span> /
<span class="time">10:15:16 o'clock CEST</span>
</font></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7774">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-10-16T14:54:55+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>Harvard Business Review Ranks David Pyott the 4th Best Performing CEO In The World [:PharmaWorld:sub:People, :PharmaWorld:sub:Finance]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7773</link>
<description>Harvard Business Review Ranks David Pyott the 4th Best Performing CEO In The World [:PharmaWorld:sub:People, :PharmaWorld:sub:Finance]</description><category>sub:People</category><category>sub:Finance</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7773</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7773">Harvard Business Review Ranks David Pyott the 4th Best Performing CEO In The World</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=sub%3aFinance"><font color="#e95e0b">:PharmaWorld:sub:Finance</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=sub%3aPeople"><font color="#e95e0b">:PharmaWorld:sub:People</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7773">Neurology7773</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 16 October 2014 | 14:24</font><br><br><div style="margin-bottom: 10px;">Comment: Allergan's CEO David Pyott was selected for this honour out of a 
total of 832 current CEOs in 30 countries who qualified for consideration.<wbr> The 
list published in HBR's November 2014 issue ranks CEOs based upon 
performance over their entire tenure.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Methodology Deployed</STRONG> </div><div style="margin-bottom: 10px;">For each CEO, HBR looked at three quantitative metrics: - </div><div style="margin-bottom: 10px;"><OL><LI>Industry-adjusted shareholder returns, </LI>
<LI>Country-adjusted shareholder returns, and </LI>
<LI>Increase in market capitalization over the CEO's tenure.<wbr> </LI>
</OL> </div><div style="margin-bottom: 10px;">HBR designed its methodology to make an objective determination of which 
global CEOs have had the greatest success delivering results over the long-term.<wbr> </div><div style="margin-bottom: 10px;">Reputation and anecdote had no bearing on the outcome of the ranking.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Allergan's Record Since Pyott Was Appointed</STRONG> </div><div style="margin-bottom: 10px;">Since becoming Allergan’s CEO in January 1998, Mr.<wbr> Pyott has delivered a 
country-adjusted shareholder return of 1,948% and an industry-adjusted 
shareholder return of 1,929%.<wbr> Allergan’s increase in market capitalization 
during this same period has exceeded $50 billion.<wbr> </div><div>Source: <A href="http://www.marketwatch.com/story/harvard-business-review-ranks-david-pyott-one-of-the-top-5-ceos-in-the-world-2014-10-15?reflink=MW_news_stmp">http:/<wbr>/<wbr>www.<wbr>marketwatch.<wbr>com/<wbr>story/<wbr>harvard-business-review-ranks-david-pyott-one-of-the-top-5-ceos-in-the-world-2014-10-15?reflink=MW_news_stmp</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7773">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-10-16T14:24:02+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>Bayer to Assess Phytomedicine as Add-On Therapy for Ulcerative Colitis</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2071</link>
<description>Bayer to Assess Phytomedicine as Add-On Therapy for Ulcerative Colitis</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2071</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2071">Bayer to Assess Phytomedicine as Add-On Therapy for Ulcerative Colitis</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2071">GastroEnterology2071</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 16 October 2014 | 09:30</font><br><br><div style="margin-bottom: 10px;">Comment: <STRONG> </STRONG>Iberogast<SUP>&reg;</SUP> is clinically proven to relieve the uncomfortable symptoms of IBS and indigestion, including bloating, pain, reflux and nausea.<wbr> Also known as STW5, it is a liquid formulation of nine herbs.<wbr> It was developed in Germany in 1961 and is available (without prescription) in other countries.<wbr>The POC trial will evaluate 12 weeks 20 drops three time daily in approx 100 participants.<wbr> PE is to measure proportion of patients being in remission at final visit.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>What is Iberogast<SUP>&reg;</SUP></STRONG> </div><div style="margin-bottom: 10px;">Iberogast<SUP>&reg; </SUP>is a mixture of extracts from bitter candytuft (<EM>Iberis amara</EM>), angelica root (<EM>Angelicae radix</EM>), milk thistle fruit (<EM>Silybi mariani fructus</EM>), celandine herb (<EM>Chelidonii herba</EM>), caraway fruit (<EM>Carvi fructus</EM>), liquorice root (<EM>Liquiritiae radix</EM>), peppermint herb (<EM>Menthae piperitae folium</EM>), balm leaf (<EM>Melissae folium</EM>) and chamomile flower (<EM>Matricariae flos</EM>).<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Business Development</STRONG> </div><div style="margin-bottom: 10px;">Q2:2013 Bayer signed an agreement to acquire 100% of the shares of Steigerwald Arzneimittelwerk GmbH, Darmstadt, Germany, a privately held pharmaceutical company specializing in pharmacy-only herbal medicines.<wbr> Steigerwald's product portfolio includes<STRONG> Iberogast<SUP>&reg;</SUP> </STRONG>for the treatment of functional gastrointestinal disorders.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Trial Details</STRONG> </div><div style="margin-bottom: 10px;"><a href="http://www.clinicaltrials.gov/ct2/show/NCT02246686?recr=Open&no_unk=Y&phase=012&fund=2&rcv_s=09%2F16%2F2014&rank=152" class="defaultlink">NCT02246686</a> </div><div style="margin-bottom: 10px;">Timelines: Oct 2014 /<wbr> Dec 2015 </div><div style="margin-bottom: 10px;"><P style="margin-top: 0ex; margin-bottom: 1ex;">Inclusion Criteria:</P> </div><div style="margin-bottom: 10px;"><UL style="margin-top: 1ex; margin-bottom: 1ex;"><LI class="color-bullet" style="margin-top: 0.7ex;">Patients with mild to moderate active ulcerative colitis (UC), i.<wbr>e.<wbr> Clinical Activity Index (CAI) &ge; 5 up to 10 points (including)
</LI>
<LI class="color-bullet" style="margin-top: 0.7ex;">Patients in whom the active UC is treated independent from any participation in the current study with oral mesalazine at least 14 days up to maximal 28 days before Visit 2
</LI>
<LI class="color-bullet" style="margin-top: 0.7ex;">Age between 18 to 80 years (including)
</LI>
<LI class="color-bullet" style="margin-top: 0.7ex;">UC may reach from left-sided colitis to pancolitis
</LI>
</UL> </div><div><P class="color-bullet" style="margin-top: 0.7ex;">Location: Germany</P> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2071">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-10-16T09:30:24+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>J&amp;J Is Initiating A Ph3 Study To Evaluate ARN509 + Abiraterone In Chemo Naive mCRPC [comp:JnJ, dis:Prostate]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology10050</link>
<description>J&amp;J Is Initiating A Ph3 Study To Evaluate ARN509 + Abiraterone In Chemo Naive mCRPC [comp:JnJ, dis:Prostate]</description><category>comp:JnJ</category><category>dis:Prostate</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology10050</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10050">J&J Is Initiating A Ph3 Study To Evaluate ARN509 + Abiraterone In Chemo Naive mCRPC</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=comp%3aJnJ"><font color="#e95e0b">:Oncology:comp:JnJ</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10050">Oncology10050</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/994">Jenny Wu</a> | 15 October 2014 | 19:14</font><br><br><div style="margin-bottom: 10px;">Comment: J&amp;J is initiating (although is not opened for recruitment yet) a Ph3 study to compare the clinical benefit of ARN509 in combination with abiraterone plus prednisone versus abiraterone + prednisolone in patients with chemotherapy na&iuml;ve metastatic castration resistant prostate cancer.<wbr> The estimated enrolment is 960 patients and study is planned to start in November 2014.<wbr> </div><div style="margin-bottom: 10px;">ClinicalTrial ID:<a href="http://clinicaltrials.gov/ct2/show/NCT02257736?cond=prostate+cancer&rcv_d=14&show_rss=Y&sel_rss=new14" class="defaultlink">02257736</a> </div><div style="margin-bottom: 10px;"><TABLE border="0" cellpadding="0" cellspacing="0" class="layout_table" style="margin-bottom: 3ex;" summary="Layout table for enrollment information"><TBODY><TR valign="top"><TD headers="enrollmentInfoTitle" nowrap="nowrap">Estimated Enrollment:</TD>
<TD headers="enrollmentInfoData" style="padding-left: 1em;">960</TD>
</TR>
<TR valign="top"><TD headers="enrollmentInfoTitle" nowrap="nowrap">Study Start Date:</TD>
<TD headers="enrollmentInfoData" style="padding-left: 1em;">November 2014</TD>
</TR>
<TR valign="top"><TD headers="enrollmentInfoTitle" nowrap="nowrap">Estimated Study Completion Date:</TD>
<TD headers="enrollmentInfoData" style="padding-left: 1em;">August 2021</TD>
</TR>
<TR valign="top"><TD headers="enrollmentInfoTitle" nowrap="nowrap">Estimated Primary Completion Date:</TD>
<TD headers="enrollmentInfoData" style="padding-left: 1em;">December 2018 (Final data collection date for primary outcome measure)</TD>
</TR>
</TBODY>
</TABLE> </div><div style="margin-bottom: 10px;">Arm 1  Participants will receive 240 milligram (mg) tablet of JNJ56021927 and 1000 mg tablet of abiraterone acetate (AA) once daily and 10 mg prednisone (P), AAP, twice daily, until disease progression, unacceptable toxicity, or end of treatment, whichever occurs first.<wbr> </div><div style="margin-bottom: 10px;">Arm 2: Participants will receive matching Placebo of JNJ56021927 and 1000 mg tablet of abiraterone acetate (AA) once daily and 10 mg prednisone (P), AAP, twice daily until disease progression, unacceptable toxicity, or end of treatment, whichever occurs first.<wbr> </div><div>This is a randomized, double blind, placebo controlled and multicentre study.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10050">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-10-15T19:14:15+02:00</dc:date><dc:creator>jew60237</dc:creator></item><item>
<title>AZ Will Be Testing Anti-PD1 And CTLA-4 Combination In Bladder Cancer [dis:Bladder, news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology10047</link>
<description>AZ Will Be Testing Anti-PD1 And CTLA-4 Combination In Bladder Cancer [dis:Bladder, news]</description><category>dis:Bladder</category><category>news</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology10047</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10047">AZ Will Be Testing Anti-PD1 And CTLA-4 Combination In Bladder Cancer</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=dis%3aBladder"><font color="#e95e0b">:Oncology:dis:Bladder</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=news"><font color="#e95e0b">:Oncology:news</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10047">Oncology10047</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/994">Jenny Wu</a> | 15 October 2014 | 18:59</font><br><br><div style="margin-bottom: 10px;">Comment: Medimmune (AstraZeneca) will be initiating a Ph1 study to evaluate its Tremelimumab (anti-CTLA4) and MEDI4736 (anti-PD1) in advanced solid tumours including metastatic bladder cancer, small cell lung cancer, soft tissue sarcoma and triple negative breast cancer.<wbr> </div><div style="margin-bottom: 10px;">ClincialTrials ID: <a href="http://clinicaltrials.gov/ct2/show/NCT02261220?cond=Bladder+cancer&lup_s=10%2F01%2F2014&lup_d=14&show_rss=Y&sel_rss=mod14" class="defaultlink">NCT02261220</a> </div><div style="margin-bottom: 10px;"><TABLE border="0" cellpadding="0" cellspacing="0" class="layout_table" style="margin-bottom: 3ex;" summary="Layout table for enrollment information"><TBODY><TR valign="top"><TD headers="enrollmentInfoTitle" nowrap="nowrap">Estimated Enrollment:</TD>
<TD headers="enrollmentInfoData" style="padding-left: 1em;">210</TD>
</TR>
<TR valign="top"><TD headers="enrollmentInfoTitle" nowrap="nowrap">Study Start Date:</TD>
<TD headers="enrollmentInfoData" style="padding-left: 1em;">October 2014</TD>
</TR>
<TR valign="top"><TD headers="enrollmentInfoTitle" nowrap="nowrap">Estimated Study Completion Date:</TD>
<TD headers="enrollmentInfoData" style="padding-left: 1em;">February 2017</TD>
</TR>
</TBODY>
</TABLE> </div><div style="margin-bottom: 10px;">Primary Outcome: Safety </div><div style="margin-bottom: 10px;">Secondary Outcome: Overall response rate, disease control rate, duration of response, PFS, OS, PK and PD </div><div>Notably, the trial also includes biomarkers evaluation as other outcome measures </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10047">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-10-15T18:59:36+02:00</dc:date><dc:creator>jew60237</dc:creator></item><item>
<title>An International Comparative Study Initiated To Evaluate White Light Assisted And SPIES Assisted TURB In Bladder Cancer [dis:Bladder, news, :PharmaWorld:sub:ClinicalTrial]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology10044</link>
<description>An International Comparative Study Initiated To Evaluate White Light Assisted And SPIES Assisted TURB In Bladder Cancer [dis:Bladder, news, :PharmaWorld:sub:ClinicalTrial]</description><category>dis:Bladder</category><category>news</category><category>sub:ClinicalTrial</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology10044</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10044">An International Comparative Study Initiated To Evaluate White Light Assisted And SPIES Assisted TURB In Bladder Cancer</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=dis%3aBladder"><font color="#e95e0b">:Oncology:dis:Bladder</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=news"><font color="#e95e0b">:Oncology:news</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=sub%3aClinicalTrial"><font color="#e95e0b">:PharmaWorld:sub:ClinicalTrial</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10044">Oncology10044</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/994">Jenny Wu</a> | 15 October 2014 | 18:39</font><br><br><div style="margin-bottom: 10px;">Comment: An academia led (Clinical Research Office of the Endourological Society) randomized study is planned to compare the outcome using the Storz Professional Image Enhancement System (SPIES) versus White Light Imaging (WLI) during TURB of non-muscle invasive bladder cancer (NMIBC).<wbr>This study is a multicenter randomized controlled trial in which the efficacy between SPIES assisted and WLI assisted TURB are compared.<wbr> Subjects in the experimental arm (Arm A) will undergo SPIES assisted TURB, whereas subjects in the control arm (Arm B) will receive treatment with WLI assisted TURB only.<wbr> Baseline characteristics will be recorded, as well as short and long-term follow up.<wbr> </div><div style="margin-bottom: 10px;">ClinicalTrials ID: <a href="http://clinicaltrials.gov/ct2/show/NCT02252549?cond=Bladder+cancer&lup_s=09%2F26%2F2014&lup_d=14&show_rss=Y&sel_rss=mod14" class="defaultlink">NCT02252549</a> </div><div style="margin-bottom: 10px;">Estimated Enrollment = 1928 </div><div style="margin-bottom: 10px;">Study Start Date: Nov 2014 </div><div style="margin-bottom: 10px;">Estimated Completion Date: May 2018 </div><div style="margin-bottom: 10px;">Study PI: Jean de la Rosette </div><div style="margin-bottom: 10px;"><DIV class="body3">Primary Outcome Measures:
<UL style="margin-top: 1ex; margin-bottom: 1ex;"><LI class="color-bullet" style="margin-top: 0.7ex;">To compare the recurrence rate of tumour at 12 months following SPIES assisted TURB (Arm A) with White Light Imaging only assisted TURB (Arm B) [ Time Frame: 1 year ] [ Designated as safety issue: No ]
</LI>
</UL>
</DIV> </div><div><DIV class="body3">Secondary Outcome Measures:
<UL style="margin-top: 1ex; margin-bottom: 1ex;"><LI class="color-bullet" style="margin-top: 0.7ex;">1.<wbr> To assess the recurrence rate of tumour at short and long term follow up (3 months and 3 years) after SPIES or WLI assisted TURB in patients with NMIBC.<wbr>
</LI>
<LI class="color-bullet" style="margin-top: 0.7ex;">2.<wbr> To assess the peri-operative morbidity (30 days) between SPIES and WLI assisted TURB by comparing the proportion of adverse events and using the Clavien-Dindo score.<wbr>
</LI>
</UL>
</DIV> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10044">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-10-15T18:39:05+02:00</dc:date><dc:creator>jew60237</dc:creator></item><item>
<title>re: Nuvilex Signed Research Agreement to Study Development of Cannabis-Based Cancer Treatments</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology10043</link>
<description>re: Nuvilex Signed Research Agreement to Study Development of Cannabis-Based Cancer Treatments</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology10043</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10043">re: Nuvilex Signed Research Agreement to Study Development of Cannabis-Based Cancer Treatments</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10043">Oncology10043</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 15 October 2014 | 18:04</font><br><br><div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Nuvilex Signed Research Agreement to Study Development of Cannabis-Based Cancer Treatments</span>&nbsp;<br><span style="font-size: 12px;">Comment: The goal of the research agreement signed with the U.<wbr> of Northern Colorado, is to develop a Cell-in-a-Box<SUP>(R)</SUP> /<wbr>cannabinoid combination that has anticancer effects coupled with low toxicity similar in concept to Nuvilex's pancreatic cancer treatment currently being prepared for Ph2b clinical trials that uses the Cell-in-a-Box<SUP>(R)</SUP> technology with low doses of the chemotherapeutic drug ifosfamide.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=9693">...</a><br><font size="-1">Brigitte DESCHAMPS / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9693" class="commentpermalink">Oncology9693</a> / <span class="date">09 May 2014</span> /
<span class="time">18:23:17 o'clock CEST</span>
</font></div><div style="margin-bottom: 10px;">Nuvilex has submitted an application to the FDA seeking orphan drug designation for its Cell-in-a-Box treatment for pancreatic cancer.<wbr> In September, the company had submitted an application to the EMA for this treatment.<wbr> </div><div style="margin-bottom: 10px;">The company's pancreatic cancer treatment combines the Cell-in-a-Box cellulose-based live cell encapsulation technology with low doses of the anticancer prodrug ifosfamide to provide targeted chemotherapy to these patients.<wbr> </div><div>During the Cell-in-a-Box encapsulation process, cells are enclosed in pin-head-sized capsules, which convert ifosfamide into its cancer-killing form at or near the site of the tumor to increase the efficiency and effectiveness of a patient's treatment.<wbr> </div><!-- Comment details --><font size="-1">Brigitte DESCHAMPS / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10043" class="commentpermalink">Oncology10043</a> / <span class="date">15 October 2014</span> /
<span class="time">18:04:31 o'clock CEST</span>
</font><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10043">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9693">View thread  Oncology9693: Nuvilex Signed Research Agreement to Study Development of Cannabis-Based Cancer Treatments</a>]]></content:encoded><dc:date>2014-10-15T18:04:31+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Synthetic Biologics Appoints GI KOLs to Support Development of its IBS-c Drug [dis:IBS]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2068</link>
<description>Synthetic Biologics Appoints GI KOLs to Support Development of its IBS-c Drug [dis:IBS]</description><category>dis:IBS</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2068</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2068">Synthetic Biologics Appoints GI KOLs to Support Development of its IBS-c Drug</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20141231&edate=20140901&cat=dis%3aIBS"><font color="#e95e0b">:GastroEnterology:dis:IBS</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2068">GastroEnterology2068</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 15 October 2014 | 17:43</font><br><br><div style="margin-bottom: 10px;">Comment: Synthetic Biologics has expanded its Clinical Advisory Board, created to support the development of SYN-010 (oral; statin-class candidate), with four new members.<wbr> The company expects to initiate a Ph2 in H1:2015.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">About the KOLs</FONT></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>William Chey</STRONG>, M.<wbr>D.<wbr>, is a Professor of Medicine, Director of the GI Physiology Laboratory, and Co-Director of the Michigan Bowel Control Program at the University of Michigan.<wbr> Dr.<wbr> Chey's clinical and research interests include: diagnosis and treatment of irritable bowel syndrome (IBS), constipation, fecal incontinence; gastroesophageal reflux disease (GERD), and <I>"H.<wbr> pylori"</I> infection.<wbr> Dr.<wbr> Chey received his medical degree and training in internal medicine from Emory University School of Medicine and went on to complete a fellowship in gastroenterology at the University of Michigan in Ann Arbor, remaining with the University for his academic career.<wbr> The author of more than 250 manuscripts, reviews, and book chapters, Dr.<wbr> Chey serves on the editorial boards of several medical journals in the field of gastroenterology.<wbr> He is Co-Editor-in-Chief of the <I>American Journal of Gastroenterology</I> and of <I>Clinical &amp; Translational Gastroenterology.<wbr></I> </div><div style="margin-bottom: 10px;"><STRONG>Gail M.<wbr> Comer</STRONG>, M.<wbr>D.<wbr>, a board-certified gastroenterologist and hepatologist, has more than 16 years of experience in the pharmaceutical industry, having spent seven years at Abbott Laboratories as a Medical Director, six years in clinical development at Wyeth Research as Senior Medical Director, Senior Director of the BioTherapeutics Research Unit at Pfizer.<wbr> She also served as the Chief Medical Officer at Synergy Pharmaceuticals before starting her own consulting business.<wbr> Throughout her career in the pharmaceutical industry.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Anthony J.<wbr> Lembo</STRONG>, M.<wbr>D.<wbr>, is Associate Professor of Medicine at Harvard Medical School.<wbr> He also serves as the Director of the GI Motility Laboratory at the Beth Israel Deaconess Medical Center's (BIDMC) Division of Gastroenterology in Boston, MA.<wbr> Dr.<wbr> Lembo earned his undergraduate degree in Mathematics at Amherst College and his MD from Tufts Medical School.<wbr> He subsequently completed his Internal Medicine Internship/<wbr>Residency as well as Gastroenterology Fellowship at UCLA Medical Center in Los Angeles, CA.<wbr> Following his fellowship he joined the faculty at UCLA Medical Center where he was Co-Director of the Functional Bowel Disorders and GI Motility Center.<wbr> In 1997 he joined the faculty at BIDMC.<wbr> Dr.<wbr> Lembo is actively researching the role of placebo in functional bowel disorders such as IBS and chronic constipation.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Philip Schoenfeld</STRONG>, M.<wbr>D.<wbr>, MSEd, MSc, is Professor of Medicine at the University of Michigan School of Medicine, Director of the University's Gastrointestinal Epidemiology Training Program, and staff physician in UM's Specialized Functional Bowel Disorder Program.<wbr> He completed his M.<wbr>D.<wbr> and Master's Degree in Medical Education at the University of Pennsylvania School of Medicine, and completed his Master of Science in clinical epidemiology at McMaster University School of Medicine.<wbr> After completing his internal medicine residency at Naval Medical Center, Portsmouth, VA, he completed his gastroenterology fellowship at National Naval Medical Center, Bethesda, MD.<wbr> He is currently Associate Editor of <I>Gastroenterology</I>, past Associate Editor (Colon) for the <I>American Journal of Gastroenterology</I>, past Chair of the AGA's Education Committee, past Chair of the AGA's Clinical Practice Section.<wbr> Dr.<wbr> Schoenfeld's research focuses on novel treatments for irritable bowel syndrome and quality improvement in colonoscopy.<wbr> He has co-authored the American College of Gastroenterology (ACG) Evidence-Based Position Statement on Management of Irritable Bowel Syndrome, ACG Evidence-Based Position Statement on Management of Chronic Constipation, ACG Guideline on Colon Cancer Screening, and ASGE/<wbr>ACG Position Statement on Quality Indicators in Colonoscopy </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Synthetic Biologics Snapshot</FONT></STRONG> </div><div style="margin-bottom: 10px;">Founded in 2001, Synthetic Biologics, Inc.<wbr> trades on the NYSE MKT, LLC under the symbol "SYN".<wbr> </div><div style="margin-bottom: 10px;">The Company's principal executive offices are located in Rockville, MD.<wbr> </div><div style="margin-bottom: 10px;">Synthetic Biologics, Inc.<wbr> is a biotechnology company focused on the development of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases.<wbr> </div><div style="margin-bottom: 10px;">The Company is developing: </div><div><UL><LI>an oral biologic to protect the gastrointestinal microflora from the effects of IV antibiotics for the prevention of <EM>C.<wbr> diff</EM> infection, </LI>
<LI>an oral treatment to reduce the impact of methane producing organisms on conditions such as constipation-predominant irritable bowel syndrome (C-IBS), </LI>
<LI>a series of monoclonal antibodies for the treatment of Pertussis and <EM>Acinetobacter</EM> infections, and a biologic targeted at the prevention and treatment of a root cause of a subset of IBS.<wbr></LI>
<LI>In addition, the Company is developing an oral estriol drug for the treatment of relapsing-remitting multiple sclerosis (MS) and cognitive dysfunction in MS</LI>
</UL> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2068">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-10-15T17:43:58+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>New Analyst Reports On Medy-Tox Provide A Progress Update On The Osong Plant &amp; Expansion Plans For Neuronox</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7768</link>
<description>New Analyst Reports On Medy-Tox Provide A Progress Update On The Osong Plant &amp; Expansion Plans For Neuronox</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7768</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7768">New Analyst Reports On Medy-Tox Provide A Progress Update On The Osong Plant & Expansion Plans For Neuronox</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7768">Neurology7768</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 15 October 2014 | 15:35</font><br><br><div style="margin-bottom: 10px;">Comment: Two investment houses have recently published reports on Medy-Tox highlighting some key points that have clearly eminated from the company regarding timelines and geographic expansion.<wbr> As noted in the past, this information requires cautious interpretation and may not be realistic or reconcile with Allergan's own internal expectations especially when it comes to the liquid toxin but is of interest in terms of geographic expansion plans for Neuronox.<wbr> </div><div style="margin-bottom: 10px;">A report from Woori Investment House notes that Medytox plans to complete building its c-GMP plant in Osong in Q215.<wbr> In Q315 Woori anticipates i) production of Innotox samples (for clinical trials) at the Osong plant; and ii) initiation of various phIII clinical trials for Innotox (for both aesthetics and therapeutics) </div><div style="margin-bottom: 10px;"><STRONG>Q314 Earnings Estimate</STRONG> </div><div style="margin-bottom: 10px;">Expectations from Woori are that Medy-tox should post record-high earnings supported by:- </div><div style="margin-bottom: 10px;"><UL><LI>Recognition of the upfront payment from Allergan that was received in Jan 2014 (W3.<wbr>9bn per quarter over the next 5 years)
</LI>
<LI>The recent launch of Innotox (premium) in Korea
</LI>
<LI>Strong sales of Neuramis (hyaluronic filler)
</LI>
</UL> </div><div style="margin-bottom: 10px;">Similarly Yuanta Securities is expecting consolidated 3Q14 sales of W30.<wbr>1bn +198% YoY +87.<wbr>3% QoQ, operating profit of W22.<wbr>7bn (+453.<wbr>7&amp; YOY +139.<wbr>7% QoQ (operating margin 75.<wbr>4%) and net profit of W17.<wbr>5bn (+386.<wbr>1% YOY , +103.<wbr>5% QoQ).<wbr> </div><div style="margin-bottom: 10px;">Besides the quartly income from Allergan's upfront, the group will also benefit from the inflow of a $15m milestone payment from Allergan in August, with Allergan apparently having received confirmation from the FDA and EMA of the necessary requirement to develop and gain marketing approval for the Medytox liquid toxin.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Neuronox Geographic Expansion Plans</STRONG> </div><div style="margin-bottom: 10px;">Woori reports that Medytox is planning an overseas expansion with its Botox biosimilar Neuronox.<wbr> In 2014 the product was launched in Mexico, Chile and Columbia and in 2015 the group plans to launch Neuronox in Russia, initiate phIII trials in the US and seek approval in China.<wbr> </div><div>Sources: Woori Invesstment Report 10/<wbr>10/<wbr>14, Yuanta Securities Report 14/<wbr>101/<wbr>4 </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7768">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-10-15T15:35:06+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>GSK Established Products Sale [news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld11000</link>
<description>GSK Established Products Sale [news]</description><category>news</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld11000</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20141231&edate=20140901&rec=11000">GSK Established Products Sale</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=news"><font color="#e95e0b">:PharmaWorld:news</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld11000">PharmaWorld11000</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 15 October 2014 | 12:02</font><br><br><div style="margin-bottom: 10px;">Comment: According to Reuters, GSK is seeking binding bids by next month for a range of established drugs worth more than $3bn, which it is looking to sell by geographical region.<wbr> Lazards hope to find buyers by the end of the year.<wbr> </div><div style="margin-bottom: 10px;">Potential bidders are reported to include private equity firm KKR in conjunction with Norgine, India's Lupin and Denmark's Lundbeck.<wbr> </div><div style="margin-bottom: 10px;">Lundbeck is reportedly interested in the North America portfolio as is the Indian group Lupin </div><div style="margin-bottom: 10px;">KRK has seemingly teamed up with Netherlands based GI specialist Norgine to acquire some of GSK's drugs sold in Europe </div><div style="margin-bottom: 10px;">A number of other private equity funds interested in healthcare are also looking at some specific products.<wbr> </div><div style="margin-bottom: 10px;">Whilst a bidder could emerge that is interested in the entire portfolio this is a scenario that is considered less likely.<wbr> Private equity funds could have more issues in acquiring the products compared to pharmaceutical manufacturers, as GSK is not planning to sell any of its factories, hence they would have to outsource manufacturing and distribution operations.<wbr> </div><div>The major brands up for sales include the antidepressant Paxil, migraine treatment Imitrex, Zantac for stomach acid and Zofran for nausea.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20141231&edate=20140901&rec=11000">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-10-15T12:02:00+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>GW Pharm's R&amp;D Day Neuro Recap [dis:Spasticity]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7767</link>
<description>GW Pharm's R&amp;D Day Neuro Recap [dis:Spasticity]</description><category>dis:Spasticity</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7767</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7767">GW Pharm's R&D Day Neuro Recap</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20141231&edate=20140901&cat=dis%3aSpasticity"><font color="#e95e0b">:Neurology:dis:Spasticity</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7767">Neurology7767</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 15 October 2014 | 11:41</font><br><br><div style="margin-bottom: 10px;">Comment: This report outlines below the Sativex ongoing programs in cerebral palsy, neuropathic pain and advanced cancer pain (top-line Ph3 results around end of 2014), as well as the emerging pipeline with further orphan projects in autism, DMD/<wbr>ALS and NHIE.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Sativex in MS Spasticity</FONT></STRONG> </div><div style="margin-bottom: 10px;">- approved in 27 countries (ex-US) for MS spasticity </div><div style="margin-bottom: 10px;">- Ph3 IND opened with FDA; subject to SPA, Ph3 trial expected to start in 2015 </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Sativex in Advanced Cancer Pain</FONT></STRONG> </div><div style="margin-bottom: 10px;">All cancer pain trials and other US-targeted studies funded by Otsuka </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7767/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG>Two Core Ph3 Trials (n=380)</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7767/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Sativex in Cerebral Palsy</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7767/3/ScreenCapture3.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Sativex in Neuropathic Pain</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7767/4/ScreenCapture4.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Emerging Pipeline - Spectrum of Cannabinoid Pharmacology</FONT></STRONG> </div><div><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7767/5/ScreenCapture5.jpg?user-agent=rss"> </div><!-- Comment details --><a name="neurology7767attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7767/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(70,6 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7767/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(49,5 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7767/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(56,6 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7767/4/ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(58,4 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7767/5/ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(62,2 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7767">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-10-15T11:41:39+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7767/1/ScreenCapture1.jpg" length="72306" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7767/2/ScreenCapture2.jpg" length="50737" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7767/3/ScreenCapture3.jpg" length="57952" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7767/4/ScreenCapture4.jpg" length="59754" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7767/5/ScreenCapture5.jpg" length="63678" type="image/jpeg"/></item><item>
<title>GW Pharma's Cannabis-Based Drug for Ulcerative Colitis Missed PE [dis:IBD]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2067</link>
<description>GW Pharma's Cannabis-Based Drug for Ulcerative Colitis Missed PE [dis:IBD]</description><category>dis:IBD</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2067</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2067">GW Pharma's Cannabis-Based Drug for Ulcerative Colitis Missed PE</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20141231&edate=20140901&cat=dis%3aIBD"><font color="#e95e0b">:GastroEnterology:dis:IBD</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2067">GastroEnterology2067</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 15 October 2014 | 11:17</font><br><br><div style="margin-bottom: 10px;">Comment: In a Phase II pilot trial involving 60 patients with uncontrolled ulcerative colitis, 41% of those in the treatment arm achieved disease remission compared to 30% taking placebo, a difference that was not statistically significant.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Highlights</FONT></STRONG> </div><div style="margin-bottom: 10px;">Of the 29 patients randomized into the GWP42003 arm of the study, an eyebrow-raising 12 dropped out due to side effects GW described as "minor THC-related adverse events such as dizziness.<wbr>" </div><div style="margin-bottom: 10px;">The 17 patients who remained--a group GW is calling the protocol-compliant population--charted marked benefits on the study's secondary goals, beating out the placebo group in patient- and physician-reported assessments of disease severity.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>PE - Induction of Remission</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2067/3/ScreenCapture3.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG>Safety </STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2067/4/ScreenCapture4.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG>Conclusions</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2067/5/ScreenCapture5.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Trial Design</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2067/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG>Patient Population</STRONG> </div><div><img src="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2067/2/ScreenCapture2.jpg?user-agent=rss"> </div><!-- Comment details --><a name="gastroenterology2067attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2067/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(70,2 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2067/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(104 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2067/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(45,1 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2067/4/ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(46,9 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2067/5/ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(40,6 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2067">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-10-15T11:17:14+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2067/1/ScreenCapture1.jpg" length="71854" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2067/2/ScreenCapture2.jpg" length="106458" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2067/3/ScreenCapture3.jpg" length="46223" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2067/4/ScreenCapture4.jpg" length="47990" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2067/5/ScreenCapture5.jpg" length="41556" type="image/jpeg"/></item><item>
<title>ESMO Intelligence Part 4 - Progress Of Immunotherapy In Prostate And Bladder Cancer [:PharmaWorld:congress:ESMO, headline, dis:Prostate, dis:Bladder, comp:BMS]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology10041</link>
<description>ESMO Intelligence Part 4 - Progress Of Immunotherapy In Prostate And Bladder Cancer [:PharmaWorld:congress:ESMO, headline, dis:Prostate, dis:Bladder, comp:BMS]</description><category>congress:ESMO</category><category>headline</category><category>dis:Prostate</category><category>dis:Bladder</category><category>comp:BMS</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology10041</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10041">ESMO Intelligence Part 4 - Progress Of Immunotherapy In Prostate And Bladder Cancer</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=comp%3aBMS"><font color="#e95e0b">:Oncology:comp:BMS</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=dis%3aBladder"><font color="#e95e0b">:Oncology:dis:Bladder</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=headline"><font color="#e95e0b">:Oncology:headline</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=congress%3aESMO"><font color="#e95e0b">:PharmaWorld:congress:ESMO</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10041">Oncology10041</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/994">Jenny Wu</a> | 14 October 2014 | 18:46</font><br><br><div style="margin-bottom: 10px;">Comment: Immuno-Oncology has generated a lot of buzzes and checkpoint protein inhibitors such as anti-CTLA4 and anti-PD1 have definitely been the centre of the attention.<wbr> One of the prevailing themes at ASCO earlier this year was the growing applications of PD-1 blockade across multiple cancers and these has certainly resonated in ESMO this year.<wbr> What is very different and exciting in ESMO - there has been increasingly more discussions around progress of these immunotherapies in genitourinary cancers - in particular ipilimumab in prostate cancer and the two PD-1 development programmes in bladder cancer.<wbr>Here we provide an overview of what has been discussed around these topics during oral abstract discussions and BMS satellite symposuim.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Immunotherapy In Prostate Cancer - Dose Ipilimumab work for Prostate Cancer ?</STRONG> </div><div style="margin-bottom: 10px;">BMS held an industry sponsored satellite symposium on Friday 26th September to discuss immnuo-oncology approaches in genitourinary cancers.<wbr> Dr.<wbr> Daniel Castellano ( Hospital Universitario 12 de Octubre, Spain) chaired the symposium and Dr David McDermott (Beth Israel Deaconess Medical Center, USA) started the session by re-introducing the idea of how immune response works in the tumour environment.<wbr> Under normal healthy condition, our effective immunosurveillance can aid cancer elimination through antigen presentation and activation of effector cells such as CD8+ and CD4+ T cells.<wbr> This results in clonal expansion of effector cells and production of antibodies and cytokines to potentiate the anti-cancer effect.<wbr> The action of anti-inflammatory cytokines that deactivate effector cells allows control of the magnitude and length of the immune response.<wbr> Immune checkpoint pathway plays a pivotal role in this process and hence a resurgence of interest has resulted in a number of emerging agents to target the immune system including: </div><div style="margin-bottom: 10px;"><UL><LI lang="en-US">CTLA-4
</LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI lang="en-US">PD-1/<wbr>PD-L1
</LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI lang="en-US">LAG-3
</LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI lang="en-US">TIM-3
</LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI lang="en-US">KIR
</LI>
</UL> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/10041/1/1.jpg?user-agent=rss"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/10041/2/2.jpg?user-agent=rss"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/10041/3/3.jpg?user-agent=rss"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/10041/4/4.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">Despite of the negative result that we have heard from ipilimumab post-docetaxel trial, Dr.<wbr> McDermott reaffirms the audience the validity of immunotherapy in genitourinary cancers by discussing the success of sipuleucel-T for the treatment in metastatic castration resistant prostate cancer and IL-2 for the treatment in metastatic renal cell carcinoma.<wbr> However, he stressed that the important lessons we learnt from the ipilimumab story in melanoma are that </div><div style="margin-bottom: 10px;"><STRONG><EM>"early recognition and early intervention is the key to manage toxicity wit immuno-oncology agents</EM></STRONG>" </div><div style="margin-bottom: 10px;">"<STRONG>not everyone is responding to the treatment.<wbr> But once they respond, you tend to see very long term benefit</STRONG>" </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/10041/5/5.jpg?user-agent=rss"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/10041/6/6.jpg?user-agent=rss"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/10041/7/7.jpg?user-agent=rss"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/10041/8/8.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">Professor Winald Gerritsen (Radboud University Medical Centre, Netherlands) then discussed the evolving evidences for the role of immuno-oncology in prostate cancer- Sipuleucel-T is the proof of the principle that the immuno-oncology approach can prolong the survival of men with prostate cancer.<wbr> Phase 3 IMPACT trial demonstrated a median survival benefit of 4.<wbr>1 months.<wbr> Another example is PROSTVAC currently being evaluated in Ph3 trial.<wbr> Professor Gerritsen stated the lessons learnt from these vaccine studies: </div><div style="margin-bottom: 10px;">"<STRONG><EM>These agents tend to work better when disease burden is low that means patients had normal LDH, haemoglobin level, and low PSA level).<wbr></EM> Objective response or PSA response often is rare following treatment of these agents and this is something that you need to discuss with your patients because they live with a PSA response and that's why it is crucial that we have biomarker</STRONG>.<wbr>" Professor Gerritsen.<wbr> </div><div style="margin-bottom: 10px;"><EM><STRONG>We can imagine if you do a study with patients with high tumour loads, we can only expect the benefit is only couple of months - 4 months in general.<wbr> What we should really go for is to start treating these patients earlier and obeying with anti-hormonal treatment</STRONG></EM>.<wbr>" Professor Winald Gerritsen.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/10041/9/9.jpg?user-agent=rss"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/10041/10/10.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/10041/11/11.jpg?user-agent=rss">11 </div><div style="margin-bottom: 10px;">Dr Karium Fizazi (Insitut Gustave Roussy, France) presented the updated OS analysis from CA-184-043 trial that was previously reported as a negative trial.<wbr> Updated OS analysis (ITT population), with survival rates up to 3 years, was consistent with the primary analysis.<wbr> The pre-specified subgroup analyses suggest greater activity in patients with lower disease burden [e.<wbr>g.<wbr>, Ipi vs.<wbr> Pbo, pts with (HR 1.<wbr>17, 0.<wbr>89&ndash;1.<wbr>53) or without (0.<wbr>74, 0.<wbr>61&ndash;0.<wbr>89) visceral metastases].<wbr> The safety profile with extended follow-up was similar to that reported previously, which included immune-related AEs (irAEs) (gastrointestinal, dermatologic, endocrine, and hepatic).<wbr> Most irAEs were manageable with established Ipi treatment algorithms.<wbr> </div><div style="margin-bottom: 10px;">"<EM><STRONG>This is only post-hoc analysis - but indicating that we probably should do more studies in patient s with low disease burden</STRONG></EM>" Professor Winald Gerritsen </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/10041/14/14.jpg.png?user-agent=rss"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/10041/15/15.jpg.png?user-agent=rss"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/10041/16/16.jpg.png?user-agent=rss"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/10041/17/17.jpg.png?user-agent=rss"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/10041/18/18jpg.png?user-agent=rss"> </div><div style="margin-bottom: 10px;"><SPAN style="text-decoration: underline;"><STRONG>ADT+ Ipilimumab in hormone na&iuml;ve metastatic prostate cancer</STRONG></SPAN> </div><div style="margin-bottom: 10px;">In parallel, Professor Winald Gerritsen discussed a study presented by Dr Sumit Sbudhi (MD Anderson, US) during oral discussion session for Immunotherapy of Cancer.<wbr> The combination of finite ADT + ipilimumab is being evaluated in hormone na&iuml;ve metastatic prostate cancer.<wbr> The primary endpoint is to estimate the rate of undetectable PSA at 7 months.<wbr> The initial result suggests the combination induced anti-tumour responses with 2 complete radiographic responses and immunological changes were identified in the peripheral blood.<wbr> However, the combination do appear to raise safety concerns with 44% patients experiencing &gt;= 3 grade 3 treatment related AEs.<wbr> Professor Gerritsen pointed out that this trial uses Ipilimumab with a dose of 10 mg/<wbr>Kg that is not current approved dose for advanced melanoma (3mg/<wbr>Kg).<wbr> He thinks future trial should still be considered but with a lower dose of ipilimumab.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/10041/19/19.jpg?user-agent=rss"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/10041/20/20.jpg?user-agent=rss"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/10041/21/21.jpg.png?user-agent=rss"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/10041/22/22.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><SPAN style="text-decoration: underline;"><STRONG> Two PD-1 programmes in progress in advanced/<wbr>metastatic bladder cancer</STRONG></SPAN> </div><div style="margin-bottom: 10px;">Bladder cancer is a disease with a high rate of recurrence and progression after primary treatment.<wbr> Patients in advanced stage do have poor prognosis with a median survival of 4-14 months .<wbr> There is a strong rationale for immunotherapy in localised bladder cancer as BCG has long been established in non muscle invasive bladder cancer.<wbr> Currently supporting evidences for the novel immunotherapy or immuno-modulation strategies are largely preclinical, and clinical investigations are currently on-going.<wbr> Two PD-1 progress in bladder cancer are being presented in ESMO this year - pembrolizumab and MPDL3280A.<wbr> </div><div style="margin-bottom: 10px;">The early finding of Merck (known as MSD outside the United States and Canada)'s pembrolizumab (KEYTRUDA) in PD-L1 positive, advanced urothelial cancer was presented during the Oral session as part of a LATE BREAKING ABSTRACT.<wbr> These data, from a cohort of the on-going Phase 1b KEYNOTE-012 study showed a confirmed overall response rate of 24 percent with KEYTRUDA as monotherapy, as measured by RECIST v1.<wbr>1, central review (n= 7/<wbr>29: 95% CI, 10.<wbr>3-43.<wbr>5) including a complete response rate of 10 percent (3/<wbr>29).<wbr> At the time of analysis, response durations ranged from 16+ to 40+ weeks with six of the seven responders continuing on therapy.<wbr> In the on-going study, 64 percent (61/<wbr>95) of patients screened had tumours that were determined to be positive for PD-L1 expression.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/10041/23/23.jpg?user-agent=rss"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/10041/24/24.jpg?user-agent=rss"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/10041/25/25.jpg?user-agent=rss"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/10041/26/26.jpg?user-agent=rss"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/10041/27/27.jpg?user-agent=rss"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/10041/28/28.jpg?user-agent=rss"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/10041/29/29.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG>MPDL3280A (Roche's anti-PDL1)</STRONG> data was presented first earlier at ASCO 2014 this year.<wbr> Dr Joaquim Bellmunt (US) presented the data during the Proffered Paper session.<wbr> The clinical response and safety profile is consistent to what was previously reported in ASCO.<wbr> This warrants additional studies of MDL3280A in bladder cancer are being planned.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/10041/30/30.jpg?user-agent=rss"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/10041/31/31.jpg?user-agent=rss"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/10041/31/31.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/10041/32/32.jpg?user-agent=rss"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/10041/33/33.jpg?user-agent=rss"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/10041/34/34.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">Dr Maria De Santis (Austria) discussed both PD-1 trials in bladder cancer and acknowledged that clinical benefit is consistent across two trials although patient population is slightly different (MSD 's trial only includes PDL1+ patients.<wbr> This brings to a question of " if PD-1 is a good biomarker and the need of standardised assay across the trials" </div><div><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/10041/40/40.jpg?user-agent=rss"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/10041/41/41.jpg?user-agent=rss"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/10041/42/42.jpg?user-agent=rss"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/10041/43/43.jpg?user-agent=rss"> </div><!-- Comment details --><a name="oncology10041attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10041/1/1.jpg">1.jpg</a>&nbsp;&nbsp;(951,8 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10041/2/2.jpg">2.jpg</a>&nbsp;&nbsp;(893,9 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10041/3/3.jpg">3.jpg</a>&nbsp;&nbsp;(983,3 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10041/4/4.jpg">4.jpg</a>&nbsp;&nbsp;(941,9 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10041/5/5.jpg">5.jpg</a>&nbsp;&nbsp;(1,1 MB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10041/6/6.jpg">6.jpg</a>&nbsp;&nbsp;(969 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10041/7/7.jpg">7.jpg</a>&nbsp;&nbsp;(910 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10041/8/8.jpg">8.jpg</a>&nbsp;&nbsp;(1,1 MB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10041/9/9.jpg">9.jpg</a>&nbsp;&nbsp;(926,5 KB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10041/10/10.jpg">10.jpg</a>&nbsp;&nbsp;(939,4 KB)<br>&nbsp;&nbsp;11.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10041/11/11.jpg">11.jpg</a>&nbsp;&nbsp;(894,4 KB)<br>&nbsp;&nbsp;12.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10041/12/12.jpg">12.jpg</a>&nbsp;&nbsp;(972,5 KB)<br>&nbsp;&nbsp;13.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10041/13/13.jpg">13.jpg</a>&nbsp;&nbsp;(1 MB)<br>&nbsp;&nbsp;14.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10041/14/14.jpg.png">14.jpg.png</a>&nbsp;&nbsp;(17,3 KB)<br>&nbsp;&nbsp;15.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10041/15/15.jpg.png">15.jpg.png</a>&nbsp;&nbsp;(20,4 KB)<br>&nbsp;&nbsp;16.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10041/16/16.jpg.png">16.jpg.png</a>&nbsp;&nbsp;(23,5 KB)<br>&nbsp;&nbsp;17.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10041/17/17.jpg.png">17.jpg.png</a>&nbsp;&nbsp;(21,7 KB)<br>&nbsp;&nbsp;18.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10041/18/18jpg.png">18jpg.png</a>&nbsp;&nbsp;(30 KB)<br>&nbsp;&nbsp;19.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10041/19/19.jpg">19.jpg</a>&nbsp;&nbsp;(930,9 KB)<br>&nbsp;&nbsp;20.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10041/20/20.jpg">20.jpg</a>&nbsp;&nbsp;(1 010,8 KB)<br>&nbsp;&nbsp;21.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10041/21/21.jpg.png">21.jpg.png</a>&nbsp;&nbsp;(741,2 KB)<br>&nbsp;&nbsp;22.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10041/22/22.jpg">22.jpg</a>&nbsp;&nbsp;(884,1 KB)<br>&nbsp;&nbsp;23.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10041/23/23.jpg">23.jpg</a>&nbsp;&nbsp;(921,8 KB)<br>&nbsp;&nbsp;24.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10041/24/24.jpg">24.jpg</a>&nbsp;&nbsp;(929,8 KB)<br>&nbsp;&nbsp;25.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10041/25/25.jpg">25.jpg</a>&nbsp;&nbsp;(971,3 KB)<br>&nbsp;&nbsp;26.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10041/26/26.jpg">26.jpg</a>&nbsp;&nbsp;(924,6 KB)<br>&nbsp;&nbsp;27.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10041/27/27.jpg">27.jpg</a>&nbsp;&nbsp;(948,6 KB)<br>&nbsp;&nbsp;28.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10041/28/28.jpg">28.jpg</a>&nbsp;&nbsp;(947,3 KB)<br>&nbsp;&nbsp;29.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10041/29/29.jpg">29.jpg</a>&nbsp;&nbsp;(895,2 KB)<br>&nbsp;&nbsp;30.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10041/30/30.jpg">30.jpg</a>&nbsp;&nbsp;(924,5 KB)<br>&nbsp;&nbsp;31.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10041/31/31.jpg">31.jpg</a>&nbsp;&nbsp;(897,1 KB)<br>&nbsp;&nbsp;32.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10041/32/32.jpg">32.jpg</a>&nbsp;&nbsp;(951,3 KB)<br>&nbsp;&nbsp;33.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10041/33/33.jpg">33.jpg</a>&nbsp;&nbsp;(945,5 KB)<br>&nbsp;&nbsp;34.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10041/34/34.jpg">34.jpg</a>&nbsp;&nbsp;(987,1 KB)<br>&nbsp;&nbsp;35.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10041/35/35.jpg">35.jpg</a>&nbsp;&nbsp;(993,8 KB)<br>&nbsp;&nbsp;36.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10041/36/36.jpg">36.jpg</a>&nbsp;&nbsp;(977,2 KB)<br>&nbsp;&nbsp;37.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10041/37/37.jpg">37.jpg</a>&nbsp;&nbsp;(909,9 KB)<br>&nbsp;&nbsp;38.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10041/38/38.jpg">38.jpg</a>&nbsp;&nbsp;(926,5 KB)<br>&nbsp;&nbsp;39.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10041/39/39.jpg">39.jpg</a>&nbsp;&nbsp;(979,7 KB)<br>&nbsp;&nbsp;40.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10041/40/40.jpg">40.jpg</a>&nbsp;&nbsp;(984,6 KB)<br>&nbsp;&nbsp;41.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10041/41/41.jpg">41.jpg</a>&nbsp;&nbsp;(964,6 KB)<br>&nbsp;&nbsp;42.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10041/42/42.jpg">42.jpg</a>&nbsp;&nbsp;(971,7 KB)<br>&nbsp;&nbsp;43.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10041/43/43.jpg">43.jpg</a>&nbsp;&nbsp;(1 MB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10041">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-10-14T18:46:53+02:00</dc:date><dc:creator>jew60237</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10041/1/1.jpg" length="974693" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10041/2/2.jpg" length="915332" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10041/3/3.jpg" length="1006890" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10041/4/4.jpg" length="964498" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10041/5/5.jpg" length="1101468" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10041/6/6.jpg" length="992232" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10041/7/7.jpg" length="931820" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10041/8/8.jpg" length="1110395" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10041/9/9.jpg" length="948787" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10041/10/10.jpg" length="961936" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10041/11/11.jpg" length="915868" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10041/12/12.jpg" length="995821" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10041/13/13.jpg" length="1065151" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10041/14/14.jpg.png" length="17670" type="image/x-png"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10041/15/15.jpg.png" length="20877" type="image/x-png"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10041/16/16.jpg.png" length="24062" type="image/x-png"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10041/17/17.jpg.png" length="22216" type="image/x-png"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10041/18/18jpg.png" length="30680" type="image/x-png"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10041/19/19.jpg" length="953224" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10041/20/20.jpg" length="1035043" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10041/21/21.jpg.png" length="759028" type="image/x-png"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10041/22/22.jpg" length="905296" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10041/23/23.jpg" length="943873" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10041/24/24.jpg" length="952165" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10041/25/25.jpg" length="994562" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10041/26/26.jpg" length="946838" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10041/27/27.jpg" length="971354" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10041/28/28.jpg" length="970086" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10041/29/29.jpg" length="916704" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10041/30/30.jpg" length="946710" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10041/31/31.jpg" length="918596" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10041/32/32.jpg" length="974130" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10041/33/33.jpg" length="968235" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10041/34/34.jpg" length="1010743" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10041/35/35.jpg" length="1017627" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10041/36/36.jpg" length="1000632" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10041/37/37.jpg" length="931774" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10041/38/38.jpg" length="948757" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10041/39/39.jpg" length="1003191" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10041/40/40.jpg" length="1008223" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10041/41/41.jpg" length="987745" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10041/42/42.jpg" length="994972" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10041/43/43.jpg" length="1096086" type="image/jpeg"/></item><item>
<title>re: Cologuard® Test Under Review for Detecting Colorectal Cancer</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2065</link>
<description>re: Cologuard® Test Under Review for Detecting Colorectal Cancer</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2065</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2065">re: Cologuard® Test Under Review for Detecting Colorectal Cancer</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2065">GastroEnterology2065</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 14 October 2014 | 17:40</font><br><br><div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Cologuard® Test Under Review for Detecting Colorectal Cancer</span>&nbsp;<font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20141231&edate=20140901&cat=sub%3aCRCPrevention"><font color="#e95e0b">:GastroEnterology:sub:CRCPrevention</font></a>]</font></font><br><span style="font-size: 12px;">Comment: The test from Exact Sciences Corp.<wbr> and the Mayo Clinic detects more tumors than methods using blood in the stool, revealed the study.<wbr> Lead author Thomas Imperiale from Indiana U.<wbr> Medical Center in Indianapolis said the test has been to be having about as much potential as colonoscopy has for detecting colon cancer.<wbr> The FDA’s Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee is scheduled to review Exact Science’s PMA application for Cologuard on March 27, 2014.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=1945">...</a><br><font size="-1">Brigitte DESCHAMPS / <a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology1945" class="commentpermalink">GastroEnterology1945</a> / <span class="date">19 March 2014</span> /
<span class="time">16:59:26 o'clock CET</span>
</font></div><div style="margin-bottom: 10px;">The Centers for Medicare and Medicaid Services (CMS) has issued a final National Coverage Determination for US company Exact Sciences' Cologuard, which will come into effect immediately.<wbr> Furthermore, based on a preliminary payment report, the CMS is considering reimbursement of the diagnostic test for the full amount of USD502 requested by Exact Sciences.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Significance</STRONG> </div><div>The CMS's reimbursement decision is positive news for Exact Sciences, as it markets the first US FDA-approved non-invasive colorectal cancer DNA test covered by Medicare.<wbr> Although the payment amount is still preliminary, it is probable that the firm will have the diagnostic test reimbursement for the full amount requested.<wbr> With more than 50 million Medicare patients, many of whom will require regular screenings, the firm is anticipated to generate significant revenues in the future.<wbr> </div><!-- Comment details --><font size="-1">Brigitte DESCHAMPS / <a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2065" class="commentpermalink">GastroEnterology2065</a> / <span class="date">14 October 2014</span> /
<span class="time">17:40:45 o'clock CEST</span>
</font><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2065">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology1945">View thread  GastroEnterology1945: Cologuard® Test Under Review for Detecting Colorectal Cancer</a>]]></content:encoded><dc:date>2014-10-14T17:40:45+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Xofigo Plant Contamination Stops Drug Manufacture &amp; Supply [comp:BayerSchering, dis:Prostate]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology10040</link>
<description>Xofigo Plant Contamination Stops Drug Manufacture &amp; Supply [comp:BayerSchering, dis:Prostate]</description><comments>http://ci.beaufour-ipsen.com/traction/permalink/Oncology10040</comments><category>comp:BayerSchering</category><category>dis:Prostate</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology10040</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10040">Xofigo Plant Contamination Stops Drug Manufacture & Supply</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=comp%3aBayerSchering"><font color="#e95e0b">:Oncology:comp:BayerSchering</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10040">Oncology10040</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 14 October 2014 | 16:44</font><br><br><div style="margin-bottom: 10px;">Comment: A problem has arisen with the manufacturing process for radium-223 
(Xofigo) necessitating that the plant where the drug is made in Norway be 
temporarily shut down.<wbr> The supply of Xofigo to the market seemingly ran out last 
Friday.<wbr> </div><div style="margin-bottom: 10px;">A spokesperson for Bayer is quoted as stating that "At this time Bayer is 
unable to anticipate when distribution of Xofigo can be resumed".<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Type of Manufacturing Issue</STRONG> </div><div style="margin-bottom: 10px;">Individual batches of drugs are inspected prior to release to patients.<wbr> 
Bayer's regular inspection process found that two batches contained material 
unrelated to Xofigo </div><div style="margin-bottom: 10px;"><STRONG>BOTTOM LINE</STRONG> </div><div style="margin-bottom: 10px;">1- Bayer has provided assurance  that any drug received by anyone to 
date is safe and meets all quality standards.<wbr><BR>2- How long this production 
shut down will last is unknown.<wbr><BR>3- Men in the middle of receiving 
Xofigo have been advised to contact their physicians to discuss what, 
if any, alternative treatments might be appropriate at the present time.<wbr> </div><div>Source: <A href="http://advancedprostatecancer.net/?p=4807">http:/<wbr>/<wbr>advancedprostatecancer.<wbr>net/<wbr>?p=4807</A> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Oncology10062c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div>Comment: Bayer has issued an update on the shortage of Xofigo - although they are yet to provide a timeline when Xofigo's supply can be resumed, Bayer has examined available data from ALSYMPCA to understand the impact of treatment delays for patients.<wbr> In the ad hoc analysis of this trial, ~30% (n=178/<wbr>600) of patients had a delay in receiving radium 223.<wbr> Of these 178 patients, 56 patients had elays caused by an adverse event an the remaining 122 patients had delays caused by other reasons.<wbr> The exposure to a full course of 6 injections was similar regarless of whether patients experienced a delay.<wbr> In the statement, Bayer did caution around this is an unplanned sub group analysis.<wbr> </div><font size="-1">Jenny Wu / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10062" class="commentpermalink">Oncology10062</a> / <span class="date">24 October 2014</span> /
<span class="time">21:59:59 o'clock CEST</span>
</font></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10040">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-10-14T16:44:14+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>Concerto Pharm Remains on Track to Advance Once-Daily Oral Treatment for Spasticity [dis:Spasticity]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7766</link>
<description>Concerto Pharm Remains on Track to Advance Once-Daily Oral Treatment for Spasticity [dis:Spasticity]</description><category>dis:Spasticity</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7766</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7766">Concerto Pharm Remains on Track to Advance Once-Daily Oral Treatment for Spasticity</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20141231&edate=20140901&cat=dis%3aSpasticity"><font color="#e95e0b">:Neurology:dis:Spasticity</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7766">Neurology7766</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 14 October 2014 | 16:33</font><br><br><div style="margin-bottom: 10px;">Comment: Concerto reported today Ph1 data of CTP-354 (a subtype-selective GABA<SUB>A</SUB> receptor modulator).<wbr> In this multiple ascending dose trial, no sedation or ataxia was observed, and the drug was generally well tolerated across all dose cohorts.<wbr> The company will be presenting these findings during a poster session at the American Neurological Association’s Annual Meeting in Baltimore, Maryland.<wbr> The Ph2 program is projected to include two trials: one evaluating spasticity associated with spinal cord injury and one evaluating spasticity associated with multiple sclerosis.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Drug Advantage</FONT></STRONG> </div><div style="margin-bottom: 10px;">GABA<SUB>A</SUB> receptors are found in the nervous system and, when activated, reduce the transmission of certain nerve signals.<wbr> Several classes of widely used drugs target GABA<SUB>A</SUB> receptors, including benzodiazepines, but do not have the receptor subtype selectivity of CTP-354.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Management Claims</FONT></STRONG> </div><div style="margin-bottom: 10px;">According to Roger Tung (President &amp; CEO) " .<wbr>.<wbr>.<wbr> In addition to being generally well tolerated in our Phase 1 clinical trials, CTP-354 also demonstrated highly favorable pharmacokinetics with low variability, dose-proportional exposure, a long half-life in the body and high levels of GABAA receptor occupancy.<wbr> Taken together, we believe these results support once-daily dosing, which would provide a substantial improvement over the three-times-daily dosing required by current standard-of-care oral spasticity medicines".<wbr> </div><div style="margin-bottom: 10px;">See Poster <A href="http://www.concertpharma.com/research/documents/CTP-354ANAPoster_FINAL13OCT2014.pdf">here</A> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Timelines</FONT></STRONG> </div><div style="margin-bottom: 10px;">Concert expects to initiate a Ph2 clinical trial evaluating CTP-354 in patients with spasticity associated with spinal cord injury by the end of 2014.<wbr> </div><div>Source: Concerto Pharm </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7766">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-10-14T16:33:44+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>J&amp;J Q3 Earnings Key Takeaway : Zytiga Continues Demonstrating Strong Growth</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology10039</link>
<description>J&amp;J Q3 Earnings Key Takeaway : Zytiga Continues Demonstrating Strong Growth</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology10039</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10039">J&J Q3 Earnings Key Takeaway : Zytiga Continues Demonstrating Strong Growth</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10039">Oncology10039</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/994">Jenny Wu</a> | 14 October 2014 | 16:23</font><br><br><div style="margin-bottom: 10px;">Comment: J&amp;J today announced sales of $18.<wbr>5 billion for the third quarter of 2014, an increase of 5.<wbr>1% as compared to the third quarter of 2013.<wbr>The strong sales results were driven by new products in hepatitis C, rivaroxaban (oral anticoagulant), canagliflozin (type 2 diabetes), abiraterone (mCRPC), ibrutinib (MCL and CLL).<wbr>Notably, abiraterone (Zytiga) continues to exhibit strong growth reporting a $568M sales worldwide and accounting 1/<wbr>2 of J&amp;J's total oncology revenues in Q3.<wbr> The positive contributors include continued increased US market share, new country launches with an increased market penetration.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/10039/1/1.JPG?user-agent=rss"> </div><div><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/10039/2/2.JPG?user-agent=rss"> </div><!-- Comment details --><a name="oncology10039attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10039/1/1.JPG">1.JPG</a>&nbsp;&nbsp;(170,4 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10039/2/2.JPG">2.JPG</a>&nbsp;&nbsp;(159,9 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10039">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-10-14T16:23:53+02:00</dc:date><dc:creator>jew60237</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10039/1/1.JPG" length="174455" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10039/2/2.JPG" length="163729" type="image/jpeg"/></item><item>
<title>A New Class Of Targeted Therapy - CDK4 /6 Inhibitor - Emerges For HER2- ER+ Breast Cancer [dis:Gynea]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology10037</link>
<description>A New Class Of Targeted Therapy - CDK4 /6 Inhibitor - Emerges For HER2- ER+ Breast Cancer [dis:Gynea]</description><comments>http://ci.beaufour-ipsen.com/traction/permalink/Oncology10037</comments><category>dis:Gynea</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology10037</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10037">A New Class Of Targeted Therapy - CDK4 /<wbr>6 Inhibitor - Emerges For HER2- ER+ Breast Cancer</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=dis%3aGynea"><font color="#e95e0b">:Oncology:dis:Gynea</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10037">Oncology10037</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/994">Jenny Wu</a> | 14 October 2014 | 13:12</font><br><br><div style="margin-bottom: 10px;">Comment: Pfizer announced FDA acceptance of palbociclib (a CDK4/<wbr>6 inhibitor) new drug application (NDA) with priority review.<wbr> This NDA requests FDA approval of palbociclib in combination with letrozole as a 1L treatment for postmenopausal women with oestrogen receptor positive, and HER2- advanced breast cancer.<wbr> This acceleration allows shortening of 4 months approval timeline.<wbr> Pfizer first received breakthrough therapy designation from the FDA in April 2013.<wbr> </div><div style="margin-bottom: 10px;">Palbociclib is an investigational oral targeted agent that selectively inhibits cyclin-dependent kinases (CDKs) 4 and 6 to regain cell cycle control and block tumour cell proliferation Loss of cell cycle control is a hallmark of cancer and CDK4/<wbr>6 are overactivated in numerous cancers, leading to loss of proliferative control.<wbr> Preclinical data suggest that dual inhibition of CDK 4/<wbr>6 and ER signalling is synergistic, and it has been shown to stop growth of oestrogen receptor positive breast cancer cell lines during the G1 phase.<wbr> </div><div style="margin-bottom: 10px;">Palbociclib is a potentially "First-In-Class" CDK4/<wbr>6 inhibitor.<wbr> Initial positive data from a Ph2 study demonstrated PFS for the combination with letrozole was 26.<wbr>2 months versus 7.<wbr>5 months.<wbr> However, final data analysis only demonstrated median progression-free survival (PFS) of 20.<wbr>2 months when used in combination with letrozole, versus letrozole as monotherapy - Some deterioration had been expected, the drop to 10 months coupled with a lack of statistically significant overall survival (OS) benefit at this stage may have proved disappointing for some investors.<wbr> Perhaps more importantly, however, is that the palbociclib 'bull thesis' is built around Pfizer's potential opportunity to file the drug based on Phase II data alone.<wbr> Some may expect the drug's development to progress quickly and palbociclib to transform the breast cancer landscape.<wbr> </div><div style="margin-bottom: 10px;">Pfizer has initiated two Phase 3 studies of palbociclib in advanced/<wbr>metastatic breast cancer.<wbr> PALOMA-2 (also known as Study 1008) is a randomized (2:1), multi-centre, double blind Phase 3 study that evaluates palbociclib in combination with letrozole versus letrozole plus placebo as a first-line treatment for post-menopausal patients with ER+, HER2- advanced breast cancer.<wbr> PALOMA-3 (also known as Study 1023) is a randomized (2:1), multi-centre, double blind Phase 3 study that evaluates palbociclib in combination with fulvestrant versus fulvestrant plus placebo in women with hormone receptor-positive (HR+), HER2- metastatic breast cancer whose disease has progressed after prior endocrine therapy.<wbr> PALOMA-2 and PALOMA-3 have recently completed enrolment.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Other Competitors In The Race</STRONG> </div><div style="margin-bottom: 10px;">Also thrown into the mix is the earlier than expected emergence of competitor CDK 4/<wbr>6 inhibitors being developed by Novartis and Eli Lilly.<wbr> Novartis provided no new data for LEE011 at the AACR meeting, but the company did catch observers off-guard in late 2013 when it announced that Phase III studies were already underway, despite not having previously unveiled or discussed any mid-stage data.<wbr> In the past week, Eli Lilly has also revealed details of its planned Phase III study for abemaciclib &ndash; also known as LY2835219 &ndash; and unveiled positive data for the compound at the AACR meeting.<wbr> With very little known about LEE011 due to the stealthy means by which Novartis has advanced its development, analysts were quick to seize on abemaciclib for comparative purposes.<wbr> </div><div style="margin-bottom: 10px;"><TABLE align="center" border="0"><TBODY><TR><TD>Drug Name</TD>
<TD>Company</TD>
<TD>Indications in Development</TD>
<TD>Clinical Development Stage</TD>
</TR>
<TR><TD>Palbociclib</TD>
<TD>Pfizer</TD>
<TD>ER+ HER2+ advanced/<wbr>met Breast Cancer - in combo with letrozole</TD>
<TD>Ph3 - Preregistration</TD>
</TR>
<TR><TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD><A class="submenu1" href="http://www.pharmaetrack.com/DiseaseDetails.aspx?IndicationIDS=1250&amp;IndicationNames=Ovarian%20Cancer" style="font-family: verdana;"><U><FONT color="#0066cc">Ovarian Cancer</FONT></U></A>; <A class="submenu1" href="http://www.pharmaetrack.com/DiseaseDetails.aspx?IndicationIDS=18332&amp;IndicationNames=Glioblastoma%20Multiforme%20(GBM)" style="font-family: verdana;"><U><FONT color="#0066cc">Glioblastoma Multiforme (GBM)</FONT></U></A>; <A class="submenu1" href="http://www.pharmaetrack.com/DiseaseDetails.aspx?IndicationIDS=18349&amp;IndicationNames=Non-Small%20Cell%20Lung%20Cancer" style="font-family: verdana;"><U><FONT color="#0066cc">Non-Small Cell Lung Cancer</FONT></U></A>; <A class="submenu1" href="http://www.pharmaetrack.com/DiseaseDetails.aspx?IndicationIDS=21350&amp;IndicationNames=Liposarcoma" style="font-family: verdana;"><U><FONT color="#0066cc">Liposarcoma</FONT></U></A>; Hepatocellular Carcinoma; Metastatic Melanoma; Refractory Multiple Myeloma; Relapsed Multiple Myeloma</TD>
<TD>Ph2</TD>
</TR>
<TR><TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD>Colorectal, Mantle Cell Lymphoma</TD>
<TD>Ph1</TD>
</TR>
<TR><TD>LEE-011</TD>
<TD>Novartis</TD>
<TD>HR+ HER2- Met Breast Cancer (MONALEESA-2) - in combo with letrozole</TD>
<TD>Ph3</TD>
</TR>
<TR><TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD>Haematological cancer, melanoma, solid tumours</TD>
<TD>Ph2</TD>
</TR>
<TR><TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD><A class="submenu1" href="http://www.pharmaetrack.com/DiseaseDetails.aspx?IndicationIDS=21350&amp;IndicationNames=Liposarcoma" style="font-family: verdana;"><U><FONT color="#0066cc">Liposarcoma</FONT></U></A>; <A class="submenu1" href="http://www.pharmaetrack.com/DiseaseDetails.aspx?IndicationIDS=7771&amp;IndicationNames=Lymphoma" style="font-family: verdana;"><U><FONT color="#0066cc">Lymphoma</FONT></U></A>; <A class="submenu1" href="http://www.pharmaetrack.com/DiseaseDetails.aspx?IndicationIDS=8315&amp;IndicationNames=Head%20And%20Neck%20Cancer" style="font-family: verdana;"><U><FONT color="#0066cc">Head And Neck Cancer</FONT></U></A>; Mantle Cell Lymphoma; Neuroblastoma</TD>
<TD>Ph1</TD>
</TR>
<TR><TD>Abemaciclib</TD>
<TD>Eli Lilly</TD>
<TD>NSCLC, HR+ HER- advanced/<wbr>met Breast Cancer (MONARCH 2) - in combo with Fulvestrant</TD>
<TD>Ph3</TD>
</TR>
<TR><TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD>Mantle Cell Lymphoma</TD>
<TD>Ph2</TD>
</TR>
<TR><TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD>Solid Tumour</TD>
<TD>Ph1</TD>
</TR>
<TR><TD>Roniciclib</TD>
<TD>Bayer</TD>
<TD>SCLC</TD>
<TD>Ph2</TD>
</TR>
<TR><TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD>Solid Tumour</TD>
<TD>Ph1</TD>
</TR>
<TR><TD>G-1T281</TD>
<TD>G1 Therapeutics</TD>
<TD>Chemotherapy induced myelosuppression</TD>
<TD>Ph1</TD>
</TR>
<TR><TD>P-1446</TD>
<TD>Piramal Enterprises</TD>
<TD>Haematological, solid tumour</TD>
<TD>Ph1</TD>
</TR>
</TBODY>
</TABLE> </div><div>Source: Pfizer.<wbr>com &amp; Pharma eTrack </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Endocrinology8029c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div>Novartis has recently listed a new clinical trial for LEE011 in Neuroendocrine Tumors of Foregut Origin (<a href="https://clinicaltrials.gov/ct2/show/NCT02420691?term=LEE011&rank=3&submit_fld_opt=" class="defaultlink">NCT02420691</a>).<wbr> The Phase II trial, not yet open for participant recruitment, is sponsored by the M.<wbr>D.<wbr> Anderson cancer Center in collaboration with Novartis and is designed to learn if LEE011, a novel CDK 4/<wbr>6 inhibitor, could play a role in controlling advanced neuroendocrine tumors of the foregut.<wbr> The safety of the drug will also be assessed during the trial that is supposed to start in July 2015, with estimated primary completion date due in July 2018.<wbr> </div><font size="-1">Giorgia VICENTINI / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology8029" class="commentpermalink">Endocrinology8029</a> / <span class="date">21 April 2015</span> /
<span class="time">12:01:12 o'clock CEST</span>
</font></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10037">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-10-14T13:12:08+02:00</dc:date><dc:creator>jew60237</dc:creator></item><item>
<title>Probi Digestis® Launched in Brazil [sub:Probiotics, :PharmaWorld:mkt:Brazil]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2064</link>
<description>Probi Digestis® Launched in Brazil [sub:Probiotics, :PharmaWorld:mkt:Brazil]</description><category>sub:Probiotics</category><category>mkt:Brazil</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2064</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2064">Probi Digestis® Launched in Brazil</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20141231&edate=20140901&cat=sub%3aProbiotics"><font color="#e95e0b">:GastroEnterology:sub:Probiotics</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=mkt%3aBrazil"><font color="#e95e0b">:PharmaWorld:mkt:Brazil</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2064">GastroEnterology2064</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 14 October 2014 | 12:08</font><br><br><div style="margin-bottom: 10px;">Comment: Probi has signed a distribution agreement with Laboratório Daudt to launch <A href="http://probidigestis.com/">Probi Digestis</A>® during 2015.<wbr> Probi Digestis® is based on Lactobacillus plantarum 299v (DSM 9843), targeting bloating, gas formation and pain.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Probiotic Market in Brazil</FONT></STRONG> </div><div style="margin-bottom: 10px;">Brazil has a growing probiotic market larger than $60 million, according to Euromonitor.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3"><A href="http://www.labdaudt.com.br/en/">About Laboratório Daudt</A></FONT></STRONG> </div><div style="margin-bottom: 10px;">Pharmaceutical manufacturer present in Brazil since 1882 with more than 300 employees and production capacity of over 40 million units per year.<wbr> </div><div style="margin-bottom: 10px;">Daudt develops and markets branded pharmaceutical products, OTCs as well as RX drugs.<wbr> </div><div style="margin-bottom: 10px;">Visiting physicians all over the country, the company covers many specialties including Gastroenterology, Orthopedics, Gynaecologists, Pediatricians, Surgeons, among others.<wbr> Beside medicine, Daudt commercializes cosmetics, medical devices and food suplements, for the health and well being of patients.<wbr> </div><div>Source: Probi </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2064">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-10-14T12:08:12+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Santha/Sanofi's Rotavirus Vaccines Enters Late-Stage Trial [dis:Diarrhoea]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2061</link>
<description>Santha/Sanofi's Rotavirus Vaccines Enters Late-Stage Trial [dis:Diarrhoea]</description><category>dis:Diarrhoea</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2061</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2061">Santha/<wbr>Sanofi's Rotavirus Vaccines Enters Late-Stage Trial</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20141231&edate=20140901&cat=dis%3aDiarrhoea"><font color="#e95e0b">:GastroEnterology:dis:Diarrhoea</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2061">GastroEnterology2061</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 14 October 2014 | 08:04</font><br><br><div style="margin-bottom: 10px;">Comment: The live, oral, ready-to-use tetravalent vaccine is designed to protect young children from severe diarrhea.<wbr> T<FONT size="3"><FONT size="2">he trial is designed to show non-inferiority against a currently licensed vaccine with the use of 3, ready-to-use liquid doses administered orally, starting from six-to-eight weeks of age, with the subsequent doses administered at 4 weeks intervals.<wbr> Close to 1,200 volunteers are being sought at 12 clinical trial sites in India.<wbr> Coinciding wit this annoucement, The International Medica Foundation was reporting yesterday the sublicensing of BravoVax' rotavirus vaccine, in Ph2 fornewborns/<wbr>young infants before they are 60 days old.<wbr></FONT></FONT> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Rationale for the BravoVax' RRV-TV Vaccines</FONT></STRONG> </div><div style="margin-bottom: 10px;">The currently marketed rotavirus vaccines do not protect very young infants since the first dose is usually administered at 2 months of age </div><div style="margin-bottom: 10px;">In addition, they are associated with an increased risk of vaccine associated intussusception (a blockage of the intestine which requires hospitalisation) and they are costly and require expensive refrigerated distribution and storage, a major issue in many resource poor countries.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">About Sanofi Vaccine</FONT></STRONG> </div><div style="margin-bottom: 10px;">Shantha, which was acquired by Sanofi Pasteur Holding in 2009, is a biotechnology pioneer from the emerging countries, founded by Dr.<wbr> K I Varaprasad Reddy in 1993 in Hyderabad, India </div><div style="margin-bottom: 10px;">Shantha’s investigational vaccine is designed to prevent severe rotavirus gastroenteritis in infants and children when administered as a 3-dose series to infants between the ages of 6 to 32 weeks Each dose is an all-in-one formulation containing an antacid.<wbr> The vaccine is a live-attenuated bovine-human reassortant comprising four serotypes, G1, G2, G3 and G4, and is targeted to be safe, confer non-inferior immunogenicity to already licensed vaccines and have the ability to prevent rotavirus gastroenteritis.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Organization Strategies</FONT></STRONG> </div><div style="margin-bottom: 10px;">The World Health Organization (WHO) recommends that vaccination with rotavirus vaccines should be included in all national immunization programs.<wbr> </div><div style="margin-bottom: 10px;"><FONT size="3"><SUP>Gavi, has established an accelerated vaccine introduction initiative with the objective of driving the sustainable introduction of rotavirus vaccine in 30 Gavi-eligible countries by 2015.<wbr> </SUP></FONT> </div><div style="margin-bottom: 10px;"><FONT size="3"><SUP>In addition, PATH, an international, non-profit organization to improve public health, is working to accelerate access to rotavirus vaccines and sustain their implementation and use in countries where children need them most urgently</SUP></FONT> </div><div>Source: Sanofi/<wbr> BravoVax </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2061">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-10-14T08:04:45+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Soft Intelligence On Ferring And J&amp;J [dis:Prostate, comp:JnJ]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology10034</link>
<description>Soft Intelligence On Ferring And J&amp;J [dis:Prostate, comp:JnJ]</description><category>dis:Prostate</category><category>comp:JnJ</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology10034</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10034">Soft Intelligence On Ferring And J&J</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=comp%3aJnJ"><font color="#e95e0b">:Oncology:comp:JnJ</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10034">Oncology10034</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/994">Jenny Wu</a> | 13 October 2014 | 18:37</font><br><br><div>Comment: Soft intelligence from Belgium (Thanks to Frank Vandernonck and Julie Lambillotte) points to Ferring has a new device to allow less pain at the injection site for the prostate cancer patients - have you heard similar comments from your customers? There are also hints of Ferring in Belgium will be co-promoting abiraterone with J&amp;J - given abiraterone is approved to use for both post chemo and chemo na&iuml;ve setting.<wbr> We know that most of the chemo na&iuml;ve patients can be under the care of urologists while the post-chemo patients are under the care of oncologists.<wbr> This could indicate J&amp;J is trying to build a differentiation between urologists and oncologists and avoiding substantial investment in additional urologist sale force.<wbr> We will appreciate your insights from your countries.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10034">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-10-13T18:37:06+02:00</dc:date><dc:creator>jew60237</dc:creator></item><item>
<title>ESMO Intelligence - Novartis's Activities At ESMO [headline, dis:MidGutNET, dis:BronchioNET, dis:pNET, class:mTORInhibitor, comp:Novartis]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7821</link>
<description>ESMO Intelligence - Novartis's Activities At ESMO [headline, dis:MidGutNET, dis:BronchioNET, dis:pNET, class:mTORInhibitor, comp:Novartis]</description><comments>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7821</comments><category>headline</category><category>dis:MidGutNET</category><category>dis:BronchioNET</category><category>dis:pNET</category><category>class:mTORInhibitor</category><category>comp:Novartis</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7821</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20141231&edate=20140901&rec=7821">ESMO Intelligence - Novartis's Activities At ESMO</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20141231&edate=20140901&cat=class%3amTORInhibitor"><font color="#e95e0b">:Endocrinology:class:mTORInhibitor</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20141231&edate=20140901&cat=comp%3aNovartis"><font color="#e95e0b">:Endocrinology:comp:Novartis</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20141231&edate=20140901&cat=dis%3aBronchioNET"><font color="#e95e0b">:Endocrinology:dis:BronchioNET</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20141231&edate=20140901&cat=dis%3aMidGutNET"><font color="#e95e0b">:Endocrinology:dis:MidGutNET</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20141231&edate=20140901&cat=dis%3apNET"><font color="#e95e0b">:Endocrinology:dis:pNET</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20141231&edate=20140901&cat=headline"><font color="#e95e0b">:Endocrinology:headline</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7821">Endocrinology7821</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 13 October 2014 | 18:09</font><br><br><div style="margin-bottom: 10px;">Comment: <FONT face="Calibri"><FONT size="3">Novartis focused its attention throughout the meeting primarily on everolimus.<wbr> highlighting in particular the final RADIANT-3 OS pNET data.<wbr> During its symposium it reinforced its position in pNET with this drug, whilst additionally, highlighting its potential for treatment of lung </FONT><FONT size="3">NET.<wbr> Indicative trends of efficacy were seen in RADIANT -2, with more lung data now anticipated from </FONT><FONT size="3">RADIANT-4 (data now expected next ASCO).<wbr> During the symposium reference to the Clarinet trial was always made in association with the term SSA not lanreotide.<wbr> From an SSA perspective, a poster highligted phI bioequivalence data of Novartis's new Sandostatin LAR formulation with it actively promoted on the Novartis booth.<wbr> Soft intelligence confirmed a Q215 launch plans for the introduction of this new formulation into the US.<wbr> Interestingly, data on the CO-OPERATE-2 study had been expected, but Kjell Oberg confirmed that the study had been stopped with no difference seen between everolimus and everolimus plus pasireotide in pNET patients.<wbr> No further information was forthcoming on this.<wbr> Finally two posters of note presented highlighted interim results from Novartis's GEPNET registry and a new global suvey that is underway.<wbr> </FONT></FONT> </div><div style="margin-bottom: 10px;"><FONT face="Calibri" size="3"><STRONG>RADIANT-3 Final OS Results Data (Presentation by James Yao)</STRONG></FONT> </div><div style="margin-bottom: 10px;"><FONT face="Calibri" size="3"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/38/ScreenCapture46.jpg?user-agent=rss"></FONT> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/39/ScreenCapture47.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/40/ScreenCapture48.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/41/ScreenCapture49.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/42/ScreenCapture50.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><FONT face="Calibri" size="3"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/43/ScreenCapture51.jpg?user-agent=rss"></FONT> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/44/ScreenCapture52.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/45/ScreenCapture53.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/46/ScreenCapture54.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/47/ScreenCapture55.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/48/ScreenCapture56.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><FONT face="Calibri" size="3"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/49/ScreenCapture57.jpg?user-agent=rss"></FONT> </div><div style="margin-bottom: 10px;"><FONT face="Calibri"><FONT size="3"><STRONG>Novartis Symposium "Current Evidence For The Treatment of NET &amp; GIST"</STRONG></FONT></FONT> </div><div style="margin-bottom: 10px;"><FONT face="Calibri"><FONT size="3">This symposium held on Day 1 of the congress was Chaired by Dermot O'Toole (GI Oncologist from Dublin), with the main NET speakers being Simron Singh from Toronto Ontario and Rachel Riechelmann from Brazil.<wbr></FONT></FONT> </div><div style="margin-bottom: 10px;"><FONT face="Calibri" size="3">Introductory comments from Dermot O'Toole focused on the latest pNET incidence data from the Candadian Ontario population</FONT> </div><div style="margin-bottom: 10px;"><FONT face="Calibri"><FONT size="3"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/50/ScreenCapture58.jpg?user-agent=rss"></FONT></FONT> </div><div style="margin-bottom: 10px;"><FONT face="Calibri"><FONT size="3">Whilst Singh's talk was focused on <STRONG>"Advanced pNET: Optimal Treatment Sequence"</STRONG></FONT></FONT> </div><div style="margin-bottom: 10px;"><FONT face="Calibri" size="3">He reviewed the ESMO &amp; ENET guidelines for pNET and also highlighted recently concluded new Candadian guidelines which do include the use of SSAs.<wbr> An overview of results with chemotherapeutic agents was also presented.<wbr></FONT> </div><div style="margin-bottom: 10px;"><FONT face="Calibri"><FONT size="3"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/3/ScreenCapture7.jpg?user-agent=rss"></FONT></FONT> </div><div style="margin-bottom: 10px;"><FONT face="Calibri"><FONT size="3"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/4/ScreenCapture8.jpg?user-agent=rss"></FONT></FONT> </div><div style="margin-bottom: 10px;"><FONT face="Calibri"><FONT size="3"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/5/ScreenCapture9.jpg?user-agent=rss"></FONT></FONT> </div><div style="margin-bottom: 10px;"><FONT face="Calibri"><FONT size="3"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/6/ScreenCapture10.jpg?user-agent=rss"></FONT></FONT> </div><div style="margin-bottom: 10px;"><FONT face="Calibri"><FONT size="3">A patient case was then used to illustrate how and when the various treatment options can be used with the audience questioned at each stage what their choice of therapy would be.<wbr> The disastrous consequences of using chemotherapy were highlighted followed by the progress then made with everolimus.<wbr></FONT></FONT> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/1/ScreenCapture5.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/2/ScreenCapture6.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/7/ScreenCapture11.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/8/ScreenCapture12.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">Following a period of more stable disease, after 8 months the patient's CT scan finally showed progression.<wbr> Again the audience was questioned as to what they would do next </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/9/ScreenCapture13.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">The results show vast majority would opt for for a targeted agent with a strong minority opting for SSA monotherapy.<wbr> </div><div style="margin-bottom: 10px;">Singh noted that targeted options for pNET include everolimus with supportive data coming from the RADIANT-3 trial.<wbr> He highlighted how even at 18 months one third of patients are still responding to the drug.<wbr> Moreoever, he presented data showing that the drug is effective whether patients are pre-treated or not pre-treated with chemotherapy.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/10/ScreenCapture15.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/11/ScreenCapture16.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">The other trial that reported around this time was the Sunitinib trial.<wbr> It was a much smaller trial but one that produced similar results.<wbr> Singh questioned how when we look at these two agents should we decide between them.<wbr> There are no head to head or sequencing trials so it really comes down to each drug's toxicity profile.<wbr> With everolimus the most common toxicity observed is stomatitis, rash and fatigue.<wbr> Infections and pneumonitis can occur but mostly amongst those that are immunocompromised and the more serious side effects you have to monitor for are aneamia and hyperglycaemia especially when you have patients with borderline diabetes.<wbr> For Sunitinib the more common more side effects are diarrhea , nausea and asthenia, others are hypertension and hand- foot syndrome.<wbr> whilst more serious side-effects can include neutropenia and hypertnesion.<wbr> Patients do need to be monitored closelty for these When you make decisions it comes down to access, toxicity, patient preference and individualisation.<wbr> If patient has hypertension I would probably choose everolimus whereas if they have uncnotrollled blood sugars sunitinib </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/12/ScreenCapture18.jpg?user-agent=rss"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/13/ScreenCapture19.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">Singh then turned to focus on the Clarinet study stating the following and always referring to somatostatin analogues rather than lanreotide </div><div style="margin-bottom: 10px;">"Added to this is somewhat of a new development, which is the Clarinet trial published earlier this year.<wbr> It basicly looked at SSAs in neuroendocrine tumours primarilyl mid-gut tumours but it also had a large pNET population.<wbr> When you look at the pNET sub-group although it is not significant you can defintely see there is a trend towards significance for SSAs.<wbr> Some of you voted for this as a treatment option and as I showed you in the guidelines many of us are already doing this, we realised that for some patients SSAs may be an option to control the disease with low levels of toxicity.<wbr>" </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/14/ScreenCapture21.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">Moving on he switched back to the patient case and how treatment was initiated with Everolimus.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/15/ScreenCapture22.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/16/ScreenCapture23.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/17/ScreenCapture24.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">Rachel Riechelmann's (Sao Paulo Brazil) presentation<STRONG> " Challenges in the Diagnosis and Treatment of Lung NET"</STRONG> focused on how difficult lung NET can be to treat.<wbr> A patient case was presented as shown below.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/18/ScreenCapture25.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/19/ScreenCapture26.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/20/ScreenCapture27.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">So because of this isolated lung nodule she was considered to have a lung NET </div><div style="margin-bottom: 10px;">Classification for lung NETS have a particular classification which contrasts with that of other NETs as shown below.<wbr> </div><div style="margin-bottom: 10px;">Patients may not have the typical symptoms either respiratory symptoms or hormonal issues.<wbr> Options to be reviewed in the presentation except for surgey were as shown below.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/21/ScreenCapture29.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/22/ScreenCapture30.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">After the chemo review attention turned back to the case and the audience was asked to vote on what they would do.<wbr> Reichelmann noted that all the answers were OK but did not agree with them.<wbr> It was decided to start with liver embolisation.<wbr> However, this didn't work so well and caused the patient a lot of problems.<wbr> It was chosen because of its availability and cost.<wbr> The audience were questioned again what would they do next.<wbr> There answers are shown below.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/23/ScreenCapture31.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">In fact the patient was started on octreotide 20mg as 30mg was not available.<wbr> Treatment was started with an anti-profliferative intent.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/24/ScreenCapture32.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/25/ScreenCapture33.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">So I added everolimus to octreotide.<wbr> After two months her symptoms improved and then went on to get a beautiful tumour response in the liver.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/26/ScreenCapture34.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/27/ScreenCapture35.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">Reichelmann continued noting that this treatment approach is based on the RADIANT-2 trial.<wbr> It was a phIII trial undertaken with everolimus in patients with GI and lung-functioning NET.<wbr> Below is the data from the lung NET sub-set showing a non statistically significant 13 month median progression favouring everolimus plus octreotide vs 5.<wbr>5 months on placebo.<wbr>The data did not reach statistical significance because of the small numbers of lung NET patients involved but she noted that we will have the final evidence on whether everolimus is effective from the RADIANT-4 trial, which is evaluating everolimus alone vs.<wbr> placebo in patients with silent GI or functioing Lung NET.<wbr> The main primary endpoint is PFs and the results are expected to be presented next ASCO.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/28/ScreenCapture36.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/29/ScreenCapture37.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">Unfortunately the patient's disease deteriorated again 9 months later and the audience was askded to vote again.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/30/ScreenCapture38.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/31/ScreenCapture39.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">She was offered PRRT.<wbr> Initially she demonstrated a good improvement but in fact overall she was not classified as a good responder.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/32/ScreenCapture40.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/33/ScreenCapture41.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">In fact currently there is little evidence on the efficacy of PRRT in lung NET.<wbr> After the course of PRRT the patient was given a break and given supportive care.<wbr> Dacarbazine was tried as a later option but unfortunately she did not respond and died.<wbr> The case illustrates how challenging it is to treat lung NETs and how patients should be referred to centres of excellence for treatment.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/34/ScreenCapture42.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/35/ScreenCapture43.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/36/ScreenCapture44.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/37/ScreenCapture45.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG>Key Novartis Posters of Interest</STRONG> </div><div style="margin-bottom: 10px;"><STRONG>Abstract 1144 P</STRONG> </div><div style="margin-bottom: 10px;"><STRONG>Octreotide Reconstituted in a new vehicle </STRONG>(poster is attached) </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/53/ScreenCapture61.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/51/ScreenCapture59.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/52/ScreenCapture60.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG>Abs 1164</STRONG> </div><div style="margin-bottom: 10px;"><STRONG>Qualifying the NET patient experinece through the first global NET patient survey</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/57/ScreenCapture65.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/58/ScreenCapture66.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG>Abs 1141</STRONG> </div><div style="margin-bottom: 10px;"><STRONG>GEP NET Registry - Interim Results</STRONG> </div><div style="margin-bottom: 10px;">Novartis initiated the GEP NET resistry in 2009 to assess </div><div style="margin-bottom: 10px;">Incidence and prevalence of GEPNET </div><div style="margin-bottom: 10px;">Trends in diagnosis, clinical management and outcomes of GEP NET patients.<wbr> Participating countries were from Asia Pacific, Middle East, North Africa as well as Turkey, Israel and South Africa.<wbr> </div><div style="margin-bottom: 10px;">1005 patients were enrolled from July -09 to Dec 12 with 933 evaluable.<wbr> Median follow-up was 32 months.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/54/ScreenCapture62.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/55/ScreenCapture63.jpg?user-agent=rss"> </div><div><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/56/ScreenCapture64.jpg?user-agent=rss"> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Endocrinology8002c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div>The new sandostatin LAR preparation has become commercially available today in UK.<wbr> Novartis had previously proven bioequivalence between octreotide LAR and the new vehicle (new Sandostatin LAR preparation).<wbr> UK prescribing details can be find on the <a href="http://www.medicines.org.uk/emc/medicine/1321" class="defaultlink">EMC website</a>.<wbr> </div><font size="-1">Giorgia VICENTINI / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology8002" class="commentpermalink">Endocrinology8002</a> / <span class="date">25 March 2015</span> /
<span class="time">17:08:09 o'clock CET</span>
</font></div><a name="endocrinology7821attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/1/ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(127 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/2/ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(93,4 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/3/ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(153,5 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/4/ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(139 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/5/ScreenCapture9.jpg">ScreenCapture9.jpg</a>&nbsp;&nbsp;(120 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/6/ScreenCapture10.jpg">ScreenCapture10.jpg</a>&nbsp;&nbsp;(128,5 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/7/ScreenCapture11.jpg">ScreenCapture11.jpg</a>&nbsp;&nbsp;(132 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/8/ScreenCapture12.jpg">ScreenCapture12.jpg</a>&nbsp;&nbsp;(104,8 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/9/ScreenCapture13.jpg">ScreenCapture13.jpg</a>&nbsp;&nbsp;(78,3 KB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/10/ScreenCapture15.jpg">ScreenCapture15.jpg</a>&nbsp;&nbsp;(113,7 KB)<br>&nbsp;&nbsp;11.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/11/ScreenCapture16.jpg">ScreenCapture16.jpg</a>&nbsp;&nbsp;(145,9 KB)<br>&nbsp;&nbsp;12.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/12/ScreenCapture18.jpg">ScreenCapture18.jpg</a>&nbsp;&nbsp;(648 B)<br>&nbsp;&nbsp;13.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/13/ScreenCapture19.jpg">ScreenCapture19.jpg</a>&nbsp;&nbsp;(128,7 KB)<br>&nbsp;&nbsp;14.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/14/ScreenCapture21.jpg">ScreenCapture21.jpg</a>&nbsp;&nbsp;(142,9 KB)<br>&nbsp;&nbsp;15.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/15/ScreenCapture22.jpg">ScreenCapture22.jpg</a>&nbsp;&nbsp;(118,4 KB)<br>&nbsp;&nbsp;16.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/16/ScreenCapture23.jpg">ScreenCapture23.jpg</a>&nbsp;&nbsp;(72 KB)<br>&nbsp;&nbsp;17.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/17/ScreenCapture24.jpg">ScreenCapture24.jpg</a>&nbsp;&nbsp;(113,4 KB)<br>&nbsp;&nbsp;18.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/18/ScreenCapture25.jpg">ScreenCapture25.jpg</a>&nbsp;&nbsp;(117,8 KB)<br>&nbsp;&nbsp;19.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/19/ScreenCapture26.jpg">ScreenCapture26.jpg</a>&nbsp;&nbsp;(102,8 KB)<br>&nbsp;&nbsp;20.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/20/ScreenCapture27.jpg">ScreenCapture27.jpg</a>&nbsp;&nbsp;(92,4 KB)<br>&nbsp;&nbsp;21.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/21/ScreenCapture29.jpg">ScreenCapture29.jpg</a>&nbsp;&nbsp;(143,4 KB)<br>&nbsp;&nbsp;22.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/22/ScreenCapture30.jpg">ScreenCapture30.jpg</a>&nbsp;&nbsp;(149,2 KB)<br>&nbsp;&nbsp;23.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/23/ScreenCapture31.jpg">ScreenCapture31.jpg</a>&nbsp;&nbsp;(73,3 KB)<br>&nbsp;&nbsp;24.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/24/ScreenCapture32.jpg">ScreenCapture32.jpg</a>&nbsp;&nbsp;(86,8 KB)<br>&nbsp;&nbsp;25.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/25/ScreenCapture33.jpg">ScreenCapture33.jpg</a>&nbsp;&nbsp;(67,4 KB)<br>&nbsp;&nbsp;26.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/26/ScreenCapture34.jpg">ScreenCapture34.jpg</a>&nbsp;&nbsp;(117,6 KB)<br>&nbsp;&nbsp;27.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/27/ScreenCapture35.jpg">ScreenCapture35.jpg</a>&nbsp;&nbsp;(102,2 KB)<br>&nbsp;&nbsp;28.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/28/ScreenCapture36.jpg">ScreenCapture36.jpg</a>&nbsp;&nbsp;(103,5 KB)<br>&nbsp;&nbsp;29.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/29/ScreenCapture37.jpg">ScreenCapture37.jpg</a>&nbsp;&nbsp;(135,6 KB)<br>&nbsp;&nbsp;30.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/30/ScreenCapture38.jpg">ScreenCapture38.jpg</a>&nbsp;&nbsp;(68,1 KB)<br>&nbsp;&nbsp;31.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/31/ScreenCapture39.jpg">ScreenCapture39.jpg</a>&nbsp;&nbsp;(62,4 KB)<br>&nbsp;&nbsp;32.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/32/ScreenCapture40.jpg">ScreenCapture40.jpg</a>&nbsp;&nbsp;(86,8 KB)<br>&nbsp;&nbsp;33.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/33/ScreenCapture41.jpg">ScreenCapture41.jpg</a>&nbsp;&nbsp;(93,5 KB)<br>&nbsp;&nbsp;34.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/34/ScreenCapture42.jpg">ScreenCapture42.jpg</a>&nbsp;&nbsp;(118,9 KB)<br>&nbsp;&nbsp;35.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/35/ScreenCapture43.jpg">ScreenCapture43.jpg</a>&nbsp;&nbsp;(84,7 KB)<br>&nbsp;&nbsp;36.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/36/ScreenCapture44.jpg">ScreenCapture44.jpg</a>&nbsp;&nbsp;(105,5 KB)<br>&nbsp;&nbsp;37.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/37/ScreenCapture45.jpg">ScreenCapture45.jpg</a>&nbsp;&nbsp;(111,7 KB)<br>&nbsp;&nbsp;38.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/38/ScreenCapture46.jpg">ScreenCapture46.jpg</a>&nbsp;&nbsp;(189,4 KB)<br>&nbsp;&nbsp;39.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/39/ScreenCapture47.jpg">ScreenCapture47.jpg</a>&nbsp;&nbsp;(133,3 KB)<br>&nbsp;&nbsp;40.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/40/ScreenCapture48.jpg">ScreenCapture48.jpg</a>&nbsp;&nbsp;(142,5 KB)<br>&nbsp;&nbsp;41.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/41/ScreenCapture49.jpg">ScreenCapture49.jpg</a>&nbsp;&nbsp;(190,7 KB)<br>&nbsp;&nbsp;42.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/42/ScreenCapture50.jpg">ScreenCapture50.jpg</a>&nbsp;&nbsp;(144,8 KB)<br>&nbsp;&nbsp;43.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/43/ScreenCapture51.jpg">ScreenCapture51.jpg</a>&nbsp;&nbsp;(140,6 KB)<br>&nbsp;&nbsp;44.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/44/ScreenCapture52.jpg">ScreenCapture52.jpg</a>&nbsp;&nbsp;(166,2 KB)<br>&nbsp;&nbsp;45.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/45/ScreenCapture53.jpg">ScreenCapture53.jpg</a>&nbsp;&nbsp;(152,4 KB)<br>&nbsp;&nbsp;46.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/46/ScreenCapture54.jpg">ScreenCapture54.jpg</a>&nbsp;&nbsp;(195,4 KB)<br>&nbsp;&nbsp;47.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/47/ScreenCapture55.jpg">ScreenCapture55.jpg</a>&nbsp;&nbsp;(175,1 KB)<br>&nbsp;&nbsp;48.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/48/ScreenCapture56.jpg">ScreenCapture56.jpg</a>&nbsp;&nbsp;(136,6 KB)<br>&nbsp;&nbsp;49.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/49/ScreenCapture57.jpg">ScreenCapture57.jpg</a>&nbsp;&nbsp;(135,4 KB)<br>&nbsp;&nbsp;50.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/50/ScreenCapture58.jpg">ScreenCapture58.jpg</a>&nbsp;&nbsp;(52 KB)<br>&nbsp;&nbsp;51.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/51/ScreenCapture59.jpg">ScreenCapture59.jpg</a>&nbsp;&nbsp;(78,6 KB)<br>&nbsp;&nbsp;52.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/52/ScreenCapture60.jpg">ScreenCapture60.jpg</a>&nbsp;&nbsp;(83,3 KB)<br>&nbsp;&nbsp;53.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/53/ScreenCapture61.jpg">ScreenCapture61.jpg</a>&nbsp;&nbsp;(51,8 KB)<br>&nbsp;&nbsp;54.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/54/ScreenCapture62.jpg">ScreenCapture62.jpg</a>&nbsp;&nbsp;(50,7 KB)<br>&nbsp;&nbsp;55.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/55/ScreenCapture63.jpg">ScreenCapture63.jpg</a>&nbsp;&nbsp;(73,4 KB)<br>&nbsp;&nbsp;56.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/56/ScreenCapture64.jpg">ScreenCapture64.jpg</a>&nbsp;&nbsp;(57,5 KB)<br>&nbsp;&nbsp;57.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/57/ScreenCapture65.jpg">ScreenCapture65.jpg</a>&nbsp;&nbsp;(108,3 KB)<br>&nbsp;&nbsp;58.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/58/ScreenCapture66.jpg">ScreenCapture66.jpg</a>&nbsp;&nbsp;(69,5 KB)<br>&nbsp;&nbsp;59.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/59/Abstract%201144P.New%20Sandostatin%20Device%20pdf.pdf">Abstract 1144P.New Sandostatin Device pdf.pdf</a>&nbsp;&nbsp;(215,2 KB)<br>&nbsp;&nbsp;60.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/60/Abs%201141PD.pdf%20Interim%20Results%20From%20GEPNET%20Registry.pdf">Abs 1141PD.pdf Interim Results From GEPNET Registry.pdf</a>&nbsp;&nbsp;(289,5 KB)<br>&nbsp;&nbsp;61.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/61/Abs1164TiP.Qualifying%20the%20NET%20Patient%20Experience%201st%20Global%20NET%20patient%20survey%20pdf.pdf">Abs1164TiP.Qualifying the NET Patient Experience 1st Global NET patient survey pdf.pdf</a>&nbsp;&nbsp;(1,2 MB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20141231&edate=20140901&rec=7821">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-10-13T18:09:52+02:00</dc:date><dc:creator>jac89886</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/1/ScreenCapture5.jpg" length="130035" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/2/ScreenCapture6.jpg" length="95677" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/3/ScreenCapture7.jpg" length="157220" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/4/ScreenCapture8.jpg" length="142365" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/5/ScreenCapture9.jpg" length="122863" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/6/ScreenCapture10.jpg" length="131565" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/7/ScreenCapture11.jpg" length="135170" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/8/ScreenCapture12.jpg" length="107301" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/9/ScreenCapture13.jpg" length="80179" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/10/ScreenCapture15.jpg" length="116431" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/11/ScreenCapture16.jpg" length="149377" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/12/ScreenCapture18.jpg" length="648" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/13/ScreenCapture19.jpg" length="131825" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/14/ScreenCapture21.jpg" length="146377" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/15/ScreenCapture22.jpg" length="121210" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/16/ScreenCapture23.jpg" length="73733" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/17/ScreenCapture24.jpg" length="116165" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/18/ScreenCapture25.jpg" length="120648" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/19/ScreenCapture26.jpg" length="105289" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/20/ScreenCapture27.jpg" length="94581" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/21/ScreenCapture29.jpg" length="146885" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/22/ScreenCapture30.jpg" length="152730" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/23/ScreenCapture31.jpg" length="75058" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/24/ScreenCapture32.jpg" length="88840" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/25/ScreenCapture33.jpg" length="69025" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/26/ScreenCapture34.jpg" length="120437" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/27/ScreenCapture35.jpg" length="104609" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/28/ScreenCapture36.jpg" length="105964" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/29/ScreenCapture37.jpg" length="138854" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/30/ScreenCapture38.jpg" length="69697" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/31/ScreenCapture39.jpg" length="63935" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/32/ScreenCapture40.jpg" length="88859" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/33/ScreenCapture41.jpg" length="95774" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/34/ScreenCapture42.jpg" length="121747" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/35/ScreenCapture43.jpg" length="86697" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/36/ScreenCapture44.jpg" length="107988" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/37/ScreenCapture45.jpg" length="114430" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/38/ScreenCapture46.jpg" length="193920" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/39/ScreenCapture47.jpg" length="136504" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/40/ScreenCapture48.jpg" length="145928" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/41/ScreenCapture49.jpg" length="195325" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/42/ScreenCapture50.jpg" length="148317" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/43/ScreenCapture51.jpg" length="144008" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/44/ScreenCapture52.jpg" length="170167" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/45/ScreenCapture53.jpg" length="156028" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/46/ScreenCapture54.jpg" length="200124" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/47/ScreenCapture55.jpg" length="179339" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/48/ScreenCapture56.jpg" length="139875" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/49/ScreenCapture57.jpg" length="138680" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/50/ScreenCapture58.jpg" length="53220" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/51/ScreenCapture59.jpg" length="80535" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/52/ScreenCapture60.jpg" length="85314" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/53/ScreenCapture61.jpg" length="53071" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/54/ScreenCapture62.jpg" length="51934" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/55/ScreenCapture63.jpg" length="75160" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/56/ScreenCapture64.jpg" length="58931" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/57/ScreenCapture65.jpg" length="110889" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/58/ScreenCapture66.jpg" length="71187" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/59/Abstract%201144P.New%20Sandostatin%20Device%20pdf.pdf" length="220349" type="application/pdf"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/60/Abs%201141PD.pdf%20Interim%20Results%20From%20GEPNET%20Registry.pdf" length="296463" type="application/pdf"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7821/61/Abs1164TiP.Qualifying%20the%20NET%20Patient%20Experience%201st%20Global%20NET%20patient%20survey%20pdf.pdf" length="1229226" type="application/pdf"/></item><item>
<title>re: Effectiveness of the Switch from Gn-RH Agonist to Degarelix for CRPC</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology10033</link>
<description>re: Effectiveness of the Switch from Gn-RH Agonist to Degarelix for CRPC</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology10033</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10033">re: Effectiveness of the Switch from Gn-RH Agonist to Degarelix for CRPC</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10033">Oncology10033</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/625">Patrick CABRI</a> | 13 October 2014 | 14:31</font><br><br><div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Effectiveness of the Switch from Gn-RH Agonist to Degarelix for CRPC</span>&nbsp;<font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=mkt%3aJapan"><font color="#e95e0b">:PharmaWorld:mkt:Japan</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=sub%3aClinicalTrial"><font color="#e95e0b">:PharmaWorld:sub:ClinicalTrial</font></a>]</font></font><br><span style="font-size: 12px;">Comment: The FELIX Ph4 study, sponsored by Yokohama City U.<wbr> Hospital and in collaboration with Astellas, will recruit approx.<wbr> 100 subjects.<wbr> PE will assess PSA responder rate at 12w.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10023">...</a><br><font size="-1">Brigitte DESCHAMPS / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10023" class="commentpermalink">Oncology10023</a> / <span class="date">10 October 2014</span> /
<span class="time">16:24:42 o'clock CEST</span>
</font></div><div><P style="margin: 0cm 0cm 0pt;"><SPAN lang="EN-US" style="color: #1f497d; font-family: 'Calibri','sans-serif'; font-size: 11pt; mso-ansi-language: EN-US;">Astellas is promoting Degarelix in Japan.<wbr> This explain why they sponsor this study.<wbr> The study takes place in Japan only.<wbr></SPAN></P> </div><!-- Comment details --><font size="-1">Patrick CABRI / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10033" class="commentpermalink">Oncology10033</a> / <span class="date">13 October 2014</span> /
<span class="time">14:31:08 o'clock CEST</span>
</font><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10033">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10023">View thread  Oncology10023: Effectiveness of the Switch from Gn-RH Agonist to Degarelix for CRPC</a>]]></content:encoded><dc:date>2014-10-13T14:31:08+02:00</dc:date><dc:creator>pac43514</dc:creator></item><item>
<title>re: Effectiveness of the Switch from Gn-RH Agonist to Degarelix for CRPC</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology10032</link>
<description>re: Effectiveness of the Switch from Gn-RH Agonist to Degarelix for CRPC</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology10032</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10032">re: Effectiveness of the Switch from Gn-RH Agonist to Degarelix for CRPC</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10032">Oncology10032</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/1044">Benedicte DUCLOS MORLAES</a> | 13 October 2014 | 13:44</font><br><br><div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Effectiveness of the Switch from Gn-RH Agonist to Degarelix for CRPC</span>&nbsp;<font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=mkt%3aJapan"><font color="#e95e0b">:PharmaWorld:mkt:Japan</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=sub%3aClinicalTrial"><font color="#e95e0b">:PharmaWorld:sub:ClinicalTrial</font></a>]</font></font><br><span style="font-size: 12px;">Comment: The FELIX Ph4 study, sponsored by Yokohama City U.<wbr> Hospital and in collaboration with Astellas, will recruit approx.<wbr> 100 subjects.<wbr> PE will assess PSA responder rate at 12w.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10023">...</a><br><font size="-1">Brigitte DESCHAMPS / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10023" class="commentpermalink">Oncology10023</a> / <span class="date">10 October 2014</span> /
<span class="time">16:24:42 o'clock CEST</span>
</font></div><div>Degarelix is promoted by Astellas in Japan.<wbr> </div><!-- Comment details --><font size="-1">Benedicte DUCLOS MORLAES / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10032" class="commentpermalink">Oncology10032</a> / <span class="date">13 October 2014</span> /
<span class="time">13:44:52 o'clock CEST</span>
</font><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10032">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10023">View thread  Oncology10023: Effectiveness of the Switch from Gn-RH Agonist to Degarelix for CRPC</a>]]></content:encoded><dc:date>2014-10-13T13:44:52+02:00</dc:date><dc:creator>bed38627</dc:creator></item><item>
<title>Costs Drug Saving Using Theranostic Test for Cronh's Disease in France [dis:IBD, sub:Diagnostic]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2060</link>
<description>Costs Drug Saving Using Theranostic Test for Cronh's Disease in France [dis:IBD, sub:Diagnostic]</description><category>dis:IBD</category><category>sub:Diagnostic</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2060</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2060">Costs Drug Saving Using Theranostic Test for Cronh's Disease in France</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20141231&edate=20140901&cat=dis%3aIBD"><font color="#e95e0b">:GastroEnterology:dis:IBD</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20141231&edate=20140901&cat=sub%3aDiagnostic"><font color="#e95e0b">:GastroEnterology:sub:Diagnostic</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2060">GastroEnterology2060</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 13 October 2014 | 11:41</font><br><br><div style="margin-bottom: 10px;">Comment: A test-based strategy is associated with major cost savings among Crohn’s disease patients treated with anti-TNF.<wbr> On Oct 8, Theradiag reported the results of a pharmaco-economic report which demonstrates that the use of anti-TNF monitoring and anti-TNF antibodies in the treatment of patients with Crohn’s disease treated by biotherapies can save up to 25% of the cost of treatment, or €131M over 5 years in France alone.<wbr> Pr Xavier Robin will present these results at UEGW on Oct.<wbr>21 </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">UEGW Presentation</FONT></STRONG> </div><div style="margin-bottom: 10px;"><A href="https://uegw.congress-online.com/guest/ID52c7de4a9c120b/AbstractView?ABSID=7565">https:/<wbr>/<wbr>uegw.<wbr>congress-online.<wbr>com/<wbr>guest/<wbr>ID52c7de4a9c120b/<wbr>AbstractView?ABSID=7565</A> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2060/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Theradiag Profile</FONT></STRONG> </div><div style="margin-bottom: 10px;"><A href="http://www.theradiag.com/en/company/">http:/<wbr>/<wbr>www.<wbr>theradiag.<wbr>com/<wbr>en/<wbr>company/<wbr></A> </div><div style="margin-bottom: 10px;"><U>Half-Year Results</U> </div><div><img src="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2060/2/ScreenCapture2.jpg?user-agent=rss"> </div><!-- Comment details --><a name="gastroenterology2060attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2060/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(27,7 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2060/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(37,9 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2060">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-10-13T11:41:09+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2060/1/ScreenCapture1.jpg" length="28404" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2060/2/ScreenCapture2.jpg" length="38827" type="image/jpeg"/></item><item>
<title>Ph3 Results of Bioniche's MCNA Published in the Journal of Urology [dis:Bladder]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology10029</link>
<description>Ph3 Results of Bioniche's MCNA Published in the Journal of Urology [dis:Bladder]</description><category>dis:Bladder</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology10029</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10029">Ph3 Results of Bioniche's MCNA Published in the Journal of Urology</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=dis%3aBladder"><font color="#e95e0b">:Oncology:dis:Bladder</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10029">Oncology10029</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 13 October 2014 | 10:06</font><br><br><div style="margin-bottom: 10px;">Comment: Intravesical MCNA offers an alternative for patients who have failed therapy with BCG and do not wish to undergo a radical cystectomy.<wbr> The data reported in this publication pertains to Ph3 study conducted with MCNA (Mycobacterium phlei cell wall-nucleic acid complex), and includes results of planned statistical analyses at study completion including efficacy rates at 3 and 6 months and 2 years after therapy.<wbr> </div><div style="margin-bottom: 10px;">Article Title: <I>Efficacy and Safety of MCNA in Patients with Non-Muscle Invasive Bladder Cancer at High-Risk of Recurrence and Progression Who Have Failed Treatment with Bacillus Calmette-Guérin</I> </div><div style="margin-bottom: 10px;">Source: <A href="http://www.jurology.com/action/doSearch?searchType=quick&amp;searchText=mcna&amp;occurrences=all&amp;journalCode=juro&amp;searchScope=fullSite">http:/<wbr>/<wbr>www.<wbr>jurology.<wbr>com/<wbr>action/<wbr>doSearch?searchType=quick&amp;searchText=mcna&amp;occurrences=all&amp;journalCode=juro&amp;searchScope=fullSite</A> </div><div style="margin-bottom: 10px;"><H2 class="sectionTitle"><FONT size="3">Abstract</FONT></H2> </div><div style="margin-bottom: 10px;"><H3 class="sectionTitle"><FONT size="2">Purpose</FONT></H3> </div><div style="margin-bottom: 10px;">Patients with high-risk recurrences after BCG failure have limited options.<wbr> We performed an open-label study to evaluate the efficacy and safety of intravesical MCNA in this setting.<wbr> </div><div style="margin-bottom: 10px;"><H3 class="sectionTitle"><FONT size="2">Materials and Methods</FONT></H3> </div><div style="margin-bottom: 10px;">Patients were treated intravesically with 8 mg MCNA weekly for 6 weeks followed by 3 weekly instillations at months 3, 6, 12, 18 and 24.<wbr> Cystoscopy and cytology were performed every 3 months for 2 years, with mandatory biopsy at 6 months and then as clinically indicated.<wbr> The primary efficacy endpoint was the DFS rate at 1 year.<wbr> </div><div style="margin-bottom: 10px;"><H3 class="sectionTitle"><FONT size="2">Results</FONT></H3> </div><div style="margin-bottom: 10px;">A total of 129 patients enrolled in the study; 91 had CIS, with or without papillary disease, and 38 had papillary only tumors.<wbr> Most patients had high-risk disease: 107 were BCG-refractory, 68 received ≥2 prior BCG induction courses.<wbr> Median duration of follow-up for all patients was 34.<wbr>7 months.<wbr> Overall DFS rate was 25.<wbr>0% at 1 year and 19.<wbr>0% at 2 years; for patients with papillary only tumors, DFS rate was 35.<wbr>1% and 32.<wbr>2% at 1 and 2 years, respectively.<wbr> Median disease-free duration for the 30 responders was 32.<wbr>7 months.<wbr> PFS rate was 87.<wbr>3%, 79.<wbr>8% and 77.<wbr>7% at 1, 2 and 3 years, respectively, with 28 patients experiencing a progression event.<wbr> MCNA was very well tolerated and few AEs lead to treatment discontinuation.<wbr> </div><div style="margin-bottom: 10px;"><H3 class="sectionTitle"><FONT size="2">Conclusions</FONT></H3> </div><div>Intravesical MCNA achieved significant activity in high-risk NMIBC patients who failed BCG treatment, especially in patients with papillary only tumors and in BCG-relapsing patients.<wbr> Durable response is seen particularly in patients with a response at 1 year.<wbr> MCNA offers an option for patients who are not candidates for or who refuse cystectomy.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10029">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-10-13T10:06:07+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>re: Effectiveness of the Switch from Gn-RH Agonist to Degarelix for CRPC</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology10027</link>
<description>re: Effectiveness of the Switch from Gn-RH Agonist to Degarelix for CRPC</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology10027</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10027">re: Effectiveness of the Switch from Gn-RH Agonist to Degarelix for CRPC</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10027">Oncology10027</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/881">Eleni BOZIKA</a> | 13 October 2014 | 07:33</font><br><br><div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Effectiveness of the Switch from Gn-RH Agonist to Degarelix for CRPC</span>&nbsp;<font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=mkt%3aJapan"><font color="#e95e0b">:PharmaWorld:mkt:Japan</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=sub%3aClinicalTrial"><font color="#e95e0b">:PharmaWorld:sub:ClinicalTrial</font></a>]</font></font><br><span style="font-size: 12px;">Comment: The FELIX Ph4 study, sponsored by Yokohama City U.<wbr> Hospital and in collaboration with Astellas, will recruit approx.<wbr> 100 subjects.<wbr> PE will assess PSA responder rate at 12w.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10023">...</a><br><font size="-1">Brigitte DESCHAMPS / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10023" class="commentpermalink">Oncology10023</a> / <span class="date">10 October 2014</span> /
<span class="time">16:24:42 o'clock CEST</span>
</font></div><div>Do we have any information in why Astellas is backing up this study? </div><!-- Comment details --><font size="-1">Eleni BOZIKA / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10027" class="commentpermalink">Oncology10027</a> / <span class="date">13 October 2014</span> /
<span class="time">07:33:07 o'clock CEST</span>
</font><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10027">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10023">View thread  Oncology10023: Effectiveness of the Switch from Gn-RH Agonist to Degarelix for CRPC</a>]]></content:encoded><dc:date>2014-10-13T07:33:07+02:00</dc:date><dc:creator>elm00051</dc:creator></item><item>
<title>Second Genome Ink Agreement with Mayo Clinic to Develop Microbiome Therapeutics [dis:IBD, news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2059</link>
<description>Second Genome Ink Agreement with Mayo Clinic to Develop Microbiome Therapeutics [dis:IBD, news]</description><category>dis:IBD</category><category>news</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2059</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2059">Second Genome Ink Agreement with Mayo Clinic to Develop Microbiome Therapeutics</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20141231&edate=20140901&cat=dis%3aIBD"><font color="#e95e0b">:GastroEnterology:dis:IBD</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20141231&edate=20140901&cat=news"><font color="#e95e0b">:GastroEnterology:news</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2059">GastroEnterology2059</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 10 October 2014 | 16:46</font><br><br><div style="margin-bottom: 10px;">Comment: The importance of the microbiome in a wide range of diseases is increasingly emerging.<wbr> The focus of the collaboration will be the development of therapeutics targeting microbiome-mediated pathways.<wbr> Last year Second Genome signed a deal with Janssen Biotech to identify the mechanisms by which microbial populations in the gut have an impact in ulcerative colitis.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Agreement with Mayo Clinic</FONT></STRONG> </div><div style="margin-bottom: 10px;">Second Genome will identify up to eight clinical indications where the microbiome has a potential role in disease and will collaborate on microbiome research with Mayo Clinic investigators who specialize in each of the designated disease areas.<wbr> </div><div style="margin-bottom: 10px;">Mayo Clinic will provide human clinical samples from patients in targeted disease areas, and Second Genome will deploy its proprietary microbiome discovery platform to identify biological pathways implicated in disease.<wbr> </div><div style="margin-bottom: 10px;">Further, Second Genome will utilize its platform to discover novel therapies that target these microbiome-mediated pathways.<wbr> Mayo Clinic will make an equity investment in Second Genome as part of the collaboration.<wbr> </div><div style="margin-bottom: 10px;">Financial details were not disclosed.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Agreement with Janssen</FONT></STRONG> </div><div style="margin-bottom: 10px;">Second Genome will receive an upfront payment and support for research activities conducted by Second Genome in collaboration with Janssen.<wbr> In addition, Second Genome is eligible to receive potential payments upon the achievement of certain research milestones.<wbr> The research will be funded through the Johnson &amp; Johnson Innovation Center and the Immunology Therapeutic Area within Janssen Research &amp; Development, LLC.<wbr> </div><div><EM>Source: Second Genome</EM> - <A href="http://www.secondgenome.com/">http:/<wbr>/<wbr>www.<wbr>secondgenome.<wbr>com/<wbr></A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2059">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-10-10T16:46:28+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>ISIS Strengthens Its Position In The Antisense Market With Positive PhII SMA Data [:Endocrinology:dis:Acromegaly, :Endocrinology:dis:Cushing, news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7764</link>
<description>ISIS Strengthens Its Position In The Antisense Market With Positive PhII SMA Data [:Endocrinology:dis:Acromegaly, :Endocrinology:dis:Cushing, news]</description><category>dis:Acromegaly</category><category>dis:Cushing</category><category>news</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7764</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7764">ISIS Strengthens Its Position In The Antisense Market With Positive PhII SMA Data</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20141231&edate=20140901&cat=dis%3aAcromegaly"><font color="#e95e0b">:Endocrinology:dis:Acromegaly</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20141231&edate=20140901&cat=dis%3aCushing"><font color="#e95e0b">:Endocrinology:dis:Cushing</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20141231&edate=20140901&cat=news"><font color="#e95e0b">:Neurology:news</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7764">Neurology7764</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 10 October 2014 | 16:28</font><br><br><div style="margin-bottom: 10px;">Comment : Further endorsement of the activity of antisense therapeutics developed by ISIS has been announced today with positive phII results being reported at the World Muscle Society Congress in Berlin demonstrating the benefit of ISIS-SMN Rx in infants and children with spinal muscular atrophy.<wbr> The group has initiated one phase III study in infants (ENDEAR) and is on track to initiate another phIII in children later this year.<wbr> The portfolio of rare and orphan drugs in development related to ISIS technology which includes ALT-1103 for acromegaly and ISIS-GCCR Rx for Cushing's disease is highlighted below.<wbr> </div><div style="margin-bottom: 10px;">The treatment is one of four antisense drugs covered by a $299m agreement with Biogen signed in 2012.<wbr> Under the terms of the agreement, ISIS handles discovery and early development, while Biogen has the option to buy into each program until it reaches a certain stage of development.<wbr> For ISIS-SMNrx the deadline is the completion of a phIII trial, giving Biogen about 13 months to make up its mind.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><U>Event-free survival data from Phase 2 study in infants with SMA</U></STRONG> </div><div style="margin-bottom: 10px;">In the Phase 2 study in infants with SMA, a total of 20 infants were dosed as of September 2, 2014, four infants in the 6 mg cohort and 16 infants in the 12 mg cohort.<wbr> As of April 7, 2014, the date of Isis' previous data update, the per protocol efficacy populations constituted four patients in the 6 mg and seven patients in the 12 mg dose cohorts.<wbr> As of September 2, 2014, the PPEP constituted four patients in the 6 mg and 12 patients in the 12 mg dose cohorts.<wbr> </div><div style="margin-bottom: 10px;">In the 6 mg cohort: </div><div style="margin-bottom: 10px;"><UL type="disc"><LI>No patients have had an event (death or permanent ventilation) since April 2014.<wbr> As of September 2, 2014, there have been two events (one accidental death and one permanent ventilation) in the 6 mg cohort.<wbr>
</LI>
<LI>Isis previously reported a median event-free age of 14 months for the infants in the PPEP on April 7, 2014.<wbr> The median event-free age on September 2, 2014 for the infants in this group is now 16.<wbr>3 months.<wbr>
</LI>
</UL> </div><div style="margin-bottom: 10px;">In the 12 mg cohort: </div><div style="margin-bottom: 10px;"><UL type="disc"><LI>Dosing in the 12 mg cohort began five months after the initiation of dosing for the 6 mg cohort.<wbr> As a result, the patients in the 12 mg cohort have participated in the study for a shorter time than those in the 6 mg cohort.<wbr> As of April 7, the PPEP in the 12 mg dose cohort contained 7 infants.<wbr> As of September 2, the PPEP for the 12 mg dose cohort contained 12 infants, which included an additional five infants who had more recently entered the study.<wbr>
</LI>
<LI>Isis previously reported a median event-free age of 9.<wbr>6 months for the infants who constituted the 12 mg PPEP as of April 7, 2014.<wbr> The median event-free age at September 2, 2014 for these infants is now 13.<wbr>8 months.<wbr>
</LI>
<LI>The median event-free age of the 12 infants in the PPEP as of September 2, 2014 for the 12 mg cohort is 11.<wbr>6 months.<wbr> Of these 12 infants, nine are alive without the need for permanent ventilation.<wbr>
</LI>
<LI>As of September 2, 2014, there have been four events (one permanent ventilation and three deaths, all related to respiratory infections) in the 16 infants from the 12 mg cohort.<wbr>
</LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG><U>Increases in muscle function scores in this study in infants with SMA</U></STRONG> </div><div style="margin-bottom: 10px;">Measures of muscle function are also being assessed in this study.<wbr> Increases in muscle function scores were observed in infants in both dosing cohorts using the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND), a motor assessment test that is used to evaluate muscle strength in infants with SMA.<wbr> </div><div style="margin-bottom: 10px;"><UL type="disc"><LI>Increases in CHOP INTEND scores occurred in a majority of infants in the study.<wbr> Infants in the PPEP from the 6 mg and 12 mg cohorts combined showed mean increases from baseline in CHOP INTEND of 9.<wbr>3 points with 14 of the 16 infants showing an increase in CHOP INTEND scores.<wbr>
</LI>
<LI>Infants from the 12 mg dose cohort PPEP showed mean increases from baseline in CHOP INTEND of 11.<wbr>7 points with 11 of the 12 infants showing an increase in CHOP INTEND scores.<wbr>
</LI>
</UL> </div><div style="margin-bottom: 10px;">This data adds to the recent positive data reported by Antisense therapeutics in acromegaly.<wbr> The portfolio of rare and orphan diseases being addressed by ISIS which includes Cushing's syndrome is highlighted below.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7764/1/ScreenCapture1.jpg?user-agent=rss"> </div><div>Source: <A href="http://www.isispharm.com">www.<wbr>isispharm.<wbr>com</A> </div><!-- Comment details --><a name="neurology7764attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7764/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(82,2 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7764">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-10-10T16:28:31+02:00</dc:date><dc:creator>jac89886</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7764/1/ScreenCapture1.jpg" length="84193" type="image/jpeg"/></item><item>
<title>Effectiveness of the Switch from Gn-RH Agonist to Degarelix for CRPC [dis:Prostate, :PharmaWorld:sub:ClinicalTrial, :PharmaWorld:mkt:Japan]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology10023</link>
<description>Effectiveness of the Switch from Gn-RH Agonist to Degarelix for CRPC [dis:Prostate, :PharmaWorld:sub:ClinicalTrial, :PharmaWorld:mkt:Japan]</description><comments>http://ci.beaufour-ipsen.com/traction/permalink/Oncology10023</comments><category>dis:Prostate</category><category>sub:ClinicalTrial</category><category>mkt:Japan</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology10023</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10023">Effectiveness of the Switch from Gn-RH Agonist to Degarelix for CRPC</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=mkt%3aJapan"><font color="#e95e0b">:PharmaWorld:mkt:Japan</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=sub%3aClinicalTrial"><font color="#e95e0b">:PharmaWorld:sub:ClinicalTrial</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10023">Oncology10023</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 10 October 2014 | 16:24</font><br><br><div style="margin-bottom: 10px;">Comment: The FELIX Ph4 study, sponsored by Yokohama City U.<wbr> Hospital and in collaboration with Astellas, will recruit approx.<wbr> 100 subjects.<wbr> PE will assess PSA responder rate at 12w.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Trial Details</FONT></STRONG> </div><div style="margin-bottom: 10px;">Timelines: the study is not yet open for recruitment </div><div style="margin-bottom: 10px;">Description: Subjects will switch from Gn-RH agonist to degarelix at a dose of 240mg subcutaneously and 80mg for every 4 weeks at a total of 12 months </div><div style="margin-bottom: 10px;">Biomarker: Kallikrein 3 (KLK3 or Prostate Specific Antigen or PSA) </div><div style="margin-bottom: 10px;">Secondary Outcomes </div><div style="margin-bottom: 10px;"><UL><LI>Time to PSA increase by 25 % compared to PSA st starting this study in Responder</LI>
<LI>Time to PSA progression survival</LI>
<LI>Time to treatoment fairule</LI>
<LI>Time to overall survival</LI>
<LI>Time to cancer specific survival</LI>
<LI>Time to radiographic PFS</LI>
<LI>Safety</LI>
</UL> </div><div>Location: &gt;20 sites (Japan) </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Oncology10027c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div>Do we have any information in why Astellas is backing up this study? </div><font size="-1">Eleni BOZIKA / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10027" class="commentpermalink">Oncology10027</a> / <span class="date">13 October 2014</span> /
<span class="time">07:33:07 o'clock CEST</span>
</font></div><a name="Oncology10032c"></a><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div>Degarelix is promoted by Astellas in Japan.<wbr> </div><font size="-1">Benedicte DUCLOS MORLAES / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10032" class="commentpermalink">Oncology10032</a> / <span class="date">13 October 2014</span> /
<span class="time">13:44:52 o'clock CEST</span>
</font></div><a name="Oncology10033c"></a><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div><P style="margin: 0cm 0cm 0pt;"><SPAN lang="EN-US" style="color: #1f497d; font-family: 'Calibri','sans-serif'; font-size: 11pt; mso-ansi-language: EN-US;">Astellas is promoting Degarelix in Japan.<wbr> This explain why they sponsor this study.<wbr> The study takes place in Japan only.<wbr></SPAN></P> </div><font size="-1">Patrick CABRI / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10033" class="commentpermalink">Oncology10033</a> / <span class="date">13 October 2014</span> /
<span class="time">14:31:08 o'clock CEST</span>
</font></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10023">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-10-10T16:24:42+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Auxilium Backtracks &amp; Accepts ENDO Healthcare's Buyout Offer Of $2.6bn [sub:Acquisition]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10994</link>
<description>Auxilium Backtracks &amp; Accepts ENDO Healthcare's Buyout Offer Of $2.6bn [sub:Acquisition]</description><category>sub:Acquisition</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10994</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20141231&edate=20140901&rec=10994">Auxilium Backtracks & Accepts ENDO Healthcare's Buyout Offer Of $2.<wbr>6bn</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=sub%3aAcquisition"><font color="#e95e0b">:PharmaWorld:sub:Acquisition</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10994">PharmaWorld10994</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 09 October 2014 | 18:41</font><br><br><div style="margin-bottom: 10px;">Comment: After its initial rebuffal at a price of $28.<wbr>10 per share, Auxilium has agreed to an ENDO Inc buyout at $33.<wbr>25 per share a 55% premium to Auxilium's closing price on September 15th.<wbr> The value of the deal at $2.<wbr>6bn includes the assumption of Auxilium's debt.<wbr> Excluding this the offer is pitched at 4x sales.<wbr> The purchase considerably strengthens Endo's Men's Health/<wbr>Urology business and has the potential with Xiaflex to enhance its Orthopedics/<wbr>pain area as well.<wbr> The third Other Specialty area of the business appears less focused, perhaps raising the possibility that some disposals may be made in this area maybe Supprelin LA.<wbr> for precocious puberty.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Deal Terms</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10994/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">Upon completion of the transaction, Endo's pharmaceutical portfolio will have a broader offering of urology and orthopedic products that are natural complements to its current men's health and pain products.<wbr> Endo expects to drive increased adoption and enhance the performance of Auxilium's XIAFLEX and accelerate development of the product in potential new indications.<wbr> Endo also intends to leverage its resources to optimize Auxilium's other products, including TESTOPEL<SUP>&reg; </SUP>and STENDRA<SUP>&reg;</SUP>.<wbr> Endo believes the combined company will be well positioned to drive organic growth across its portfolio and to capitalize on additional future strategic M&amp;A opportunities.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10994/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG>Significant Synergy Opportunities:</STRONG> Given the complementary nature of the companies' product portfolios, Endo expects the combined company to achieve annual cost synergies of approximately $175 million.<wbr> This synergy run-rate is expected to be fully realized on an annual basis in the first year after closing and includes Auxilium's reduction in annual operating expenses previously announced on September 9, 2014.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Strong Financial Profile:</STRONG> Following the completion of the transaction, Endo expects to have a strong financial profile with a solid balance sheet, enhanced cash flow and improved financial flexibility to continue to execute on its strategy.<wbr> In addition, the significant synergy opportunity is expected to drive improved operating margins.<wbr> The transaction is expected to be immediately accretive post-close and meaningfully accretive in each year thereafter.<wbr> </div><div>Source: <A href="http://www.endo.com">www.<wbr>endo.<wbr>com</A> </div><!-- Comment details --><a name="pharmaworld10994attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10994/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(142,9 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10994/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(123 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20141231&edate=20140901&rec=10994">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-10-09T18:41:38+02:00</dc:date><dc:creator>jac89886</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10994/1/ScreenCapture1.jpg" length="146333" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10994/2/ScreenCapture2.jpg" length="125965" type="image/jpeg"/></item><item>
<title>ESMO Intelligence Part 3 - Other Progress in Prostate Cancer: Biomarkers And The Role Of Chemotherapy [:PharmaWorld:congress:ESMO, headline]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology10018</link>
<description>ESMO Intelligence Part 3 - Other Progress in Prostate Cancer: Biomarkers And The Role Of Chemotherapy [:PharmaWorld:congress:ESMO, headline]</description><category>congress:ESMO</category><category>headline</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology10018</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10018">ESMO Intelligence Part 3 - Other Progress in Prostate Cancer: Biomarkers And The Role Of Chemotherapy</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=headline"><font color="#e95e0b">:Oncology:headline</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=congress%3aESMO"><font color="#e95e0b">:PharmaWorld:congress:ESMO</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10018">Oncology10018</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/994">Jenny Wu</a> | 09 October 2014 | 18:06</font><br><br><div style="margin-bottom: 10px;">Comment: Now we have both abiraterone and enzalutamide approved for chemo na&iuml;ve mCRPC patients, an important topic has emerged and was intensively discussed in ESMO this year - what do we do when patients become resistant to these two androgen targeting agents? Is there a way we can identify patients who might develop resistance prior to the treatment? If we can, should we consider giving these patients chemotherapy like docetaxel instead? Here we provide a summary of what has been discussed around these questions.<wbr> </div><div style="margin-bottom: 10px;"><SPAN style="text-decoration: underline;"><STRONG>AR-V7 as a valid biomarker?</STRONG></SPAN> </div><div style="margin-bottom: 10px;">Earlier this year at ASCO, the finding of the resistance to enzalutamide in the presence of the androgen receptor splice variant 7 (AR-V7) variant was presented and results have also been published in New England Journal of Medicine (NEJM).<wbr> AR-V7 is found to associate with resistance to abiraterone and enzalutamide - detection of the AR-V7 variant in circulating tumor cells (CTCs) following treatment with either enzalutamide or abiraterone correlated with a worse prognosis (including a lower PSA response, shorter PFS, and OS).<wbr> </div><div style="margin-bottom: 10px;">In an accompanying editorial of the article published, Dr.<wbr> Peter Nelson (MD, Fred Hutchinson Cancer Research Center, Seattle) commented: <EM>&ldquo;this compelling clinical data endorsing the importance of androgen-receptor variants in mediating treatment resistance.<wbr> A biomarker such as AR-V7 with 100% specificity in predicting a lack of treatment response would be a major step forward and would probably achieve rapid adoption.<wbr> Still, because these results are from a relatively small sample of patients, a larger prospective study is necessary for validation</EM>.<wbr> " </div><div style="margin-bottom: 10px;">During the Prostate Cancer Proffered Paper Session on Monday (29th Sept) ESMO, Dr.<wbr> Emmanuel S.<wbr> Antonarakis (Assistant professor of oncology, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore) presented the OS finding from the study of 62 mCRPC patients treated with either enzalutamide or abirateorne.<wbr> They tested for the presence of both the full-length androgen receptor messenger RNA (mRNA) and the AR-V7 mRNA in the CTCs.<wbr> Levels of AR-V7 were lower prior to treatment exposure and increased after post-treatment progression with either therapy.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/10018/1/1.jpg?user-agent=rss"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/10018/2/2.jpg?user-agent=rss"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/10018/3/3.jpg?user-agent=rss"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/10018/4/4.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">Enzalutamide Treated (n=31): 39% had detectable AR-V7 levels.<wbr> These men had a 0% PSA response compared with a 53% response in men with no detectable AR-V7 (P = .<wbr>004).<wbr> The median PFS was 1.<wbr>4 months in AR-V7&ndash;positive patients compared with 6.<wbr>0 months in AR-V7&ndash;negative patients (P &lt; .<wbr>001).<wbr> </div><div style="margin-bottom: 10px;">Abiraterone Treated (n=31), 19% had detectable levels of AR-V7, as well as a lower PSA response compared with those with no detectable AR-V7 (0% vs 68%, respectively; P = .<wbr>004).<wbr> AR-V7+ patients had a median PFS of 1.<wbr>3 months, while the PFS of men with no detectable AR-V7 has not yet been reached (P &lt; .<wbr>001).<wbr> Overall survival was also shorter in men with detectable AR-V7 in both treatment groups.<wbr> Antonarakis cautioned that the enzalutamide and abiraterone cohorts from this study cannot be directly compared because the enzalutamide-treated cohort generally had more advanced disease compared with the abiraterone-treated patients.<wbr> </div><div style="margin-bottom: 10px;">Dr Gerhardt Attard (Sutton, UK) said, " <EM>there has been various groups providing preclinical evidences with conflicting results, therefore a clinical translational study like this is very important.<wbr> This is clearly a positive result, however we must be cautious that this is a very small study and uses home brewing assay.<wbr> This needs to further validate in a larger and multi-centre trial.<wbr> Repetition is the key</EM>! " </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/10018/5/5.jpg?user-agent=rss"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/10018/6/6.jpg?user-agent=rss"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/10018/7/7.jpg?user-agent=rss"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/10018/8/8.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><SPAN style="text-decoration: underline;"><STRONG>Galeterone (ARMOR2) - Updated Data Supports Development in Patients with Splice Variants</STRONG></SPAN> </div><div style="margin-bottom: 10px;">Galeterone is a selective, multi-targeted, small molecule that is similar to abiraterone and enzalutamide.<wbr> It targets CYP17 (like abiraterone), blocks androgen binding to the receptor (like enzalutmade).<wbr> It is also an AR degrader (that is unique and different from both abi and enz) and active in C terminal loss AR splice variant.<wbr> Dr.<wbr> Mary-Ellen Taplin (Associate Professor, Dana-Faber Cancer Institiute) is the co-principal investigator of ARMOR2 presented the data during the Prostate Cancer Proffered Paper Session on Monday.<wbr> The ongoing ARMOR2 trial, for which enrollment is now complete, is a two-part Phase 2 study designed to confirm the dose of galeterone (Part 1) and demonstrate safety and efficacy in distinct CRPC patient cohorts (Part 2).<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/10018/9/9.jpg?user-agent=rss"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/10018/25/25.jpg?user-agent=rss"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/10018/11/11.jpg?user-agent=rss"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/10018/12/12.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">As from data cut-off on 15th August 2014, among 39 treatment na&iuml;ve metastatic CRPC patients, 85% achieved a maximal reduction in PSA levels of at least 30% (PSA30) and 77% achieved a maximal reduction in PSA levels of at least 50% (PSA50).<wbr> Among 60 combined non-metastatic and metastatic treatment na&iuml;ve CRPC patients, 83% achieved a PSA30 and 70% achieved a PSA50.<wbr> Among 30 abiraterone-refractory patients, 37% had a PSA decline during the treatment period and among nine enzalutamide-refractory patients, 44% had a PSA decline during the treatment period.<wbr> Galeterone was well tolerated, with approximately 90% of reported adverse events (AEs) classified as Grade 1 or 2.<wbr> These data demonstrated clinically meaningful reductions in prostate-specific androgen (PSA) levels, a marker of prostate cancer growth.<wbr> Expanded data in patients with C-terminal loss also provide additional support for galeterone&rsquo;s potential activity in CRPC patients whose tumors express androgen receptor (AR) splice variants, which are believed to be associated with resistance to hormonal agents commonly used to treat CRPC.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/10018/13/13.jpg?user-agent=rss"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/10018/14/14.jpg?user-agent=rss"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/10018/15/15.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">CTC exploratory analysis as In Part 2 of ARMOR2 was also presented as preclinical data showing galeterone activity in splice variants that cause a C-terminal deletion, including AR-V7.<wbr> As of August 15, 2014, seven treatment-na&iuml;ve CRPC patients had been identified as having C-terminal loss in a retrospective subset analysis of treatment-na&iuml;ve patients in the ARMOR2 trial.<wbr> Six of these patients had maximal reductions in PSA levels of at least 50%.<wbr> The seventh patient, who did not show any PSA reduction, discontinued therapy due to an adverse event unrelated to galeterone after approximately six weeks in the trial and did not receive the full treatment regimen.<wbr> Of the six responders, four elected to continue into an optional extension phase of the trial following the initial 12 week treatment period.<wbr> As of August 15, 2014, the time on treatment for the patients in the extension phase, ranged from 155 days to 274 days.<wbr> Independent clinical data presented at ESMO on Sunday, September 28 from researchers at Memorial Sloan Kettering Cancer Center, Weill Cornell Medical Center and Epic Sciences, Inc.<wbr> (Posters 237P and 238P) also showed an association between non-responsiveness to abiraterone and enzalutamide and the presence of C-terminal loss using the same assay used in ARMOR2.<wbr> Currently, TOKAI has planned a pivotal Ph3 ARMOR3 in the resistant population and expected to start in 1H 2015.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/10018/16/16.jpg?user-agent=rss"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/10018/17/17.jpg?user-agent=rss"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/10018/18/18.jpg?user-agent=rss"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/10018/19/19.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><SPAN style="text-decoration: underline;"><STRONG>The role of chemotherapy - should we use it earlier or later?</STRONG></SPAN> </div><div style="margin-bottom: 10px;">On Monday 29th Sept, Dr Eleni Esthathiou held a controversy session to discuss " is docetaxel the standard of care for metastatic prostate cancer patients starting androgen deprivation therapy (ADT)? " She started to present a patient case - </div><div style="margin-bottom: 10px;">"A 76 year old man with no comorbidities present with 8 bone mets with NO symptoms.<wbr> PSA = 20ng/<wbr>ml.<wbr> This is a metastatic recurrence of a GS 8 (4+4) diagnosed 5 years ago and treated with radiation therapy + 6 months ADT.<wbr>" Would you use docetaxel? </div><div style="margin-bottom: 10px;">58% of audience said no but 36.<wbr>1% of audience said yes.<wbr> Interestingly, following the debate session, the results remain similar.<wbr> </div><div style="margin-bottom: 10px;">Dr.<wbr> Karim Fizazi (France) presented the evidences why he supported the idea to use docetaxel in the earlier setting - the data from Chaarted and GETUG15 were discussed.<wbr> He noted we have not made any improvement in overall or cause specific survival for men presenting with metastatic prostate cancer over a 20 year period.<wbr> The median survival for patients presenting hormone sensitive metastatic disease is around 4-5 years, and the hypothesis for the two ph3 trials - Chaarted and GETUG15 - is to understand if early docetaxel will postpone progression to CRPC /<wbr>death.<wbr> There is a proven clinical benefit, however, Fizazi stated this should remain to be a patient's choice due to the classical docetaxel toxicity.<wbr> From an environmental perspective, this could be a more cost effective solution due to the availability of generic version.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/10018/20/20.jpg?user-agent=rss"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/10018/21/21.jpg?user-agent=rss"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/10018/22/22.jpg?user-agent=rss"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/10018/23/23.jpg?user-agent=rss"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/10018/24/24.jpg?user-agent=rss"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/10018/25/25.jpg?user-agent=rss"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/10018/26/26.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">However, the clinical benefit in terms of PFS seen in both trials do not necessary translating into overall survival (OS).<wbr> No OS benefit is reported from GETUG 15 trial, however, a significant &gt;12 months OS benefit was reported from Chaarted.<wbr> Fizazi emphasized that both trials are well designed trials and both led by very experienced investigators.<wbr> However, the conflicting result may largely due to the patient population included in the trials - Chaarted appears to have higher risk, more advanced staged patients with high disease burden.<wbr> These evidences along with the data we have seen from both trials for the treatment the patients received beyond progression suggest : the earlier that we give docetaxel to the patients with extensive disease seem to be better.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/10018/27/27.jpg?user-agent=rss"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/10018/28/28.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">What we should do with patients with low volume disease - we should look into both GETUG14 and Charrted data.<wbr> Currently more ongoing trials - including GETUG15, STAMPEDE, LATITUDE - are trying to address the question of if we should use chemotherapy earlier or if we should use the novel targeting agent such as abiraterone instead? </div><div style="margin-bottom: 10px;">"<EM> STAMPEDE will further address the question of local control that has become crucial.<wbr> Maybe it is time to rethink our approach of the recurrent or early CRPC patient</EM>" said Dr.<wbr> Bertrand Tombal (Belgium) </div><div style="margin-bottom: 10px;">" <EM>We need a standardised definition of high volume disease</EM>.<wbr>" said Dr.<wbr> Stephane Oudard (France) </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/10018/29/29.jpg?user-agent=rss"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/10018/30/30.jpg?user-agent=rss"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/10018/31/31.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">Professor Ian Tannock (Princess Margaret Cancer Centre, Toronto) defended his against position by first criticizing that the results should not be taken into account unless and until it is repeated.<wbr> He introduced Bayes Theorem meaning " <EM>if one expects a negative result, but then the outcome is positive.<wbr> Then the probability that it is a true positve result remains LOW - regardless of the quality of the trial and the p-value</EM>!" </div><div><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/10018/32/32.jpg?user-agent=rss"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/10018/33/33.jpg?user-agent=rss"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/10018/34/34.jpg?user-agent=rss"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/10018/35/35.jpg?user-agent=rss"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/10018/36/36.jpg?user-agent=rss"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/10018/37/37.jpg?user-agent=rss"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/10018/38/38.jpg?user-agent=rss"> </div><!-- Comment details --><a name="oncology10018attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10018/1/1.jpg">1.jpg</a>&nbsp;&nbsp;(1,1 MB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10018/2/2.jpg">2.jpg</a>&nbsp;&nbsp;(1 MB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10018/3/3.jpg">3.jpg</a>&nbsp;&nbsp;(957,5 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10018/4/4.jpg">4.jpg</a>&nbsp;&nbsp;(931,8 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10018/5/5.jpg">5.jpg</a>&nbsp;&nbsp;(1 021 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10018/6/6.jpg">6.jpg</a>&nbsp;&nbsp;(927,8 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10018/7/7.jpg">7.jpg</a>&nbsp;&nbsp;(878,5 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10018/8/8.jpg">8.jpg</a>&nbsp;&nbsp;(919 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10018/9/9.jpg">9.jpg</a>&nbsp;&nbsp;(996 KB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10018/10/10.jpg">10.jpg</a>&nbsp;&nbsp;(993,9 KB)<br>&nbsp;&nbsp;11.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10018/11/11.jpg">11.jpg</a>&nbsp;&nbsp;(1 MB)<br>&nbsp;&nbsp;12.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10018/12/12.jpg">12.jpg</a>&nbsp;&nbsp;(938,8 KB)<br>&nbsp;&nbsp;13.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10018/13/13.jpg">13.jpg</a>&nbsp;&nbsp;(1 MB)<br>&nbsp;&nbsp;14.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10018/14/14.jpg">14.jpg</a>&nbsp;&nbsp;(973,8 KB)<br>&nbsp;&nbsp;15.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10018/15/15.jpg">15.jpg</a>&nbsp;&nbsp;(917,3 KB)<br>&nbsp;&nbsp;16.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10018/16/16.jpg">16.jpg</a>&nbsp;&nbsp;(1 002,7 KB)<br>&nbsp;&nbsp;17.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10018/17/17.jpg">17.jpg</a>&nbsp;&nbsp;(1 012,7 KB)<br>&nbsp;&nbsp;18.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10018/18/18.jpg">18.jpg</a>&nbsp;&nbsp;(941,3 KB)<br>&nbsp;&nbsp;19.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10018/19/19.jpg">19.jpg</a>&nbsp;&nbsp;(977,3 KB)<br>&nbsp;&nbsp;20.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10018/20/20.jpg">20.jpg</a>&nbsp;&nbsp;(961,1 KB)<br>&nbsp;&nbsp;21.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10018/21/21.jpg">21.jpg</a>&nbsp;&nbsp;(954 KB)<br>&nbsp;&nbsp;22.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10018/22/22.jpg">22.jpg</a>&nbsp;&nbsp;(936,7 KB)<br>&nbsp;&nbsp;23.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10018/23/23.jpg">23.jpg</a>&nbsp;&nbsp;(871,5 KB)<br>&nbsp;&nbsp;24.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10018/24/24.jpg">24.jpg</a>&nbsp;&nbsp;(971,6 KB)<br>&nbsp;&nbsp;25.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10018/25/25.jpg">25.jpg</a>&nbsp;&nbsp;(983,3 KB)<br>&nbsp;&nbsp;26.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10018/26/26.jpg">26.jpg</a>&nbsp;&nbsp;(954,5 KB)<br>&nbsp;&nbsp;27.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10018/27/27.jpg">27.jpg</a>&nbsp;&nbsp;(915 KB)<br>&nbsp;&nbsp;28.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10018/28/28.jpg">28.jpg</a>&nbsp;&nbsp;(1 013,4 KB)<br>&nbsp;&nbsp;29.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10018/29/29.jpg">29.jpg</a>&nbsp;&nbsp;(866,2 KB)<br>&nbsp;&nbsp;30.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10018/30/30.jpg">30.jpg</a>&nbsp;&nbsp;(965,5 KB)<br>&nbsp;&nbsp;31.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10018/31/31.jpg">31.jpg</a>&nbsp;&nbsp;(939 KB)<br>&nbsp;&nbsp;32.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10018/32/32.jpg">32.jpg</a>&nbsp;&nbsp;(1 006,2 KB)<br>&nbsp;&nbsp;33.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10018/33/33.jpg">33.jpg</a>&nbsp;&nbsp;(930 KB)<br>&nbsp;&nbsp;34.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10018/34/34.jpg">34.jpg</a>&nbsp;&nbsp;(1 MB)<br>&nbsp;&nbsp;35.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10018/35/35.jpg">35.jpg</a>&nbsp;&nbsp;(926,7 KB)<br>&nbsp;&nbsp;36.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10018/36/36.jpg">36.jpg</a>&nbsp;&nbsp;(971,8 KB)<br>&nbsp;&nbsp;37.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10018/37/37.jpg">37.jpg</a>&nbsp;&nbsp;(913,9 KB)<br>&nbsp;&nbsp;38.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10018/38/38.jpg">38.jpg</a>&nbsp;&nbsp;(973,8 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10018">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-10-09T18:06:55+02:00</dc:date><dc:creator>jew60237</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10018/1/1.jpg" length="1177046" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10018/2/2.jpg" length="1097261" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10018/3/3.jpg" length="980516" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10018/4/4.jpg" length="954214" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10018/5/5.jpg" length="1045459" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10018/6/6.jpg" length="950095" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10018/7/7.jpg" length="899616" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10018/8/8.jpg" length="941097" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10018/9/9.jpg" length="1019945" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10018/10/10.jpg" length="1017722" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10018/11/11.jpg" length="1056589" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10018/12/12.jpg" length="961375" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10018/13/13.jpg" length="1081305" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10018/14/14.jpg" length="997198" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10018/15/15.jpg" length="939349" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10018/16/16.jpg" length="1026726" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10018/17/17.jpg" length="1036997" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10018/18/18.jpg" length="963843" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10018/19/19.jpg" length="1000756" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10018/20/20.jpg" length="984204" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10018/21/21.jpg" length="976894" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10018/22/22.jpg" length="959189" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10018/23/23.jpg" length="892461" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10018/24/24.jpg" length="994915" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10018/25/25.jpg" length="1006858" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10018/26/26.jpg" length="977453" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10018/27/27.jpg" length="936993" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10018/28/28.jpg" length="1037714" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10018/29/29.jpg" length="886939" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10018/30/30.jpg" length="988695" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10018/31/31.jpg" length="961584" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10018/32/32.jpg" length="1030375" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10018/33/33.jpg" length="952322" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10018/34/34.jpg" length="1068381" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10018/35/35.jpg" length="948913" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10018/36/36.jpg" length="995172" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10018/37/37.jpg" length="935824" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10018/38/38.jpg" length="997216" type="image/jpeg"/></item><item>
<title>Resolor/Prucalopride May Be Useful in the Preparation of Colon Capsule Endoscopy [sub:CRCPrevention]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2058</link>
<description>Resolor/Prucalopride May Be Useful in the Preparation of Colon Capsule Endoscopy [sub:CRCPrevention]</description><category>sub:CRCPrevention</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2058</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2058">Resolor/<wbr>Prucalopride May Be Useful in the Preparation of Colon Capsule Endoscopy</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20141231&edate=20140901&cat=sub%3aCRCPrevention"><font color="#e95e0b">:GastroEnterology:sub:CRCPrevention</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2058">GastroEnterology2058</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 09 October 2014 | 16:31</font><br><br><div style="margin-bottom: 10px;">Comment: Findings from a pilot study with 50 patients (cases) prepared with Prucalopride+Polyethylene glycol plus ascorbic acid compared with 50 control patients prepared with PEG/<wbr>Fosfosoda show that the higher excretion rate as well as the shortened gastric and intestinal transits, without modifying the colon transit, with the new preparation (Prucalopride+Polyethylene glycol plus ascorbic acid), allow conducting a higher quality study of the colon over time and with less adverse effects and better tolerance as a result of excluding sodium phosphate.<wbr> </div><div style="margin-bottom: 10px;">It is suggested that the procedure may be considered as an alternative, particularly for patients in whom sodium phosphate-based preparations are contraindicated.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Rationale for the Study</FONT></STRONG> </div><div style="margin-bottom: 10px;">Prucalopride is a highly selective serotonin 5HT4 receptor agonist which stimulate the release of acetylcholine necessary for smooth bowel muscle contraction and therefore peristalsis.<wbr> </div><div style="margin-bottom: 10px;">After observing its benefits on the treatment for constipation, researchers believe that Prucalopride could be useful in the preparation of colon capsule endoscopy, speeding up intestinal transit and therefore making the examination shorter, increasing the excretion rate.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Preparation Protocol</FONT></STRONG> </div><div style="margin-bottom: 10px;">Two days of residue-free diet - Day before the test, liquid diet - Resolor 2 mg, 1 on each day of the diet and 2 on the examination day - Moviprep, 1 liter in the evening prior to the examination and 1 liter in the morning of the examination – Then 2 boosters of half a liter each in alarms 1 and 2.<wbr> </div><div>Source: UEGW Vienna 2014 - KINETICS OF COLON CAPSULE ENDOSCOPY: A NEW MODEL OF PREPARATION (Oct 21 2014) - <A href="http://uegw.congress-online.com/guest/AbstractView?ABSID=7457">http:/<wbr>/<wbr>uegw.<wbr>congress-online.<wbr>com/<wbr>guest/<wbr>AbstractView?ABSID=7457</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2058">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-10-09T16:31:36+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Allergan Raises Its Guidance Underpinning The Need For A Raised Offer From Valeant [:PharmaWorld:sub:Acquisition]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7763</link>
<description>Allergan Raises Its Guidance Underpinning The Need For A Raised Offer From Valeant [:PharmaWorld:sub:Acquisition]</description><category>sub:Acquisition</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7763</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7763">Allergan Raises Its Guidance Underpinning The Need For A Raised Offer From Valeant</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=sub%3aAcquisition"><font color="#e95e0b">:PharmaWorld:sub:Acquisition</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7763">Neurology7763</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 09 October 2014 | 15:20</font><br><br><div style="margin-bottom: 10px;">Comment: Allergan has today updated its sales and earnings guidance for both 
the third quarter and full year 2014/<wbr>15 and 16.<wbr> Commenting on the new figures 
David Pyott emphasised that "Our expectations for the third quarter 
and updated future outlook further demonstrate that there is a vast value gap 
between Valeant's offer and the intrinsic value of Allergan.<wbr>" </div><div style="margin-bottom: 10px;">He reinforced this view by stating "The Company continues to 
perform exceptionally well, driven by accelerating sales growth since early 2013 
across a broad range of products and geographies.<wbr>" </div><div style="margin-bottom: 10px;">Momentum appears to bederived from many sources: robust growth of 
worldwide markets in which <ORG value="NYSE:AGN">Allergan</ORG> operates; increases in market share in most 
categories; many regulatory approvals for new products in the U.<wbr>S.<wbr> and 
internationally; and targeted investments to create and grow new products and 
new categories.<wbr> </div><div style="margin-bottom: 10px;">Earnings will start to see the benefit of the previously announced 
restructuring programme in the fourth quarter onwards </div><div style="margin-bottom: 10px;"><SPAN style="TEXT-DECORATION: underline"><B>Third Quarter 2014</B></SPAN> </div><div style="margin-bottom: 10px;"><UL><LI style="MARGIN-BOTTOM: 10px"><ORG value="NYSE:AGN">Allergan</ORG> expects non-GAAP diluted EPS attributable to 
  stockholders for the third quarter of 2014 to be between <MONEY>$1.<wbr>76</MONEY> 
  and <MONEY>$1.<wbr>78</MONEY>, + 43 -45 % compared to previous guidance 
  provided for non-GAAP diluted EPS of  
  $1.<wbr>44- <MONEY>$1.<wbr>47</MONEY>.<wbr> 
  </LI>
<LI style="MARGIN-BOTTOM: 10px"><ORG value="NYSE:AGN"></ORG>Net sales for the third quarter of 2014 are 
  expected to increase in excess of 17% in dollars compared to 
  product net sales for the third quarter of 2013.<wbr> </LI>
</UL> </div><div style="margin-bottom: 10px;"><SPAN style="TEXT-DECORATION: underline"><B>Full year 2014</B></SPAN> </div><div style="margin-bottom: 10px;"><UL><LI style="MARGIN-BOTTOM: 10px"><ORG value="NYSE:AGN">Non-GAAP diluted EPS F/<wbr>Y 2014 to be between 
  <MONEY>$6.<wbr>20</MONEY> and <MONEY>$6.<wbr>25</MONEY>, representing an increase of 
  between 30 and 31 percent compared to F/<wbr>Y 2013.<wbr> 
  <LI style="MARGIN-BOTTOM: 10px"></LI>

</ORG><ORG value="NYSE:AGN"></ORG>Product net sales for F/<wbr>Y 2014 to increase 
  between 14-15% percent in dollars compared to F/<wbr>Y 2013.<wbr>  </LI>
</UL> </div><div style="margin-bottom: 10px;"><SPAN style="TEXT-DECORATION: underline"><B>2015 and 2016</B></SPAN> </div><div style="margin-bottom: 10px;">Due to the continued strength of the business, <ORG value="NYSE:AGN">Allergan</ORG> expects the following increases to EPS: </div><div><UL><LI style="MARGIN-BOTTOM: 10px"><ORG value="NYSE:AGN"></ORG>Non-GAAP diluted EPS attributable to stockholders for 
  full year 2015 to be approximately <MONEY>$8.<wbr>60</MONEY>.<wbr> 
  </LI>
<LI style="MARGIN-BOTTOM: 10px"><ORG value="NYSE:AGN"></ORG>Non-GAAP diluted EPS attributable to stockholders for 
  full year 2016 to be approximately <MONEY>$10.<wbr>25</MONEY>.<wbr> </LI>
</UL> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7763">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-10-09T15:20:36+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>Novo's Anti-NKG2D for Cronh's Available for Licensing [dis:IBD, :PharmaWorld:sub:xLicensing]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2056</link>
<description>Novo's Anti-NKG2D for Cronh's Available for Licensing [dis:IBD, :PharmaWorld:sub:xLicensing]</description><category>dis:IBD</category><category>sub:xLicensing</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2056</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2056">Novo's Anti-NKG2D for Cronh's Available for Licensing</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20141231&edate=20140901&cat=dis%3aIBD"><font color="#e95e0b">:GastroEnterology:dis:IBD</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=sub%3axLicensing"><font color="#e95e0b">:PharmaWorld:sub:xLicensing</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2056">GastroEnterology2056</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 09 October 2014 | 14:03</font><br><br><div style="margin-bottom: 10px;">Comment: Beginning of last month, Novo reported its strategy to drop its inflammation business.<wbr> One of the two investigational compounds in Ph2a development for Crohn's disease, NNC0142-0002 (anti-NKG2D mAb), will be presented at the next UEGW in the free paper session titled "Targeting new pathways in IBD".<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Novo' Strategy with Anti-NKG2D</FONT></STRONG> </div><div style="margin-bottom: 10px;">End of 2012, Novo reported its decision to discontinue further development with the drug.<wbr> </div><div style="margin-bottom: 10px;"><UL><LI><U>Rationale</U>: The analysis performed on the basis of 74 randomised patients did not meet the pre-specified criteria for effect.<wbr> No safety concerns were identified in the trial.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">UEGW</FONT></STRONG> - On Oct 22 2014, Matthieu Allez will be speaking on this particularly trial </div><div style="margin-bottom: 10px;"><UL><LI>RANDOMISED, DOUBLE-BLIND, SINGLE-DOSE, PHASE 2 TRIAL ASSESSING EFFICACY AND SAFETY OF THE NOVEL ANTI-NKG2D MONOCLONAL ANTIBODY NNC0142-0002 IN CROHN'S DISEASE: INSIGHTS FROM AN EXPOSURE-RESPONSE ANALYSIS</LI>
</UL> </div><div style="margin-bottom: 10px;">The findings conclude that </div><div style="margin-bottom: 10px;">A single s.<wbr>c.<wbr> dose of 2 mg/<wbr>kg NNC0142‑0002 (anti‑NKG2D mAb) did not reduce disease activity at Week 4 (primary outcome) compared with placebo, but significantly reduced disease activity at Week 12, and was well tolerated.<wbr> </div><div style="margin-bottom: 10px;">Exposure-response analysis in patients with baseline CDAI ≥330 provides supportive evidence for a treatment effect of NNC0142‑0002 and <U>suggests that higher doses and repeated dosing may further optimise the effect of NNC0142‑0002 in Crohn’s disease</U>.<wbr> </div><div>Please see @ <A href="http://uegw.congress-online.com/guest/AbstractView?ABSID=8916">http:/<wbr>/<wbr>uegw.<wbr>congress-online.<wbr>com/<wbr>guest/<wbr>AbstractView?ABSID=8916</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2056">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-10-09T14:03:38+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Cortendo AB Appoints Officer to Lead Commercial Strategy for Cushing Drug [:PharmaWorld:sub:People, dis:Cushing]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7820</link>
<description>Cortendo AB Appoints Officer to Lead Commercial Strategy for Cushing Drug [:PharmaWorld:sub:People, dis:Cushing]</description><category>sub:People</category><category>dis:Cushing</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7820</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20141231&edate=20140901&rec=7820">Cortendo AB Appoints Officer to Lead Commercial Strategy for Cushing Drug</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20141231&edate=20140901&cat=dis%3aCushing"><font color="#e95e0b">:Endocrinology:dis:Cushing</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=sub%3aPeople"><font color="#e95e0b">:PharmaWorld:sub:People</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7820">Endocrinology7820</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 09 October 2014 | 11:36</font><br><br><div style="margin-bottom: 10px;">Comment: Robert Luz will be leading the commercial strategy for NormoCort/<wbr>COR-003 (levdexketoconazole), which is currently being evaluated in a global Ph3 (SONIC trial).<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Drug Status</FONT></STRONG> </div><div style="margin-bottom: 10px;">R.<wbr> Luts has both professional and personal involvement in orphan diseases.<wbr> The investigational compound has received orphan designation from both the EMA and the FDA.<wbr> </div><div style="margin-bottom: 10px;">NormoCort has an issued patent in Europe (EP 1853266B1) and a similar patent has been filed in the US </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Luz Short Bio</FONT></STRONG> </div><div style="margin-bottom: 10px;">Held key leadership positions at Shire, with global responsibilities.<wbr> </div><div style="margin-bottom: 10px;">Prior to joining Shire, Luz served in a variety of financial, strategic and executive positions at energy companies.<wbr> </div><div>Source: Cortendo AB </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20141231&edate=20140901&rec=7820">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-10-09T11:36:11+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Ferring Offers New Flavor Option for PREPOPIK [sub:CRCPrevention, headline]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2054</link>
<description>Ferring Offers New Flavor Option for PREPOPIK [sub:CRCPrevention, headline]</description><category>sub:CRCPrevention</category><category>headline</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2054</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2054">Ferring Offers New Flavor Option for PREPOPIK</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20141231&edate=20140901&cat=headline"><font color="#e95e0b">:GastroEnterology:headline</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20141231&edate=20140901&cat=sub%3aCRCPrevention"><font color="#e95e0b">:GastroEnterology:sub:CRCPrevention</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2054">GastroEnterology2054</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 08 October 2014 | 18:12</font><br><br><div style="margin-bottom: 10px;">Comment: To offer an alternative choice in bowel preparation, Ferring Pharmaceuticals Inc.<wbr> will introduce a new cranberry flavor option of PREPOPIK in January 2015.<wbr> The cranberry flavor was approved by the FDA on August 22, 2014.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">About PREPOPIK</FONT></STRONG> </div><div style="margin-bottom: 10px;">PREPOPIK orange-flavor was approved by the FDA on July 17, 2012, based on data from the pivotal SEE CLEAR I and II studies.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2054/3/ScreenCapture3.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2054/1/ScreenCapture1.jpg?user-agent=rss"> </div><div><img src="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2054/4/ScreenCapture4.jpg?user-agent=rss"> </div><!-- Comment details --><a name="gastroenterology2054attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2054/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(36,6 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2054/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(36,7 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2054/4/ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(50,4 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2054">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-10-08T18:12:04+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2054/2/ScreenCapture2.jpg" length="37479" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2054/3/ScreenCapture3.jpg" length="37588" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2054/4/ScreenCapture4.jpg" length="51618" type="image/jpeg"/></item><item>
<title>re: NICE Rejects Sativex On Cost Efficacy Grounds</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7761</link>
<description>re: NICE Rejects Sativex On Cost Efficacy Grounds</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7761</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7761">re: NICE Rejects Sativex On Cost Efficacy Grounds</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7761">Neurology7761</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 08 October 2014 | 17:38</font><br><br><div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">NICE Rejects Sativex On Cost Efficacy Grounds</span>&nbsp;<font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20141231&edate=20140901&cat=dis%3aSpasticity"><font color="#e95e0b">:Neurology:dis:Spasticity</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20141231&edate=20140901&cat=news"><font color="#e95e0b">:Neurology:news</font></a>]</font></font><br><span style="font-size: 12px;">Comment: UK NICE has today rejected GW Pharma's spasticity drug Sativex as being not cost-effective.<wbr> NICE has also rejected Acorda Therapeutics Fampyra.<wbr>These determinations have both arisen as a results of a major review by the agnecy on improveing care for multiple sclerosis patients.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7756">...</a><br><font size="-1">Jacquelyne CANTLE MEYRICK / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7756" class="commentpermalink">Neurology7756</a> / <span class="date">08 October 2014</span> /
<span class="time">09:35:52 o'clock CEST</span>
</font></div><div style="margin-bottom: 10px;">Two days ago, Ireland's National Centre for Pharmacoeconomics (NCPE) issued guidance not recommending Sativex for reimbursement as an add-on treatment for improving symptoms in patients with moderate-to-severe spasticity due to multiple sclerosis (MS), who have not responded adequately to other antispasticity medication and who demonstrated clinically significant improvement in spasticity-related symptoms during an initial trial of therapy.<wbr> </div><div style="margin-bottom: 10px;">For cost-effectiveness evidence the manufacturer submitted a cost-utility analysis in which Sativex was compared with standard of care (SoC), with the health-state utilities values having been derived from data based on an EQ-5D questionnaire in the Phase III GWSP0604 study randomised population.<wbr> </div><div style="margin-bottom: 10px;">However, the NCPE's review group raised several concerns regarding the economic model, including the fact that the company did not present a comparison between Sativex and SoC among the Sativex-eligible population and not just Sativex responders.<wbr> The group also stated that the validity of creating a disease model that is based on the stratified numerical rating (NRS) was not demonstrated.<wbr> </div><div style="margin-bottom: 10px;">The company's base assumptions yielded total five-year costs per Sativex-treated patient at EUR26,039 (USD32,579) and quality-adjusted life years (QALYs) of 2.<wbr>6, with the incremental cost-effectiveness ratio of EUR17,826 per QALY when compared with SoC.<wbr> </div><div style="margin-bottom: 10px;">The company estimated that the gross budget impact of Sativex will be EUR396,901 in year one, increasing to EUR797,014 in year five.<wbr> The NCPE concluded that "clinical significance of the observed difference of 0.<wbr>84 on the 0–10 point NRS spasticity scale is difficult to assess".<wbr> Furthermore it was noted that cost-effectiveness evaluation of the drug in addition to SoC among the Sativex-eligible population was not presented, and that the cost effectiveness of continued treatment with the drug was likely to be over the willingness to pay threshold, in particular if the period of treatment were to extend over the four-week trial period in non-responders.<wbr> </div><div>The reimbursement of Sativex under the submitted price was therefore not recommended.<wbr> </div><!-- Comment details --><font size="-1">Brigitte DESCHAMPS / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7761" class="commentpermalink">Neurology7761</a> / <span class="date">08 October 2014</span> /
<span class="time">17:38:07 o'clock CEST</span>
</font><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7761">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7756">View thread  Neurology7756: NICE Rejects Sativex On Cost Efficacy Grounds</a>]]></content:encoded><dc:date>2014-10-08T17:38:07+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Merz Reports a Moderate 1.4% Increase in Revenue to EUR 994M [comp:Merz, :PharmaWorld:sub:Finance, headline]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7759</link>
<description>Merz Reports a Moderate 1.4% Increase in Revenue to EUR 994M [comp:Merz, :PharmaWorld:sub:Finance, headline]</description><category>comp:Merz</category><category>sub:Finance</category><category>headline</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7759</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7759">Merz Reports a Moderate 1.<wbr>4% Increase in Revenue to EUR 994M</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20141231&edate=20140901&cat=comp%3aMerz"><font color="#e95e0b">:Neurology:comp:Merz</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20141231&edate=20140901&cat=headline"><font color="#e95e0b">:Neurology:headline</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=sub%3aFinance"><font color="#e95e0b">:PharmaWorld:sub:Finance</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7759">Neurology7759</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 08 October 2014 | 17:20</font><br><br><div style="margin-bottom: 10px;">Comment: With patent expiration reducing revenue from Memantine, Merz has been continually and significantly expanding its Aesthetic and Neurotoxin business.<wbr> Management said fiscal 2013/<wbr>2014 was the most successful year for the botulinum toxins Bocouture® and Xeomin® since they were launched in Germany.<wbr> It expects growth coming from the strategic acquisitions of Neocutis, Anteis and Ulthera System.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">A New Regional Focus</FONT></STRONG> </div><div style="margin-bottom: 10px;">Business will be organized on the basis of 4 regions: EMEA, North America, Asia-Pacific, and Latin America (previous regional breakdown was: Western EU, North America and Emercing Markets).<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">International as a Decisive Growth Driver</FONT></STRONG> </div><div style="margin-bottom: 10px;">Merz earned revenue of EUR 874M from its international business (up from EUR 837.<wbr>4M in the previous year), which accounted for 87.<wbr>9% of Group revenue (up from 85.<wbr>4%).<wbr> </div><div style="margin-bottom: 10px;">Merz recorded sharply increasing revenue from Asia (up 24.<wbr>1% at constant exchange rates) and the U.<wbr>S.<wbr> (up 8.<wbr>5% at constant exchange rates) in particular.<wbr> </div><div style="margin-bottom: 10px;">Business in Russia also showed vigorous growth despite a weaker ruble.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Merz Consumer Care</FONT></STRONG> </div><div style="margin-bottom: 10px;">At EUR 67.<wbr>8 million (compared with EUR 63.<wbr>6 million in the previous year), Merz Consumer Care generated roughly 7% of the Group’s total revenue.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">High Investment in R&amp;D</FONT></STRONG> </div><div style="margin-bottom: 10px;">R&amp;D outlays across the entire Group totaled EUR 146.<wbr>9M (14.<wbr>8% of revenue).<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">2012/<wbr>2013 Figures</FONT></STRONG> </div><div style="margin-bottom: 10px;"><EM><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7759/1/ScreenCapture1.jpg?user-agent=rss"></EM> </div><div><EM>Source: Merz</EM> </div><!-- Comment details --><a name="neurology7759attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7759/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(53,9 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7759">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-10-08T17:20:31+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7759/1/ScreenCapture1.jpg" length="55193" type="image/jpeg"/></item><item>
<title>FDA Recommends New Endpoint To Allow Faster Approval For Neoadjuvant Therapy To Treat Breast Cancer [:PharmaWorld:func:RnD, :PharmaWorld:news, :PharmaWorld:mkt:NorthAmerica, :PharmaWorld:sub:Regulatory, dis:Gynea]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology10016</link>
<description>FDA Recommends New Endpoint To Allow Faster Approval For Neoadjuvant Therapy To Treat Breast Cancer [:PharmaWorld:func:RnD, :PharmaWorld:news, :PharmaWorld:mkt:NorthAmerica, :PharmaWorld:sub:Regulatory, dis:Gynea]</description><category>func:RnD</category><category>news</category><category>mkt:NorthAmerica</category><category>sub:Regulatory</category><category>dis:Gynea</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology10016</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10016">FDA Recommends New Endpoint To Allow Faster Approval For Neoadjuvant Therapy To Treat Breast Cancer</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=dis%3aGynea"><font color="#e95e0b">:Oncology:dis:Gynea</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=func%3aRnD"><font color="#e95e0b">:PharmaWorld:func:RnD</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=mkt%3aNorthAmerica"><font color="#e95e0b">:PharmaWorld:mkt:NorthAmerica</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=news"><font color="#e95e0b">:PharmaWorld:news</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=sub%3aRegulatory"><font color="#e95e0b">:PharmaWorld:sub:Regulatory</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10016">Oncology10016</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/994">Jenny Wu</a> | 08 October 2014 | 14:47</font><br><br><div style="margin-bottom: 10px;">Comment: FDA has released a guidance document aiming to expedite the approaval process for novel neoadjuvant therapy to treat early stage breast cancer.<wbr>The guidelines are intended to help pharmaceutical companies design trials that will get approved more quickly so they can begin marketing the breast cancer therapies before they've completed testing.<wbr> </div><div style="margin-bottom: 10px;">Historically, novel agents have been developed and approved based on improvement of disease free survival (DFS) or overall survival (OS).<wbr> However, these agents are initially being explored for patients who have metastatic disease, whose expected survival is generally less than 2 years.<wbr> As a result, adopting similar endpoint in neoadjuvant trial would mean a lengthier process.<wbr> In the guidance, FDA recommends to use 'pathological complete response'(pCR) as a surrogate clinical measurement in the neoadjuvant trial as pCR could reasonably predict clinical benefit within several months of initiation of an investigational drug.<wbr> And therefore this could help accerlation of the approval process to help address unmet need in high risk populations in a shorter time frame.<wbr> </div><div style="margin-bottom: 10px;">The goal is to reduce the number of people who receive mastectomies by using innovative therapies instead.<wbr> There are several potential reasons to consider neoadjuvant treatment for early-stage breast cancer," the agency wrote.<wbr> "Giving chemotherapy preoperatively permits breast conservation in some patients who would otherwise require mastectomy and may improve cosmesis in existing candidates for breast conservation.<wbr>" </div><div>The full details of the guidance can be found here: <A href="http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM305501.pdf">http:/<wbr>/<wbr>www.<wbr>fda.<wbr>gov/<wbr>downloads/<wbr>Drugs/<wbr>GuidanceComplianceRegulatoryInformation/<wbr>Guidances/<wbr>UCM305501.<wbr>pdf</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10016">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-10-08T14:47:25+02:00</dc:date><dc:creator>jew60237</dc:creator></item><item>
<title>Actavis's Potential Bid Talks With Allergan Prompt Valeant To Consider A Revised Offer [:PharmaWorld:sub:Acquisition, headline]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7758</link>
<description>Actavis's Potential Bid Talks With Allergan Prompt Valeant To Consider A Revised Offer [:PharmaWorld:sub:Acquisition, headline]</description><category>sub:Acquisition</category><category>headline</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7758</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7758">Actavis's Potential Bid Talks With Allergan Prompt Valeant To Consider A Revised Offer</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20141231&edate=20140901&cat=headline"><font color="#e95e0b">:Neurology:headline</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=sub%3aAcquisition"><font color="#e95e0b">:PharmaWorld:sub:Acquisition</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7758">Neurology7758</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 08 October 2014 | 14:13</font><br><br><div style="margin-bottom: 10px;">Comment: Whilst not confirmed, the Valeant/<wbr>Allergan deal saga takes 
potentially another turn today, with Valeant apparently poised to raise its 
offer for Allergan amidst speculation that Actavis may be about to 
re-initiate talks with Allergan.<wbr> </div><div style="margin-bottom: 10px;">The rumoured increase in Valeant's offer is likely to be of the order 
of $15 per share valuing the stock at about $191 per share and closer 
to what is suggested in the market might be an offer that 
Allergan could find acceptable of $200 per share.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Actavis Profile</STRONG> </div><div style="margin-bottom: 10px;">Actavis itself has had a busy year on the acquisition front, with its most 
notable purchases being Forest Labs in Feburary and Aptalis in January.<wbr> This 
effectively transformed Actavis from what was a generic company into more of a 
specialised pharmaceutical company with approx $15bn in potential annual 
revenue generation (50/<wbr>50 brand/<wbr>generic),  with a therapeutic profile 
as shown below and a desire to maintain a high level of investment in 
R&amp;D.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7758/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7758/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7758/3/ScreenCapture3.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7758/4/ScreenCapture4.jpg?user-agent=rss"> </div><div>Source: Reuters </div><!-- Comment details --><a name="neurology7758attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7758/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(102,1 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7758/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(134,7 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7758/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(130 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7758/4/ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(85,5 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7758">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-10-08T14:13:37+02:00</dc:date><dc:creator>jac89886</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7758/1/ScreenCapture1.jpg" length="104579" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7758/2/ScreenCapture2.jpg" length="137936" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7758/3/ScreenCapture3.jpg" length="133147" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7758/4/ScreenCapture4.jpg" length="87556" type="image/jpeg"/></item><item>
<title>NICE Rejects Sativex On Cost Efficacy Grounds [dis:Spasticity, news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7756</link>
<description>NICE Rejects Sativex On Cost Efficacy Grounds [dis:Spasticity, news]</description><comments>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7756</comments><category>dis:Spasticity</category><category>news</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7756</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7756">NICE Rejects Sativex On Cost Efficacy Grounds</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20141231&edate=20140901&cat=dis%3aSpasticity"><font color="#e95e0b">:Neurology:dis:Spasticity</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20141231&edate=20140901&cat=news"><font color="#e95e0b">:Neurology:news</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7756">Neurology7756</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 08 October 2014 | 09:35</font><br><br><div style="margin-bottom: 10px;">Comment: UK NICE has today rejected GW Pharma's spasticity drug Sativex as being not cost-effective.<wbr> NICE has also rejected Acorda Therapeutics Fampyra.<wbr>These determinations have both arisen as a results of a major review by the agnecy on improveing care for multiple sclerosis patients.<wbr> </div><div style="margin-bottom: 10px;">The exact wording in the press release is:- </div><div style="margin-bottom: 10px;">"The guidance does not recommend the use of the cannabinoid drug Sativex or fampridine as they provide only a modest benefit at a significant cost to the NHS.<wbr> Sativex costs &pound;50,000 per quality-adjusted life year (QALY), while fampridine costs in the region of &pound;160,000 per QALY.<wbr> Both are well above NICE&rsquo;s threshold of &pound;30,000 per QALY.<wbr>" </div><div style="margin-bottom: 10px;">With a typical patient taking four sprays of Sativex per day, GW estmated that the real-life daily cost of treatment with Sativex is &pound;5.<wbr>56 per day.<wbr> </div><div style="margin-bottom: 10px;">The new guidance for the treatment of MS replaces that last issued in 2003.<wbr> With specific reference to spasticity it states the following:- </div><div style="margin-bottom: 10px;"><A id="spasticity"></A>Spasticity </div><div style="margin-bottom: 10px;"><P class="numbered-paragraph">1.<wbr>5.<wbr>16 In people with MS assess and offer treatment for factors that may aggravate spasticity such as constipation, urinary tract or other infections, inappropriately fitted mobility aids, pressure ulcers, posture and pain.<wbr></P> </div><div style="margin-bottom: 10px;"><P class="numbered-paragraph">1.<wbr>5.<wbr>17 Encourage people with MS to manage their own spasticity symptoms by explaining how doses of drugs can be adjusted within agreed limits.<wbr></P> </div><div style="margin-bottom: 10px;"><P class="numbered-paragraph">1.<wbr>5.<wbr>18 Ensure that the person with MS:</P> </div><div style="margin-bottom: 10px;"><DIV class="itemizedlist indented">
<UL class="itemizedlist"><LI class="listitem">
has tried the drug at an optimal dose, or the maximum dose they can tolerate

</LI>
<LI class="listitem">
stops the drug if there is no benefit at the maximum tolerated dose

</LI>
<LI class="listitem">
has their drug treatment reviewed at least annually once the optimal dose has been reached.<wbr>

</LI>
</UL>
</DIV> </div><div style="margin-bottom: 10px;"><P class="numbered-paragraph">1.<wbr>5.<wbr>19 Consider baclofen or gabapentin<SUP><FONT size="2">[</FONT><A class="footnote" href="https://www.nice.org.uk/guidance/cg186/chapter/1-recommendations#ftn.footnote_7" id="footnote_7" name="footnote_7"><U><FONT color="#0066cc" size="2">7</FONT></U></A><FONT size="2">]</FONT></SUP> as a first‑line drug to treat spasticity in MS depending on contraindications and the person's comorbidities and preferences.<wbr> If the person with MS cannot tolerate one of these drugs consider switching to the other.<wbr></P> </div><div style="margin-bottom: 10px;"><P class="numbered-paragraph">1.<wbr>5.<wbr>20 Consider a combination of baclofen and gabapentin<SUP><FONT size="2">[</FONT><A class="footnoteref" href="https://www.nice.org.uk/guidance/cg186/chapter/1-recommendations#ftn.footnote_7"><U><FONT color="#0066cc" size="2">7</FONT></U></A><FONT size="2">]</FONT></SUP><SUP><FONT size="2">,</FONT></SUP><SUP><FONT size="2">[</FONT><A class="footnote" href="https://www.nice.org.uk/guidance/cg186/chapter/1-recommendations#ftn.footnote_8" id="footnote_8" name="footnote_8"><U><FONT color="#0066cc" size="2">8</FONT></U></A><FONT size="2">]</FONT></SUP> for people with MS if:</P> </div><div style="margin-bottom: 10px;"><DIV class="itemizedlist indented">
<UL class="itemizedlist"><LI class="listitem">
individual drugs do not provide adequate relief <STRONG>or </STRONG>

</LI>
<LI class="listitem">
side effects from individual drugs prevent the dose being increased.<wbr>

</LI>
</UL>
</DIV> </div><div style="margin-bottom: 10px;"><P class="numbered-paragraph">1.<wbr>5.<wbr>21 Consider tizanidine or dantrolene as a second‑line option to treat spasticity in people with MS.<wbr></P> </div><div style="margin-bottom: 10px;"><P class="numbered-paragraph">1.<wbr>5.<wbr>22 Consider benzodiazepines as a third‑line option to treat spasticity in MS and be aware of their potential benefit in treating nocturnal spasms.<wbr></P> </div><div style="margin-bottom: 10px;"><P class="numbered-paragraph">1.<wbr>5.<wbr>23 Do not offer Sativex to treat spasticity in people with MS because it is not a cost effective treatment<SUP><FONT size="2">[</FONT><A class="footnote" href="https://www.nice.org.uk/guidance/cg186/chapter/1-recommendations#ftn.footnote_9" id="footnote_9" name="footnote_9"><U><FONT color="#0066cc" size="2">9</FONT></U></A><FONT size="2">]</FONT></SUP>.<wbr></P> </div><div style="margin-bottom: 10px;"><P class="numbered-paragraph">1.<wbr>5.<wbr>24 If spasticity cannot be managed with any of the above pharmacological treatments, refer the person to specialist spasticity services.<wbr></P> </div><div><A href="http://www.NICE.com">www.<wbr>nice.<wbr>org.<wbr>uk.<wbr>com</A> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Neurology7761c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">Two days ago, Ireland's National Centre for Pharmacoeconomics (NCPE) issued guidance not recommending Sativex for reimbursement as an add-on treatment for improving symptoms in patients with moderate-to-severe spasticity due to multiple sclerosis (MS), who have not responded adequately to other antispasticity medication and who demonstrated clinically significant improvement in spasticity-related symptoms during an initial trial of therapy.<wbr> </div><div style="margin-bottom: 10px;">For cost-effectiveness evidence the manufacturer submitted a cost-utility analysis in which Sativex was compared with standard of care (SoC), with the health-state utilities values having been derived from data based on an EQ-5D questionnaire in the Phase III GWSP0604 study randomised population.<wbr> </div><div style="margin-bottom: 10px;">However, the NCPE's review group raised several concerns regarding the economic model, including the fact that the company did not present a comparison between Sativex and SoC among the Sativex-eligible population and not just Sativex responders.<wbr> The group also stated that the validity of creating a disease model that is based on the stratified numerical rating (NRS) was not demonstrated.<wbr> </div><div style="margin-bottom: 10px;">The company's base assumptions yielded total five-year costs per Sativex-treated patient at EUR26,039 (USD32,579) and quality-adjusted life years (QALYs) of 2.<wbr>6, with the incremental cost-effectiveness ratio of EUR17,826 per QALY when compared with SoC.<wbr> </div><div style="margin-bottom: 10px;">The company estimated that the gross budget impact of Sativex will be EUR396,901 in year one, increasing to EUR797,014 in year five.<wbr> The NCPE concluded that "clinical significance of the observed difference of 0.<wbr>84 on the 0–10 point NRS spasticity scale is difficult to assess".<wbr> Furthermore it was noted that cost-effectiveness evaluation of the drug in addition to SoC among the Sativex-eligible population was not presented, and that the cost effectiveness of continued treatment with the drug was likely to be over the willingness to pay threshold, in particular if the period of treatment were to extend over the four-week trial period in non-responders.<wbr> </div><div>The reimbursement of Sativex under the submitted price was therefore not recommended.<wbr> </div><font size="-1">Brigitte DESCHAMPS / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7761" class="commentpermalink">Neurology7761</a> / <span class="date">08 October 2014</span> /
<span class="time">17:38:07 o'clock CEST</span>
</font></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7756">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-10-08T09:35:52+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>Merck Serono To Collaborate With ICR And Welcome Trust For Cancer Drug Discovery</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology10013</link>
<description>Merck Serono To Collaborate With ICR And Welcome Trust For Cancer Drug Discovery</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology10013</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10013">Merck Serono To Collaborate With ICR And Welcome Trust For Cancer Drug Discovery</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10013">Oncology10013</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/994">Jenny Wu</a> | 07 October 2014 | 17:50</font><br><br><div style="margin-bottom: 10px;">Comment: Merck Serono today announced a co-development and license agreement to identify inhibitors of tankyrase, an enzyme of the PARP family with collaboration with the Institute of Cancer Research (ICR).<wbr> ICR was founded as a research department of the Royal Marsden Hospital and it has been responsible for a number of breakthrough discoveries including discovery of one of the hallmarks in cancer - DNA damage.<wbr> And perhaps more significantly, ICR, with close collaboration with Royal Marsden NHS Foundation Trust, is where abiraterone was once discovered and developed.<wbr> </div><div style="margin-bottom: 10px;">The collaboration will be jointly funded by Merck Serono and the Wellcome Trust.<wbr> Wellcome Trust is one the UK largest provided of non-governmental funding for scientific research.<wbr>The existing drug discovery program at the ICR is supported by a Wellcome Trust Seeding Drug Discovery Award.<wbr> In a joint effort, a team led by Dr.<wbr> Chris Lord and Professor Alan Ashworth at the ICR and a research group at Merck Serono will aim to progress chemical compounds that have emerged from both organizations' tankyrase inhibitor programs towards clinical development.<wbr> At the end of the collaboration period, Merck Serono will take over full responsibility for the selected clinical development candidate, with the goal of bringing a new cancer therapeutic drug to patients.<wbr> Under the terms of the agreement, Merck Serono will make milestone payments based on achieving regulatory and sales goals plus royalty payments on net sales of future products discovered or developed under the agreement </div><div>Dr.<wbr> Chris Lord, Team Leader in the Division of Breast Cancer Research at The Institute of Cancer Research, London, said: "Tankyrase inhibitors provide a uniqueopportunity to target one of the most common characteristics of cancer cells - their dependency on the so-called 'Wnt signaling' pathway.<wbr> Both Merck Serono and the group at the ICR have already made notable progress in developing tankyrase inhibitors.<wbr> Working with Merck Serono will allow us to jointly accelerate our program with the aim to ultimately make tankyrase inhibitors available to cancer patients.<wbr>" </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10013">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-10-07T17:50:23+02:00</dc:date><dc:creator>jew60237</dc:creator></item><item>
<title>Teva Reports New Strategy [dis:Gynea]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology10012</link>
<description>Teva Reports New Strategy [dis:Gynea]</description><category>dis:Gynea</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology10012</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10012">Teva Reports New Strategy</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=dis%3aGynea"><font color="#e95e0b">:Oncology:dis:Gynea</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10012">Oncology10012</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 07 October 2014 | 10:43</font><br><br><div style="margin-bottom: 10px;">Comment: Management said it will stop R&amp;D in areas such as oncology and women's health to cut costs, though it will maintain a commercial presence in these areas.<wbr> As a resul of the strategic review, 14 projects in the pipeline will be discontinued or divested.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Rationale</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/10012/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">- to increase resources in Teva's core therapeutic areas - central nervous system (CNS) and respiratory - while another part will support the company's drive to improve efficiency.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Fact Sheet Q1:14</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/10012/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/10012/3/ScreenCapture3.jpg?user-agent=rss"> </div><div>Source: <A href="http://www.tevapharm.com/Media/News/Pages/2014/1974272.aspx">http:/<wbr>/<wbr>www.<wbr>tevapharm.<wbr>com/<wbr>Media/<wbr>News/<wbr>Pages/<wbr>2014/<wbr>1974272.<wbr>aspx</A> </div><!-- Comment details --><a name="oncology10012attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10012/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(36,7 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10012/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(54,3 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10012/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(36,5 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10012">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-10-07T10:43:46+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10012/1/ScreenCapture1.jpg" length="37560" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10012/2/ScreenCapture2.jpg" length="55567" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10012/3/ScreenCapture3.jpg" length="37388" type="image/jpeg"/></item><item>
<title>American Peptide Enters Co-Prmotion Agreement for GlyTech's Glycosylation Technology [news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10986</link>
<description>American Peptide Enters Co-Prmotion Agreement for GlyTech's Glycosylation Technology [news]</description><category>news</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10986</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20141231&edate=20140901&rec=10986">American Peptide Enters Co-Prmotion Agreement for GlyTech's Glycosylation Technology</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=news"><font color="#e95e0b">:PharmaWorld:news</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10986">PharmaWorld10986</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 07 October 2014 | 09:48</font><br><br><div style="margin-bottom: 10px;">Comment: GlyTech’s technology was one of the finalists for the 2013 CPhI Pharma Award for Best Innovation in Process Development, and has been used in multiple projects, such as glycosylated somatostatin analogue, synthetic interferon beta 1a, and glycosylated GLP-1.<wbr> GlyTech’s technologies can contribute to developing better and lower-cost biopharmaceuticals.<wbr> GlyTech expects to play a significant role in developing bio-betters, biosimilars, and innovative biopharmaceutical products.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Terms of the Agreement</FONT></STRONG> </div><div style="margin-bottom: 10px;">American Peptide (APC) will leverage its sales and marketing resources to enhance GlyTech’s partnering efforts </div><div style="margin-bottom: 10px;">GlyTech will promote APC as a partner of choice for manufacture of its glycopeptides and glycoproteins.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">About GlyTech</FONT></STRONG> </div><div style="margin-bottom: 10px;"><U>Profile</U> </div><div style="margin-bottom: 10px;">HQ: Tokyo (Japan) </div><div style="margin-bottom: 10px;">GlyTech is a world leader in glycotechnology, having established the large-scale manufacturing process for highly purified and characterized human type N-glycans as well as the chemical synthesis of glycosylated compounds, especially glycopeptides and glycoproteins.<wbr> .<wbr> </div><div style="margin-bottom: 10px;"><U>Technology</U> </div><div style="margin-bottom: 10px;">GlyTech’s glycosylation technology allows the synthesis of peptide and proteins with pre-attached glycans (sugars), taken from a library of over 50 different glycans.<wbr> It has been shown to markedly improve drug properties such as half-life, binding affinity and selectivity, and heterogeneity.<wbr> </div><div>Source: American Peptide </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20141231&edate=20140901&rec=10986">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-10-07T09:48:49+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Preclinical Data of Peregrine's Bavituximab in Combination with Immune Checkpoint Inhibitors [news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology10011</link>
<description>Preclinical Data of Peregrine's Bavituximab in Combination with Immune Checkpoint Inhibitors [news]</description><category>news</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology10011</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10011">Preclinical Data of Peregrine's Bavituximab in Combination with Immune Checkpoint Inhibitors</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=news"><font color="#e95e0b">:Oncology:news</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10011">Oncology10011</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 07 October 2014 | 09:38</font><br><br><div style="margin-bottom: 10px;">Comment: Bavituximab, a phosphatidylserine (PS)-targeting antibody, in combination with immune checkpoint inhibitors, such as anti-PD-1 or anti-CTLA-4, promote a robust and localized anti-tumor response in models of melanoma and breast cancer and decrease levels of myeloid derived suppressor cells (MDSC) in the tumor microenvironment.<wbr> Data were presented at the Cancer Research Institutes' "Cancer Immunotherapy: Out of the Gate" conference (please see poster attached).<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Rationale for Combination Immunotherapy</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/10011/3/ScreenCapture3.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">About the Findings</FONT></STRONG> </div><div style="margin-bottom: 10px;">Poster titled: "Antibody-mediated blockade of phosphatidylserine enhances the anti-tumor activity of immune checkpoint inhibitors by affecting myeloid-derived suppressor cell (MDSC) and lymphocyte populations in the tumor microenvironment" </div><div style="margin-bottom: 10px;">Speaker: Rolf Brekken, Ph.<wbr>D.<wbr>, Effie Marie Cain Research Scholar in Angiogenesis Research and an Associate Professor, in the Departments of Surgery and Pharmacology at the Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center in Dallas, Texas.<wbr> </div><div style="margin-bottom: 10px;">Data from these studies show that the PS-targeting antibody ch1N11, the preclinical equivalent to bavituximab, significantly enhances tumor growth inhibition of anti-CTLA-4 or anti-PD-1 in the B16 and K1735 melanoma models and the efficacy of anti-PD-1 in the EMT-6 breast tumor model.<wbr> </div><div style="margin-bottom: 10px;">New data show that the combination of ch1N11 and an anti-PD-1 antibody produce a statistically significant difference (p=0.<wbr>018) in tumor growth suppression over anti-PD-1 alone in the B16 melanoma model.<wbr> In addition, PS blockade with ch1N11 combined with either anti-CTLA-4 or anti-PD-1 resulted in greater T cell infiltration into B16 and K1735 tumors than tumors treated with either antibody alone.<wbr> </div><div style="margin-bottom: 10px;">Consistent with these results, ch1N11 combined with anti-PD-1 showed an enhanced percentage of T cells producing the cytokines IL-2 and IFNg, factors associated with immune activation, when compared with T cells from tumors being treated with anti-PD-1 alone.<wbr> </div><div style="margin-bottom: 10px;"><U>In summary</U>, the targeting and blocking of PS with ch1N11 significantly improved the anti-tumor efficacy of immune checkpoint blockade in robust models of melanoma and breast cancer in immunocompetent animals.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Bavituximab Development Program</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/10011/1/ScreenCapture1.jpg?user-agent=rss"> </div><div><EM>Source: Peregrine</EM> </div><!-- Comment details --><a name="oncology10011attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10011/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(45,9 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10011/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(55,2 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10011/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(63,5 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10011/4/Peregrine%5fcri%5f2014%5fbf.pdf">Peregrine_cri_2014_bf.pdf</a>&nbsp;&nbsp;(802,4 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10011">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-10-07T09:38:04+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10011/1/ScreenCapture1.jpg" length="46966" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10011/2/ScreenCapture2.jpg" length="56544" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10011/3/ScreenCapture3.jpg" length="65039" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10011/4/Peregrine%5fcri%5f2014%5fbf.pdf" length="821651" type="application/pdf"/></item><item>
<title>Galderma Moves Forward With Aesthetic Development of Liquid Toxin [news, sub:Aesthetics]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7755</link>
<description>Galderma Moves Forward With Aesthetic Development of Liquid Toxin [news, sub:Aesthetics]</description><category>news</category><category>sub:Aesthetics</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7755</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7755">Galderma Moves Forward With Aesthetic Development of Liquid Toxin</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20141231&edate=20140901&cat=news"><font color="#e95e0b">:Neurology:news</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20141231&edate=20140901&cat=sub%3aAesthetics"><font color="#e95e0b">:Neurology:sub:Aesthetics</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7755">Neurology7755</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 06 October 2014 | 21:39</font><br><br><div style="margin-bottom: 10px;">Comment: Galderma has today announced the initiation of a phII clinical trial 
with its liquid formulation of botulinum toxin in the United States.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Commenting on this development Humberto C Antunes President &amp; CEO 
of Galderma stated:-</STRONG> </div><div style="margin-bottom: 10px;"><P style="MARGIN-BOTTOM: 12pt; TEXT-ALIGN: justify">“This trial initiation 
demonstrates Galderma’s commitment to innovation in the aesthetic market and is 
designed to strengthen and complement our current neurotoxin franchise.<wbr> Our 
current neurotoxin business, which includes Dysport and Azzalure, continues its 
strong performance in key markets around the world.<wbr> The development of a liquid 
neurotoxin represents a significant advancement over existing commercial 
products and would allow us to further strengthen our position in the aesthetic 
category by better meeting physician and patient needs.<wbr>”</P> </div><div style="margin-bottom: 10px;"><P style="MARGIN-BOTTOM: 12pt; TEXT-ALIGN: justify"><STRONG>Study 
Design</STRONG></P> </div><div style="margin-bottom: 10px;"><P style="MARGIN-BOTTOM: 12pt; TEXT-ALIGN: justify">The Phase II clinical 
trial is a multicenter, dose-ranging study designed to evaluate the safety and 
effectiveness of Galderma’s internally developed liquid form of botulinum toxin 
for the treatment of glabellar lines.<wbr> It follows successful 
completion of Phase I study earlier this 
year.<wbr>  </P> </div><div style="margin-bottom: 10px;"><P style="MARGIN-BOTTOM: 12pt; TEXT-ALIGN: justify"><STRONG>Collaborative 
Agreement With Ipsen </STRONG></P> </div><div style="margin-bottom: 10px;"><P style="MARGIN-BOTTOM: 12pt; TEXT-ALIGN: justify">In July 2014, 
Galderma acquired the U.<wbr>S.<wbr> and Canadian rights to a portfolio of injectable 
aesthetic medicine products from Valeant, completing its global footprint and 
extending its leadership in aesthetic medicine.<wbr> Galderma also announced it had 
strengthened its collaboration with Ipsen focused on the development and 
commercialization of new neurotoxins, increasing the scope of their R&amp;D 
collaboration to further enhance their capabilities to meet the needs of 
patients and physicians worldwide.<wbr> Each company will benefit from the other 
party's research compounds within its respective and exclusive areas of focus.<wbr> 
In this regard Ipsen gaine control of the intellectual property for Galderma's 
liquid toxin in the US, Canada, Brazil and Europe in exchange for a €10m 
payment, while Galderma retains commercialisation rights (1)</P> </div><div style="margin-bottom: 10px;"><P style="MARGIN-BOTTOM: 12pt; TEXT-ALIGN: justify">1) Ipsen Press 
Release 11th July 2014</P> </div><div><P style="MARGIN-BOTTOM: 12pt; TEXT-ALIGN: justify">Source: <A href="http://www.galderma.com">www.<wbr>galderma.<wbr>com</A></P> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7755">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-10-06T21:39:54+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>Salix Drops Cosmo Buy, Opting To Talk Takeover With Actavis [sub:Acquisition]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10984</link>
<description>Salix Drops Cosmo Buy, Opting To Talk Takeover With Actavis [sub:Acquisition]</description><category>sub:Acquisition</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10984</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20141231&edate=20140901&rec=10984">Salix Drops Cosmo Buy, Opting To Talk Takeover With Actavis</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=sub%3aAcquisition"><font color="#e95e0b">:PharmaWorld:sub:Acquisition</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10984">PharmaWorld10984</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/14">Thi-Le-Xuan-Ann NGUYEN-LAIRAUD</a> | 06 October 2014 | 19:01</font><br><br><div style="margin-bottom: 10px;">Comment : Salix seeks deal with Actavis after calling off Cosmo Pharmaceuticals merger due to US tax rule changes </div><div style="margin-bottom: 10px;">The U.<wbr>S.<wbr> Treasury Department chalked up a victory, whose new rules put a brake on Salix Pharmaceuticals' inversion deal for Cosmo's Irish unit.<wbr> </div><div style="margin-bottom: 10px;"><P align="left" dir="ltr">Salix transaction over Cosmo is ongoing since last July.<wbr> Under such transaction the US company would have combined with Cosmo's Irish subsidiary in an all-stock deal valued at around $2.<wbr>7 billion.<wbr> The plan is designed to establish a "tax-efficient corporate structure" and boost Salix's US-market position for products treating Gastrointestinal diseases (see <A href="traction/permalink/GastroEnterology1993"><FONT face="Calibri,Calibri"><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=1993" class="defaultlink">GastroEnterology1993: Strategic Rationale of the Salix and Cosmo Unit Transaction</a></FONT></A><FONT face="Calibri,Calibri">).<wbr></FONT></P> </div><div style="margin-bottom: 10px;"><P align="left" dir="ltr">Last month however, the US Treasury Department announced steps of the country's tax code to make tax inversions harder and less profitable to accomplish, and Salix becomes <FONT face="Calibri,Calibri"><FONT face="Calibri,Calibri">the first U.<wbr>S.<wbr> pharma company to scrap its inversion plans in the face of tougher rules.<wbr> A</FONT></FONT>s pointed out by Salix CEO Carolyn Logan "they create more uncertainty regarding the potential benefits Salix expected to achieve through a Cosmo buy".<wbr></P> </div><div><P align="left" dir="ltr">But that doesn't mean Salix is walking away from the M&amp;A table as it is <FONT color="#1a1a1a" face="Calibri,Calibri"><FONT color="#1a1a1a" face="Calibri,Calibri">reportedly in takeover discussions with Actavis.<wbr> Although no transaction is imminent, an agreement between Salix and Actavis has become very likely in the past week, while Allergan's efforts to acquire the former have recently stalled over valuation concerns.<wbr></FONT></FONT></P> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20141231&edate=20140901&rec=10984">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-10-06T19:01:36+02:00</dc:date><dc:creator>len82156</dc:creator></item><item>
<title>Novartis Further Advances Development in the Field of Immunotherapy [comp:Novartis]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology10008</link>
<description>Novartis Further Advances Development in the Field of Immunotherapy [comp:Novartis]</description><category>comp:Novartis</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology10008</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10008">Novartis Further Advances Development in the Field of Immunotherapy</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=comp%3aNovartis"><font color="#e95e0b">:Oncology:comp:Novartis</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10008">Oncology10008</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 06 October 2014 | 17:03</font><br><br><div style="margin-bottom: 10px;">Comment: Novartis and BMS evaluate the safety, tolerability and preliminary efficacy of 3 molecularly targeted compounds in combination with BMs' investigational PD-1 immune checkpoint inhibitor, Opdivo<SUP class="hugin" style="FONT-SIZE: 0.8em; VERTICAL-ALIGN: text-top">®</SUP> (nivolumab), in Ph2/<wbr>3 for NSCLC.<wbr> Earlier this year, Novartis acquired CoStim, adding late discovery stage immunotherapy programs focused on key oncogenic targets, including PD-1.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Rationale for Novartis</FONT></STRONG> </div><div style="margin-bottom: 10px;">Preclinical data suggests that combining molecularly targeted agents with immunotherapies such as nivolumab may have synergistic effects and lead to better outcomes for patients," said Alessandro Riva, MD, Global Head, Novartis Oncology Development and Medical Affairs.<wbr> </div><div style="margin-bottom: 10px;">"This collaboration enables us to study several key compounds, including our new highly-potent ALK inhibitor Zykadia, together with a promising, novel immunotherapy agent, paving the way for potential new treatment approaches for patients with NSCLC.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">About the Studies</FONT></STRONG> </div><div style="margin-bottom: 10px;">One trial will evaluate the combination of Opdivo with <STRONG>Zykadia(TM) (ceritinib),</STRONG> an FDA-approved treatment for patients with anaplastic lymphoma kinase-positive (ALK+) metastatic NSCLC who have progressed on or are intolerant to crizotinib[1].<wbr> </div><div style="margin-bottom: 10px;">A second study will investigate Opdivo with <STRONG>INC280</STRONG>, a potent and highly selective inhibitor of c-MET receptor tyrosine kinase, and separately with <STRONG>EGF816</STRONG>, a potent, third-generation EGFR tyrosine kinase inhibitor that is active against T790 mutations.<wbr> </div><div style="margin-bottom: 10px;"><EM>Source: Novartis</EM> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Acquisition of Costim</FONT></STRONG> </div><div>Please see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=9466" class="defaultlink">Oncology9466: Novartis Acquiers CoStim and Expands in Immunotherapy for Cancer</a> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10008">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-10-06T17:03:25+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>ESMO Intelligence Part 2 - The Astellas Symposia [:PharmaWorld:congress:ESMO, comp:Astellas, headline]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology10002</link>
<description>ESMO Intelligence Part 2 - The Astellas Symposia [:PharmaWorld:congress:ESMO, comp:Astellas, headline]</description><category>congress:ESMO</category><category>comp:Astellas</category><category>headline</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology10002</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10002">ESMO Intelligence Part 2 - The Astellas Symposia</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=comp%3aAstellas"><font color="#e95e0b">:Oncology:comp:Astellas</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=headline"><font color="#e95e0b">:Oncology:headline</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=congress%3aESMO"><font color="#e95e0b">:PharmaWorld:congress:ESMO</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10002">Oncology10002</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 06 October 2014 | 15:03</font><br><br><div style="margin-bottom: 10px;">Comment:The Astellas symposium provided significant insight into predicitive factors that can be used to potentially assess the likely therapeutic benefit of the newer androgen modulators, ARV-7 splice variant status being the most promising predictive biomarker at the present time.<wbr> Some perspectives on what future treatment paradigms may look like were also highlighted based on i) new trials that are ongoing or about to commence and incorporating enzalutamide e.<wbr>g.<wbr> PLATO, PRESIDE &amp; PRIMCAB (these are evaluating combination and seqeuncing strategies) and ii) new pathways that may merit evaluation.<wbr> </div><div style="margin-bottom: 10px;">Professor Cora Sternberg Chaired the Symposia with the faculty including Dr Robert Jones from Glasgow UK and Professor Charles Ryan UCSF Medical Centre San Francisco US.<wbr> </div><div style="margin-bottom: 10px;">Dr Jones started the session talking about the evolving treatment landscape in 2014 alongside providing some case examples that focused on usuage of some of the newer options.<wbr> It was an introductory session essentially bringing everyone up to date.<wbr> The more interesting and enlightening talks were those given by Cora Sternberg and Charles Ryan who respectively focused on how to select the right treatment for the right patient and understanding disease biology in order to design the future treatment paradigm for the therapy of mCRPC.<wbr> Their slides and some of their key comments are highlighted below.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Cora Sternberg's Presentation</STRONG> </div><div style="margin-bottom: 10px;">Cora noted that these are exciting times with 5 new therapies available and showing an improvement in overall survival and quality of life However, the question remains as to whether we have predicitve factors to guide treatment choice.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/10002/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/10002/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><FONT face="Times New Roman" size="3">The first set of data that gave an indication on whether patients with a response less than 16 months came from a French group and demonstrated that these patients were less likely to respond to future hormonal therapies and this was in contrast to what was seen with docetaxel.<wbr> However, newer data from the AFFIRM trial that shows all sub-groups with different ADT response rates can respond albeit those that respond for less than 12 months will not respond as well as those responding greater than 26 months on ADT.<wbr></FONT> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/10002/3/ScreenCapture5.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/10002/4/ScreenCapture6.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG>Do baseline testosterone levels predict overall survival?</STRONG> </div><div style="margin-bottom: 10px;">Data from COU-AA-301 abiraterone trial has in fact shown that patients who have higher testosterone levels at the outset have an improved overall survival -  another words baseline testosterone can be used as a prognostic predictor of OS.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/10002/5/ScreenCapture7.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">Results from the PREVAIL trial showed there is no correlation between PSA response (stratified by below or above median) and overall suvival.<wbr> PSA therefore doesn't seem to predict response and is not a good predictive marker.<wbr> Similarly Gleason score is not a good predictive factor -  post hoc analysis of two abiraterone &amp; enzalutamide trials evaluating responses amongst those with a Gleason score &lt;8 as well as those with score &gt; 8 have demonstrated no difference in benefit.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/10002/6/ScreenCapture8.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/10002/7/ScreenCapture9.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG>What about response to hormonal therapy in patients with visceral metastases?</STRONG> </div><div style="margin-bottom: 10px;">Some people think patients with visceral metastases should only receive chemotherapy.<wbr> However, post-hoc data analysis from the PREVAIL trial demonstrates that enzalutamide is statistically signicicantly in terms of rPFS in patients with visceral metastasis and shows a trend towards a benifit in OS.<wbr> Similarly although COU-AA-301 trial is looking at different patient population (I.<wbr>e post-docetaxel setting), patients included in the trials had visceral metastases.<wbr> The trial demonstrates a statistically signigicant benefit in terms of rPFS and again a positive trend in terms of OS.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/10002/8/ScreenCapture10.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/10002/9/ScreenCapture11.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/10002/10/ScreenCapture12.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG>CTC Counts And LDH Level As Surrogate Biomarkers</STRONG> (Data from the COU-AA-301 study) </div><div style="margin-bottom: 10px;">Howard Scherer has shown that patients can be sub-categorised according to their CTC and LDH levels at 12 weeks.<wbr> This does appear to demonstrate a correlation with improvements in OS, with a clean split being seen between high, intermediate and low risk groups.<wbr> CTCs could therefore be a useful biomarker in the future.<wbr> However, at this stage these biomarkers do need further validation.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/10002/11/ScreenCapture13.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/10002/12/ScreenCapture14.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG>What about the response to AR Splice Variants?</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/10002/13/ScreenCapture15.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">Below is work recently published in NEJM from John Hopkins group Data comes from small groups but the results are quite impressive.<wbr> If patients had the ARV7 splice variant (i.<wbr>e.<wbr> ARV7+), the PSA response is zero both in enzalutamide and abiraterone groups.<wbr> A 52% and 68% response seen in ARV7 negative patients in enzalutamide and abiraterone group, respectively.<wbr>  ARV7 negative patients had a 8.<wbr>5 fold improved chance of clinical and rPFS on enzalutamide and a 16.<wbr>5 fold better chance on abiraterone.<wbr> </div><div style="margin-bottom: 10px;">Cora Sternberg claimed that "<STRONG><EM>the data is extrenmely interesting and clearly needs to be repeated</EM></STRONG>.<wbr>" </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/10002/14/ScreenCapture16.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/10002/15/ScreenCapture17.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/10002/16/ScreenCapture18.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/10002/17/ScreenCapture19.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG>Charles Ryan's Presentation</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/10002/18/ScreenCapture20.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG>How biology can direct us in terms of future therapies or future combinations of therapy?</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/10002/19/ScreenCapture21.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">He tried to breakdown the taxonomy of the disease and provide an easier shcematic &amp; definition to understand.<wbr> </div><div style="margin-bottom: 10px;">There are essentially three forms of resistance:- </div><div style="margin-bottom: 10px;">i) primary resistance where the abiraterone and enzalutamide don't work at all and the prognosis is grim </div><div style="margin-bottom: 10px;">ii) resistance associated with a phenotypic change such as the cells behave more like neuroendocrine tissue - represents a significant challenge </div><div style="margin-bottom: 10px;">iii) acquired resistance the most common form of resistance - patients do benefit from treatment but eventually develop resistance due to adaptive changes </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/10002/20/ScreenCapture22.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">The data below is derived from the COU-AA-302 show that 15% of patients had no response at all to abiraterone and had primary resistance.<wbr> A similar picture is seen for enzalutamide.<wbr> Targeting an AR receptor may not be the best approach for these patients.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/10002/21/ScreenCapture23.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/10002/22/ScreenCapture24.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">For the most part mCRPC is an adenocarcinoma androgen receptor driven disease.<wbr> With the availability of AR targeted agents (e.<wbr>g.<wbr> enzalutamide and abiraterone), these agents could eliminate AR dependent adenocarcinoma and the 'survived' androgen independent neuroendocrine may become prominent.<wbr> In future it is possible to see more patients emerging with a neuroendocrine derived phenotype </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/10002/23/ScreenCapture25.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">Acquired resistance takes on its own heterogeneity and emerges in various forms (i.<wbr>e.<wbr> slow vs rapid).<wbr> This may be worth thinking about in terms of the underlying mechanisms driving different forms of acquired resistance.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/10002/24/ScreenCapture26.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG>Should we sequence or rotate?</STRONG> </div><div style="margin-bottom: 10px;">This is done in other cancers and needs to be explored in prostate cancer.<wbr> It might make sense to continue highly activie androgen receptor therapy and the data below indeed shows that there can be a benefit with this approach.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/10002/25/ScreenCapture27.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/10002/26/ScreenCapture28.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">Studies are now underway looking at the concept below where treatment is continued but another treatment is added to therapy.<wbr> The PLATO study with enzalutamide (undertaken by Astellas) is such an example.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/10002/27/ScreenCapture29.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/10002/28/ScreenCapture30.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">Others such as PRESIDE &amp; ABIDO are looking at radnomisation to either docetaxel or the addition of docetaxel on progression to enzalutamide and abiraterone resepctively.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/10002/29/ScreenCapture31.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">The other approach being evaluate is combination therapy vs sequencing.<wbr> The question is whether combination would be superior or inferior to sequencing.<wbr> Underway within the next couple of months in the US will be the <STRONG>PRIMCAB </STRONG>study which will evaluate what to do next in patients with primary resistance to abiraterone or enzalutamide (represents15-20% of patients who shows no benefit).<wbr> It will evaluate whether they should be sequenced with another AR modulator or switched immediately to chemotherapy.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/10002/30/ScreenCapture32.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/10002/31/ScreenCapture33.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">The major phIII combination study that is underway is the Alliance study.<wbr> Accruing well in North America and interesting to see the result.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/10002/32/ScreenCapture34.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">The other combination study is STAMPEDE which has 8 arms included, the enzalutamide/<wbr> abiraterone part of the trial as shown below.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/10002/33/ScreenCapture35.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">Finally, there is a phIII combination study with radium -223.<wbr> This is an interesting combination concept because radium might be able to treat some of the tumour components that are not impacted by androgen receptor modulation </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/10002/34/ScreenCapture36.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/10002/35/ScreenCapture37.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/10002/36/ScreenCapture38.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">The schematic above gives due consideration to possbile other mechanisms/<wbr>pathways that might be appropriate to address.<wbr>Below are some of the approaches that are currently being considered.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/10002/37/ScreenCapture39.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/10002/38/ScreenCapture41.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/10002/39/ScreenCapture42.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">New ways of targeting the androgen receptor are also being considered.<wbr> AKR1C3 is involved in the conversion of andrestedione to dihydrotestosterone and represents a critical step in the androgen pathway.<wbr> It might be more effective to target a downstream inhibitor of androgen production than those targeted by current AR modulators.<wbr> Alternatively the use of HSP90 inhibitors, inhibitors of chaperone proteins which may involved in translocation of the AR to the nucleus are also being evaluated.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/10002/40/ScreenCapture43.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/10002/41/ScreenCapture44.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">Up-regulation of the glucocorticoid receptor induced by enzalutamide and abiraterone is another concept that is being evaluated in the context of the development of resistance.<wbr> </div><div style="margin-bottom: 10px;">In discussing the heterogeneity of the disease Charles Ryan noted that we are faced with many challenges.<wbr> In the last decade there has been a lot of talk about taking biopsies as the means of determining the cause of resistance.<wbr> This is now happening with a number of studies now underway including one that Ryan is invovled with.<wbr> The West Coast Dream Team will evaluate 300 biopsies over 3 years and investigate many molecular factors that could be causing this heterogeneity.<wbr> These factors are being looked at not in isolation but in aggregation utilising sophisticated high-powered IT technology.<wbr> Early data is emerging and more mutations are being seen than what had been expected.<wbr> It is a big and ambitious project that should help to identify predicitive factors that will guide which patients should be treated with which therapies at which time.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/10002/42/ScreenCapture45.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/10002/43/ScreenCapture46.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/10002/44/ScreenCapture47.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/10002/45/ScreenCapture48.jpg?user-agent=rss"> </div><div><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/10002/46/ScreenCapture49.jpg?user-agent=rss"> </div><!-- Comment details --><a name="oncology10002attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10002/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(77,6 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10002/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(60,6 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10002/3/ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(97,3 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10002/4/ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(108,5 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10002/5/ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(105,8 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10002/6/ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(113,9 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10002/7/ScreenCapture9.jpg">ScreenCapture9.jpg</a>&nbsp;&nbsp;(119,4 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10002/8/ScreenCapture10.jpg">ScreenCapture10.jpg</a>&nbsp;&nbsp;(104,4 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10002/9/ScreenCapture11.jpg">ScreenCapture11.jpg</a>&nbsp;&nbsp;(122,6 KB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10002/10/ScreenCapture12.jpg">ScreenCapture12.jpg</a>&nbsp;&nbsp;(101,2 KB)<br>&nbsp;&nbsp;11.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10002/11/ScreenCapture13.jpg">ScreenCapture13.jpg</a>&nbsp;&nbsp;(105,4 KB)<br>&nbsp;&nbsp;12.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10002/12/ScreenCapture14.jpg">ScreenCapture14.jpg</a>&nbsp;&nbsp;(84,7 KB)<br>&nbsp;&nbsp;13.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10002/13/ScreenCapture15.jpg">ScreenCapture15.jpg</a>&nbsp;&nbsp;(84,4 KB)<br>&nbsp;&nbsp;14.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10002/14/ScreenCapture16.jpg">ScreenCapture16.jpg</a>&nbsp;&nbsp;(112,1 KB)<br>&nbsp;&nbsp;15.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10002/15/ScreenCapture17.jpg">ScreenCapture17.jpg</a>&nbsp;&nbsp;(95,1 KB)<br>&nbsp;&nbsp;16.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10002/16/ScreenCapture18.jpg">ScreenCapture18.jpg</a>&nbsp;&nbsp;(112 KB)<br>&nbsp;&nbsp;17.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10002/17/ScreenCapture19.jpg">ScreenCapture19.jpg</a>&nbsp;&nbsp;(95 KB)<br>&nbsp;&nbsp;18.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10002/18/ScreenCapture20.jpg">ScreenCapture20.jpg</a>&nbsp;&nbsp;(79,4 KB)<br>&nbsp;&nbsp;19.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10002/19/ScreenCapture21.jpg">ScreenCapture21.jpg</a>&nbsp;&nbsp;(80,7 KB)<br>&nbsp;&nbsp;20.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10002/20/ScreenCapture22.jpg">ScreenCapture22.jpg</a>&nbsp;&nbsp;(107,4 KB)<br>&nbsp;&nbsp;21.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10002/21/ScreenCapture23.jpg">ScreenCapture23.jpg</a>&nbsp;&nbsp;(102,6 KB)<br>&nbsp;&nbsp;22.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10002/22/ScreenCapture24.jpg">ScreenCapture24.jpg</a>&nbsp;&nbsp;(95,6 KB)<br>&nbsp;&nbsp;23.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10002/23/ScreenCapture25.jpg">ScreenCapture25.jpg</a>&nbsp;&nbsp;(93,6 KB)<br>&nbsp;&nbsp;24.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10002/24/ScreenCapture26.jpg">ScreenCapture26.jpg</a>&nbsp;&nbsp;(79,9 KB)<br>&nbsp;&nbsp;25.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10002/25/ScreenCapture27.jpg">ScreenCapture27.jpg</a>&nbsp;&nbsp;(88,1 KB)<br>&nbsp;&nbsp;26.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10002/26/ScreenCapture28.jpg">ScreenCapture28.jpg</a>&nbsp;&nbsp;(71,4 KB)<br>&nbsp;&nbsp;27.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10002/27/ScreenCapture29.jpg">ScreenCapture29.jpg</a>&nbsp;&nbsp;(77,6 KB)<br>&nbsp;&nbsp;28.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10002/28/ScreenCapture30.jpg">ScreenCapture30.jpg</a>&nbsp;&nbsp;(87,6 KB)<br>&nbsp;&nbsp;29.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10002/29/ScreenCapture31.jpg">ScreenCapture31.jpg</a>&nbsp;&nbsp;(109,2 KB)<br>&nbsp;&nbsp;30.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10002/30/ScreenCapture32.jpg">ScreenCapture32.jpg</a>&nbsp;&nbsp;(88 KB)<br>&nbsp;&nbsp;31.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10002/31/ScreenCapture33.jpg">ScreenCapture33.jpg</a>&nbsp;&nbsp;(73,1 KB)<br>&nbsp;&nbsp;32.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10002/32/ScreenCapture34.jpg">ScreenCapture34.jpg</a>&nbsp;&nbsp;(103,5 KB)<br>&nbsp;&nbsp;33.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10002/33/ScreenCapture35.jpg">ScreenCapture35.jpg</a>&nbsp;&nbsp;(76,6 KB)<br>&nbsp;&nbsp;34.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10002/34/ScreenCapture36.jpg">ScreenCapture36.jpg</a>&nbsp;&nbsp;(125,8 KB)<br>&nbsp;&nbsp;35.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10002/35/ScreenCapture37.jpg">ScreenCapture37.jpg</a>&nbsp;&nbsp;(75,4 KB)<br>&nbsp;&nbsp;36.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10002/36/ScreenCapture38.jpg">ScreenCapture38.jpg</a>&nbsp;&nbsp;(88 KB)<br>&nbsp;&nbsp;37.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10002/37/ScreenCapture39.jpg">ScreenCapture39.jpg</a>&nbsp;&nbsp;(78,8 KB)<br>&nbsp;&nbsp;38.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10002/38/ScreenCapture41.jpg">ScreenCapture41.jpg</a>&nbsp;&nbsp;(83,9 KB)<br>&nbsp;&nbsp;39.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10002/39/ScreenCapture42.jpg">ScreenCapture42.jpg</a>&nbsp;&nbsp;(70,9 KB)<br>&nbsp;&nbsp;40.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10002/40/ScreenCapture43.jpg">ScreenCapture43.jpg</a>&nbsp;&nbsp;(100,5 KB)<br>&nbsp;&nbsp;41.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10002/41/ScreenCapture44.jpg">ScreenCapture44.jpg</a>&nbsp;&nbsp;(80,6 KB)<br>&nbsp;&nbsp;42.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10002/42/ScreenCapture45.jpg">ScreenCapture45.jpg</a>&nbsp;&nbsp;(103,6 KB)<br>&nbsp;&nbsp;43.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10002/43/ScreenCapture46.jpg">ScreenCapture46.jpg</a>&nbsp;&nbsp;(98,7 KB)<br>&nbsp;&nbsp;44.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10002/44/ScreenCapture47.jpg">ScreenCapture47.jpg</a>&nbsp;&nbsp;(112 KB)<br>&nbsp;&nbsp;45.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10002/45/ScreenCapture48.jpg">ScreenCapture48.jpg</a>&nbsp;&nbsp;(122,3 KB)<br>&nbsp;&nbsp;46.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/10002/46/ScreenCapture49.jpg">ScreenCapture49.jpg</a>&nbsp;&nbsp;(62,7 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10002">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-10-06T15:03:40+02:00</dc:date><dc:creator>jac89886</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10002/1/ScreenCapture1.jpg" length="79443" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10002/2/ScreenCapture2.jpg" length="62036" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10002/3/ScreenCapture5.jpg" length="99662" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10002/4/ScreenCapture6.jpg" length="111154" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10002/5/ScreenCapture7.jpg" length="108338" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10002/6/ScreenCapture8.jpg" length="116669" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10002/7/ScreenCapture9.jpg" length="122248" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10002/8/ScreenCapture10.jpg" length="106878" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10002/9/ScreenCapture11.jpg" length="125590" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10002/10/ScreenCapture12.jpg" length="103651" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10002/11/ScreenCapture13.jpg" length="107931" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10002/12/ScreenCapture14.jpg" length="86755" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10002/13/ScreenCapture15.jpg" length="86403" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10002/14/ScreenCapture16.jpg" length="114792" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10002/15/ScreenCapture17.jpg" length="97384" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10002/16/ScreenCapture18.jpg" length="114656" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10002/17/ScreenCapture19.jpg" length="97307" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10002/18/ScreenCapture20.jpg" length="81291" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10002/19/ScreenCapture21.jpg" length="82619" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10002/20/ScreenCapture22.jpg" length="110026" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10002/21/ScreenCapture23.jpg" length="105048" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10002/22/ScreenCapture24.jpg" length="97866" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10002/23/ScreenCapture25.jpg" length="95886" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10002/24/ScreenCapture26.jpg" length="81809" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10002/25/ScreenCapture27.jpg" length="90175" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10002/26/ScreenCapture28.jpg" length="73138" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10002/27/ScreenCapture29.jpg" length="79501" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10002/28/ScreenCapture30.jpg" length="89698" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10002/29/ScreenCapture31.jpg" length="111860" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10002/30/ScreenCapture32.jpg" length="90120" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10002/31/ScreenCapture33.jpg" length="74808" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10002/32/ScreenCapture34.jpg" length="106002" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10002/33/ScreenCapture35.jpg" length="78468" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10002/34/ScreenCapture36.jpg" length="128839" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10002/35/ScreenCapture37.jpg" length="77197" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10002/36/ScreenCapture38.jpg" length="90061" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10002/37/ScreenCapture39.jpg" length="80711" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10002/38/ScreenCapture41.jpg" length="85964" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10002/39/ScreenCapture42.jpg" length="72583" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10002/40/ScreenCapture43.jpg" length="102879" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10002/41/ScreenCapture44.jpg" length="82488" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10002/42/ScreenCapture45.jpg" length="106068" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10002/43/ScreenCapture46.jpg" length="101068" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10002/44/ScreenCapture47.jpg" length="114641" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10002/45/ScreenCapture48.jpg" length="125241" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/10002/46/ScreenCapture49.jpg" length="64255" type="image/jpeg"/></item><item>
<title>Partner Sought for AVAX' Oral Anti-TNF Antibody for Ulcerative Colitis [dis:IBD, :PharmaWorld:sub:xLicensing]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2053</link>
<description>Partner Sought for AVAX' Oral Anti-TNF Antibody for Ulcerative Colitis [dis:IBD, :PharmaWorld:sub:xLicensing]</description><category>dis:IBD</category><category>sub:xLicensing</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2053</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2053">Partner Sought for AVAX' Oral Anti-TNF Antibody for Ulcerative Colitis</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20141231&edate=20140901&cat=dis%3aIBD"><font color="#e95e0b">:GastroEnterology:dis:IBD</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=sub%3axLicensing"><font color="#e95e0b">:PharmaWorld:sub:xLicensing</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2053">GastroEnterology2053</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 06 October 2014 | 13:53</font><br><br><div style="margin-bottom: 10px;">Comment: AVX-470, which has completed a Ph1b trial, is an orally administered anti-TNF antibody that acts locally in the intestines where the disease occurs.<wbr> The investigatonal compound will be presented at next UEGW, during the session 'New drugs in IBD'.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Competitive Advantage of the Oral Form</FONT></STRONG> </div><div style="margin-bottom: 10px;">Anti-TNF antibodies are injected or infused and travel throughout the body where they can cause rare but serious side effects, such as opportunistic infections and certain cancers when they dampen the immune system.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">About the Ph1b</FONT></STRONG> </div><div style="margin-bottom: 10px;"><U>Timelines</U>: Completed in December 2013 </div><div style="margin-bottom: 10px;"><U>Design</U>: double-blind, placebo-controlled, ascending dose study of AVX-470 in active ulcerative colitis patients.<wbr> </div><div style="margin-bottom: 10px;"><U>Protocol</U>: Three different dose levels of AVX-470 were administered for a period of 28 days.<wbr> </div><div style="margin-bottom: 10px;"><U>Location</U>: The study involved 14 trial centers in the U.<wbr>S.<wbr>, Canada, Belgium and Hungary.<wbr> </div><div style="margin-bottom: 10px;"><U>Recruitment</U>: A total of 36 patients were treated in the trial, with 9 patients receiving placebo and 27 patients receiving the drug.<wbr> </div><div style="margin-bottom: 10px;"><U>PE</U>: to evaluate the safety and tolerability of AVX-470.<wbr> </div><div><STRONG>Findings</STRONG>: The trial successfully met its objectives.<wbr> No treatment-related serious adverse events (SAEs) were observed, and there were no allergic reactions or opportunistic infections.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2053">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-10-06T13:53:45+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Valeant's Bridgewater Site Receives Warning Letter from FDA [TAL:Aesthetic]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7754</link>
<description>Valeant's Bridgewater Site Receives Warning Letter from FDA [TAL:Aesthetic]</description><category>TAL:Aesthetic</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7754</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7754">Valeant's Bridgewater Site Receives Warning Letter from FDA</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20141231&edate=20140901&cat=TAL%3aAesthetic"><font color="#e95e0b">:Neurology:TAL:Aesthetic</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7754">Neurology7754</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 06 October 2014 | 11:41</font><br><br><div style="margin-bottom: 10px;">Comment: The US agency has issued a warning letter after an inspection at the company's facilities revealed deviation from GMPs in connection with Sculptra Aesthetics, the facial injectable filler, which competes with Juvederm.<wbr> The letter raises the possibility that Allergan and its supporters may use the agency warning to support their argument that Valeant cutbacks focus too heavily on areas other than marketing, which may jeopardize R&amp;D or patient safety.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">About the Warining Letter</FONT></STRONG> </div><div style="margin-bottom: 10px;">The Warning Letter pertains to the management of Valeant's contract manufacturers (rather than Valeant's own internal manufacturing) with regard to some specific Good Manufacturing Practice (GMP) activities, including review and documentation of supplier's deviation reports prior to batch release and performing corrective and preventive action (CAPA) effectiveness checks as required by procedure.<wbr> </div><div style="margin-bottom: 10px;">The warning letter does not prevent the manufacturing or distribution of Sculptra nor the manufacture or distribution of any of Valeant's products, and does not relate to the pending review of any Bausch + Lomb compounds.<wbr> </div><div><EM>Source: Market Watch, Financial Time</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7754">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-10-06T11:41:34+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Sigmoid Pharma and Pendopharm Ink Agreement on UC Drug for Canada [dis:IBD, :PharmaWorld:mkt:Canada, :PharmaWorld:sub:Partnership]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2051</link>
<description>Sigmoid Pharma and Pendopharm Ink Agreement on UC Drug for Canada [dis:IBD, :PharmaWorld:mkt:Canada, :PharmaWorld:sub:Partnership]</description><category>dis:IBD</category><category>mkt:Canada</category><category>sub:Partnership</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2051</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2051">Sigmoid Pharma and Pendopharm Ink Agreement on UC Drug for Canada</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20141231&edate=20140901&cat=dis%3aIBD"><font color="#e95e0b">:GastroEnterology:dis:IBD</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=mkt%3aCanada"><font color="#e95e0b">:PharmaWorld:mkt:Canada</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=sub%3aPartnership"><font color="#e95e0b">:PharmaWorld:sub:Partnership</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2051">GastroEnterology2051</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 03 October 2014 | 16:55</font><br><br><div style="margin-bottom: 10px;">Comment: CyCol<SUP>®</SUP> is SIGMOID’s proprietary oral formulation of solubilised cyclosporine targeted to the site of disease in the colon.<wbr> Pendopharm portfolio lists colonoscopy preparations; laxative and oral dehydration products.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Terms of the Agreement</FONT></STRONG> </div><div style="margin-bottom: 10px;">SIGMOID has received an upfront payment and will be eligible for future milestone payments in addition to significant double-digit, tiered royalties on net sales in Canada.<wbr> </div><div style="margin-bottom: 10px;">Pursuant to the licence agreement, PENDOPHARM has invested EUR 5 million in SIGMOID at a premium to the most recent fundraising in 2014.<wbr> The investment will support the advancement of CyCol<SUP>®</SUP> into Phase 3 clinical trials; mainly the scale up of SIGMOID’s manufacturing process for CyCol<SUP>®</SUP> and the underlying SmPill<SUP>®</SUP> drug delivery technology.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">About Sigmoid Pharma</FONT></STRONG> </div><div style="margin-bottom: 10px;">- Founded in 2003 (private) HQ: Dublin </div><div style="margin-bottom: 10px;">- Technology <A href="http://www.sigmoidpharma.com/dynamicdata/ProprietaryTechnology.asp">http:/<wbr>/<wbr>www.<wbr>sigmoidpharma.<wbr>com/<wbr>dynamicdata/<wbr>ProprietaryTechnology.<wbr>asp</A> </div><div style="margin-bottom: 10px;">Pipeline </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2051/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">About PendoPharm</FONT></STRONG> </div><div style="margin-bottom: 10px;">PENDOPHARM is a division of Pharmascience Inc.<wbr>, a Canadian privately-owned company.<wbr> </div><div style="margin-bottom: 10px;">Established in 1983, Pharmascience Inc.<wbr> is Canada’s 10th largest pharmaceutical company, with a highly-skilled workforce of 1,400 people.<wbr> Pharmascience commercializes over 400 products, including branded prescription, OTC and BTC products as well as generic products in Canada and with its affiliates and distributors in over 60 countries worldwide.<wbr> </div><div><EM>Source: Pendopharm; Sigmoid Pharm</EM> </div><!-- Comment details --><a name="gastroenterology2051attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2051/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(195,9 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2051">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-10-03T16:55:12+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2051/1/ScreenCapture1.jpg" length="200599" type="image/jpeg"/></item><item>
<title>EMA Adopts Landmark Policy Effective January 1st [sub:Regulatory]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10981</link>
<description>EMA Adopts Landmark Policy Effective January 1st [sub:Regulatory]</description><category>sub:Regulatory</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10981</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20141231&edate=20140901&rec=10981">EMA Adopts Landmark Policy Effective January 1st</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=sub%3aRegulatory"><font color="#e95e0b">:PharmaWorld:sub:Regulatory</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10981">PharmaWorld10981</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 03 October 2014 | 15:28</font><br><br><div style="margin-bottom: 10px;">Comment: The EMA has decided to publish the clinical reports that underpin 
decision-making on new medicines.<wbr> Following extensive consultations over 
the past 18 months, the EMA Management Board unanimously adopted this new policy 
at its meeting on 2 October 2014.<wbr> Its adoption will set a new standard for 
transparency in public health and pharmaceutical R&amp;D.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>How Will This Decision Be Applied?</STRONG> </div><div style="margin-bottom: 10px;">It will apply to clinical reports contained in all applications for 
centralised marketing authorisations submitted after that date.<wbr> The reports will 
be released as soon as a decision on the application has been taken.<wbr> </div><div style="margin-bottom: 10px;">The new EMA policy will serve as a useful complementary tool ahead of the 
implementation of the new EU Clinical Trials Regulation that will come into 
force not before May 2016.<wbr> </div><div style="margin-bottom: 10px;">EMA expects the new policy to increase trust in its regulatory work as it 
will allow the general public to better understand the Agency’s decision-making.<wbr> 
In addition, academics and researchers will be able to re-assess data sets.<wbr> It 
is suggested that the publication of clinical reports will also help to avoid 
duplication of clinical trials, foster innovation and encourage development of 
new medicines.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Public Access?</STRONG> </div><div style="margin-bottom: 10px;">According to the policy’s terms of use, the public can either browse or 
search the data on screen, or download, print and save the information.<wbr> The 
reports cannot be used for commercial purposes.<wbr> In general, the clinical reports 
do not contain commercially confidential 
information.<wbr> Information that, in limited instances, may be considered 
commercially confidential will be redacted.<wbr> The redaction will be made in 
accordance with principles outlined in the policy’s annexes.<wbr> The decision on 
such redactions lies with the Agency.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Phased Implementation</STRONG> </div><div style="margin-bottom: 10px;">The policy will be implemented in phases.<wbr> The first phase starts on 1 January 
2015.<wbr> Once a medicine has received a marketing 
authorisation.<wbr> in one, several or all European Union Member States.<wbr> </div><div style="margin-bottom: 10px;">For line extensions and extensions of indications of already approved 
medicines, the Agency will give access to clinical reports for applications 
submitted as of 1 July 2015 after a decision has been taken.<wbr> </div><div style="margin-bottom: 10px;">In future, EMA plans to also make available individual patient data.<wbr> </div><div style="margin-bottom: 10px;">To address the various legal and technical issues linked with the access to 
patient data, the Agency will first consult patients, healthcare professionals, 
academia and industry.<wbr> It is critically important for EMA that the privacy of 
patients is adequately protected before their data are released.<wbr> </div><div>Source: <A href="http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2014/10/news_detail_002181.jsp&amp;mid=WC0b01ac058004d5c1">http:/<wbr>/<wbr>www.<wbr>ema.<wbr>europa.<wbr>eu/<wbr>ema/<wbr>index.<wbr>jsp?curl=pages/<wbr>news_and_events/<wbr>news/<wbr>2014/<wbr>10/<wbr>news_detail_002181.<wbr>jsp&amp;mid=WC0b01ac058004d5c1</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20141231&edate=20140901&rec=10981">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-10-03T15:28:53+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>First Patient Enroled in Norgine US Ph3 to Assess Novel Low Volume Bowel Preparation [sub:CRCPrevention, headline]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2050</link>
<description>First Patient Enroled in Norgine US Ph3 to Assess Novel Low Volume Bowel Preparation [sub:CRCPrevention, headline]</description><comments>http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2050</comments><category>sub:CRCPrevention</category><category>headline</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2050</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2050">First Patient Enroled in Norgine US Ph3 to Assess Novel Low Volume Bowel Preparation</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20141231&edate=20140901&cat=headline"><font color="#e95e0b">:GastroEnterology:headline</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20141231&edate=20140901&cat=sub%3aCRCPrevention"><font color="#e95e0b">:GastroEnterology:sub:CRCPrevention</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2050">GastroEnterology2050</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 03 October 2014 | 15:19</font><br><br><div style="margin-bottom: 10px;">Comment: Norgine's NER1006 is a novel, low volume polyethylene glycol based bowel preparation that has been developed to provide whole bowel cleansing, with an additional focus on the <STRONG>ascending</STRONG> colon.<wbr> The Ph3 programme also includes 2 studies in Europe, planned to start late 2014.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Trial Details </FONT></STRONG><A href="http://clinicaltrials.gov/ct2/show/NCT02254486?term=ner1006&amp;rank=1&amp;submit_fld_opt="><STRONG><FONT size="3">NCT02254486</FONT></STRONG><BR></A> </div><div style="margin-bottom: 10px;">The US Ph3, NOCT, will evaluate the bowel cleansing efficacy of a two-day split-dosing regimen of NER1006 vs a split-dosing regimen of a trisulfate bowel cleansing solution (SUPREP) in adult patients.<wbr> </div><div style="margin-bottom: 10px;">PE will use of Harefield Cleansing Scale to grade bowel cleansing efficacy.<wbr> </div><div style="margin-bottom: 10px;">Recruitment approx 540 </div><div style="margin-bottom: 10px;">Timelines July 2015 /<wbr> Dec 2015 </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">NER1006 EU Ph3 Programs</FONT></STRONG> </div><div style="margin-bottom: 10px;">The MORA study will compare NER1006 vs MOVIPREP <FONT style="BACKGROUND-COLOR: #ffffff"><FONT color="#000000" style="BACKGROUND-IMAGE: none; BACKGROUND-REPEAT: repeat; BACKGROUND-ATTACHMENT: scroll; BACKGROUND-POSITION: 0% 0%; COLOR: rgb(255,0,0); FONT-STYLE: italic"><FONT color="#000000">using a 2-day split-doing regimen and a 1-day morning split-dosing regimen in adults</FONT>.<wbr> </FONT></FONT> </div><div style="margin-bottom: 10px;"><FONT color="#000000">The DAYB study will compare NER1006 vs CITRAFLEET </FONT><FONT color="#000000" style="BACKGROUND: #ffffff; COLOR: rgb(255,0,0); FONT-STYLE: italic"><FONT color="#000000">using a day before only dosing regimen in adults</FONT>.<wbr></FONT> </div><div><EM><FONT color="#000000">Source: <A href="file:///C:/Program%20Files/WebSite-Watcher/bookmark_wsw/0005/Norgi_120121109134822456511.htm_chg.htm">Norgine PR</A></FONT></EM> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="GastroEnterology2077c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">Norgine presented positive Ph2 data at the 79<SUP>th</SUP> Annual Scientific Meeting of the American College of Gastroenterology (ACG), Philadelphia, PA, and today at the UEGW, Vienna.<wbr> </div><div style="margin-bottom: 10px;">Study Design </div><div style="margin-bottom: 10px;">The Phase II open-label, randomised study (OPT, n=240) investigated the pharmacodynamics (stool weight), clinical efficacy and tolerability of dose and taste-optimised low-volume PEG-based formulations (NER1006), after split dosing, compared with MOVIPREP<SUP>&reg;</SUP>.<wbr> </div><div style="margin-bottom: 10px;">Ph2 Findings </div><div>Results demonstrate that NER1006 achieved high quality bowel cleansing in screening colonoscopy patients, comparable with MOVIPREP<SUP>&reg;</SUP>.<wbr> Cleansing success rates were 90-100%.<wbr> Stool output was consistently higher with NER1006, and safety and tolerability profiles between treatments were comparable.<wbr><SUP>[</SUP><SUP>1</SUP><SUP>]</SUP> In addition, most subjects in the NER1006 arms reached clear effluent </div><font size="-1">Brigitte DESCHAMPS / <a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2077" class="commentpermalink">GastroEnterology2077</a> / <span class="date">21 October 2014</span> /
<span class="time">12:47:02 o'clock CEST</span>
</font></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2050">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-10-03T15:19:31+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>EU Pharmacovigilance Agency Requested Variation of Eligard Label and Recommended Actions [comp:Astellas, :PharmaWorld:mkt:Europe, news, :PharmaWorld:sub:Regulatory]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology10001</link>
<description>EU Pharmacovigilance Agency Requested Variation of Eligard Label and Recommended Actions [comp:Astellas, :PharmaWorld:mkt:Europe, news, :PharmaWorld:sub:Regulatory]</description><category>comp:Astellas</category><category>mkt:Europe</category><category>news</category><category>sub:Regulatory</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology10001</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10001">EU Pharmacovigilance Agency Requested Variation of Eligard Label and Recommended Actions</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=comp%3aAstellas"><font color="#e95e0b">:Oncology:comp:Astellas</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=news"><font color="#e95e0b">:Oncology:news</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=mkt%3aEurope"><font color="#e95e0b">:PharmaWorld:mkt:Europe</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=sub%3aRegulatory"><font color="#e95e0b">:PharmaWorld:sub:Regulatory</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10001">Oncology10001</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 03 October 2014 | 14:40</font><br><br><div style="margin-bottom: 10px;">Comment: The European Pharmacovigilance Risk Assessment Committee (PRAC) has requested that Marketing Authorization Holder (MAH) of Eligard should submit a variation within 1 month to the National Competent Authority (NCA) to amend the product label by adding under  special warning section 4.<wbr>4 the following sentence:  “lack of clinical efficacy may occur due to incorrect <STRONG>reconstitution</STRONG> of the product”.<wbr> Please find below the two main recommended actions, as well as a comment of the Uro/<wbr>Onco Franchise.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Recommended Actions</FONT></STRONG> </div><div style="margin-bottom: 10px;">In addition following actions have been recommended by the PRAC to be submitted within 1 month : </div><div style="margin-bottom: 10px;"><UL><LI>MAH should submit to the NCA a variation to allow storage of the product (not reconstituted) at room temperature for up to 1 month.<wbr></LI>
<LI>To provide  a justification pro or against the PRAC request to make a proposal for a new presentation of Eligard with fewer and easier handling steps.<wbr> The MAH should submit a time table for the<STRONG> reformulation</STRONG> of the product otherwise the Marketing <FONT size="3"><FONT size="2">Authorization of the current presentation may be reconsidered.<wbr></FONT><STRONG> </STRONG></FONT></LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">URO/<wbr>ONCO Franchise Comments</FONT></STRONG> </div><div style="margin-bottom: 10px;">1)      <B>Lack of clinical efficacy :</B> the PRAC recommendation confirm the notion we already had from the field about  the lack of maintenance of castration in some patients.<wbr> </div><div>2)      <B>Reformulation</B> : should be read as new device/<wbr>presentation.<wbr> <STRONG>Any feedback from countries is highly appreciated!</STRONG> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=10001">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-10-03T14:40:17+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>re: Heat Biologics Amends Protocol Permitting Early Advancement Of HS-401 Into Phase 2 For NMIBC</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9999</link>
<description>re: Heat Biologics Amends Protocol Permitting Early Advancement Of HS-401 Into Phase 2 For NMIBC</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9999</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=9999">re: Heat Biologics Amends Protocol Permitting Early Advancement Of HS-401 Into Phase 2 For NMIBC</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9999">Oncology9999</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 03 October 2014 | 14:04</font><br><br><div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Heat Biologics Amends Protocol Permitting Early Advancement Of HS-401 Into Phase 2 For NMIBC</span>&nbsp;<font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=dis%3aBladder"><font color="#e95e0b">:Oncology:dis:Bladder</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=news"><font color="#e95e0b">:Oncology:news</font></a>]</font></font><br><span style="font-size: 12px;">Comment: Heat Biologics has now amended its Phase 1/<wbr>2 study protocol for HS-401 (<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=9505" class="defaultlink">Oncology9505: Heat Biologics Commences Dosing of First Patient in Phase 1/<wbr>2 Study of HS-410 for The Treatment of Non Muscle Invasive Bladder Cancer</a><A class="title" href="traction/permalink/Oncology9505" title="Permanent Link to Oncology9505"><U><FONT color="#0066cc">)</FONT></U></A> to permit Heat Biologics to advance directly into Ph2 following enrolment of a single cohort of Ph1 study.<wbr> The amended protocol changes the treatment regimen from HS-401 (vesigenurtacel-L) monotherapy post BCG to combination with BCG.<wbr> This will also allow HS-401 to be evaluated in the earlier setting for non-muscle invasive bladder cancer (NMIBC).<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=9861">...</a><br><font size="-1">Jenny Wu / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9861" class="commentpermalink">Oncology9861</a> / <span class="date">05 August 2014</span> /
<span class="time">11:26:52 o'clock CEST</span>
</font></div><div style="margin-bottom: 10px;">The company has dosed the ninth and final patient required in the Ph1 portion of its Phase 1/<wbr>2 clinical study for Vesigenurtacel-L (HS-410) in patients with high-risk non-muscle invasive bladder cancer.<wbr> It now expects to commence the Ph2 portion of the bladder cancer clinical trial during Q4:14 (a full quarter sooner that originally reported).<wbr> </div><div style="margin-bottom: 10px;"><STRONG>New Timelines</STRONG> </div><div style="margin-bottom: 10px;">Patient enrollment and dosing in the Vesigenurtacel-L Ph2 study for the treatment of bladder cancer is expected to be completed in the third quarter of 2015.<wbr> </div><div>Heat then anticipates reporting top-line recurrence-free survival results in the third quarter of 2016 after the protocol's twelve-month patient observation period ends.<wbr> </div><!-- Comment details --><font size="-1">Brigitte DESCHAMPS / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9999" class="commentpermalink">Oncology9999</a> / <span class="date">03 October 2014</span> /
<span class="time">14:04:36 o'clock CEST</span>
</font><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=9999">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9861">View thread  Oncology9861: Heat Biologics Amends Protocol Permitting Early Advancement Of HS-401 Into Phase 2 For NMIBC</a>]]></content:encoded><dc:date>2014-10-03T14:04:36+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Pfizer Is Now Entering The Race In Immuno-Oncology [:PharmaWorld:sub:Partnership]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9998</link>
<description>Pfizer Is Now Entering The Race In Immuno-Oncology [:PharmaWorld:sub:Partnership]</description><category>sub:Partnership</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9998</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=9998">Pfizer Is Now Entering The Race In Immuno-Oncology</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=sub%3aPartnership"><font color="#e95e0b">:PharmaWorld:sub:Partnership</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9998">Oncology9998</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/994">Jenny Wu</a> | 03 October 2014 | 10:07</font><br><br><div style="margin-bottom: 10px;">Comment: Immuno-oncology has become increasinly the hottest topic in ASCO and ESMO.<wbr> Pfizer and Kyowa Hakko Kirin have entered into an agreement to explore the therapeutic potential of the combination of Phizer's PF-05082566, an investigational, fully humanized monoclonal antibody (mAb) that stimulates signaling through 4-1BB (CD-137), a protein involved in regulation of immune cell activation, proliferation and survival, with Kyowa Hakko Kirin's anti-CCR4 antibody mogamulizumab, which suppresses some of the immune cells that shield the tumor from the immune system, in a Phase Ib clinical study evaluating the safety and tolerability of the combination in patients with solid tumors.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Terms of the Agreement</FONT></STRONG> </div><div style="margin-bottom: 10px;">Pfizer and Kyowa Hakko Kirin will co-fund the clinical study, which will be conducted by Pfizer.<wbr> This study is expected to establish a recommended dose regimen and assess the safety and preliminary efficacy of the combination.<wbr> This study is expected to begin in 2015 and the results will determine the future clinical development of the combination.<wbr> </div><div>Pfizer's PF-05082566 targets CD137 (also known as 4-1BB and TNFRSF9) is a member of the tumor necrosis factor receptor superfamily.<wbr> Originally identified as a costimulatory molecule expressed by activated T cells and NK cells, CD137 is also expressed by follicular dendritic cells, monocytes, mast cells, granulocytes, and endothelial cells.<wbr> Pfizer is currently evaluating PF-05082566 in a Phase I study as a single agent in multiple tumor types, as well as in several combination studies, including a clinical study of PF-05082566 in combination with rituximab in non-Hodgkin lymphoma patients.<wbr> PF-05082566 is not approved for any indications in any markets.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=9998">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-10-03T10:07:47+02:00</dc:date><dc:creator>jew60237</dc:creator></item><item>
<title>ESMO Intelligence Part 1 - Focusing on J&amp;J's Abiraterone And ARN509 [congress:ESMO, :Oncology:comp:JnJ, :Oncology:headline]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10979</link>
<description>ESMO Intelligence Part 1 - Focusing on J&amp;J's Abiraterone And ARN509 [congress:ESMO, :Oncology:comp:JnJ, :Oncology:headline]</description><category>congress:ESMO</category><category>comp:JnJ</category><category>headline</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10979</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20141231&edate=20140901&rec=10979">ESMO Intelligence Part 1 - Focusing on J&J's Abiraterone And ARN509</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=comp%3aJnJ"><font color="#e95e0b">:Oncology:comp:JnJ</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=headline"><font color="#e95e0b">:Oncology:headline</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=congress%3aESMO"><font color="#e95e0b">:PharmaWorld:congress:ESMO</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10979">PharmaWorld10979</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/994">Jenny Wu</a> | 02 October 2014 | 19:52</font><br><br><div style="margin-bottom: 10px;">Comment: The first prostate cancer session in ESMO this year was opened by J&amp;J sponsored satellite symposium on Friday 26th September.<wbr> Bearing in mind with the approval of enzalutamide in chemo naive setting last month and Astellas' story on its survival benefit, J&amp;J defends abiraterone by demonstrating in ESMO this year that patients treated in abiraterone arm form COU-AA-302 had overall survival benefit that is <SPAN style="TEXT-DECORATION: underline"><STRONG>statistically significant</STRONG> </SPAN>with longer follow up period of over 4 years (49.<wbr>2 months).<wbr> Also, updated results of the ARN509 Ph2 study in M0 CRPC setting are presented.<wbr> The U.<wbr>S.<wbr> Food and Drug Administration based its approval of ZYTIGA plus prednisone for treating men with mCRPC prior to chemotherapy on a planned second interim analysis of COU-AA-302, which met the co-primary endpoint of radiographic progression-free survival (rPFS).<wbr> Based on results from the final analysis, Janssen has initiated regulatory submissions to relevant health authorities for a revision to the ZYTIGA label.<wbr> The reimbursement and availability of abiraterone for chemo naïve mCRPC patients is expected to improve in some countries based on the final OS analysis.<wbr> </div><div style="margin-bottom: 10px;">When a prostate patient develops metastases, the first treatment they receive is androgen deprivation therapy.<wbr> When the patients become resistant to this castration, prior to 2014 docetaxel is the forefront of the treatment with of these patients who have rising PSA, asymptomatic, and metastatic disease.<wbr> Given the approval of abiraterone, enzalutamide and radium 223, mCRPC pre chemo setting is now become a crowded space with many options available but lack of real world evidence to support patient selection strategy for each treatment.<wbr> CRPC remains driven androgen receptor signalling, and current paradigm is changing as now we have novel androgen targeting agents (e.<wbr>g.<wbr> abiraterone and enzalutamide) available in earlier setting - chemo naïve mCRPC.<wbr> </div><div style="margin-bottom: 10px;"><BR><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10979/1/1.jpg?user-agent=rss"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10979/2/2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">At ESMO this year, J&amp;J sponsored satellite symposium focused on the comparison of COU-AA-302 and PREVAIL trials.<wbr> The last updated result that we have heard from COU-AA-302 following its second interim data analysis were abiraterone demonstrated improved rPFS with HR of 0.<wbr>43 (p&lt;0.<wbr>0001) although the overall survival benefit did not reach statistical significance.<wbr> J&amp;J presented the final analysis to demonstrate a statistically significant improvement in OS in this study.<wbr> OS is particularly noteworthy in COU-AA-302, because 67 percent of men in the ZYTIGA plus prednisone arm and 80 percent in the control arm received subsequent therapy.<wbr> Also there is no additional safety signal from the third interim analysis.<wbr> </div><div style="margin-bottom: 10px;">"<EM><STRONG>This includes 44 percent of men in the control arm who subsequently received ZYTIGA plus prednisone.<wbr> The use of subsequent therapies did not impact the statistical significance between the ZYTIGA and control arms - and makes these results all the more compelling after adjusting for the crossover effect</STRONG></EM>.<wbr>" said Charles Ryan, M.<wbr>D.<wbr>, Professor of Clinical Medicine, Urology at the University of California, San Francisco, and lead investigator of the COU-AA-302 study.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10979/3/3.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10979/4/4.jpg?user-agent=rss"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10979/6/6.jpg?user-agent=rss"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10979/7/7.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">On Sunday 28th Sept, final analysis from COU-AA-302 was presented by Dr.<wbr> Charles Ryan during proffered paper oral session.<wbr> He noted that the four other new agents approved for mCRPC (including Sipuleucel-T, Cabazitaxel, Enzalutamide, Radium223) only occur after the initiation of first patient in COU-AA-302 trial.<wbr> In the final analysis, abiraterone has demonstrated statistical significance improvement for all endpoints including survival benefit, and improvement of time to all landmarks (PSA progression, bone progression, initiation of chemotherapy, pain, and ECOG performance status decline).<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10979/5/5.jpg?user-agent=rss"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10979/17/IMG%5f4826.JPG?user-agent=rss"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10979/17/IMG%5f4826.JPG?user-agent=rss"> </div><div style="margin-bottom: 10px;">Final analysis now shows abiraterone treatment arm has a median overall survival of 34.<wbr>7 months versus prednisone arm of 30.<wbr>3 months.<wbr> With a longer follow up of 49.<wbr>2 months, abiraterone has now demonstrated OS benefit with statistical significance (p=0.<wbr>0033).<wbr> Due to the early unblended decision, significant amounts of patients were allowed to cross over.<wbr> Interestingly, when adjusting for 44% of prednisone patients who received subsequent abiraterone, abiraterone treatment effect is more pronounced with hazard ratio of 0.<wbr>74.<wbr> Also, abiraterone arm showed significant improvement in time to opiate use for cancer related pain (33.<wbr>4 months versus 23.<wbr>4 months, p&lt;0.<wbr>0001).<wbr> He highlighted the future challenges in demonstrating OS benefit in mCRPC patients including: </div><div style="margin-bottom: 10px;"><UL><LI>Multiple new treatments now available with proven OS benefit </LI>
<LI>Sequential use of 2 or more of these treatments is common </LI>
<LI>Chronicity and heterogeneity of mCRPC treatment sequencing may confound ability to measure OS benefit </LI>
<LI>Requires larger and longer subsequent clinical studies </LI>
</UL> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10979/18/IMG%5f4809.JPG?user-agent=rss"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10979/18/IMG%5f4809.JPG?user-agent=rss"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10979/19/IMG%5f4815.JPG?user-agent=rss"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10979/20/IMG%5f4821.JPG?user-agent=rss"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10979/21/IMG%5f4824.JPG?user-agent=rss"> </div><div style="margin-bottom: 10px;"><SPAN style="TEXT-DECORATION: underline"><STRONG>Selecting First Line Treatment For mCRPC</STRONG></SPAN> </div><div style="margin-bottom: 10px;">Now given that we have two androgen targeting agents and both demonstrating OS benefit with statistical significance in chemo naïve setting, this has proven the CRPC is a androgen dependent disease.<wbr> The biggest questions is how do we select, prioritize or combine available treatments based on objective criteria as the outcome of the trials for the front line option is not comparable as there are some differences (e.<wbr>g.<wbr> visceral disease allowed in TAX327 and PREVAIL only) in patient populations included in the trials.<wbr> The principal questions to answer are :<BR>• The use of androgen signalling inhibitor in mCRPC prior to docetaxel? Which one to use first?<BR>• Should we allow upfront use of chemo in mCRPC?<BR>• Would combination strategy be a better choice? </div><div style="margin-bottom: 10px;"><BR><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10979/8/8.jpg?user-agent=rss"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10979/9/9.jpg?user-agent=rss"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10979/10/10.jpg?user-agent=rss"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10979/11/11.jpg?user-agent=rss"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10979/12/12.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><SPAN style="TEXT-DECORATION: underline"><STRONG>Update on ARN-509-001 in M0CRPC setting</STRONG></SPAN><BR>ARN-509, an antiandrogen that is similar to enzalutamide, is currently under investigation by J&amp;J in M0CRPC setting and in combination with ADT in high risk prostate cancer (SPARTAN).<wbr> The Phase 2 of a multicenter phase 1/<wbr>2 study (NCT01171898) evaluated ARN-509 activity in 3 patient populations with CRPC: 1) high-risk M0 CRPC; 2) chemotherapy- and AA-naïve mCRPC; 3) mCRPC post-AA treatment; were reported in the oral session.<wbr> ARN-509 is safe and well tolerated in patients with high-risk M0 CRPC, and the safety profile was consistent with the previous phase 1 study.<wbr> ARN-509 exhibited robust activity in patients with high-risk M0 CRPC based on durable PSA responses and disease control.<wbr><BR>–– 91% of patients had ≥ 50% PSA decline from baseline at 12 weeks.<wbr><BR>–– Median PFS was 103 weeks.<wbr><BR>–– At 20.<wbr>2 months of follow-up, the median time to PSA progression and median MFS<BR>were not reached.<wbr> </div><div style="margin-bottom: 10px;">During the congress highlight Prostate Session, Dr.<wbr> Eleni Efatathious stated " <EM><STRONG>this is somewhat in line with what we have observed with enzalutamide in the similar setting</STRONG></EM>" </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10979/13/13.jpg?user-agent=rss"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10979/14/14.jpg?user-agent=rss"> </div><div>Also SPARTAN (Selective Prostate AR Targeting with ARN509) is being presented as a TRIAL IN PROGRESS poster.<wbr> SPARTAN is a multicenter, double-blind, placebo controlled, phase 3 trial evaluating the efficacy and safety of ARN509 in patients with M0-CRPC at high risk for progression, defined as PSA doubling time (PSADT) ≤ 10 months.<wbr> Patients will be randomized (2:1) to either ARN + ADT or placebo + ADT.<wbr> Continuous ADT is mandatory in order to maintain castrate concentrations of testosterone (&lt; 50 ng/<wbr>dL).<wbr> Patients will be stratified based on PSADT (≤ 6 vs &gt; 6 months), baseline use of bone-sparing agents for osteoporosis, and presence of locoregional disease.<wbr> The study aims to enroll 1200 patients across North America, Europe, Australia, New Zealand, and Asia according to the key inclusion and exclusion criteria.<wbr> Approximately 300 sites are planned in 23 countries.<wbr> Enrollment began September 2013 and is ongoing.<wbr> The first patient was screened on 19 September 2013 and randomized on 16 October 2013.<wbr><BR><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10979/15/15.jpg?user-agent=rss"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10979/16/16.jpg?user-agent=rss"> </div><!-- Comment details --><a name="pharmaworld10979attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10979/1/1.jpg">1.jpg</a>&nbsp;&nbsp;(973,3 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10979/2/2.jpg">2.jpg</a>&nbsp;&nbsp;(900 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10979/3/3.jpg">3.jpg</a>&nbsp;&nbsp;(885,9 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10979/4/4.jpg">4.jpg</a>&nbsp;&nbsp;(904,4 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10979/5/5.jpg">5.jpg</a>&nbsp;&nbsp;(930,4 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10979/6/6.jpg">6.jpg</a>&nbsp;&nbsp;(959,6 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10979/7/7.jpg">7.jpg</a>&nbsp;&nbsp;(937 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10979/8/8.jpg">8.jpg</a>&nbsp;&nbsp;(905,7 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10979/9/9.jpg">9.jpg</a>&nbsp;&nbsp;(1 018,3 KB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10979/10/10.jpg">10.jpg</a>&nbsp;&nbsp;(1 MB)<br>&nbsp;&nbsp;11.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10979/11/11.jpg">11.jpg</a>&nbsp;&nbsp;(946,8 KB)<br>&nbsp;&nbsp;12.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10979/12/12.jpg">12.jpg</a>&nbsp;&nbsp;(998,3 KB)<br>&nbsp;&nbsp;13.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10979/13/13.jpg">13.jpg</a>&nbsp;&nbsp;(854,5 KB)<br>&nbsp;&nbsp;14.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10979/14/14.jpg">14.jpg</a>&nbsp;&nbsp;(921,6 KB)<br>&nbsp;&nbsp;15.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10979/15/15.jpg">15.jpg</a>&nbsp;&nbsp;(81,2 KB)<br>&nbsp;&nbsp;16.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10979/16/16.jpg">16.jpg</a>&nbsp;&nbsp;(9,4 KB)<br>&nbsp;&nbsp;17.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10979/17/IMG%5f4826.JPG">IMG_4826.JPG</a>&nbsp;&nbsp;(893,4 KB)<br>&nbsp;&nbsp;18.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10979/18/IMG%5f4809.JPG">IMG_4809.JPG</a>&nbsp;&nbsp;(1,2 MB)<br>&nbsp;&nbsp;19.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10979/19/IMG%5f4815.JPG">IMG_4815.JPG</a>&nbsp;&nbsp;(1,1 MB)<br>&nbsp;&nbsp;20.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10979/20/IMG%5f4821.JPG">IMG_4821.JPG</a>&nbsp;&nbsp;(1,1 MB)<br>&nbsp;&nbsp;21.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10979/21/IMG%5f4824.JPG">IMG_4824.JPG</a>&nbsp;&nbsp;(1,1 MB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20141231&edate=20140901&rec=10979">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-10-02T19:52:41+02:00</dc:date><dc:creator>jew60237</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10979/1/1.jpg" length="996704" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10979/2/2.jpg" length="921593" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10979/3/3.jpg" length="907194" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10979/4/4.jpg" length="926109" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10979/5/5.jpg" length="952684" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10979/6/6.jpg" length="982640" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10979/7/7.jpg" length="959530" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10979/8/8.jpg" length="927441" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10979/9/9.jpg" length="1042704" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10979/10/10.jpg" length="1048900" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10979/11/11.jpg" length="969555" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10979/12/12.jpg" length="1022292" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10979/13/13.jpg" length="874977" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10979/14/14.jpg" length="943756" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10979/15/15.jpg" length="83102" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10979/16/16.jpg" length="9637" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10979/17/IMG%5f4826.JPG" length="914879" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10979/18/IMG%5f4809.JPG" length="1220583" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10979/19/IMG%5f4815.JPG" length="1147442" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10979/20/IMG%5f4821.JPG" length="1160568" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10979/21/IMG%5f4824.JPG" length="1192310" type="image/jpeg"/></item><item>
<title>New PBS listings include Astellas' Xtandi [mkt:Australia, :Oncology:prod:Zytiga, :Oncology:prod:MDV3100, :Oncology:dis:Prostate, :Oncology:comp:Astellas, :GastroEnterology:dis:IBD]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10976</link>
<description>New PBS listings include Astellas' Xtandi [mkt:Australia, :Oncology:prod:Zytiga, :Oncology:prod:MDV3100, :Oncology:dis:Prostate, :Oncology:comp:Astellas, :GastroEnterology:dis:IBD]</description><category>mkt:Australia</category><category>prod:Zytiga</category><category>prod:MDV3100</category><category>dis:Prostate</category><category>comp:Astellas</category><category>dis:IBD</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10976</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20141231&edate=20140901&rec=10976">New PBS listings include Astellas' Xtandi</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20141231&edate=20140901&cat=dis%3aIBD"><font color="#e95e0b">:GastroEnterology:dis:IBD</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=comp%3aAstellas"><font color="#e95e0b">:Oncology:comp:Astellas</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=prod%3aMDV3100"><font color="#e95e0b">:Oncology:prod:MDV3100</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=prod%3aZytiga"><font color="#e95e0b">:Oncology:prod:Zytiga</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=mkt%3aAustralia"><font color="#e95e0b">:PharmaWorld:mkt:Australia</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10976">PharmaWorld10976</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 02 October 2014 | 15:02</font><br><br><div style="margin-bottom: 10px;">Comment: The new listing recommends enzalutamide for the treatment of metastatic prostate cancer after treatment failure with docetaxel, on a cost-minimisation basis with abiraterone.<wbr> Noteworthy among the rejected submissions was Zytiga, and Entyvio for UC.<wbr> </div><div style="margin-bottom: 10px;"><IMG height="128" name="C:\Users\brd97880\Documents\Traction Instant Publisher\Autosaved\10-2-2014\ScreenCapture1.jpg" src="file:///C:/Users/brd97880/Documents/Traction%20Instant%20Publisher/Autosaved/10-2-2014/ScreenCapture1.jpg" width="1639"> </div><div style="margin-bottom: 10px;"><IMG height="23" name="C:\Users\brd97880\Documents\Traction Instant Publisher\Autosaved\10-2-2014\ScreenCapture3.jpg" src="file:///C:/Users/brd97880/Documents/Traction%20Instant%20Publisher/Autosaved/10-2-2014/ScreenCapture3.jpg" width="1646"> </div><div><IMG height="44" name="C:\Users\brd97880\Documents\Traction Instant Publisher\Autosaved\10-2-2014\ScreenCapture2.jpg" src="file:///C:/Users/brd97880/Documents/Traction%20Instant%20Publisher/Autosaved/10-2-2014/ScreenCapture2.jpg" width="1666"> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20141231&edate=20140901&rec=10976">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-10-02T15:02:50+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Soft Intelligence on AAA's Activities [dis:MidGutNET, headline]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7819</link>
<description>Soft Intelligence on AAA's Activities [dis:MidGutNET, headline]</description><category>dis:MidGutNET</category><category>headline</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7819</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20141231&edate=20140901&rec=7819">Soft Intelligence on AAA's Activities</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20141231&edate=20140901&cat=dis%3aMidGutNET"><font color="#e95e0b">:Endocrinology:dis:MidGutNET</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20141231&edate=20140901&cat=headline"><font color="#e95e0b">:Endocrinology:headline</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7819">Endocrinology7819</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 02 October 2014 | 14:52</font><br><br><div style="margin-bottom: 10px;">Comment: Discussions with AAA at ESMO revealed that the NETTER-1 study is 
close to completing enrollment and that there should be sufficient events 
(78) to close the study in March/<wbr>April.<wbr> A decision regarding the next 
indication that will be pursued with Lutathera in what will be the  
NETTER-2 trial (most probably pNET) will be taken this month with a view to 
initiating the trial in 2015.<wbr> Meanwhile, the company is waiting for FDA/<wbr>EMA 
approval to start soon a 20 patient PK tolerability study with its 
Ga68 Dotatate KIT.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Lutathera Trial</STRONG> </div><div style="margin-bottom: 10px;">The NETTER-1 timeline coincides with Kjell Objerg's statement at the 
EANM (Oct 2013) that the study should conclude in 18 months time i.<wbr>e.<wbr> April 2015 
with results published thereafter possibly at the EANM meeting in October 2015.<wbr> 
On this basis the company looks to be on track for marketing authorisation 
1H17.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Ga68-Dotatate PET KIT Development</STRONG> </div><div>Commenting on this topic, AAA noted that it was trying to build a bridging 
database based one existing European experience with the agent and 
depending on the quality of this it may or may not have to do a phIII trial with 
the kit.<wbr> It is hoping that it will not have to but will gain approval to 
distribute the kit for further investigator led studies.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20141231&edate=20140901&rec=7819">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-10-02T14:52:59+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>Update on Revance's RT001 Program for CFL [class:BotulinumToxins, sub:Aesthetics]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7752</link>
<description>Update on Revance's RT001 Program for CFL [class:BotulinumToxins, sub:Aesthetics]</description><category>class:BotulinumToxins</category><category>sub:Aesthetics</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7752</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7752">Update on Revance's RT001 Program for CFL</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20141231&edate=20140901&cat=class%3aBotulinumToxins"><font color="#e95e0b">:Neurology:class:BotulinumToxins</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20141231&edate=20140901&cat=sub%3aAesthetics"><font color="#e95e0b">:Neurology:sub:Aesthetics</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7752">Neurology7752</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 02 October 2014 | 10:30</font><br><br><div style="margin-bottom: 10px;">Comment: Revance has initiated a study to confirm this quarter the successful transfer of production of the topical RT001 drug product to Revance’s U.<wbr>S.<wbr> commercial manufacturing facility.<wbr> Following successful confirmation of this transfer, the company plans to initiate its first U.<wbr>S.<wbr> Ph3 pivotal study for Crow's Feet Lines (CFL).<wbr> Results now anticipated for Q1:15 (previously expected by end of 2014).<wbr> Management explained that this study had been planned but previously unannounced  They had hoped to complete the study in time to begin the Ph3 study on time.<wbr> However due to a longer than- expected timeline for the production verification, the study’s start was simply taking longer than expected.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Impact &amp; Analysis</FONT></STRONG> </div><div style="margin-bottom: 10px;">For analysts with BMO Capital, this news is a negative development that introduces a new risk /<wbr> uncertainty.<wbr> They now adjust the launch of RT001 as followed: </div><div style="margin-bottom: 10px;"><UL><LI>
US launch of RT001 in 4Q17 to 1Q18</LI>
<LI>
EU launch in 4Q18 to 1Q19</LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Pipeline</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7752/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG>Key Milestones (as of August 2014)</STRONG> </div><div><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7752/2/ScreenCapture2.jpg?user-agent=rss"> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7752">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-10-02T10:30:31+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Key Developments In Cushing's Disease With Different Forms Of Ketoconazole [dis:Cushing, headline]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7816</link>
<description>Key Developments In Cushing's Disease With Different Forms Of Ketoconazole [dis:Cushing, headline]</description><category>dis:Cushing</category><category>headline</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7816</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20141231&edate=20140901&rec=7816">Key Developments In Cushing's Disease With Different Forms Of Ketoconazole</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20141231&edate=20140901&cat=dis%3aCushing"><font color="#e95e0b">:Endocrinology:dis:Cushing</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20141231&edate=20140901&cat=headline"><font color="#e95e0b">:Endocrinology:headline</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7816">Endocrinology7816</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 01 October 2014 | 16:56</font><br><br><div style="margin-bottom: 10px;">Comment: Coinciding with the HRA Pharma's announcement last week about 
CHMP's positive recommendation regarding ketoconazole HRA 200mg tablets for 
patients with Cushing's syndrome, Cortendo was highlighting yesterday 
the opportunity that exists with its product Normocort (a ketoconazole 
enantiomer) at the 14th Annual Biotech Forum in Basel.<wbr> </div><div style="margin-bottom: 10px;">Key slides highlighting Cortendo's ambition, its assumptions about market 
sizing and the potential benefits of Normocort vs.<wbr> ketoconazole were 
presented as shown below.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7816/1/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7816/2/ScreenCapture3.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7816/3/ScreenCapture4.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7816/4/ScreenCapture5.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7816/5/ScreenCapture6.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7816/6/ScreenCapture7.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7816/7/ScreenCapture9.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7816/8/ScreenCapture10.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7816/9/ScreenCapture11.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7816/10/ScreenCapture12.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7816/11/ScreenCapture13.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7816/12/ScreenCapture14.jpg?user-agent=rss"> </div><div><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7816/13/ScreenCapture15.jpg?user-agent=rss"> </div><!-- Comment details --><a name="endocrinology7816attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7816/1/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(96,5 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7816/2/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(97,2 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7816/3/ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(64,4 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7816/4/ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(78,1 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7816/5/ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(100,1 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7816/6/ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(98,2 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7816/7/ScreenCapture9.jpg">ScreenCapture9.jpg</a>&nbsp;&nbsp;(107 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7816/8/ScreenCapture10.jpg">ScreenCapture10.jpg</a>&nbsp;&nbsp;(79,7 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7816/9/ScreenCapture11.jpg">ScreenCapture11.jpg</a>&nbsp;&nbsp;(109,4 KB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7816/10/ScreenCapture12.jpg">ScreenCapture12.jpg</a>&nbsp;&nbsp;(96,3 KB)<br>&nbsp;&nbsp;11.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7816/11/ScreenCapture13.jpg">ScreenCapture13.jpg</a>&nbsp;&nbsp;(85,4 KB)<br>&nbsp;&nbsp;12.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7816/12/ScreenCapture14.jpg">ScreenCapture14.jpg</a>&nbsp;&nbsp;(86,5 KB)<br>&nbsp;&nbsp;13.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7816/13/ScreenCapture15.jpg">ScreenCapture15.jpg</a>&nbsp;&nbsp;(119,8 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20141231&edate=20140901&rec=7816">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-10-01T16:56:35+02:00</dc:date><dc:creator>jac89886</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7816/1/ScreenCapture2.jpg" length="98864" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7816/2/ScreenCapture3.jpg" length="99524" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7816/3/ScreenCapture4.jpg" length="65903" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7816/4/ScreenCapture5.jpg" length="80008" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7816/5/ScreenCapture6.jpg" length="102507" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7816/6/ScreenCapture7.jpg" length="100506" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7816/7/ScreenCapture9.jpg" length="109570" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7816/8/ScreenCapture10.jpg" length="81611" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7816/9/ScreenCapture11.jpg" length="112053" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7816/10/ScreenCapture12.jpg" length="98632" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7816/11/ScreenCapture13.jpg" length="87493" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7816/12/ScreenCapture14.jpg" length="88616" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7816/13/ScreenCapture15.jpg" length="122633" type="image/jpeg"/></item><item>
<title>Hikma's Colchicine Approved by FDA for Gout [dis:Gout]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2048</link>
<description>Hikma's Colchicine Approved by FDA for Gout [dis:Gout]</description><category>dis:Gout</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2048</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2048">Hikma's Colchicine Approved by FDA for Gout</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20141231&edate=20140901&cat=dis%3aGout"><font color="#e95e0b">:GastroEnterology:dis:Gout</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2048">GastroEnterology2048</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 01 October 2014 | 16:19</font><br><br><div style="margin-bottom: 10px;">Comment: The company has announced the approval of its NDA for colchicine 0.<wbr>6mg capsules by the FDA.<wbr> Hikma will market its colchicine under the brand name MITIGARE<SUP>™</SUP>.<wbr> Having been forced to withdraw the product in 2010 post URL Pharma’s approval of the drug, Hikma has worked in the background to get colchicine back on the market.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Regulatory pathway</STRONG>: This NDA has been approved under Section 505(b)(2) of the US Federal Food Drug and Cosmetic Act.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Indication</STRONG>: prophylaxis of gout flares in adults.<wbr> </div><div>Source: Hikma </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2048">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-10-01T16:19:56+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Takeda's Entyvio for UC and CD Receives Positive Reaction from U.S. Gastro [dis:IBD, :PharmaWorld:mkt:NorthAmerica]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2047</link>
<description>Takeda's Entyvio for UC and CD Receives Positive Reaction from U.S. Gastro [dis:IBD, :PharmaWorld:mkt:NorthAmerica]</description><category>dis:IBD</category><category>mkt:NorthAmerica</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2047</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2047">Takeda's Entyvio for UC and CD Receives Positive Reaction from U.<wbr>S.<wbr> Gastro</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20141231&edate=20140901&cat=dis%3aIBD"><font color="#e95e0b">:GastroEnterology:dis:IBD</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=mkt%3aNorthAmerica"><font color="#e95e0b">:PharmaWorld:mkt:NorthAmerica</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2047">GastroEnterology2047</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 01 October 2014 | 16:00</font><br><br><div style="margin-bottom: 10px;">Comment: Entyvio (vedolizumab) gained FDA approval in May, and launched in June 2014.<wbr> Takeda conducted a survey among 72 gastroenterologists to assess trends and prescriptions of the drug in the US.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">About the Survey</FONT></STRONG> </div><div style="margin-bottom: 10px;">Objectives: The report evaluates physicians’ current awareness and familiarity with Entyvio, the advantages and disadvantages compared to currently available therapies, and the current and anticipated usage of the drug; as well as the drug’s promotional activity.<wbr> </div><div style="margin-bottom: 10px;">Timelines: Three waves of the syndicated report will assess physician perceptions at one month, six months and one year post-launch.<wbr> </div><div style="margin-bottom: 10px;">Milestones:The reports will further explore where Entyvio is being placed in the treatment algorithm and in which patient types, strengths and weaknesses of the product profile compared to other agents, and the overall impact of the launch on the market landscape.<wbr> </div><div style="margin-bottom: 10px;">Online survey: of 72 gastro; qualitative interviews with 10 respondents </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Headlines of the Survey</FONT></STRONG> </div><div style="margin-bottom: 10px;"><U>Entyvio's Biggest Advantages</U> </div><div style="margin-bottom: 10px;">Mechanism of action of the drug has been cited as one of the biggest advantage of Entyvio compared to other treatment currently available.<wbr> </div><div style="margin-bottom: 10px;"><U>Entyvio's Use</U> </div><div style="margin-bottom: 10px;">Primarily among UC and CD TNF-refractory patients </div><div style="margin-bottom: 10px;"><U>Entyvio's Safety</U> </div><div style="margin-bottom: 10px;">The majority of the gastroenterologists are planning on prescribing Entyvio to their patients within a year, even though the risk of progressive multifocal leukoencephalopathy (PML) is one of the lingering concerns for most of them.<wbr> </div><div style="margin-bottom: 10px;">PML has been constraining Entyvio use as a first-line biologic.<wbr> The drug has been considered as an alternative therapy to Janssen Biotech’s Remicade and AbbVie’s Humira.<wbr> </div><div>Source: <EM>LaunchTrends: Entyvio (vedolizumab) Wave 1 (U.<wbr>S.<wbr>)</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2047">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-10-01T16:00:36+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>AstraZeneca / Ardelyx' IBS-c Drug Met PE in Mid-Stage Trial [dis:IBS, dis:Constipation]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2045</link>
<description>AstraZeneca / Ardelyx' IBS-c Drug Met PE in Mid-Stage Trial [dis:IBS, dis:Constipation]</description><category>dis:IBS</category><category>dis:Constipation</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2045</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2045">AstraZeneca /<wbr> Ardelyx' IBS-c Drug Met PE in Mid-Stage Trial</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20141231&edate=20140901&cat=dis%3aConstipation"><font color="#e95e0b">:GastroEnterology:dis:Constipation</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20141231&edate=20140901&cat=dis%3aIBS"><font color="#e95e0b">:GastroEnterology:dis:IBS</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2045">GastroEnterology2045</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 01 October 2014 | 15:11</font><br><br><div style="margin-bottom: 10px;">Comment: The company has announced positive results from its 371 patient Ph2b clinical trial evaluating tenapanor in patients with constipation-predominant irritable bowel syndrome (IBS-C).<wbr> Results from this study demonstrated statistically significant and clinically meaningful improvement in IBS-C symptoms for tenapanor-treated patients compared to patients receiving placebo.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Results and Findings</FONT></STRONG> </div><div style="margin-bottom: 10px;">Ardelyx said the trial met its main goal in 60.<wbr>7 percent of patients taking the drug, tenapanor, compared with 33.<wbr>7 percent in the placebo group.<wbr> </div><div style="margin-bottom: 10px;">Half the patients given the drug experienced at least a 30 percent reduction in abdominal pain, compared with 23.<wbr>6 percent in the placebo group </div><div style="margin-bottom: 10px;"><U>Phase 2b Design</U> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3"><img src="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2045/3/ScreenCapture3.jpg?user-agent=rss"></FONT></STRONG> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Drug Description</FONT></STRONG> </div><div style="margin-bottom: 10px;">Tenapanor, a minimally-absorbed inhibitor of the intestinal sodium transporter NHE3, has demonstrated the ability to reduce the absorption of dietary sodium and phosphate.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2045/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Business Development</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2045/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">Ardelyx licensed tenapanor to AstraZeneca in October 2012.<wbr> </div><div style="margin-bottom: 10px;">In addition to IBS-C, Ardelyx and AstraZeneca are evaluating tenapanor for the treatment of hyperphosphatemia in patients with end-stage renal disease (ESRD) in an ongoing Phase 2b study, and in an ongoing Phase 2a study, tenapanor is being evaluated for its effect on markers of kidney disease and fluid status in patients with chronic kidney disease (CKD).<wbr> </div><div><EM>Source: Ardelyx PR</EM> </div><!-- Comment details --><a name="gastroenterology2045attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2045/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(44,8 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2045/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(53 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2045/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(64,8 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2045">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-10-01T15:11:31+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2045/1/ScreenCapture1.jpg" length="45857" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2045/2/ScreenCapture2.jpg" length="54279" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2045/3/ScreenCapture3.jpg" length="66360" type="image/jpeg"/></item><item>
<title>FDA Awards Grants to Stimulate Clinical Studies on Rare Diseases</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9996</link>
<description>FDA Awards Grants to Stimulate Clinical Studies on Rare Diseases</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9996</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=9996">FDA Awards Grants to Stimulate Clinical Studies on Rare Diseases</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9996">Oncology9996</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 01 October 2014 | 13:51</font><br><br><div style="margin-bottom: 10px;">Comment: The FDA has awarded more than $19M to boost the development of medical device, drug and biological products for patients with rare diseases.<wbr> Of note, among the 15 grants awareded by the US agency, one pertains to HCC and another to pancreatic cancer.<wbr> The full list of the 2014 recipients detailing university, program and grant is provided below, </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Program Administration</FONT></STRONG> </div><div style="margin-bottom: 10px;">The program is administered through the FDA's Orphan Products Grants Program.<wbr> This program was created by the Orphan Drug Act, passed in 1983, to promote the development of products for rare diseases.<wbr> Since its inception, the program has given more than $330 million to fund more than 530 new clinical studies on developing treatments for rare diseases and has been used to bring more than 50 products to marketing approval </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">2014 Grant Recipients</FONT></STRONG> </div><div style="margin-bottom: 10px;">Denise Adams, Cincinnati Children's Hospital Medical Center (Cincinnati, Ohio), Phase 2 Study of Vincristine vs.<wbr> Sirolimus for the Treatment of High Risk Kaposiform Hemangioendothelioma—$1.<wbr>6 million over four years </div><div style="margin-bottom: 10px;">Mitesh Borad, Mayo Clinic Arizona (Scottsdale, Ariz.<wbr>), <STRONG>Phase 1 Study of VSV-hIFN-B for the Treatment of Hepatocellular Carcinoma</STRONG>— approximately $600,000 over three years </div><div style="margin-bottom: 10px;">Andrew Brenner, University of Texas Health Center San Antonio (San Antonio, Texas), Phase 2 Study of TH-302 for the Treatment of Glioblastoma— approximately $1.<wbr>6 million over four years </div><div style="margin-bottom: 10px;">Kelly Dooley, The Johns Hopkins University (Baltimore, Md.<wbr>), Phase 2 Study of PA-824 for the Treatment of Pulmonary Tuberculosis— $1.<wbr>6 million over four years </div><div style="margin-bottom: 10px;">Donald Durden, University of California San Diego (San Diego, Calif.<wbr>), Phase 2 Study of Poly-ICLC for the Treatment of Pediatric Low Grade Gliomas— $1.<wbr>6 million over four years </div><div style="margin-bottom: 10px;">Alfred Lane, Stanford University (Stanford, Calif.<wbr>), Phase 2 Study of Sildenafil for the Treatment of Lymphatic Malformations— approximately $1.<wbr>6 million over four years </div><div style="margin-bottom: 10px;">Dung Le, The Johns Hopkins University (Baltimore, Md.<wbr>), <STRONG>Phase 2 Study of Folfirinox followed by Ipilimumab/<wbr>GVAX for the Treatment of Pancreatic Cancer</STRONG>— $1.<wbr>6 million over four years </div><div style="margin-bottom: 10px;">Phillip Low, Mayo Clinic Rochester (Rochester, Minn.<wbr>), Phase 1 Study of Intrathecal Autologous Mesenchymal Stem Cell Therapy for the Treatment of Multiple System Atrophy—$600,000 over three years </div><div style="margin-bottom: 10px;">Guido Magni, River Vision Development Corporation (New York, N.<wbr>Y.<wbr>), Phase 2 Study of RV001 for the Treatment of Thyroid Eye Disease—$1.<wbr>2 million over three years </div><div style="margin-bottom: 10px;">Michael Portman, Seattle Children's Hospital (Seattle, Wash.<wbr>), Phase 3 Study of Triiodothyronine Supplementation for the Treatment of Young Infants After Cardiopulmonary Bypass— approximately $1.<wbr>6 million over four years </div><div style="margin-bottom: 10px;">Jana Portnow, City of Hope Beckman Research Institute (Duarte, Calif.<wbr>), Phase 1 Study of Neural Stem Cells &amp; 5-FC/<wbr>Leucovorin for the Treatment of Recurrent High Grade Gliomas—$600,000 over three years </div><div style="margin-bottom: 10px;">Scott Rollins, Selexys Pharmaceuticals Corporation (Oklahoma City, Okla.<wbr>), Phase 2 Study of SelG1 for the Treatment of Sickle Cell Disease— $1.<wbr>6 million over four years </div><div style="margin-bottom: 10px;">Beena Sood, Wayne State University (Detroit, Mich.<wbr>), Phase 1/<wbr>2 Study of Aerosolized Survanta for the Treatment of Neonatal Respiratory Distress Syndrome— approximately $1.<wbr>4 million over four years </div><div style="margin-bottom: 10px;">Warren Stern, Aesrx, LLC (Newton, Mass.<wbr>), Phase 2 Study of Aes103 (5-HMF) for the Treatment of Stable Sickle Cell Disease—approximately $1.<wbr>6 million over four years </div><div>Pamela Zeitlin, The Johns Hopkins University (Baltimore, Md.<wbr>), Phase 2 Study of Digitoxin for the Treatment of Cystic Fibrosis— approximately $290,000 for one year </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=9996">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-10-01T13:51:50+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>GE Healthcare Established Collaboration with GSK to Improve Biomarker Diagnosis [sub:Diagnostic, sub:Biomarkers, news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9992</link>
<description>GE Healthcare Established Collaboration with GSK to Improve Biomarker Diagnosis [sub:Diagnostic, sub:Biomarkers, news]</description><category>sub:Diagnostic</category><category>sub:Biomarkers</category><category>news</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9992</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=9992">GE Healthcare Established Collaboration with GSK to Improve Biomarker Diagnosis</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=news"><font color="#e95e0b">:Oncology:news</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=sub%3aBiomarkers"><font color="#e95e0b">:Oncology:sub:Biomarkers</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=sub%3aDiagnostic"><font color="#e95e0b">:Oncology:sub:Diagnostic</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9992">Oncology9992</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/994">Jenny Wu</a> | 01 October 2014 | 11:24</font><br><br><div style="margin-bottom: 10px;">Comment: As we are entering an era in oncology when increasing efforts have been focused on biomarker discovery to improve patient selection for appropriate treatment, GE Healthcare announced an agreement between its affiliate, Clarient Diagnostic Services, Inc.<wbr> (Clarient) and GlaxoSmithKline (GSK).<wbr> The collaboration aims to improve access to diagnostic testing for cancer patients by establishing a network of clinical laboratories to identify genetic mutations associated with different tumour types.<wbr> The collaboration will enable GE to develop a broader laboratory and data analytics service that will enable better efficiency in the healthcare market related to oncology precision medicine.<wbr> This will be made available as a subscription-based service and operated by GE Healthcare.<wbr> </div><div style="margin-bottom: 10px;">Cindy Collins, CEO of Clarient (GE Healthcare) said " <EM>this global network of high quality diagnostic capability can be leveraged with confidence by all pharmaceutical companies in search of rigorously standardized oncology diagnostic services and data.<wbr>"</EM> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Terms of the Agreement</FONT></STRONG> </div><div style="margin-bottom: 10px;">GE Healthcare, through its Clarient affiliate, will initially use its clinical laboratory, pathology and genomics expertise, to certify laboratories and generate diagnostic data on metastatic melanoma patients.<wbr> The first Clarient certified laboratories to initiate this work, are expected to be operational in several countries in early 2015.<wbr> Laboratory testing will initially focus on more than 70 mutations relevant to melanoma, including BRAF V600E and V600K, with the opportunity to expand testing beyond melanoma into other tumor types, as the network of clinical laboratories develops.<wbr> </div><div style="margin-bottom: 10px;">Joonathan Pan, Head of Oncology Companion Diagnoistics and Disease Strategy , GSK, said “<EM>Through this agreement, we hope to better address the variability in access and quality of diagnostic testing which is a common problem seen with targeted oncology therapies and related companion diagnostics globally.<wbr> The commercial testing infrastructure created through this collaboration will enable advanced diagnostic solutions that should improve how patient care is delivered, where the certified laboratories are operational</EM>.<wbr>” </div><div style="margin-bottom: 10px;">Clarient’s laboratory and data analytics service will be available to other healthcare organizations worldwide through a subscription service, which is expected to be available next year.<wbr> The laboratory service, which is standardized, will enable pharmaceutical and other healthcare organizations to have the ability to offer diagnostic testing in any market where Clarient certified laboratories exist.<wbr> The data analytics service can also provide customizable insights and its possible uses include geospatial analysis, provision of aggregated epidemiological data and the identification and matching of potential patients to clinical trials.<wbr> </div><div>source: GE Healthcare Press Realease </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=9992">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-10-01T11:24:20+02:00</dc:date><dc:creator>jew60237</dc:creator></item><item>
<title>Allergan Has Started PMS Study of BOTOX® for LCL in Korea [sub:Aesthetics, :PharmaWorld:mkt:Korea, :PharmaWorld:sub:ClinicalTrial]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7751</link>
<description>Allergan Has Started PMS Study of BOTOX® for LCL in Korea [sub:Aesthetics, :PharmaWorld:mkt:Korea, :PharmaWorld:sub:ClinicalTrial]</description><category>sub:Aesthetics</category><category>mkt:Korea</category><category>sub:ClinicalTrial</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7751</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7751">Allergan Has Started PMS Study of BOTOX® for LCL in Korea</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20141231&edate=20140901&cat=sub%3aAesthetics"><font color="#e95e0b">:Neurology:sub:Aesthetics</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=mkt%3aKorea"><font color="#e95e0b">:PharmaWorld:mkt:Korea</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=sub%3aClinicalTrial"><font color="#e95e0b">:PharmaWorld:sub:ClinicalTrial</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7751">Neurology7751</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 30 September 2014 | 17:40</font><br><br><div style="margin-bottom: 10px;">Comment: This is a postmarketing surveillance study in Korea to evaluate the safety and effectiveness of BOTOX® for lateral canthal lines (crow's feet lines) with or without simultaneous glabellar lines.<wbr> PE will measure number of participants with AEs.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Trial Details</FONT></STRONG> </div><div style="margin-bottom: 10px;">Reference <A href="http://clinicaltrials.gov/ct2/show/NCT02248844?recr=Open&amp;no_unk=Y&amp;phase=0123&amp;fund=2&amp;rcv_s=08%2F30%2F2014&amp;rank=180">NCT02248844</A> </div><div style="margin-bottom: 10px;">Recruitment approx 600 </div><div style="margin-bottom: 10px;">Timelines Study to complete in Feb 2018 </div><div>Location Korea (1 site listed) </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7751">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-09-30T17:40:14+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Trelstar® 6M Available in Canada for Prostate Cancer [comp:Debiopharm, dis:Prostate, :PharmaWorld:mkt:Canada]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9990</link>
<description>Trelstar® 6M Available in Canada for Prostate Cancer [comp:Debiopharm, dis:Prostate, :PharmaWorld:mkt:Canada]</description><category>comp:Debiopharm</category><category>dis:Prostate</category><category>mkt:Canada</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9990</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=9990">Trelstar® 6M Available in Canada for Prostate Cancer</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=comp%3aDebiopharm"><font color="#e95e0b">:Oncology:comp:Debiopharm</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=mkt%3aCanada"><font color="#e95e0b">:PharmaWorld:mkt:Canada</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9990">Oncology9990</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 30 September 2014 | 17:01</font><br><br><div style="margin-bottom: 10px;">Comment: Trelstar® (triptorelin pamoate) was previously marketed by Paladin in Canada, and is currently marketed by Actavis Specialty Pharmaceuticals Co.<wbr> as of July 1st, 2014.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Actavis North American Specialty Brands</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9990/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Trelstar® Site</FONT></STRONG> </div><div><A href="https://www.trelstar.com/">https:/<wbr>/<wbr>www.<wbr>trelstar.<wbr>com/<wbr></A> </div><!-- Comment details --><a name="oncology9990attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9990/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(100,5 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=9990">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-09-30T17:01:45+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9990/1/ScreenCapture1.jpg" length="102861" type="image/jpeg"/></item><item>
<title>New Launch for Cerbios' Probiotic Product [sub:Probiotics, dis:Diarrhoea]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2043</link>
<description>New Launch for Cerbios' Probiotic Product [sub:Probiotics, dis:Diarrhoea]</description><category>sub:Probiotics</category><category>dis:Diarrhoea</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2043</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2043">New Launch for Cerbios' Probiotic Product</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20141231&edate=20140901&cat=dis%3aDiarrhoea"><font color="#e95e0b">:GastroEnterology:dis:Diarrhoea</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20141231&edate=20140901&cat=sub%3aProbiotics"><font color="#e95e0b">:GastroEnterology:sub:Probiotics</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2043">GastroEnterology2043</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 30 September 2014 | 11:25</font><br><br><div style="margin-bottom: 10px;">Comment: Even in territories where low cost products dominate the market, customers appreciate the quality standard of Cerbios production in Switzerland.<wbr> After Japan and Korea, NewfloraTM has been launched in Pakistan by RG Pharmaceutica.<wbr> The product is based on Cerbios’ <EM>Enterococcus faecium</EM> SF68® and indicated for the prevention and treatment of intestinal disorders.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">About Cerbios</FONT></STRONG> </div><div style="margin-bottom: 10px;">- privately held company located in Lugano (Switzerland) specialized in the development and manufacturing of chemical and biological APIs.<wbr> </div><div style="margin-bottom: 10px;">- APIs made by Cerbios cover small molecules (Chemical Division), large molecules and Probiotics (Biological Division).<wbr> </div><div style="margin-bottom: 10px;">- Services for third parties under exclusive manufacturing are offered in the area of HPAIs for the Chemical Division and Recombinant Proteins or monoclonal Antibodies for the Biological Division.<wbr> </div><div style="margin-bottom: 10px;">- Full CMC support is provided to partners in order to supply them with cGMP clinical batches, registration/<wbr>validation material, and APIs from commercial manufacturing.<wbr> </div><div style="margin-bottom: 10px;">- Cerbios is selling commercial products mainly in Europe, USA, Japan and India.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">About Newflora</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2043/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">In Switzerland Cerbios’ <EM>Enterococcus faecium</EM> SF68® was registered as pharmaceutical probiotic in 1979 and commercialized under the trade name Bioflorin.<wbr> In the 80’s it quickly took over the market lead and is today still No 1 in class A7F.<wbr> </div><div style="margin-bottom: 10px;">It is used in clinical conditions in which changes in the intestinal flora and, as their consequence, any disorder of the intestinal balance play a decisive role, such as </div><div style="margin-bottom: 10px;">.<wbr> Enteritis, enterocolitis of adults </div><div style="margin-bottom: 10px;">· Enteritis, enterocolitis of children </div><div style="margin-bottom: 10px;">· Dyspepsia due to dietary changes of infants </div><div style="margin-bottom: 10px;">· Dysbacteria in intestinal tract of various origin, such as after antibiotic therapy or disorders due to dietary and diet-related changes </div><div>· Traveller’s diarrhoea </div><!-- Comment details --><a name="gastroenterology2043attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2043/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(11 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2043">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-09-30T11:25:13+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2043/1/ScreenCapture1.jpg" length="11246" type="image/jpeg"/></item><item>
<title>Pharma Companies Sponsor Digital Training Study for Growth Hormone Therapy [:PharmaWorld:congress:ESPE]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7813</link>
<description>Pharma Companies Sponsor Digital Training Study for Growth Hormone Therapy [:PharmaWorld:congress:ESPE]</description><category>congress:ESPE</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7813</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20141231&edate=20140901&rec=7813">Pharma Companies Sponsor Digital Training Study for Growth Hormone Therapy</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=congress%3aESPE"><font color="#e95e0b">:PharmaWorld:congress:ESPE</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7813">Endocrinology7813</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 29 September 2014 | 17:57</font><br><br><div style="margin-bottom: 10px;">Comment: The objectives of the LEARN2GROW tablet training app are to increase self confidence and involvment of both parents and children, decrease fears and shorten the time devoted by the nurses for GH therapy education.<wbr> The pilot prospective study, sponsored by Ferring, Novo and Pfizer, has been conducted in Israel, and planned to end in September 2015.<wbr> The initiative was presented at ESPE2014, in the working group for Pediatric Endocrine Nurse Specialists and Allied Health Professionals (PENSWG).<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">About the Study</FONT></STRONG> </div><div style="margin-bottom: 10px;">- aim : to evaluate and compare the ‘conventional’ and ‘interactive’ GHT patient training </div><div style="margin-bottom: 10px;">- program: children-friendly with interactive apps </div><div style="margin-bottom: 10px;">- location: Institute for Endocrinology and Diabetes National Center for Childhood Diabetes Schneider Children’s Medical Center of Israel, Petah Tivka, Israel </div><div><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7813/1/ScreenCapture1.jpg?user-agent=rss"> </div><!-- Comment details --><a name="endocrinology7813attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7813/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(61,1 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20141231&edate=20140901&rec=7813">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-09-29T17:57:05+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7813/1/ScreenCapture1.jpg" length="62540" type="image/jpeg"/></item><item>
<title>Sucampo and Takeda Launch DTC Advertising Campaign for AMITIZA® [dis:Constipation, :PharmaWorld:mkt:NorthAmerica]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2042</link>
<description>Sucampo and Takeda Launch DTC Advertising Campaign for AMITIZA® [dis:Constipation, :PharmaWorld:mkt:NorthAmerica]</description><category>dis:Constipation</category><category>mkt:NorthAmerica</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2042</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2042">Sucampo and Takeda Launch DTC Advertising Campaign for AMITIZA®</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20141231&edate=20140901&cat=dis%3aConstipation"><font color="#e95e0b">:GastroEnterology:dis:Constipation</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=mkt%3aNorthAmerica"><font color="#e95e0b">:PharmaWorld:mkt:NorthAmerica</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2042">GastroEnterology2042</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 29 September 2014 | 17:28</font><br><br><div style="margin-bottom: 10px;">Comment: The pilot direct-to-consumer advertising campaign has been launched in select U.<wbr>S.<wbr> markets for AMITIZA® (lubiprostone) for adults with chronic idiopathic constipation (CIC).<wbr> The campaign will consist of a 60-second television spot.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Rationale</FONT></STRONG> </div><div style="margin-bottom: 10px;">the launch of the patient-focused campaign is critical </div><div style="margin-bottom: 10px;"><UL><LI>to educating patients and physicians about AMITIZA</LI>
<LI>to encourage patients to talk to their doctors about CIC</LI>
</UL> </div><div>Source: Takeda /<wbr> Sucampo </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2042">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-09-29T17:28:17+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Daewoong to Proceed with R&amp;D Effort to Expand the Lacfidus Lineup [sub:Probiotics]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2041</link>
<description>Daewoong to Proceed with R&amp;D Effort to Expand the Lacfidus Lineup [sub:Probiotics]</description><category>sub:Probiotics</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2041</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2041">Daewoong to Proceed with R&D Effort to Expand the Lacfidus Lineup</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20141231&edate=20140901&cat=sub%3aProbiotics"><font color="#e95e0b">:GastroEnterology:sub:Probiotics</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2041">GastroEnterology2041</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 29 September 2014 | 16:32</font><br><br><div style="margin-bottom: 10px;">Comment: The company has launched LacfidusNew and LacfidusNew I, the new probiotic lactic acid bacteria products which upgraded existing Lacfidus.<wbr> Both products suppress harmful bacteria in the intestines and multiply beneficial bacteria to promote smooth bowel movements.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Description</FONT></STRONG> </div><div style="margin-bottom: 10px;">The probiotic species were diversified to 8 species from 3 species, compared to existing ‘Lacfidus’.<wbr> </div><div style="margin-bottom: 10px;">In addition, Lactobacillus casei species were added to help avert helicobacter pylori infection and ensure gastrointestinal health, as well as the health of small and large intestines.<wbr> <BR> </div><div><img src="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2041/1/ScreenCapture1.jpg?user-agent=rss"> </div><!-- Comment details --><a name="gastroenterology2041attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2041/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(20,3 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2041">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-09-29T16:32:40+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2041/1/ScreenCapture1.jpg" length="20763" type="image/jpeg"/></item><item>
<title>HRA Pharma's Cushing Drug Has Received Positive Opinion from CHMP [dis:Cushing, :PharmaWorld:mkt:Europe]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7810</link>
<description>HRA Pharma's Cushing Drug Has Received Positive Opinion from CHMP [dis:Cushing, :PharmaWorld:mkt:Europe]</description><category>dis:Cushing</category><category>mkt:Europe</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7810</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20141231&edate=20140901&rec=7810">HRA Pharma's Cushing Drug Has Received Positive Opinion from CHMP</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20141231&edate=20140901&cat=dis%3aCushing"><font color="#e95e0b">:Endocrinology:dis:Cushing</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=mkt%3aEurope"><font color="#e95e0b">:PharmaWorld:mkt:Europe</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7810">Endocrinology7810</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 29 September 2014 | 15:21</font><br><br><div style="margin-bottom: 10px;">Comment: The drug, normally used to fight fungal infections, has actually been used off-label to treat Cushing’s for more than 30 years, but has never been formally approved for this indication.<wbr> Will be the first ever ketoconazole product registered and labelled for the treatment of endogenous Cushing’s syndrome in adults and adolescents above the age of 12 years.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">About Ketoconazole</FONT></STRONG> </div><div style="margin-bottom: 10px;">Ketoconazole is a steroidogenesis inhibitor that blocks cortisol synthesis.<wbr> </div><div style="margin-bottom: 10px;">It was originally marketed to treat fungal infections but was withdrawn from the EU market in October 2013 following a referral procedure.<wbr> </div><div style="margin-bottom: 10px;">Indication: Ketoconazole has been found to be effective for treating endogenous Cushing’s syndrome from all causes in patients unwilling or unable to have surgery or in whom surgery has failed or while awaiting radiotherapy efficacy.<wbr> </div><div><DIV>Orphan Drug Status: Ketoconazole HRA was designated as an orphan medicinal product in April 2012 

<P><STRONG><FONT size="3">HRA Parma Strategic Milestones</FONT></STRONG> </P>
<P>In May the company's Metopirone (metyrapone that works by stopping the natural production of a steroid hormone called cortisol) has been positively assessed through a mutual recognitionprocedure (MRP) for 15 Eu countries as a diagostic test for ACTH insufficiency, in the differental diagnosis of ACTh- dependent Cushing syndrome and for th emanagement of patients with endogenous Cushing's syndrome.<wbr> </P>
<BLOCKQUOTE dir="ltr" style="MARGIN-RIGHT: 0px">
<P>HRA Pharma has acquired Metopirone from Novartis in 2011 with the objective to make it available to the largest number of patients.<wbr> </P>
<P>Outside the European Union, Metopirone is approved and marketed in Switzerland, Israel, Australia, Japan, USA, New Zealand and Hong Kong.<wbr> </P>
<P>In addition to the 15 European markets included in this MPR, registrations then launches are also currently being planned in the rest of the world where <STRONG>HRA is actively seeking partnerships</STRONG></P></BLOCKQUOTE></DIV> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20141231&edate=20140901&rec=7810">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-09-29T15:21:07+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Novartis's Acromegaly Drug Closer to EU Approval [class:SomatostatinAnalogue, comp:Novartis, dis:Acromegaly, :PharmaWorld:mkt:Europe]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7809</link>
<description>Novartis's Acromegaly Drug Closer to EU Approval [class:SomatostatinAnalogue, comp:Novartis, dis:Acromegaly, :PharmaWorld:mkt:Europe]</description><comments>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7809</comments><category>class:SomatostatinAnalogue</category><category>comp:Novartis</category><category>dis:Acromegaly</category><category>mkt:Europe</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7809</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20141231&edate=20140901&rec=7809">Novartis's Acromegaly Drug Closer to EU Approval</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20141231&edate=20140901&cat=class%3aSomatostatinAnalogue"><font color="#e95e0b">:Endocrinology:class:SomatostatinAnalogue</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20141231&edate=20140901&cat=comp%3aNovartis"><font color="#e95e0b">:Endocrinology:comp:Novartis</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20141231&edate=20140901&cat=dis%3aAcromegaly"><font color="#e95e0b">:Endocrinology:dis:Acromegaly</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=mkt%3aEurope"><font color="#e95e0b">:PharmaWorld:mkt:Europe</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7809">Endocrinology7809</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 29 September 2014 | 14:47</font><br><br><div style="margin-bottom: 10px;">Comment: The CHMP of the European Medicines Agency (EMA) adopted a positive opinion for Signifor® LAR (pasireotide) to treat adult patients with acromegaly for whom surgery is not an option or has not been curative and who are inadequately controlled on treatment with a first-generation somatostatin analogue (SSA).<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Registration Dossier</FONT></STRONG> </div><div>The CHMP recommendation was based on two multicenter Phase III studies, C2402 and C2305.<wbr> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Endocrinology7864c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">The European Commission has approved Signifor reported Novartis on Monday Nov 24.<wbr> The approval concerns all 27 EU members, plus Iceland and Norway.<wbr> This approval is in line with Ipsen expectations.<wbr> </div><div>An estimated one to two people per 10,000 are affected with the disease in the European Union, according to Novartis.<wbr> </div><font size="-1">Brigitte DESCHAMPS / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7864" class="commentpermalink">Endocrinology7864</a> / <span class="date">24 November 2014</span> /
<span class="time">10:32:38 o'clock CET</span>
</font></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20141231&edate=20140901&rec=7809">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-09-29T14:47:47+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Additional Claim Approved for Probiotic Product in Canada [sub:Probiotics, :PharmaWorld:mkt:Canada]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2040</link>
<description>Additional Claim Approved for Probiotic Product in Canada [sub:Probiotics, :PharmaWorld:mkt:Canada]</description><category>sub:Probiotics</category><category>mkt:Canada</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2040</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2040">Additional Claim Approved for Probiotic Product in Canada</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20141231&edate=20140901&cat=sub%3aProbiotics"><font color="#e95e0b">:GastroEnterology:sub:Probiotics</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=mkt%3aCanada"><font color="#e95e0b">:PharmaWorld:mkt:Canada</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2040">GastroEnterology2040</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 26 September 2014 | 09:42</font><br><br><div style="margin-bottom: 10px;">Comment: HMF IBS Relief strains were selected and tested in double-blind, placebo controlled clinical trials.<wbr> The additional claim mentions: <EM>Adults and children over 11 years</EM> <EM>only:</EM> <EM>Helps improve symptoms of irritable bowel syndrome (IBS) such as bloating, satisfaction with bowel habits, and days with pain within 6 weeks;</EM> </div><div style="margin-bottom: 10px;"><a href="http://www.seroyal.com/ca/brands/genestrabrands/products/2013/5/h/hmf-ibs-relief.html" class="defaultlink">About HMF IBS Relief</a> </div><div style="margin-bottom: 10px;"><STRONG>ABOUT GENESTRA BRANDS<SUP>&reg;</SUP></STRONG> </div><div style="margin-bottom: 10px;">GENESTRA BRANDS<STRONG><SUP>&reg;</SUP></STRONG>, a trusted brand of Seroyal<STRONG><SUP>&reg;</SUP></STRONG>, a business unit of Atrium Innovations Inc.<wbr> supports individualized treatment plans with more than 400 professional-grade nutraceutical products in a variety of formats.<wbr> </div><div style="margin-bottom: 10px;">For more than 28 years, Genestra products have been proven safe, effective, and reliable, backed by clinical or traditional evidence.<wbr> </div><div>GENESTRA BRANDS<STRONG><SUP>&reg; </SUP></STRONG>is headquartered in Richmond Hill, ON, Canada </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2040">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-09-26T09:42:02+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Acorda to Purchase Parkinson's Disease Company Civitas For $525m In Cash [dis:Parkinson, :PharmaWorld:sub:Acquisition]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7750</link>
<description>Acorda to Purchase Parkinson's Disease Company Civitas For $525m In Cash [dis:Parkinson, :PharmaWorld:sub:Acquisition]</description><category>dis:Parkinson</category><category>sub:Acquisition</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7750</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7750">Acorda to Purchase Parkinson's Disease Company Civitas For $525m In Cash</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20141231&edate=20140901&cat=dis%3aParkinson"><font color="#e95e0b">:Neurology:dis:Parkinson</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=sub%3aAcquisition"><font color="#e95e0b">:PharmaWorld:sub:Acquisition</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7750">Neurology7750</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 25 September 2014 | 18:33</font><br><br><div style="margin-bottom: 10px;">Comment: Acorda will obtain worldwide rights to CVT-301, a Phase 3 
treatment candidate for OFF episodes of Parkinson’s disease (PD).<wbr> The 
acquisition also includes rights to Civitas’ proprietary ARCUS<SUP>TM</SUP> 
pulmonary delivery technology and manufacturing facility with commercial-scale 
capabilities based in <LOCATION value="LU/us.ma.chlsea">Chelsea, MA.<wbr></LOCATION> 
<STRONG>Commenting on the acquisition Ron Cohen Acorda's President &amp; CEO 
stated</STRONG> </div><div style="margin-bottom: 10px;">“This acquisition marks a great day for Acorda and Civitas.<wbr> Both companies 
share a passion for developing novel therapies that can restore function to 
people with neurological diseases.<wbr> We also see substantial synergies between our 
capabilities, people and pipelines.<wbr>The acquisition adds an exciting product 
candidate to Acorda’s pipeline that addresses a significant unmet need in 
Parkinson’s disease.<wbr> It also leverages Acorda’s existing development and 
commercial capabilities and creates an opportunity for us to develop a global 
presence.<wbr>" </div><div style="margin-bottom: 10px;">Additionally he noted.<wbr> "Strongly positive data from a recent Phase 2b trial, 
together with a clearly defined regulatory pathway and extensive IP protection, 
make this a compelling opportunity, with estimated U.<wbr>S.<wbr> sales expected to exceed 
<MONEY>$500 million</MONEY>.<wbr>” </div><div style="margin-bottom: 10px;"><STRONG>What is CVT-301?</STRONG> </div><div style="margin-bottom: 10px;">CVT-301 is a system comprised of a dry powder L-dopa formulation that is 
contained within blister-packed capsules and administered via a proprietary, 
pocket-size, reusable inhaler.<wbr> CVT-301.<wbr> It can provide rapid delivery of 
L-dopa in conjunction with a patient’s optimized oral L-dopa regimen.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Next Steps</STRONG> </div><div style="margin-bottom: 10px;">The pivotal Phase 3 study for treatment of OFF episodes in people with PD is 
expected to begin enrolling in early 2015 and if successful, a filing for 
regulatory approval in <LOCATION value="LC/us;LB/nam">the 
United States</LOCATION> is expected by the end of 2016.<wbr> </div><div>.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7750">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-09-25T18:33:48+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>Sir Philip Hampton Is Appointed As GSK's Next Chairman</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10973</link>
<description>Sir Philip Hampton Is Appointed As GSK's Next Chairman</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10973</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20141231&edate=20140901&rec=10973">Sir Philip Hampton Is Appointed As GSK's Next Chairman</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10973">PharmaWorld10973</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/994">Jenny Wu</a> | 25 September 2014 | 18:03</font><br><br><div style="margin-bottom: 10px;">Comment: Following the substancial fine decision by Chinese authorities for bribery, Sir Philip Hampton - now chairman of Royal Bank of Scotland -has taken another of the most challenging jobs in British business.<wbr> Sir Philip will join the GSK board as a non-executive director in January and will become deputy chairman on 1st April 2015.<wbr> </div><div>During financial crisis, Sir  Philip took over as RBS chairman in 2009 after the bank's bailout.<wbr> He has chaired the bank through the most challenging period for implementing a significant restructuring and rebuilding programme.<wbr>  At GSK, he will oversee to rebuild GSK's reputation in China after the scadal to offset the decline of Advair (its best selling asthma drug).<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20141231&edate=20140901&rec=10973">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-09-25T18:03:34+02:00</dc:date><dc:creator>jew60237</dc:creator></item><item>
<title>Key Messages from Sandoz Presence at ESPE 2014 [class:GrowthHormone, comp:Sandoz, :PharmaWorld:congress:ESPE]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7807</link>
<description>Key Messages from Sandoz Presence at ESPE 2014 [class:GrowthHormone, comp:Sandoz, :PharmaWorld:congress:ESPE]</description><category>class:GrowthHormone</category><category>comp:Sandoz</category><category>congress:ESPE</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7807</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20141231&edate=20140901&rec=7807">Key Messages from Sandoz Presence at ESPE 2014</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20141231&edate=20140901&cat=class%3aGrowthHormone"><font color="#e95e0b">:Endocrinology:class:GrowthHormone</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20141231&edate=20140901&cat=comp%3aSandoz"><font color="#e95e0b">:Endocrinology:comp:Sandoz</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=congress%3aESPE"><font color="#e95e0b">:PharmaWorld:congress:ESPE</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7807">Endocrinology7807</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 25 September 2014 | 17:59</font><br><br><div style="margin-bottom: 10px;">Comment: This report reviews some of the most interesting Omnitrope data presented by Sandoz.<wbr> It focuses on i) recent outcomes from the PATRO study (notably the diabetogenic potential of GH in short children born SGA, and the risk of malignancies), ii) long-term safety data of the FU study of patients that participated in the Spanish Ph3 trial, and iii) results from a single ped centre in Spain assessing the consequences of switching treament from original rhGH to Omnitrope.<wbr> During the satellite symposium the diagnosis and management of precocious puberty was largely discussed by a panel of experts using case examples in interaction with the audience.<wbr> Key messages are provided below.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3" style="BACKGROUND-COLOR: #fdfd00">Biggest Booth Designed with Giant SurePal Pens</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7807/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3" style="BACKGROUND-COLOR: #fdfd00">Poster Sessions</FONT></STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>
<STRONG>P2-D3-442 - Poster Presentation</STRONG> Two-Year Results from Patro Children, a Multi-Centre, Non-Interventional Study of the Long-Term Efficacy and Safety of Omnitropew in Children Requiring GH Treatment</LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG><U>Full Poster attached</U></STRONG> </div><div style="margin-bottom: 10px;">Baseline characteristics of the patients </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7807/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">Reasons for treatment discontinuation </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7807/3/ScreenCapture3.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">Summary of AEs </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7807/4/ScreenCapture4.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">Conclusion : This 2-year analysis shows that Omnitropew was safe and well tolerated in a wide range of paediatric indications.<wbr> Omnitropew was effective in the majority of children.<wbr> This ongoing study will extend the evidence base for Omnitropew, and GH in general, in paediatric indications.<wbr> </div><div style="margin-bottom: 10px;"><UL><LI>The switch from the original to the biosimilar rhGH, Omnitrope, had no negative impact on the growth of children with GHD.<wbr> No adverse drug reactions were reported after the switch (presented in<STRONG> poster P3-D2-853</STRONG>)</LI>
</UL> </div><div style="margin-bottom: 10px;"><U>Objective</U>: To evaluate the consequences on growth parameters of switching treatment, from original rhGHs to Omnitropew in children with GHD, in a window period of 36 months.<wbr> Method: This study was a single centre, retrospective, observational study.<wbr> It included children with GHD treated with an original rhGH at least 2 years before the switch.<wbr> Auxological data was obtained from 20 patients.<wbr> <U>Results</U>: Data from 15 boys (75%) and five girls (25%) was gathered.<wbr> The mean age of the patients was 14.<wbr>5 years.<wbr> 65% (13) had idiopathic GHD.<wbr> The mean duration of treatment prior to switching was 38,3 months.<wbr> At the beginning of treatment the mean height was 105.<wbr>5G16.<wbr>2 cm and the height SDS (HSDS) was K3.<wbr>25G0.<wbr>93.<wbr> Eighteen months before the switch the mean height was 118.<wbr>5G 10.<wbr>9 cm, the HSDS was K2.<wbr>16G0.<wbr>80, the HV was 8.<wbr>77G 2.<wbr>04 cm/<wbr>year and the HVSDS was 3.<wbr>87G2.<wbr>66.<wbr> At the time of the switch to Omnitrope the mean height was 128.<wbr>1G10.<wbr>6 cm, the HSDS was K1.<wbr>82G0.<wbr>88, the HV was 6.<wbr>20G1.<wbr>39 cm/<wbr>year and the HVSDS was 1.<wbr>03G1.<wbr>80.<wbr> Eighteen months after the switch the mean height was 139.<wbr>4G12.<wbr>9 cm, the HSDS wasK1.<wbr>41G0.<wbr>91, the HV was 6.<wbr>92G2.<wbr>88 cm/<wbr>year and the HVSDS was 0.<wbr>89G1.<wbr>57.<wbr> No adverse drug reactions were reported after the switch and three patients had transitory problems with the Omnitropew device.<wbr> </div><div style="margin-bottom: 10px;"><UL><LI><STRONG>P3-D2-850 Poster Presentation</STRONG> A Follow-up Study up to Adult Height of the Patients Included in the Phase iii Clinical Trial with the Biosimilar Human Recombinant GH (omnitrope) on the Treatment of Spanish Children with GH Deficit</LI>
</UL> </div><div style="margin-bottom: 10px;">This study was a multicentre, observational, retrospective follow-up study of the patients that participated in the Spanish phase III clinical trial (70 patients recruited).<wbr> Height data up to adult height was obtained from 39 patients.<wbr> The conclusion shows that the patients recruited in the Spanish phase III clinical trial had a positive growth achieving an adult height SDS of K1.<wbr>01C0.<wbr>59 (men: K1.<wbr>07G0.<wbr>52 and women: K0.<wbr>86G0.<wbr>72).<wbr> No adverse events were reported.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Satellite Symposium</FONT></STRONG> </div><div style="margin-bottom: 10px;">Chaired by Claire Bouvattier (Ped Endo at Bicêtre Hosp, Paris, France) and Wieland Kiess (General Ped at Klinik für Kinder und Jugendmedizin, Leipzig, Germany) </div><div style="margin-bottom: 10px;">Speaker JP Bourguignon; Jesus Argente; Margaret Zacharin </div><div style="margin-bottom: 10px;"><STRONG>Key messages</STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>factors to condiser before making the decision to treat: aetiology of PP, pathology of disease (idiopathic or intracranial), rate of sexual maturation/<wbr>progression, growth velocity, bone age, predicted adult height and the potential psychological consequences of PP on the patient.<wbr></LI>
<LI>new genes are being discovered that are possibly involved in PP</LI>
</UL> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7807/6/ScreenCapture5.jpg?user-agent=rss"> </div><div><UL><LI>The Spanish CPP database indicate the global incidence rate of CPP was 5.<wbr>66 cases per million person-years at risk, with an annual incidence ranging between 0.<wbr>02 and 1.<wbr>07 new cases per 100,000.<wbr></LI>
</UL> </div><!-- Comment details --><a name="endocrinology7807attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7807/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(52,4 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7807/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(101,8 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7807/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(41,2 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7807/4/ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(48,8 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7807/5/PATRO%20Poster%5fESPE.pdf">PATRO Poster_ESPE.pdf</a>&nbsp;&nbsp;(132,5 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7807/6/ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(40,5 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20141231&edate=20140901&rec=7807">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-09-25T17:59:31+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7807/1/ScreenCapture1.jpg" length="53618" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7807/2/ScreenCapture2.jpg" length="104231" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7807/3/ScreenCapture3.jpg" length="42228" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7807/4/ScreenCapture4.jpg" length="49955" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7807/5/PATRO%20Poster%5fESPE.pdf" length="135728" type="application/pdf"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7807/6/ScreenCapture5.jpg" length="41474" type="image/jpeg"/></item><item>
<title>Newly-Developed Baclofen Formulation Moves Ahead in Clinical Trials [dis:Palsy, dis:Dystonia, dis:Spasticity, :PharmaWorld:sub:ClinicalTrial]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7749</link>
<description>Newly-Developed Baclofen Formulation Moves Ahead in Clinical Trials [dis:Palsy, dis:Dystonia, dis:Spasticity, :PharmaWorld:sub:ClinicalTrial]</description><category>dis:Palsy</category><category>dis:Dystonia</category><category>dis:Spasticity</category><category>sub:ClinicalTrial</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7749</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7749">Newly-Developed Baclofen Formulation Moves Ahead in Clinical Trials</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20141231&edate=20140901&cat=dis%3aDystonia"><font color="#e95e0b">:Neurology:dis:Dystonia</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20141231&edate=20140901&cat=dis%3aPalsy"><font color="#e95e0b">:Neurology:dis:Palsy</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20141231&edate=20140901&cat=dis%3aSpasticity"><font color="#e95e0b">:Neurology:dis:Spasticity</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=sub%3aClinicalTrial"><font color="#e95e0b">:PharmaWorld:sub:ClinicalTrial</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7749">Neurology7749</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 25 September 2014 | 16:44</font><br><br><div style="margin-bottom: 10px;">Comment: According to the article, the newly developed IV drug formulation has passed an initial Ph1, and is now entering a second Ph1 dosing escalation trial.<wbr> Baclofen is currently available as an oral tablet and as an intrathecal solution.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Rationale of Developing a IV Form</FONT></STRONG> </div><div style="margin-bottom: 10px;">If illness or mechanical problems with the intrathecal pump occur or if a patient cannot take the drug by mouth, baclofen administration can be interrupted.<wbr> This interruption may result in baclofen withdrawal syndrome, a serious complication </div><div style="margin-bottom: 10px;"><BLOCKQUOTE dir="ltr" style="MARGIN-RIGHT: 0px">
<P>- more effectively manage, and even prevent baclofen withdrawal for many patients (which can result in increased stiffness, seizures or even liver and kidney failures)</P></BLOCKQUOTE> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Drug Development</FONT></STRONG> </div><div>The U.<wbr> of Minenesota has partnered with <STRONG>Allaysis Pharm</STRONG>, a pharmaceutical company focused on bringing orphan drugs to market, located in Philadelphia, to advance the drug through clinical trials and on to anticipated sales and distribution.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7749">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-09-25T16:44:57+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Bayer Annouced EMSO 2014 To Feature Their New Oncology Data Across Multiple Franchises [:PharmaWorld:congress:ESMO, comp:BayerSchering]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9986</link>
<description>Bayer Annouced EMSO 2014 To Feature Their New Oncology Data Across Multiple Franchises [:PharmaWorld:congress:ESMO, comp:BayerSchering]</description><category>congress:ESMO</category><category>comp:BayerSchering</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9986</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=9986">Bayer Annouced EMSO 2014 To Feature Their New Oncology Data Across Multiple Franchises</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=comp%3aBayerSchering"><font color="#e95e0b">:Oncology:comp:BayerSchering</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=congress%3aESMO"><font color="#e95e0b">:PharmaWorld:congress:ESMO</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9986">Oncology9986</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/994">Jenny Wu</a> | 25 September 2014 | 07:42</font><br><br><div style="margin-bottom: 10px;">Comment: Positive Results of the Phase III CONCUR trial of regorafenib in Asian patients with metastatic colorectal cancer to be presented in Proffered Paper Session /<wbr> Includes data from studies evaluating regorafenib, sorafenib in metastatic colorectal cancer, hepatocellular carcinoma, renal cell carcinoma, metastatic HER2- breast cancer, and gastrointestinal stromal tumours (GIST).<wbr> Radium Ra 223 dichloride combination trial with abiraterone will also be presented as a trial in  progress poster on Saturday between 12:45 - 13:45.<wbr> </div><div style="margin-bottom: 10px;"><H3>Radium Ra 223 Dichloride (radium-223)</H3> </div><div style="margin-bottom: 10px;">- <EM>External-beam radiation therapy (EBRT) use and safety with radium-223 dichloride (Ra) in patients (pts) with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases (mets) from the ALSYMPCA trial </EM><BR>- Abstract 768P, Poster Display Session: Genitourinary tumors, prostate<BR>- Saturday, September 27, 12:45 - 1:45 PM, Poster Area<BR>- <EM>1.<wbr>5-year post-treatment follow-up of radium-223 dichloride (Ra-223) safety in patients (pts) with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases from ALSYMPCA: characterization of hematologic safety profiles </EM><BR>- Abstract 769P, Poster Display Session: Genitourinary tumors, prostate<BR>- Saturday, September 27, 12:45 -1:45 PM, Poster Area<BR>- <EM>Reasons for Patients (Pts) Discontinuing Study Treatment (Tx) in the Phase 3 ALSYMPCA Trial of Radium-223 Dichloride (Ra-223) in Castration-Resistant Prostate Cancer (CRPC) With Bone Metastases (Mets) </EM><BR>- Abstract 770P, Poster Display Session: Genitourinary tumors, prostate<BR>- Saturday, September 27, 12:45-1:45 PM, Poster Area<BR>- <EM>ERA 223 &acirc;&euro;&ldquo; a phase 3 trial of radium-223 dichloride (Ra-223) in combination with abiraterone acetate (AA) and prednisone in the treatment of asymptomatic or mildly symptomatic chemotherapy-na&Atilde;&macr;ve patients with bone-predominant metastatic castration-resistant prostate cancer (CRPC) </EM><BR>- Abstract 803TiP, Poster Display Session: Genitourinary tumors, prostate<BR>- Saturday, September 27, 12:45-1:45 PM, Poster Area<BR>- <EM>Safety of radium-223 dichloride (Ra) with docetaxel (D) in patients (pts) with bone metastases (mets) from castration-resistant prostate cancer (CRPC): a phase 1/<wbr>2a clinical trial </EM><BR>- Abstract 765PD, Poster Discussion Session: Genitourinary tumors, prostate<BR>- Sunday, September 28, 1:00 -2:00 PM, Granada Room </div><div style="margin-bottom: 10px;">Notable studies evaluating Bayer's two other oncology products at ESMO 2014 are listed below.<wbr> </div><div style="margin-bottom: 10px;"><H3>Regorafenib</H3> </div><div style="margin-bottom: 10px;">- <EM>CONCUR: A randomized, placebo-controlled phase 3 study of regorafenib (REG) monotherapy in Asian patients with previously treated metastatic colorectal cancer (mCRC) </EM><BR>- Oral Presentation 500O, Proffered Paper Session: Gastrointestinal tumors, colorectal<BR>- Saturday, September 27, 10:20 - 10:35 AM (CET), Madrid Room<BR>- <EM>REBECCA: A large cohort study of Regorafenib (REG) in the real-life setting in patients (pts) previously treated for metastatic colorectal cancer (mCRC)</EM><BR>- Abstract 602P, Poster Display Session: Gastrointestinal tumors, colorectal<BR>- Monday, September 29, 12:45 -1:45 PM (CET), Poster Area<BR>- <EM>The Cost of Survival Gains in Metastatic Colorectal Cancer (mCRC) in Four European Countries </EM><BR>- Abstract 604P_PR, Poster Display Session: Gastrointestinal tumors, colorectal<BR>- Monday, September 29, 12:45 -1:45 PM (CET), Poster Area<BR>- <EM>Adjuvant regorafenib (REG) in stage IV colorectal cancer (CRC) after curative treatment of liver metastases: a phase III randomized, placebo (PBO)-controlled trial (COAST)</EM><BR>- Abstract 611TiP, Poster Display Session: Gastrointestinal tumors, colorectal<BR>- Monday, September 29, 12:45 -1:45 PM (CET), Poster Area<BR>- <EM>A prospective, observational trial to further assess safety and efficacy of regorafenib in patients with metastatic colorectal cancer (mCRC) in routine clinical practice (CORRELATE)</EM><BR>- Abstract 613TiP, Poster Display Session: Gastrointestinal tumors, colorectal<BR>- Monday, September 29, 12:45 -1:45 PM (CET), Poster Area<BR>- <EM>Analysis of treatment patterns of patients with advanced gastrointestinal stromal tumors (GIST) in EU5 </EM><BR>- Abstract 1427P, Poster Display Session: Sarcoma <BR>- Monday, September 29, 12:45 -1:45 PM (CET), Poster Area </div><div style="margin-bottom: 10px;"><H3>Sorafenib</H3> </div><div style="margin-bottom: 10px;">- <EM>Correlation of sorafenib exposure with safety and efficacy from pivotal clinical trials in hepatocellular carcinoma (HCC) and renal cell cancer (RCC) </EM><BR>- Abstract 485P, Poster Display Session: Developmental therapeutics<BR>- Saturday, September 27, 12:45 -1:45 PM (CET), Poster Area<BR>- <EM>Health economic analysis of the randomized multicenter phase II trial SAKK 77/<wbr>08: sorafenib with or without everolimus in patients with unresectable hepatocellular carcinoma (HCC) </EM><BR>- Abstract 1039P, Poster Display Session: Health economics<BR>- Sunday, September 28, 12:45-1:45 PM (CET), Poster Area<BR>- <EM>A phase III randomized, double-blind, trial comparing sorafenib plus capecitabine versus placebo plus capecitabine in the treatment of locally advanced or metastatic HER2-negative breast cancer (RESILIENCE)</EM><BR>- Oral Presentation LBA8, Proffered Paper Session: Breast cancer, metastatic<BR>- Sunday, September 28, 2:10 -3:45 PM (CET), Madrid Room<BR>- <EM>Final analysis of overall survival per subgroups of HCC patients in the prospective, non-interventional INSIGHT study treated with sorafenib </EM><BR>- Abstract 728P, Poster Display Session: Gastrointestinal tumors, non-colorectal<BR>- Monday, September 29, 12:45-1:45 PM (CET), Poster Area<BR>- <EM>An international observational study to assess the use of sorafenib after transarterial chemoembolization (TACE) in patients with hepatocellular carcinoma (HCC): OPTIMIS </EM><BR>- Abstract 743TiP, Poster Display Session: Gastrointestinal tumors, non-colorectal<BR>- Monday, September 29, 12:45-1:45 PM (CET), Poster Area </div><div>Source:bayer.<wbr>com </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=9986">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-09-25T07:42:18+02:00</dc:date><dc:creator>jew60237</dc:creator></item><item>
<title>Janssen Has Initiated a Study to Observe the Treatment of Prostate Cancer Under Routine Medical Care [dis:Prostate]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9985</link>
<description>Janssen Has Initiated a Study to Observe the Treatment of Prostate Cancer Under Routine Medical Care [dis:Prostate]</description><category>dis:Prostate</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9985</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=9985">Janssen Has Initiated a Study to Observe the Treatment of Prostate Cancer Under Routine Medical Care</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9985">Oncology9985</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 24 September 2014 | 18:28</font><br><br><div style="margin-bottom: 10px;">Comment: The observational study, just published in <EM>clinicaltrials.<wbr>gov</EM>, started in June last year.<wbr> The objective is to document the characteristics and management of patients with mCRPC in routine clinical practice, independent of treatment used.<wbr> Only data available from routine clinical practice will be collected.<wbr> It is expected that approximately 3,000 patients will participate in this registry.<wbr> PE will measure sequencing of treatment initiation, termination, and duration.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Trial Details</FONT></STRONG> </div><div style="margin-bottom: 10px;">Ref <A href="http://clinicaltrials.gov/ct2/show/NCT02236637?recr=Open&amp;no_unk=Y&amp;phase=0123&amp;fund=2&amp;rcv_s=08%2F24%2F2014&amp;rank=164">NCT02236637</A> </div><div style="margin-bottom: 10px;">Recruitment approx.<wbr> 3000 </div><div style="margin-bottom: 10px;"><UL><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Patients with a histologically or cytologically confirmed diagnosis of adenocarcinoma of the prostate</LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Patients with documented metastatic prostate cancer</LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Patients with documented castration resistance</LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Patients either: Initiating a new systemic mCRPC treatment; or considered to be in surveillance according to clinical practice</LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Sign (or their legally-acceptable representatives must sign) a participation agreement or informed consent form (ICF), per local regulations</LI>
</UL> </div><div style="margin-bottom: 10px;"><P class="color-bullet" style="MARGIN-TOP: 0.7ex">Timelines Start date June 2013 /<wbr> Completion March 2018/<wbr>Sept2018</P> </div><div><P class="color-bullet" style="MARGIN-TOP: 0.7ex">Location: EU (165 sites)</P> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=9985">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-09-24T18:28:37+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Baxter and Merrimack Ink License Agreement to Develop and Commercialize MM-398 [news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9983</link>
<description>Baxter and Merrimack Ink License Agreement to Develop and Commercialize MM-398 [news]</description><category>news</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9983</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=9983">Baxter and Merrimack Ink License Agreement to Develop and Commercialize MM-398</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=news"><font color="#e95e0b">:Oncology:news</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9983">Oncology9983</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 24 September 2014 | 18:00</font><br><br><div style="margin-bottom: 10px;">Comment: Merrimack is preparing a NDA for patients with metastatic pancreatic cancer previously treated with gemcitabine.<wbr> The agreement gives Baxter exclusive rights for all potential indications of the drug outside the US and Taiwan.<wbr> Baxter expects to submit for regulatory approvals outside the US beginningof 2015.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Terms of the Agreement</FONT></STRONG> </div><div style="margin-bottom: 10px;">Merrimack will receive $100M upfront from Baxter, and be eligible to receive: </div><div style="margin-bottom: 10px;"><UL><LI>
$120M in regulatory milestone related to the first pancreatic cancer indications </LI>
<LI>
$280M in development and regulatory milestone payments for a second pancreatic cancer indication</LI>
<LI>
$220 million in future development and regulatory milestone payments related to two additional indications</LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">About the Drug Dev and Progress</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9983/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG>In May 2014</STRONG> Merrimack announced that the Ph3 trialn studying MM-398 in combination with 5-FU and leucoverin achieved its Primary and secondary endpoints.<wbr> </div><div>See <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=9672" class="defaultlink">Oncology9672: Merrimack Meets Primary Endpoint of OS In PhIII Metastatic Pancreatic Cancer Study</a>; <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=9807" class="defaultlink">Oncology9807: re: Merrimack Meets Primary Endpoint of OS In PhIII Metastatic Pancreatic Cancer Study</a> </div><!-- Comment details --><a name="oncology9983attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9983/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(34,8 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=9983">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-09-24T18:00:03+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9983/1/ScreenCapture1.jpg" length="35641" type="image/jpeg"/></item><item>
<title>Latest Developments In the Valeant/Allergan Takeover Battle [comp:Allergan, :PharmaWorld:sub:Acquisition]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7748</link>
<description>Latest Developments In the Valeant/Allergan Takeover Battle [comp:Allergan, :PharmaWorld:sub:Acquisition]</description><category>comp:Allergan</category><category>sub:Acquisition</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7748</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7748">Latest Developments In the Valeant/<wbr>Allergan Takeover Battle</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20141231&edate=20140901&cat=comp%3aAllergan"><font color="#e95e0b">:Neurology:comp:Allergan</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=sub%3aAcquisition"><font color="#e95e0b">:PharmaWorld:sub:Acquisition</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7748">Neurology7748</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 24 September 2014 | 17:45</font><br><br><div style="margin-bottom: 10px;">Comment: Rumours have been circulating this week that Allergan is about to 
announce the acquisition of Salix Pharmaceuticals for $10bn as a means 
of thwarting Valeant's takeover plans.<wbr> Pershing Square Capital has 
responded by threatening to sue Allergan if it proceeds with a bid without 
seeking shareholders views on Valeant's offer.<wbr> Meanwhile, Valeant's CEO has 
sent an olive branch to David Pyott in the form of a letter, providing 
new guidance on the group's expected third quarter results and 
expressing Valeant's continued willingness to negotiate a mutually agreeable 
transaction with Allergan.<wbr> </div><div style="margin-bottom: 10px;"><DIV class="copy-paste-block">
<P>Bill Ackman from Pershing Square warned Allergan's board on Tuesday 
that a Salix deal would break the Allergan board's fiduciary duty and its 
commitment to give its shareholders a vote on Valeant's hostile takeover offer 
for the company.<wbr> Ackmann stated:-</P>
<P>"We do not believe you can lawfully undertake such a transaction, 
particularly given your failure to engage with Valeant," </P><STRONG>Content of 
the letter:- </STRONG></DIV> </div><div style="margin-bottom: 10px;">Dear David, </div><div style="margin-bottom: 10px;">It has been five months since Valeant proposed a combination with Allergan 
that would create an unrivaled platform for growth and value creation in 
healthcare.<wbr> All noise aside, the arguments for combining our companies are, at 
this point, obvious and well-known.<wbr> Simply put, we can create and deliver 
extraordinary value for our both sets of our shareholders.<wbr> </div><div style="margin-bottom: 10px;">While I recognize that takeover battles can become very heated, it is 
regrettable that the tone of our public back and forth has become acrimonious at 
times.<wbr> I have not appreciated what I believe are baseless attacks on our 
business model, and I am sure there are things that have not sat well with you.<wbr> </div><div style="margin-bottom: 10px;">Last week, after much wrangling, you unconditionally agreed to hold a special 
meeting on December 18.<wbr> Given that 51 of your major stockholders owning 
approximately 39% of your company went to great lengths to request a special 
meeting, we believe that stockholders are strongly supportive of the combination 
we have proposed and we are confident about the outcome of that meeting.<wbr> We 
could be wrong, but we don't think so.<wbr> </div><div style="margin-bottom: 10px;">We are committed to this transaction.<wbr> While we would much prefer avoiding a 
three-month proxy contest, we will pursue it if we need to.<wbr> </div><div style="margin-bottom: 10px;">It may be too late, but I believe we still have an opportunity to take the 
temperature down, and come together to see if we can begin a conversation that 
could lead to even more value for your stockholders, while still being the right 
transaction for ours.<wbr> I don't see how you can properly assess our offer without 
sitting down and understanding the details of our business.<wbr> I would think that 
you, as an astute and well-respected businessman, would agree.<wbr> We are prepared 
to meet directly with you and/<wbr>or your Board to answer any questions they may 
have about our business.<wbr> And we are open to seeing any information you may have 
that would show that there is more value for your company.<wbr> </div><div style="margin-bottom: 10px;">I think your shareholders and ours would prefer to see a constructive 
discussion about value, rather than more mudslinging.<wbr> </div><div style="margin-bottom: 10px;">Please consider the olive branch extended.<wbr> I hope you will accept it.<wbr> </div><div style="margin-bottom: 10px;">Sincerely, </div><div style="margin-bottom: 10px;">J.<wbr> Michael Pearson Chairman &amp; Chief Executive Officer </div><div style="margin-bottom: 10px;">cc: Board of Directors of Allergan, Inc.<wbr> </div><div style="margin-bottom: 10px;">Sources:-<a href="http://www.stockhouse.com/news/bulletins/2014/09/23/petal-threatens-to-sue-allergan" class="defaultlink" title="http://www.stockhouse.com/news/bulletins/2014/09/23/petal-threatens-to-sue-allergan">stockhouse.com/<wbr>ne&hellip;</a> </div><div><A href="http://www.emarketsdaily.com/major-news-of-market-allergan-inc-nyseagn-carmax-inc-nysekmx-cf-industries-holdings-inc-nysecf/1818358/">http:/<wbr>/<wbr>www.<wbr>emarketsdaily.<wbr>com/<wbr>major-news-of-market-allergan-inc-nyseagn-carmax-inc-nysekmx-cf-industries-holdings-inc-nysecf/<wbr>1818358/<wbr></A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7748">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-09-24T17:45:54+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>New Results on LA-hGH Presented @ ESPE 2014 (Sept 18-20 Dublin) [class:GrowthHormone, dis:GrowthHormoneDeficiency, headline, :PharmaWorld:congress:ESPE]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7803</link>
<description>New Results on LA-hGH Presented @ ESPE 2014 (Sept 18-20 Dublin) [class:GrowthHormone, dis:GrowthHormoneDeficiency, headline, :PharmaWorld:congress:ESPE]</description><category>class:GrowthHormone</category><category>dis:GrowthHormoneDeficiency</category><category>headline</category><category>congress:ESPE</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7803</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20141231&edate=20140901&rec=7803">New Results on LA-hGH Presented @ ESPE 2014 (Sept 18-20 Dublin)</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20141231&edate=20140901&cat=class%3aGrowthHormone"><font color="#e95e0b">:Endocrinology:class:GrowthHormone</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20141231&edate=20140901&cat=dis%3aGrowthHormoneDeficiency"><font color="#e95e0b">:Endocrinology:dis:GrowthHormoneDeficiency</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20141231&edate=20140901&cat=headline"><font color="#e95e0b">:Endocrinology:headline</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=congress%3aESPE"><font color="#e95e0b">:PharmaWorld:congress:ESPE</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7803">Endocrinology7803</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 24 September 2014 | 17:09</font><br><br><div style="margin-bottom: 10px;">Comment: There are approx.<wbr> 7 LA-hGH drugs in development we are aware of, although 3 of them, Novo's NC0195-0092, OPKO/<wbr>Prolor's MOD-4023 and Versartis' VRS317, were presented during the congress.<wbr> We have noted the abscence this year of LG Life Sciences (LB03002 has been approved in the EU but not marketed, and launched in Korea; US status unclear).<wbr> Thanks to E.<wbr> Arnold and P.<wbr> Caglioni we have got interesting KOLs' views on the LA.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">LA-hGH Landscape for AGHD and PGHD</FONT></STRONG> </div><div style="margin-bottom: 10px;">The slide below represents the LA-hGH drugs in development (+ the Critical Pharm's nasal drug).<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Discussion with Oren Herskovitz from Prolor Biotech</STRONG> has outlined that the Ph3 in PGHD will be 'relatively large' regarding the number of patients as well as the locations (US; EU; Asia; LatAm, Australia).<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7803/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3" style="BACKGROUND-COLOR: #fdfd00">Interview with KOLs</FONT></STRONG> </div><div style="margin-bottom: 10px;">- Italy - "The long acting would be more appropriate for the treatment of adult patients where is not so important to respect the circadian GH trend.<wbr> In child in the most of cases is necessary to increase and adjust the doses daily or weekly and it is not possible with long acting, also the control of side effects it would be not easy .<wbr>.<wbr>.<wbr>.<wbr> currently stop drug therapy and in 2 or 3 days the sides effect recedes with long acting need more time for the washout of the drug .<wbr> Not very know the pharmacodynamics and pharmacokinetics" </div><div style="margin-bottom: 10px;">- UK - "from a KOL closely involved with safety, regarding long-acting GH.<wbr> He was very clear that long-acting was unlikely to be a player in the UK market in the foreseeable future, both from a safety and also from a pricing perspective.<wbr> Whilst he appreciated that there is some potential compliance advantage over daily GH, he was clearly not of the opinion that a weekly preparation would be worth the inevitably higher cost, and was also sceptical over the longer term safety implications of high levels of IGF-1 generated by such a preparation".<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Novo Nordisk - Once-weekly</FONT></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>Poster presentation</STRONG> - "S.<wbr>c.<wbr> Injections of a Reversible Albumin-Binding GH Derivative (NNC0195-0092) in Adult Subjects with GH Deficiency is Well Tolerated" </div><div style="margin-bottom: 10px;">Results: Multiple doses of NNC0195-0092 administered s.<wbr>c.<wbr> to AGHD subjects were well tolerated at all doses investigated, with no serious safety issues, or clinically significant local tolerability issues identified.<wbr> No positive test results for anti NNC0195-0092 antibodies or anti hGH antibodies were reported.<wbr> The reported adverse events (AE’s) were overall similar to AE’s observed in trials with daily hGH treatment and were thus well-known GH AE’s (peripheral oedema, headache, myalgia, and arthralgia).<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">OPKO/<wbr>Prolor - <FONT style="BACKGROUND-COLOR: #fdfd00">First Report</FONT> in 42 Ped Pts</FONT></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>Free Communication </STRONG>- <STRONG>Late Breaking</STRONG> Top Line results of once-weekly, CTP-modified hGH: Ph2 dose finding study in children with GHD </div><div style="margin-bottom: 10px;"><UL><LI>all doses provided excellent catch-up growth response compared to control group, and historical controls.<wbr></LI>
<LI>clean safety profile to date</LI>
<LI>no lipoatrophy</LI>
<LI>volume of &lt;/<wbr>= 0.<wbr>6ml up tp 65kg body weight, non viscous &gt; 30/<wbr>31G needle</LI>
<LI><STRONG>The value of glucose and insulin was not detailed, but Ron Rosenfeld (speaker) outlined it "was within the normal range" for the 6 mo-period.<wbr></STRONG></LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG>Selected slides of the presentation</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7803/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7803/3/ScreenCapture3.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7803/4/ScreenCapture4.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG>P1-D3-163 Poster</STRONG> "Six Months Follow-Up Pharmacokinetics and Pharmacodynamics Profile of Once-weekly, CTP-modified Human GH (MOD-4023;): phase 2 Dose Finding Study in Children with GHD Deficiency" </div><div style="margin-bottom: 10px;">Results: MOD-4023 long acting properties were confirmed in GHD children treated for more than 6 months as compared to daily hGH.<wbr> MOD-4023 demonstrated extended half-life, increased exposure and reduced clearance.<wbr> Long term monitoring of predose and trough levels indicated no accumulation of MOD-4023.<wbr> Following 6 months of MOD-4023 treatment IGF1 SDS increased gradually at a dose proportional manner with no indication for excessive levels.<wbr> As anticipated, IGFBP3 levels increased reaching the normal range but as anticipated, not at a dose sensitive manner.<wbr> </div><div style="margin-bottom: 10px;">Conclusions: MOD-4023 once-weekly injections during the first six months of treatment demonstrated an excellent PK and PD profile supporting once weekly injection in pediatric GHD population and therefore can potentially promote proper growth.<wbr> In addition, the changes observed in IGF1 and IGFBP3 demonstrate adequate stimulation of the GH–IGF1 axes which were shown to be comparable to that observed with daily hGH treatment.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>P1-D3- 164 Poster </STRONG>- "Characterization of MOD-4023 Glycosylation, a CTP Modified Long Acting GH in Advanced Clinical Stages" </div><div style="margin-bottom: 10px;">Results: Glycoprofyling analysis of different batches shows that the major O-glycan structure in MOD-4023 is mono-sialylated core 1 with a comparable site occupancy of the O-glycans in MOD-4023 between different batches.<wbr> Reproducible high levels at different GMP batches of O-glycan and sialic acid content were obtained.<wbr> The high glycosylation levels contributes to the significant increased hydrodynamic volume of MOD-4023 as compared to recombinant hGH, which results in the elongated circulating time of MOD-4023.<wbr> </div><div style="margin-bottom: 10px;">Conclusion: MOD-4023 manufacturing process is robust, producing a highly O-glycosylated product.<wbr> Based on these findings and combined with its excellent safety profile and significant prolonged GH activity MOD-4023 has the potential to replace the daily injections of hGH now required for the treatment of GH deficiency with a weekly regimen.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Discussion with Gili Hart and Oren Herskovitz (from Prolor Biotech)</STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>pharmaco-economics: a)the drug requires only approx.<wbr> 60% material compared to the 7 cumulative daily doses of regular hGH injected along one week b)simple and standard manufacturing process.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Versartis - Once-Monthly</FONT></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>Versartis already presented 6 month VRS-317 data in pediatric growth hormone (GH) deficient patients at the ENDO in June:</STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>
Efficacy: VRS-317 showed strong annualized height velocity data at 6 mos that was similar to age-matched historical controls from Pfizer’s KIGS database (Ex.<wbr> 1).<wbr> The 6 mo height velocity is slightly lower than at 3 mo (difference of ~0.<wbr>2-0.<wbr>5).<wbr> This small delta is expected given that “catch-up” growth tends to be stronger in the first 3 mos and wanes over time</LI>
<LI>
Safety: Safety is consistent with 3 mo data</LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG>Below is the poster presented at ESPE</STRONG> </div><div style="margin-bottom: 10px;"><STRONG>P1 -D3 -171 Poster</STRONG>: Safety and Efficacy Results of a <STRONG>6 Month</STRONG>, Randomized, Multi-Center Trial of a Novel Long-Acting rhGH (VRS-317) in Naı¨ve to Treatment, Pre-Pubertal Children with GH Deficiency </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7803/5/ScreenCapture5.jpg?user-agent=rss"> </div><div>Conclusions: Overall, results to date in the phase 2a clinical trial of GHD children indicate that VRS-317 has a comparable safety and efficacy profile to historical studies of daily rhGH administered at comparable doses.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20141231&edate=20140901&rec=7803">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-09-24T17:09:42+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Probi and Pharmavite Expand Probiotic Product Partnership in the US and International Markets [sub:Probiotics, :PharmaWorld:mkt:NorthAmerica]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2038</link>
<description>Probi and Pharmavite Expand Probiotic Product Partnership in the US and International Markets [sub:Probiotics, :PharmaWorld:mkt:NorthAmerica]</description><category>sub:Probiotics</category><category>mkt:NorthAmerica</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2038</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2038">Probi and Pharmavite Expand Probiotic Product Partnership in the US and International Markets</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20141231&edate=20140901&cat=sub%3aProbiotics"><font color="#e95e0b">:GastroEnterology:sub:Probiotics</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=mkt%3aNorthAmerica"><font color="#e95e0b">:PharmaWorld:mkt:NorthAmerica</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2038">GastroEnterology2038</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 24 September 2014 | 12:39</font><br><br><div style="margin-bottom: 10px;">Comment: Pharmavite and Probi have signed a new long-term agreement under which Pharmavite will broaden the distribution of Probi Digestis® capsules through additional sales channels in the US.<wbr> The companies have also signed an international agreement under which Pharmavite will launch Probi Digestis® internationally on markets where Pharmavite is currently selling the Nature Made® brand (UAE first, followed by several countries in the Middle East).<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Rationale for Pharmavite</FONT></STRONG> </div><div style="margin-bottom: 10px;">Probiotic products are an important part of Pharmavite’s strategic focus for the coming year.<wbr> Pharmavite will together with Probi expand it´s probiotic range with additional products and offerings.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Probi AB</FONT></STRONG> </div><div style="margin-bottom: 10px;"><FONT size="3"><FONT size="2">Probi’s Probi Digestis® is based on solid clinical data from a large number of clinical trials</FONT><FONT size="2">.<wbr></FONT></FONT> </div><div style="margin-bottom: 10px;"><FONT size="3"><FONT size="2"><U>Lactobacillus plantarum 299v (LP299V<SUP>®</SUP>)</U> is Probi’s best-documented bacterium.<wbr> It was isolated from healthy human colon tissue, and its health effects have been patented.<wbr> The bacterium was originally isolated during a research project in Lund in 1986.<wbr> LP299V<SUP>®</SUP> has demonstrated an ability to adhere to human epithelial cells in laboratory tests and establishes itself well in the human intestine.<wbr> More than 40 human studies have been conducted, focusing on gastrointestinal health.<wbr> For example, the ability of LP299V<SUP>®</SUP> to reduce the formation of gases in the intestines is well-documented, and was also one of the first approved health effects, which after examination by external experts, was permitted to be used as a product specific health claim.<wbr> LP299V<SUP>®</SUP> can ferment various plant materials including oats, fruit and berries.<wbr></FONT></FONT> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3"><img src="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2038/1/ScreenCapture1.jpg?user-agent=rss"></FONT></STRONG> </div><div style="margin-bottom: 10px;"><U>Recent Partnerships</U> </div><div style="margin-bottom: 10px;">In Korea with Sanofi and DongKook (<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=1966" class="defaultlink">GastroEnterology1966: Sanofi Korea to Launch Probi Digestis® for IBS</a>; <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=1956" class="defaultlink">GastroEnterology1956: DongKook to Distribute Probi's Gut Health Product in Korea</a>).<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Pharmavite Snapshot</FONT></STRONG> </div><div style="margin-bottom: 10px;">- subsidiary of the global pharmaceutical company Otsuka Pharmaceutical Ltd </div><div style="margin-bottom: 10px;">- global leader and manufacturer of dietary supplements as well as soy-based all natural snack bars.<wbr> Pharmavite produces and distributes more than 120 dietary supplement products in the U.<wbr>S.<wbr> and more than 100 internationally throughout Japan, Taiwan, Mexico, S.<wbr> Korea and Iran </div><div>- based in Northridge, California </div><!-- Comment details --><a name="gastroenterology2038attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2038/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(98,4 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2038">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-09-24T12:39:03+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2038/1/ScreenCapture1.jpg" length="100737" type="image/jpeg"/></item><item>
<title>Boehringer to Cut Up to 600 Jobs in Germany by 2016 [:GastroEnterology:news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10970</link>
<description>Boehringer to Cut Up to 600 Jobs in Germany by 2016 [:GastroEnterology:news]</description><category>news</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10970</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20141231&edate=20140901&rec=10970">Boehringer to Cut Up to 600 Jobs in Germany by 2016</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20141231&edate=20140901&cat=news"><font color="#e95e0b">:GastroEnterology:news</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10970">PharmaWorld10970</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 24 September 2014 | 11:52</font><br><br><div style="margin-bottom: 10px;">Comment: The rationale claimed by the company is a "changing competitive and market environment", with stricter reimbursement in Germany, and healthcare budget cuts in the USA (largest market for the company).<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Net Sales by Geographic Region</FONT></STRONG> </div><div style="margin-bottom: 10px;">The majority of Boehringer Ingelheim’s sales in 2013 were achieved in the Americas (46%) and Europe (30%), with around 57% of the group’s net sales generated in the USA, Japan and Germany.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10970/5/ScreenCapture5.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10970/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Best Selling products in Consumer HC</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10970/4/ScreenCapture4.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10970/3/ScreenCapture3.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">- Market Access Increasingly Difficult in Germany</FONT></STRONG> </div><div style="margin-bottom: 10px;">Recently, the company had to take the decision not to offer TRAJENTA®, for the treatment of diabetes, in Germany.<wbr> "In 2013, an added benefit of the medicine was rejected so that we would have had to place this medicine, in the meantime approved in more than 50 countries, on the German market at a price that could not be justified".<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">- Unfavourable Exchange Rate Development in the US</FONT></STRONG> </div><div>BI’s half-year sales had dropped 8% to 6.<wbr>5 billion euros, primarily because of currency effects and price reductions in the US.<wbr> </div><!-- Comment details --><a name="pharmaworld10970attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10970/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(3,6 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10970/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(22,7 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10970/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(13,4 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10970/4/ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(2,6 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10970/5/ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(21,6 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20141231&edate=20140901&rec=10970">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-09-24T11:52:44+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10970/1/ScreenCapture1.jpg" length="3724" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10970/2/ScreenCapture2.jpg" length="23293" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10970/3/ScreenCapture3.jpg" length="13731" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10970/4/ScreenCapture4.jpg" length="2633" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10970/5/ScreenCapture5.jpg" length="22089" type="image/jpeg"/></item><item>
<title>Hikma Opens New API facility In Jordan To Support Its Oncology Pipeline [:PharmaWorld:func:MSO, class:Antihormonals]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9982</link>
<description>Hikma Opens New API facility In Jordan To Support Its Oncology Pipeline [:PharmaWorld:func:MSO, class:Antihormonals]</description><category>func:MSO</category><category>class:Antihormonals</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9982</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=9982">Hikma Opens New API facility In Jordan To Support Its Oncology Pipeline</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=class%3aAntihormonals"><font color="#e95e0b">:Oncology:class:Antihormonals</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=func%3aMSO"><font color="#e95e0b">:PharmaWorld:func:MSO</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9982">Oncology9982</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 23 September 2014 | 18:39</font><br><br><div style="margin-bottom: 10px;">Comment: The new faciilty is located in Amman Jordan and represents an 
extension to an existing API site  adjacent to the company's headquarters.<wbr> 
Hikma is a company to monitor because of its  focus on sterile 
oncology injectables and its relationship with Spanish company GP Pharm 
covering <SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'; LINE-HEIGHT: 115%">Lutrate® 
1 month</SPAN>.<wbr> </div><div style="margin-bottom: 10px;">It currently has <FONT face="Arial">a license and supply agreement 
for the registration and marketing of </FONT><SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'; LINE-HEIGHT: 115%">Lutrate® 
1 month, </SPAN><SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'; LINE-HEIGHT: 115%">for 
the Middle East and North Africa (“MENA”) region</SPAN> Germany &amp; Portugal 
and the potential to become GP Pharm's partner for its 3M &amp; 6M 
formulations.<wbr> </div><div style="margin-bottom: 10px;">The group claims to have 5 oncology APIs in its development pipeline  
The firm recently rebuffed offers from Amgen and Novartis to sell its 
sterile injectable business and in May  concluded the purchase of 
Ben Venue Labs in the US for $300m.<wbr><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9982/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9982/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9982/3/ScreenCapture3.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9982/4/ScreenCapture4.jpg?user-agent=rss"> </div><div><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9982/5/ScreenCapture5.jpg?user-agent=rss"> </div><!-- Comment details --><a name="oncology9982attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9982/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(111 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9982/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(133,1 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9982/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(191,3 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9982/4/ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(192,9 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9982/5/ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(146,1 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=9982">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-09-23T18:39:43+02:00</dc:date><dc:creator>jac89886</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9982/1/ScreenCapture1.jpg" length="113668" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9982/2/ScreenCapture2.jpg" length="136308" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9982/3/ScreenCapture3.jpg" length="195843" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9982/4/ScreenCapture4.jpg" length="197551" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9982/5/ScreenCapture5.jpg" length="149562" type="image/jpeg"/></item><item>
<title>Allergan to Assess the Doses of BOTOX® and Xeomin® in Clincal Practice in Mexico [comp:Allergan, prod:Botox, prod:Xeomin, dis:Dystonia, :PharmaWorld:mkt:Mexico, :PharmaWorld:sub:ClinicalTrial]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7745</link>
<description>Allergan to Assess the Doses of BOTOX® and Xeomin® in Clincal Practice in Mexico [comp:Allergan, prod:Botox, prod:Xeomin, dis:Dystonia, :PharmaWorld:mkt:Mexico, :PharmaWorld:sub:ClinicalTrial]</description><category>comp:Allergan</category><category>prod:Botox</category><category>prod:Xeomin</category><category>dis:Dystonia</category><category>mkt:Mexico</category><category>sub:ClinicalTrial</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7745</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7745">Allergan to Assess the Doses of BOTOX® and Xeomin® in Clincal Practice in Mexico</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20141231&edate=20140901&cat=comp%3aAllergan"><font color="#e95e0b">:Neurology:comp:Allergan</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20141231&edate=20140901&cat=dis%3aDystonia"><font color="#e95e0b">:Neurology:dis:Dystonia</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20141231&edate=20140901&cat=prod%3aBotox"><font color="#e95e0b">:Neurology:prod:Botox</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20141231&edate=20140901&cat=prod%3aXeomin"><font color="#e95e0b">:Neurology:prod:Xeomin</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=mkt%3aMexico"><font color="#e95e0b">:PharmaWorld:mkt:Mexico</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=sub%3aClinicalTrial"><font color="#e95e0b">:PharmaWorld:sub:ClinicalTrial</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7745">Neurology7745</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 23 September 2014 | 17:54</font><br><br><div style="margin-bottom: 10px;">Comment: The study is a retrospective chart review to evaluate both drugs for the treatment of Cervical Dystonia and Blepharospasm in clinical practice.<wbr> PE will measure dose of botulinum toxin used to treat CD and BPS.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Trial Details</FONT></STRONG> </div><div style="margin-bottom: 10px;">Ref <A href="http://clinicaltrials.gov/ct2/show/study/NCT02245958?recr=Open&amp;no_unk=Y&amp;phase=0123&amp;fund=2&amp;rcv_s=08%2F23%2F2014&amp;rank=146#contacts">NCT02245958</A> </div><div style="margin-bottom: 10px;">Recruitment approx 230 (both genders 18 years and older) </div><div style="margin-bottom: 10px;"><BLOCKQUOTE dir="ltr" style="MARGIN-RIGHT: 0px">
<P class="color-bullet" style="MARGIN-TOP: 0.7ex">Confirmed primary diagnosis of idiopathic cervical dystonia or blepharospasm for at least 2 years</P>
<P class="color-bullet" style="MARGIN-TOP: 0.7ex">Treatment with Xeomin® and BOTOX® for at least 2 years each.<wbr></P></BLOCKQUOTE> </div><div style="margin-bottom: 10px;"><P class="color-bullet" style="MARGIN-TOP: 0.7ex">Timelines Ph4 trial to start Oct 2014 and complete March 2015</P> </div><div>Location Mexico </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7745">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-09-23T17:54:45+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>re: 4d Pharma Progresses with New Treatment for IBS and Crohn</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2036</link>
<description>re: 4d Pharma Progresses with New Treatment for IBS and Crohn</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2036</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2036">re: 4d Pharma Progresses with New Treatment for IBS and Crohn</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2036">GastroEnterology2036</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 23 September 2014 | 17:39</font><br><br><div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">4d Pharma Progresses with New Treatment for IBS and Crohn</span>&nbsp;<font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20141231&edate=20140901&cat=dis%3aIBD"><font color="#e95e0b">:GastroEnterology:dis:IBD</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20141231&edate=20140901&cat=dis%3aIBS"><font color="#e95e0b">:GastroEnterology:dis:IBS</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20141231&edate=20140901&cat=headline"><font color="#e95e0b">:GastroEnterology:headline</font></a>]</font></font><br><span style="font-size: 12px;">Comment: The company has reported its "live biotherapeutics", Blautix for IBS and Thetanix for ped CD, are set to enter clinical studies in Q2:15.<wbr> On Aug.<wbr> 7th, Rosburix, its UC drug for ped patients won orphan drug designation from the FDA.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2019">...</a><br><font size="-1">Brigitte DESCHAMPS / <a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2019" class="commentpermalink">GastroEnterology2019</a> / <span class="date">03 September 2014</span> /
<span class="time">11:35:37 o'clock CEST</span>
</font></div><div style="margin-bottom: 10px;">On Sept 23, 4D Pharma posted a pretax loss in its maiden half-year results as its costs offset revenue for the period.<wbr> The company, which is focusing on developing a range of projects targeting new therapeutic areas, said its pretax loss in the six months to June 30 was GBP501,000, with no comparative figures as the company only  incorporated in January 2014.<wbr> </div><div>Revenue in the period was GBP116,000, which was offset by GBP130,000 in product development costs and GBP507,000 in administrative expenses.<wbr> </div><!-- Comment details --><font size="-1">Brigitte DESCHAMPS / <a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2036" class="commentpermalink">GastroEnterology2036</a> / <span class="date">23 September 2014</span> /
<span class="time">17:39:06 o'clock CEST</span>
</font><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2036">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2019">View thread  GastroEnterology2019: 4d Pharma Progresses with New Treatment for IBS and Crohn</a>]]></content:encoded><dc:date>2014-09-23T17:39:06+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Deep Brain Stimulation Device Approved in EU for Essential Tremor (ET) [dis:Parkinson, dis:Dystonia, :PharmaWorld:sub:Devices, :PharmaWorld:mkt:Europe]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7744</link>
<description>Deep Brain Stimulation Device Approved in EU for Essential Tremor (ET) [dis:Parkinson, dis:Dystonia, :PharmaWorld:sub:Devices, :PharmaWorld:mkt:Europe]</description><category>dis:Parkinson</category><category>dis:Dystonia</category><category>sub:Devices</category><category>mkt:Europe</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7744</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7744">Deep Brain Stimulation Device Approved in EU for Essential Tremor (ET)</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20141231&edate=20140901&cat=dis%3aDystonia"><font color="#e95e0b">:Neurology:dis:Dystonia</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20141231&edate=20140901&cat=dis%3aParkinson"><font color="#e95e0b">:Neurology:dis:Parkinson</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=mkt%3aEurope"><font color="#e95e0b">:PharmaWorld:mkt:Europe</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=sub%3aDevices"><font color="#e95e0b">:PharmaWorld:sub:Devices</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7744">Neurology7744</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 23 September 2014 | 17:30</font><br><br><div style="margin-bottom: 10px;">Comment: Boston Scientific has received CE Mark for Vercise™ Deep Brain Stimulation for the treatment of essential tremor (ET).<wbr> One of the first commercial implantations of the system was performed at the U.<wbr> Hospital Cologne, Germany, by a team of physicians, led by Prof.<wbr> Dr.<wbr> Veerle Visser Vandewalle, Head of the Department of Stereotaxy and Functional Neurosurgery, and Prof.<wbr> Dr.<wbr> Lars Timmermann, neurologist and professor of Neurological Movement Disorders.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">EU Status</FONT></STRONG> </div><div style="margin-bottom: 10px;">2012 - The Vercise DBS System obtained both CE Mark and TGA (Australia Therapeutic Goods Administration) approval for the treatment of Parkinson's disease.<wbr> </div><div style="margin-bottom: 10px;">2013 - It obtained CE Mark for intractable primary and secondary dystonia, and is available for sale in Europe, Israel, Australia and select countries in Latin America </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Device Design &amp; Features</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7744/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">- therapy can be adjusted precisely to target patients' anatomies and needs.<wbr> </div><div style="margin-bottom: 10px;">- 25-year battery life </div><div style="margin-bottom: 10px;">- features multiple independent current control, which gives clinicians the ability to control stimulation precisely for a neural target to help minimize unwanted side effects.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Status in the US</STRONG> </div><div style="margin-bottom: 10px;">- currently undergoing a clinical trial for treating Parkinson's </div><div style="margin-bottom: 10px;">The INTREPID clinical trial began enrollment in the U.<wbr>S.<wbr> in mid-2013 to evaluate the safety and effectiveness of the Vercise DBS System for the treatment of Parkinson's disease.<wbr> </div><div>Source: Boston Scientific </div><!-- Comment details --><a name="neurology7744attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7744/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(22,2 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7744">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-09-23T17:30:00+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7744/1/ScreenCapture1.jpg" length="22710" type="image/jpeg"/></item><item>
<title>US Government Steps-In To Prevent Tax Inversion Deals [sub:Finance]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10968</link>
<description>US Government Steps-In To Prevent Tax Inversion Deals [sub:Finance]</description><category>sub:Finance</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10968</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20141231&edate=20140901&rec=10968">US Government Steps-In To Prevent Tax Inversion Deals</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=sub%3aFinance"><font color="#e95e0b">:PharmaWorld:sub:Finance</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10968">PharmaWorld10968</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 23 September 2014 | 14:58</font><br><br><div style="margin-bottom: 10px;">Comment: Shares in AstraZeneca and Shire fell sharply yesterday as the US 
treasury took immediate action to curb tax inversion deals, effectively 
preventing Pfizer from making another attempt to acquire AZ based on such 
financial engineering.<wbr> </div><div style="margin-bottom: 10px;">Steps taken on Monday by the US treasury were more far-reaching than had 
been anticipated and are effective immediately.<wbr> The key elements of 
the new legislation is as follows :- </div><div style="margin-bottom: 10px;">i) a tightening of the limits on the level of ownership that former US owners 
can have in an inverted company to qualify for foreign tax treatment from the 
IRS.<wbr> </div><div style="margin-bottom: 10px;">ii) rules that will prevent inverted companies from using "hopscotch" loans 
that allow them to avoid dividend taxes when tapping such tax-deffered foriegn 
profiles or gain access to the same kind of profits by using "decontrolling" 
strategies that restructure foreign units so they are no longer 
US-controlled.<wbr> </div><div style="margin-bottom: 10px;">Whilst there is a belief that the Abbvie Shire deal may still  
go-ahead there is a lot more scepticism about Pfizer trying to re-launch its bid 
for AZ in November when the 6-month cooling off period expires.<wbr> </div><div style="margin-bottom: 10px;">Eight companies in total have or are about to benefit from tax 
inversion over the last two years including, Salix, Mallinckrodt, 
Actavis , Medtronic, Perrigo, Questor, Endo Health Soloutions and Abbvie.<wbr> </div><div>Source: Reuters </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20141231&edate=20140901&rec=10968">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-09-23T14:58:47+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>RedHill to Showcase at Europe Forum for Global Partnering and Investment (Sept30-Oct1 Basel) [dis:Diarrhoea, dis:IBS, :PharmaWorld:func:BusDev]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2035</link>
<description>RedHill to Showcase at Europe Forum for Global Partnering and Investment (Sept30-Oct1 Basel) [dis:Diarrhoea, dis:IBS, :PharmaWorld:func:BusDev]</description><category>dis:Diarrhoea</category><category>dis:IBS</category><category>func:BusDev</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2035</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2035">RedHill to Showcase at Europe Forum for Global Partnering and Investment (Sept30-Oct1 Basel)</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20141231&edate=20140901&cat=dis%3aDiarrhoea"><font color="#e95e0b">:GastroEnterology:dis:Diarrhoea</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20141231&edate=20140901&cat=dis%3aIBS"><font color="#e95e0b">:GastroEnterology:dis:IBS</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=func%3aBusDev"><font color="#e95e0b">:PharmaWorld:func:BusDev</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2035">GastroEnterology2035</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 23 September 2014 | 12:51</font><br><br><div style="margin-bottom: 10px;">Comment: RedHill business model is to commercialize through partnerships.<wbr> The Israeli company's pipeline lists two late clinical stage drugs for Corhn's disease (patent-protected combo of 3 antibiotics drugs) and gastroenteritis (once-daily CR tablet formulationof odansetron).<wbr> Recently it out-licensed the first encapsultated bowel cleanser to Salix for $7M upfront and $5M milestones.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">RHB-104 for Crohn's</FONT></STRONG> </div><div style="margin-bottom: 10px;">- Ph3 initiated in Sept 30 2013; n=240; locations &gt;90 sites (US; Canada; Israel and other countries); PE state of remission at wk26.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2035/3/ScreenCapture3.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">In October 2013, RHB-104 Ped Study results were presented at ACG </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2035/4/ScreenCapture4.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG>Milestones</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2035/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">RHB-102 for Gastroenteritis</FONT></STRONG> </div><div style="margin-bottom: 10px;">Ph3 planned to start in sept 2014 n=320 adults/<wbr>children; locations (&gt;10 sites in the US); PE the abscence of vomiting after 30mn after the 1st dose through the discharge from the emergency department.<wbr> (<A href="http://clinicaltrials.gov/ct2/show/NCT02246439?recr=Open&amp;no_unk=Y&amp;phase=0123&amp;fund=2&amp;rcv_s=08%2F23%2F2014&amp;rank=49">NCT02246439</A>) </div><div style="margin-bottom: 10px;"><STRONG>Milestones</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2035/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Business Development</FONT></STRONG> </div><div>See <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=9501" class="defaultlink">Oncology9501: Salix In-licenses 1st Encapsulated Bowel Cleanser</a>.<wbr> </div><!-- Comment details --><a name="gastroenterology2035attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2035/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(13,3 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2035/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(19,3 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2035/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(73,1 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2035/4/ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(88,1 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2035">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-09-23T12:51:37+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2035/1/ScreenCapture1.jpg" length="13614" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2035/2/ScreenCapture2.jpg" length="19724" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2035/3/ScreenCapture3.jpg" length="74840" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2035/4/ScreenCapture4.jpg" length="90176" type="image/jpeg"/></item><item>
<title>Novartis Publishes Data Demonstrating Panobinostat Offers A 4-month PFS Benefit In Multiple Myeloma [news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9979</link>
<description>Novartis Publishes Data Demonstrating Panobinostat Offers A 4-month PFS Benefit In Multiple Myeloma [news]</description><category>news</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9979</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=9979">Novartis Publishes Data Demonstrating Panobinostat Offers A 4-month PFS Benefit In Multiple Myeloma</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=news"><font color="#e95e0b">:Oncology:news</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9979">Oncology9979</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 22 September 2014 | 17:57</font><br><br><div style="margin-bottom: 10px;">Comment: Data published in the Lancet Oncology highlgihts how the pan-DAC inhibitor LBH589 (panobinostat) can help to extend the benefit of standard of care therapy for patients with relapsed/<wbr>refractory multiple myeloma.<wbr> The PANORAMA-1 trial is the first phIII trial to demonstrate the superiority of three-drugs over the current two-drug combination (bortezomib and dexamethasone).<wbr> </div><div style="margin-bottom: 10px;">The triple drug combination demonstrated a 4-month improvement in median progression-free survival (HR=0.<wbr>63), The addition of LBH589 led to a clinically meaningful increase in complet and near complete response rates and duration of response.<wbr> across all patient sub-groups.<wbr> </div><div style="margin-bottom: 10px;">Based on the PANORAMA-1 data, LBH has been granted priority review by the US FDA and a regulatory submission has been submitted to the EMA.<wbr> </div><div>Source: <A href="http://www.novartis.com">www.<wbr>novartis.<wbr>com</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=9979">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-09-22T17:57:05+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>Bifidobacterium lactis HN109 Tested in Constipation [dis:Constipation, sub:Probiotics, :PharmaWorld:mkt:France, :PharmaWorld:sub:ClinicalTrial]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2034</link>
<description>Bifidobacterium lactis HN109 Tested in Constipation [dis:Constipation, sub:Probiotics, :PharmaWorld:mkt:France, :PharmaWorld:sub:ClinicalTrial]</description><category>dis:Constipation</category><category>sub:Probiotics</category><category>mkt:France</category><category>sub:ClinicalTrial</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2034</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2034">Bifidobacterium lactis HN109 Tested in Constipation</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20141231&edate=20140901&cat=dis%3aConstipation"><font color="#e95e0b">:GastroEnterology:dis:Constipation</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20141231&edate=20140901&cat=sub%3aProbiotics"><font color="#e95e0b">:GastroEnterology:sub:Probiotics</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=mkt%3aFrance"><font color="#e95e0b">:PharmaWorld:mkt:France</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=sub%3aClinicalTrial"><font color="#e95e0b">:PharmaWorld:sub:ClinicalTrial</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2034">GastroEnterology2034</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 22 September 2014 | 16:37</font><br><br><div style="margin-bottom: 10px;">Comment: Sponsored by Danisco Sweeteners Oy, the POC trial will evaluate the effects of 4-week <EM>Bifidobacterium-lactis HN019</EM> supplementation on colonic transit time (primary endpoint) in approx.<wbr> 228 participants.<wbr> Eurofins Optimed will ensure the recruitment of the participants.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Trial Details</FONT></STRONG> </div><div style="margin-bottom: 10px;"><U>Reference</U> <A href="http://clinicaltrials.gov/ct2/show/NCT02189707?term=probiotics&amp;recr=Open&amp;no_unk=Y&amp;fund=2&amp;rank=7&amp;submit_fld_opt=">NCT02189707</A> </div><div style="margin-bottom: 10px;"><U>Timelines</U> from Aug 2014 (but not yet open for participant recruitment) to Feb 2015 /<wbr> March 2015 </div><div style="margin-bottom: 10px;"><U>Recruitment</U> approx 228 </div><div style="margin-bottom: 10px;"><UL><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Age 18 to 70 years</LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">2.<wbr>Body mass index between 18.<wbr>5 and 34.<wbr>9 kg/<wbr>m2</LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">
3.<wbr> Meets the Rome III criteria for functional constipation as follows: (Criteria fulfilled for the last 3 months with symptom onset at least 6 months prior to diagnosis):</LI>
</UL> </div><div><UL style="MARGIN-BOTTOM: 1ex; MARGIN-TOP: 1ex"><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">
Must meet 2 or more of the following criteria:
<UL style="MARGIN-BOTTOM: 1ex; MARGIN-TOP: 1ex"><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Straining during at least 25% of defecations</LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Lumpy or hard stools in at least 25% of defecations</LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Sensation of incomplete evacuation for at least 25% of defecations</LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Sensation of anorectal obstruction/<wbr>blockage for at least 25% of defecations+ Manual maneuvers to facilitate at least 25% of defecations (e.<wbr>g.<wbr>, digital evacuation, support of the pelvic floor)</LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Fewer than three defecations per week</LI>
</UL></LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Loose stools are rarely present without the use of laxatives</LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Insufficient criteria for irritable bowel syndrome</LI>
</UL> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2034">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-09-22T16:37:47+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Highlights from a New Report On Probiotics Markets [sub:Probiotics]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2032</link>
<description>Highlights from a New Report On Probiotics Markets [sub:Probiotics]</description><category>sub:Probiotics</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2032</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2032">Highlights from a New Report On Probiotics Markets</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20141231&edate=20140901&cat=sub%3aProbiotics"><font color="#e95e0b">:GastroEnterology:sub:Probiotics</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2032">GastroEnterology2032</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 22 September 2014 | 14:13</font><br><br><div style="margin-bottom: 10px;">Comment: The global market for probiotics is expected to reach $52.<wbr>34bln by 2020.<wbr> The report highlights a highly fragmented market, with top5 participants catering over 35% of the total demand.<wbr> Suggestions and key findings from the report are provided below.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Key Findings from the Report</FONT></STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>The probiotic market is stil lat a relatively novice stage.<wbr></LI>
<LI>Lack of clarity on usage patterns among consumers.<wbr></LI>
<LI>Labeling regulations, especially in the U.<wbr>S.<wbr> and European Union, are expected to have significant impact on market growth.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><U>Food &amp; beverages</U> dominated the application market and accounted for over 80% of the total probiotics market.<wbr> </div><div style="margin-bottom: 10px;"><U>Dietary supplements</U> are expected to be the fastest growing application segment, at an estimated CAGR of 7.<wbr>7% from 2012 to 2020.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2032/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><U>Asia Pacific</U> emerged as most dominant regional market, owing to the fact that the concept started in Japan, accounting for over 50% of the total market share in Asia Pacific.<wbr> Asia Pacific is also expected to be the fastest growing market, at an estimated CAGR of 7.<wbr>7% from 2012 to 2020 </div><div style="margin-bottom: 10px;"><U>Actors</U> </div><div style="margin-bottom: 10px;">Danone accounted for over 10% of the overall market share for probiotics, followed by Yakult, Nestle, Chr Hansen, and Danisco.<wbr> Other participants include Arla Foods, BioGaia Biologics AB, General Mills Inc.<wbr>, Probi AB, Mnm View, Mother Dairy Food Processing, Lifeway Foods Inc.<wbr>, Institute Rosell, E.<wbr> I.<wbr> DuPont, Royal Dsm N.<wbr>V, ConAgra and Nebraska Cultures Inc.<wbr> </div><div style="margin-bottom: 10px;"><P style="TEXT-ALIGN: justify"><SPAN style="TEXT-DECORATION: underline"><FONT size="3"><STRONG>Key questions answered by the report</STRONG></FONT></SPAN></P> </div><div style="margin-bottom: 10px;"><UL style="TEXT-ALIGN: justify"><LI>What was the size of the probiotics market in 2013; what are the expected growth trends and market forecast for 2014 to 2020</LI>
<LI>Which companies were the leaders in 2013, what are their current products and what are the strategic initiatives taken by them</LI>
<LI>What opportunities are available to these and other contenders in this space</LI>
<LI>What are the barriers and opportunities in the probiotics market</LI>
<LI>Which were the top-performing applications segments in 2013? How will these segments perform in 2020</LI>
<LI>Which were the top-performing end-use segments in 2013? How will these segments perform in 2020</LI>
<LI>Which were the top-performing bacteria segments in 2013? How will these segments perform in 2020</LI>
<LI>Which were the top-performing regional markets in 2013? How will these markets perform in 2020</LI>
</UL> </div><div><STRONG><FONT size="3">To purchase the report please click here</FONT></STRONG> : <A href="http://www.grandviewresearch.com/industry-analysis/probiotics-market">http:/<wbr>/<wbr>www.<wbr>grandviewresearch.<wbr>com/<wbr>industry-analysis/<wbr>probiotics-market</A> </div><!-- Comment details --><a name="gastroenterology2032attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2032/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(36,7 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2032">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-09-22T14:13:47+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2032/1/ScreenCapture1.jpg" length="37621" type="image/jpeg"/></item><item>
<title>Takeda Announces Plans to Redesign its Global Organization Structure [comp:Takeda]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9977</link>
<description>Takeda Announces Plans to Redesign its Global Organization Structure [comp:Takeda]</description><category>comp:Takeda</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9977</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=9977">Takeda Announces Plans to Redesign its Global Organization Structure</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=comp%3aTakeda"><font color="#e95e0b">:Oncology:comp:Takeda</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9977">Oncology9977</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 22 September 2014 | 13:49</font><br><br><div style="margin-bottom: 10px;">Comment: The company's objective is to become a more agile, best-in-class pharma company with both a patient and customer focus.<wbr> Five Regional Business Units and two Specialty Business Units will be established.<wbr> The R&amp;D organization will be simplified with four Therapeutic Area Units.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">New Global Organization</FONT></STRONG> </div><div style="margin-bottom: 10px;">Please see <A href="http://www.takeda.com/news/files/orgcahrt20140916_en.png">http:/<wbr>/<wbr>www.<wbr>takeda.<wbr>com/<wbr>news/<wbr>files/<wbr>orgcahrt20140916_en.<wbr>png</A> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">About the 5 Regional BUs</FONT></STRONG> </div><div style="margin-bottom: 10px;"><P dir="ltr" style="MARGIN-RIGHT: 0px">- the Japan Pharma Business Unit, the US Business Unit, the EUCAN Business Unit (Europe and Canada), the Emerging Markets Business Unit, and the Japan Consumer Healthcare Business Unit.<wbr> </P> </div><div style="margin-bottom: 10px;"><BLOCKQUOTE dir="ltr" style="MARGIN-RIGHT: 0px">
<P dir="ltr" style="MARGIN-RIGHT: 0px"><U>Objectives</U>: <SPAN style="LINE-HEIGHT: 1.3">Each Business Unit will promote business within their responsible countries and regions, strengthen essential functions, and firmly establish business operations with high degree of specialization that allows them to realize patient and customer centricity.<wbr><BR></SPAN></P></BLOCKQUOTE> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">About the 2 Specialty BUs</FONT></STRONG> </div><div style="margin-bottom: 10px;">- Oncology and Vaccines </div><div style="margin-bottom: 10px;"><BLOCKQUOTE dir="ltr" style="MARGIN-RIGHT: 0px">
<P><U>Objectives</U>: to accelerate the globalization of specialty businesses.<wbr></P></BLOCKQUOTE> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">About the 4 Therapeutic Area Units (TAU)</FONT></STRONG> </div><div style="margin-bottom: 10px;"><SPAN style="LINE-HEIGHT: 1.3">- Central Nervous System (CNS), Cardiovascular and Metabolic (CVM), Gastroenterology (GI), and Oncology.<wbr> </SPAN> </div><div style="margin-bottom: 10px;"><BLOCKQUOTE dir="ltr" style="MARGIN-RIGHT: 0px">
<UL><LI>Current research in the Immunology area will be integrated into the CNS TAU.<wbr> </LI>
<LI>Current research in the Respiratory area will be integrated into the CVM TAU.<wbr></LI>
</UL></BLOCKQUOTE> </div><div style="margin-bottom: 10px;">Global Medical Office and Global Development Operations will support the above four TAUs.<wbr> </div><div><EM>Source: </EM><A href="http://www.takeda.com/news/2014/20140916_6750.html"><EM>http:/<wbr>/<wbr>www.<wbr>takeda.<wbr>com/<wbr>news/<wbr>2014/<wbr>20140916_6750.<wbr>html</EM></A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=9977">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-09-22T13:49:11+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Interim Results from a 4-Year Combination Therapy of GH and GnRHa Presented at ESPE Congress [:PharmaWorld:congress:ESPE, class:GrowthHormone]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7802</link>
<description>Interim Results from a 4-Year Combination Therapy of GH and GnRHa Presented at ESPE Congress [:PharmaWorld:congress:ESPE, class:GrowthHormone]</description><category>congress:ESPE</category><category>class:GrowthHormone</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7802</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20141231&edate=20140901&rec=7802">Interim Results from a 4-Year Combination Therapy of GH and GnRHa Presented at ESPE Congress</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20141231&edate=20140901&cat=class%3aGrowthHormone"><font color="#e95e0b">:Endocrinology:class:GrowthHormone</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=congress%3aESPE"><font color="#e95e0b">:PharmaWorld:congress:ESPE</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7802">Endocrinology7802</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 22 September 2014 | 13:30</font><br><br><div style="margin-bottom: 10px;">Comment: Ferring provided free Zomacton and Decapeptyl 3.<wbr>75mg drugs for the ZOMATRIP Ph4 study, sponsored by the Belgian Study Group for Pediatric Endocrinology.<wbr> Participants include 18 girls (age 8-13).<wbr> The interim results show that the combination was safe, and significantly increased height (7.<wbr>2 cm or 1.<wbr>2 SDS) above the predicted adult height after the treatment phase (primary outcome measures).<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Interim Results</FONT></STRONG> </div><div style="margin-bottom: 10px;">In the PP group, height (meanGS.<wbr>D.<wbr>) increased from 130.<wbr>9G4.<wbr>0 cm to 154.<wbr>8G4.<wbr>7 cm so that height at the end of treatment surpassed their initial predicted height by 7.<wbr>2G3.<wbr>9.<wbr> </div><div style="margin-bottom: 10px;">Bone age progressed by 2.<wbr>4G0.<wbr>5 from 10.<wbr>4 G0.<wbr>6 to 12.<wbr>8G0.<wbr>6 years.<wbr> </div><div style="margin-bottom: 10px;">Final height prediction after 4 years of treatment (161.<wbr>8G5.<wbr>1 cm) increased by 15.<wbr>1 cm compared to the prediction at the start of treatment (147.<wbr>6G2.<wbr>0 cm).<wbr> </div><div style="margin-bottom: 10px;">Adverse events were restricted to injection site reactions (pain, bruising, and scarring) and common health problems for this age group.<wbr> </div><div style="margin-bottom: 10px;">Mean IGF1 levels rose from 316G124 to 695G264 ng/<wbr>ml (after 3 years of treatment).<wbr> </div><div style="margin-bottom: 10px;">Fasting insulin levels increased 2.<wbr>5-fold but fasting glucose and HbA1c levels remained within the normal range.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Please see poster attached</STRONG> <a href="http://ci.beaufour-ipsen.com/traction?type=np&proj=*&sdate=20141231&edate=20140901&rs=/link%20Endocrinology7802%401" class="defaultlink">@1</a> </div><div style="margin-bottom: 10px;"><STRONG>About the Trial</STRONG> - <A href="http://clinicaltrials.gov/ct2/show/NCT00840944?term=NCT00840944&amp;rank=1">NCT00840944</A> - Efficacy and Safety of a 4 Year Combination Therapy of Growth Hormone and Gonadotropin- Releasing Hormone Agonist in Children With a Short Predicted Height </div><div><EM>Source: ESPE</EM> </div><!-- Comment details --><a name="endocrinology7802attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7802/1/ZOMATRIP%5fESPE2014.JPG">ZOMATRIP_ESPE2014.JPG</a>&nbsp;&nbsp;(3 MB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20141231&edate=20140901&rec=7802">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-09-22T13:30:42+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7802/1/ZOMATRIP%5fESPE2014.JPG" length="3195018" type="image/jpeg"/></item><item>
<title>Nobelpharma and SRI Partner on Endometriosis Drug Development [dis:Gynea]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9976</link>
<description>Nobelpharma and SRI Partner on Endometriosis Drug Development [dis:Gynea]</description><category>dis:Gynea</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9976</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=9976">Nobelpharma and SRI Partner on Endometriosis Drug Development</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=dis%3aGynea"><font color="#e95e0b">:Oncology:dis:Gynea</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9976">Oncology9976</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 22 September 2014 | 11:26</font><br><br><div style="margin-bottom: 10px;">Comment: The companies have entered into a licensing agreement to test SRI's oral selective estrogen receptor modulators (SERMs).<wbr> SRI claims the drug has the potential to address the disease's underlying cause.<wbr> The drug highest status is Ph2 for metastatic breast cancer.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Nobelpharma Responsibilities</FONT></STRONG> </div><div style="margin-bottom: 10px;">Nobelpharma hopes to advance the drug into clinical trials in Japan once the upcoming preliminary studies are completed.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Nobelpharma Snapshot</STRONG> </div><div style="margin-bottom: 10px;"><U>Objective</U>: to develop existing medicines for unmet needs that other pharmaceutical companies do not develop.<wbr> </div><div style="margin-bottom: 10px;"><U>Pipeline</U> (as of August 2013) </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9976/1/ScreenCapture1.jpg?user-agent=rss"> </div><div>Source: Nobelpharma; SRI International </div><!-- Comment details --><a name="oncology9976attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9976/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(81 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=9976">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-09-22T11:26:40+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9976/1/ScreenCapture1.jpg" length="82955" type="image/jpeg"/></item><item>
<title>Merck Serono to Expand its General Medicines Portfolio in Emerging Markets [:Endocrinology:comp:MerckSerono]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10964</link>
<description>Merck Serono to Expand its General Medicines Portfolio in Emerging Markets [:Endocrinology:comp:MerckSerono]</description><category>comp:MerckSerono</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10964</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20141231&edate=20140901&rec=10964">Merck Serono to Expand its General Medicines Portfolio in Emerging Markets</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20141231&edate=20140901&cat=comp%3aMerckSerono"><font color="#e95e0b">:Endocrinology:comp:MerckSerono</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10964">PharmaWorld10964</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 22 September 2014 | 10:22</font><br><br><div style="margin-bottom: 10px;">Comment: The company has announced a strategic partnership with Lupin.<wbr> The agreement builds on an established working relationship between the two companies, and could add up to 20 new products to the current portfolio.<wbr> The first launches are expected in 2016.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Rationale for Merck serono</FONT></STRONG> </div><div style="margin-bottom: 10px;">- Sales in the emerging markets are one of the key growth drivers for Merck Serono amounting to approx.<wbr> €1.<wbr>8 billion in 2013.<wbr> </div><div style="margin-bottom: 10px;">- Merck Serono will expand its overall portfolio in core therapeutic areas of Merck Serono´s General Medicine &amp; Endocrinology franchise in selected countries in Latin America, Asia, Central Eastern Europe, and Africa.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Territories Covered by the Collaboration</FONT></STRONG> </div><div style="margin-bottom: 10px;">- covers major markets such as Brazil, Mexico, Indonesia, Philippines alongside several countries in Africa and Central Eastern Europe as well as other countries in emerging markets, focusing on cardiovascular and diabetes diseases.<wbr> </div><div style="margin-bottom: 10px;">- In Africa, medicines will also be supplied for additional therapeutic areas, reflecting local healthcare needs such as availability of antibiotics.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Terms of the Collaboration</FONT></STRONG> </div><div style="margin-bottom: 10px;">- Lupin will develop products, provide product dossiers and supply finished products to Merck Serono.<wbr> </div><div style="margin-bottom: 10px;">- Merck Serono will be the marketing authorization holder for the products, and will leverage its strong commercial and medical teams in emerging markets to bring the new medicines in its portfolio to customers.<wbr> </div><div style="margin-bottom: 10px;">- Both Lupin and Merck Serono aim to provide high quality, affordable medicines to patients in emerging markets through this alliance.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Financial Terms</STRONG> </div><div style="margin-bottom: 10px;">Lupin and Merck agreed not to release any financial details of the transaction.<wbr> </div><div><EM>Source: Merck Serono</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20141231&edate=20140901&rec=10964">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-09-22T10:22:34+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>GSK to Pay a Fine of £297M to the Chinese Government [mkt:China]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10962</link>
<description>GSK to Pay a Fine of £297M to the Chinese Government [mkt:China]</description><category>mkt:China</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10962</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20141231&edate=20140901&rec=10962">GSK to Pay a Fine of £297M to the Chinese Government</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=mkt%3aChina"><font color="#e95e0b">:PharmaWorld:mkt:China</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10962">PharmaWorld10962</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 22 September 2014 | 10:06</font><br><br><div style="margin-bottom: 10px;">Comment: The company has reported that the fine will be funded through existing cash resources.<wbr> Associated costs and charges related to restructuring will be included in GSK's Q3 update.<wbr> GSK has published a statement of apology to the Chinese government and its people on its website : <A href="http://www.gsk-china.com/asp/News/client/newconten/919201492228.htm">http:/<wbr>/<wbr>www.<wbr>gsk-china.<wbr>com/<wbr>asp/<wbr>News/<wbr>client/<wbr>newconten/<wbr><a title="Track using ups.com" href="http://www.ups.com/WebTracking/track?InquiryNumber1=919201492228">919201492228</a>.<wbr>htm</A> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Next Steps</FONT></STRONG> </div><div style="margin-bottom: 10px;">GSK has co-operated fully with the authorities and has taken steps to comprehensively rectify the issues identified at the operations of GSKCI.<wbr> This includes </div><div style="margin-bottom: 10px;"><UL><LI>fundamentally changing the incentive program for its salesforces (decoupling sales targets from compensation); </LI>
<LI>significantly reducing and changing engagement activities with healthcare professionals; and </LI>
<LI>expanding processes for review and monitoring of invoicing and payments</LI>
</UL> </div><div><EM>Source: GSK</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20141231&edate=20140901&rec=10962">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-09-22T10:06:07+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Mechanistically Unique DMD Therapy Acquired By Akashi [news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7743</link>
<description>Mechanistically Unique DMD Therapy Acquired By Akashi [news]</description><category>news</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7743</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7743">Mechanistically Unique DMD Therapy Acquired By Akashi</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20141231&edate=20140901&cat=news"><font color="#e95e0b">:Neurology:news</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7743">Neurology7743</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 19 September 2014 | 15:22</font><br><br><div style="margin-bottom: 10px;">Comment: Akashi 
Therapeutics, Inc.<wbr>( formerly Dart Therapeutics Inc.<wbr>), a clinical stage 
biopharmaceutical company, has acquired global rights of GsMTx-4 from Tonus 
Therapeutics, Inc for undisclose financial terms.<wbr> GsMTx-4 is a peptide to 
address calcium level imbalance in muscle, a critical issue in Duchenne muscular 
dystrophy (DMD) contributing to loss of function and other associated 
pathologies.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Deal Terms</STRONG>
Akashi Therapeutics will acquire global rights to the compound, including 
intellectual property and commercialization rights,and will be responsible for 
all ongoing development costs.<wbr> Tonus will be eligible to receive potential 
milestones and royalties on future sales of any resulting DMD products.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Basis For Use Of GsMTx-4 in DMD</STRONG> </div><div style="margin-bottom: 10px;">Commenting on the disease pathology and the utility of GsMTx-4 
 Professor Urs Ruegg Dept of Pharmacology at the University of Geneva 
stated “Loss of calcium homeostasis, in particular increased calcium influx 
through stretch-activated channels,in muscle cells of DMD boys is a key 
initiating process of DMD pathology leading to muscle degeneration and muscle 
function loss, As GsMTx-4 is a blocker of stretch-activated channels, it has the 
potential to help restore this homeostasis through modulation of these 
channels.<wbr>” </div><div style="margin-bottom: 10px;"><STRONG>Akashi's Ambition To Become A Leader In DMD Therapies</STRONG> </div><div style="margin-bottom: 10px;">Marc B.<wbr> Blaustein, CEO of Akashi Therapeutics notes that “Calcium level 
imbalance and associated muscle function loss is a critical problem facing 
children with DMD and an area that is not being fully addressed by other DMD 
therapies in development,” said  “Our mission at Akashi Therapeutics is to 
develop a portfolio of treatments for Duchenne muscular dystrophy.<wbr> We are 
pleased to add GsMTx-4 to our growing pipeline of products, which includes 
HT-100, our most advanced drug candidate, currently being evaluated in patients 
with DMD in phase 1a/<wbr>2b clinical studies, and DT-200, a clinical-stage selective 
androgen receptor modulator.<wbr>” </div><div style="margin-bottom: 10px;"><STRONG>What is GsMTx-4?</STRONG> </div><div style="margin-bottom: 10px;">GsMTx-4 is a peptide discovered in the venom of the Chilean Rose Tarantula 
(Grammostola spatulata) spider by researchers at the State University of New 
York at Buffalo.<wbr> These researchers have shown that GsMTx-4 inhibits 
mechanosensitive calcium channels.<wbr> </div><div style="margin-bottom: 10px;">In preclinical models of dystrophic mice, GsMTx-4 was shown to make muscles 
less sensitive to mechanical stress by inhibiting the abnormally increased 
stretch-induced calcium entry into muscle cells lacking dystrophin, decreasing 
muscle degeneration.<wbr> </div><div style="margin-bottom: 10px;">GsMTx-4, the only known specific agent for this class of ion channel, is a 
patented new molecular entity, which has been granted Orphan drug designation by 
the U.<wbr>S.<wbr> Food and Drug Administration.<wbr> </div><div>Source: <a href="http://www.akahirx.com" class="defaultlink" title="www.akahirx.com">akahirx.com</a> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7743">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-09-19T15:22:11+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>Merck KGaA in Advanced Discussions to Partner its Anti-PD-L1 Agent</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9968</link>
<description>Merck KGaA in Advanced Discussions to Partner its Anti-PD-L1 Agent</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9968</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=9968">Merck KGaA in Advanced Discussions to Partner its Anti-PD-L1 Agent</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9968">Oncology9968</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 19 September 2014 | 10:38</font><br><br><div style="margin-bottom: 10px;">Comment: As a mid-sized competitor, Merck KGaA has decided to seek a partner for its product, seen as a potential treatment in lung, ovarian and Merkel cell skin cancer.<wbr> Alongside the ongoing discussions to partner the drug the company repoted  it planned to invest an additional 130 to 150 million euros ($168 to $192 million) next year in its unit developing biosimilars, on top of 100 million euros this year, depending on the outcome of ongoing clinical studies.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Main Players in the PD-L1 Area</STRONG> </div><div style="margin-bottom: 10px;">Merck &amp; Co, Bristol-Myers Squibb, Roche and AstraZeneca </div><div style="margin-bottom: 10px;"><STRONG>Merck Biosimilar Business Strategy</STRONG> </div><div>- to expand existing partnerships with India's Dr Reddy's and Brazil's Bionovis with another, as yet undisclosed in-licensing agreement for a late-stage biosimilar, initially for smaller emerging markets </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=9968">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-09-19T10:38:08+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Gilead 's Simtuzumab Failed for The Treatment Of Pancreatic Cancer</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9967</link>
<description>Gilead 's Simtuzumab Failed for The Treatment Of Pancreatic Cancer</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9967</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=9967">Gilead 's Simtuzumab Failed for The Treatment Of Pancreatic Cancer</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9967">Oncology9967</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/994">Jenny Wu</a> | 18 September 2014 | 17:40</font><br><br><div style="margin-bottom: 10px;">Comment: Gilead reported a Phase II study in pancreatic cancer for simtuzumab with chemo (gemcitabine) did not improve progression free survival (PFS) versus chemo alone.<wbr> This is one of the most promising mid Stage drug in Gilead's pipeline.<wbr> However, treatment of pancreatic cancer represents a very challenging indication given the aggressive nature and complexity of the disease.<wbr> One of the critical challenge is the lack of access of chemotherapy to the tumour, due to poor vascularization and the surround fibrous tissue "stroma".<wbr> Simtuzumab works to improve the scarring and hence improving the vasculature to allow chemo entry to the tumour site.<wbr> It is a "nice" concept but analysts believe that it is still a long shot and therefore not surprised by the negative outcome.<wbr> </div><div>The study failed its main goal of improving progression-free-survival (PFS).<wbr> There was no statistically significant difference in PFS between patients on simtuzumab and those on the placebo, Gilead said on Wednesday.<wbr> Also there was no difference in adverse events between patients talking simtuzumab versus a placebo.<wbr> Simtuzumab is also being tested for use in colorectal cancer, myelofibrosis, idiopathic pulmonary fibrosis and liver fibrosis.<wbr>Last week, Gilead said the next generation version of its $84,000 hepatitis C drug, Sovaldi, already under fire for its record-breaking costs, was going to be even more expensive.<wbr>Separately, the biotechnology company also licensed Sovaldi to seven India-based drug makers that will sell far cheaper versions of the drug in 91 developing nations.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=9967">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-09-18T17:40:01+02:00</dc:date><dc:creator>jew60237</dc:creator></item><item>
<title>Bayer To Transform Itself Into A Pure Life Science Company [news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10957</link>
<description>Bayer To Transform Itself Into A Pure Life Science Company [news]</description><category>news</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10957</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20141231&edate=20140901&rec=10957">Bayer To Transform Itself Into A Pure Life Science Company</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=news"><font color="#e95e0b">:PharmaWorld:news</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10957">PharmaWorld10957</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 18 September 2014 | 17:11</font><br><br><div style="margin-bottom: 10px;">Comment: Bayer has announced today its intention plan a capital-market exit for its Material Science business within the next 12 to18 months, re-focusing its strategy on becoming a global leader in Life Sciences and at the same time recognising the level of investment required to achieve this ambition </div><div style="margin-bottom: 10px;">Management in its press conference noted that Material Science is a world-class business which has the poetntial to creat significant long-term value as a stand-alone business.<wbr> It will be the fourth largest European Chemical Player and it will gain from being better able to fund the investment needed to develop its portfolio.<wbr> </div><div style="margin-bottom: 10px;">Resources and ambition seem to be at the crux of this decision as the slide below illustrates.<wbr> Putting this into context Dr Marijin Dekkers Chairman of the Board of Management noted:- </div><div style="margin-bottom: 10px;"><FONT face="Times New Roman" size="3">"We have already demosntrated the transformation nature of our pharma pipeline and we want to continue exploiting our research assets.<wbr> And that means, amongst others, increasing our R&amp;D spend.<wbr> Above-market growth in our Life Sciences business will also entail the expansion of capacities, as we are now for instance seeing with more than a &euro;500m invetment in a new Factor-VIII plant.<wbr>And lastly we will continue to complement organic growth with the targeted bolt-on acquisitions to gain scale or fill gaps in our portfolio.<wbr>"</FONT> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10957/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><FONT face="Arial">Bayer expects to use any potential proceeds mainly for investing in the further development of its Life Science businesses and /<wbr> or for reducing net debt so that it can deleverage the balance sheet following its recent acquisitions of Algeta and Merck &amp; Co.<wbr> Consumer Care.<wbr> </FONT> </div><div style="margin-bottom: 10px;"><FONT face="Arial">Source: <a href="http://www.bayer.com" class="defaultlink" title="http://www.bayer.com">bayer.com</a></FONT> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10957/2/ScreenCapture2.jpg?user-agent=rss"> </div><div><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10957/3/ScreenCapture3.jpg?user-agent=rss"> </div><!-- Comment details --><a name="pharmaworld10957attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10957/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(102,7 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10957/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(72,4 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10957/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(47,8 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20141231&edate=20140901&rec=10957">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-09-18T17:11:25+02:00</dc:date><dc:creator>jac89886</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10957/1/ScreenCapture1.jpg" length="105114" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10957/2/ScreenCapture2.jpg" length="74164" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10957/3/ScreenCapture3.jpg" length="48913" type="image/jpeg"/></item><item>
<title>Recent Deal Terms From Sun Pharma &amp; Boehringer for Psoriasis and Oncology Drugs [sub:xLicensing]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10956</link>
<description>Recent Deal Terms From Sun Pharma &amp; Boehringer for Psoriasis and Oncology Drugs [sub:xLicensing]</description><category>sub:xLicensing</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10956</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20141231&edate=20140901&rec=10956">Recent Deal Terms From Sun Pharma & Boehringer for Psoriasis and Oncology Drugs</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=sub%3axLicensing"><font color="#e95e0b">:PharmaWorld:sub:xLicensing</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10956">PharmaWorld10956</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 18 September 2014 | 16:00</font><br><br><div style="margin-bottom: 10px;">Comment: Boehringer Ingelheime betting on an early stage cancer vaccine to 
fight lung tumours has signed a deal worth up to $600m with US based CureVac, 
whilst Merck has outlicensed a late stage Psoriasis drug to Sun Pharma 
for $80m upfront plus undisclosed development and regulatory milestones on 
approval.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Boehringer Deal</STRONG> </div><div style="margin-bottom: 10px;">Boehringer is paying €35m upfront to secure the global development and 
commercialisation rights to CureVac's CV9202 (phI) with a further €430m 
planned in milestones plus royalties on sales.<wbr> CV9202 is composed of six 
RNActive-derived molecules coding for 6 different NSCLC associated antigens, 
MAGE-C1, MAGE-C2, NY-ESO-1, survivin, 5T4 and Muc1.<wbr> The development of 
therapeutic candidate is based on RNActive technology </div><div style="margin-bottom: 10px;"><STRONG>Sun Pharma Deal</STRONG> </div><div>Sun has acquired worldwide commercialisation rights to the phIII 
drug tildrakizumab for all possible indications including the lead 
indication of chronic plaque psoriasis.<wbr> Merck will continue with the clinical 
development and regulatory activities which will be funded by Sun Pharma upon 
product approval.<wbr>  Sun Pharma will be responsible for regulatory 
activities, including subsequent submissions, pharmacovigilance, post approval 
studies, manufacturing and commercialization of the approved product.<wbr> Merck will 
receive payments associated with regulatory (including product approval) and 
sales milestones, as well as tiered royalties ranging from mid-single digit 
through teen percentage (that is, from about 5% to 19%) rates on sales.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20141231&edate=20140901&rec=10956">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-09-18T16:00:22+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>PhII Osteoarthritis Drug Placed On Clinical Hold [news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7741</link>
<description>PhII Osteoarthritis Drug Placed On Clinical Hold [news]</description><category>news</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7741</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7741">PhII Osteoarthritis Drug Placed On Clinical Hold</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20141231&edate=20140901&cat=news"><font color="#e95e0b">:Neurology:news</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7741">Neurology7741</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 18 September 2014 | 15:55</font><br><br><div style="margin-bottom: 10px;">Comment: Flexion Therapeutics has had its osteoarthritis drug FX-006 put on 
clinical hold by the FDA.<wbr> The drug is a novel , non-opiod, sustained-release, 
intra-articular formulation of traimcinolone targeting moderate-to-severe OA 
pain and as such a potential competitor to any toxin use in such 
circumstances.<wbr> </div><div style="margin-bottom: 10px;">The FDA has indicated to Flexion that the clinical hold is due to a single 
occurence of an infection in the injected knee joint of a patient in the 
company's phIIb clinical trial.<wbr> </div><div style="margin-bottom: 10px;">The company has confirmed that it will work closely with the FDA to 
expedite its review and evaluation of this event.<wbr> </div><div>Source: <A href="http://www.flexion.com">www.<wbr>flexion.<wbr>com</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7741">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-09-18T15:55:50+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>New Dermato JV Formed in China [class:BotulinumToxins, sub:Aesthetics, :PharmaWorld:mkt:China]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7739</link>
<description>New Dermato JV Formed in China [class:BotulinumToxins, sub:Aesthetics, :PharmaWorld:mkt:China]</description><category>class:BotulinumToxins</category><category>sub:Aesthetics</category><category>mkt:China</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7739</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7739">New Dermato JV Formed in China</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20141231&edate=20140901&cat=class%3aBotulinumToxins"><font color="#e95e0b">:Neurology:class:BotulinumToxins</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20141231&edate=20140901&cat=sub%3aAesthetics"><font color="#e95e0b">:Neurology:sub:Aesthetics</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=mkt%3aChina"><font color="#e95e0b">:PharmaWorld:mkt:China</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7739">Neurology7739</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 18 September 2014 | 13:40</font><br><br><div style="margin-bottom: 10px;">Comment: Milestone Scientific Inc has formed a dermatological JV with Milestone China to develop a botox injection system, consisting of a computer controlled injection device and a related disposable.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Terms of the JV</STRONG> </div><div style="margin-bottom: 10px;"><UL><LI><SPAN style="text-align: justify; widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 12px Arial, Helvetica, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">The JV company, Milestone Advanced Cosmetic Systems, Inc.<wbr>,, will be 50% owned by Milestone Scientific and 50% owned by Milestone China</SPAN>
</LI>
<LI>The JV will have exclusive WW rights to the botox drug delivery system
</LI>
<LI>Milestone Scientific will be responsible for sales and distribution of the instrument in China and other parts of Asia
</LI>
<LI>The JV plans to start development within the next 90 days
</LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG>About Milestone Scientific</STRONG> </div><div style="margin-bottom: 10px;"><SPAN style="text-decoration: underline;">Technology</SPAN><STRONG> <A href="http://www.milestonescientific.com/about_technology.html">http:/<wbr>/<wbr>www.<wbr>milestonescientific.<wbr>com/<wbr>about_technology.<wbr>html</A></STRONG> </div><div>R&amp;D company that designs, patents, incubates and commercializes a growing innovative injection technologies.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7739">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-09-18T13:40:11+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>re: Tokai Files For IPO</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9966</link>
<description>re: Tokai Files For IPO</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9966</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=9966">re: Tokai Files For IPO</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9966">Oncology9966</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/994">Jenny Wu</a> | 18 September 2014 | 12:10</font><br><br><div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Tokai Files For IPO</span>&nbsp;<br><span style="font-size: 12px;">Comment: Tokai currently has galeterone being evaluated in metasatatic CRPC, in particular, preliminary evidence suggested potential benefit for patients who are refractory or show resistant to abiraterone or enzalutamide.<wbr> Now with the lead drug candidate, galeterone, on the precipice of a late stage trial, Tokai is taking the pitch to Wall Street.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=9889">...</a><br><font size="-1">Jenny Wu / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9889" class="commentpermalink">Oncology9889</a> / <span class="date">13 August 2014</span> /
<span class="time">09:51:01 o'clock CEST</span>
</font></div><div>Comment: Tokai was up $8.<wbr>76 (58%) to $23.<wbr>76 on its first day of trading Wednesday (17th Sept) after raising $97.<wbr>2 million through the sale of 6.<wbr>5 million shares at $15 in an IPO.<wbr> The IPO price valued the company at $327.<wbr>6 million.<wbr> Earlier this month, Tokai said it planned to sell 5.<wbr>4 million shares at $13-$15.<wbr> At $14, the offering would have raised $75.<wbr>6 million.<wbr> This IPO is the 14th in biotech for Massachusetts this year.<wbr> Next half, Tokai plans to start Phase III testing of galeterone (<A href="http://www.biocentury.com/products/tok-001" target="_blank" title="TOK-001 product news and analysis from BCIQ"><U><FONT color="#0066cc">TOK-001</FONT></U></A>) to treat castration-resistant prostate cancer (CRPC).<wbr> </div><!-- Comment details --><font size="-1">Jenny Wu / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9966" class="commentpermalink">Oncology9966</a> / <span class="date">18 September 2014</span> /
<span class="time">12:10:33 o'clock CEST</span>
</font><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=9966">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9889">View thread  Oncology9889: Tokai Files For IPO</a>]]></content:encoded><dc:date>2014-09-18T12:10:33+02:00</dc:date><dc:creator>jew60237</dc:creator></item><item>
<title>re: Plenary Presentation of ADT Duration For High Risk Prostate Cancer Patients At ASTRO</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9965</link>
<description>re: Plenary Presentation of ADT Duration For High Risk Prostate Cancer Patients At ASTRO</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9965</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=9965">re: Plenary Presentation of ADT Duration For High Risk Prostate Cancer Patients At ASTRO</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9965">Oncology9965</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/1015">Stefan PFEIFER</a> | 18 September 2014 | 11:12</font><br><br><div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Plenary Presentation of ADT Duration For High Risk Prostate Cancer Patients At ASTRO</span>&nbsp;<font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=class%3aHormonals"><font color="#e95e0b">:Oncology:class:Hormonals</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a>]</font></font><br><span style="font-size: 12px;">Comment: Yesterday PhIII data was presented on the opitmal duration of ADT therapy with high-dose conformational Radiotherapy in intermediate and high-risk localised prostate cancer.<wbr> The five-year results of the study show that the combination of high-dose external radiotherapy utilizing new technologies, such as IMRT, VAMT and IGRT, and<SPAN style="text-decoration: underline;"><STRONG> 28 months</STRONG> </SPAN>of hormone therapy are a very successful combination to achieve positive prostate cancer control.<wbr> Of paramount consideration, long term androgen deprivation therapy in combination with HDRT provides good quality of life through a non-invasive, safe and efficient treatment approach for patients with high-risk prostate cancer.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=9953">...</a><br><font size="-1">Jacquelyne CANTLE MEYRICK / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9953" class="commentpermalink">Oncology9953</a> / <span class="date">16 September 2014</span> /
<span class="time">10:47:21 o'clock CEST</span>
</font></div><div>These seems to be the same study as presented by Zapatero at ASCO.<wbr> N=362, 78Gy, same results </div><!-- Comment details --><font size="-1">Stefan PFEIFER / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9965" class="commentpermalink">Oncology9965</a> / <span class="date">18 September 2014</span> /
<span class="time">11:12:11 o'clock CEST</span>
</font><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=9965">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9953">View thread  Oncology9953: Plenary Presentation of ADT Duration For High Risk Prostate Cancer Patients At ASTRO</a>]]></content:encoded><dc:date>2014-09-18T11:12:11+02:00</dc:date><dc:creator>stp43055</dc:creator></item><item>
<title>Andarix Selected to Present Targeted Radiotherapy at Orphan Drug Conference</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7800</link>
<description>Andarix Selected to Present Targeted Radiotherapy at Orphan Drug Conference</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7800</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20141231&edate=20140901&rec=7800">Andarix Selected to Present Targeted Radiotherapy at Orphan Drug Conference</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7800">Endocrinology7800</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 17 September 2014 | 18:46</font><br><br><div style="margin-bottom: 10px;">Comment: The conference will take place on <a href="http://www.orphandrugssummit.com/" class="defaultlink">Sept. 17-19 in Copenhagen</a>.<wbr> Andarix develops a novel, best-in-class therapy for lung and other cancers based on the radio-labeled somatostatin peptide Tozaride.<wbr> The targeted radiotherapy may represent a new treatment paradigm which is expected to yield significant clinicla benefit for both SCLC and NSCLC.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Clinical Results</STRONG> </div><div style="margin-bottom: 10px;">Early clinical studies of Tozaride demonstrated that it is well tolerated and may produce prolonged stable disease and improved OS in heavily pre-treated advanced lung cancer patients.<wbr> </div><div style="margin-bottom: 10px;">The company is currently developing a Phase II clinical program.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Product Snapshot</STRONG> </div><div style="margin-bottom: 10px;">The peptide drug P2045 is a synthetic high-affinity somatostatin analog which binds to somatostatin receptors (SSTR).<wbr> The hexapeptide domain on P2045 contains the pharmacophore tyrosine-D-tryptophan-Iysinethreonine, which binds to somatostatin receptors (SSTR).<wbr> Studies on the binding affinity of the P2045 peptide to somatostatin receptor rich tumor membranes and CHO cells transfected with the human somatostatin receptor have shown that P2045 has a high affinity for somatostatin receptors (ICso 0.<wbr>09 to 0.<wbr>2nM), similar to that of native somatostatin.<wbr> In addition, it is highly specific for somatostatin receptor SST2.<wbr> Studies have shown the somatostatin receptors, and SSTR2 in particular, are up-regulated in lung cancer.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Mechanism of Action</STRONG> </div><div style="margin-bottom: 10px;">188Re-P2045 binds to somatostatin receptors (SSTR) on tumors and kills them directly.<wbr> </div><div><EM>Source: Andarix</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20141231&edate=20140901&rec=7800">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-09-17T18:46:13+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>An University led Ph2 Trial In JP To Evaluate The Effect Of Degarelix On Prostate Volume</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9964</link>
<description>An University led Ph2 Trial In JP To Evaluate The Effect Of Degarelix On Prostate Volume</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9964</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=9964">An University led Ph2 Trial In JP To Evaluate The Effect Of Degarelix On Prostate Volume</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9964">Oncology9964</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/994">Jenny Wu</a> | 17 September 2014 | 18:05</font><br><br><div style="margin-bottom: 10px;">Comment: This is an university led (Keio University) interventional, non-randomized, historical controlled, single-group assignment, open label and  treatment study to evaluate the influence of degarelix on prostate volume in subjects with prostate cancer who are undergoing prostate brachytherapy with permanent seed implantation.<wbr> The study only takes place in Japan only.<wbr> </div><div style="margin-bottom: 10px;">Trial ID: UMIN000015129 </div><div style="margin-bottom: 10px;">No of patients planned :20 </div><div style="margin-bottom: 10px;">Primary Objective: Prostate volume reduction rate </div><div style="margin-bottom: 10px;">Study Duration: 1 year </div><div>Estimated Start Date : 25 August 2014 </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=9964">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-09-17T18:05:11+02:00</dc:date><dc:creator>jew60237</dc:creator></item><item>
<title>Northwest Biotherapeutics' DCVax-L Becomes First Approval Under The New UK Early Access Scheme</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9962</link>
<description>Northwest Biotherapeutics' DCVax-L Becomes First Approval Under The New UK Early Access Scheme</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9962</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=9962">Northwest Biotherapeutics' DCVax-L Becomes First Approval Under The New UK Early Access Scheme</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9962">Oncology9962</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/994">Jenny Wu</a> | 17 September 2014 | 17:47</font><br><br><div style="margin-bottom: 10px;">Comment: Following the first launch of Early Access Scheme - the system mimicking FDA's "breakthrough designation" concept - in UK in April 2014, Northwest Biotherapeutics' DCVax-L for the treatment of glioblastoma becomes the first medicine to be approved for early use under the new fast track access programme.<wbr> The cell therapy DCVax-L has received the first ever 'Promising Innovative Medicine' (PIM) designation, marking the first step in the new Early Access to Medicines Scheme (EAMS).<wbr> The Scheme is designed to offer patients with life-threatening or seriously debilitating conditions the chance to receive innovative and promising new drugs much earlier than normal, as soon as the Medicines and Healthcare products Regulatory Agency (MHRA) has concluded that the benefits outweigh the risks.<wbr> </div><div style="margin-bottom: 10px;">US Food and Drug Administration&rsquo;s (FDA&rsquo;s) first introduced of the &lsquo;breakthrough&rsquo; designation concept as a way of improving earlier access to medicines for patients with high unmet medical need.<wbr> The Early Access to Medicines Scheme (EAMS) is a similar scheme launched by the UK&rsquo;s Medicines and Healthcare products Regulatory Agency (MHRA) in April 2014.<wbr> EAMS is a voluntary scheme that provides an accelerated route to market for drugs in the UK and aims to &ldquo;give patients with life threatening or seriously debilitating conditions access to medicines that do not yet have marketing authorisation&rdquo;.<wbr><A href="http://www.mhra.gov.uk/home/groups/comms-ic/documents/websiteresources/con392849.pdf" name="_ednref1" target="_self"></A> </div><div style="margin-bottom: 10px;">Three conditions must be met in sequential order for a drug to be accepted onto EAMS: </div><div style="margin-bottom: 10px;"><UL><LI>a drug must first be awarded the status of &lsquo;promising innovative medicine&rsquo; (PIM) by the MHRA, a step that mirrors the FDA&rsquo;s &lsquo;breakthrough&rsquo; status.<wbr> PIM is reserved for drugs that are &ldquo;likely to demonstrate significant benefit for patients in life-threatening or seriously debilitating conditions.<wbr>&rdquo;
</LI>
<LI>the drug manufacturer must then apply for &lsquo;EAMS scientific opinion&rsquo; &ndash; the final MHRA evaluation process.<wbr> The primary aim is to ensure an acceptable risk/<wbr> reward trade-off using available clinical trial data.<wbr> The secondary aim is to develop guidelines and information to allow prescribers and patients to make informed decisions on drug use
</LI>
<LI>if accepted the manufacturer must make the drug available to the NHS free of charge for as long as it&rsquo;s included in EAMS.<wbr> Inclusion is guaranteed for a maximum of a year on the condition that subsequent clinical trial data is shared periodically and does not compromise the risk/<wbr> reward trade-off.<wbr> Once an EAMS drug receives approval through traditional approval channels it is automatically removed from EAMS
</LI>
</UL> </div><div style="margin-bottom: 10px;">As a result, the patients will greatly benefit from earlier access to treatments and it is thought that the scheme could allow a medicine to reach to the patients 2 years earlier than is currently the case.<wbr> However, there is financial risk that a pharmaceutical company should consider as it is estimated the total direct cost of applying for EAMS approval, excluding the cost of preparing the submission, is &pound;33,027 (&pound;4,027 for a PIM application and &pound;29,000 for a &lsquo;scientific opinion&rsquo; of a new molecular entity).<wbr> A positive EAMS opinion will incur additional costs in relation to providing the drug and any necessary non-standard diagnostic technology, given these are to be provided free of charge to the treatable patient population.<wbr> There are also costs associated with keeping an EAMS opinion up to date.<wbr> Financial risks are only likely to deter smaller biotech companies but, as the source of much of today&rsquo;s innovation, these represent an important stakeholder group.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>About DCVax-L</STRONG> </div><div><P style="margin: 0px; padding: 0px; color: #000000; font-family: Helvetica;">DCVax-L works by &lsquo;retraining&rsquo; an individual&rsquo;s immune system to recognise and attack cancer cells and, according to the firm, has the potential to treat many solid tumour cancers.<wbr> It&rsquo;s PIM, however, specifically covers the treatment of malignant melanomas, including the most severe form Glioblastoma multiforme, as well as newly diagnosed and recurrent cases.<wbr></P> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=9962">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-09-17T17:47:48+02:00</dc:date><dc:creator>jew60237</dc:creator></item><item>
<title>Endo Bid's $2.2bn To Acquire Auxillium Pharma [sub:Acquisition]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10955</link>
<description>Endo Bid's $2.2bn To Acquire Auxillium Pharma [sub:Acquisition]</description><category>sub:Acquisition</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10955</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20141231&edate=20140901&rec=10955">Endo Bid's $2.<wbr>2bn To Acquire Auxillium Pharma</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=sub%3aAcquisition"><font color="#e95e0b">:PharmaWorld:sub:Acquisition</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10955">PharmaWorld10955</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 17 September 2014 | 16:33</font><br><br><div style="margin-bottom: 10px;">Comment: Endo has made a $2.<wbr>2bn offer to buy Auxillium 
Pharmaceuticals with its bid representing a 30.<wbr>6% premium to Auxillium's closing 
price on Tuesday.<wbr> Auxillium has as yet not  responded to this unsolicited 
offer.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Background</STRONG> </div><div style="margin-bottom: 10px;">Endo which has already through the tax inversion acquisition of Paladin 
Labs last year relocated its HQ to Dublin is interested in Auxillium as a means 
of expanding its men's healthcare product business.<wbr> In particular it 
wishes to gain access to Xiaflex a drug now FDA approved for the treatment 
of men with a curvature of the penis.<wbr> </div><div style="margin-bottom: 10px;">Xiaflex is also being evaluated for frozen should syndrome (phII) and is 
approved for Duputren's contracture Last month Auxillium also announced that a 
mid-stage study had showed that two doses of the drug smoothed cellulite.<wbr> Endo's 
CEO De Silva has noted that he would invest to expand the brand's use for other 
indications.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Commenting further on the rationale for 
the acquisition De Silva noted the following:- </STRONG> </div><div style="margin-bottom: 10px;">"We believe that adding Auxilium's highly complementary product portfolio will maximize the value of their commercial products.<wbr> As referenced earlier, Auxilium's approved products in urology, orthopedics, and other specialty areas are natural complements to the men's health and pain products in Endo's pharmaceutical 
portfolio.<wbr>" </div><div style="margin-bottom: 10px;"><P class="pwrapper">"We expect to enhance Auxilium's portfolio of products by leveraging our scale, competencies, and resources to drive increased adoption and stronger performance for Auxilium's Xiaflex and to support development in potential new indications for the product.<wbr> Ultimately, an Endo-Auxilium combined company would be well positioned to drive organic growth for the combined companies' branded pharmaceuticals 
business.<wbr>"</P> </div><div style="margin-bottom: 10px;"><P class="pwrapper"> "If you look at the target audience for Auxilium's products, we span a good spectrum of those target therapeutic areas, 
clearly, in 
the area of testosterone products, as well as the use of Xiaflex in Peyronie's, we have a capability in urology which we will look to supplement with some of Auxilium's own capabilities.<wbr>" 
</P> </div><div style="margin-bottom: 10px;"><P class="pwrapper">"And then, when it comes to Xiaflex in other indications, like 
Dupuytren's contracture, given our long heritage in the pain space we have a deep understanding 
of the orthopedic space, 
we call on orthopedists, hand specialists and others, with our pain products.<wbr> And we also cover some of the peripheral referring 
target markets 
as well, like rheumatologists.<wbr> 
So we believe that with our existing field force supplemented 
with some of Auxilium's capabilities that we should be able to support both companies' products at a superior level than either company could by themself.<wbr>"</P> </div><div style="margin-bottom: 10px;"><P class="pwrapper"><STRONG>Financial Benefits Of The 
Deal</STRONG></P> </div><div style="margin-bottom: 10px;">In terms of pro forma financial profile of the combined Endo-Auxilium, management claim that the combined company stands to benefit from both an enhanced near and long-term revenue growth profile, improved operating margins due to the significant synergy opportunities 
and robust returns that are well in excess of the combined cost of capital.<wbr> The transaction is expected to be immediately accretive and meaningfully accretive 
in 2015 and beyond.<wbr> </div><div>Source: <A href="http://phx.corporate-ir.net/phoenix.zhtml?c=123046&amp;p=irol-eventDetails&amp;EventId=5169376">http:/<wbr>/<wbr>phx.<wbr>corporate-ir.<wbr>net/<wbr>phoenix.<wbr>zhtml?c=123046&amp;p=irol-eventDetails&amp;EventId=5169376</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20141231&edate=20140901&rec=10955">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-09-17T16:33:34+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>OncoGenex Announced Completion of Patient Enrollment for AFFINITY in mCRPC Post-Docetaxel Setting [dis:Prostate]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9961</link>
<description>OncoGenex Announced Completion of Patient Enrollment for AFFINITY in mCRPC Post-Docetaxel Setting [dis:Prostate]</description><category>dis:Prostate</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9961</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=9961">OncoGenex Announced Completion of Patient Enrollment for AFFINITY in mCRPC Post-Docetaxel Setting</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9961">Oncology9961</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/994">Jenny Wu</a> | 17 September 2014 | 10:34</font><br><br><div style="margin-bottom: 10px;">Comment: Following announcement of disappointment from SYNERGY trial, OncoGenex has completed patient enrolment in the phase 3 Affinity trial of custirsen in combination with cabazitaxel as second line chemotherapy in mCRPC patients.<wbr> This is in line with their expectation as outlined during their Q2 financial results (<A href="traction/permalink/Oncology9875" title="Permanent Link to Oncology9875"><U><FONT color="#0066cc"><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=9875" class="defaultlink">Oncology9875: OncoGenex's Q2 Key Takeaway Highlighting Development Progress of Curtisen and Apaorsen In mCRPC And Bladder Cancer</a></FONT></U></A>).<wbr> Phase 3 AFFINITY trial is designed to evaluate the potential of custirsen to improve survival outcomes in approximately 630 men with metastatic castrate-resistant prostate cancer (CRPC).<wbr> Patients have been randomized to receive second-line Jevtana&reg; (cabazitaxel) and prednisone with or without custirsen.<wbr> The timing of the survival primary endpoint data is event-driven and results are currently expected in late 2015 or early 2016.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><U>About Custirsen </U> </STRONG>Custirsen is an experimental drug that is designed to block the production of the protein clusterin, which may play a fundamental role in cancer cell survival and treatment resistance.<wbr> Clusterin is upregulated in tumor cells in response to treatment interventions such as chemotherapy, hormone ablation and radiation therapy and has been found to be overexpressed in a number of cancers, including prostate, lung, breast and bladder.<wbr> Increased clusterin production has been linked to faster rates of cancer progression, treatment resistance and shorter survival duration.<wbr> By inhibiting clusterin, custirsen is designed to alter tumor dynamics, slowing tumor growth and resistance to partner treatments, so that the benefits of therapy, including survival, may be extended.<wbr> </div><div style="margin-bottom: 10px;">As part of Phase 1 and Phase 2 clinical trials, custirsen was administered to 294 patients with various types of cancer.<wbr> The majority of adverse events were mild.<wbr> The most common adverse events associated with custirsen consisted of flu-like symptoms.<wbr> The most common serious adverse events (SAE) associated with custirsen were febrile neutropenia, fever, pleural effusion, and dyspnea.<wbr> Each SAE event was observed in approximately 2%-4% of patients.<wbr> In the Phase 3 SYNERGY trial in men with metastatic CRPC, adverse events observed were similar to custirsen's known adverse event profile.<wbr> </div><div>Source: Oncogenex.<wbr>com </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=9961">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-09-17T10:34:39+02:00</dc:date><dc:creator>jew60237</dc:creator></item><item>
<title>Jury Out On Merck's New Osteoporosis Drug Odanacatib [news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7798</link>
<description>Jury Out On Merck's New Osteoporosis Drug Odanacatib [news]</description><category>news</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7798</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20141231&edate=20140901&rec=7798">Jury Out On Merck's New Osteoporosis Drug Odanacatib</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20141231&edate=20140901&cat=news"><font color="#e95e0b">:Endocrinology:news</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7798">Endocrinology7798</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 16 September 2014 | 19:02</font><br><br><div style="margin-bottom: 10px;">Comment: Eighteen months ago Merck &amp; Co's osteoporosis drug 
odanacatib was the company's most valuable asset.<wbr> Since then it has been hit by 
safety concerns and we have seen the astonishing rise of the group's 
immuno-oncology agent Keytruda (recently approved for melanoma).<wbr> Yesterday, 
Merck released data from the 16,000 patient LOFT study confirming that 
odanacatib's safety fears may be justified.<wbr> Moreoever, further analysis of 
cardiac events will push the US filing out until 2015.<wbr> In a January 
2013 PharmaPoint Report odanacatib  was cited as one of the 
future leaders in the osteoporosis market alongside products from Amgen, Lilly 
and Radius Health.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Key Efficacy Findings</STRONG> </div><div style="margin-bottom: 10px;">In LOFT, odanacatib significantly reduced the risk of three types of 
osteoporotic fractures compared to placebo in the primary efficacy analysis, and 
also reduced the risk of the secondary endpoint of clinical vertebral fractures.<wbr> 
Specifically, compared to patients receiving placebo, patients who received 
odanacatib had a: </div><div style="margin-bottom: 10px;"><UL><LI class="bwlistitemmargb">54% relative risk reduction of new and worsening 
  morphometric (radiographically-assessed) vertebral fractures (p&lt;0.<wbr>001), 
  </LI>
<LI class="bwlistitemmargb">47% relative risk reduction of clinical hip 
  fractures (p&lt;0.<wbr>001), </LI>
<LI class="bwlistitemmargb">23% relative risk reduction of clinical 
  non-vertebral fractures (p&lt;0.<wbr>001), and </LI>
<LI class="bwlistitemmargb">72% relative risk reduction of clinical vertebral 
  fractures (p&lt;0.<wbr>001).<wbr> </LI>
</UL> </div><div style="margin-bottom: 10px;">In addition, treatment with odanacatib led to progressive increases over five 
years in bone mineral density (BMD) at the lumbar spine and total hip.<wbr> Compared 
to placebo, the change in BMD from baseline at five years with odanacatib for 
lumbar spine was 11.<wbr>2% (p&lt;0.<wbr>001) and for total hip was 9.<wbr>5% (p&lt;0.<wbr>001).<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Key Safety Issues</STRONG> </div><div style="margin-bottom: 10px;">Although the oversall rate of side effects was similar in the two patient 
groups, those taking odanacatib had a slightly higher  incidence of death 
and atrial fibrillation.<wbr> Overall there were similar numbers of cardiovascular 
events in both patient groups although a numerically higher incidence of strokes 
in the odanacatib group.<wbr> Five patients also developed atypical fractures of the 
thigh-bone compared to the placeobo group although similar fractures have been 
seen amongst patients using bisphosphonates.<wbr> Certain skin leisions also occurred 
more frequently.<wbr> </div><div style="margin-bottom: 10px;">Whilst these safety issues may raise some red flags with the FDA, overall the 
company considers that the drug has a positive risk benefit profile and analysts 
that know the product well are suggesting that it should still be 
approvable.<wbr> </div><div>Source: <A href="http://www.merck.com">www.<wbr>merck.<wbr>com</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20141231&edate=20140901&rec=7798">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-09-16T19:02:31+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>re: BGI Completed Joint Venture Partnership With VPC With A Focus On GU Cancers</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9957</link>
<description>re: BGI Completed Joint Venture Partnership With VPC With A Focus On GU Cancers</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9957</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=9957">re: BGI Completed Joint Venture Partnership With VPC With A Focus On GU Cancers</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9957">Oncology9957</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/994">Jenny Wu</a> | 16 September 2014 | 17:47</font><br><br><div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">BGI Completed Joint Venture Partnership With VPC With A Focus On GU Cancers</span>&nbsp;<br><span style="font-size: 12px;">Comment: BGI, the world's largest genomic organization based in China announced the establishment of the BGI - Vancouver Prostate Cancer (VPC) Joint Laboratory to focus on developing new biomarker and achieve a deeper understanding on drug resistant with specific focus on bladder cancer, kidney and prostate cancer.<wbr> BGI has plan for IPO in Hong Kong where BGI tech is planning a $400 million initial public offering in February and aims to start the offering in the Q4.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=9952">...</a><br><font size="-1">Jenny Wu / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9952" class="commentpermalink">Oncology9952</a> / <span class="date">15 September 2014</span> /
<span class="time">19:10:41 o'clock CEST</span>
</font></div><div style="margin-bottom: 10px;">Comment: To also highlight the increasingly focus on genetic research from biomarker discovery perspective, Olama et al.<wbr> published in <a href="http://www.nature.com/ng/journal/vaop/ncurrent/full/ng.3094.html#affil-auth" class="defaultlink">Nature Genetics</a>on 14 September a meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer.<wbr> Scientists discovered 23 new genetic variations that raise the risk of prostate cancer, bringing the total to 100.<wbr> In this research, scientists from The Institute of Cancer Research, University of Cambridge and the University of Southern California in the US examined the genetic information of 87,040 men from all over the world.<wbr> They combined genetic population studies of 43,303 men with prostate cancer and 43,737 controls from European, African, Japanese or Latino heritage to map their genetic profiles and identify variants that were more common among the prostate cancer patients.<wbr> From this combined population, they identified 16 new genetic markers linked to prostate cancer risk in European men - one of them associated with increased risk of early-onset disease - and seven in men of mixed heritage.<wbr> A new clinical trial, BARCODE, will aim to genetically screen 5,000 men for prostate cancer, and will investigate if these genetic markers can improve on other tests for the disease.<wbr> </div><div>They are investigating whether genetic testing could help diagnose more men at risk of developing dangerous forms of prostate cancer that need urgent treatment.<wbr> The new study shows that for European men assessed for the 100 common variants, the 10 per cent at highest risk are 2.<wbr>9 times more likely than the average person to develop prostate cancer, while the top one per cent are 5.<wbr>7 times more likely to develop the disease.<wbr> </div><!-- Comment details --><font size="-1">Jenny Wu / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9957" class="commentpermalink">Oncology9957</a> / <span class="date">16 September 2014</span> /
<span class="time">17:47:36 o'clock CEST</span>
</font><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=9957">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9952">View thread  Oncology9952: BGI Completed Joint Venture Partnership With VPC With A Focus On GU Cancers</a>]]></content:encoded><dc:date>2014-09-16T17:47:36+02:00</dc:date><dc:creator>jew60237</dc:creator></item><item>
<title>re: Ferring's Picoprep New Dosage to Enter Registration Trial</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2031</link>
<description>re: Ferring's Picoprep New Dosage to Enter Registration Trial</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2031</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2031">re: Ferring's Picoprep New Dosage to Enter Registration Trial</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2031">GastroEnterology2031</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/473">Anne Kornowski</a> | 16 September 2014 | 16:30</font><br><br><div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Ferring's Picoprep New Dosage to Enter Registration Trial</span>&nbsp;<font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20141231&edate=20140901&cat=sub%3aCRCPrevention"><font color="#e95e0b">:GastroEnterology:sub:CRCPrevention</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=sub%3aClinicalTrial"><font color="#e95e0b">:PharmaWorld:sub:ClinicalTrial</font></a>]</font></font><br><span style="font-size: 12px;">Comment: Planned to start next month, the study will be comparing efficacy/<wbr>safety and tolerability of the Picoprep tailored dosing schedule to the Picoprep day-before schedule for colon cleansing in preparation for colonoscopy.<wbr> PE will measure overall colon cleasing procedure.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2026">...</a><br><font size="-1">Brigitte DESCHAMPS / <a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2026" class="commentpermalink">GastroEnterology2026</a> / <span class="date">15 September 2014</span> /
<span class="time">18:17:07 o'clock CEST</span>
</font></div><div style="margin-bottom: 10px;">Clarification on tailored dose: </div><div>First dose one day before colonoscopy or on the day of colonoscopy, dependent on the planned time for colonoscopy, and second dose on the day of colonoscopy </div><!-- Comment details --><font size="-1">Anne Kornowski / <a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2031" class="commentpermalink">GastroEnterology2031</a> / <span class="date">16 September 2014</span> /
<span class="time">16:30:01 o'clock CEST</span>
</font><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2031">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2026">View thread  GastroEnterology2026: Ferring's Picoprep New Dosage to Enter Registration Trial</a>]]></content:encoded><dc:date>2014-09-16T16:30:01+02:00</dc:date><dc:creator>ank40391</dc:creator></item><item>
<title>Ascendis Reports Positive Interim Results from a Ph2 Ped Study of its Once-Weekly GH [class:GrowthHormone, dis:GrowthHormoneDeficiency]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7795</link>
<description>Ascendis Reports Positive Interim Results from a Ph2 Ped Study of its Once-Weekly GH [class:GrowthHormone, dis:GrowthHormoneDeficiency]</description><category>class:GrowthHormone</category><category>dis:GrowthHormoneDeficiency</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7795</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20141231&edate=20140901&rec=7795">Ascendis Reports Positive Interim Results from a Ph2 Ped Study of its Once-Weekly GH</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20141231&edate=20140901&cat=class%3aGrowthHormone"><font color="#e95e0b">:Endocrinology:class:GrowthHormone</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20141231&edate=20140901&cat=dis%3aGrowthHormoneDeficiency"><font color="#e95e0b">:Endocrinology:dis:GrowthHormoneDeficiency</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7795">Endocrinology7795</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 16 September 2014 | 15:52</font><br><br><div style="margin-bottom: 10px;">Comment: This interim analysis consists of 25 patients, which represents approx.<wbr> 50% of the anticipated total enrollment in the study, completing 3 months of the total 6 months of treatment.<wbr> In Q1:15, Ascendis plans to report six-month height velocity data from 50% of the patients completing the Ph2 pediatric study, and top-line data for all patients in the study in mid-2015.<wbr> Key conclusions from the interim analysis are provided below.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Interim Results</FONT></STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>mean annualized height velocities ranged from 13.<wbr>0 cm to 14.<wbr>1 cm for the three weekly dose levels of TransCon Growth Hormone, which were comparable to the active comparator, daily injections of Genotropin®;</LI>
<LI>there have been no reports of serious or unexpected adverse events;</LI>
<LI>injection site reactions were generally mild and transient and occurred in only a few patients;</LI>
<LI>thus far, there have been no observations of injection site nodule formation or lipoatrophy; and</LI>
<LI>a dose-proportional increase in IGF-I levels was observed following dosing of the three TransCon Growth Hormone doses.<wbr> Transient point values of IGF‐I SDS &gt; +2 have been observed in a small number of patients and only in the high-dose treatment arm.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7795/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">About the Ongoing Ph2</FONT></STRONG> </div><div style="margin-bottom: 10px;">Reference<A href="http://clinicaltrials.gov/ct2/show/NCT01947907?term=ascendis&amp;recr=Open&amp;rank=1"> NCT01947907 </A>- </div><div style="margin-bottom: 10px;">The ongoing Phase 2 pediatric study is being conducted to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of TransCon Growth Hormone in up to 52 treatment-naïve pre-pubertal patients with GHD, who meet internationally recognized criteria for GHD.<wbr> </div><div style="margin-bottom: 10px;">The study is a 6-month multi-center, randomized study comparing three dose levels of TransCon Growth Hormone (0.<wbr>14; 0.<wbr>21; and 0.<wbr>30 mg hGH/<wbr>kg/<wbr>week), administered once per week, to the active control Genotropin (0.<wbr>21 mg hGH/<wbr>kg/<wbr>week), administered as 7 daily injections.<wbr> </div><div style="margin-bottom: 10px;">The efficacy endpoint is height velocity at 6 months.<wbr> </div><div style="margin-bottom: 10px;">The protocol for the Phase 2 pediatric study calls for 2 interim data analyses.<wbr> This interim analysis reports height velocity in 50% of the evaluable patients completing the first three months of the study.<wbr> </div><div><EM>Source: Ascendis</EM> </div><!-- Comment details --><a name="endocrinology7795attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7795/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(43,4 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20141231&edate=20140901&rec=7795">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-09-16T15:52:28+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7795/1/ScreenCapture1.jpg" length="44483" type="image/jpeg"/></item><item>
<title>Bayer/Orion to Initiate Ph3 of ODM-201 in Men with High-Risk Non-Metastatic CRPC [comp:BayerSchering, dis:Prostate, :PharmaWorld:sub:ClinicalTrial]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9954</link>
<description>Bayer/Orion to Initiate Ph3 of ODM-201 in Men with High-Risk Non-Metastatic CRPC [comp:BayerSchering, dis:Prostate, :PharmaWorld:sub:ClinicalTrial]</description><category>comp:BayerSchering</category><category>dis:Prostate</category><category>sub:ClinicalTrial</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9954</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=9954">Bayer/<wbr>Orion to Initiate Ph3 of ODM-201 in Men with High-Risk Non-Metastatic CRPC</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=comp%3aBayerSchering"><font color="#e95e0b">:Oncology:comp:BayerSchering</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=sub%3aClinicalTrial"><font color="#e95e0b">:PharmaWorld:sub:ClinicalTrial</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9954">Oncology9954</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 16 September 2014 | 14:22</font><br><br><div style="margin-bottom: 10px;">Comment: The ARAMIS trial is designed to determine the effects of the treatment on metastasis-free survival (MFS).<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Trial Details</FONT></STRONG> </div><div style="margin-bottom: 10px;">Reference: <A href="http://clinicaltrials.gov/ct2/show/NCT02200614?term=odm-201&amp;rank=4">NCT02200614</A> </div><div style="margin-bottom: 10px;">Design: randomized, multicenter, double-blind, plcebo-controlled trial </div><div style="margin-bottom: 10px;">Recruitment: approx 1500 </div><div style="margin-bottom: 10px;"><UL><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Histologically or cytologically confirmed adenocarcinoma of prostate without neuroendocrine differentiation or small cell features.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Progressive Castration-resistant prostate cancer (CRPC) with castrate level of serum testosterone.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Prostate-specific antigen doubling time of ≤ 10 months.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Blood counts at screening: haemoglobin ≥ 9.<wbr>0 g/<wbr>dl,absolute neutrophil count ≥ 1500/<wbr>µl (1.<wbr>5x109/<wbr>l), platelet count ≥ 100,000/<wbr>µl (100x109/<wbr>l ).<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Screening values of serum alanine aminotransferase (ALT) and/<wbr>or aspartate transaminase (AST) ≤ 2.<wbr>5 x upper limit of normal (ULN), total bilirubin ≤ 1.<wbr>5 x ULN, creatinine ≤ 2.<wbr>0 x ULN.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Sexually active patients, unless surgically sterile, must agree to use condoms as an effective barrier method during the study treatment and for 3 months after the end of the study treatment.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;">Dosage 2:1 ratio to receive 600mg of ODM-201 twice a day or matching placebo </div><div style="margin-bottom: 10px;">PE: MFS up to 72 months </div><div style="margin-bottom: 10px;">Timelines: completion March 2018 /<wbr> Dec 2020 </div><div>Location: USA (7 sites) </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=9954">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-09-16T14:22:59+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Plenary Presentation of ADT Duration For High Risk Prostate Cancer Patients At ASTRO [dis:Prostate, class:Hormonals]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9953</link>
<description>Plenary Presentation of ADT Duration For High Risk Prostate Cancer Patients At ASTRO [dis:Prostate, class:Hormonals]</description><comments>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9953</comments><category>dis:Prostate</category><category>class:Hormonals</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9953</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=9953">Plenary Presentation of ADT Duration For High Risk Prostate Cancer Patients At ASTRO</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=class%3aHormonals"><font color="#e95e0b">:Oncology:class:Hormonals</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9953">Oncology9953</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 16 September 2014 | 10:47</font><br><br><div style="margin-bottom: 10px;">Comment: Yesterday PhIII data was presented on the opitmal duration of ADT therapy with high-dose conformational Radiotherapy in intermediate and high-risk localised prostate cancer.<wbr> The five-year results of the study show that the combination of high-dose external radiotherapy utilizing new technologies, such as IMRT, VAMT and IGRT, and<SPAN style="text-decoration: underline;"><STRONG> 28 months</STRONG> </SPAN>of hormone therapy are a very successful combination to achieve positive prostate cancer control.<wbr> Of paramount consideration, long term androgen deprivation therapy in combination with HDRT provides good quality of life through a non-invasive, safe and efficient treatment approach for patients with high-risk prostate cancer.<wbr> </div><div style="margin-bottom: 10px;">According to research presented at the American Society for Radiation Oncology&rsquo;s (ASTRO&rsquo;s) 56th Annual Meeting, prostate cancer patients who receive high-dose radiation therapy (HDRT) followed by a longer period of hormone suppression therapy, or androgen deprivation therapy (ADT), have higher five-year biochemical, disease-free survival (bDFS) and overall survival rates compared to patients who receive HDRT and a shorter duration of ADT This multi-center study evaluated whether HDRT combined with long-term androgen deprivation (LTAD) therapy for 28 months was associated with better patient outcomes compared to HDRT combined with short-term ADT (STAD) for four months.<wbr> </div><div style="margin-bottom: 10px;">Between 2006 and 2010, 362 patients were enrolled in the study at 9 cancer centers in Spain, and 355 patients met all study criteria.<wbr> The patients had cT1c &ndash; T3aN0M0 prostate cancer (with no lymph node involvement and no metastases and unfavorable risk factors), and prostate specific antigen (PSA) levels of less than 100 ng/<wbr>ml.<wbr> </div><div style="margin-bottom: 10px;">All patients received four months of neoadjuvant and concomitant ADT + HDRT, meaning the ADT was simultaneous to the RT treatment and began prior to radiation in an attempt to reduce tumor size.<wbr> The median RT dose to the prostate was 78 Gy.<wbr> </div><div style="margin-bottom: 10px;">Patients were then randomly assigned to two groups: 177 patients received adjuvant Goserelin (a luteinizing hormone that suppresses production of testosterone) subcutaneously for 24 additional months to form the LTAD group; the remaining 178 patients received only four months of ADT and were categorized as the STAD group.<wbr> A comparable number of intermediate risk (IR) patients and high-risk (HR) patients were assigned to each group.<wbr> There were 166 IR patients (85 in the LTAD group; 81 in the STAD group), and 189 HR patients (92 in the LTAD group; 97 in the STAD group).<wbr> </div><div style="margin-bottom: 10px;">The study&rsquo;s primary endpoints were bDFS and toxicity scores (radiation-related side effects).<wbr> The bDFS rate with prostate cancer is based upon the measurement of a patient&rsquo;s PSA level.<wbr> If a patient&rsquo;s PSA level does not rise upon post-treatment follow-up evaluations, the patient is considered to not be in biochemical failure, or does not have biochemical disease&mdash;meaning the cancer is considered to be ablated and not growing or spreading.<wbr> <BR>A total of 11 patients in the LTAD group and 15 patients in the STAD group had bDFS, according to Phoenix Consensus definition (p=0.<wbr>003).<wbr> </div><div style="margin-bottom: 10px;">After a median follow-up of 63 months, the five-year bDFS was significantly higher in the LTAD group (89.<wbr>8 percent, compared to the STAD group (81.<wbr>3 percent) (p=0.<wbr>019).<wbr> </div><div>The study also evaluated metastasis free survival (MFS) and overall survival (OS).<wbr> The five-year MFS was also significantly higher for the LTAD group&mdash;93.<wbr>6 percent compared to 83.<wbr>4 percent in the STAD group (p=0.<wbr>009).<wbr> There was also a significant benefit in the OS for patients treated with LTAD (94.<wbr>8 percent) versus STAD (86.<wbr>1 percent, p=0.<wbr>009), this benefit being more evident in patients with high-risk prostate cancer (p=0.<wbr>010).<wbr> Radiation-related side effects of &ge;Grade 2 were acceptably low and not significantly different in both groups.<wbr> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Oncology9965c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div>These seems to be the same study as presented by Zapatero at ASCO.<wbr> N=362, 78Gy, same results </div><font size="-1">Stefan PFEIFER / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9965" class="commentpermalink">Oncology9965</a> / <span class="date">18 September 2014</span> /
<span class="time">11:12:11 o'clock CEST</span>
</font></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=9953">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-09-16T10:47:21+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>BGI Completed Joint Venture Partnership With VPC With A Focus On GU Cancers</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9952</link>
<description>BGI Completed Joint Venture Partnership With VPC With A Focus On GU Cancers</description><comments>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9952</comments><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9952</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=9952">BGI Completed Joint Venture Partnership With VPC With A Focus On GU Cancers</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9952">Oncology9952</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/994">Jenny Wu</a> | 15 September 2014 | 19:10</font><br><br><div style="margin-bottom: 10px;">Comment: BGI, the world's largest genomic organization based in China announced the establishment of the BGI - Vancouver Prostate Cancer (VPC) Joint Laboratory to focus on developing new biomarker and achieve a deeper understanding on drug resistant with specific focus on bladder cancer, kidney and prostate cancer.<wbr> BGI has plan for IPO in Hong Kong where BGI tech is planning a $400 million initial public offering in February and aims to start the offering in the Q4.<wbr> </div><div>Over the next five years, the aim is to allow scientists to utilize clinical expertise, a unique repository of metastatic and post-treated cancer specimens, and cutting edge genomics with the goal of improving patient outcomes and quality of life through development of targeted therapies and ultimately evidence based precision oncology.<wbr> In addition, with the participation of Dr.<wbr> Yuzhuo Wang, Senior Scientist at Vancouver Prostate Centre and BC Cancer Agency, researchers will use unique and clinically relevant patient derived xenograft models to dissect the inner workings of tumours.<wbr> It is anticipated that future collaborative research will range from health and agriculture to environmental research.<wbr> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Oncology9957c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">Comment: To also highlight the increasingly focus on genetic research from biomarker discovery perspective, Olama et al.<wbr> published in <a href="http://www.nature.com/ng/journal/vaop/ncurrent/full/ng.3094.html#affil-auth" class="defaultlink">Nature Genetics</a>on 14 September a meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer.<wbr> Scientists discovered 23 new genetic variations that raise the risk of prostate cancer, bringing the total to 100.<wbr> In this research, scientists from The Institute of Cancer Research, University of Cambridge and the University of Southern California in the US examined the genetic information of 87,040 men from all over the world.<wbr> They combined genetic population studies of 43,303 men with prostate cancer and 43,737 controls from European, African, Japanese or Latino heritage to map their genetic profiles and identify variants that were more common among the prostate cancer patients.<wbr> From this combined population, they identified 16 new genetic markers linked to prostate cancer risk in European men - one of them associated with increased risk of early-onset disease - and seven in men of mixed heritage.<wbr> A new clinical trial, BARCODE, will aim to genetically screen 5,000 men for prostate cancer, and will investigate if these genetic markers can improve on other tests for the disease.<wbr> </div><div>They are investigating whether genetic testing could help diagnose more men at risk of developing dangerous forms of prostate cancer that need urgent treatment.<wbr> The new study shows that for European men assessed for the 100 common variants, the 10 per cent at highest risk are 2.<wbr>9 times more likely than the average person to develop prostate cancer, while the top one per cent are 5.<wbr>7 times more likely to develop the disease.<wbr> </div><font size="-1">Jenny Wu / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9957" class="commentpermalink">Oncology9957</a> / <span class="date">16 September 2014</span> /
<span class="time">17:47:36 o'clock CEST</span>
</font></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=9952">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-09-15T19:10:41+02:00</dc:date><dc:creator>jew60237</dc:creator></item><item>
<title>Mitomycin C Is Being Evaluated As An Alternative Of Surgical Management In Low Risk NMIBC In UK [dis:Bladder, class:Cytotoxics]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9951</link>
<description>Mitomycin C Is Being Evaluated As An Alternative Of Surgical Management In Low Risk NMIBC In UK [dis:Bladder, class:Cytotoxics]</description><category>dis:Bladder</category><category>class:Cytotoxics</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9951</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=9951">Mitomycin C Is Being Evaluated As An Alternative Of Surgical Management In Low Risk NMIBC In UK</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=class%3aCytotoxics"><font color="#e95e0b">:Oncology:class:Cytotoxics</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=dis%3aBladder"><font color="#e95e0b">:Oncology:dis:Bladder</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9951">Oncology9951</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/994">Jenny Wu</a> | 15 September 2014 | 18:24</font><br><br><div style="margin-bottom: 10px;">Comment: ICR (Institute of Cancer Research) in UK has received approval from MHRA (Medicines and Healthcare Products Regulatory Agency) to investigate mitomycin C as an alternative option to surgical management (such as TURB or Ablation) for low risk bladder cancer (non muscle invasive bladder cancer) patients.<wbr> This is a phase 2, multicentre, randomized, controlled, double blind open label study to evaluate safety and efficacy of chemoresection and surgical management in low risk NMIBC (CALIBER).<wbr> </div><div style="margin-bottom: 10px;">Clinical Trial ID : NCT02070120 </div><div style="margin-bottom: 10px;">Estimated start date: 01 Oct 2014 </div><div style="margin-bottom: 10px;">Estimated Completion Date: 01 Oct 2016 </div><div style="margin-bottom: 10px;">A total of 174 patients are planned to be enrolled in the study.<wbr> All subjects will be followed up at 3 weeks from the start of treatment and each will receive a cystoscopy 3 months from the end of treatment to assess response (in accordance with EAU guidelines).<wbr> subsequent cystoscopic follow up will take place 12 months after treatment if recurrence free at 3 months and then annually.<wbr> Subjects will be randomized into two arms: </div><div style="margin-bottom: 10px;">Comparison Arm: patients will be treated with mitomycin C at a dose of 40mg intravesicel instillations 4 times once weekly </div><div style="margin-bottom: 10px;">Control Arm: patients will be treated according to local surgical standard practice (i.<wbr>e TUR or ablation) </div><div style="margin-bottom: 10px;">Primary Objective: Complete response rate at 3 months.<wbr> </div><div style="margin-bottom: 10px;">Secondary Objective: Salvage surgery rates up to 3 years (i.<wbr>e.<wbr> re-TUR), Progression free survival up to 3 years, Quality of life, Health service utilisation up to 12 months, Recurrence free interval up to 12 months, toxicity </div><div style="margin-bottom: 10px;">List of Recruitment sites include: </div><div><TABLE border="0" cellpadding="0" cellspacing="0" style="width: 347px; height: 1013px;"><COLGROUP><COL width="289">
</COLGROUP>
<TBODY><TR height="20"><TD height="20" width="289"> 
<DIV> <FONT face="Calibri" size="3"> Royal Berkshire Hospital</FONT></DIV>
</TD>
</TR>
<TR height="20"><TD height="20"><FONT face="Calibri" size="3">Stepping Hill Hospital</FONT></TD>
</TR>
<TR height="20"><TD height="20"><FONT face="Calibri" size="3">James Cook University Hospital</FONT></TD>
</TR>
<TR height="20"><TD height="20"><FONT face="Calibri" size="3">Royal Derby Hospital</FONT></TD>
</TR>
<TR height="20"><TD height="20"><FONT face="Calibri" size="3">Royal Bournemouth Hospital</FONT></TD>
</TR>
<TR height="20"><TD height="20"><FONT face="Calibri" size="3">Dorset County Hospital</FONT></TD>
</TR>
<TR height="20"><TD height="20"><FONT face="Calibri" size="3">Cumberland Infirmary</FONT></TD>
</TR>
<TR height="20"><TD height="20"><FONT face="Calibri" size="3">Broomfield Hospital</FONT></TD>
</TR>
<TR height="20"><TD height="20"><FONT face="Calibri" size="3">Cheltenham General Hospital</FONT></TD>
</TR>
<TR height="20"><TD height="20"><FONT face="Calibri" size="3">Gloucestershire Royal Hospital</FONT></TD>
</TR>
<TR height="20"><TD height="20"><FONT face="Calibri" size="3">Basingstoke and North Hampshire Hospital</FONT></TD>
</TR>
<TR height="20"><TD height="20"><FONT face="Calibri" size="3">Darent Valley Hospital</FONT></TD>
</TR>
<TR height="20"><TD height="20"><FONT face="Calibri" size="3">Medway Maritime Hospital</FONT></TD>
</TR>
<TR height="20"><TD height="20"><FONT face="Calibri" size="3">Leicester General Hospital</FONT></TD>
</TR>
<TR height="20"><TD height="20"><FONT face="Calibri" size="3">Harrogate District Hospital</FONT></TD>
</TR>
<TR height="20"><TD height="20"><FONT face="Calibri" size="3">King's Mills Hospital</FONT></TD>
</TR>
<TR height="20"><TD height="20"><FONT face="Calibri" size="3">Royal Hallamshire Hospital</FONT></TD>
</TR>
<TR height="20"><TD height="20"><FONT face="Calibri" size="3">Ipswich Hospital</FONT></TD>
</TR>
<TR height="20"><TD height="20"><FONT face="Calibri" size="3">Ashford and St Peter's Hospitals</FONT></TD>
</TR>
<TR height="20"><TD height="20"><FONT face="Calibri" size="3">Frimley Park Hospital</FONT></TD>
</TR>
<TR height="20"><TD height="20"><FONT face="Calibri" size="3">Royal Surrey County Hospital</FONT></TD>
</TR>
<TR height="20"><TD height="20"><FONT face="Calibri" size="3">Freeman Hospital</FONT></TD>
</TR>
<TR height="20"><TD height="20"><FONT face="Calibri" size="3">University Hospital Coventry</FONT></TD>
</TR>
<TR height="20"><TD height="20"><FONT face="Calibri" size="3">New Cross Hospital</FONT></TD>
</TR>
<TR height="20"><TD height="20"><FONT face="Calibri" size="3">St Richard's Hospital</FONT></TD>
</TR>
<TR height="20"><TD height="20"><FONT face="Calibri" size="3">Worthing Hospital</FONT></TD>
</TR>
<TR height="20"><TD height="20"><FONT face="Calibri" size="3">Pinderfields General Hospital</FONT></TD>
</TR>
<TR height="20"><TD height="20"><FONT face="Calibri" size="3">Worcester Royal Hospital</FONT></TD>
</TR>
<TR height="20"><TD height="20"><FONT face="Calibri" size="3">York District Hospital</FONT></TD>
</TR>
<TR height="20"><TD height="20"><FONT face="Calibri" size="3">Hereford County Hospital</FONT></TD>
</TR>
<TR height="20"><TD height="20"><FONT face="Calibri" size="3">University College Hospital</FONT></TD>
</TR>
<TR height="20"><TD height="20"><FONT face="Calibri" size="3">Charing Cross Hospital</FONT></TD>
</TR>
<TR height="20"><TD height="20"><FONT face="Calibri" size="3">Wythenshawe Hospital</FONT></TD>
</TR>
<TR height="20"><TD height="20"><FONT face="Calibri" size="3">Withington Hospital</FONT></TD>
</TR>
</TBODY>
</TABLE> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=9951">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-09-15T18:24:04+02:00</dc:date><dc:creator>jew60237</dc:creator></item><item>
<title>Ferring's Picoprep New Dosage to Enter Registration Trial [sub:CRCPrevention, :PharmaWorld:sub:ClinicalTrial]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2026</link>
<description>Ferring's Picoprep New Dosage to Enter Registration Trial [sub:CRCPrevention, :PharmaWorld:sub:ClinicalTrial]</description><comments>http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2026</comments><category>sub:CRCPrevention</category><category>sub:ClinicalTrial</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2026</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2026">Ferring's Picoprep New Dosage to Enter Registration Trial</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20141231&edate=20140901&cat=sub%3aCRCPrevention"><font color="#e95e0b">:GastroEnterology:sub:CRCPrevention</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=sub%3aClinicalTrial"><font color="#e95e0b">:PharmaWorld:sub:ClinicalTrial</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2026">GastroEnterology2026</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 15 September 2014 | 18:17</font><br><br><div style="margin-bottom: 10px;">Comment: Planned to start next month, the study will be comparing efficacy/<wbr>safety and tolerability of the Picoprep tailored dosing schedule to the Picoprep day-before schedule for colon cleansing in preparation for colonoscopy.<wbr> PE will measure overall colon cleasing procedure.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Trial Details</FONT></STRONG> </div><div style="margin-bottom: 10px;">Reference <A href="http://clinicaltrials.gov/ct2/show/NCT02239692?recr=Open&amp;no_unk=Y&amp;cond=CLEANSING&amp;phase=012&amp;fund=2&amp;rcv_s=08%2F15%2F2014&amp;rank=1">NCT02239692</A> </div><div style="margin-bottom: 10px;">Recruitment approx 198 </div><div style="margin-bottom: 10px;"><UL><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Male or female, 18 years of age or above, being scheduled to undergo elective colonoscopy</LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Subjects must have had more than or equal to 3 spontaneous bowel movements (i.<wbr>e.<wbr> without use of any laxative within 24 hours before the bowel movement, with the exception for bulk-forming laxatives (ATC code A06AC)) per week for one month prior to the colonoscopy</LI>
</UL> </div><div style="margin-bottom: 10px;">Timelines from Oct 2014 to Feb 2015 </div><div>Location: France (E Herriot Hospital); Germany (Gastroenterologie am Bayerischen Platz); Netherlands (Medisch Centrum Alkmaar) - There may be other sites in those contries.<wbr> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="GastroEnterology2031c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">Clarification on tailored dose: </div><div>First dose one day before colonoscopy or on the day of colonoscopy, dependent on the planned time for colonoscopy, and second dose on the day of colonoscopy </div><font size="-1">Anne Kornowski / <a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2031" class="commentpermalink">GastroEnterology2031</a> / <span class="date">16 September 2014</span> /
<span class="time">16:30:01 o'clock CEST</span>
</font></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2026">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-09-15T18:17:07+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>OPKO Launches Blood Test to Identify Risk fo Aggressive PCa [dis:Prostate, sub:Biomarkers, sub:Diagnostic]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9950</link>
<description>OPKO Launches Blood Test to Identify Risk fo Aggressive PCa [dis:Prostate, sub:Biomarkers, sub:Diagnostic]</description><category>dis:Prostate</category><category>sub:Biomarkers</category><category>sub:Diagnostic</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9950</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=9950">OPKO Launches Blood Test to Identify Risk fo Aggressive PCa</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=sub%3aBiomarkers"><font color="#e95e0b">:Oncology:sub:Biomarkers</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=sub%3aDiagnostic"><font color="#e95e0b">:Oncology:sub:Diagnostic</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9950">Oncology9950</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 15 September 2014 | 17:40</font><br><br><div style="margin-bottom: 10px;">Comment: The EU launch of the '4Kscore Test' is being done in partnership with Barnaclínic, a branch of Hospital Clínic de Barcelona.<wbr> The test was launched earlier this year in the U.<wbr>S.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">What is 4KScore ?</FONT></STRONG> </div><div style="margin-bottom: 10px;">The 4Kscore measures the blood plasma levels of four different prostate-derived kallikrein proteins: Total PSA, Free PSA, Intact PSA and Human Kallikrein 2 (hK2).<wbr> </div><div style="margin-bottom: 10px;">These biomarkers are combined with a patient's age, Digital Rectal Exam (DRE) status (nodule /<wbr> no nodule), and prior negative biopsy status (yes /<wbr> no) using a proprietary algorithm to calculate the risk (probability) of finding a Gleason Score 7 or higher prostate cancer.<wbr> </div><div style="margin-bottom: 10px;">The four kallikrein panel of biomarkers utilized in the 4Kscore Test is based on over a decade of research conducted by scientists at Memorial Sloan-Kettering Cancer Center and leading European institutions.<wbr> </div><div><EM>Source: OPKO</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=9950">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-09-15T17:40:41+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Allergan to Reduce Workforce [comp:Allergan]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7732</link>
<description>Allergan to Reduce Workforce [comp:Allergan]</description><category>comp:Allergan</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7732</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7732">Allergan to Reduce Workforce</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20141231&edate=20140901&cat=comp%3aAllergan"><font color="#e95e0b">:Neurology:comp:Allergan</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7732">Neurology7732</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 15 September 2014 | 11:12</font><br><br><div style="margin-bottom: 10px;">Comment: Allergan has announced its plans to cut 129 jobs in Irvine (CA).<wbr> The job cuts are part of an intiative to eliminate 1500 jobs as the company attempts to resist takeover efforts by Valeant and Pershing Suqare Capital Management.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Details and Timelines</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7732/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">The layoffs are effective Oct 31.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Traction Article</STRONG> </div><div style="margin-bottom: 10px;">See <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7659" class="defaultlink">Neurology7659: Allergan Cuts Costs - Challenging What More Valeant Could Achieve</a> </div><div>Source: <A href="http://www.ocbj.com/news/2014/sep/12/allergan-cut-129-irvine-jobs/">http:/<wbr>/<wbr>www.<wbr>ocbj.<wbr>com/<wbr>news/<wbr>2014/<wbr>sep/<wbr>12/<wbr>allergan-cut-129-irvine-jobs/<wbr></A> </div><!-- Comment details --><a name="neurology7732attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7732/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(30,7 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7732">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-09-15T11:12:11+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7732/1/ScreenCapture1.jpg" length="31451" type="image/jpeg"/></item><item>
<title>New Alpha-based PRRT Agent Demonstrates First-In-Human Efficacy In NET [headline]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7792</link>
<description>New Alpha-based PRRT Agent Demonstrates First-In-Human Efficacy In NET [headline]</description><category>headline</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7792</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20141231&edate=20140901&rec=7792">New Alpha-based PRRT Agent Demonstrates First-In-Human Efficacy In NET</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20141231&edate=20140901&cat=headline"><font color="#e95e0b">:Endocrinology:headline</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7792">Endocrinology7792</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 12 September 2014 | 17:03</font><br><br><div style="margin-bottom: 10px;">Comment: UK NET highlighted yesterday the first data demonstrating the effectiveness of a new alpha radionuclide <STRONG><SUP>213</SUP>Bi-DOTATOC </STRONG>therapy that induces remission in NET refractory to currently known beta radiation agents in clinical development.<wbr>.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Background</STRONG> </div><div style="margin-bottom: 10px;"><P class="a-plus-plus">7 patients with progressive advanced neuroendocrine liver metastases refractory to treatment with <STRONG><SUP class="a-plus-plus">90</SUP>Y/<wbr><SUP class="a-plus-plus">177</SUP>Lu-DOTATOC</STRONG> were treated with an intraarterial infusion of <STRONG><SUP class="a-plus-plus">213</SUP>Bi-DOTATOC</STRONG>, and one patient with bone marrow carcinosis was treated with a systemic infusion of <STRONG><SUP class="a-plus-plus">213</SUP>Bi-DOTATOC</STRONG>.<wbr></P> </div><div style="margin-bottom: 10px;"><P class="a-plus-plus"><STRONG>Evaluations</STRONG></P> </div><div style="margin-bottom: 10px;"><UL><LI>Haematological, kidney and endocrine toxicities were assessed according to CTCAE criteria.<wbr>
</LI>
<LI>Radiological response was assessed with contrast-enhanced MRI and <SUP class="a-plus-plus">68</SUP>Ga-DOTATOC-PET.<wbr>
</LI>
</UL> </div><div style="margin-bottom: 10px;"><P class="a-plus-plus"><STRONG>Key Findings</STRONG></P> </div><div style="margin-bottom: 10px;"><P class="a-plus-plus">More than 2 years of follow-up data on the 7 patients is now available.<wbr> Enduring responses were observed in all 7 treated patients.<wbr> Chronic kidney toxicity was moderate.<wbr> Acute haematotoxicity was even less pronounced than with the preceding beta therapies.<wbr></P> </div><div style="margin-bottom: 10px;"><P class="a-plus-plus">The authors of the paper conclude that <STRONG><SUP>213</SUP>Bi-DOTATOC </STRONG>can induce remission of tumours refractory to beta radiation with favourable acute and mid-term toxicity at therapeutic effective doses.<wbr></P> </div><div style="margin-bottom: 10px;">Source: <a href="http://www.ukinets.org/news/" class="defaultlink" title="http://www.ukinets.org/news/">ukinets.org/<wbr>news/<wbr></a> </div><div><A href="http://link.springer.com/journal/259">European Journal of Nuclear Medicine and Molecular Imaging</A> July 2014 Date: 29 Jul 2014 </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20141231&edate=20140901&rec=7792">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-09-12T17:03:59+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>Altor Concludes Its First Commercialisation Agreement For ALT-803 In China [dis:Bladder]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9948</link>
<description>Altor Concludes Its First Commercialisation Agreement For ALT-803 In China [dis:Bladder]</description><category>dis:Bladder</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9948</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=9948">Altor Concludes Its First Commercialisation Agreement For ALT-803 In China</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=dis%3aBladder"><font color="#e95e0b">:Oncology:dis:Bladder</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9948">Oncology9948</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 12 September 2014 | 16:13</font><br><br><div style="margin-bottom: 10px;">Comment: Altor BioScience Corporation has concluded an agreement with Shenzhen Beike Biotechnology Co.<wbr>, Ltd.<wbr> (Beike), a leading Chinese cell-based therapy company which covers the development and commercialisation of ALT-803 in China.<wbr>.<wbr> ALT-803 is proprietary Interleukin-15 (IL-15) based superagonist complex that is being developed for NMIBC </div><div style="margin-bottom: 10px;"><STRONG>Deal Terms</STRONG> </div><div style="margin-bottom: 10px;">The agreement reached covers all human disease indications being pursued.<wbr>, Altor will receive an up-front fee of US$4 million and could potentially receive over US$200 million in development and sales milestones, and tiered double-digit royalties based on sales of licensed products.<wbr> Beike has also made a strategic equity investment of approximately US$5 million into Altor.<wbr> Whilst Beike has marketing rights for licensed products in China Altor retains marketing rights in all other countries.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>ALT-803 is a potent immunotherapeutic agent</STRONG> that as shown in the pipeline chart below is being developed for the multiple myeloma but also for non-muscle invasive bladder cancer (NMIBC).<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9948/1/ScreenCapture1.jpg?user-agent=rss"> </div><div>Source <A href="http://www.altor.com">www.<wbr>altor.<wbr>com</A> </div><!-- Comment details --><a name="oncology9948attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9948/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(77 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=9948">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-09-12T16:13:51+02:00</dc:date><dc:creator>jac89886</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9948/1/ScreenCapture1.jpg" length="78892" type="image/jpeg"/></item><item>
<title>Colon Capsule Maker to Raise $40-60M in IPO [sub:CRCPrevention]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2022</link>
<description>Colon Capsule Maker to Raise $40-60M in IPO [sub:CRCPrevention]</description><comments>http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2022</comments><category>sub:CRCPrevention</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2022</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2022">Colon Capsule Maker to Raise $40-60M in IPO</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20141231&edate=20140901&cat=sub%3aCRCPrevention"><font color="#e95e0b">:GastroEnterology:sub:CRCPrevention</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2022">GastroEnterology2022</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 12 September 2014 | 14:36</font><br><br><div style="margin-bottom: 10px;">Comment: Check-Cap's disposable capsules which relies on X-ray technology is expected to be approved in 2015 (EU/<wbr>US).<wbr> The X-ray Radar technology is designed to image only the colon interior through which it travels.<wbr> It is self-administered, non-invasive and<STRONG> does not require</STRONG> <STRONG>preparation</STRONG>.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">About the Company</FONT></STRONG> </div><div style="margin-bottom: 10px;">Financials backers include Pontifax Venture Capital Fund and a General Electric Co Investment arm.<wbr> </div><div style="margin-bottom: 10px;">In talks for a New-York listing in approx 6 to 8 months </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">About the Technology</FONT></STRONG> </div><div style="margin-bottom: 10px;">- expected to detect clinically significant polyps within the same range of accuracy as a standard colonoscopy, and to detect polyps behind colon folds as well.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2022/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG>Advantages</STRONG> </div><div style="margin-bottom: 10px;">- No hospital beds or expensive equipment are required.<wbr> </div><div style="margin-bottom: 10px;">- A trained GI physician can analyze the data collected by the wrist-worn receiver from any computer in about 10 minutes, and a colonoscopy will be needed only if polyps are detected.<wbr> </div><div style="margin-bottom: 10px;">- Doctors will spend less time on screenings, and more time with patients who need therapeutic colonoscopies.<wbr> </div><div>Source: Check-Cap </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="GastroEnterology2090c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">Check-Cap has announced the closing of a financing to support clinical development of the Check-Cap imaging system.<wbr>  The financing was led by Fosun Pharma, a leading Chinese healthcare company, joined by existing investors; General Electric Ventures, Pontifax, Docor, Counterpoint, together with MNS and several additional investors.<wbr> The Check-Cap imaging system requires <STRONG>no fasting or prior bowel cleansing</STRONG> as the imaging capsule employs X-rays for colon section measurements.<wbr> </div><div style="margin-bottom: 10px;">The X-rays are ultra-low dose (with radiation exposure approximating that of a single chest X-ray) and allow for 3-dimensional imaging of the lining of the colon even when the capsule is surrounded by intestinal content.<wbr> The ability to transmit a full 360-degree radius around the capsule is expected to allow for the detection of polyps including those located behind colon folds.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>About the Clinical Programs</STRONG> </div><div style="margin-bottom: 10px;">Check-Cap plans to expand its clinical program by launching a pivotal study in Europe and expects to submit a request for CE mark toward the end of 2015.<wbr> </div><div style="margin-bottom: 10px;">A pivotal study in the U.<wbr>S.<wbr> is planned subsequently.<wbr> </div><div>The company also intends to pursue regulatory approvals in China and Japan </div><font size="-1">Brigitte DESCHAMPS / <a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2090" class="commentpermalink">GastroEnterology2090</a> / <span class="date">24 October 2014</span> /
<span class="time">17:48:29 o'clock CEST</span>
</font></div><a name="GastroEnterology2256c"></a><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;"><SPAN style="color: #000000;"><SPAN style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; display: inline !important; font: 14px/16px Calibri, Tahoma, Arial; white-space: normal; orphans: 2; float: none; letter-spacing: normal; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">The company has announced p</SPAN>ricing of IPO, and expects to raise $24M in IPO and simultaneous private placement.<wbr> Next month, two new directors will be joining the company to help bringing the capsule to the market.<wbr></SPAN> </div><div style="margin-bottom: 10px;">Mr.<wbr> Yuval Yanai is a senior executive, bringing more than 25 years of cross-functional experience to Check-Cap Ltd<SPAN style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; display: inline !important; font: 14px/16px Calibri, Tahoma, Arial; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #2e4b80; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">.<wbr> <SPAN style="color: #000000;">From 2005 through 2014, Mr.<wbr> Yanai served as Senior Vice President and Chief Financial Officer of Given Imaging Ltd.<wbr>, a developer and manufacturer of diagnostic products for the visualization and detection of disorders of the gastrointestinal tract (sold to Covidien for </SPAN></SPAN><SPAN style="color: #000000;"><SPAN class="xn-money" style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; font: 14px/16px Calibri, Tahoma, Arial; white-space: normal; orphans: 2; letter-spacing: normal; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">$1 billion</SPAN><SPAN style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; display: inline !important; font: 14px/16px Calibri, Tahoma, Arial; white-space: normal; orphans: 2; float: none; letter-spacing: normal; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"> in 2014)</SPAN></SPAN> </div><div><SPAN style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; display: inline !important; font: 14px/16px Calibri, Tahoma, Arial; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">Mr.<wbr> Steven J.<wbr> Hanley is an experienced global business leader who has managed highly complex pharmaceutical and medical device operations with annual global revenue exceeding $1 billion<SPAN style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; display: inline !important; font: 14px/16px Calibri, Tahoma, Arial; white-space: normal; orphans: 2; float: none; letter-spacing: normal; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">.<wbr> As the President of Covidien plc's Imaging Solutions business unit, he led a multifunctional organization that included sales, marketing, logistics, manufacturing, as well as research and development.<wbr> Internationally, his track record includes numerous new drug and device product introductions and sales force expansion in </SPAN><SPAN class="xn-location" style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; font: 14px/16px Calibri, Tahoma, Arial; white-space: normal; orphans: 2; letter-spacing: normal; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">Eastern Europe</SPAN><SPAN style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; display: inline !important; font: 14px/16px Calibri, Tahoma, Arial; white-space: normal; orphans: 2; float: none; letter-spacing: normal; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">, </SPAN><SPAN class="xn-location" style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; font: 14px/16px Calibri, Tahoma, Arial; white-space: normal; orphans: 2; letter-spacing: normal; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">China</SPAN><SPAN style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; display: inline !important; font: 14px/16px Calibri, Tahoma, Arial; white-space: normal; orphans: 2; float: none; letter-spacing: normal; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"> and </SPAN><SPAN class="xn-location" style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; font: 14px/16px Calibri, Tahoma, Arial; white-space: normal; orphans: 2; letter-spacing: normal; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">Latin America</SPAN><SPAN style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; display: inline !important; font: 14px/16px Calibri, Tahoma, Arial; white-space: normal; orphans: 2; float: none; letter-spacing: normal; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">.<wbr></SPAN></SPAN> </div><font size="-1">Brigitte DESCHAMPS / <a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2256" class="commentpermalink">GastroEnterology2256</a> / <span class="date">20 February 2015</span> /
<span class="time">15:22:22 o'clock CET</span>
</font></div><a name="gastroenterology2022attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2022/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(29,1 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2022">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-09-12T14:36:08+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2022/1/ScreenCapture1.jpg" length="29799" type="image/jpeg"/></item><item>
<title>AAA's Expansion Plans in Italy [sub:Diagnostic, :PharmaWorld:mkt:Italy]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7791</link>
<description>AAA's Expansion Plans in Italy [sub:Diagnostic, :PharmaWorld:mkt:Italy]</description><category>sub:Diagnostic</category><category>mkt:Italy</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7791</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20141231&edate=20140901&rec=7791">AAA's Expansion Plans in Italy</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20141231&edate=20140901&cat=sub%3aDiagnostic"><font color="#e95e0b">:Endocrinology:sub:Diagnostic</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=mkt%3aItaly"><font color="#e95e0b">:PharmaWorld:mkt:Italy</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7791">Endocrinology7791</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 12 September 2014 | 14:00</font><br><br><div style="margin-bottom: 10px;">Comment: Advanced Accelerator Applications (AAA) has entered into an agreement with GE Healthcare in Italy to acquire its Italian FDG-PET imaging agent business (fluorodeoxyglucose photon emission tomography).<wbr> This acquisition includes the licence to market GE Healthcare’s SteriPET® (FDG) imaging agent in Italy.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Rationale for AAA</FONT></STRONG> </div><div style="margin-bottom: 10px;">- to consolidate its leading pan-EU position in nuclear diagnostics in addition to US expansion (see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20141231&edate=20140901&rec=7649" class="defaultlink">Endocrinology7649: AAA's Expansion Plans For The US</a>).<wbr> </div><div style="margin-bottom: 10px;">- to benefit from economies of scale in order to provide quality products and services at reduced costs.<wbr> </div><div style="margin-bottom: 10px;">- to broaden its presence in the Italian PET market, and add to its existing production capacity portfolio.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">AAA EU Position</FONT></STRONG> </div><div style="margin-bottom: 10px;">-leader in Molecular Nuclear Medicine  in Europe with a portfolio of 6 diagnostic PET and SPECT products and several diagnostic and therapeutic product candidates including Lu-DOTATATE, currently in a pivotal Ph3 trial for the treatment of GEPNETs  in 51 clinical centers in the US and Europe.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Leading Diagnostic Product</FONT></STRONG> </div><div style="margin-bottom: 10px;">- Gluscan®, fluorodeoxyglucose (FDG) PET imaging agent.<wbr> Gluscan® assists in the diagnosis of serious diseases, primarily in oncology, by assessing glucose metabolism.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Production Facilities</FONT></STRONG> </div><div style="margin-bottom: 10px;">- 13 PET production facilities based in France, Germany, Italy, Poland, Portugal and Spain.<wbr> </div><div><EM>Source: AAA</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20141231&edate=20140901&rec=7791">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-09-12T14:00:30+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>re: Xtandi Approved by the FDA for Pre-Chemo Setting</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9947</link>
<description>re: Xtandi Approved by the FDA for Pre-Chemo Setting</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9947</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=9947">re: Xtandi Approved by the FDA for Pre-Chemo Setting</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9947">Oncology9947</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/994">Jenny Wu</a> | 11 September 2014 | 18:40</font><br><br><div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Xtandi Approved by the FDA for Pre-Chemo Setting</span>&nbsp;<font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=comp%3aAstellas"><font color="#e95e0b">:Oncology:comp:Astellas</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=prod%3aMDV3100"><font color="#e95e0b">:Oncology:prod:MDV3100</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=sub%3aRegulatory"><font color="#e95e0b">:PharmaWorld:sub:Regulatory</font></a>]</font></font><br><span style="font-size: 12px;">Comment: The U.<wbr>S agency has approved the use of Medivation <MDVN.O>and Astellas's Xtandi in men who have not yet received chemotherapy.<wbr> The decision comes a week before Sept 18 PDUFA date, and triggers a $90M milestone payment to Medivation.<wbr> A filing for pre-chemo use is in process in Europe, and label changes are under negotiation in Japan.<wbr> This new approval significantly expands the potential patient population, and enables the drug to better compete with Zytiga.<wbr> Wedbusch view remains that urologists will prefer Xtandi in the pre-chemotherapy setting due to its numerically better prevention of disease progression (relative to competitor Zytiga), including its 17-month extension of time to chemotherapy, and dosing convenience (no steroid requirement).<wbr></MDVN.O></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=9942">...</a><br><font size="-1">Brigitte DESCHAMPS / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9942" class="commentpermalink">Oncology9942</a> / <span class="date">11 September 2014</span> /
<span class="time">11:54:09 o'clock CEST</span>
</font></div><div style="margin-bottom: 10px;">Comment: Medivation held a conference call earlier today to make a statement in response to FDA's approval decision of Xtandi's extended label in chemo na&iuml;ve mCRPC setting.<wbr> Overall the updated Xtandi label is in-line with expectations and is now better than the Zytiga label.<wbr> The new indication is for the treatment of patients with metastatic castration-resistant prostate cancer which is the same as the Zytiga indication and encompasses the pre-chemo and post-chemo segments.<wbr> In the clinical section of the label the statistically significant improvement in overall survival from PREVAIL is included, compared to the Zytiga label which states the analysis of overall survival did <STRONG><SPAN style="text-decoration: underline;">not</SPAN></STRONG> meet statistical significance.<wbr> Despite of approval decision, FDA still requires Medivation to provide a follow-up OS analysis with the minimum of 765 events that was planned initially.<wbr> Medivation has the co-promoting rights with Astellas in US.<wbr> This approval means that Medivation's commercial strategy and effort will be targeting urologists community - with a focus of selling Xtandi's 'better efficacy story'.<wbr> </div><div style="margin-bottom: 10px;">Clinical Data Up to date </div><div style="margin-bottom: 10px;"><TABLE align="center" border="0" style="width: 686px; height: 187px;"><TBODY><TR><TD>&nbsp;</TD>
<TD>Enzalutamide</TD>
<TD>Placebo</TD>
</TR>
<TR><TD>Reduction Risk Of Death</TD>
<TD colspan="2" style="text-align: center;">
<P>29% (HR = 0.<wbr>71, p&lt;0.<wbr>0001)</P>
</TD>
</TR>
<TR><TD>Reduction Risk of Radiologic Progression </TD>
<TD colspan="2" style="text-align: center;">83% (HR=0.<wbr>17, p&lt;0.<wbr>001)</TD>
</TR>
<TR><TD>Risk of First SKE event</TD>
<TD colspan="2" style="text-align: center;">28% (HR=0.<wbr>72, p&lt;0.<wbr>0001)</TD>
</TR>
<TR><TD>Median Treatment Duration</TD>
<TD style="text-align: center;">17.<wbr>5 months</TD>
<TD style="text-align: center;">4.<wbr>6 months</TD>
</TR>
<TR><TD colspan="3"><STRONG>Subsequent Therapies</STRONG></TD>
</TR>
<TR><TD>Use of subsequent life extending therapies</TD>
<TD style="text-align: center;">40%</TD>
<TD style="text-align: center;">70%</TD>
</TR>
<TR><TD>Time to initiation of chemotherapy</TD>
<TD style="text-align: center;">28 months</TD>
<TD style="text-align: center;">10.<wbr>8 months</TD>
</TR>
<TR><TD>&nbsp;</TD>
<TD colspan="2" style="text-align: center;">(HR= 0.<wbr>35, p&lt;0.<wbr>0001)</TD>
</TR>
</TBODY>
</TABLE> </div><div style="margin-bottom: 10px;">Safety Profile: No major safety concerns.<wbr> The most common AE were asthenia and fatigue, back pain, decreased appetite, constipation arthralgia, diarrhoea, hot flush, upper respiratory track infection, peripheral oedema, dyspnea, musculoskeletal pain, weight decrease, headache, hypertension, dizziness and vertigo.<wbr> In previously reported analysis from AFFIRM and PREVAIL trial, seizure occurred in 0.<wbr>9% of patients.<wbr> In the chemo na&iuml;ve setting, 0.<wbr>1% of patient, one in each treatment arm, experience seizure.<wbr> Discontinuation of the treatment due to AEs were recorded for 6% of each arm, and the most common AE leading to treatment discontinuation was fatigue and asthenia (~1% of patient in each arm).<wbr> </div><div>During the Q&amp;A Session, Dr .<wbr> David Hung (President &amp; CEO of Medivation Inc.<wbr>) has confirmed their plan to entry M0 CRPC space, and targeting urologists will definitely be their key to success in anticipation of entry in M0 CRPC market.<wbr> Hung also threw a splash of hint on Medivation/<wbr>Astellas' ambition to expand into even earlier setting to replace Casodex with the ongoing head to head STRIVE (<a href="https://clinicaltrials.gov/ct2/show/NCT01664923?term=STRIVE%2C+enzalutamide&rank=1" class="defaultlink">NCT01664923</a>) and TERRAIN (<a href="http://clinicaltrials.gov/show/NCT01288911" class="defaultlink">NCT01288911</a>) trial.<wbr> The data is expected to be available end of 2014 or early 2015.<wbr> There was no interim analysis and the TERRAIN study has enrolled metastatic patients so PFS is likely to be similar to the 16 months that was in PREVAIL.<wbr> </div><!-- Comment details --><font size="-1">Jenny Wu / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9947" class="commentpermalink">Oncology9947</a> / <span class="date">11 September 2014</span> /
<span class="time">18:40:55 o'clock CEST</span>
</font><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=9947">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9942">View thread  Oncology9942: Xtandi Approved by the FDA for Pre-Chemo Setting</a>]]></content:encoded><dc:date>2014-09-11T18:40:55+02:00</dc:date><dc:creator>jew60237</dc:creator></item><item>
<title>CHDI and Evotec Extend Collaboration to Fight HD [dis:Huntington]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7730</link>
<description>CHDI and Evotec Extend Collaboration to Fight HD [dis:Huntington]</description><category>dis:Huntington</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7730</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7730">CHDI and Evotec Extend Collaboration to Fight HD</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20141231&edate=20140901&cat=dis%3aHuntington"><font color="#e95e0b">:Neurology:dis:Huntington</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7730">Neurology7730</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 11 September 2014 | 14:01</font><br><br><div style="margin-bottom: 10px;">Comment: CHDI has extended and restated its collaboration with Evotec through 2017.<wbr> The partnership with Evotec, which has been ongoing since 2006, is one of CHDI largest and longest-standing relationships with a CRO.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">CHDI Committment</FONT></STRONG> </div><div style="margin-bottom: 10px;">- will fund up to 52 full-time scientists at Evotec over the next 3 years.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Objectives of the New Collaboration</FONT></STRONG> </div><div style="margin-bottom: 10px;">- further validate Evotec's broad drug discovery expertise in the field of neurosciences </div><div style="margin-bottom: 10px;">- to utilise Evotec's high throughtput screening and <A href="http://www.evotec.com/uploads/media_library/31/2013-09_S6_Proteomics.pdf">proteomics platforms</A> </div><div><EM>Source: Evotec; CHDI</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7730">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-09-11T14:01:41+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Xtandi Approved by the FDA for Pre-Chemo Setting [comp:Astellas, dis:Prostate, prod:MDV3100, :PharmaWorld:sub:Regulatory]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9942</link>
<description>Xtandi Approved by the FDA for Pre-Chemo Setting [comp:Astellas, dis:Prostate, prod:MDV3100, :PharmaWorld:sub:Regulatory]</description><comments>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9942</comments><category>comp:Astellas</category><category>dis:Prostate</category><category>prod:MDV3100</category><category>sub:Regulatory</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9942</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=9942">Xtandi Approved by the FDA for Pre-Chemo Setting</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=comp%3aAstellas"><font color="#e95e0b">:Oncology:comp:Astellas</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=prod%3aMDV3100"><font color="#e95e0b">:Oncology:prod:MDV3100</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=sub%3aRegulatory"><font color="#e95e0b">:PharmaWorld:sub:Regulatory</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9942">Oncology9942</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 11 September 2014 | 11:54</font><br><br><div style="margin-bottom: 10px;">Comment: The U.<wbr>S agency has approved the use of Medivation <MDVN.O>and Astellas's Xtandi in men who have not yet received chemotherapy.<wbr> The decision comes a week before Sept 18 PDUFA date, and triggers a $90M milestone payment to Medivation.<wbr> A filing for pre-chemo use is in process in Europe, and label changes are under negotiation in Japan.<wbr> This new approval significantly expands the potential patient population, and enables the drug to better compete with Zytiga.<wbr> Wedbusch view remains that urologists will prefer Xtandi in the pre-chemotherapy setting due to its numerically better prevention of disease progression (relative to competitor Zytiga), including its 17-month extension of time to chemotherapy, and dosing convenience (no steroid requirement).<wbr></MDVN.O> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Analyst Forecasts</FONT></STRONG> </div><div style="margin-bottom: 10px;">Sanford Bernstein analyst believes that the average duration of treatment should double and the addressable patient population triple in this setting.<wbr> </div><div style="margin-bottom: 10px;">SMBC NIKKO Securities has forecast eventual peak annual Xtandi sales to reach $5 bln.<wbr> </div><div style="margin-bottom: 10px;">Wedbusch are forecasting $630.<wbr>9M in US Xtandi sales in 2014 ($167.<wbr>3M and $195.<wbr>4M in Q3:14 and Q4:14, respectively), and with the expected inflection in sales from the additional indication, growth to $1.<wbr>05B in 2015 US Xtandi sales.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Xtandi Last Figures</FONT></STRONG> </div><div style="margin-bottom: 10px;">Astellas reported WW Xtandi sales of $227M in the second quarter.<wbr> </div><div>Source : <A href="http://investors.medivation.com/releasedetail.cfm?ReleaseID=870267">http:/<wbr>/<wbr>investors.<wbr>medivation.<wbr>com/<wbr>releasedetail.<wbr>cfm?ReleaseID=870267</A> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Oncology9947c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">Comment: Medivation held a conference call earlier today to make a statement in response to FDA's approval decision of Xtandi's extended label in chemo na&iuml;ve mCRPC setting.<wbr> Overall the updated Xtandi label is in-line with expectations and is now better than the Zytiga label.<wbr> The new indication is for the treatment of patients with metastatic castration-resistant prostate cancer which is the same as the Zytiga indication and encompasses the pre-chemo and post-chemo segments.<wbr> In the clinical section of the label the statistically significant improvement in overall survival from PREVAIL is included, compared to the Zytiga label which states the analysis of overall survival did <STRONG><SPAN style="text-decoration: underline;">not</SPAN></STRONG> meet statistical significance.<wbr> Despite of approval decision, FDA still requires Medivation to provide a follow-up OS analysis with the minimum of 765 events that was planned initially.<wbr> Medivation has the co-promoting rights with Astellas in US.<wbr> This approval means that Medivation's commercial strategy and effort will be targeting urologists community - with a focus of selling Xtandi's 'better efficacy story'.<wbr> </div><div style="margin-bottom: 10px;">Clinical Data Up to date </div><div style="margin-bottom: 10px;"><TABLE align="center" border="0" style="width: 686px; height: 187px;"><TBODY><TR><TD>&nbsp;</TD>
<TD>Enzalutamide</TD>
<TD>Placebo</TD>
</TR>
<TR><TD>Reduction Risk Of Death</TD>
<TD colspan="2" style="text-align: center;">
<P>29% (HR = 0.<wbr>71, p&lt;0.<wbr>0001)</P>
</TD>
</TR>
<TR><TD>Reduction Risk of Radiologic Progression </TD>
<TD colspan="2" style="text-align: center;">83% (HR=0.<wbr>17, p&lt;0.<wbr>001)</TD>
</TR>
<TR><TD>Risk of First SKE event</TD>
<TD colspan="2" style="text-align: center;">28% (HR=0.<wbr>72, p&lt;0.<wbr>0001)</TD>
</TR>
<TR><TD>Median Treatment Duration</TD>
<TD style="text-align: center;">17.<wbr>5 months</TD>
<TD style="text-align: center;">4.<wbr>6 months</TD>
</TR>
<TR><TD colspan="3"><STRONG>Subsequent Therapies</STRONG></TD>
</TR>
<TR><TD>Use of subsequent life extending therapies</TD>
<TD style="text-align: center;">40%</TD>
<TD style="text-align: center;">70%</TD>
</TR>
<TR><TD>Time to initiation of chemotherapy</TD>
<TD style="text-align: center;">28 months</TD>
<TD style="text-align: center;">10.<wbr>8 months</TD>
</TR>
<TR><TD>&nbsp;</TD>
<TD colspan="2" style="text-align: center;">(HR= 0.<wbr>35, p&lt;0.<wbr>0001)</TD>
</TR>
</TBODY>
</TABLE> </div><div style="margin-bottom: 10px;">Safety Profile: No major safety concerns.<wbr> The most common AE were asthenia and fatigue, back pain, decreased appetite, constipation arthralgia, diarrhoea, hot flush, upper respiratory track infection, peripheral oedema, dyspnea, musculoskeletal pain, weight decrease, headache, hypertension, dizziness and vertigo.<wbr> In previously reported analysis from AFFIRM and PREVAIL trial, seizure occurred in 0.<wbr>9% of patients.<wbr> In the chemo na&iuml;ve setting, 0.<wbr>1% of patient, one in each treatment arm, experience seizure.<wbr> Discontinuation of the treatment due to AEs were recorded for 6% of each arm, and the most common AE leading to treatment discontinuation was fatigue and asthenia (~1% of patient in each arm).<wbr> </div><div>During the Q&amp;A Session, Dr .<wbr> David Hung (President &amp; CEO of Medivation Inc.<wbr>) has confirmed their plan to entry M0 CRPC space, and targeting urologists will definitely be their key to success in anticipation of entry in M0 CRPC market.<wbr> Hung also threw a splash of hint on Medivation/<wbr>Astellas' ambition to expand into even earlier setting to replace Casodex with the ongoing head to head STRIVE (<a href="https://clinicaltrials.gov/ct2/show/NCT01664923?term=STRIVE%2C+enzalutamide&rank=1" class="defaultlink">NCT01664923</a>) and TERRAIN (<a href="http://clinicaltrials.gov/show/NCT01288911" class="defaultlink">NCT01288911</a>) trial.<wbr> The data is expected to be available end of 2014 or early 2015.<wbr> There was no interim analysis and the TERRAIN study has enrolled metastatic patients so PFS is likely to be similar to the 16 months that was in PREVAIL.<wbr> </div><font size="-1">Jenny Wu / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9947" class="commentpermalink">Oncology9947</a> / <span class="date">11 September 2014</span> /
<span class="time">18:40:55 o'clock CEST</span>
</font></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=9942">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-09-11T11:54:09+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>re: Nymox Reports Top-Line Results From Localised Prostate Cancer Study</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9941</link>
<description>re: Nymox Reports Top-Line Results From Localised Prostate Cancer Study</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9941</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=9941">re: Nymox Reports Top-Line Results From Localised Prostate Cancer Study</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9941">Oncology9941</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/994">Jenny Wu</a> | 11 September 2014 | 11:14</font><br><br><div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">re: Nymox Reports Top-Line Results From Localised Prostate Cancer Study</span>&nbsp;<br><span style="font-size: 12px;">Comment: Nymox Pharmaceutical Corporation reported new positive data confirming the advantageous side effect profile of the Company's lead compound NX-1207.<wbr> Results from the Brief Male Sexual Function Questionnaire (BMSF) in the Company's recently completed NX03-0040 trial of NX-1207 2.<wbr>5 mg and 15 mg for the treatment of low grade localized prostate cancer indicate that targeted treatment with NX-1207 at either dose had no significant effect on reported sexual function score post-treatment.<wbr> Current approved drugs for prostate enlargement (BPH or benign prostatic hyperplasia) can produce significant sexual side effects such as impotence, decreased libido, ejaculation disorders, and male breast enlargement.<wbr> NX-1207 has been shown not to have these sexual drawbacks in results to date.<wbr> As well, certain of the approved BPH drugs, including the combination drug therapies, are also associated with an increased risk of high-grade prostate cancer.<wbr> By contrast, the area of the prostate targeted with NX-1207 treatment showed less prostate cancer progression with less radiation and surgery due to cancer progression as compared to controls in the recent NX03-0040 trial.<wbr></span>&nbsp;<br><font size="-1">Jenny Wu / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9739" class="commentpermalink">Oncology9739</a> / <span class="date">22 May 2014</span> /
<span class="time">17:37:49 o'clock CEST</span>
</font></div><div style="margin-bottom: 10px;">Comment: Nymox Pharmaceutical Corporation announced on 10th Sept their new positive outcome results for their prostate cancer Ph2 US trial.<wbr> The new findings extend the previously reported study results which showed that patients with NX-1207 treatment after 2 months had less clinical progression and significantly less Gleason grade progression, lower average PSA levels, lower numbers of biopsy cores showing greater malignancy, and lower total volume of more malignant cancer compared to controls.<wbr> NX-1207 is now in Phase 3 development in the US and Europe for benign prostatic hyperplasia (BPH).<wbr> </div><div style="margin-bottom: 10px;">146 patients were enrolled in the NX03-0040 Phase 2 U.<wbr>S.<wbr> trial and either randomized to one of two doses of NX-1207 (2.<wbr>5 mg or 15 mg) or to active surveillance.<wbr> The drug was injected into the area of the prostate where the cancer was detected and repeat biopsies were then performed on all patients, drug treated and controls.<wbr> The patients in the active surveillance group in the study who were eligible could elect crossover drug treatment after their first follow-up rebiopsy.<wbr> Follow-up studies are being conducted of all consenting patients in the study to continue to monitor outcome and safety data.<wbr> </div><div style="margin-bottom: 10px;">To date, NX-1207 has had an excellent safety profile as both a treatment for benign prostatic hyperplasia (BPH) and localized low-risk prostate cancer.<wbr> In the current trial, a new high dose of drug (15 mg) was safely used without drug-related adverse effects.<wbr> NX-1207 has shown safety in repeat injection studies (NX02-0020 and NX02-0022).<wbr> The drug does not lead to immune responses such as antibody formation which can cause significant drug toxicity and/<wbr>or limit usage to single treatments due to drug neutralizing effects.<wbr> </div><div>Clinical outcomes were determined at 8 months from the initial treatments.<wbr> A controlled comparison was conducted of patients who required and received radiation and surgery treatments for their cancer based on blinded post-treatment upgraded evaluations of their pre-treatment initially positive lower grade cancers.<wbr> The study found after 8 months for NX-1207 single-injection treated patients that there was a statistically significant reduction compared to controls of more than 75% (p=.<wbr>002) in the proportion of patients who had upgraded blinded biopsy and laboratory results and went on to require and receive radiation therapy and/<wbr>or surgery.<wbr> The new results also indicated that the NX-1207 treated patients had 67% less progression to surgery and/<wbr>or radiotherapy compared to controls (p=.<wbr>008) for all reasons (including elective surgery and/<wbr>or radiotherapy with no biopsy or laboratory upgrades).<wbr> </div><!-- Comment details --><font size="-1">Jenny Wu / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9941" class="commentpermalink">Oncology9941</a> / <span class="date">11 September 2014</span> /
<span class="time">11:14:18 o'clock CEST</span>
</font><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=9941">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9670">View thread  Oncology9670: Nymox Reports Top-Line Results From Localised Prostate Cancer Study</a>]]></content:encoded><dc:date>2014-09-11T11:14:18+02:00</dc:date><dc:creator>jew60237</dc:creator></item><item>
<title>POC of Q-Med's Botulinum Toxin for Glabellar Frown Lines [sub:Aesthetics, :PharmaWorld:mkt:NorthAmerica, :PharmaWorld:sub:ClinicalTrial, headline]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7728</link>
<description>POC of Q-Med's Botulinum Toxin for Glabellar Frown Lines [sub:Aesthetics, :PharmaWorld:mkt:NorthAmerica, :PharmaWorld:sub:ClinicalTrial, headline]</description><category>sub:Aesthetics</category><category>mkt:NorthAmerica</category><category>sub:ClinicalTrial</category><category>headline</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7728</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7728">POC of Q-Med's Botulinum Toxin for Glabellar Frown Lines</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20141231&edate=20140901&cat=headline"><font color="#e95e0b">:Neurology:headline</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20141231&edate=20140901&cat=sub%3aAesthetics"><font color="#e95e0b">:Neurology:sub:Aesthetics</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=mkt%3aNorthAmerica"><font color="#e95e0b">:PharmaWorld:mkt:NorthAmerica</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=sub%3aClinicalTrial"><font color="#e95e0b">:PharmaWorld:sub:ClinicalTrial</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7728">Neurology7728</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 10 September 2014 | 17:26</font><br><br><div style="margin-bottom: 10px;">Comment: Q-Med has started a Ph2 multicentre randomized trial to evaluate the efficacy in wrinkle reduction of a single treatment of 3 different doses (30U; 45U; 60U) of botulinum toxin compared to placebo, for moderate to very severe glabellar frown lines.<wbr> PE will measure the reduction of glabellar frown line severity on Day 14 following treatment with the toxin.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Trial Details</STRONG> </div><div style="margin-bottom: 10px;">Reference <a href="http://clinicaltrials.gov/ct2/show/NCT02236312?recr=Open&phase=012&fund=2&rcv_s=08%2F10%2F2014&rank=54" class="defaultlink">NCT02236312</a> </div><div style="margin-bottom: 10px;">Recruitment approx 350 </div><div style="margin-bottom: 10px;"><UL><LI>Both genders (from 18 years old)
</LI>
<LI class="color-bullet" style="margin-top: 0.7ex;">Moderate to Very Severe glabellar lines at maximum frown as assessed by the subject and the Investigator and at least Mild glabellar lines at rest
</LI>
</UL> </div><div style="margin-bottom: 10px;">Timelines from Sept 2014 to August 2015 </div><div>Location US (8 private practices) </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7728">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-09-10T17:26:30+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>NICE Bladder Cancer Guideline First Draft Stated Photodynamic Diagnosis Should Be Used For Initial Diagnosis [dis:Bladder, :PharmaWorld:mkt:UK]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9938</link>
<description>NICE Bladder Cancer Guideline First Draft Stated Photodynamic Diagnosis Should Be Used For Initial Diagnosis [dis:Bladder, :PharmaWorld:mkt:UK]</description><category>dis:Bladder</category><category>mkt:UK</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9938</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=9938">NICE Bladder Cancer Guideline First Draft Stated Photodynamic Diagnosis Should Be Used For Initial Diagnosis</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=dis%3aBladder"><font color="#e95e0b">:Oncology:dis:Bladder</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=mkt%3aUK"><font color="#e95e0b">:PharmaWorld:mkt:UK</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9938">Oncology9938</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/994">Jenny Wu</a> | 10 September 2014 | 17:03</font><br><br><div style="margin-bottom: 10px;">comment: NICE is developing its first guidance on bladder cancer diagnosis and treatment to address the variation in the treatment practices across England.<wbr> The intensive treatment and prolonged hospital stays are often needed, and bladder cancer is thought to be one of the most expensive cancers for the NHS.<wbr> This guideline is aimed to help to ensure patients are diagnosed quickly and accurately and receive the best possible care.<wbr> the draft guidance clearly stated that photodynamic diagnosis (PDD) appears to be a cost effective alternative to white light cystoscopy as an initial diagnostic tool.<wbr> GDG considered PDD or narrow band imaging (NBI) are likely to be cost effective over the long term although they could not make recommendation for the preferential benefit from use of PDD or NBI due to lack of comparison data.<wbr> </div><div style="margin-bottom: 10px;">The draft document is available in <a href="http://cis12103:8080/qesipsen/servlet/QESServlet_prepare" class="defaultlink">PEARL</a> and the final guidance will be published in February 2015.<wbr> This will implicate additional investment required from trusts to invest in new equipment (blue light or narrow band imaging system) and training to urologists.<wbr> </div><div style="margin-bottom: 10px;">Recommendations in Draft Document stated: </div><div style="margin-bottom: 10px;">"<STRONG>Offer white-light-guided TURBT, with photodynamic diagnosis, narrow-band imaging, cytology or a urinary biomarker (FISH, ImmunoCyt or NMP22) to people with suspected bladder cancer.<wbr> This should be carried out or supervised by a urologist experienced in TURBT"</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9938/1/diagnosis.JPG?user-agent=rss"> </div><div style="margin-bottom: 10px;">Relative value placed on the outcomes considered: </div><div style="margin-bottom: 10px;"><TABLE border="1" cellpadding="7" cellspacing="0" dir="ltr" style="width: 1035px; height: 75px;"><TBODY><TR><TD height="63" valign="top">
<P>Sensitivity, specificity, and recurrence were considered by the GDG to be the most important outcomes.<wbr> Sensitivity and specificity provide information about the accuracy of the test in detecting bladder cancer.<wbr> Recurrence is a measure of the efficacy of the test.<wbr> <FONT size="2">Morbidity was not considered to be an important outcome because all patients have to undergo cystoscopy.<wbr> Consideration was given to the need for a catheter pre-PDD.<wbr> </FONT></P>
</TD>
</TR>
</TBODY>
</TABLE> </div><div style="margin-bottom: 10px;">Quality of the evidence: </div><div style="margin-bottom: 10px;"><TABLE border="1" cellpadding="7" cellspacing="0" dir="ltr" style="width: 1033px; height: 218px;"><TBODY><TR><TD height="249" valign="top">
<P>Moderate to high quality evidence was identified for sensitivity and specificity and was assessed with the QUADAS tool.<wbr> Recurrence data was assessed as being of moderate quality using GRADE.<wbr> The evidence was limited by a lack of long-term follow-up.<wbr> There were <SPAN style="background-color: #ffff00;">no direct comparisons </SPAN>between PDD and NBI and all patients were initially diagnosed by white light flexible cystoscopy.<wbr> <SPAN style="background-color: #ffff00;">The evidence suggests enhancement of diagnostic accuracy of WLC by the addition of PDD or NBI but due to the lack of direct comparison it is not known if one is more effective than the other.<wbr></SPAN> This prevented the GDG from being able to make a specific recommendation for either PDD or NBI.<wbr> Therefore, the GDG recommended either PDD or NBI to increase diagnostic accuracy, and also made a research recommendation to compare the two tests.<wbr> A research recommendation was made because there is no existing comparison of PDD with NBI and it was considered important to ascertain whether either test affects long-term outcomes.<wbr> The GDG reviewed the data that the use of an initial biomarker might be an effective strategy but using clinical experience they considered that flexible cystoscopy should remain the initial screening investigation in order to diagnose non bladder cancer causes of bladder symptoms.<wbr></P>
<P>Moderate quality health economic evidence was identified.<wbr> The evidence was limited by the assumptions about the benefits of detecting bladder cancer earlier.<wbr> QALYs were not used in the base case analysis, and the economic model did not include NBI.<wbr> <FONT size="2"><SPAN style="background-color: #ffff00;">The GDG assumed that NBI would perform similarly to PDD in cost-effectiveness analysis.<wbr> The cost-effectiveness evidence was used for guidance rather than overriding clinical imperatives</SPAN>.<wbr></FONT></P>
</TD>
</TR>
</TBODY>
</TABLE> </div><div style="margin-bottom: 10px;">Trade-Off between clinical benefits and harms </div><div style="margin-bottom: 10px;"><TABLE border="1" cellpadding="7" cellspacing="0" dir="ltr" style="width: 1030px; height: 83px;"><TBODY><TR><TD height="63" valign="top">
<P>The potential benefit of the recommendations is improved diagnostic accuracy of cystoscopy.<wbr> This may lead to fewer recurrences and therefore fewer TURBTs.<wbr></P>
<P><FONT size="2">This was balanced against the potential harms from more biopsies (some due to false positive findings) leading to increased risk of complications and patient anxiety.<wbr> There may also be extra catheterisation from an increase in patients undergoing PDD.<wbr> <FONT size="2">The GDG agreed that the benefits would outweigh the harms.<wbr> Improved sensitivity was considered more important for patients than false positives.<wbr> Improved diagnostic accuracy would also reduce over-treatment resulting from false positive test results </FONT></FONT></P>
</TD>
</TR>
</TBODY>
</TABLE> </div><div style="margin-bottom: 10px;">Cost Effectiveness Consideration </div><div style="margin-bottom: 10px;"><TABLE border="1" cellpadding="7" cellspacing="0" dir="ltr" style="width: 1031px; height: 140px;"><TBODY><TR><TD height="203" valign="top">
<P>The GDG considered the cost-effectiveness evidence presented but this did not override the clinical evidence.<wbr> <SPAN style="background-color: #ffff00;">The GDG felt that a strategy with flexible cystoscopy as the first line test would always be used, and therefore excluded all strategies that did not include flexible cystoscopy as the initial test</SPAN>.<wbr> The recommendations may incur costs by the increased use of PDD, NBI or urinary biomarkers as well as the costs associated with more biopsies (including histopathology and morbidity<SPAN style="background-color: #ffff00;">).<wbr> However, there are potential savings from more accurate diagnosis and the reduction of recurrences and residual tumours.<wbr> </SPAN>Based on their judgement and the economic evidence presented, the GDG considered that their recommendations were likely to be cost-effective over the long-term.<wbr></P>
<P>In the economic evidence, the strategy considered to represent current practice was found to be clinically inferior to most other strategies.<wbr> <FONT size="2">In a modified analysis for the GDG (where all strategies that did not include flexible cystoscopy as the initial test were excluded), recommended strategies were either dominant (i.<wbr>e.<wbr> more effective and less expensive) or had an ICER ranging from &pound;700 to &pound;7,960 per life year gained.<wbr> Therefore, the recommended approaches are likely to be cost-effective compared to current practice.<wbr> </FONT></P>
</TD>
</TR>
</TBODY>
</TABLE> </div><div>Source: <A href="http://www.nice.org.uk">http:/<wbr>/<wbr>www.<wbr>nice.<wbr>org.<wbr>uk</A>.<wbr> </div><!-- Comment details --><a name="oncology9938attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9938/1/diagnosis.JPG">diagnosis.JPG</a>&nbsp;&nbsp;(71,7 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=9938">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-09-10T17:03:57+02:00</dc:date><dc:creator>jew60237</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9938/1/diagnosis.JPG" length="73415" type="image/jpeg"/></item><item>
<title>The US FDA is Preparing to Approve the First Biosimilar Product [mkt:NorthAmerica, sub:Generics, news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10953</link>
<description>The US FDA is Preparing to Approve the First Biosimilar Product [mkt:NorthAmerica, sub:Generics, news]</description><category>mkt:NorthAmerica</category><category>sub:Generics</category><category>news</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10953</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20141231&edate=20140901&rec=10953">The US FDA is Preparing to Approve the First Biosimilar Product</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=mkt%3aNorthAmerica"><font color="#e95e0b">:PharmaWorld:mkt:NorthAmerica</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=news"><font color="#e95e0b">:PharmaWorld:news</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=sub%3aGenerics"><font color="#e95e0b">:PharmaWorld:sub:Generics</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10953">PharmaWorld10953</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 10 September 2014 | 16:45</font><br><br><div style="margin-bottom: 10px;">Comment: Ahead of the approval of Novartis' biosimilar version of Amgen's Neupogen (filgrastim), the FDA has published a list of biological products in a new database called the Purple Book, which will include biosimilar and interchangeable biological products approved by the regulator under the Public Health Service (PHS) Act.<wbr> According to the Purple Book, J&amp;J's Remicade (infliximab) reference product exclusivity has expired and the bestseller anti-inflammatory monoclonal antibody (mAb) may be expecting biosimilar entry in the US in the near future.<wbr> The launch of the first biosimilar glycoprotein and biosimilar mAb in the US will mark a milestone for the biosimilars industry as a wave of biosimilars is anticipated to follow soon.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>About the Purple Book Database</STRONG> </div><div style="margin-bottom: 10px;">The database will hold information regarding the date of licensure, if a product has been assessed for reference product exclusivity, and if a product is determined to be biosimilar to or interchangeable with a reference product.<wbr> Biosimilars licensed by the US FDA under the PHS Act will be listed under the reference product.<wbr> </div><div style="margin-bottom: 10px;">The Purple Book will also include separate lists for biologic drugs approved by the Center for Drug Evaluation and Research (CDER) and those processed by the Center for Biologics Evaluation and Research (CBER).<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Significance</STRONG> </div><div style="margin-bottom: 10px;">The US FDA is preparing to approve Novartis' biosimilar version of Amgen's Neupogen (filgrastim) &ndash; under an official abbreviated pathway established under the Biologics Price Competition and Innovation Act (BPCIA) enacted in 2010.<wbr> </div><div style="margin-bottom: 10px;">Although progress has been made to bring licensed biosimilars to market for the first time in the United States, the agency has yet to issue final guidance regarding nomenclature, labelling, indication extrapolation, and interchangeability for these products &ndash; aspects that remain somewhat controversial in the US </div><div style="margin-bottom: 10px;">Although biosimilars are anticipated to generate significant savings, several states have taken steps to hinder or limit substitutability and interchangeability with the reference product within their jurisdictions, citing immunogenicity risks among other concerns.<wbr> It is likely, however, that the first set of biosimilars will pave the way for others to follow, and uptake will gradually increase as the new products are deemed safe and effective in patients.<wbr> </div><div style="margin-bottom: 10px;">According to the PHS Act, reference product exclusivity spans 12 years from the date of first licensure unless any additional paediatric exclusivity is granted.<wbr> Upon expiry, an application made under section 351(k) of the PHS act using the biologic drug as a reference product may be licensed by the agency, if it is not blocked due to orphan exclusivity.<wbr> </div><div><EM>Source: IHS Global Insight</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20141231&edate=20140901&rec=10953">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-09-10T16:45:45+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Merck's BCG Shortage In Canada [class:Vaccines, dis:Bladder, :PharmaWorld:mkt:Canada]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9937</link>
<description>Merck's BCG Shortage In Canada [class:Vaccines, dis:Bladder, :PharmaWorld:mkt:Canada]</description><category>class:Vaccines</category><category>dis:Bladder</category><category>mkt:Canada</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9937</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=9937">Merck's BCG Shortage In Canada</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=class%3aVaccines"><font color="#e95e0b">:Oncology:class:Vaccines</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=dis%3aBladder"><font color="#e95e0b">:Oncology:dis:Bladder</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=mkt%3aCanada"><font color="#e95e0b">:PharmaWorld:mkt:Canada</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9937">Oncology9937</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/994">Jenny Wu</a> | 10 September 2014 | 14:51</font><br><br><div style="margin-bottom: 10px;">Comment: Merck's OncoTICE (bacillus Calmette-Guerin Strain Tice)  is experiencing shortage in Canada due to manufacturing problems at a company plant in Durham, N.<wbr>C, and Ani Armenian, a spokesperson for Merck Canada, declared the issue is not directly related to the drug.<wbr> Sanofi Pasteur's ImmuCyst has not been available since 2012 when production was suspended due to problem at its plant outside Toronto and the drug is expected to become available in mid 2015.<wbr> </div><div style="margin-bottom: 10px;">BCG is the standard of treatment for non-muscle invasive bladder cancer patients.<wbr> Patients get an initial treatment of 6 doses then maintenance doses every 3 months for up to 3 years.<wbr> Without BCG, some patients might require surgery to remove their bladders.<wbr> This shortage could have a substantial impact for bladder patients in Canada.<wbr> </div><div>During an interview, Neil Fleshner (Head of Urology, University Health Network, Toronto) said "<EM>We&rsquo;re struggling with how to ration our stock.<wbr> This shortage could last weeks or months and if we run out it will be a travesty.<wbr>&rdquo;</EM> To ensure all patients get treatment despite dwindling stocks, Dr.<wbr> Fleshner said they could be treated temporarily with one-third of the regular dose as some literature evidences suggest getting 1/<wbr>3 of a dose in a short term could be a minor compromise.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=9937">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-09-10T14:51:14+02:00</dc:date><dc:creator>jew60237</dc:creator></item><item>
<title>Foresee's Leuprolide Mesylate Has Entered Ph3 for Advanced Prostate Carcinoma [dis:Prostate, :PharmaWorld:sub:ClinicalTrial, :PharmaWorld:mkt:Worldwide]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9934</link>
<description>Foresee's Leuprolide Mesylate Has Entered Ph3 for Advanced Prostate Carcinoma [dis:Prostate, :PharmaWorld:sub:ClinicalTrial, :PharmaWorld:mkt:Worldwide]</description><comments>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9934</comments><category>dis:Prostate</category><category>sub:ClinicalTrial</category><category>mkt:Worldwide</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9934</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=9934">Foresee's Leuprolide Mesylate Has Entered Ph3 for Advanced Prostate Carcinoma</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=mkt%3aWorldwide"><font color="#e95e0b">:PharmaWorld:mkt:Worldwide</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=sub%3aClinicalTrial"><font color="#e95e0b">:PharmaWorld:sub:ClinicalTrial</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9934">Oncology9934</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 10 September 2014 | 13:34</font><br><br><div style="margin-bottom: 10px;">Comment: According to the company, FP-001 (leuprolide mesylate 50mg) is designed to overcome the drawbacks of the commercial depot products containing GnRH agonists.<wbr> By using a proprietary delivery system, the stability of the depot formulation is significantly improved, resulting in a much longer shelf-life.<wbr> In this trial, PE will assess efficacy.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Trial Details</FONT></STRONG> </div><div style="margin-bottom: 10px;">Reference <A href="http://clinicaltrials.gov/ct2/show/NCT02234115?recr=Open&amp;phase=012&amp;fund=2&amp;rcv_s=08%2F09%2F2014&amp;rank=54">NCT02234115</A> </div><div style="margin-bottom: 10px;"><STRONG>Recruitment</STRONG> approx 130 </div><div style="margin-bottom: 10px;"><UL><LI>Baseline morning serum testosterone level &gt;150 ng/<wbr>dL</LI>
<LI>Eastern Cooperative Oncology Group (ECOG)Performance score ≤ 2</LI>
<LI>Life expectancy of at least 18 months</LI>
<LI>Absolute neutrophil count ≥ 1,500 cells/<wbr>μL</LI>
<LI>Platelets ≥100,000 cells/<wbr>μL</LI>
<LI>Hemoglobin ≥ 10 gm/<wbr>dL</LI>
<LI>Total bilirubin ≤ 1.<wbr>5 × upper limit of normal (ULN)</LI>
<LI>AST (SGOT) ≤ 2.<wbr>5 × ULN</LI>
<LI>ALT (SGPT) ≤ 2.<wbr>5 × ULN</LI>
<LI>Serum creatinine ≤ 1.<wbr>5 mg/<wbr>dL</LI>
<LI>Lipid profile within acceptable range according to investigator's opinion</LI>
<LI>Serum glucose within acceptable range according to investigator's opinion</LI>
<LI>HgbA1c within acceptable range according to investigator's opinion</LI>
<LI>Clinical chemistries (K, Na, Mg, Ca and P) within acceptable range according to investigator's opinion</LI>
<LI>Urinalysis within normal range according to the investigator's opinion</LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG>Timelines</STRONG> from Aug 2014 to Oct 2016 /<wbr> Dec 2016 </div><div style="margin-bottom: 10px;"><STRONG>Protocol </STRONG>Part I will provide a vanguard of the first 30 subjects who will have more frequent monitoring of their safety.<wbr> If safety is established, the remainder of the subjects will be entered into the clinical study (i.<wbr>e.<wbr>, Part II).<wbr> All subjects will be males with advanced prostate carcinoma judged to be candidates for medical androgen ablation therapy, and all will receive two injections of LMIS 50 mg six-month apart in an unblinded fashion.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Location</STRONG> USA; EU (Austria; Czech Republic; Germany; Slovakia;); Asia (Taiwan).<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Technology in Brief</FONT></STRONG> </div><div style="margin-bottom: 10px;"><P class="Paragraph">The SIF drug delivery system consists of biodegradable materials dissolved in biocompatible solvents and a bioactive agent that is modified to achieve optimal formulation stability and release profile.<wbr> The enhanced stability allows the formulation to be pre-filled into a ready-to-use syringe with a suitable storage shelf-life.<wbr> The fill-finished product can be conveniently administered to patients via a small gauge needle to form a depot in situ.<wbr> </P> </div><div style="margin-bottom: 10px;"><P class="Paragraph">The bioactive agent encapsulated in the depot is then released in a controlled manner through diffusion and biodegradation of the depot matrix.<wbr> The SIF drug delivery system can be designed to achieve a customized controlled-release profile over a period ranging from days to months.<wbr> To date, the SIF delivery system has been demonstrated its applications to small molecules and peptides.<wbr></P> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9934/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Background in Traction</FONT></STRONG> </div><div>Also see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=8751" class="defaultlink">Oncology8751: JV Formed to Develop Peptide Injectable Drugs for Cancer</a> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Oncology10531c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">Foresee will be showcasing next month @ BioTaiwan, Asia's largest Biotechnology Expo.<wbr> In the presentation program it is noted that " .<wbr>.<wbr>.<wbr> LMIS 50mg mg is a novel 6-month sustained release leuprolide depot in a pre-filled sterile syringe that ready-to-use format offers advantages over marketed products.<wbr> Foresee is currently conducting a global multi-center Phase 3 registration study (Study FP01C-13-001, Clinical Trials.<wbr>gov NCT 02234115) in advanced prostate cancer patients in the US, six European countries, and TW.<wbr> Results of this study will be used to support the global registration of LMIS 50 mg.<wbr> A 3-month formulation is following".<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Market Penetration - US First</STRONG> </div><div style="margin-bottom: 10px;">In the US, the regulatory submission will be via Provisions of CFR 505(b)(2) </div><div>In 2013, at the time of the creation of a JV with ScinoPharm, it was rported that '.<wbr>.<wbr>.<wbr> The product, which is pending a successful filing and NDA approval, is expected to be introduced in the US in 2016-2017 with international filings to follow".<wbr> (<A href="http://resources.made-in-china.com/article/company-news/lnJxGEqwFmik/Scinopharm-Foresee-to-Form-JV-to-Develop-Oncological-Peptide-Drugs/">http:/<wbr>/<wbr>resources.<wbr>made-in-china.<wbr>com/<wbr>article/<wbr>company-news/<wbr>lnJxGEqwFmik/<wbr>Scinopharm-Foresee-to-Form-JV-to-Develop-Oncological-Peptide-Drugs/<wbr></A>).<wbr> </div><font size="-1">Brigitte DESCHAMPS / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10531" class="commentpermalink">Oncology10531</a> / <span class="date">05 June 2015</span> /
<span class="time">20:43:56 o'clock CEST</span>
</font></div><a name="oncology9934attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9934/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(32,4 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=9934">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-09-10T13:34:07+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9934/1/ScreenCapture1.jpg" length="33156" type="image/jpeg"/></item><item>
<title>ASCO Published New Guideline Recommending ADT Should Be Continued With New mCRPC Treatment Including Abiraterone And Enzalutamide [dis:Prostate]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9932</link>
<description>ASCO Published New Guideline Recommending ADT Should Be Continued With New mCRPC Treatment Including Abiraterone And Enzalutamide [dis:Prostate]</description><category>dis:Prostate</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9932</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=9932">ASCO Published New Guideline Recommending ADT Should Be Continued With New mCRPC Treatment Including Abiraterone And Enzalutamide</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9932">Oncology9932</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/994">Jenny Wu</a> | 10 September 2014 | 11:42</font><br><br><div style="margin-bottom: 10px;">Comment: The American Society of Clinical Oncology (ASCO) and Cancer Care Ontario (CCO) issued a joint clinical practice guideline on treating metastatic castration resistant prostate cancer.<wbr> Specifically, the question on the use of androgen deprivation therapy (ADT) is sometimes the debatable topic that we often hear from different conferences.<wbr> The guideline includes recommendations on systemic therapies that are indicated for use alongside ADT, addressing survival and quality of life benefits, side effects, and cost considerations for each.<wbr> More importantly, the guideline specifies ADT (chemical or surgical) should be continued indefinitely, and abiraterone/<wbr>prednisone, enzalutamide, or radium-223 should be offered <SPAN style="text-decoration: underline;"><STRONG>in addition</STRONG> </SPAN>to ADT.<wbr> </div><div style="margin-bottom: 10px;">Many men with hormone-sensitive metastatic prostate cancer ultimately develop CRPC.<wbr> While continuing on androgen deprivation therapy, such men now have a range of additional treatments available that have the potential to improve their survival and quality of life.<wbr> </div><div style="margin-bottom: 10px;">Key guideline recommendations: </div><div style="margin-bottom: 10px;"><UL><LI>Continue androgen deprivation therapy (pharmaceutical or surgical) indefinitely.<wbr>
</LI>
<LI>Abiraterone/<wbr>prednisone, enzalutamide, or radium-223 (for men whose cancer spread predominantly to the bones) should be offered in addition to androgen deprivation therapy, as all three treatments are associated with improved survival, quality of life, and favorable balance of benefits and harms.<wbr>
</LI>
<LI>If chemotherapy is being considered, docetaxel/<wbr>prednisone should be offered but side effect risks should be discussed.<wbr>
</LI>
<LI>Cabazitaxel may be offered to men whose disease worsens despite treatment with docetaxel, accompanied by discussion of side effect risks.<wbr>
</LI>
<LI>Sipuleucel-T may be offered to men with no symptoms or minimal symptoms.<wbr>
</LI>
<LI>Mitoxantrone may be offered, accompanied by discussion of limited clinical benefit and side effect risk.<wbr>
</LI>
<LI>Ketoconazole or antiandrogens (bicalutamide, flutamide, nilutamide) may be offered, accompanied by discussion of limited clinical benefit.<wbr>
</LI>
<LI>Bevacizumab, estramustine, or sunitinib should not be offered.<wbr> 
</LI>
<LI>Palliative care should be offered early to all patients in discussion of treatment options.<wbr>
</LI>
</UL> </div><div style="margin-bottom: 10px;">The detailed guideline is published in <a href="http://jco.ascopubs.org/content/early/2014/09/03/JCO.2013.54.8404" class="defaultlink">JCO September</a> 10 2014 (pdf article is available via <a href="http://cis12103:8080/qesipsen/servlet/QESServlet_prepare" class="defaultlink">PEARL</a>).<wbr> </div><div>Source: <a href="http://www.asco.org/" class="defaultlink" title="http://www.asco.org/">asco.org/<wbr></a> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=9932">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-09-10T11:42:10+02:00</dc:date><dc:creator>jew60237</dc:creator></item><item>
<title>Botulinum Toxin (aka Botox) to Treat Depression [class:BotulinumToxins]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7726</link>
<description>Botulinum Toxin (aka Botox) to Treat Depression [class:BotulinumToxins]</description><category>class:BotulinumToxins</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7726</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7726">Botulinum Toxin (aka Botox) to Treat Depression</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20141231&edate=20140901&cat=class%3aBotulinumToxins"><font color="#e95e0b">:Neurology:class:BotulinumToxins</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7726">Neurology7726</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 09 September 2014 | 17:14</font><br><br><div style="margin-bottom: 10px;">Comment: The authors of three independent double-blind, randomized, placebo controlled clinical trials will present "Botulinum Toxin, An Emerging Therapeutic for Depression" and their respective research study findings to mental health professionals at the XVI World Congress of Psychiatry (WCP2014) meeting in Madrid, Spain, on September 18th.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Largest Study to Date</FONT></STRONG> </div><div style="margin-bottom: 10px;">In the largest study to date on the effect of botulinum toxin on depression, researchers Eric Finzi, MD, PhD, and Norman E.<wbr> Rosenthal, MD, found that 52% of subjects suffering from moderate to severe depression showed relief from depression after injection of botulinum toxin to the glabellar area between the eyes, compared with only 15% of those who received the saline placebo.<wbr> </div><div style="margin-bottom: 10px;">Source: “<I>Treatment of depression with onabotulinumtoxinA: A randomized, double-blind, placebo controlled trial</I>” - <I>Journal of Psychiatric Research</I>, Volume 52 (May 2014).<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">About WCP2014</FONT></STRONG> </div><div style="margin-bottom: 10px;"><A href="http://www.wpamadrid2014.com/">http:/<wbr>/<wbr>www.<wbr>wpamadrid2014.<wbr>com/<wbr></A> </div><div style="margin-bottom: 10px;">Organized by the World Psychiatric Association </div><div style="margin-bottom: 10px;">Dates:Location: September 14-18 in Madrid </div><div style="margin-bottom: 10px;">Focus: Access, quality and humane care.<wbr> </div><div>Attendance: Over ten thousand psychiatrists from all over the world </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7726">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-09-09T17:14:00+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>NICE's Draft Guidance Does Not Recomment Celgene's Abraxane [dis:pNET, :PharmaWorld:sub:Pricing, :PharmaWorld:mkt:UK]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7790</link>
<description>NICE's Draft Guidance Does Not Recomment Celgene's Abraxane [dis:pNET, :PharmaWorld:sub:Pricing, :PharmaWorld:mkt:UK]</description><category>dis:pNET</category><category>sub:Pricing</category><category>mkt:UK</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7790</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20141231&edate=20140901&rec=7790">NICE's Draft Guidance Does Not Recomment Celgene's Abraxane</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20141231&edate=20140901&cat=dis%3apNET"><font color="#e95e0b">:Endocrinology:dis:pNET</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=mkt%3aUK"><font color="#e95e0b">:PharmaWorld:mkt:UK</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=sub%3aPricing"><font color="#e95e0b">:PharmaWorld:sub:Pricing</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7790">Endocrinology7790</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 09 September 2014 | 16:38</font><br><br><div style="margin-bottom: 10px;">Comment: NICE has issued a draft guidance not recommending paclitaxel (Abraxane; Celgene; US) as albumin-bound nanoparticles (nab-paclitaxel) in combination with gemcitabine, within its marketing authorisation, for previously untreated metastatic adenocarcinoma of the pancreas.<wbr> The draft guidance is available for comment until 30 September with the final guidance expected in January 2015.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Significance</FONT></STRONG> </div><div style="margin-bottom: 10px;">In terms of clinical effectiveness, NICE's Appraisal Committee concluded that while nab-paclitaxel in combination gemcitabine was more clinically effective versus gemcitabine alone, there were more adverse effects.<wbr> </div><div style="margin-bottom: 10px;">On the other hand, FOLFIRINOX (a combination of fluorouracil, leucovorin, irinotecan and oxaliplatin), was more clinically effective than nab-paclitaxel in combination with gemcitabine.<wbr> </div><div style="margin-bottom: 10px;">For the cost-effectiveness evidence, the company presented a de novo economic model for nab-paclitaxel in combination with gemcitabine versus gemcitabine alone, as well as scenario analyses that compared nab-paclitaxel plus gemcitabine with FOLFIRINOX and with gemcitabine in combination with capecitabine.<wbr> </div><div style="margin-bottom: 10px;">For nab-paclitaxel plus gemcitabine versus gemcitabine alone the most plausible incremental cost-effectiveness ratios (ICERs) was estimated at GBP78,500 (USD126,898) per quality-adjusted life years (QALYs) gained.<wbr> Additionally, FOLFIRINOX dominated nab-paclitaxel , and the ICER when compared to gemcitabine plus capecitabine was estimated at GBP87,100 per QALY gained.<wbr> It was thus noted by NICE that the benefits of nab-paclitaxel plus gemcitabine were limited, with the treatment also being more expensive.<wbr> </div><div>Source: <A href="https://www.nice.org.uk/guidance/gid-tag453/resources/pancreatic-adenocarcinoma-untreated-metastatic-paclitaxel-albuminbound-nanoparticles-with-gemcitabine-id680-appraisal-consultation-document">https:/<wbr>/<wbr>www.<wbr>nice.<wbr>org.<wbr>uk/<wbr>guidance/<wbr>gid-tag453/<wbr>resources/<wbr>pancreatic-adenocarcinoma-untreated-metastatic-paclitaxel-albuminbound-nanoparticles-with-gemcitabine-id680-appraisal-consultation-document</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20141231&edate=20140901&rec=7790">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-09-09T16:38:49+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>ALPHAEON Acquires Clarion Medical Technologies [sub:Aesthetics]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7725</link>
<description>ALPHAEON Acquires Clarion Medical Technologies [sub:Aesthetics]</description><category>sub:Aesthetics</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7725</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7725">ALPHAEON Acquires Clarion Medical Technologies</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20141231&edate=20140901&cat=sub%3aAesthetics"><font color="#e95e0b">:Neurology:sub:Aesthetics</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7725">Neurology7725</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 09 September 2014 | 11:33</font><br><br><div style="margin-bottom: 10px;">Comment: The acquisition will close this month.<wbr> The combination is expected to provide one of the strongest lifestyle healthcare portfolios in Canada, with skin injectables and energy devices.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Rationale for ALPHAEON</FONT></STRONG> </div><div style="margin-bottom: 10px;">- expand geo footprint in Canada for TEOXANE<STRONG>®</STRONG>'s full-line of dermal fillers </div><div style="margin-bottom: 10px;">- complement with strong energy device platform, and 40 product licenses </div><div style="margin-bottom: 10px;">- opportunity to launch ShoutMD<STRONG>®</STRONG> as well as the portfolio of Performance Wellness and Beauty products </div><div style="margin-bottom: 10px;">- take advantage of Clarion's more than 100 employees and 36 reps </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Clarion Medical Technologies Snapshot</FONT></STRONG> </div><div style="margin-bottom: 10px;">- founded 1989.<wbr> </div><div style="margin-bottom: 10px;">- network: hospitals, aesthetic clinics and private medical practices.<wbr> </div><div style="margin-bottom: 10px;">- products/<wbr>services: laser technologies, diagnostic equipment, skin care, injectable fillers, intra-ocular lenses, laser fibers.<wbr> </div><div style="margin-bottom: 10px;">The aesthetic branche features: </div><div><UL><LI>Kiss (HA-based dermal fillers)</LI>
<LI>Ultherapy (non-invasive ultrasound procedure)</LI>
<LI>ResurFX</LI>
<LI>Focus (laser for onychomycosis)</LI>
<LI>LightSheerDUET (laser hair removal)</LI>
<LI>Sunforgettable (miineral sun protection)</LI>
</UL> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7725">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-09-09T11:33:23+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Sirtex Medical Expands Business in Latin America</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7789</link>
<description>Sirtex Medical Expands Business in Latin America</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7789</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20141231&edate=20140901&rec=7789">Sirtex Medical Expands Business in Latin America</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7789">Endocrinology7789</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 08 September 2014 | 17:59</font><br><br><div style="margin-bottom: 10px;">Comment: Sirtex’s SIR-Spheres® microspheres are now available to treat inoperable liver tumors in Brazil.<wbr> The first SIR-Spheres microspheres treatments took place the first week of September at Hospital Sirio-Libanes in Sao Paulo.<wbr> Sirtex received product approval from the Agência Nacional de Vigilância Sanitária (ANVISA) for SIR-Spheres microspheres early in 2014.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Encouraging Growth in the Amercas Organization</FONT></STRONG> </div><div style="margin-bottom: 10px;">In July, the company announced dose sales of its SIR-Spheres® microspheres targeted radiation therapy for liver cancer grew 27.<wbr>1% for the quarter ended June 2014 compared to the previous corresponding period.<wbr> </div><div style="margin-bottom: 10px;">The Americas achieved dose sales growth of 33%.<wbr> </div><div><EM>Source: Sirtex Medical</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20141231&edate=20140901&rec=7789">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-09-08T17:59:27+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>re: MSD's Won the PD-1 Race Becoming First-To-Market In US</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9931</link>
<description>re: MSD's Won the PD-1 Race Becoming First-To-Market In US</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9931</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=9931">re: MSD's Won the PD-1 Race Becoming First-To-Market In US</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9931">Oncology9931</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 08 September 2014 | 11:47</font><br><br><div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">MSD's Won the PD-1 Race Becoming First-To-Market In US</span>&nbsp;<br><span style="font-size: 12px;">Comment: FDA has approved MSD's PD-1 inhibitor on 4th September, a decision almost 2 months earlier than anticipation.<wbr> Keytruda (pembrolizumab) has been granted of accelerated approval for advanced or unresectable melanoma.<wbr> It was approved just 3.<wbr>5 years after the first doses of the medicine was given to patients in clinical trials.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=9926">...</a><br><font size="-1">Jenny Wu / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9926" class="commentpermalink">Oncology9926</a> / <span class="date">08 September 2014</span> /
<span class="time">10:31:47 o'clock CEST</span>
</font></div><div style="margin-bottom: 10px;"><P align="left">Bloomberg reported on Sep 5 that Ono and BMS filed a suit in the US (Delaware district court) on Sep 4 alleging PD-1 patent violation by Merck.<wbr> The suit alleges that Merck&rsquo;s PD-1 antibody Keytruda (approved in the US on Sep 4) infringes the broad application method of use patent (USPatent No.<wbr> 8,728,474) held by Ono.<wbr></P> </div><div style="margin-bottom: 10px;"><P align="left">The patent dispute between the2 parties has been intensifying since the first half of this year as the PD-1 launch comes into view.<wbr></P> </div><div><P align="left">Ono&rsquo;s patent was established in the US in May this year, and Merck&rsquo;s objections were dismissed in Europe in June (confirming the validity of Ono&rsquo;s patent).<wbr></P> </div><!-- Comment details --><font size="-1">Brigitte DESCHAMPS / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9931" class="commentpermalink">Oncology9931</a> / <span class="date">08 September 2014</span> /
<span class="time">11:47:22 o'clock CEST</span>
</font><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=9931">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9926">View thread  Oncology9926: MSD's Won the PD-1 Race Becoming First-To-Market In US</a>]]></content:encoded><dc:date>2014-09-08T11:47:22+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Novatis Invests in the Mobile Health Market [:Endocrinology:comp:Novartis]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10950</link>
<description>Novatis Invests in the Mobile Health Market [:Endocrinology:comp:Novartis]</description><category>comp:Novartis</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10950</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20141231&edate=20140901&rec=10950">Novatis Invests in the Mobile Health Market</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20141231&edate=20140901&cat=comp%3aNovartis"><font color="#e95e0b">:Endocrinology:comp:Novartis</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10950">PharmaWorld10950</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 08 September 2014 | 11:32</font><br><br><div style="margin-bottom: 10px;">Comment: Novartis currently has 13 iPhone apps in Apple's App Store, and 9 of them are designed for patients and consumers.<wbr> Patients with NET can use the company's "My NET Manager" to learn about their condition, monitor symptoms and medications, schedule doctor's visits, and track insurance claims.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Novartis' Companion Apps</FONT></STRONG> </div><div style="margin-bottom: 10px;">Games: "Sickel Cell Iron Invaders"; "Marley's World" </div><div style="margin-bottom: 10px;">Apps: "Clinical Trial Seek" </div><div style="margin-bottom: 10px;">Training Apps: "Podhaler Pro" </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Investment in the 'Internet of Things'</FONT></STRONG> </div><div style="margin-bottom: 10px;">Last year, Novartis sponsored a digital health challenge that was won by home monitoring start-up Sense.<wbr>ly.<wbr> (Sense.<wbr>ly's platform collects data from wireless home medical devices, and sends the information to a virtual caretaker who appears as a digital avatar).<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Size of the Market</FONT></STRONG> </div><div style="margin-bottom: 10px;">The global mobile health market is expected to grow from $1.<wbr>95 billion in 2012 to $49 billion in 2020 (source: Grand View Research).<wbr> </div><div>Source: <A href="http://www.fool.com/investing/general/2014/09/07/why-is-novartis-investing-in-this-49-billion-marke.aspx">http:/<wbr>/<wbr>www.<wbr>fool.<wbr>com/<wbr>investing/<wbr>general/<wbr>2014/<wbr>09/<wbr>07/<wbr>why-is-novartis-investing-in-this-49-billion-marke.<wbr>aspx</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20141231&edate=20140901&rec=10950">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-09-08T11:32:05+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Takeda's Leuplin ® 6M Depot Submitted in Japan for Prostate Cancer and Breast Cancer [comp:Takeda, :PharmaWorld:mkt:Japan, prod:Lupron]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9928</link>
<description>Takeda's Leuplin ® 6M Depot Submitted in Japan for Prostate Cancer and Breast Cancer [comp:Takeda, :PharmaWorld:mkt:Japan, prod:Lupron]</description><category>comp:Takeda</category><category>mkt:Japan</category><category>prod:Lupron</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9928</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=9928">Takeda's Leuplin ® 6M Depot Submitted in Japan for Prostate Cancer and Breast Cancer</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=comp%3aTakeda"><font color="#e95e0b">:Oncology:comp:Takeda</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=prod%3aLupron"><font color="#e95e0b">:Oncology:prod:Lupron</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=mkt%3aJapan"><font color="#e95e0b">:PharmaWorld:mkt:Japan</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9928">Oncology9928</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 08 September 2014 | 10:58</font><br><br><div style="margin-bottom: 10px;">Comment: The 6M formulation becomes the world's first submission for the treatment of premonopausal breast cancer.<wbr> </div><div style="margin-bottom: 10px;"><SPAN style="WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FLOAT: none; COLOR: rgb(26,26,26); FONT: 14px/22px Helvetica, Arial, sans-serif; DISPLAY: inline !important; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(49,102,50); TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"><FONT face="Verdana" size="3" style="BACKGROUND-COLOR: #ffffff"><STRONG>Regulatory Dossier</STRONG></FONT></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FLOAT: none; COLOR: rgb(26,26,26); FONT: 14px/22px Helvetica, Arial, sans-serif; DISPLAY: inline !important; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(49,102,50); TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"><FONT style="BACKGROUND-COLOR: #ffffff"><SPAN style="LINE-HEIGHT: 1.3">This submission is based on the results of two clinical Ph3 studies in patients with prostate cancer and those with premenopausal breast cancer through multicenter, randomized, open label, comparative studies, evaluating the safety, efficacy, pharmacokinetics, hormone dynamics and others.<wbr></SPAN></FONT></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FLOAT: none; COLOR: rgb(26,26,26); FONT: 14px/22px Helvetica, Arial, sans-serif; DISPLAY: inline !important; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(49,102,50); TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"><FONT face="Verdana" size="3" style="BACKGROUND-COLOR: #ffffff"><STRONG>Availability</STRONG></FONT></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FLOAT: none; COLOR: rgb(26,26,26); FONT: 14px/22px Helvetica, Arial, sans-serif; DISPLAY: inline !important; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(49,102,50); TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"><FONT face="Verdana" size="2" style="BACKGROUND-COLOR: #ffffff">Leuplin is currently available in 1M and 3M.<wbr></FONT></SPAN> </div><div><SPAN style="WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FLOAT: none; COLOR: rgb(26,26,26); FONT: 14px/22px Helvetica, Arial, sans-serif; DISPLAY: inline !important; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(49,102,50); TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"><FONT face="Verdana" size="2" style="BACKGROUND-COLOR: #ffffff"><EM>Source: Takeda</EM></FONT></SPAN> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=9928">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-09-08T10:58:16+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>MSD's Won the PD-1 Race Becoming First-To-Market In US</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9926</link>
<description>MSD's Won the PD-1 Race Becoming First-To-Market In US</description><comments>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9926</comments><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9926</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=9926">MSD's Won the PD-1 Race Becoming First-To-Market In US</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9926">Oncology9926</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/994">Jenny Wu</a> | 08 September 2014 | 10:31</font><br><br><div style="margin-bottom: 10px;">Comment: FDA has approved MSD's PD-1 inhibitor on 4th September, a decision almost 2 months earlier than anticipation.<wbr> Keytruda (pembrolizumab) has been granted of accelerated approval for advanced or unresectable melanoma.<wbr> It was approved just 3.<wbr>5 years after the first doses of the medicine was given to patients in clinical trials.<wbr> </div><div style="margin-bottom: 10px;">Keytruda is intended for use after Yervoy (ipilimumab, BMS) which blocks CTLA-4.<wbr> In the event the patient&rsquo;s melanoma expresses the V600E amino acid change in the BRAF cell signaling protein, Keytruda should be given only after ipilimumab and a BRAF inhibitor such as Zelboraf (vermurafenib, Roche) or Tafinlar (dabrafenib, GSK).<wbr> </div><div style="margin-bottom: 10px;">Bristol-Myers Squibb received approval in Japan for their anti-PD-1 drug, Opdivo (nivolumab), leading to speculation that it might be the first to be approved in the U.<wbr>S.<wbr> BMS and Ono have priced Opdivo at an average annual cost equivalent to $143,000.<wbr> One can likely expect Keytruda to come in at a similar cost here.<wbr> </div><div style="margin-bottom: 10px;">In a 411-patient efficacy and safety presented in preliminary form in June at the ASCO meeting, not enough time had passed to gauge median overall survival, with 69% of patients alive after one year and an average progression-free survival time of 5.<wbr>6 months.<wbr> However bearing in mind that 5 year survival rate of metastatic melanoma patients is 10-15%.<wbr> </div><div style="margin-bottom: 10px;">Accelerated approval is granted by the FDA for drugs targeting serious or life-threatening diseases where a surrogate marker of efficacy (e.<wbr>g.<wbr>, <STRONG>progression-free survival</STRONG>) provides an indication that the drug is &ldquo;reasonably likely&rdquo; to benefit patients.<wbr> As the agency&rsquo;s statement notes today, &ldquo;<EM>This program provides earlier patient access to promising new drugs while the company conducts confirmatory clinical trials</EM>.<wbr>&rdquo; </div><div>The remarkable rapid FDA approval has allowed MSD to leapfrog BMS's Opdivo and is a triumph for research head Roger Perlmutter (executive vice president and president of Merck Research Laboratories).<wbr> Instead of advancing pembrolizumab to lager studies, Roger Perlmutter expanded the existing phase I trial, which lacked a comparison arm, to 3,500 patients with a variety of solid tumours.<wbr> This approval was based on 173 patients with advanced melanoma, and 41 of them have had a durable tumour shrinkage response from 1.<wbr>4 months to 8.<wbr>5 months.<wbr> Also the new "breakthrough designation" allowed MSD to be in weekly contact with the FDA reviewers who evaluated not only Keytruda's safety and efficacy, but also manufacturing processes.<wbr> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Oncology9931c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;"><P align="left">Bloomberg reported on Sep 5 that Ono and BMS filed a suit in the US (Delaware district court) on Sep 4 alleging PD-1 patent violation by Merck.<wbr> The suit alleges that Merck&rsquo;s PD-1 antibody Keytruda (approved in the US on Sep 4) infringes the broad application method of use patent (USPatent No.<wbr> 8,728,474) held by Ono.<wbr></P> </div><div style="margin-bottom: 10px;"><P align="left">The patent dispute between the2 parties has been intensifying since the first half of this year as the PD-1 launch comes into view.<wbr></P> </div><div><P align="left">Ono&rsquo;s patent was established in the US in May this year, and Merck&rsquo;s objections were dismissed in Europe in June (confirming the validity of Ono&rsquo;s patent).<wbr></P> </div><font size="-1">Brigitte DESCHAMPS / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9931" class="commentpermalink">Oncology9931</a> / <span class="date">08 September 2014</span> /
<span class="time">11:47:22 o'clock CEST</span>
</font></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=9926">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-09-08T10:31:47+02:00</dc:date><dc:creator>jew60237</dc:creator></item><item>
<title>First Recipients of the CUA-CUOG Astellas Research Grant Program [comp:Astellas, :PharmaWorld:func:RnD, dis:Prostate]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9923</link>
<description>First Recipients of the CUA-CUOG Astellas Research Grant Program [comp:Astellas, :PharmaWorld:func:RnD, dis:Prostate]</description><category>comp:Astellas</category><category>func:RnD</category><category>dis:Prostate</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9923</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=9923">First Recipients of the CUA-CUOG Astellas Research Grant Program</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=comp%3aAstellas"><font color="#e95e0b">:Oncology:comp:Astellas</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=func%3aRnD"><font color="#e95e0b">:PharmaWorld:func:RnD</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9923">Oncology9923</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 05 September 2014 | 15:27</font><br><br><div style="margin-bottom: 10px;">Comment: The Canadian Urologic Oncology Group (CUOG), Canadian Urological Association (CUA) and Astellas Pharma Canada, Inc.<wbr> have announced the four inaugural recipients (please see below) of the CUA-CUOG Astellas Research Grant.<wbr> Last year, Astellas pledged $450,000 over three years to the program, which supports Canadian peer-reviewed research in uro-oncologic disorders.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Recipients Name and Research</FONT></STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>Khurram Siddiqui Western University
</LI>
</UL> </div><div style="margin-bottom: 10px;">"Achieving the oligometastatic state in end-stage prostate cancer by pharmacologic and genetic manipulation of Invadopodia formed by tumor cells" </div><div style="margin-bottom: 10px;"><UL><LI>Muhammad Abdul Lateef University of Montreal
</LI>
</UL> </div><div style="margin-bottom: 10px;">"A new strategy for personalized medicine: a microfluidic platform designed to test prostate cancer responses to targeted therapies" </div><div style="margin-bottom: 10px;"><UL><LI>Nader Al Nakouzi University of British Columbia
</LI>
</UL> </div><div style="margin-bottom: 10px;">"Developing a new and promising orally bioavailable inhibitor Hsp27" </div><div style="margin-bottom: 10px;"><UL><LI>Tal Ben Zvi Laval University
</LI>
</UL> </div><div>"Omega 3 fatty acids and prostate cancer: where to measure quantification in RBC, plasma and prostate tissue" </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=9923">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-09-05T15:27:30+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>RedHill's 5-HT3 Antagonist Has Entered Ph3 for Acute Gastroenteritis [dis:Diarrhoea, :PharmaWorld:sub:ClinicalTrial]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2021</link>
<description>RedHill's 5-HT3 Antagonist Has Entered Ph3 for Acute Gastroenteritis [dis:Diarrhoea, :PharmaWorld:sub:ClinicalTrial]</description><category>dis:Diarrhoea</category><category>sub:ClinicalTrial</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2021</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2021">RedHill's 5-HT3 Antagonist Has Entered Ph3 for Acute Gastroenteritis</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20141231&edate=20140901&cat=dis%3aDiarrhoea"><font color="#e95e0b">:GastroEnterology:dis:Diarrhoea</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=sub%3aClinicalTrial"><font color="#e95e0b">:PharmaWorld:sub:ClinicalTrial</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2021">GastroEnterology2021</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 05 September 2014 | 15:09</font><br><br><div style="margin-bottom: 10px;">Comment: If approved for marketing by the FDA, RHB-102 is expected to be the first-ever 5-HT3 antagonist drug indicated for acute gastroenteritis.<wbr> The company business model is to commercailize its products through partnerships.<wbr> In February, it licensed-out WW rights of its bowel preparation to Salix.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">About the Trial</FONT></STRONG> </div><div style="margin-bottom: 10px;">Title: Randomized, Double-Blind, Placebo Controlled, Parallel Group Phase III Study (“GUARD”) to Assess the Safety and Efficacy of RHB-102 in the Treatment of Acute Gastroenteritis.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2021/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">What is RHB-102</FONT></STRONG> </div><div style="margin-bottom: 10px;">Oral, extended-release, once-daily formulation of the antiemetic drug ondansetron.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Development Update</FONT></STRONG> </div><div style="margin-bottom: 10px;">RedHill is currently conducting three Ph3 GI studies in the U.<wbr>S.<wbr>, including the RHB-102 GUARD study for gastroenteritis </div><div style="margin-bottom: 10px;"><UL><LI>RHB-104 (Crohn’s): ongoing Ph3 study in the U.<wbr>S.<wbr>, Canada and Israel; European Ph3 study planned to commence H2/<wbr>2014 </LI>
<LI>RHB-105 (H.<wbr> pylori): ongoing Ph3 study in the U.<wbr>S.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Late Clinical Stage Pipeline</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2021/1/ScreenCapture1.jpg?user-agent=rss"> </div><div><EM>Source: RedHill</EM> </div><!-- Comment details --><a name="gastroenterology2021attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2021/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(128,5 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2021/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(86,2 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2021">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-09-05T15:09:40+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2021/1/ScreenCapture1.jpg" length="131573" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2021/2/ScreenCapture2.jpg" length="88226" type="image/jpeg"/></item><item>
<title>ODD Granted to Prana's PBT2 for HD [dis:Huntington]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7723</link>
<description>ODD Granted to Prana's PBT2 for HD [dis:Huntington]</description><category>dis:Huntington</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7723</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7723">ODD Granted to Prana's PBT2 for HD</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20141231&edate=20140901&cat=dis%3aHuntington"><font color="#e95e0b">:Neurology:dis:Huntington</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7723">Neurology7723</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 05 September 2014 | 14:30</font><br><br><div style="margin-bottom: 10px;">Comment: Shares in Prana Biotech rocketed more than 42% after the granting of the Orphan Drug Designation (ODD) by the FDA.<wbr> The company now intends to apply for ODD in Europe and other jurisdictions.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Development Plan Update</FONT></STRONG> </div><div style="margin-bottom: 10px;">Prana is preparing its "Post Ph2 Tria"l dossier for submission to the FDA to start discussions on the next development steps for PBT2.<wbr> </div><div style="margin-bottom: 10px;"><EM>Source: Prana</EM> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7723/1/ScreenCapture1.jpg?user-agent=rss"> </div><div><EM>(Source: BI Department)</EM> </div><!-- Comment details --><a name="neurology7723attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7723/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(141,3 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7723">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-09-05T14:30:40+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7723/1/ScreenCapture1.jpg" length="144644" type="image/jpeg"/></item><item>
<title>ALPHAEON Has Obtained FDA Approval to Conduct IND Program with Evosyal [sub:Aesthetics, :PharmaWorld:mkt:NorthAmerica, news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7722</link>
<description>ALPHAEON Has Obtained FDA Approval to Conduct IND Program with Evosyal [sub:Aesthetics, :PharmaWorld:mkt:NorthAmerica, news]</description><category>sub:Aesthetics</category><category>mkt:NorthAmerica</category><category>news</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7722</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7722">ALPHAEON Has Obtained FDA Approval to Conduct IND Program with Evosyal</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20141231&edate=20140901&cat=news"><font color="#e95e0b">:Neurology:news</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20141231&edate=20140901&cat=sub%3aAesthetics"><font color="#e95e0b">:Neurology:sub:Aesthetics</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=mkt%3aNorthAmerica"><font color="#e95e0b">:PharmaWorld:mkt:NorthAmerica</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7722">Neurology7722</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 05 September 2014 | 12:03</font><br><br><div style="margin-bottom: 10px;">Comment: The clinical study will support safety and efficacy of Evosyal, a 900kDa neurotoxin molecular complex with high purity.<wbr> ALPHAEON expect the initial trial to be fully enrolled by end of the year.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Business Development</FONT></STRONG> </div><div style="margin-bottom: 10px;">End of 2013 ALPHAEON received an exclusive license to market Daewoong toxin, under the brand name Evosyal, in the US and several international markets.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Drug Status</FONT></STRONG> </div><div>Launched in Korea by Daewoong as Nabota (for GL).<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7722">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-09-05T12:03:32+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>The Battle For Control Intensifies As Pershing Square Acheives 31% Share Required For Allergan To Call A Special AGM [headline, comp:Allergan, :PharmaWorld:sub:Acquisition]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7721</link>
<description>The Battle For Control Intensifies As Pershing Square Acheives 31% Share Required For Allergan To Call A Special AGM [headline, comp:Allergan, :PharmaWorld:sub:Acquisition]</description><category>headline</category><category>comp:Allergan</category><category>sub:Acquisition</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7721</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7721">The Battle For Control Intensifies As Pershing Square Acheives 31% Share Required For Allergan To Call A Special AGM</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20141231&edate=20140901&cat=comp%3aAllergan"><font color="#e95e0b">:Neurology:comp:Allergan</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20141231&edate=20140901&cat=headline"><font color="#e95e0b">:Neurology:headline</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=sub%3aAcquisition"><font color="#e95e0b">:PharmaWorld:sub:Acquisition</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7721">Neurology7721</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 05 September 2014 | 10:24</font><br><br><div style="margin-bottom: 10px;">Comment: A few days ago Pershing Square announced it had acheived the 
necessary 31% backing required by Allergan's By-laws for the company to call a 
Special AGM.<wbr> This level of support was subsequently validated by 
Allergan yesterday and a meeting called for December 18th 2014.<wbr> </div><div style="margin-bottom: 10px;">The battle for control is now likely to hinge on the outcome of this Special 
AGM, where Valeant &amp; Pershing will attempt to remove key members of the 
Allergan board.<wbr> The aim will be to replace them with executives 
who are willing to enter into discussions with Valeant giving due 
consideration to the offer on the table.<wbr> </div><div>Source; <A href="http://www.investors.com/">www.<wbr>investors.<wbr>com</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7721">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-09-05T10:24:42+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>First Ph2 Assessing OCLU in Patients with WDpNET [dis:pNET, :PharmaWorld:sub:ClinicalTrial]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7787</link>
<description>First Ph2 Assessing OCLU in Patients with WDpNET [dis:pNET, :PharmaWorld:sub:ClinicalTrial]</description><category>dis:pNET</category><category>sub:ClinicalTrial</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7787</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20141231&edate=20140901&rec=7787">First Ph2 Assessing OCLU in Patients with WDpNET</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20141231&edate=20140901&cat=dis%3apNET"><font color="#e95e0b">:Endocrinology:dis:pNET</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=sub%3aClinicalTrial"><font color="#e95e0b">:PharmaWorld:sub:ClinicalTrial</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7787">Endocrinology7787</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 04 September 2014 | 18:15</font><br><br><div style="margin-bottom: 10px;">Comment: The study will assess the efficacy and safety of 177Lu-DOTA0-Tyr3-Octreotate (OCLU) in subjects with pretreated progressive pancreatic, inoperable, somatostatin receptor positive, well differentiated pancreatic neuroendocrine tumors (WDpNET).<wbr> PE will determine the 12 months PFS.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Trial Details</FONT></STRONG> </div><div style="margin-bottom: 10px;">Reference <A href="http://clinicaltrials.gov/ct2/show/NCT02230176?recr=Open&amp;no_unk=Y&amp;fund=2&amp;rcv_s=08%2F04%2F2014&amp;rank=372">NCT02230176</A> </div><div style="margin-bottom: 10px;">Sponsor Gustave Roussy, Cancer Campus, Grand Paris.<wbr> </div><div style="margin-bottom: 10px;">Recruitment Approx.<wbr> 80 </div><div style="margin-bottom: 10px;"><UL><LI>
Subjects must have experienced documented progression of disease within 1 year prior to the start of the study.<wbr> The control group of patients receiving Sutent will be used as internal control to assess the hypothesis of 12 months PFS equal to 35% in patients receiving Sutent.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;">Timelines Oct.<wbr>2014 to Oct.<wbr>2023 </div><div style="margin-bottom: 10px;">Principal Investigator Eric BAUDIN </div><div>Location France </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20141231&edate=20140901&rec=7787">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-09-04T18:15:31+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Allergan to Initiate POC Trial with BOTOX® for Painful OA [comp:Allergan, prod:Botox]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7719</link>
<description>Allergan to Initiate POC Trial with BOTOX® for Painful OA [comp:Allergan, prod:Botox]</description><category>comp:Allergan</category><category>prod:Botox</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7719</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7719">Allergan to Initiate POC Trial with BOTOX® for Painful OA</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20141231&edate=20140901&cat=comp%3aAllergan"><font color="#e95e0b">:Neurology:comp:Allergan</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20141231&edate=20140901&cat=prod%3aBotox"><font color="#e95e0b">:Neurology:prod:Botox</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7719">Neurology7719</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 04 September 2014 | 18:04</font><br><br><div style="margin-bottom: 10px;">Comment: The new study will evaluate the efficacy and safety of a single intra-articular injection of 2 doses of BOTOX® compared with placebo as treatment for knee osteoarthritis symptoms.<wbr> PE will measure change from baseline in the 7-Day Average Daily Pain Score Using an 11-Point Scale.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Trial Details</FONT></STRONG> </div><div style="margin-bottom: 10px;">Reference <A href="http://clinicaltrials.gov/ct2/show/NCT02230956?recr=Open&amp;no_unk=Y&amp;fund=2&amp;rcv_s=08%2F04%2F2014&amp;rank=193">NCT02230956</A> </div><div style="margin-bottom: 10px;">Recruitment approx.<wbr>160 
 </div><div style="margin-bottom: 10px;">
<UL><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Painful osteoarthritis</LI>
</UL> </div><div style="margin-bottom: 10px;">
<UL><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Able to discontinue anti-inflammatory drugs and analgesics</LI>
</UL> </div><div style="margin-bottom: 10px;">
<UL><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Must be ambulatory without assistive walking devices</LI>
</UL> </div><div style="margin-bottom: 10px;">Timelines from Set.<wbr>2014 to Jan2016 /<wbr> April 2016 </div><div>Location USA </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7719">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-09-04T18:04:03+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Real Life Trial of PCa Patients with CV Events Treated with Ferring's Degarelix [dis:Prostate, prod:Firmagon, :PharmaWorld:sub:ClinicalTrial]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9922</link>
<description>Real Life Trial of PCa Patients with CV Events Treated with Ferring's Degarelix [dis:Prostate, prod:Firmagon, :PharmaWorld:sub:ClinicalTrial]</description><category>dis:Prostate</category><category>prod:Firmagon</category><category>sub:ClinicalTrial</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9922</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=9922">Real Life Trial of PCa Patients with CV Events Treated with Ferring's Degarelix</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=prod%3aFirmagon"><font color="#e95e0b">:Oncology:prod:Firmagon</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=sub%3aClinicalTrial"><font color="#e95e0b">:PharmaWorld:sub:ClinicalTrial</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9922">Oncology9922</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 04 September 2014 | 17:53</font><br><br><div style="margin-bottom: 10px;">Comment: Patients with prostate cancer and a history of cardiovascular disease treated with degarelix for their prostate cancer, will be followed for a period of 1 year.<wbr> PE will assess CV event rate in hormone naïve cancer patients with CV comorbidity at baseline, treated with degarelix in daily practice.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Trial Details</FONT></STRONG> </div><div style="margin-bottom: 10px;">Reference <A href="http://clinicaltrials.gov/ct2/show/NCT02229253?recr=Open&amp;no_unk=Y&amp;fund=2&amp;rcv_s=08%2F04%2F2014&amp;rank=180">NCT02229253</A> </div><div style="margin-bottom: 10px;">Recruitment Approx.<wbr> 200 (Patients will be selected from prostate cancer patients in a hospital setting, meeting the inclusion criteria) </div><div style="margin-bottom: 10px;">Timelines from Sept.<wbr>2014 to Sept.<wbr>2016 </div><div>Location: one country listed (NL) </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=9922">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-09-04T17:53:32+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Novo's Once-Weekly GH to Enter PH3 for AGHD [class:GrowthHormone, comp:NovoNordisk, dis:GrowthHormoneDeficiency, :PharmaWorld:sub:ClinicalTrial]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7786</link>
<description>Novo's Once-Weekly GH to Enter PH3 for AGHD [class:GrowthHormone, comp:NovoNordisk, dis:GrowthHormoneDeficiency, :PharmaWorld:sub:ClinicalTrial]</description><category>class:GrowthHormone</category><category>comp:NovoNordisk</category><category>dis:GrowthHormoneDeficiency</category><category>sub:ClinicalTrial</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7786</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20141231&edate=20140901&rec=7786">Novo's Once-Weekly GH to Enter PH3 for AGHD</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20141231&edate=20140901&cat=class%3aGrowthHormone"><font color="#e95e0b">:Endocrinology:class:GrowthHormone</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20141231&edate=20140901&cat=comp%3aNovoNordisk"><font color="#e95e0b">:Endocrinology:comp:NovoNordisk</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20141231&edate=20140901&cat=dis%3aGrowthHormoneDeficiency"><font color="#e95e0b">:Endocrinology:dis:GrowthHormoneDeficiency</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=sub%3aClinicalTrial"><font color="#e95e0b">:PharmaWorld:sub:ClinicalTrial</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7786">Endocrinology7786</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 04 September 2014 | 17:45</font><br><br><div style="margin-bottom: 10px;">Comment: The purpose of the study, which is conducted globally, is to demonstrate the efficacy of once weekly dosing of NNC0195-0092 compared to placebo and once-daily dosing of somatropin after 35 weeks of treatment in AGHD.<wbr> PE will measure change in truncal fat percentage.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Novo Strategy</FONT></STRONG>
 </div><div style="margin-bottom: 10px;"><UL><LI><FONT size="3"><FONT size="2"><STRONG>Adult trials</STRONG>: 2 Ph1 completed</FONT></FONT></LI>
</UL> </div><div style="margin-bottom: 10px;"><FONT size="3"><FONT size="2">The drug development program for AGHD does not include a POC trial.<wbr></FONT></FONT> </div><div style="margin-bottom: 10px;"><UL><LI><STRONG>Ped trial</STRONG>:  Ph1 ongoing (to complete in Nov.<wbr>2014)</LI>
</UL> </div><div style="margin-bottom: 10px;"><FONT size="3"><STRONG>Trial Details</STRONG></FONT> </div><div style="margin-bottom: 10px;"><A href="http://clinicaltrials.gov/ct2/show/NCT02229851?recr=Open&amp;no_unk=Y&amp;fund=2&amp;rcv_s=08%2F04%2F2014&amp;rank=173">NCT02229851</A> </div><div style="margin-bottom: 10px;">Recruitment: approx.<wbr> 280 (both genders; 23 years to 79 years) </div><div style="margin-bottom: 10px;">Timelines Nov.<wbr>2014 to Jan.<wbr>2018 /<wbr> Jan.<wbr>2018 </div><div>Location: 16 countries listed </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20141231&edate=20140901&rec=7786">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-09-04T17:45:07+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Janssen's Observational Study Will Describe Clinical Course of UC in Korea [dis:IBD, :PharmaWorld:mkt:Korea, :PharmaWorld:sub:ClinicalTrial]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2020</link>
<description>Janssen's Observational Study Will Describe Clinical Course of UC in Korea [dis:IBD, :PharmaWorld:mkt:Korea, :PharmaWorld:sub:ClinicalTrial]</description><category>dis:IBD</category><category>mkt:Korea</category><category>sub:ClinicalTrial</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2020</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2020">Janssen's Observational Study Will Describe Clinical Course of UC in Korea</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20141231&edate=20140901&cat=dis%3aIBD"><font color="#e95e0b">:GastroEnterology:dis:IBD</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=mkt%3aKorea"><font color="#e95e0b">:PharmaWorld:mkt:Korea</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=sub%3aClinicalTrial"><font color="#e95e0b">:PharmaWorld:sub:ClinicalTrial</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2020">GastroEnterology2020</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 04 September 2014 | 17:22</font><br><br><div style="margin-bottom: 10px;">Comment: The objective of the study is to describe clinical course of newly diagnosed moderate to severe UC in tertiary referral hospitals in Korea for 5-year follow-up under usual care.<wbr> PE will measure total number of relapses in 1; 3 and 5 years.<wbr> Blood sample will be collected and stored for genetic and biomarker research.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3"><A href="http://clinicaltrials.gov/ct2/show/NCT02229344?recr=Open&amp;no_unk=Y&amp;fund=2&amp;rcv_s=08%2F04%2F2014&amp;rank=152">NCT02229344</A> - Trial Details</FONT></STRONG> </div><div style="margin-bottom: 10px;">Recruitment: Approx.<wbr> 400 (both genders; 7 years and older) </div><div style="margin-bottom: 10px;"><UL><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Participant is newly diagnosed with moderate to severe ulcerative colitis in a tertiary referral hospital within 4 weeks prior to enrollment</LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">The diagnosis was based on symptoms consistent with ulcerative colitis lasting for more than 4 weeks, excluding infections and other acute or chronic non-infectious bowel syndrome conditions</LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Participants meet diagnostic criteria for ulcerative colitisif at least 3 out of 4 of the following are met: 1) A History of diarrhea and/<wbr>or blood/<wbr>pus in stool, 2) Macroscopic appearance at endoscopy, with continuous mucosal inflammation affecting the rectum in continuity with some or all of the colon, 3) Microscopic features on biopsy consistent with ulcerative colitis, 4) No suspicion of Crohn's disease or indeterminate colitis</LI>
</UL> </div><div style="margin-bottom: 10px;">Timelines: Aug.<wbr>2014 to July/<wbr>Aug.<wbr>2021 </div><div>Location: Korea (&gt;15 sites) </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2020">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-09-04T17:22:45+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>re: PhII ATL1103 Acromegaly Study Results Expected By End August</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7784</link>
<description>re: PhII ATL1103 Acromegaly Study Results Expected By End August</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7784</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20141231&edate=20140901&rec=7784">re: PhII ATL1103 Acromegaly Study Results Expected By End August</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7784">Endocrinology7784</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 03 September 2014 | 17:18</font><br><br><div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">PhII ATL1103 Acromegaly Study Results Expected By End August</span>&nbsp;<font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20141231&edate=20140901&cat=dis%3aAcromegaly"><font color="#e95e0b">:Endocrinology:dis:Acromegaly</font></a>]</font></font><br><span style="font-size: 12px;">Comment: Antisense Therapeutics has reported completion of enrolment in its 26 patient phII acromegaly trial with results now expected by the end of August 2014.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20141231&edate=20140901&rec=7751">...</a><br><font size="-1">Jacquelyne CANTLE MEYRICK / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7751" class="commentpermalink">Endocrinology7751</a> / <span class="date">30 July 2014</span> /
<span class="time">18:26:09 o'clock CEST</span>
</font></div><div style="margin-bottom: 10px;">The company has reported that the Ph2 trial met its primary efficacy endpoint, showing a statistically significant average reduction in the serum insulin-like growth factor levels of 26% from baseline.<wbr> Management plans to conduct a small study at a higher dose than 400mg for potential use in a Ph3 trial.<wbr> </div><div style="margin-bottom: 10px;">Preparation for the Ph3 </div><div>Preparatory work for a Ph3 trial of 6-12 months of treatment includes manufacture and formulation of drug product and further animal toxicology studies which the company plans to undertake with a future development Partner.<wbr> </div><!-- Comment details --><font size="-1">Brigitte DESCHAMPS / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7784" class="commentpermalink">Endocrinology7784</a> / <span class="date">03 September 2014</span> /
<span class="time">17:18:31 o'clock CEST</span>
</font><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20141231&edate=20140901&rec=7784">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7751">View thread  Endocrinology7751: PhII ATL1103 Acromegaly Study Results Expected By End August</a>]]></content:encoded><dc:date>2014-09-03T17:18:31+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Clinicians Dismissive Of The Cost-Effectiveness Of Plenadren As A Treatment For Adrenal Insufficiency [news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7780</link>
<description>Clinicians Dismissive Of The Cost-Effectiveness Of Plenadren As A Treatment For Adrenal Insufficiency [news]</description><category>news</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7780</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20141231&edate=20140901&rec=7780">Clinicians Dismissive Of The Cost-Effectiveness Of Plenadren As A Treatment For Adrenal Insufficiency</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20141231&edate=20140901&cat=news"><font color="#e95e0b">:Endocrinology:news</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7780">Endocrinology7780</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 03 September 2014 | 15:20</font><br><br><div style="margin-bottom: 10px;">Comment: Thanks to Philip Harris (VP Scientific Affairs), we are alerted to a BMJ editorial published in mid-August that is very dismissive of the cost-effectiveness of the cortisol replacement therapy  Plenadren (Abbvie/<wbr>Shire).<wbr> </div><div style="margin-bottom: 10px;">The editorial written by Anjali Amin (Clinical Research Fellow) and Amir Sam (Senior Lecturer In Endocrinology) at Imperial College London UK, suggests the drug is the least cost-effective option for the treatment of adrenal insufficiency.<wbr> Although Plenadren is a once-a-day formulation that patients may prefer it is noted that adherance and quality of life scores do not differ between Plenadren and hydrocortisone.<wbr> Moreover, it is highlighted that Plenadren costs almost 4x as much as standard hydrocortisone, the drug most commonly prescribed for adrenal insufficiency in the UK today.<wbr> </div><div style="margin-bottom: 10px;">In the pivotal study that formed the basis for approval of Plenadren, cortisol exposure in the hydrocortisone arm was higher than in the Plenadren arm, which probably explains the apparent beneficial clinical profile of Plenadren.<wbr> It is suggested that if clinicians prescribed lower doses than the 20-30mg normally used similar benefits to those seen with Plenadren may be observed.<wbr> </div><div style="margin-bottom: 10px;">The editorial goes on to suggest that whilst hydrocortisone was the most cost-effective option up until 2008, prednisolone should now be the first-line option for glucocorticoid replacement therapy since hydrocortisone's price increased by 60-fold in 2008.<wbr>.<wbr> </div><div>Source: 16th August BMJ </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20141231&edate=20140901&rec=7780">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-09-03T15:20:26+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>Cortendo To Enter PC Development With Next Generation Cortisol Inhibitors in 2015. [dis:Cushing, news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7777</link>
<description>Cortendo To Enter PC Development With Next Generation Cortisol Inhibitors in 2015. [dis:Cushing, news]</description><category>dis:Cushing</category><category>news</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7777</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20141231&edate=20140901&rec=7777">Cortendo To Enter PC Development With Next Generation Cortisol Inhibitors in 2015.<wbr></a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20141231&edate=20140901&cat=dis%3aCushing"><font color="#e95e0b">:Endocrinology:dis:Cushing</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20141231&edate=20140901&cat=news"><font color="#e95e0b">:Endocrinology:news</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7777">Endocrinology7777</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 03 September 2014 | 15:01</font><br><br><div style="margin-bottom: 10px;">Comment: Sweden's Cortendo released interim results last week showing a net loss of $9.<wbr>7m for the half year, reflecting increased R&amp;D activities associated with the phIII Cushing's syndrome SONICS trial with NormoCort.<wbr> It was announced that the group has a new CEO former Insmed Chief Commercial Officer and ex Shire executive Matthew Pauls (SVP Global Commerical Operations Shire) appointed to take the company during Q413.<wbr> Interestingly, the group also provided an update on its next generation cortisol inhibitors.<wbr> </div><div style="margin-bottom: 10px;">Much of Cortendo's press release was dedicated to the status of the SONIC PhIII trial previously reviewed in Traction (see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20141231&edate=20140901&rec=7775" class="defaultlink">Endocrinology7775: re: Cortendo AB to Start Ph3 for Endogenous Cushing's Syndrome</a>), however the update on the next generation cortisol inhibitors for Cushing's Disease is of interest.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Next Generation Cushing's Drugs</STRONG> </div><div style="margin-bottom: 10px;">The group claims that the next generation programme has been focused on the selection of the most promising lead compounds from a group of compounds identified through the chemical synthesis and screening programme perfomed 2011-2013.<wbr> Investment in this area has been reportedly low suring 2014, as the company has been focused on the NormoCort phIII trial implementation.<wbr> The primary goal of the project now is to identify a lead candidate and back-up that can enter preclinical development in 2015.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Strategic Refocus</STRONG> </div><div style="margin-bottom: 10px;">During the second quarter the board of the company made the decision that the company should further strengthen its focus on orphan drugs and metabolic disease.<wbr> Cortendo intents to prioritize investments in its lead PhIII orpha drug NormoCort, next generation inhibitors for Cushing's Syndrome and its innovative diabetes project acquired theough BioPancreate, a wholly owned subsidiary of Cortendo.<wbr> It will discontinue investment in osteoarthritis and the licens for the commercial rigts to Crespine will be returned to the licensor.<wbr> </div><div>Source: <A href="http://www.cortendo.com">www.<wbr>cortendo.<wbr>com</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20141231&edate=20140901&rec=7777">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-09-03T15:01:53+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>Allergan Faces Revived Lawsuit Over Improper Marketing Of Botox [comp:Allergan, prod:Botox]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7718</link>
<description>Allergan Faces Revived Lawsuit Over Improper Marketing Of Botox [comp:Allergan, prod:Botox]</description><category>comp:Allergan</category><category>prod:Botox</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7718</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7718">Allergan Faces Revived Lawsuit Over Improper Marketing Of Botox</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20141231&edate=20140901&cat=comp%3aAllergan"><font color="#e95e0b">:Neurology:comp:Allergan</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20141231&edate=20140901&cat=prod%3aBotox"><font color="#e95e0b">:Neurology:prod:Botox</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7718">Neurology7718</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 03 September 2014 | 13:04</font><br><br><div style="margin-bottom: 10px;">Comment: A US appeals court yesterday revived a 2010 shareholder lawsuit 
against Allergan over allegations that the company improperly marketed Botox for 
off-label use in headache and migraine.<wbr> </div><div style="margin-bottom: 10px;">In 2010 it was alleged that Allergan's board authorised plans to promote 
Botox for these conditions which at the time were off-label.<wbr> </div><div style="margin-bottom: 10px;">A lower court judge in Santa Anna California dismissed the lawsuit stating 
that the shareholders had not followed proper procedure by first requesting that 
Alleragan's board file legal claims in the company's own name.<wbr> </div><div style="margin-bottom: 10px;">On Tuesday the 9th Circuit disagreed with this ruling saying that 
shareholders allegations were specific enough to raise doubts as to whether the 
board faces liability and as a result they did not have to approach the board 
before heading to court, </div><div style="margin-bottom: 10px;">The case involved is Rosenbloom vs Pyott ,12-55516 </div><div>Source: Reuters </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20141231&edate=20140901&rec=7718">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-09-03T13:04:23+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>4d Pharma Progresses with New Treatment for IBS and Crohn [headline, dis:IBS, dis:IBD]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2019</link>
<description>4d Pharma Progresses with New Treatment for IBS and Crohn [headline, dis:IBS, dis:IBD]</description><comments>http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2019</comments><category>headline</category><category>dis:IBS</category><category>dis:IBD</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2019</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2019">4d Pharma Progresses with New Treatment for IBS and Crohn</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20141231&edate=20140901&cat=dis%3aIBD"><font color="#e95e0b">:GastroEnterology:dis:IBD</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20141231&edate=20140901&cat=dis%3aIBS"><font color="#e95e0b">:GastroEnterology:dis:IBS</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20141231&edate=20140901&cat=headline"><font color="#e95e0b">:GastroEnterology:headline</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2019">GastroEnterology2019</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 03 September 2014 | 11:35</font><br><br><div style="margin-bottom: 10px;">Comment: The company has reported its "live biotherapeutics", Blautix for IBS and Thetanix for ped CD, are set to enter clinical studies in Q2:15.<wbr> On Aug.<wbr> 7th, Rosburix, its UC drug for ped patients won orphan drug designation from the FDA.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Blautix and Thetanix Profile</FONT></STRONG> </div><div style="margin-bottom: 10px;">Both products are "live biotherapeutics", which use live bacteria as the active agent, rather than chemicals or biological agents, such as antibodies.<wbr> </div><div style="margin-bottom: 10px;">Quoting A.<wbr> Stevenson, CSO of the company, " .<wbr>.<wbr>.<wbr> <EM>The Blautix and Thetanix are a new class of therapeutic, designed to treat the underlying causes of diseases rather than just the symptoms".<wbr></EM> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Rosburix Gets ODD</FONT></STRONG> </div><div style="margin-bottom: 10px;">Rosburix is the second 4d pharma biotherapeutic to receive orphan designation, having received orphan designation from the FDA for the treatment of paediatric Crohns with Thetanix in September 2013.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">About 4d Pharma</FONT></STRONG> </div><div style="margin-bottom: 10px;">Location: Manchester (UK) </div><div style="margin-bottom: 10px;">4d pharma works exclusively in the new drug class of live biotherapeutics.<wbr> </div><div>On July 18th, it acquired Microbiota to further complements its unique platform technology and strengthen its portfolio of drug candidates in development.<wbr> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="GastroEnterology2036c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">On Sept 23, 4D Pharma posted a pretax loss in its maiden half-year results as its costs offset revenue for the period.<wbr> The company, which is focusing on developing a range of projects targeting new therapeutic areas, said its pretax loss in the six months to June 30 was GBP501,000, with no comparative figures as the company only  incorporated in January 2014.<wbr> </div><div>Revenue in the period was GBP116,000, which was offset by GBP130,000 in product development costs and GBP507,000 in administrative expenses.<wbr> </div><font size="-1">Brigitte DESCHAMPS / <a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2036" class="commentpermalink">GastroEnterology2036</a> / <span class="date">23 September 2014</span> /
<span class="time">17:39:06 o'clock CEST</span>
</font></div><a name="GastroEnterology2203c"></a><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">4D Pharma has raised &pound;34m through a shares placing.<wbr> 4D discovers and develops new live biotherapeutic candidates using its MicroRx platform.<wbr> This technology allows for the rapid screening of the Company's library of commensal bacteria, isolated from the human gut, for therapeutic effect.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Financial Background</STRONG> </div><div style="margin-bottom: 10px;">The Manchester company  floated on AIM London Stock Exchange in February last year, raising &pound;16.<wbr>5m.<wbr> </div><div style="margin-bottom: 10px;">Only a few months later the company raised an additional &pound;21.<wbr>5m because of the conditional placing of more than 14m new shares at a price of 150p.<wbr> </div><div>Its latest fundraising, through broker Zeus Capital of 8,475,610 new ordinary shares at a placing price of 410p, will be used to step-up its research efforts </div><font size="-1">Brigitte DESCHAMPS / <a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2203" class="commentpermalink">GastroEnterology2203</a> / <span class="date">21 January 2015</span> /
<span class="time">18:11:46 o'clock CET</span>
</font></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2019">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-09-03T11:35:37+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>MSD To Present New Data From Studies Evaluating Their Anti-PD1 Including Bladder Cancer At ESMO 2014</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9921</link>
<description>MSD To Present New Data From Studies Evaluating Their Anti-PD1 Including Bladder Cancer At ESMO 2014</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9921</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=9921">MSD To Present New Data From Studies Evaluating Their Anti-PD1 Including Bladder Cancer At ESMO 2014</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9921">Oncology9921</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/994">Jenny Wu</a> | 03 September 2014 | 10:36</font><br><br><div style="margin-bottom: 10px;">Comment: MSD today announced the presentation of data from ongoing clinical trials evaluating the anti-tumor activity of pembrolizumab, the company&rsquo;s investigational anti-PD-1 antibody, at the European Society of Medical Oncology (ESMO) 2014 in Madrid, Spain, September 26 &ndash; 30.<wbr> Data on pembrolizumab are planned to be presented in five advanced solid tumor types, including the first presentation of data evaluating pembrolizumab for the treatment of gastric and bladder (urothelial tract) cancers.<wbr> Three late-breaking abstracts have been accepted for oral presentation.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Abstracts involving Merck Oncology-sponsored studies at ESMO 2014 include:</STRONG> </div><div style="margin-bottom: 10px;"><EM id="yui_3_16_0_1_1409733120267_1272"><STRONG id="yui_3_16_0_1_1409733120267_1271">Bladder and Gastric Cancers</STRONG></EM> </div><div style="margin-bottom: 10px;"><UL id="yui_3_16_0_1_1409733120267_1260"><LI class="bwlistitemmargb" id="yui_3_16_0_1_1409733120267_1263"><EM id="yui_3_16_0_1_1409733120267_1266"><STRONG id="yui_3_16_0_1_1409733120267_1265">(Abstract #LBA23) Late-Breaker (Oral presentation):</STRONG></EM> <STRONG id="yui_3_16_0_1_1409733120267_1264">A Phase 1b Study of Pembrolizumab (Pembro; MK-3475) in Patients (Pts) With Advanced Urothelial Tract Cancer.<wbr> </STRONG>E.<wbr> Plimack.<wbr> Monday, September 29, 11:00 AM-11:15 AM CEST.<wbr> Location: Sevilla.<wbr>
</LI>
<LI class="bwlistitemmargb" id="yui_3_16_0_1_1409733120267_1259"><EM id="yui_3_16_0_1_1409733120267_1262"><STRONG id="yui_3_16_0_1_1409733120267_1261">(Abstract #LBA15) Late-Breaker (Oral presentation):</STRONG></EM><STRONG id="yui_3_16_0_1_1409733120267_1258"> A Phase 1b Study of Pembrolizumab (Pembro; MK-3475) in Patients (Pts) With Advanced Gastric Cancer</STRONG>.<wbr> K.<wbr> Muro.<wbr> Sunday, September 28.<wbr> 09:15 AM-09:30 AM CEST.<wbr> Location: Madrid.<wbr>
</LI>
</UL> </div><div style="margin-bottom: 10px;"><EM><STRONG>Advanced Melanoma</STRONG></EM> </div><div style="margin-bottom: 10px;"><UL id="yui_3_16_0_1_1409733120267_1277"><LI class="bwlistitemmargb" id="yui_3_16_0_1_1409733120267_1276"><EM id="yui_3_16_0_1_1409733120267_1275"><STRONG id="yui_3_16_0_1_1409733120267_1274">(Abstract #LBA34) Late-Breaker (Poster discussion): </STRONG></EM><STRONG id="yui_3_16_0_1_1409733120267_1278">Pembrolizumab (Pembro; MK-3475) for Advanced Melanoma (MEL): Randomized Comparison of Two Dosing Schedules</STRONG>.<wbr> C.<wbr> Robert, Monday, September 29.<wbr> 1:00 PM-2:00 PM CEST.<wbr> Location: Valencia.<wbr>
</LI>
<LI class="bwlistitemmargb" id="yui_3_16_0_1_1409733120267_1280"><EM id="yui_3_16_0_1_1409733120267_1299"><STRONG id="yui_3_16_0_1_1409733120267_1298">(Abstract #1075TiP) Poster:</STRONG></EM><STRONG id="yui_3_16_0_1_1409733120267_1279"> KEYNOTE-029: Phase 1/<wbr>2 Study of MK-3475 in Combination With Pegylated Interferon Alfa-2b (PEG-IFN) or Ipilimumab (IPI) in Patients (Pts) With Advanced Melanoma (MEL) or Renal Cell Carcinoma (RCC)</STRONG>.<wbr> T.<wbr>K.<wbr> Choueiri.<wbr> Monday, September 29; 12:45 PM-1:45 PM CEST.<wbr> Location: Poster Area.<wbr>
</LI>
<LI class="bwlistitemmargb" id="yui_3_16_0_1_1409733120267_1281"><EM><STRONG>(Abstract #1097P) Poster:</STRONG></EM><STRONG id="yui_3_16_0_1_1409733120267_1282"> PD-L1 Expression and Overall Survival Among Patients With Melanoma</STRONG>.<wbr> T.<wbr> Steiniche.<wbr> Sunday, September 28; 12:45 PM-1:45 PM CEST.<wbr> Location: Poster Area.<wbr>
</LI>
</UL> </div><div style="margin-bottom: 10px;"><EM><STRONG>NSCLC</STRONG></EM> </div><div style="margin-bottom: 10px;"><UL id="yui_3_16_0_1_1409733120267_1297"><LI class="bwlistitemmargb" id="yui_3_16_0_1_1409733120267_1296"><EM id="yui_3_16_0_1_1409733120267_1302"><STRONG id="yui_3_16_0_1_1409733120267_1301">(Abstract #LBA43) Late-Breaker (Oral presentation):</STRONG></EM><STRONG id="yui_3_16_0_1_1409733120267_1295"> Antitumor Activity of Pembrolizumab (Pembro; MK-3475) and Correlation With Programmed Death Ligand 1 (PD-L1) Expression in a Pooled Analysis of Patients (pts) With Advanced Non&ndash;Small Cell Lung Carcinoma (NSCLC)</STRONG>.<wbr> E.<wbr> Garon.<wbr> Sunday, September 28; 09:15 AM-10:30 AM CEST.<wbr> Location: Barcelona.<wbr>
</LI>
<LI class="bwlistitemmargb" id="yui_3_16_0_1_1409733120267_1304"><EM><STRONG>(Abstract #1328P) Poster:</STRONG></EM><STRONG id="yui_3_16_0_1_1409733120267_1303"> PD-L1 Expression and Survival Among Advanced Non&ndash;Small Cell Lung Cancer (NSCLC) Patients Treated With Chemotherapy</STRONG>.<wbr> S.<wbr> Sorensen.<wbr> Saturday, September 27; 12:45 PM-1:45 PM CEST.<wbr> Location: Poster Area.<wbr>
</LI>
</UL> </div><div style="margin-bottom: 10px;"><EM><STRONG>Head and Neck Cancer</STRONG></EM> </div><div><UL id="yui_3_16_0_1_1409733120267_1309"><LI class="bwlistitemmargb" id="yui_3_16_0_1_1409733120267_1308"><EM><STRONG>(Abstract #LBA31) Late-Breaker (Poster discussion):</STRONG></EM><STRONG> A Phase Ib Study of Pembrolizumab (Pembro; MK-3475) in Patients (Pts) With Human Papillomavirus Virus (HPV)-Positive and Negative Head and Neck Cancer (HNC)</STRONG>.<wbr> L.<wbr> Chow.<wbr> Sunday, September 28; 1:00 PM-2:00 PM CEST.<wbr> Location: Poster Area.<wbr>
</LI>
</UL> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=9921">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-09-03T10:36:36+02:00</dc:date><dc:creator>jew60237</dc:creator></item><item>
<title>Actavis' Potential Treatment for IBS-D Granted Priority Review Status by FDA [dis:IBS, dis:Diarrhoea, :PharmaWorld:mkt:NorthAmerica]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2018</link>
<description>Actavis' Potential Treatment for IBS-D Granted Priority Review Status by FDA [dis:IBS, dis:Diarrhoea, :PharmaWorld:mkt:NorthAmerica]</description><category>dis:IBS</category><category>dis:Diarrhoea</category><category>mkt:NorthAmerica</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2018</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2018">Actavis' Potential Treatment for IBS-D Granted Priority Review Status by FDA</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20141231&edate=20140901&cat=dis%3aDiarrhoea"><font color="#e95e0b">:GastroEnterology:dis:Diarrhoea</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20141231&edate=20140901&cat=dis%3aIBS"><font color="#e95e0b">:GastroEnterology:dis:IBS</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20141231&edate=20140901&cat=mkt%3aNorthAmerica"><font color="#e95e0b">:PharmaWorld:mkt:NorthAmerica</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2018">GastroEnterology2018</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 02 September 2014 | 17:45</font><br><br><div style="margin-bottom: 10px;">Comment: Actavis, through its subsidiary Forest, acquired Furiex last July as well as eluxadoline, its lead product.<wbr> The company expects the PDUFA date to be in Q2:15.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">What is Eluxadoline</FONT></STRONG> </div><div style="margin-bottom: 10px;">First-in-class, locally-acting mu opioid receptor agonist and delta opiod receptor antagonist for treating symptoms of IBS-D.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Acquisition of Furiex</FONT></STRONG> </div><div style="margin-bottom: 10px;">See <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=1970" class="defaultlink">GastroEnterology1970: Forest to Acquire Furiex for Up to $1.<wbr>46bln</a>.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Actavis - Specialty Brands in the US</FONT></STRONG> </div><div><img src="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2018/1/ScreenCapture1.jpg?user-agent=rss"> </div><!-- Comment details --><a name="gastroenterology2018attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2018/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(99,8 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2018">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-09-02T17:45:13+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2018/1/ScreenCapture1.jpg" length="102167" type="image/jpeg"/></item><item>
<title>Novo Drops Inflammation Business [dis:IBD, :Endocrinology:comp:NovoNordisk]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2017</link>
<description>Novo Drops Inflammation Business [dis:IBD, :Endocrinology:comp:NovoNordisk]</description><category>dis:IBD</category><category>comp:NovoNordisk</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2017</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2017">Novo Drops Inflammation Business</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20141231&edate=20140901&cat=comp%3aNovoNordisk"><font color="#e95e0b">:Endocrinology:comp:NovoNordisk</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20141231&edate=20140901&cat=dis%3aIBD"><font color="#e95e0b">:GastroEnterology:dis:IBD</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2017">GastroEnterology2017</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 02 September 2014 | 17:19</font><br><br><div style="margin-bottom: 10px;">Comment: The company will focus on diabetes, and would look into selling or licensing out some of the drugs from the inflammatory business pipeline, which includes two invesitgational compounds for Crohn's disease (Ph2).<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Rationale</FONT></STRONG> </div><div style="margin-bottom: 10px;">The decision to stop R&amp;D activities in inflammatory disorders follows the termination of the development of anti-IL-20, the company's most advanced candidate, on Aug.<wbr> 7th.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">New Focus</FONT></STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>Prevention/<wbr>treatment/<wbr>complications of diabetes</LI>
<LI>Obesity</LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Consequences</FONT></STRONG> </div><div style="margin-bottom: 10px;">Approx 400 employees to be affected by the decision.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Inflammatory Pipeline</FONT></STRONG> </div><div><img src="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2017/1/ScreenCapture1.jpg?user-agent=rss"> </div><!-- Comment details --><a name="gastroenterology2017attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2017/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(47,8 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20141231&edate=20140901&rec=2017">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-09-02T17:19:13+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2017/1/ScreenCapture1.jpg" length="48912" type="image/jpeg"/></item><item>
<title>Exelixis To Potentially Cease Development Of Cabozantinib in mCRPC [headline]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9916</link>
<description>Exelixis To Potentially Cease Development Of Cabozantinib in mCRPC [headline]</description><category>headline</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9916</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=9916">Exelixis To Potentially Cease Development Of Cabozantinib in mCRPC</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=headline"><font color="#e95e0b">:Oncology:headline</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9916">Oncology9916</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 02 September 2014 | 15:54</font><br><br><div style="margin-bottom: 10px;">Comment: Exelixis today announced disappointing top-line results from the final analysis of COMET-1, the ph3 pivotal trial of cabozantinib in men with mCRPC whose disease progressed after treatment with docetaxel as well as abiraterone and/<wbr>or enzalutamide.<wbr> The trial failed to meet its primary endpoint of demonstrating a statistically significant increase in overall survival (OS).<wbr> Exelixis will, as a result, initiate a significant workforce reduction to enable the company to focus its financial resources on the late-stage clinical trials of cabozantinib in mRCC (the METEOR trial top-line data 2015) and advanced HCC (the CELESTIAL trial top-line data 2017) reducing its workforce by approximately 70 percent (160 employees).<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Key Results From The COMET-1 Trial</STRONG> </div><div style="margin-bottom: 10px;">The median OS for the cabozantinib arm of the trial was 11.<wbr>0 months versus 9.<wbr>8 months for the prednisone arm (hazard ratio 0.<wbr>90; 95% confidence interval 0.<wbr>76 &ndash; 1.<wbr>06; p value 0.<wbr>212).<wbr> </div><div style="margin-bottom: 10px;">Besides OS, the exploratory endpoint of PFS as assessed by the investigators is the only time-to-event-based endpoint for which data are available.<wbr> Median PFS was 5.<wbr>5 months for the cabozantinib arm of the trial versus 2.<wbr>8 months for the prednisone arm (hazard ratio 0.<wbr>50; 95% confidence interval 0.<wbr>42 &ndash; 0.<wbr>60; p value &lt;0.<wbr>0001).<wbr> Safety data were consistent with those observed in earlier-stage trials of cabozantinib in mCRPC.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Situation Regarding Other mCRPC Trials</STRONG> </div><div style="margin-bottom: 10px;">Based on the outcome of COMET-1, Exelixis has deprioritized the clinical development of cabozantinib in mCRPC.<wbr> Enrollment in COMET-2, which is the second pivotal trial in mCRPC and evaluates pain palliation, has been halted.<wbr> The company expects top-line data before the end of this year.<wbr> Based on the outcome of COMET-2, Exelixis will discuss with regulatory authorities the potential regulatory path, if any, of cabozantinib in mCRPC.<wbr> Other company-sponsored studies in mCRPC, including a randomized phase 2 study of cabozantinib in combination with abiraterone, will also be halted.<wbr> </div><div>Based on its restructuring, Exelixis believes it has sufficient cash to complete the METEOR study next-year.<wbr> It does of course have revenues it is generating from the sale of cabozantanib to treat medullary thyroid cancer and more financial information will be released with the group's third quarter figures.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=9916">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-09-02T15:54:37+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>Telik Reports Progress With Novel Antibody Based Pancreatic  Cancer Therapeutic &amp; Imaging Agent [news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9911</link>
<description>Telik Reports Progress With Novel Antibody Based Pancreatic  Cancer Therapeutic &amp; Imaging Agent [news]</description><category>news</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9911</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=9911">Telik Reports Progress With Novel Antibody Based Pancreatic  Cancer Therapeutic & Imaging Agent</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20141231&edate=20140901&cat=news"><font color="#e95e0b">:Oncology:news</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9911">Oncology9911</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 02 September 2014 | 14:28</font><br><br><div style="margin-bottom: 10px;">Comment: Telik a clinical stage oncology drug develompent company has announced significant prelinical progress related to the development of its lead antibody program designated 5BI.<wbr> The antibody can potentially be used both to treat and image pancreatic cancer.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Basis for 5BI Development</STRONG> </div><div style="margin-bottom: 10px;">MabVax Therapeutics a wholly owned subsidiary of Telik, discovered the fully-human antibody from the natural immune response produced by a cancer patient who was vaccinated with sialyl-Lewisa anti-cancer vaccine licensed to the company from the MSKCC.<wbr> The carbohydrate antigen sialyly-Lewisa is an attractive molecular target since it is expressed on pancreatic, colon and stomach cancer cells at high levels and used as a tumour biomarker.<wbr> </div><div style="margin-bottom: 10px;">Preclinical results prompted the company to engage a leading biomanufacturing company to produce clinical supplies for a phI trial it anticipates starting in the second half of 2015.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Antibody Drug Conjugate Development Progress</STRONG> </div><div style="margin-bottom: 10px;">The company has also successfully demonstrated the feasibility of using the antibody as the targeting component for both an antibody drug conjugate and an imaging agent.<wbr> </div><div style="margin-bottom: 10px;">It recently received in vitro and in vivo results conducted by a third-party which demonstrated that the antibody conjugated to a toxin payload can be internalised by multiple human pancreatic cancer cell lines and that the toxin payload signficantly increased the potency of the antibody.<wbr> The 5B1 -based ADC was reasonably well tolerated in animal studies and produced a measurable reduction in tumour burden.<wbr> A development plan for this product is being created with the conjugate being positioned as a follow-on product to the full-length antibody.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Pancreatic Imaging Potential</STRONG> </div><div style="margin-bottom: 10px;">Meanwhile the company's early work combining the 5B1 antibody with a radiolabel creating a PET imaging agent has led to a publication in the Journal of Nucleur Medicine (J Nucl Med 3013:54:1-7) demonstrating its ability to detect and assess pancreatic cancer.<wbr> The work described formed the basis for Telik's successful NCI contract award of $1.<wbr>5m in late August.<wbr> </div><div>Source: <A href="http://www.telik.com/">www.<wbr>telik.<wbr>com</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20141231&edate=20140901&rec=9911">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-09-02T14:28:51+02:00</dc:date><dc:creator>jac89886</dc:creator></item></channel>
</rss>